Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer

ABSTRACT

A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a non-provisional utility patent application that isa continuation of United States non-provisional utility application U.S.Ser. No. 10/435,751, filed 9 May 2003, now U.S. Pat. No. 7,115,727, andthis application claims priority from U.S. provisional patentapplication U.S. Ser. No. 60/404,306, filed 16 Aug. 2002, and thisapplication claims priority from U.S. provisional patent applicationU.S. Ser. No. 60/423,290, filed 1 Nov. 2002. The contents of theapplications listed in this paragraph are fully incorporated byreference herein.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSOREDRESEARCH

Not applicable.

FIELD OF THE INVENTION

The invention described herein relates to genes and their encodedproteins, termed 282P1G3, expressed in certain cancers, and todiagnostic and therapeutic methods and compositions useful in themanagement of cancers that express 282P1G3.

SUBMISSION ON COMPACT DISC

The content of the following submission on compact discs is incorporatedherein by reference in its entirety: A computer readable form (CRF) ofthe Sequence Listing on compact disc (file name: 511582008401, daterecorded: Jul. 18, 2006, size: 1,013,760 bytes); a duplicate compactdisc copy of the Sequence Listing (COPY 1) (file name: 511582008401,date recorded: Jul. 18, 2006, size: 1,013,760 bytes); and a duplicatecompact disc copy of the Sequence Listing (COPY 2) (file name:511582008401, date recorded: Jul. 18, 2006, size: 1,013,760 bytes).

BACKGROUND OF THE INVENTION

Cancer is the second leading cause of human death next to coronarydisease. Worldwide, millions of people die from cancer every year. Inthe United States alone, as reported by the American Cancer Society,cancer causes the death of well over a half-million people annually,with over 1.2 million new cases diagnosed per year. While deaths fromheart disease have been declining significantly, those resulting fromcancer generally are on the rise. In the early part of the next century,cancer is predicted to become the leading cause of death.

Worldwide, several cancers stand out as the leading killers. Inparticular, carcinomas of the lung, prostate, breast, colon, pancreas,and ovary represent the primary causes of cancer death. These andvirtually all other carcinomas share a common lethal feature. With veryfew exceptions, metastatic disease from a carcinoma is fatal. Moreover,even for those cancer patients who initially survive their primarycancers, common experience has shown that their lives are dramaticallyaltered. Many cancer patients experience strong anxieties driven by theawareness of the potential for recurrence or treatment failure. Manycancer patients experience physical debilitations following treatment.Furthermore, many cancer patients experience a recurrence.

Worldwide, prostate cancer is the fourth most prevalent cancer in men.In North America and Northern Europe, it is by far the most commoncancer in males and is the second leading cause of cancer death in men.In the United States alone, well over 30,000 men die annually of thisdisease—second only to lung cancer. Despite the magnitude of thesefigures, there is still no effective treatment for metastatic prostatecancer. Surgical prostatectomy, radiation therapy, hormone ablationtherapy, surgical castration and chemotherapy continue to be the maintreatment modalities. Unfortunately, these treatments are ineffectivefor many and are often associated with undesirable consequences.

On the diagnostic front, the lack of a prostate tumor marker that canaccurately detect early-stage, localized tumors remains a significantlimitation in the diagnosis and management of this disease. Although theserum prostate specific antigen (PSA) assay has been a very useful tool,however its specificity and general utility is widely regarded aslacking in several important respects.

Progress in identifying additional specific markers for prostate cancerhas been improved by the generation of prostate cancer xenografts thatcan recapitulate different stages of the disease in mice. The LAPC (LosAngeles Prostate Cancer) xenografts are prostate cancer xenografts thathave survived passage in severe combined immune deficient (SCID) miceand have exhibited the capacity to mimic the transition from androgendependence to androgen independence (Klein et al., 1997, Nat. Med.3:402). More recently identified prostate cancer markers include PCTA-1(Su et al., 1996, Proc. Natl. Acad. Sci. USA 93: 7252),prostate-specific membrane (PSM) antigen (Pinto et al., Clin Cancer Res1996 Sep. 2 (9): 1445-51), STEAP (Hubert, et al., Proc Natl Acad SciUSA. 1999 Dec. 7; 96(25): 14523-8) and prostate stem cell antigen (PSCA)(Reiter et al., 1998, Proc. Natl. Acad. Sci. USA 95: 1735).

While previously identified markers such as PSA, PSM, PCTA and PSCA havefacilitated efforts to diagnose and treat prostate cancer, there is needfor the identification of additional markers and therapeutic targets forprostate and related cancers in order to further improve diagnosis andtherapy.

Renal cell carcinoma (RCC) accounts for approximately 3 percent of adultmalignancies. Once adenomas reach a diameter of 2 to 3 cm, malignantpotential exists. In the adult, the two principal malignant renal tumorsare renal cell adenocarcinoma and transitional cell carcinoma of therenal pelvis or ureter. The incidence of renal cell adenocarcinoma isestimated at more than 29,000 cases in the United States, and more than11,600 patients died of this disease in 1998. Transitional cellcarcinoma is less frequent, with an incidence of approximately 500 casesper year in the United States.

Surgery has been the primary therapy for renal cell adenocarcinoma formany decades. Until recently, metastatic disease has been refractory toany systemic therapy. With recent developments in systemic therapies,particularly immunotherapies, metastatic renal cell carcinoma may beapproached aggressively in appropriate patients with a possibility ofdurable responses. Nevertheless, there is a remaining need for effectivetherapies for these patients.

Of all new cases of cancer in the United States, bladder cancerrepresents approximately 5 percent in men (fifth most common neoplasm)and 3 percent in women (eighth most common neoplasm). The incidence isincreasing slowly, concurrent with an increasing older population. In1998, there was an estimated 54,500 cases, including 39,500 in men and15,000 in women. The age-adjusted incidence in the United States is 32per 100,000 for men and eight per 100,000 in women. The historicmale/female ratio of 3:1 may be decreasing related to smoking patternsin women. There were an estimated 11,000 deaths from bladder cancer in1998 (7,800 in men and 3,900 in women). Bladder cancer incidence andmortality strongly increase with age and will be an increasing problemas the population becomes more elderly.

Most bladder cancers recur in the bladder. Bladder cancer is managedwith a combination of transurethral resection of the bladder (TUR) andintravesical chemotherapy or immunotherapy. The multifocal and recurrentnature of bladder cancer points out the limitations of TUR. Mostmuscle-invasive cancers are not cured by TUR alone. Radical cystectomyand urinary diversion is the most effective means to eliminate thecancer but carry an undeniable impact on urinary and sexual function.There continues to be a significant need for treatment modalities thatare beneficial for bladder cancer patients.

An estimated 130,200 cases of colorectal cancer occurred in 2000 in theUnited States, including 93,800 cases of colon cancer and 36,400 ofrectal cancer. Colorectal cancers are the third most common cancers inmen and women. Incidence rates declined significantly during 1992-1996(−2.1% per year). Research suggests that these declines have been due toincreased screening and polyp removal, preventing progression of polypsto invasive cancers. There were an estimated 56,300 deaths (47,700 fromcolon cancer, 8,600 from rectal cancer) in 2000, accounting for about11% of all U.S. cancer deaths.

At present, surgery is the most common form of therapy for colorectalcancer, and for cancers that have not spread, it is frequently curative.Chemotherapy, or chemotherapy plus radiation, is given before or aftersurgery to most patients whose cancer has deeply perforated the bowelwall or has spread to the lymph nodes. A permanent colostomy (creationof an abdominal opening for elimination of body wastes) is occasionallyneeded for colon cancer and is infrequently required for rectal cancer.There continues to be a need for effective diagnostic and treatmentmodalities for colorectal cancer.

There were an estimated 164,100 new cases of lung and bronchial cancerin 2000, accounting for 14% of all U.S. cancer diagnoses. The incidencerate of lung and bronchial cancer is declining significantly in men,from a high of 86.5 per 100,000 in 1984 to 70.0 in 1996. In the 1990s,the rate of increase among women began to slow. In 1996, the incidencerate in women was 42.3 per 100,000.

Lung and bronchial cancer caused an estimated 156,900 deaths in 2000,accounting for 28% of all cancer deaths. During 1992-1996, mortalityfrom lung cancer declined significantly among men (−1.7% per year) whilerates for women were still significantly increasing (0.9% per year).Since 1987, more women have died each year of lung cancer than breastcancer, which, for over 40 years, was the major cause of cancer death inwomen. Decreasing lung cancer incidence and mortality rates most likelyresulted from decreased smoking rates over the previous 30 years;however, decreasing smoking patterns among women lag behind those ofmen. Of concern, although the declines in adult tobacco use have slowed,tobacco use in youth is increasing again.

Treatment options for lung and bronchial cancer are determined by thetype and stage of the cancer and include surgery, radiation therapy, andchemotherapy. For many localized cancers, surgery is usually thetreatment of choice. Because the disease has usually spread by the timeit is discovered, radiation therapy and chemotherapy are often needed incombination with surgery. Chemotherapy alone or combined with radiationis the treatment of choice for small cell lung cancer; on this regimen,a large percentage of patients experience remission, which in some casesis long lasting. There is however, an ongoing need for effectivetreatment and diagnostic approaches for lung and bronchial cancers.

An estimated 182,800 new invasive cases of breast cancer were expectedto occur among women in the United States during 2000. Additionally,about 1,400 new cases of breast cancer were expected to be diagnosed inmen in 2000. After increasing about 4% per year in the 1980s, breastcancer incidence rates in women have leveled off in the 1990s to about110.6 cases per 100,000.

In the U.S. alone, there were an estimated 41,200 deaths (40,800 women,400 men) in 2000 due to breast cancer. Breast cancer ranks second amongcancer deaths in women. According to the most recent data, mortalityrates declined significantly during 1992-1996 with the largest decreasesin younger women, both white and black. These decreases were probablythe result of earlier detection and improved treatment.

Taking into account the medical circumstances and the patient'spreferences, treatment of breast cancer may involve lumpectomy (localremoval of the tumor) and removal of the lymph nodes under the arm;mastectomy (surgical removal of the breast) and removal of the lymphnodes under the arm; radiation therapy; chemotherapy; or hormonetherapy. Often, two or more methods are used in combination. Numerousstudies have shown that, for early stage disease, long-term survivalrates after lumpectomy plus radiotherapy are similar to survival ratesafter modified radical mastectomy. Significant advances inreconstruction techniques provide several options for breastreconstruction after mastectomy. Recently, such reconstruction has beendone at the same time as the mastectomy.

Local excision of ductal carcinoma in situ (DCIS) with adequate amountsof surrounding normal breast tissue may prevent the local recurrence ofthe DCIS. Radiation to the breast and/or tamoxifen may reduce the chanceof DCIS occurring in the remaining breast tissue. This is importantbecause DCIS, if left untreated, may develop into invasive breastcancer. Nevertheless, there are serious side effects or sequelae tothese treatments. There is, therefore, a need for efficacious breastcancer treatments.

There were an estimated 23,100 new cases of ovarian cancer in the UnitedStates in 2000. It accounts for 4% of all cancers among women and rankssecond among gynecologic cancers. During 1992-1996, ovarian cancerincidence rates were significantly declining. Consequent to ovariancancer, there were an estimated 14,000 deaths in 2000. Ovarian cancercauses more deaths than any other cancer of the female reproductivesystem.

Surgery, radiation therapy, and chemotherapy are treatment options forovarian cancer. Surgery usually includes the removal of one or bothovaries, the fallopian tubes (salpingo-oophorectomy), and the uterus(hysterectomy). In some very early tumors, only the involved ovary willbe removed, especially in young women who wish to have children. Inadvanced disease, an attempt is made to remove all intra-abdominaldisease to enhance the effect of chemotherapy. There continues to be animportant need for effective treatment options for ovarian cancer.

There were an estimated 28,300 new cases of pancreatic cancer in theUnited States in 2000. Over the past 20 years, rates of pancreaticcancer have declined in men. Rates among women have remainedapproximately constant but may be beginning to decline. Pancreaticcancer caused an estimated 28,200 deaths in 2000 in the United States.Over the past 20 years, there has been a slight but significant decreasein mortality rates among men (about −0.9% per year) while rates haveincreased slightly among women.

Surgery, radiation therapy, and chemotherapy are treatment options forpancreatic cancer. These treatment options can extend survival and/orrelieve symptoms in many patients but are not likely to produce a curefor most. There is a significant need for additional therapeutic anddiagnostic options for pancreatic cancer.

SUMMARY OF THE INVENTION

The present invention relates to a gene, designated 282P1G3, that hasnow been found to be over-expressed in the cancer(s) listed in Table 1.Northern blot expression analysis of 282P1G3 gene expression in normaltissues shows a restricted expression pattern in adult tissues. Thenucleotide (FIG. 2) and amino acid (FIG. 2, and FIG. 3) sequences of282P1G3 are provided. The tissue-related profile of 282P1G3 in normaladult tissues, combined with the over-expression observed in the tissueslisted in Table 1, shows that 282P1G3 is aberrantly over-expressed in atleast some cancers, and thus serves as a useful diagnostic,prophylactic, prognostic, and/or therapeutic target for cancers of thetissue(s) such as those listed in Table 1.

The invention provides polynucleotides corresponding or complementary toall or part of the 282P1G3 genes, mRNAs, and/or coding sequences,preferably in isolated form, including polynucleotides encoding282P1G3-related proteins and fragments of 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more than 25contiguous amino acids; at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 80,85, 90, 95, 100 or more than 100 contiguous amino acids of a282P1G3-related protein, as well as the peptides/proteins themselves;DNA, RNA, DNA/RNA hybrids, and related molecules, polynucleotides oroligonucleotides complementary or having at least a 90% homology to the282P1G3 genes or mRNA sequences or parts thereof, and polynucleotides oroligonucleotides that hybridize to the 282P1G3 genes, mRNAs, or to282P1G3-encoding polynucleotides. Also provided are means for isolatingcDNAs and the genes encoding 282P1G3. Recombinant DNA moleculescontaining 282P1G3 polynucleotides, cells transformed or transduced withsuch molecules, and host-vector systems for the expression of 282P1G3gene products are also provided. The invention further providesantibodies that bind to 282P1G3 proteins and polypeptide fragmentsthereof, including polyclonal and monoclonal antibodies, murine andother mammalian antibodies, chimeric antibodies, humanized and fullyhuman antibodies, and antibodies labeled with a detectable marker ortherapeutic agent. In certain embodiments, there is a proviso that theentire nucleic acid sequence of FIG. 2 is not encoded and/or the entireamino acid sequence of FIG. 2 is not prepared. In certain embodiments,the entire nucleic acid sequence of FIG. 2 is encoded and/or the entireamino acid sequence of FIG. 2 is prepared, either of which are inrespective human unit dose forms.

The invention further provides methods for detecting the presence andstatus of 282P1G3 polynucleotides and proteins in various biologicalsamples, as well as methods for identifying cells that express 282P1G3.A typical embodiment of this invention provides methods for monitoring282P1G3 gene products in a tissue or hematology sample having orsuspected of having some form of growth dysregulation such as cancer.

The invention further provides various immunogenic or therapeuticcompositions and strategies for treating cancers that express 282P1G3such as cancers of tissues listed in Table I, including therapies aimedat inhibiting the transcription, translation, processing or function of282P1G3 as well as cancer vaccines. In one aspect, the inventionprovides compositions, and methods comprising them, for treating acancer that expresses 282P1G3 in a human subject wherein the compositioncomprises a carrier suitable for human use and a human unit dose of oneor more than one agent that inhibits the production or function of282P1G3. Preferably, the carrier is a uniquely human carrier. In anotheraspect of the invention, the agent is a moiety that is immunoreactivewith 282P1G3 protein. Non-limiting examples of such moieties include,but are not limited to, antibodies (such as single chain, monoclonal,polyclonal, humanized, chimeric, or human antibodies), functionalequivalents thereof (whether naturally occurring or synthetic), andcombinations thereof. The antibodies can be conjugated to a diagnosticor therapeutic moiety. In another aspect, the agent is a small moleculeas defined herein.

In another aspect, the agent comprises one or more than one peptidewhich comprises a cytotoxic T lymphocyte (CTL) epitope that binds an HLAclass I molecule in a human to elicit a CTL response to 282P1G3 and/orone or more than one peptide which comprises a helper T lymphocyte (HTL)epitope which binds an HLA class II molecule in a human to elicit an HTLresponse. The peptides of the invention may be on the same or on one ormore separate polypeptide molecules. In a further aspect of theinvention, the agent comprises one or more than one nucleic acidmolecule that expresses one or more than one of the CTL or HTL responsestimulating peptides as described above. In yet another aspect of theinvention, the one or more than one nucleic acid molecule may express amoiety that is immunologically reactive with 282P1G3 as described above.The one or more than one nucleic acid molecule may also be, or encodes,a molecule that inhibits production of 282P1G3. Non-limiting examples ofsuch molecules include, but are not limited to, those complementary to anucleotide sequence essential for production of 282P1G3 (e.g. antisensesequences or molecules that form a triple helix with a nucleotide doublehelix essential for 282P1G3 production) or a ribozyme effective to lyse282P1G3 mRNA.

Note that to determine the starting position of any peptide set forth inTables VIII-XXI and XXII to XLIX (collectively HLA Peptide Tables)respective to its parental protein, e.g., variant 1, variant 2, etc.,reference is made to three factors: the particular variant, the lengthof the peptide in an HLA Peptide Table, and the Search Peptides in TableVII. Generally, a unique Search Peptide is used to obtain HLA peptidesof a particular for a particular variant. The position of each SearchPeptide relative to its respective parent molecule is listed in TableVII. Accordingly, if a Search Peptide begins at position “X”, one mustadd the value “X-1” to each position in Tables VIII-XXI and XXII to XLIXto obtain the actual position of the HLA peptides in their parentalmolecule. For example, if a particular Search Peptide begins at position150 of its parental molecule, one must add 150-1, i.e., 149 to each HLApeptide amino acid position to calculate the position of that amino acidin the parent molecule.

One embodiment of the invention comprises an HLA peptide, that occurs atleast twice in Tables VIII-XXI and XXII to XLIX collectively, or anoligonucleotide that encodes the HLA peptide. Another embodiment of theinvention comprises an HLA peptide that occurs at least once in TablesVIII-XXI and at least once in tables XXII to XLIX, or an oligonucleotidethat encodes the HLA peptide.

Another embodiment of the invention is antibody epitopes, which comprisea peptide regions, or an oligonucleotide encoding the peptide region,that has one two, three, four, or five of the following characteristics:

i) a peptide region of at least 5 amino acids of a particular peptide ofFIG. 3, in any whole number increment up to the full length of thatprotein in FIG. 3, that includes an amino acid position having a valueequal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a valueequal to 1.0, in the Hydrophilicity profile of FIG. 5;

ii) a peptide region of at least 5 amino acids of a particular peptideof FIG. 3, in any whole number increment up to the full length of thatprotein in FIG. 3, that includes an amino acid position having a valueequal to or less than 0.5, 0.4, 0.3, 0.2, 0.1, or having a value equalto 0.0, in the Hydropathicity profile of FIG. 6;

iii) a peptide region of at least 5 amino acids of a particular peptideof FIG. 3, in any whole number increment up to the full length of thatprotein in FIG. 3, that includes an amino acid position having a valueequal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a valueequal to 1.0, in the Percent Accessible Residues profile of FIG. 7;

iv) a peptide region of at least 5 amino acids of a particular peptideof FIG. 3, in any whole number increment up to the full length of thatprotein in FIG. 3, that includes an amino acid position having a valueequal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a valueequal to 1.0, in the Average Flexibility profile of FIG. 8; or

v) a peptide region of at least 5 amino acids of a particular peptide ofFIG. 3, in any whole number increment up to the full length of thatprotein in FIG. 3, that includes an amino acid position having a valueequal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9, or having a valueequal to 1.0, in the Beta-turn profile of FIG. 9.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. The 282P1G3 SSH sequence of 321 nucleotides.

FIG. 2. A) The cDNA and amino acid sequence of 282P1G3 variant 1 (alsocalled “282P1G3 v.1” or “282P1G3 variant 1”) is shown in FIG. 2A. Thestart methionine is underlined. The open reading frame extends fromnucleic acid 272-3946 including the stop codon.

B) The cDNA and amino acid sequence of 282P1G3 variant 2 (also called“282P1G3 v.2”) is shown in FIG. 2B. The codon for the start methionineis underlined. The open reading frame extends from nucleic acid 272-3787including the stop codon.

C) The cDNA and amino acid sequence of 282P1G3 variant 3 (also called“282P1G3 v.3”) is shown in FIG. 2C. The codon for the start methionineis underlined. The open reading frame extends from nucleic acid 272-2953including the stop codon.

D) The cDNA and amino acid sequence of 282P1G3 variant 4 (also called“282P1G3 v.4”) is shown in FIG. 2D. The codon for the start methionineis underlined. The open reading frame extends from nucleic acid 272-3625including the stop codon.

E) The cDNA and amino acid sequence of 282P1G3 variant 5 (also called“282P1G3 v.5”) is shown in FIG. 2E. The codon for the start methionineis underlined. The open reading frame extends from nucleic acid 272-3898including the stop codon.

F) The cDNA and amino acid sequence of 282P1G3 variant 6 (also called“282P1G3 v.6”) is shown in FIG. 2F. The codon for the start methionineis underlined. The open reading frame extends from nucleic acid 272-3823including the stop codon.

G) The cDNA and amino acid sequence of 282P1G3 variant 7 (also called“282P1G3 v.7”) is shown in FIG. 2G. The codon for the start methionineis underlined. The open reading frame extends from nucleic acid 272-3982including the stop codon.

H) The cDNA and amino acid sequence of 282P1G3 variant 8 (also called“282P1G3 v.8”) is shown in FIG. 2H. The codon for the start methionineis underlined. The open reading frame extends from nucleic acid 272-3859including the stop codon.

I) The cDNA and amino acid sequence of 282P1G3 variant 28 (also called“282P1G3 v.28”) is shown in FIG. 21. The codon for the start methionineis underlined. The open reading frame extends from nucleic acid 192-3866including the stop codon.

J) The cDNA and amino acid sequence of 282P1G3 variant 14 (also called“282P1G3 v.14”) is shown in FIG. 2J. The codon for the start methionineis underlined. The open reading frame extends from nucleic acid 272-3946including the stop codon.

K) SNP variants of 282P1G3 v.1. 282P1G3 v.9 through v.25. The 282P1G3v.9 through v.23 proteins have 1224 amino acids. Variants 282P1G3 v.9through v.25 are variants with single nucleotide difference from 282P1G3v.1. 282P1G3 v.9, v.10, v.11, v.24 and v.25 proteins differ from282P1G3v.1 by one amino acid. 282P1G3v.12 through v.23, v.26 and v.27code for the same protein as v.1. Though these SNP variants are shownseparately, they can also occur in any combinations and in any of thetranscript variants listed above in FIGS. 2A through 2I.

FIG. 3. A) The amino acid sequence of 282P1G3 v.1 is shown in FIG. 3A;it has 1224 amino acids.

B) The amino acid sequence of 282P1G3 v.2 is shown in FIG. 3B; it has1171 amino acids.

C) The amino acid sequence of 282P1G3 v.3 is shown in FIG. 3C; it has893 amino acids.

D) The amino acid sequence of 282P1G3 v.4 is shown in FIG. 3D; it has1117 amino acids.

E) The amino acid sequence of 282P1G3 v.5 is shown in FIG. 3E; it has1208 amino acids.

F) The amino acid sequence of 282P1G3 v.6 is shown in FIG. 3F; it has1183 amino acids.

G) The amino acid sequence of 282P1G3 v.7 is shown in FIG. 3G; it has1236 amino acids.

H) The amino acid sequence of 282P1G3 v.8 is shown in FIG. 3H; it has1195 amino acids.

I) The amino acid sequence of 282P1G3 v.9 is shown in FIG. 31; it has1224 amino acids.

J) The amino acid sequence of 282P1G3 v.10 is shown in FIG. 3J; it has1224 amino acids.

K) The amino acid sequence of 282P1G3 v.11 is shown in FIG. 3 k; it has1224 amino acids.

L) The amino acid sequence of 282P1G3 v.24 is shown in FIG. 3L; it has1224 amino acids.

M) The amino acid sequence of 282P1G3 v.25 is shown in FIG. 3M; it has1224 amino acids.

As used herein, a reference to 282P1G3 includes all variants thereof,including those shown in FIGS. 2, 3, 10, and 11, unless the contextclearly indicates otherwise.

FIG. 4. FIG. 4A: Alignment of 282P1G3 with human close homolog of L1 (gi27894376). FIG. 4B: Alignment of 282P1G3 with mouse close homolog of L1(gi6680936).

FIG. 5. FIGS. 5( a)-(c): Hydrophilicity amino acid profile of282P1G3v.1, v.3, and v.7 determined by computer algorithm sequenceanalysis using the method of Hopp and Woods (Hopp T. P., Woods K. R.,1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828) accessed on theProtscale website located on the World Wide Web at(expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biologyserver.

FIG. 6. FIGS. 6( a)-(c): Hydropathicity amino acid profile of282P1G3v.1, v.3, and v.7 determined by computer algorithm sequenceanalysis using the method of Kyte and Doolittle (Kyte J., Doolittle R.F., 1982. J. Mol. Biol. 157:105-132) accessed on the ProtScale websitelocated on the World Wide Web at (.expasy.ch/cgi-bin/protscale.pl)through the ExPasy molecular biology server.

FIG. 7. FIGS. 7( a)-(c): Percent accessible residues amino acid profileof 282P1G3v.1, v.3, and v.7 determined by computer algorithm sequenceanalysis using the method of Janin (Janin J., 1979 Nature 277:491-492)accessed on the ProtScale website located on the World Wide Web at(.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biologyserver.

FIG. 8. FIGS. 8( a)-(c): Average flexibility amino acid profile of282P1G3v.1, v.3, and v.7 determined by computer algorithm sequenceanalysis using the method of Bhaskaran and Ponnuswamy (Bhaskaran R., andPonnuswamy P. K., 1988. Int. J. Pept. Protein Res. 32:242-255) accessedon the ProtScale website located on the World Wide Web at(.expasy.ch/cgi-bin/protscale.pl) through the ExPasy molecular biologyserver.

FIG. 9. FIGS. 9( a)-(c): Beta-turn amino acid profile of 282P1G3v.1,v.3, and v.7 determined by computer algorithm sequence analysis usingthe method of Deleage and Roux (Deleage, G., Roux B. 1987 ProteinEngineering 1:289-294) accessed on the ProtScale website located on theWorld Wide Web at (.expasy.ch/cgi-bin/protscale.pl) through the ExPasymolecular biology server.

FIG. 10. Schematic alignment of SNP variants of 282P1G03 v.1. Variants282P1G03 v.9 through v.27 are variants with single nucleotide differencefrom v.1. Variant v.14 inserted a ‘T’ between 4635 and 4636 of v.1.Though these SNP variants are shown separately, they can also occur inany combinations and in any transcript variants as shown in FIG. 12,e.g. v.2, that contains the bases. Numbers correspond to those of282P1G03 v.1. Black box shows the same sequence as 282P1G03 v.1. SNPsare indicated above the box.

FIG. 11. Schematic alignment of protein variants of 282P1G03. Proteinvariants are named to correspond to nucleotide variants. Variants v.2through v.8 were translated from splice variants. Variants v.7 and v.8had an insertion of 12 amino acids. Variants v.9 through v.11, v.24, andv.25 were translated from SNP variants. Nucleotide variants 282P1G03v.12 through v.23 coded for the same protein as v.1. Single amino aciddifferences among the proteins translated from SNP variants wereindicated above the boxes. Black boxes represent the same sequence as282P1G03 v.1. Numbers underneath the box correspond to positions in282P1G03 v.1.

FIG. 12. Structures of transcript variants of 282P1G03. Variant 282P1G03v.2 through v.8 and v.28 are transcript variants of 282P1G03 v.1.Variant 282P1G03 v.3 deleted exons 22 through 27, 3′ portion of exon 21and 5′ portion of exon 28 of variant 282P1G03 v.1. Variants v.2, v.4,v.5 and v.6 spliced out exon 25, exons 21-22, exon 8, and exon 6,respectively, in v.1. Variant 282P1G03 v.7 extended 36 bp at the 5′ endof exon 11 of variant 282P1G03v.1. In addition to such an extension of36 bp to exon 11 of v.1, variant 282P1G03 v.8 deleted exon 6 of variant282P1G03 v.1. The 11th potential exon had two forms: the longer form was36 bp longer than the shorter form. The 21st and 28th potential exonscould also have a long and a short form, as seen in v. 3. Poly A tailsare not shown here. Numbers in “( )” underneath the boxes correspond tothose of 282P1G03 v. 1. Lengths of introns and exons are notproportional.

FIG. 13. Secondary structure and transmembrane domains prediction for282P1G3B protein variants.

The secondary structure of 282P1G3B protein variants 1 through 8 (FIGS.13A (SEQ ID NO: 199), 13B (SEQ ID NO: 200), 13C (SEQ ID NO: 201), 13D(SEQ ID NO: 202), 13E (SEQ ID NO: 203), 13F (SEQ ID NO: 204), 13G (SEQID NO: 205), and 13H (SEQ ID NO: 206) respectively) were predicted usingthe HNN—Hierarchical Neural Network method (NPS @: Network ProteinSequence Analysis TIBS 2000 March Vol. 25, No 3 [291]:147-150 Combet C.,Blanchet C., Geourjon C. and Deléage G accessed from the ExPasymolecular biology server located on the World Wide Web at(.expasy.ch/tools/). This method predicts the presence and location ofalpha helices, extended strands, and random coils from the primaryprotein sequence. The percent of the protein in a given secondarystructure is also listed.

FIGS. 13I, 13K, 13M, 13O, 13Q, 13S, 13U, and 13W: Show schematicrepresentations of the probability of existence of transmembrane regionsand orientation of 282P1G3B variants 1 through 9, respectively, based onthe TMpred algorithm of Hofmann and Stoffel which utilizes TMBASE (K.Hofmann, W. Stoffel. TMBASE—A database of membrane spanning proteinsegments Biol. Chem. Hoppe-Seyler 374:166, 1993). FIGS. 13J, 13L, 13N,13P, 13R, 13T, 13V, and 13X: Show schematic representations of theprobability of the existence of transmembrane regions and theextracellular and intracellular orientation of 282P1G3B variants 1through 9, respectively, based on the TMHMM algorithm of Sonnhammer, vonHeijne, and Krogh (Erik L. L. Sonnhammer, Gunnar von Heijne, and AndersKrogh: A hidden Markov model for predicting transmembrane helices inprotein sequences. In Proc. of Sixth Int. Conf. on Intelligent Systemsfor Molecular Biology, p 175-182 Ed J. Glasgow, T. Littlejohn, F. Major,R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, Calif.: AAAI Press,1998). The TMpred and TMHMM algorithms are accessed from the ExPasymolecular biology server located on the World Wide Web at(.expasy.ch/tools/).

FIG. 14. 282P1G3 Expression by RT-PCR. First strand cDNA was preparedfrom (A) vital pool 1 (liver, lung and kidney), vital pool 2 (pancreas,colon and stomach), normal pancreas, ovary cancer pool, and pancreascancer pool; (B) normal stomach, normal brain, normal heart, normalliver, normal skeletal muscle, normal testis, normal prostate, normalbladder, normal kidney, normal colon, normal lung, normal pancreas, anda pool of cancer specimens from pancreas cancer patients, ovary cancerpatients, and cancer metastasis specimens. Normalization was performedby PCR using primers to actin. Semi-quantitative PCR, using primers to282P1G3, was performed at 26 and 30 cycles of amplification. (A)Expression of 282P1G3 was detected in ovary cancer pool, pancreas cancerpool vital pool 1, but not in vital pool 2 nor in normal pancreas. (B)Samples were run on an agarose gel, and PCR products were quantitatedusing the Alphalmager software. Results show strong expression inpancreas cancer, ovary cancer, cancer metastasis, and normal braincompared to all other normal tissues tested.

FIG. 15. 282P1G3 expression in normal tissues. Two multiple tissuenorthern blots (Clontech) both with 2 ug of mRNA/lane were probed withthe 282P1G3 sequence. Size standards in kilobases (kb) are indicated onthe side. Results show expression of an approximately 9-10 kb 282P1G3transcript in normal brain, but not in any other normal tissue tested.

FIG. 16. Expression of 282P1G3 in Pancreas Cancer Patient Specimens. RNAwas extracted from pancreas cancer cell lines (CL), normal pancreas (N),and pancreas cancer patient tumor (T). Northern blots with 10 ug oftotal RNA were probed with the 282P1G3 DNA probe. Size standards inkilobases are on the side. Results show expression of 282P1G3 inpancreas cancer patient tumor specimen but not in the cell lines nor inthe normal pancreas.

FIG. 17. Expression of 282P1G3 in Ovary Cancer Patient Specimens. RNAwas extracted from ovary cancer cell lines (CL), normal ovary (N), andovary cancer patient tumor (T). Northern blots with 10 ug of total RNAwere probed with the 282P1G3 DNA probe. Size standards in kilobases areon the side. Results show expression of 282P1G3 in ovary cancer patienttumor specimen but not in the cell lines nor in the normal ovary.

FIG. 18. Expression of 282P1G3 in Lymphoma Cancer Patient Specimens. RNAwas extracted from peripheral blood lymphocytes, cord blood isolatedfrom normal individuals, and from lymphoma patient cancer specimens.Northern blots with 10 ug of total RNA were probed with the 282P1G3sequence. Size standards in kilobases are on the side. Results showexpression of 282P1G3 in lymphoma patient specimens but not in thenormal blood cells tested.

FIG. 19. 282P1G3 Expression in 293T Cells Following Transfection of282P1G3.pcDNA3.1/MycHis Construct. The complete ORF of 282P1G3 v.2 wascloned into the pcDNA3.1/MycHis construct to generate282P1G3.pcDNA3.1/MycHis. 293T cells were transfected with either282P1G3.pcDNA3.1/MycHis or pcDNA3.1/MycHis vector control. Forty hourslater, cell lysates were collected. Samples were run on an SDS-PAGEacrylamide gel, blotted and stained with anti-his antibody. The blot wasdeveloped using the ECL chemiluminescence kit and visualized byautoradiography. Results show expression of 282P1G3 from the282P1G3.pcDNA3.1/MycHis construct in the lysates of transfected cells.

FIG. 20. 282P1G3 Expression in 293T Cells Following Transfection of282P1G3.pcDNA3.1/MycHis Construct. The extracellular domain, amino acids26-1043, of 282P1G3 v.2 was cloned into the pTag5 construct to generate282P1G3.pTag5. 293T cells were transfected with 282P1G3.pTag5 construct.Forty hours later, supernatant as well as cell lysates were collected.Samples were run on an SDS-PAGE acrylamide gel, blotted and stained withanti-his antibody. The blot was developed using the ECLchemiluminescence kit and visualized by autoradiography. Results showexpression and secretion of 282P1G3 from the 282P1G3.pTag5 transfectedcells.

DETAILED DESCRIPTION OF THE INVENTION

Outline of Sections

I.) Definitions

II.) 282P1G3 Polynucleotides

II.A.) Uses of 282P1G3 Polynucleotides

II.A.1.) Monitoring of Genetic Abnormalities

II.A.2.) Antisense Embodiments

II.A.3.) Primers and Primer Pairs

II.A.4.) Isolation of 282P1G3-Encoding Nucleic Acid Molecules

II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems

III.) 282P1G3-related Proteins

-   -   III.A.) Motif-bearing Protein Embodiments    -   III.B.) Expression of 282P1G3-related Proteins    -   III.C.) Modifications of 282P1G3-related Proteins    -   III.D.) Uses of 282P1G3-related Proteins

IV.) 282P1G3 Antibodies

V.) 282P1G3 Cellular Immune Responses

VI.) 282P1G3 Transgenic Animals

VII.) Methods for the Detection of 282P1G3

VIII.) Methods for Monitoring the Status of 282P1G3-related Genes andTheir Products

IX.) Identification of Molecules That Interact With 282P1G3

X.) Therapeutic Methods and Compositions

-   -   X.A.) Anti-Cancer Vaccines    -   X.B.) 282P1G3 as a Target for Antibody-Based Therapy    -   X.C.) 282P1G3 as a Target for Cellular Immune Responses    -   X.C.1. Minigene Vaccines    -   X.C.2. Combinations of CTL Peptides with Helper Peptides    -   X.C.3. Combinations of CTL Peptides with T Cell Priming Agents    -   X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or        HTL Peptides

X.D.) Adoptive Immunotherapy

X.E.) Administration of Vaccines for Therapeutic or ProphylacticPurposes

XI.) Diagnostic and Prognostic Embodiments of 282P1G3.

XII.) Inhibition of 282P1G3 Protein Function

-   -   XII.A.) Inhibition of 282P1G3 With Intracellular Antibodies    -   XII.B.) Inhibition of 282P1G3 with Recombinant Proteins    -   XII.C.) Inhibition of 282P1G3 Transcription or Translation    -   XII.D.) General Considerations for Therapeutic Strategies

XIII.) Identification, Characterization and Use of Modulators of 282P1G3

XIV.) KITS/Articles of Manufacture

I.) Definitions:

Unless otherwise defined, all terms of art, notations and otherscientific terms or terminology used herein are intended to have themeanings commonly understood by those of skill in the art to which thisinvention pertains. In some cases, terms with commonly understoodmeanings are defined herein for clarity and/or for ready reference, andthe inclusion of such definitions herein should not necessarily beconstrued to represent a substantial difference over what is generallyunderstood in the art. Many of the techniques and procedures describedor referenced herein are well understood and commonly employed usingconventional methodology by those skilled in the art, such as, forexample, the widely utilized molecular cloning methodologies describedin Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd. edition(1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Asappropriate, procedures involving the use of commercially available kitsand reagents are generally carried out in accordance with manufacturerdefined protocols and/or parameters unless otherwise noted.

The terms “advanced prostate cancer”, “locally advanced prostatecancer”, “advanced disease” and “locally advanced disease” mean prostatecancers that have extended through the prostate capsule, and are meantto include stage C disease under the American Urological Association(AUA) system, stage C₁-C₂ disease under the Whitmore-Jewett system, andstage T3-T4 and N+ disease under the TNM (tumor, node, metastasis)system. In general, surgery is not recommended for patients with locallyadvanced disease, and these patients have substantially less favorableoutcomes compared to patients having clinically localized(organ-confined) prostate cancer. Locally advanced disease is clinicallyidentified by palpable evidence of induration beyond the lateral borderof the prostate, or asymmetry or induration above the prostate base.Locally advanced prostate cancer is presently diagnosed pathologicallyfollowing radical prostatectomy if the tumor invades or penetrates theprostatic capsule, extends into the surgical margin, or invades theseminal vesicles.

“Altering the native glycosylation pattern” is intended for purposesherein to mean deleting one or more carbohydrate moieties found innative sequence 282P1G3 (either by removing the underlying glycosylationsite or by deleting the glycosylation by chemical and/or enzymaticmeans), and/or adding one or more glycosylation sites that are notpresent in the native sequence 282P1G3. In addition, the phrase includesqualitative changes in the glycosylation of the native proteins,involving a change in the nature and proportions of the variouscarbohydrate moieties present.

The term “analog” refers to a molecule which is structurally similar orshares similar or corresponding attributes with another molecule (e.g. a282P1G3-related protein). For example, an analog of a 282P1G3 proteincan be specifically bound by an antibody or T cell that specificallybinds to 282P1G3.

The term “antibody” is used in the broadest sense. Therefore, an“antibody” can be naturally occurring or man-made such as monoclonalantibodies produced by conventional hybridoma technology. Anti-282P1G3antibodies comprise monoclonal and polyclonal antibodies as well asfragments containing the antigen-binding domain and/or one or morecomplementarity determining regions of these antibodies.

An “antibody fragment” is defined as at least a portion of the variableregion of the immunoglobulin molecule that binds to its target, i.e.,the antigen-binding region. In one embodiment it specifically coverssingle anti-282P1G3 antibodies and clones thereof (including agonist,antagonist and neutralizing antibodies) and anti-282P1G3 antibodycompositions with polyepitopic specificity.

The term “codon optimized sequences” refers to nucleotide sequences thathave been optimized for a particular host species by replacing anycodons having a usage frequency of less than about 20%. Nucleotidesequences that have been optimized for expression in a given hostspecies by elimination of spurious polyadenylation sequences,elimination of exon/intron splicing signals, elimination oftransposon-like repeats and/or optimization of GC content in addition tocodon optimization are referred to herein as an “expression enhancedsequences.”

A “combinatorial library” is a collection of diverse chemical compoundsgenerated by either chemical synthesis or biological synthesis bycombining a number of chemical “building blocks” such as reagents. Forexample, a linear combinatorial chemical library, such as a polypeptide(e.g., mutein) library, is formed by combining a set of chemicalbuilding blocks called amino acids in every possible way for a givencompound length (i.e., the number of amino acids in a polypeptidecompound). Numerous chemical compounds are synthesized through suchcombinatorial mixing of chemical building blocks (Gallop et al., J. Med.Chem. 37(9): 1233-1251 (1994)).

Preparation and screening of combinatorial libraries is well known tothose of skill in the art. Such combinatorial chemical librariesinclude, but are not limited to, peptide libraries (see, e.g., U.S. Pat.No. 5,010,175, Furka, Pept. Prot. Res. 37:487-493 (1991), Houghton etal., Nature, 354:84-88 (1991)), peptoids (PCT Publication No WO91/19735), encoded peptides (PCT Publication WO 93/20242), randombio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat.No. 5,288,514), diversomers such as hydantoins, benzodiazepines anddipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913(1993)),vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc.114:6568(1992)), nonpeptidal peptidomimetics with a Beta-D-Glucosescaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218(1992)), analogous organic syntheses of small compound libraries (Chenet al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, etal., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell etal., J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al., J.Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g.,Stratagene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Pat.No. 5,539,083), antibody libraries (see, e.g., Vaughn et al., NatureBiotechnology 14(3): 309-314 (1996), and PCT/US96/10287), carbohydratelibraries (see, e.g., Liang et al., Science 274:1520-1522 (1996), andU.S. Pat. No. 5,593,853), and small organic molecule libraries (see,e.g., benzodiazepines, Baum, C&EN, January 18, page 33 (1993);isoprenoids, U.S. Pat. No. 5,569,588; thiazolidinones andmetathiazanones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos.5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337;benzodiazepines, U.S. Pat. No. 5,288,514; and the like).

Devices for the preparation of combinatorial libraries are commerciallyavailable (see, e.g., 357 NIPS, 390 NIPS, Advanced Chem Tech, LouisvilleKy.; Symphony, Rainin, Woburn, Mass.; 433A, Applied Biosystems, FosterCity, Calif.; 9050, Plus, Millipore, Bedford, NIA). A number ofwell-known robotic systems have also been developed for solution phasechemistries. These systems include automated workstations such as theautomated synthesis apparatus developed by Takeda Chemical Industries,LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms(Zymate H, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard,Palo Alto, Calif.), which mimic the manual synthetic operationsperformed by a chemist. Any of the above devices are suitable for usewith the present invention. The nature and implementation ofmodifications to these devices (if any) so that they can operate asdiscussed herein will be apparent to persons skilled in the relevantart. In addition, numerous combinatorial libraries are themselvescommercially available (see, e.g., ComGenex, Princeton, N.J.; Asinex,Moscow, RU; Tripos, Inc., St. Louis, Mo.; ChemStar, Ltd, Moscow, RU; 3DPharmaceuticals, Exton, Pa.; Martek Biosciences, Columbia, Md.; etc.).

The term “cytotoxic agent” refers to a substance that inhibits orprevents the expression activity of cells, function of cells and/orcauses destruction of cells. The term is intended to include radioactiveisotopes chemotherapeutic agents, and toxins such as small moleculetoxins or enzymatically active toxins of bacterial, fungal, plant oranimal origin, including fragments and/or variants thereof. Examples ofcytotoxic agents include, but are not limited to auristatins,auromycins, maytansinoids, yttrium, bismuth, ricin, ricin A-chain,combrestatin, duocarmycins, dolostatins, doxorubicin, daunorubicin,taxol, cisplatin, cc1065, ethidium bromide, mitomycin, etoposide,tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracindione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40,abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin,mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin,calicheamicin, Sapaonaria officinalis inhibitor, and glucocorticoid andother chemotherapeutic agents, as well as radioisotopes such as At²¹¹,I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi^(212 or 213), P³² andradioactive isotopes of Lu including Lu¹⁷⁷. Antibodies may also beconjugated to an anti-cancer pro-drug activating enzyme capable ofconverting the pro-drug to its active form.

The “gene product” is sometimes referred to herein as a protein or mRNA.For example, a “gene product of the invention” is sometimes referred toherein as a “cancer amino acid sequence”, “cancer protein”, “protein ofa cancer listed in Table I”, a “cancer mRNA”, “mRNA of a cancer listedin Table I”, etc. In one embodiment, the cancer protein is encoded by anucleic acid of FIG. 2. The cancer protein can be a fragment, oralternatively, be the full-length protein to the fragment encoded by thenucleic acids of FIG. 2. In one embodiment, a cancer amino acid sequenceis used to determine sequence identity or similarity. In anotherembodiment, the sequences are naturally occurring allelic variants of aprotein encoded by a nucleic acid of FIG. 2. In another embodiment, thesequences are sequence variants as further described herein.

“High throughput screening” assays for the presence, absence,quantification, or other properties of particular nucleic acids orprotein products are well known to those of skill in the art. Similarly,binding assays and reporter gene assays are similarly well known. Thus,e.g., U.S. Pat. No. 5,559,410 discloses high throughput screeningmethods for proteins; U.S. Pat. No. 5,585,639 discloses high throughputscreening methods for nucleic acid binding (i.e., in arrays); while U.S.Pat. Nos. 5,576,220 and 5,541,061 disclose high throughput methods ofscreening for ligand/antibody binding.

In addition, high throughput screening systems are commerciallyavailable (see, e.g., Amersham Biosciences, Piscataway, N.J.; ZymarkCorp., Hopkinton, Mass.; Air Technical Industries, Mentor, Ohio; BeckmanInstruments, Inc. Fullerton, Calif.; Precision Systems, Inc., Natick,Mass.; etc.). These systems typically automate entire procedures,including all sample and reagent pipetting, liquid dispensing, timedincubations, and final readings of the microplate in detector(s)appropriate for the assay. These configurable systems provide highthroughput and rapid start up as well as a high degree of flexibilityand customization. The manufacturers of such systems provide detailedprotocols for various high throughput systems. Thus, e.g., Zymark Corp.provides technical bulletins describing screening systems for detectingthe modulation of gene transcription, ligand binding, and the like.

The term “homolog” refers to a molecule which exhibits homology toanother molecule, by for example, having sequences of chemical residuesthat are the same or similar at corresponding positions.

“Human Leukocyte Antigen” or “HLA” is a human class I or class II MajorHistocompatibility Complex (MHC) protein (see, e.g., Stites, et al.,IMMUNOLOGY, 8^(TH) ED., Lange Publishing, Los Altos, Calif. (1994).

The terms “hybridize”, “hybridizing”, “hybridizes” and the like, used inthe context of polynucleotides, are meant to refer to conventionalhybridization conditions, preferably such as hybridization in 50%formamide/6×SSC/0.1% SDS/100 μg/ml ssDNA, in which temperatures forhybridization are above 37 degrees C. and temperatures for washing in0.1×SSC/0.1% SDS are above 55 degrees C.

The phrases “isolated” or “biologically pure” refer to material which issubstantially or essentially free from components which normallyaccompany the material as it is found in its native state. Thus,isolated peptides in accordance with the invention preferably do notcontain materials normally associated with the peptides in their in situenvironment. For example, a polynucleotide is said to be “isolated” whenit is substantially separated from contaminant polynucleotides thatcorrespond or are complementary to genes other than the 282P1G3 genes orthat encode polypeptides other than 282P1G3 gene product or fragmentsthereof. A skilled artisan can readily employ nucleic acid isolationprocedures to obtain an isolated 282P1G3 polynucleotide. A protein issaid to be “isolated,” for example, when physical, mechanical orchemical methods are employed to remove the 282P1G3 proteins fromcellular constituents that are normally associated with the protein. Askilled artisan can readily employ standard purification methods toobtain an isolated 282P1G3 protein. Alternatively, an isolated proteincan be prepared by chemical means.

The term “mammal” refers to any organism classified as a mammal,including mice, rats, rabbits, dogs, cats, cows, horses and humans. Inone embodiment of the invention, the mammal is a mouse. In anotherembodiment of the invention, the mammal is a human.

The terms “metastatic prostate cancer” and “metastatic disease” meanprostate cancers that have spread to regional lymph nodes or to distantsites, and are meant to include stage D disease under the AUA system andstage T×N×M+under the TNM system. As is the case with locally advancedprostate cancer, surgery is generally not indicated for patients withmetastatic disease, and hormonal (androgen ablation) therapy is apreferred treatment modality. Patients with metastatic prostate cancereventually develop an androgen-refractory state within 12 to 18 monthsof treatment initiation. Approximately half of these androgen-refractorypatients die within 6 months after developing that status. The mostcommon site for prostate cancer metastasis is bone. Prostate cancer bonemetastases are often osteoblastic rather than osteolytic (i.e.,resulting in net bone formation). Bone metastases are found mostfrequently in the spine, followed by the femur, pelvis, rib cage, skulland humerus. Other common sites for metastasis include lymph nodes,lung, liver and brain. Metastatic prostate cancer is typically diagnosedby open or laparoscopic pelvic lymphadenectomy, whole body radionuclidescans, skeletal radiography, and/or bone lesion biopsy.

The term “modulator” or “test compound” or “drug candidate” orgrammatical equivalents as used herein describe any molecule, e.g.,protein, oligopeptide, small organic molecule, polysaccharide,polynucleotide, etc., to be tested for the capacity to directly orindirectly alter the cancer phenotype or the expression of a cancersequence, e.g., a nucleic acid or protein sequences, or effects ofcancer sequences (e.g., signaling, gene expression, protein interaction,etc.) In one aspect, a modulator will neutralize the effect of a cancerprotein of the invention. By “neutralize” is meant that an activity of aprotein is inhibited or blocked, along with the consequent effect on thecell. In another aspect, a modulator will neutralize the effect of agene, and its corresponding protein, of the invention by normalizinglevels of said protein. In preferred embodiments, modulators alterexpression profiles, or expression profile nucleic acids or proteinsprovided herein, or downstream effector pathways. In one embodiment, themodulator suppresses a cancer phenotype, e.g. to a normal tissuefingerprint. In another embodiment, a modulator induced a cancerphenotype. Generally, a plurality of assay mixtures is run in parallelwith different agent concentrations to obtain a differential response tothe various concentrations. Typically, one of these concentrationsserves as a negative control, i.e., at zero concentration or below thelevel of detection.

Modulators, drug candidates or test compounds encompass numerouschemical classes, though typically they are organic molecules,preferably small organic compounds having a molecular weight of morethan 100 and less than about 2,500 Daltons. Preferred small moleculesare less than 2000, or less than 1500 or less than 1000 or less than 500D. Candidate agents comprise functional groups necessary for structuralinteraction with proteins, particularly hydrogen bonding, and typicallyinclude at least an amine, carbonyl, hydroxyl or carboxyl group,preferably at least two of the functional chemical groups. The candidateagents often comprise cyclical carbon or heterocyclic structures and/oraromatic or polyaromatic structures substituted with one or more of theabove functional groups. Modulators also comprise biomolecules such aspeptides, saccharides, fatty acids, steroids, purines, pyrimidines,derivatives, structural analogs or combinations thereof. Particularlypreferred are peptides. One class of modulators are peptides, forexample of from about five to about 35 amino acids, with from about fiveto about 20 amino acids being preferred, and from about 7 to about 15being particularly preferred. Preferably, the cancer modulatory proteinis soluble, includes a non-transmembrane region, and/or, has anN-terminal Cys to aid in solubility. In one embodiment, the C-terminusof the fragment is kept as a free acid and the N-terminus is a freeamine to aid in coupling, i.e., to cysteine. In one embodiment, a cancerprotein of the invention is conjugated to an immunogenic agent asdiscussed herein. In one embodiment, the cancer protein is conjugated toBSA. The peptides of the invention, e.g., of preferred lengths, can belinked to each other or to other amino acids to create a longerpeptide/protein. The modulatory peptides can be digests of naturallyoccurring proteins as is outlined above, random peptides, or ‘biased’random peptides. In a preferred embodiment, peptide/protein-basedmodulators are antibodies, and fragments thereof, as defined herein.

Modulators of cancer can also be nucleic acids. Nucleic acid modulatingagents can be naturally occurring nucleic acids, random nucleic acids,or “biased” random nucleic acids. For example, digests of prokaryotic oreukaryotic genomes can be used in an approach analogous to that outlinedabove for proteins.

The term “monoclonal antibody” refers to an antibody obtained from apopulation of substantially homogeneous antibodies, i.e., the antibodiescomprising the population are identical except for possible naturallyoccurring mutations that are present in minor amounts.

A “motif”, as in biological motif of a 282P1G3-related protein, refersto any pattern of amino acids forming part of the primary sequence of aprotein, that is associated with a particular function (e.g.protein-protein interaction, protein-DNA interaction, etc) ormodification (e.g. that is phosphorylated, glycosylated or amidated), orlocalization (e.g. secretory sequence, nuclear localization sequence,etc.) or a sequence that is correlated with being immunogenic, eitherhumorally or cellularly. A motif can be either contiguous or capable ofbeing aligned to certain positions that are generally correlated with acertain function or property. In the context of HLA motifs, ‘motif’refers to the pattern of residues in a peptide of defined length,usually a peptide of from about 8 to about 13 amino acids for a class IHLA motif and from about 6 to about 25 amino acids for a class II HLAmotif, which is recognized by a particular HLA molecule. Peptide motifsfor HLA binding are typically different for each protein encoded by eachhuman HLA allele and differ in the pattern of the primary and secondaryanchor residues.

A “pharmaceutical excipient” comprises a material such as an adjuvant, acarrier, pH-adjusting and buffering agents, tonicity adjusting agents,wetting agents, preservative, and the like.

“Pharmaceutically acceptable” refers to a non-toxic, inert, and/orcomposition that is physiologically compatible with humans or othermammals.

The term “polynucleotide” means a polymeric form of nucleotides of atleast 10 bases or base pairs in length, either ribonucleotides ordeoxynucleotides or a modified form of either type of nucleotide, and ismeant to include single and double stranded forms of DNA and/or RNA. Inthe art, this term if often used interchangeably with “oligonucleotide”.A polynucleotide can comprise a nucleotide sequence disclosed hereinwherein thymidine (T), as shown for example in FIG. 2, can also beuracil (U); this definition pertains to the differences between thechemical structures of DNA and RNA, in particular the observation thatone of the four major bases in RNA is uracil (U) instead of thymidine(T).

The term “polypeptide” means a polymer of at least about 4, 5, 6, 7, or8 amino acids. Throughout the specification, standard three letter orsingle letter designations for amino acids are used. In the art, thisterm is often used interchangeably with “peptide” or “protein”.

An HLA “primary anchor residue” is an amino acid at a specific positionalong a peptide sequence which is understood to provide a contact pointbetween the immunogenic peptide and the HLA molecule. One to three,usually two, primary anchor residues within a peptide of defined lengthgenerally defines a “motif” for an immunogenic peptide. These residuesare understood to fit in close contact with peptide binding groove of anHLA molecule, with their side chains buried in specific pockets of thebinding groove. In one embodiment, for example, the primary anchorresidues for an HLA class I molecule are located at position 2 (from theamino terminal position) and at the carboxyl terminal position of a 8,9, 10, 11, or 12 residue peptide epitope in accordance with theinvention. Alternatively, in another embodiment, the primary anchorresidues of a peptide binds an HLA class II molecule are spaced relativeto each other, rather than to the termini of a peptide, where thepeptide is generally of at least 9 amino acids in length. The primaryanchor positions for each motif and supermotif are set forth in TableIV. For example, analog peptides can be created by altering the presenceor absence of particular residues in the primary and/or secondary anchorpositions shown in Table IV. Such analogs are used to modulate thebinding affinity and/or population coverage of a peptide comprising aparticular HLA motif or supermotif.

“Radioisotopes” include, but are not limited to the following(non-limiting exemplary uses are also set forth):

Examples of Medical Isotopes: Isotope Description of use Actinium-225See Thorium-229 (Th-229) (AC-225) Actinium-227 Parent of Radium-223(Ra-223) which is an alpha emitter used to treat metastases in theskeleton resulting (AC-227) from cancer (i.e., breast and prostatecancers), and cancer radioimmunotherapy Bismuth-212 See Thorium-228(Th-228) (Bi-212) Bismuth-213 See Thorium-229 (Th-229) (Bi-213)Cadmium-109 Cancer detection (Cd-109) Cobalt-60 Radiation source forradiotherapy of cancer, for food irradiators, and for sterilization ofmedical supplies (Co-60) Copper-64 A positron emitter used for cancertherapy and SPECT imaging (Cu-64) Copper-67 Beta/gamma emitter used incancer radioimmunotherapy and diagnostic studies (i.e., breast and colon(Cu-67) cancers, and lymphoma) Dysprosium-166 Cancer radioimmunotherapy(Dy-166) Erbium-169 Rheumatoid arthritis treatment, particularly for thesmall joints associated with fingers and toes (Er-169) Europium-152Radiation source for food irradiation and for sterilization of medicalsupplies (Eu-152) Europium-154 Radiation source for food irradiation andfor sterilization of medical supplies (Eu-154) Gadolinium-153Osteoporosis detection and nuclear medical quality assurance devices(Gd-153) Gold-198 Implant and intracavity therapy of ovarian, prostate,and brain cancers (Au-198) Holmium-166 Multiple myeloma treatment intargeted skeletal therapy, cancer radioimmunotherapy, bone marrowablation, (Ho-166) and rheumatoid arthritis treatment Iodine-125Osteoporosis detection, diagnostic imaging, tracer drugs, brain cancertreatment, radiolabeling, tumor (I-125) imaging, mapping of receptors inthe brain, interstitial radiation therapy, brachytherapy for treatmentof prostate cancer, determination of glomerular filtration rate (GFR),determination of plasma volume, detection of deep vein thrombosis of thelegs Iodine-131 Thyroid function evaluation, thyroid disease detection,treatment of thyroid cancer as well as other non- (I-131) malignantthyroid diseases (i.e., Graves disease, goiters, and hyperthyroidism),treatment of leukemia, lymphoma, and other forms of cancer (e.g., breastcancer) using radioimmunotherapy Iridium-192 Brachytherapy, brain andspinal cord tumor treatment, treatment of blocked arteries (i.e.,arteriosclerosis and (Ir-192) restenosis), and implants for breast andprostate tumors Lutetium-177 Cancer radioimmunotherapy and treatment ofblocked arteries (i.e., arteriosclerosis and restenosis) (Lu-177)Molybdenum-99 Parent of Technetium-99m (Tc-99m) which is used forimaging the brain, liver, lungs, heart, and other organs. (Mo-99)Currently, Tc-99m is the most widely used radioisotope used fordiagnostic imaging of various cancers and diseases involving the brain,heart, liver, lungs; also used in detection of deep vein thrombosis ofthe legs Osmium-194 Cancer radioimmunotherapy (Os-194) Palladium-103Prostate cancer treatment (Pd-103) Platinum-195m Studies onbiodistribution and metabolism of cisplatin, a chemotherapeutic drug(Pt-195m) Phosphorus-32 Polycythemia rubra vera (blood cell disease) andleukemia treatment, bone cancer diagnosis/treatment; (P-32) colon,pancreatic, and liver cancer treatment; radiolabeling nucleic acids forin vitro research, diagnosis of superficial tumors, treatment of blockedarteries (i.e., arteriosclerosis and restenosis), and intracavitytherapy Phosphorus-33 Leukemia treatment, bone diseasediagnosis/treatment, radiolabeling, and treatment of blocked arteries(i.e., (P-33) arteriosclerosis and restenosis) Radium-223 SeeActinium-227 (Ac-227) (Ra-223) Rhenium-186 Bone cancer pain relief,rheumatoid arthritis treatment, and diagnosis and treatment of lymphomaand bone, (Re-186) breast, colon, and liver cancers usingradioimmunotherapy Rhenium-188 Cancer diagnosis and treatment usingradioimmunotherapy, bone cancer pain relief, treatment of rheumatoid(Re-188) arthritis, and treatment of prostate cancer Rhodium-105 Cancerradioimmunotherapy (Rh-105) Samarium-145 Ocular cancer treatment(Sm-145) Samarium-153 Cancer radioimmunotherapy and bone cancer painrelief (Sm-153) Scandium-47 Cancer radioimmunotherapy and bone cancerpain relief (Sc-47) Selenium-75 Radiotracer used in brain studies,imaging of adrenal cortex by gamma-scintigraphy, lateral locations of(Se-75) steroid secreting tumors, pancreatic scanning, detection ofhyperactive parathyroid glands, measure rate of bile acid loss from theendogenous pool Strontium-85 Bone cancer detection and brain scans(Sr-85) Strontium-89 Bone cancer pain relief, multiple myelomatreatment, and osteoblastic therapy (Sr-89) Technetium-99m SeeMolybdenum-99 (Mo-99) (Tc-99m) Thorium-228 Parent of Bismuth-212(Bi-212) which is an alpha emitter used in cancer radioimmunotherapy(Th-228) Thorium-229 Parent of Actinium-225 (Ac-225) and grandparent ofBismuth-213 (Bi-213) which are alpha emitters used in (Th-229) cancerradioimmunotherapy Thulium-170 Gamma source for blood irradiators,energy source for implanted medical devices (Tm-170) Tin-117m Cancerimmunotherapy and bone cancer pain relief (Sn-117m) Tungsten-188 Parentfor Rhenium-188 (Re-188) which is used for cancer diagnostics/treatment,bone cancer pain relief, (W-188) rheumatoid arthritis treatment, andtreatment of blocked arteries (i.e., arteriosclerosis and restenosis)Xenon-127 Neuroimaging of brain disorders, high resolution SPECTstudies, pulmonary function tests, and cerebral (Xe-127) blood flowstudies Ytterbium-175 Cancer radioimmunotherapy (Yb-175) Yttrium-90Microseeds obtained from irradiating Yttrium-89 (Y-89) for liver cancertreatment (Y-90) Yttrium-91 A gamma-emitting label for Yttrium-90 (Y-90)which is used for cancer radioimmunotherapy (i.e., lymphoma, (Y-91)breast, colon, kidney, lung, ovarian, prostate, pancreatic, andinoperable liver cancers)

By “randomized” or grammatical equivalents as herein applied to nucleicacids and proteins is meant that each nucleic acid and peptide consistsof essentially random nucleotides and amino acids, respectively. Theserandom peptides (or nucleic acids, discussed herein) can incorporate anynucleotide or amino acid at any position. The synthetic process can bedesigned to generate randomized proteins or nucleic acids, to allow theformation of all or most of the possible combinations over the length ofthe sequence, thus forming a library of randomized candidate bioactiveproteinaceous agents.

In one embodiment, a library is “fully randomized,” with no sequencepreferences or constants at any position. In another embodiment, thelibrary is a “biased random” library. That is, some positions within thesequence either are held constant, or are selected from a limited numberof possibilities. For example, the nucleotides or amino acid residuesare randomized within a defined class, e.g., of hydrophobic amino acids,hydrophilic residues, sterically biased (either small or large)residues, towards the creation of nucleic acid binding domains, thecreation of cysteines, for cross-linking, prolines for SH-3 domains,serines, threonines, tyrosines or histidines for phosphorylation sites,etc., or to purines, etc.

A “recombinant” DNA or RNA molecule is a DNA or RNA molecule that hasbeen subjected to molecular manipulation in vitro.

Non-limiting examples of small molecules include compounds that bind orinteract with 282P1G3, ligands including hormones, neuropeptides,chemokines, odorants, phospholipids, and functional equivalents thereofthat bind and preferably inhibit 282P1G3 protein function. Suchnon-limiting small molecules preferably have a molecular weight of lessthan about 10 kDa, more preferably below about 9, about 8, about 7,about 6, about 5 or about 4 kDa. In certain embodiments, small moleculesphysically associate with, or bind, 282P1G3 protein; are not found innaturally occurring metabolic pathways; and/or are more soluble inaqueous than non-aqueous solutions

“Stringency” of hybridization reactions is readily determinable by oneof ordinary skill in the art, and generally is an empirical calculationdependent upon probe length, washing temperature, and saltconcentration. In general, longer probes require higher temperatures forproper annealing, while shorter probes need lower temperatures.Hybridization generally depends on the ability of denatured nucleic acidsequences to reanneal when complementary strands are present in anenvironment below their melting temperature. The higher the degree ofdesired homology between the probe and hybridizable sequence, the higherthe relative temperature that can be used. As a result, it follows thathigher relative temperatures would tend to make the reaction conditionsmore stringent, while lower temperatures less so. For additional detailsand explanation of stringency of hybridization reactions, see Ausubel etal., Current Protocols in Molecular Biology, Wiley IntersciencePublishers, (1995).

“Stringent conditions” or “high stringency conditions”, as definedherein, are identified by, but not limited to, those that: (1) employlow ionic strength and high temperature for washing, for example 0.015 Msodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at50° C.; (2) employ during hybridization a denaturing agent, such asformamide, for example, 50% (v/v) formamide with 0.1% bovine serumalbumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphatebuffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at42° C.; or (3) employ 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodiumcitrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS,and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC(sodium chloride/sodium citrate) and 50% formamide at 55° C., followedby a high-stringency wash consisting of 0.1×SSC containing EDTA at 55°C. “Moderately stringent conditions” are described by, but not limitedto, those in Sambrook et al., Molecular Cloning: A Laboratory Manual,New York: Cold Spring Harbor Press, 1989, and include the use of washingsolution and hybridization conditions (e.g., temperature, ionic strengthand % SDS) less stringent than those described above. An example ofmoderately stringent conditions is overnight incubation at 37° C. in asolution comprising: 20% formamide, 5×SSC (150 mM NaCl, 15 mM trisodiumcitrate), 50 mM sodium phosphate (pH 7.6), 5× Denhardt's solution, 10%dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA,followed by washing the filters in 1×SSC at about 37-50° C. The skilledartisan will recognize how to adjust the temperature, ionic strength,etc. as necessary to accommodate factors such as probe length and thelike.

An HLA “supermotif” is a peptide binding specificity shared by HLAmolecules encoded by two or more HLA alleles. Overall phenotypicfrequencies of HLA-supertypes in different ethnic populations are setforth in Table IV (F). The non-limiting constituents of varioussupetypes are as follows:

A2: A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*6802, A*6901,A*0207

A3: A3, A11, A31, A*3301, A*6801, A*0301, A*1101, A*3101

B7: B7, B*3501-03, B*51, B*5301, B*5401, B*5501, B*5502, B*5601, B*6701,B*7801, B*0702, B*5101, B*5602

B44: B*3701, B*4402, B*4403, B*60 (B*4001), B61 (B*4006)

A1: A*0102, A*2604, A*3601, A*4301, A*8001

A24: A*24, A*30, A*2403, A*2404, A*3002, A*3003

B27: B*1401-02, B*1503, B*1509, B*1510, B*1518, B*3801-02, B*3901,B*3902, B*3903-04, B*4801-02, B*7301, B*2701-08

B58: B*1516, B*1517, B*5701, B*5702, B58

B62: B*4601, B52, B*1501 (B62), B*1502 (B75), B*1513 (B77)

Calculated population coverage afforded by different HLA-supertypecombinations are set forth in Table IV (G).

As used herein “to treat” or “therapeutic” and grammatically relatedterms, refer to any improvement of any consequence of disease, such asprolonged survival, less morbidity, and/or a lessening of side effectswhich are the byproducts of an alternative therapeutic modality; fulleradication of disease is not required.

A “transgenic animal” (e.g., a mouse or rat) is an animal having cellsthat contain a transgene, which transgene was introduced into the animalor an ancestor of the animal at a prenatal, e.g., an embryonic stage. A“transgene” is a DNA that is integrated into the genome of a cell fromwhich a transgenic animal develops.

As used herein, an HLA or cellular immune response “vaccine” is acomposition that contains or encodes one or more peptides of theinvention. There are numerous embodiments of such vaccines, such as acocktail of one or more individual peptides; one or more peptides of theinvention comprised by a polyepitopic peptide; or nucleic acids thatencode such individual peptides or polypeptides, e.g., a minigene thatencodes a polyepitopic peptide. The “one or more peptides” can includeany whole unit integer from 1-150 or more, e.g., at least 2, 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100,105, 110, 115, 120, 125, 130, 135, 140, 145, or 150 or more peptides ofthe invention. The peptides or polypeptides can optionally be modified,such as by lipidation, addition of targeting or other sequences. HLAclass I peptides of the invention can be admixed with, or linked to, HLAclass II peptides, to facilitate activation of both cytotoxic Tlymphocytes and helper T lymphocytes. HLA vaccines can also comprisepeptide-pulsed antigen presenting cells, e.g., dendritic cells.

The term “variant” refers to a molecule that exhibits a variation from adescribed type or norm, such as a protein that has one or more differentamino acid residues in the corresponding position(s) of a specificallydescribed protein (e.g. the 282P1G3 protein shown in FIG. 2 or FIG. 3.An analog is an example of a variant protein. Splice isoforms and singlenucleotides polymorphisms (SNPs) are further examples of variants.

The “282P1G3-related proteins” of the invention include thosespecifically identified herein, as well as allelic variants,conservative substitution variants, analogs and homologs that can beisolated/generated and characterized without undue experimentationfollowing the methods outlined herein or readily available in the art.Fusion proteins that combine parts of different 282P1G3 proteins orfragments thereof, as well as fusion proteins of a 282P1G3 protein and aheterologous polypeptide are also included. Such 282P1G3 proteins arecollectively referred to as the 282P1G3-related proteins, the proteinsof the invention, or 282P1G3. The term “282P1G3-related protein” refersto a polypeptide fragment or a 282P1G3 protein sequence of 4, 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, ormore than 25 amino acids; or, at least 30, 35, 40, 45, 50, 55, 60, 65,70, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145,150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275,300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, or 576 ormore amino acids.

II.) 282P1G3 Polynucleotides

One aspect of the invention provides polynucleotides corresponding orcomplementary to all or part of a 282P1G3 gene, mRNA, and/or codingsequence, preferably in isolated form, including polynucleotidesencoding a 282P1G3-related protein and fragments thereof, DNA, RNA,DNA/RNA hybrid, and related molecules, polynucleotides oroligonucleotides complementary to a 282P1G3 gene or mRNA sequence or apart thereof, and polynucleotides or oligonucleotides that hybridize toa 282P1G3 gene, mRNA, or to a 282P1G3 encoding polynucleotide(collectively, “282P1G3 polynucleotides”). In all instances whenreferred to in this section, T can also be U in FIG. 2.

Embodiments of a 282P1G3 polynucleotide include: a 282P1G3polynucleotide having the sequence shown in FIG. 2, the nucleotidesequence of 282P1G3 as shown in FIG. 2 wherein T is U; at least 10contiguous nucleotides of a polynucleotide having the sequence as shownin FIG. 2; or, at least 10 contiguous nucleotides of a polynucleotidehaving the sequence as shown in FIG. 2 where T is U. For example,embodiments of 282P1G3 nucleotides comprise, without limitation:

(I) a polynucleotide comprising, consisting essentially of, orconsisting of a sequence as shown in FIG. 2, wherein T can also be U;

(II) a polynucleotide comprising, consisting essentially of, orconsisting of the sequence as shown in FIG. 2A, from nucleotide residuenumber 272 through nucleotide residue number 3946, including the stopcodon, wherein T can also be U;

(III) a polynucleotide comprising, consisting essentially of, orconsisting of the sequence as shown in FIG. 2B, from nucleotide residuenumber 272 through nucleotide residue number 3787, including the stopcodon, wherein T can also be U;

(IV) a polynucleotide comprising, consisting essentially of, orconsisting of the sequence as shown in FIG. 2C, from nucleotide residuenumber 272 through nucleotide residue number 3953, including the a stopcodon, wherein T can also be U;

(V) a polynucleotide comprising, consisting essentially of, orconsisting of the sequence as shown in FIG. 2D, from nucleotide residuenumber 272 through nucleotide residue number 3625, including the stopcodon, wherein T can also be U;

(VI) a polynucleotide comprising, consisting essentially of, orconsisting of the sequence as shown in FIG. 2E, from nucleotide residuenumber 272 through nucleotide residue number 3898, including the stopcodon, wherein T can also be U;

(VII) a polynucleotide comprising, consisting essentially of, orconsisting of the sequence as shown in FIG. 2F, from nucleotide residuenumber 272 through nucleotide residue number 3823, including the stopcodon, wherein T can also be U;

(VIII) a polynucleotide comprising, consisting essentially of, orconsisting of the sequence as shown in FIG. 2G, from nucleotide residuenumber 272 through nucleotide residue number 3982, including the stopcodon, wherein T can also be U;

(IX) a polynucleotide comprising, consisting essentially of, orconsisting of the sequence as shown in FIG. 2H, from nucleotide residuenumber 272 through nucleotide residue number 3859, including the stopcodon, wherein T can also be U;

(X) a polynucleotide comprising, consisting essentially of, orconsisting of the sequence as shown in FIG. 21, from nucleotide residuenumber 192 through nucleotide residue number 3866, including the stopcodon, wherein T can also be U;

(XI) a polynucleotide that encodes a 282P1G3-related protein that is atleast 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% homologous to anentire amino acid sequence shown in FIG. 2A-J;

(XII) a polynucleotide that encodes a 282P1G3-related protein that is atleast 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identical to anentire amino acid sequence shown in FIG. 2A-J;

(XIII) a polynucleotide that encodes at least one peptide set forth inTables VIII-XXI and XXII-XLIX;

(XIV) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS.3A and 3I-3M in any whole number increment up to 1224 that includes atleast 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 aminoacid position(s) having a value greater than 0.5 in the Hydrophilicityprofile of FIG. 5;

(XV) a polynucleotide that encodes a peptide region of at least 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS.3A and 3I-3M in any whole number increment up to 1224 that includes 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value less than 0.5 in the Hydropathicity profileof FIG. 6;

(XVI) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS.3A and 3I-3M in any whole number increment up to 1224 that includes 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Percent AccessibleResidues profile of FIG. 7;

(XVII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS.3A and 3I-3M in any whole number increment up to 1224 that includes 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Average Flexibilityprofile of FIG. 8;

(XVIII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIGS.3A and 3I-3M in any whole number increment up to 1224 that includes 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9;

(XIX) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3B in any whole number increment up to 1171 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XX) a polynucleotide that encodes a peptide region of at least 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3B in any whole number increment up to 1171 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value less than 0.5 in the Hydropathicity profile of FIG. 6;

(XXI) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3B in any whole number increment up to 1171 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Percent Accessible Residues profile ofFIG. 7;

(XXII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3B in any whole number increment up to 1171 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Average Flexibility profile of FIG. 8;

(XXIII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3B in any whole number increment up to 1171 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Beta-turn profile of FIG. 9

(XXIV) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3C in any whole number increment up to 893 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XXV) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3C in any whole number increment up to 893 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value less than 0.5 in the Hydropathicity profile of FIG. 6;

(XXVI) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3C in any whole number increment up to 893 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Percent Accessible Residues profile ofFIG. 7;

(XXVII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3C in any whole number increment up to 893 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Average Flexibility profile of FIG. 8;

(XXVIII) a polynucleotide that encodes a peptide region of at least 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide ofFIG. 3C in any whole number increment up to 893 that includes 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9

(XXIX) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3D in any whole number increment up to 1117 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XXX) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3D in any whole number increment up to 1117 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value less than 0.5 in the Hydropathicity profile of FIG. 6;

(XXXI) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3D in any whole number increment up to 1117 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Percent Accessible Residues profile ofFIG. 7;

(XXXII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3D in any whole number increment up to 1117 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Average Flexibility profile of FIG. 8;

(XXXIII) a polynucleotide that encodes a peptide region of at least 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide ofFIG. 3D in any whole number increment up to 1117 that includes 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9

(XXXIV) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3E in any whole number increment up to 1208 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XXXV) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3E in any whole number increment up to 1208 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value less than 0.5 in the Hydropathicity profile of FIG. 6;

(XXXVI) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3E in any whole number increment up to 1208 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Percent Accessible Residues profile ofFIG. 7;

(XXXVII) a polynucleotide that encodes a peptide region of at least 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide ofFIG. 3E in any whole number increment up to 1208 that includes 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Average Flexibilityprofile of FIG. 8;

(XXXVIII) a polynucleotide that encodes a peptide region of at least 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide ofFIG. 3E in any whole number increment up to 1208 that includes 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9

(XXXIX) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3F in any whole number increment up to 1183 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XL) a polynucleotide that encodes a peptide region of at least 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3F in any whole number increment up to 1183 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value less than 0.5 in the Hydropathicity profile of FIG. 6;

(XLI) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3F in any whole number increment up to 1183 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Percent Accessible Residues profile ofFIG. 7;

(XLII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3F in any whole number increment up to 1183 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Average Flexibility profile of FIG. 8;

(XLIII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3F in any whole number increment up to 1183 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Beta-turn profile of FIG. 9

(XLIV) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3G in any whole number increment up to 1236 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XLV) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3G in any whole number increment up to 1236 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value less than 0.5 in the Hydropathicity profile of FIG. 6;

(XLVI) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3G in any whole number increment up to 1236 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Percent Accessible Residues profile ofFIG. 7;

(XLVII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3G in any whole number increment up to 1236 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Average Flexibility profile of FIG.

(XLVIII) a polynucleotide that encodes a peptide region of at least 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide ofFIG. 3G in any whole number increment up to 1236 that includes 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9

(XLIX) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3E in any whole number increment up to 1208 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(L) a polynucleotide that encodes a peptide region of at least 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3H in any whole number increment up to 1195 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value less than 0.5 in the Hydropathicity profile of FIG. 6;

(LI) a polynucleotide that encodes a peptide region of at least 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3H in any whole number increment up to 1195 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Percent Accessible Residues profile ofFIG. 7;

(LII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3H in any whole number increment up to 1195 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid positon(s) havinga value greater than 0.5 in the Average Flexibility profile of FIG. 8;

(LIII) a polynucleotide that encodes a peptide region of at least 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acids of a peptide of FIG.3H in any whole number increment up to 1195 that includes 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Beta-turn profile of FIG. 9

(LIV) a polynucleotide that is fully complementary to a polynucleotideof any one of (I)-(LIII).

(LV) a peptide that is encoded by any of (I) to (LIV); and

(LVI) a composition comprising a polynucleotide of any of (I)-(LIV) orpeptide of (LV) together with a pharmaceutical excipient and/or in ahuman unit dose form.

(LVII) a method of using a polynucleotide of any (I)-(LIV) or peptide of(LV) or a composition of (LVI) in a method to modulate a cell expressing282P1G3,

(LVIII) a method of using a polynucleotide of any (I)-(LIV) or peptideof (LV) or a composition of (LVI) in a method to diagnose, prophylax,prognose, or treat an individual who bears a cell expressing 282P1G3

(LIX) a method of using a polynucleotide of any (I)-(LIV) or peptide of(LV) or a composition of (LVI) in a method to diagnose, prophylax,prognose, or treat an individual who bears a cell expressing 282P1G3,said cell from a cancer of a tissue listed in Table I;

(LX) a method of using a polynucleotide of any (I)-(LIV) or peptide of(LV) or a composition of (LVI) in a method to diagnose, prophylax,prognose, or treat a a cancer;

(LXI) a method of using a polynucleotide of any (I)-(LIV) or peptide of(LV) or a composition of (LVI) in a method to diagnose, prophylax,prognose, or treat a a cancer of a tissue listed in Table I; and,

(LXII) a method of using a polynucleotide of any (I)-(LIV) or peptide of(LV) or a composition of (LVI) in a method to identify or characterize amodulator of a cell expressing 282P1G3.

As used herein, a range is understood to disclose specifically all wholeunit positions thereof.

Typical embodiments of the invention disclosed herein include 282P1G3polynucleotides that encode specific portions of 282P1G3 mRNA sequences(and those which are complementary to such sequences) such as those thatencode the proteins and/or fragments thereof, for example:

(a) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165,170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375,400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725,750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050,1075, 1100, 1125, 1150, 1175, 1200, 1210, 1220, and 1224 or morecontiguous amino acids of 282P1G3 variant 1; the maximal lengthsrelevant for other variants are: variant 2, 1171 amino acids; variant 3,893 amino acids, variant 4, 1117 amino acids, variant 5, 1208 aminoacids, variant 6, 1183 amono acids, variant 7, 1236 amino acids, variant8, 1195 amino acids, variant 9, 1224 amino acids, variant 10, 1224 aminoacids, variant 11, 1224 amino acids, variant 24, 1224 amino acids, andvariant 25, 1224 amino acids.

For example, representative embodiments of the invention disclosedherein include: polynucleotides and their encoded peptides themselvesencoding about amino acid 1 to about amino acid 10 of the 282P1G3protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about aminoacid 10 to about amino acid 20 of the 282P1G3 protein shown in FIG. 2 orFIG. 3, polynucleotides encoding about amino acid 20 to about amino acid30 of the 282P1G3 protein shown in FIG. 2 or FIG. 3, polynucleotidesencoding about amino acid 30 to about amino acid 40 of the 282P1G3protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about aminoacid 40 to about amino acid 50 of the 282P1G3 protein shown in FIG. 2 orFIG. 3, polynucleotides encoding about amino acid 50 to about amino acid60 of the 282P1G3 protein shown in FIG. 2 or FIG. 3, polynucleotidesencoding about amino acid 60 to about amino acid 70 of the 282P1G3protein shown in FIG. 2 or FIG. 3, polynucleotides encoding about aminoacid 70 to about amino acid 80 of the 282P1G3 protein shown in FIG. 2 orFIG. 3, polynucleotides encoding about amino acid 80 to about amino acid90 of the 282P1G3 protein shown in FIG. 2 or FIG. 3, polynucleotidesencoding about amino acid 90 to about amino acid 100 of the 282P1G3protein shown in FIG. 2 or FIG. 3, in increments of about 10 aminoacids, ending at the carboxyl terminal amino acid set forth in FIG. 2 orFIG. 3. Accordingly, polynucleotides encoding portions of the amino acidsequence (of about 10 amino acids), of amino acids, 100 through thecarboxyl terminal amino acid of the 282P1G3 protein are embodiments ofthe invention. Wherein it is understood that each particular amino acidposition discloses that position plus or minus five amino acid residues.

Polynucleotides encoding relatively long portions of a 282P1G3 proteinare also within the scope of the invention. For example, polynucleotidesencoding from about amino acid 1 (or 20 or 30 or 40 etc.) to about aminoacid 20, (or 30, or 40 or 50 etc.) of the 282P1G3 protein “or variant”shown in FIG. 2 or FIG. 3 can be generated by a variety of techniqueswell known in the art. These polynucleotide fragments can include anyportion of the 282P1G3 sequence as shown in FIG. 2.

Additional illustrative embodiments of the invention disclosed hereininclude 282P1G3 polynucleotide fragments encoding one or more of thebiological motifs contained within a 282P1G3 protein “or variant”sequence, including one or more of the motif-bearing subsequences of a282P1G3 protein “or variant” set forth in Tables VIII-XXI and XXII-XLIX.In another embodiment, typical polynucleotide fragments of the inventionencode one or more of the regions of 282P1G3 protein or variant thatexhibit homology to a known molecule. In another embodiment of theinvention, typical polynucleotide fragments can encode one or more ofthe 282P1G3 protein or variant N-glycosylation sites, cAMP andcGMP-dependent protein kinase phosphorylation sites, casein kinase 11phosphorylation sites or N-myristoylation site and amidation sites.

Note that to determine the starting position of any peptide set forth inTables VIII-XXI and Tables XXII to XLIX (collectively HLA PeptideTables) respective to its parental protein, e.g., variant 1, variant 2,etc., reference is made to three factors: the particular variant, thelength of the peptide in an HLA Peptide Table, and the Search Peptideslisted in Table VII. Generally, a unique Search Peptide is used toobtain HLA peptides for a particular variant. The position of eachSearch Peptide relative to its respective parent molecule is listed inTable VII. Accordingly, if a Search Peptide begins at position “X”, onemust add the value “X minus 1” to each position in Tables VIII-XXI andTables XXII-IL to obtain the actual position of the HLA peptides intheir parental molecule. For example if a particular Search Peptidebegins at position 150 of its parental molecule, one must add 150−1,i.e., 149 to each HLA peptide amino acid position to calculate theposition of that amino acid in the parent molecule.

II.A.) Uses of 282P1G3 Polynucleotides

II.A.1.) Monitoring of Genetic Abnormalities

The polynucleotides of the preceding paragraphs have a number ofdifferent specific uses. The human 282P1G3 gene maps to the chromosomallocation set forth in the Example entitled “Chromosomal Mapping of282P1G3.” For example, because the 282P1G3 gene maps to this chromosome,polynucleotides that encode different regions of the 282P1G3 proteinsare used to characterize cytogenetic abnormalities of this chromosomallocale, such as abnormalities that are identified as being associatedwith various cancers. In certain genes, a variety of chromosomalabnormalities including rearrangements have been identified as frequentcytogenetic abnormalities in a number of different cancers (see e.g.Krajinovic et al., Mutat. Res. 382(3-4): 81-83(1998); Johansson et al.,Blood 86(10): 3905-3914(1995) and Finger et al., P.N.A.S. 85(23):9158-9162 (1988)). Thus, polynucleotides encoding specific regions ofthe 282P1G3 proteins provide new tools that can be used to delineate,with greater precision than previously possible, cytogeneticabnormalities in the chromosomal region that encodes 282P1G3 that maycontribute to the malignant phenotype. In this context, thesepolynucleotides satisfy a need in the art for expanding the sensitivityof chromosomal screening in order to identify more subtle and lesscommon chromosomal abnormalities (see e.g. Evans et al., Am. J. Obstet.Gynecol 171(4): 1055-1057 (1994)).

Furthermore, as 282P1G3 was shown to be highly expressed in prostate andother cancers, 282P1G3 polynucleotides are used in methods assessing thestatus of 282P1G3 gene products in normal versus cancerous tissues.Typically, polynucleotides that encode specific regions of the 282P1G3proteins are used to assess the presence of perturbations (such asdeletions, insertions, point mutations, or alterations resulting in aloss of an antigen etc.) in specific regions of the 282P1G3 gene, suchas regions containing one or more motifs. Exemplary assays include bothRT-PCR assays as well as single-strand conformation polymorphism (SSCP)analysis (see, e.g., Marrogi et al., J. Cutan. Pathol. 26(8): 369-378(1999), both of which utilize polynucleotides encoding specific regionsof a protein to examine these regions within the protein.

II.A.2.) Antisense Embodiments

Other specifically contemplated nucleic acid related embodiments of theinvention disclosed herein are genomic DNA, cDNAs, ribozymes, andantisense molecules, as well as nucleic acid molecules based on analternative backbone, or including alternative bases, whether derivedfrom natural sources or synthesized, and include molecules capable ofinhibiting the RNA or protein expression of 282P1G3. For example,antisense molecules can be RNAs or other molecules, including peptidenucleic acids (PNAs) or non-nucleic acid molecules such asphosphorothioate derivatives that specifically bind DNA or RNA in a basepair-dependent manner. A skilled artisan can readily obtain theseclasses of nucleic acid molecules using the 282P1G3 polynucleotides andpolynucleotide sequences disclosed herein.

Antisense technology entails the administration of exogenousoligonucleotides that bind to a target polynucleotide located within thecells. The term “antisense” refers to the fact that sucholigonucleotides are complementary to their intracellular targets, e.g.,282P1G3. See for example, Jack Cohen, Oligodeoxynucleotides, AntisenseInhibitors of Gene Expression, CRC Press, 1989; and Synthesis 1:1-5(1988). The 282P1G3 antisense oligonucleotides of the present inventioninclude derivatives such as S-oligonucleotides (phosphorothioatederivatives or S-oligos, see, Jack Cohen, supra), which exhibit enhancedcancer cell growth inhibitory action. S-oligos (nucleosidephosphorothioates) are isoelectronic analogs of an oligonucleotide(O-oligo) in which a nonbridging oxygen atom of the phosphate group isreplaced by a sulfur atom. The S-oligos of the present invention can beprepared by treatment of the corresponding O-oligos with3H-1,2-benzodithiol-3-one-1,1-dioxide, which is a sulfur transferreagent. See, e.g., Iyer, R. P. et al., J. Org. Chem. 55:4693-4698(1990); and Iyer, R. P. et al., J. Am. Chem. Soc. 112:1253-1254 (1990).Additional 282P1G3 antisense oligonucleotides of the present inventioninclude morpholino antisense oligonucleotides known in the art (see,e.g., Partridge et al., 1996, Antisense & Nucleic Acid Drug Development6: 169-175).

The 282P1G3 antisense oligonucleotides of the present inventiontypically can be RNA or DNA that is complementary to and stablyhybridizes with the first 100 5′ codons or last 100 3′ codons of a282P1G3 genomic sequence or the corresponding mRNA. Absolutecomplementarity is not required, although high degrees ofcomplementarity are preferred. Use of an oligonucleotide complementaryto this region allows for the selective hybridization to 282P1G3 mRNAand not to mRNA specifying other regulatory subunits of protein kinase.In one embodiment, 282P1G3 antisense oligonucleotides of the presentinvention are 15 to 30-mer fragments of the antisense DNA molecule thathave a sequence that hybridizes to 282P1G3 mRNA. Optionally, 282P1G3antisense oligonucleotide is a 30-mer oligonucleotide that iscomplementary to a region in the first 10 5′ codons or last 10 3′ codonsof 282P1G3. Alternatively, the antisense molecules are modified toemploy ribozymes in the inhibition of 282P1G3 expression, see, e.g., L.A. Couture & D. T. Stinchcomb; Trends Genet 12: 510-515 (1996).

II.A.3.) Primers and Primer Pairs

Further specific embodiments of these nucleotides of the inventioninclude primers and primer pairs, which allow the specific amplificationof polynucleotides of the invention or of any specific parts thereof,and probes that selectively or specifically hybridize to nucleic acidmolecules of the invention or to any part thereof. Probes can be labeledwith a detectable marker, such as, for example, a radioisotope,fluorescent compound, bioluminescent compound, a chemiluminescentcompound, metal chelator or enzyme. Such probes and primers are used todetect the presence of a 282P1G3 polynucleotide in a sample and as ameans for detecting a cell expressing a 282P1G3 protein.

Examples of such probes include polypeptides comprising all or part ofthe human 282P1G3 cDNA sequence shown in FIG. 2. Examples of primerpairs capable of specifically amplifying 282P1G3 mRNAs are alsodescribed in the Examples. As will be understood by the skilled artisan,a great many different primers and probes can be prepared based on thesequences provided herein and used effectively to amplify and/or detecta 282P1G3 mRNA.

The 282P1G3 polynucleotides of the invention are useful for a variety ofpurposes, including but not limited to their use as probes and primersfor the amplification and/or detection of the 282P1G3 gene(s), mRNA(s),or fragments thereof; as reagents for the diagnosis and/or prognosis ofprostate cancer and other cancers; as coding sequences capable ofdirecting the expression of 282P1G3 polypeptides; as tools formodulating or inhibiting the expression of the 282P1G3 gene(s) and/ortranslation of the 282P1G3 transcript(s); and as therapeutic agents.

The present invention includes the use of any probe as described hereinto identify and isolate a 282P1G3 or 282P1G3 related nucleic acidsequence from a naturally occurring source, such as humans or othermammals, as well as the isolated nucleic acid sequence per se, whichwould comprise all or most of the sequences found in the probe used.

II.A.4.) Isolation of 282P1G3-Encoding Nucleic Acid Molecules

The 282P1G3 cDNA sequences described herein enable the isolation ofother polynucleotides encoding 282P1G3 gene product(s), as well as theisolation of polynucleotides encoding 282P1G3 gene product homologs,alternatively spliced isoforms, allelic variants, and mutant forms of a282P1G3 gene product as well as polynucleotides that encode analogs of282P1G3-related proteins. Various molecular cloning methods that can beemployed to isolate full length cDNAs encoding a 282P1G3 gene are wellknown (see, for example, Sambrook, J. et al., Molecular Cloning: ALaboratory Manual, 2d edition, Cold Spring Harbor Press, New York, 1989;Current Protocols in Molecular Biology. Ausubel et al., Eds., Wiley andSons, 1995). For example, lambda phage cloning methodologies can beconveniently employed, using commercially available cloning systems(e.g., Lambda ZAP Express, Stratagene). Phage clones containing 282P1G3gene cDNAs can be identified by probing with a labeled 282P1G3 cDNA or afragment thereof. For example, in one embodiment, a 282P1G3 cDNA (e.g.,FIG. 2) or a portion thereof can be synthesized and used as a probe toretrieve overlapping and full-length cDNAs corresponding to a 282P1G3gene. A 282P1G3 gene itself can be isolated by screening genomic DNAlibraries, bacterial artificial chromosome libraries (BACs), yeastartificial chromosome libraries (YACs), and the like, with 282P1G3 DNAprobes or primers.

II.A.5.) Recombinant Nucleic Acid Molecules and Host-Vector Systems

The invention also provides recombinant DNA or RNA molecules containinga 282P1G3 polynucleotide, a fragment, analog or homologue thereof,including but not limited to phages, plasmids, phagemids, cosmids, YACs,BACs, as well as various viral and non-viral vectors well known in theart, and cells transformed or transfected with such recombinant DNA orRNA molecules. Methods for generating such molecules are well known(see, for example, Sambrook et al., 1989, supra).

The invention further provides a host-vector system comprising arecombinant DNA molecule containing a 282P1G3 polynucleotide, fragment,analog or homologue thereof within a suitable prokaryotic or eukaryotichost cell. Examples of suitable eukaryotic host cells include a yeastcell, a plant cell, or an animal cell, such as a mammalian cell or aninsect cell (e.g., a baculovirus-infectible cell such as an Sf9 orHighFive cell). Examples of suitable mammalian cells include variousprostate cancer cell lines such as DU145 and TsuPr1, other transfectableor transducible prostate cancer cell lines, primary cells (PrEC), aswell as a number of mammalian cells routinely used for the expression ofrecombinant proteins (e.g., COS, CHO, 293, 293T cells). Moreparticularly, a polynucleotide comprising the coding sequence of 282P1G3or a fragment, analog or homolog thereof can be used to generate 282P1G3proteins or fragments thereof using any number of host-vector systemsroutinely used and widely known in the art.

A wide range of host-vector systems suitable for the expression of282P1G3 proteins or fragments thereof are available, see for example,Sambrook et al., 1989, supra; Current Protocols in Molecular Biology,1995, supra). Preferred vectors for mammalian expression include but arenot limited to pcDNA 3.1 myc-His-tag (Invitrogen) and the retroviralvector pSRαtkneo (Muller et al., 1991, MCB 11:1785). Using theseexpression vectors, 282P1G3 can be expressed in several prostate cancerand non-prostate cell lines, including for example 293, 293T, rat-1, NIH3T3 and TsuPr1. The host-vector systems of the invention are useful forthe production of a 282P1G3 protein or fragment thereof. Suchhost-vector systems can be employed to study the functional propertiesof 282P1G3 and 282P1G3 mutations or analogs.

Recombinant human 282P1G3 protein or an analog or homolog or fragmentthereof can be produced by mammalian cells transfected with a constructencoding a 282P1G3-related nucleotide. For example, 293T cells can betransfected with an expression plasmid encoding 282P1G3 or fragment,analog or homolog thereof, a 282P1G3-related protein is expressed in the293T cells, and the recombinant 282P1G3 protein is isolated usingstandard purification methods (e.g., affinity purification usinganti-282P1G3 antibodies). In another embodiment, a 282P1G3 codingsequence is subcloned into the retroviral vector pSRαMSVtkneo and usedto infect various mammalian cell lines, such as NIH 3T3, TsuPr1, 293 andrat-1 in order to establish 282P1G3 expressing cell lines. Various otherexpression systems well known in the art can also be employed.Expression constructs encoding a leader peptide joined in frame to a282P1G3 coding sequence can be used for the generation of a secretedform of recombinant 282P1G3 protein.

As discussed herein, redundancy in the genetic code permits variation in282P1G3 gene sequences. In particular, it is known in the art thatspecific host species often have specific codon preferences, and thusone can adapt the disclosed sequence as preferred for a desired host.For example, preferred analog codon sequences typically have rare codons(i.e., codons having a usage frequency of less than about 20% in knownsequences of the desired host) replaced with higher frequency codons.Codon preferences for a specific species are calculated, for example, byutilizing codon usage tables available on the INTERNET.

Additional sequence modifications are known to enhance proteinexpression in a cellular host. These include elimination of sequencesencoding spurious polyadenylation signals, exon/intron splice sitesignals, transposon-like repeats, and/or other such well-characterizedsequences that are deleterious to gene expression. The GC content of thesequence is adjusted to levels average for a given cellular host, ascalculated by reference to known genes expressed in the host cell. Wherepossible, the sequence is modified to avoid predicted hairpin secondarymRNA structures. Other useful modifications include the addition of atranslational initiation consensus sequence at the start of the openreading frame, as described in Kozak, Mol. Cell Biol., 9:5073-5080(1989). Skilled artisans understand that the general rule thateukaryotic ribosomes initiate translation exclusively at the 5′ proximalAUG codon is abrogated only under rare conditions (see, e.g., Kozak PNAS92(7): 2662-2666, (1995) and Kozak NAR 15(20): 8125-8148 (1987)).

III.) 282P1G3-Related Proteins

Another aspect of the present invention provides 282P1G3-relatedproteins. Specific embodiments of 282P1G3 proteins comprise apolypeptide having all or part of the amino acid sequence of human282P1G3 as shown in FIG. 2 or FIG. 3. Alternatively, embodiments of282P1G3 proteins comprise variant, homolog or analog polypeptides thathave alterations in the amino acid sequence of 282P1G3 shown in FIG. 2or FIG. 3.

Embodiments of a 282P1G3 polypeptide include: a 282P1G3 polypeptidehaving a sequence shown in FIG. 2, a peptide sequence of a 282P1G3 asshown in FIG. 2 wherein T is U; at least 10 contiguous nucleotides of apolypeptide having the sequence as shown in FIG. 2; or, at least 10contiguous peptides of a polypeptide having the sequence as shown inFIG. 2 where T is U. For example, embodiments of 282P1G3 peptidescomprise, without limitation:

(I) a protein comprising, consisting essentially of, or consisting of anamino acid sequence as shown in FIG. 2A-J or FIG. 3A-M;

(II) a 282P1G3-related protein that is at least 90, 91, 92, 93, 94, 95,96, 97, 98, 99 or 100% homologous to an entire amino acid sequence shownin FIG. 2A-J or 3A-M;

(III) a 282P1G3-related protein that is at least 90, 91, 92, 93, 94, 95,96, 97, 98, 99 or 100% identical to an entire amino acid sequence shownin FIG. 2A-J or 3A-M;

(IV) a protein that comprises at least one peptide set forth in TablesVIII to XLIX, optionally with a proviso that it is not an entire proteinof FIG. 2;

(V) a protein that comprises at least one peptide set forth in TablesVIII-XXI, collectively, which peptide is also set forth in Tables XXIIto XLIX, collectively, optionally with a proviso that it is not anentire protein of FIG. 2;

(VI) a protein that comprises at least two peptides selected from thepeptides set forth in Tables VIII-XLIX, optionally with a proviso thatit is not an entire protein of FIG. 2;

(VII) a protein that comprises at least two peptides selected from thepeptides set forth in Tables VIII to XLIX collectively, with a provisothat the protein is not a contiguous sequence from an amino acidsequence of FIG. 2;

(VIII) a protein that comprises at least one peptide selected from thepeptides set forth in Tables VIII-XXI; and at least one peptide selectedfrom the peptides set forth in Tables XXII to XLIX, with a proviso thatthe protein is not a contiguous sequence from an amino acid sequence ofFIG. 2;

(IX) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3A, 3I-3M in any wholenumber increment up to 1224 respectively that includes at least 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Hydrophilicityprofile of FIG. 5;

(x) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,33, 34, 35 amino acids of a protein of FIG. 3A, 3I-3M, in any wholenumber increment up to 1224 respectively that includes at least at least1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value less than 0.5 in the Hydropathicity profileof FIG. 6;

(XI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3A, 3I-3M, in any wholenumber increment up to 1224 respectively that includes at least at least1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Percent AccessibleResidues profile of FIG. 7;

(XII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3A, 3I-3M, in any wholenumber increment up to 1224 respectively that includes at least at least1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Average Flexibilityprofile of FIG. 8;

(XIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, amino acids of a protein of FIG. 3A, 3I-3M in any wholenumber increment up to 1224 respectively that includes at least at least1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9;

(XIV) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3B, in any whole numberincrement up to 1171 respectively that includes at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XV) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3B, in any whole numberincrement up to 1171 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value less than 0.5 in the Hydropathicity profileof FIG. 6;

(XVI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3B, in any whole numberincrement up to 1171 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Percent AccessibleResidues profile of FIG. 7;

(XVII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3B, in any whole numberincrement up to 1171 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Average Flexibilityprofile of FIG. 8;

(XVIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, amino acids of a protein of FIG. 3B in any whole numberincrement up to 1171 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9;

(XIX) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3C, in any whole numberincrement up to 893 respectively that includes at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XX) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3C, in any whole numberincrement up to 893 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value less than 0.5 in the Hydropathicity profileof FIG. 6;

(XXI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3C, in any whole numberincrement up to 893 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Percent AccessibleResidues profile of FIG. 7;

(XXII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3C, in any whole numberincrement up to 893 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Average Flexibilityprofile of FIG. 8;

(XXIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, amino acids of a protein of FIG. 3C in any whole numberincrement up to 893 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9;

(XXIV) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3D, in any whole numberincrement up to 1117 respectively that includes at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XXV) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3D, in any whole numberincrement up to 1117 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value less than 0.5 in the Hydropathicity profileof FIG. 6;

(XXVI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3D, in any whole numberincrement up to 1117 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Percent AccessibleResidues profile of FIG. 7;

(XXVII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3D, in any whole numberincrement up to 1117 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Average Flexibilityprofile of FIG. 8;

(XXVIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,31, 32, 33, 34, amino acids of a protein of FIG. 3D in any whole numberincrement up to 1117 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9;

(XXIX) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3E, in any whole numberincrement up to 1208 respectively that includes at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XXX) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3E, in any whole numberincrement up to 1208 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value less than 0.5 in the Hydropathicity profileof FIG. 6;

(XXXI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3E, in any whole numberincrement up to 1208 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Percent AccessibleResidues profile of FIG. 7;

(XXXII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3E, in any whole numberincrement up to 1208 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Average Flexibilityprofile of FIG. 8;

(XXXIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,31, 32, 33, 34, amino acids of a protein of FIG. 3E in any whole numberincrement up to 1208 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9;

(XXXIV) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3F, in any whole numberincrement up to 1183 respectively that includes at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XXXV) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3F, in any whole numberincrement up to 1183 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value less than 0.5 in the Hydropathicity profileof FIG. 6;

(XXXVI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3F, in any whole numberincrement up to 1183 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Percent AccessibleResidues profile of FIG. 7;

(XXXVII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,31, 32, 33, 34, 35 amino acids of a protein of FIG. 3F, in any wholenumber increment up to 1183 respectively that includes at least at least1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Average Flexibilityprofile of FIG. 8;

(XXXVIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,31, 32, 33, 34, amino acids of a protein of FIG. 3F in any whole numberincrement up to 1183 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9;

(XXXIX) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3G, in any whole numberincrement up to 1236 respectively that includes at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XL) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3G, in any whole numberincrement up to 1236 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value less than 0.5 in the Hydropathicity profileof FIG. 6;

(XLI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3G, in any whole numberincrement up to 1236 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Percent AccessibleResidues profile of FIG. 7;

(XLII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3G, in any whole numberincrement up to 1236 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Average Flexibilityprofile of FIG. 8;

(XLIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, amino acids of a protein of FIG. 3G in any whole numberincrement up to 1236 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9;

(XLIV) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3H, in any whole numberincrement up to 1195 respectively that includes at least 1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acid position(s) havinga value greater than 0.5 in the Hydrophilicity profile of FIG. 5;

(XLV) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3H, in any whole numberincrement up to 1195 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value less than 0.5 in the Hydropathicity profileof FIG. 6;

(XLVI) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3H, in any whole numberincrement up to 1195 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Percent AccessibleResidues profile of FIG. 7;

(XLVII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,32, 33, 34, 35 amino acids of a protein of FIG. 3H, in any whole numberincrement up to 1195 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Average Flexibilityprofile of FIG. 8;

(XLVIII) a polypeptide comprising at least 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,31, 32, 33, 34, amino acids of a protein of FIG. 3H in any whole numberincrement up to 1195 respectively that includes at least at least 1, 2,3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 amino acidposition(s) having a value greater than 0.5 in the Beta-turn profile ofFIG. 9;

(XLIX) a peptide that occurs at least twice in Tables VIII-XXI and XXIIto XLIX, collectively;

(L) a peptide that occurs at least three times in Tables VIII-XXI andXXII to XLIX, collectively;

(LI) a peptide that occurs at least four times in Tables VIII-XXI andXXII to XLIX, collectively;

(LII) a peptide that occurs at least five times in Tables VIII-XXI andXXII to XLIX, collectively;

(LIII) a peptide that occurs at least once in Tables VIII-XXI, and atleast once in tables XXII to XLIX;

(LIV) a peptide that occurs at least once in Tables VIII-XXI, and atleast twice in tables XXII to XLIX;

(LV) a peptide that occurs at least twice in Tables VIII-XXI, and atleast once in tables XXII to XLIX;

(LVI) a peptide that occurs at least twice in Tables VIII-XXI, and atleast twice in tables XXII to XLIX;

(LVII) a peptide which comprises one two, three, four, or five of thefollowing characteristics, or an oligonucleotide encoding such peptide:

-   -   i) a region of at least 5 amino acids of a particular peptide of        FIG. 3, in any whole number increment up to the full length of        that protein in FIG. 3, that includes an amino acid position        having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9,        or having a value equal to 1.0, in the Hydrophilicity profile of        FIG. 5;    -   ii) a region of at least 5 amino acids of a particular peptide        of FIG. 3, in any whole number increment up to the full length        of that protein in FIG. 3, that includes an amino acid position        having a value equal to or less than 0.5, 0.4, 0.3, 0.2, 0.1, or        having a value equal to 0.0, in the Hydropathicity profile of        FIG. 6;    -   iii) a region of at least 5 amino acids of a particular peptide        of FIG. 3, in any whole number increment up to the full length        of that protein in FIG. 3, that includes an amino acid position        having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9,        or having a value equal to 1.0, in the Percent Accessible        Residues profile of FIG. 7;    -   iv) a region of at least 5 amino acids of a particular peptide        of FIG. 3, in any whole number increment up to the full length        of that protein in FIG. 3, that includes an amino acid position        having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9,        or having a value equal to 1.0, in the Average Flexibility        profile of FIG. 8; or,    -   v) a region of at least 5 amino acids of a particular peptide of        FIG. 3, in any whole number increment up to the full length of        that protein in FIG. 3, that includes an amino acid position        having a value equal to or greater than 0.5, 0.6, 0.7, 0.8, 0.9,        or having a value equal to 1.0, in the Beta-turn profile of FIG.        9;

(LVIII) a composition comprising a peptide of (I)-(LVII) or an antibodyor binding region thereof together with a pharmaceutical excipientand/or in a human unit dose form.

(LIX) a method of using a peptide of (I)-(LVII), or an antibody orbinding region thereof or a composition of (LVIII) in a method tomodulate a cell expressing 282P1G3,

(LX) a method of using a peptide of (I)-(LVII) or an antibody or bindingregion thereof or a composition of (LVIII) in a method to diagnose,prophylax, prognose, or treat an individual who bears a cell expressing282P1G3

(LXI) a method of using a peptide of (1)-(LVII) or an antibody orbinding region thereof or a composition (LVIII) in a method to diagnose,prophylax, prognose, or treat an individual who bears a cell expressing282P1G3, said cell from a cancer of a tissue listed in Table I;

(LXII) a method of using a peptide of (I)-(LVII) or an antibody orbinding region thereof or a composition of (LVIII) in a method todiagnose, prophylax, prognose, or treat a a cancer;

(LXIII) a method of using a peptide of (I)-(LVII) or an antibody orbinding region thereof or a composition of (LVIII) in a method todiagnose, prophylax, prognose, or treat a cancer of a tissue listed inTable I; and,

(LXIV) a method of using a a peptide of (1)-(LVII) or an antibody orbinding region thereof or a composition (LVIII) in a method to identifyor characterize a modulator of a cell expressing 282P1G3.

As used herein, a range is understood to specifically disclose all wholeunit positions thereof.

Typical embodiments of the invention disclosed herein include 282P1G3polynucleotides that encode specific portions of 282P1G3 mRNA sequences(and those which are complementary to such sequences) such as those thatencode the proteins and/or fragments thereof, for example:

(a) 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165,170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 350, 375,400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725,750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050,1075, 1100, 1125, 1150, 1175, 1200, 1210, 1215, 1220, and 1224 or morecontiguous amino acids of 282P1G3 variant 1; the maximal lengthsrelevant for other variants are: variant 2, 1171 amino acids; variant 3,893 amino acids, variant 4, 1117 amino acids, variant 5, 1208 aminoacids, variant 6, 1183 amino acids, variant 7, 1236 amino acids, variant8, 1195 amino acids, variant 9, 1224 amino acids, variant 10, 1224 aminoacids, variant 11, 1224 amino acids, variant 24, 1224 amino acids, andvariant 25, 1224 amino acids.

In general, naturally occurring alelic variants of human 282P1G3 share ahigh degree of structural identity and homology (e.g., 90% or morehomology). Typically, allelic variants of a 282P1G3 protein containconservative amino acid substitutions within the 282P1G3 sequencesdescribed herein or contain a substitution of an amino acid from acorresponding position in a homologue of 282P1G3. One class of 282P1G3allelic variants are proteins that share a high degree of homology withat least a small region of a particular 282P1G3 amino acid sequence, butfurther contain a radical departure from the sequence, such as anon-conservative substitution, truncation, insertion or frame shift. Incomparisons of protein sequences, the terms, similarity, identity, andhomology each have a distinct meaning as appreciated in the field ofgenetics. Moreover, orthology and paralogy can be important conceptsdescribing the relationship of members of a given protein family in oneorganism to the members of the same family in other organisms.

Amino acid abbreviations are provided in Table II. Conservative aminoacid substitutions can frequently be made in a protein without alteringeither the conformation or the function of the protein. Proteins of theinvention can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15conservative substitutions. Such changes include substituting any ofisoleucine (I), valine (V), and leucine (L) for any other of thesehydrophobic amino acids; aspartic acid (D) for glutamic acid (E) andvice versa; glutamine (O) for asparagine (N) and vice versa; and serine(S) for threonine (T) and vice versa. Other substitutions can also beconsidered conservative, depending on the environment of the particularamino acid and its role in the three-dimensional structure of theprotein. For example, glycine (G) and alanine (A) can frequently beinterchangeable, as can alanine (A) and valine (V). Methionine (M),which is relatively hydrophobic, can frequently be interchanged withleucine and isoleucine, and sometimes with valine. Lysine (K) andarginine (R) are frequently interchangeable in locations in which thesignificant feature of the amino acid residue is its charge and thediffering pK's of these two amino acid residues are not significant.Still other changes can be considered “conservative” in particularenvironments (see, e.g. Table III herein; pages 13-15 “Biochemistry” 2ndED. Lubert Stryer ed (Stanford University); Henikoff et al., PNAS 1992Vol 89 10915-10919; Lei et al., J Biol Chem 1995 May 19;270(20):11882-6).

Embodiments of the invention disclosed herein include a wide variety ofart-accepted variants or analogs of 282P1G3 proteins such aspolypeptides having amino acid insertions, deletions and substitutions.282P1G3 variants can be made using methods known in the art such assite-directed mutagenesis, alanine scanning, and PCR mutagenesis.Site-directed mutagenesis (Carter et al., Nucl. Acids Res., 13:4331(1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)), cassettemutagenesis (Wells et al., Gene, 34:315 (1985)), restriction selectionmutagenesis (Wells et al., Philos. Trans. R. Soc. London SerA, 317:415(1986)) or other known techniques can be performed on the cloned DNA toproduce the 282P1G3 variant DNA.

Scanning amino acid analysis can also be employed to identify one ormore amino acids along a contiguous sequence that is involved in aspecific biological activity such as a protein-protein interaction.Among the preferred scanning amino acids are relatively small, neutralamino acids. Such amino acids include alanine, glycine, serine, andcysteine. Alanine is typically a preferred scanning amino acid amongthis group because it eliminates the side-chain beyond the beta-carbonand is less likely to alter the main-chain conformation of the variant.Alanine is also typically preferred because it is the most common aminoacid. Further, it is frequently found in both buried and exposedpositions (Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia,J. Mol. Biol., 150:1 (1976)). If alanine substitution does not yieldadequate amounts of variant, an isosteric amino acid can be used.

As defined herein, 282P1G3 variants, analogs or homologs, have thedistinguishing attribute of having at least one epitope that is “crossreactive” with a 282P1G3 protein having an amino acid sequence of FIG.3. As used in this sentence, “cross reactive” means that an antibody orT cell that specifically binds to a 282P1G3 variant also specificallybinds to a 282P1G3 protein having an amino acid sequence set forth inFIG. 3. A polypeptide ceases to be a variant of a protein shown in FIG.3, when it no longer contains any epitope capable of being recognized byan antibody or T cell that specifically binds to the starting 282P1G3protein. Those skilled in the art understand that antibodies thatrecognize proteins bind to epitopes of varying size, and a grouping ofthe order of about four or five amino acids, contiguous or not, isregarded as a typical number of amino acids in a minimal epitope. See,e.g., Nair et al., J. Immunol 2000 165(12): 6949-6955; Hebbes et al.,Mol Immunol (1989) 26(9):865-73; Schwartz et al., J Immunol (1985)135(4):2598-608.

Other classes of 282P1G3-related protein variants share 70%, 75%, 80%,85% or 90% or more similarity with an amino acid sequence of FIG. 3, ora fragment thereof. Another specific class of 282P1G3 protein variantsor analogs comprises one or more of the 282P1G3 biological motifsdescribed herein or presently known in the art. Thus, encompassed by thepresent invention are analogs of 282P1G3 fragments (nucleic or aminoacid) that have altered functional (e.g. immunogenic) propertiesrelative to the starting fragment. It is to be appreciated that motifsnow or which become part of the art are to be applied to the nucleic oramino acid sequences of FIG. 2 or FIG. 3.

As discussed herein, embodiments of the claimed invention includepolypeptides containing less than the full amino acid sequence of a282P1G3 protein shown in FIG. 2 or FIG. 3. For example, representativeembodiments of the invention comprise peptides/proteins having any 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids of a282P1G3 protein shown in FIG. 2 or FIG. 3.

Moreover, representative embodiments of the invention disclosed hereininclude polypeptides consisting of about amino acid 1 to about aminoacid 10 of a 282P1G3 protein shown in FIG. 2 or FIG. 3, polypeptidesconsisting of about amino acid 10 to about amino acid 20 of a 282P1G3protein shown in FIG. 2 or FIG. 3, polypeptides consisting of aboutamino acid 20 to about amino acid 30 of a 282P1G3 protein shown in FIG.2 or FIG. 3, polypeptides consisting of about amino acid 30 to aboutamino acid 40 of a 282P1G3 protein shown in FIG. 2 or FIG. 3,polypeptides consisting of about amino acid 40 to about amino acid 50 ofa 282P1G3 protein shown in FIG. 2 or FIG. 3, polypeptides consisting ofabout amino acid 50 to about amino acid 60 of a 282P1G3 protein shown inFIG. 2 or FIG. 3, polypeptides consisting of about amino acid 60 toabout amino acid 70 of a 282P1G3 protein shown in FIG. 2 or FIG. 3,polypeptides consisting of about amino acid 70 to about amino acid 80 ofa 282P1G3 protein shown in FIG. 2 or FIG. 3, polypeptides consisting ofabout amino acid 80 to about amino acid 90 of a 282P1G3 protein shown inFIG. 2 or FIG. 3, polypeptides consisting of about amino acid 90 toabout amino acid 100 of a 282P1G3 protein shown in FIG. 2 or FIG. 3,etc. throughout the entirety of a 282P1G3 amino acid sequence. Moreover,polypeptides consisting of about amino acid 1 (or 20 or 30 or 40 etc.)to about amino acid 20, (or 130, or 140 or 150 etc.) of a 282P1G3protein shown in FIG. 2 or FIG. 3 are embodiments of the invention. Itis to be appreciated that the starting and stopping positions in thisparagraph refer to the specified position as well as that position plusor minus 5 residues.

282P1G3-related proteins are generated using standard peptide synthesistechnology or using chemical cleavage methods well known in the art.Alternatively, recombinant methods can be used to generate nucleic acidmolecules that encode a 282P1G3-related protein. In one embodiment,nucleic acid molecules provide a means to generate defined fragments ofa 282P1G3 protein (or variants, homologs or analogs thereof).

III.A.) Motif-Bearing Protein Embodiments

Additional illustrative embodiments of the invention disclosed hereininclude 282P1G3 polypeptides comprising the amino acid residues of oneor more of the biological motifs contained within a 282P1G3 polypeptidesequence set forth in FIG. 2 or FIG. 3. Various motifs are known in theart, and a protein can be evaluated for the presence of such motifs by anumber of publicly available Internet sites (see, e.g., Epimabix™andEpimer™, Brown University, and BIMAS).

Motif bearing subsequences of all 282P1G3 variant proteins are set forthand identified in Tables VIII-XXI and XXII-XLIX.

Table V sets forth several frequently occurring motifs based on pfamsearches on the INTERNET. The columns of Table V list (1) motif nameabbreviation, (2) percent identity found amongst the different member ofthe motif family, (3) motif name or description and (4) most commonfunction; location information is included if the motif is relevant forlocation.

Polypeptides comprising one or more of the 282P1G3 motifs discussedabove are useful in elucidating the specific characteristics of amalignant phenotype in view of the observation that the 282P1G3 motifsdiscussed above are associated with growth dysregulation and because282P1G3 is overexpressed in certain cancers (See, e.g., Table I). Caseinkinase 11, cAMP and camp-dependent protein kinase, and Protein Kinase C,for example, are enzymes known to be associated with the development ofthe malignant phenotype (see e.g. Chen et al., Lab Invest., 78(2):165-174 (1998); Gaiddon et al., Endocrinology 136(10): 4331-4338 (1995);Hall et al., Nucleic Acids Research 24(6): 1119-1126 (1996); Peterzielet al., Oncogene 18(46): 6322-6329 (1999) and O'Brian, Oncol. Rep. 5(2):305-309 (1998)). Moreover, both glycosylation and myristoylation areprotein modifications also associated with cancer and cancer progression(see e.g. Dennis et al., Biochem. Biophys. Acta 1473(1):21-34 (1999);Raju et al., Exp. Cell Res. 235(1): 145-154 (1997)). Amidation isanother protein modification also associated with cancer and cancerprogression (see e.g. Treston et al., J. Natl. Cancer Inst. Monogr.(13): 169-175 (1992)).

In another embodiment, proteins of the invention comprise one or more ofthe immunoreactive epitopes identified in accordance with art-acceptedmethods, such as the peptides set forth in Tables VIII-XXI andXXII-XLIX. CTL epitopes can be determined using specific algorithms toidentify peptides within a 282P1G3 protein that are capable ofoptionally binding to specified HLA alleles (e.g., Table IV; Epimatrix™and Epimer™, Brown University, and BIMAS). Moreover, processes foridentifying peptides that have sufficient binding affinity for HLAmolecules and which are correlated with being immunogenic epitopes, arewell known in the art, and are carried out without undueexperimentation. In addition, processes for identifying peptides thatare immunogenic epitopes, are well known in the art, and are carried outwithout undue experimentation either in vitro or in vivo.

Also known in the art are principles for creating analogs of suchepitopes in order to modulate immunogenicity. For example, one beginswith an epitope that bears a CTL or HTL motif (see, e.g., the HLA ClassI and HLA Class II motifs/supermotifs of Table IV): The epitope isanaloged by substituting out an amino acid at one of the specifiedpositions, and replacing it with another amino acid specified for thatposition. For example, on the basis of residues defined in Table IV, onecan substitute out a deleterious residue in favor of any other residue,such as a preferred residue; substitute a less-preferred residue with apreferred residue; or substitute an originally-occurring preferredresidue with another preferred residue. Substitutions can occur atprimary anchor positions or at other positions in a peptide; see, e.g.,Table IV.

A variety of references reflect the art regarding the identification andgeneration of epitopes in a protein of interest as well as analogsthereof. See, for example, WO 97/33602 to Chesnut et al.; Sette,Immunogenetics 1999 50(3-4): 201-212; Selle et al., J. Immunol. 2001166(2): 1389-1397; Sidney et al., Hum. Immunol. 1997 58(1): 12-20; Kondoet al., Immunogenetics 1997 45(4): 249-258; Sidney et al., J. Immunol.1996 157(8): 3480-90; and Falk et al., Nature 351: 290-6 (1991); Hunt etal., Science 255:1261-3 (1992); Parker et al., J. Immunol. 149:3580-7(1992); Parker et al., J. Immunol. 152:163-75 (1994)); Kast et al., 1994152(8): 3904-12; Borras-Cuesta et al., Hum. Immunol. 2000 61(3):266-278; Alexander et al., J. Immunol. 2000 164(3); 164(3): 1625-1633;Alexander et al., PMID: 7895164, UI: 95202582; O'Sullivan et al., J.Immunol. 1991 147(8): 2663-2669; Alexander et al., Immunity 1994 1(9):751-761 and Alexander et al., Immunol. Res. 1998 18(2): 79-92.

Related embodiments of the invention include polypeptides comprisingcombinations of the different motifs set forth in Table VI, and/or, oneor more of the predicted CTL epitopes of Tables VIII-XXI and XXII-XLIX,and/or, one or more of the predicted HTL epitopes of Tables XLVI-XLIX,and/or, one or more of the T cell binding motifs known in the art.Preferred embodiments contain no insertions, deletions or substitutionseither within the motifs or within the intervening sequences of thepolypeptides. In addition, embodiments which include a number of eitherN-terminal and/or C-terminal amino acid residues on either side of thesemotifs may be desirable (to, for example, include a greater portion ofthe polypeptide architecture in which the motif is located). Typically,the number of N-terminal and/or C-terminal amino acid residues on eitherside of a motif is between about 1 to about 100 amino acid residues,preferably 5 to about 50 amino acid residues.

282P1G3-related proteins are embodied in many forms, preferably inisolated form. A purified 282P1G3 protein molecule will be substantiallyfree of other proteins or molecules that impair the binding of 282P1G3to antibody, T cell or other ligand. The nature and degree of isolationand purification will depend on the intended use. Embodiments of a282P1G3-related proteins include purified 282P1G3-related proteins andfunctional, soluble 282P1G3-related proteins. In one embodiment, afunctional, soluble 282P1G3 protein or fragment thereof retains theability to be bound by antibody, T cell or other ligand.

The invention also provides 282P1G3 proteins comprising biologicallyactive fragments of a 282P1G3 amino acid sequence shown in FIG. 2 orFIG. 3. Such proteins exhibit properties of the starting 282P1G3protein, such as the ability to elicit the generation of antibodies thatspecifically bind an epitope associated with the starting 282P1G3protein; to be bound by such antibodies; to elicit the activation of HTLor CTL; and/or, to be recognized by HTL or CTL that also specificallybind to the starting protein.

282P1G3-related polypeptides that contain particularly interestingstructures can be predicted and/or identified using various analyticaltechniques well known in the art, including, for example, the methods ofChou-Fasman, Garnier-Robson, Kyte-Doolittle, Eisenberg, Karplus-Schultzor Jameson-Wolf analysis, or based on immunogenicity. Fragments thatcontain such structures are particularly useful in generatingsubunit-specific anti-282P1G3 antibodies or T cells or in identifyingcellular factors that bind to 282P1G3. For example, hydrophilicityprofiles can be generated, and immunogenic peptide fragments identified,using the method of Hopp, T. P. and Woods, K. R., 1981, Proc. Natl.Acad. Sci. U.S.A. 78:3824-3828. Hydropathicity profiles can begenerated, and immunogenic peptide fragments identified, using themethod of Kyte, J. and Doolittle, R. F., 1982, J. Mol. Biol.157:105-132. Percent (%) Accessible Residues profiles can be generated,and immunogenic peptide fragments identified, using the method of JaninJ., 1979, Nature 277:491-492. Average Flexibility profiles can begenerated, and immunogenic peptide fragments identified, using themethod of Bhaskaran R., Ponnuswamy P. K., 1988, Int. J. Pept. ProteinRes. 32:242-255. Beta-turn profiles can be generated, and immunogenicpeptide fragments identified, using the method of Deleage, G., Roux B.,1987, Protein Engineering 1:289-294.

CTL epitopes can be determined using specific algorithms to identifypeptides within a 282P1G3 protein that are capable of optimally bindingto specified HLA alleles (e.g., by using the SYFPEITHI site at the WorldWide Web; the listings in Table IV(A)-(E); Epimatrix™ and Epimer™, BrownUniversity, and BIMAS. Illustrating this, peptide epitopes from 282P1G3that are presented in the context of human MHC Class I molecules, e.g.,HLA-A1, A2, A3, A11, A24, B7 and B35 were predicted (see, e.g., TablesVIII-XXI, XXII-XLIX). Specifically, the complete amino acid sequence ofthe 282P1G3 protein and relevant portions of other variants, i.e., forHLA Class I predictions 9 flanking residues on either side of a pointmutation or exon junction, and for HLA Class II predictions 14 flankingresidues on either side of a point mutation or exon junctioncorresponding to that variant, were entered into the HLA Peptide MotifSearch algorithm found in the Bioinformatics and Molecular AnalysisSection (BIMAS) web site on the World Wide Web; in addition to the siteSYFPEITHI.

The HLA peptide motif search algorithm was developed by Dr. Ken Parkerbased on binding of specific peptide sequences in the groove of HLAClass I molecules, in particular HLA-A2 (see, e.g., Falk et al., Nature351: 290-6 (1991); Hunt et al., Science 255:1261-3 (1992); Parker etal., J. Immunol. 149:3580-7 (1992); Parker et al., J. Immunol.152:163-75 (1994)). This algorithm allows location and ranking of 8-mer,9-mer, and 10-mer peptides from a complete protein sequence forpredicted binding to HLA-A2 as well as numerous other HLA Class Imolecules. Many HLA class I binding peptides are 8-, 9-, 10 or 11-mers.For example, for Class I HLA-A2, the epitopes preferably contain aleucine (L) or methionine (M) at position 2 and a valine (V) or leucine(L) at the C-terminus (see, e.g., Parker et al., J. Immunol. 149:3580-7(1992)). Selected results of 282P1G3 predicted binding peptides areshown in Tables VIII-XXI and XXII-XLIX herein. In Tables VIII-XXI andXXII-XLVII, selected candidates, 9-mers and 10-mers, for each familymember are shown along with their location, the amino acid sequence ofeach specific peptide, and an estimated binding score. In TablesXLVI-XLIX, selected candidates, 15-mers, for each family member areshown along with their location, the amino acid sequence of eachspecific peptide, and an estimated binding score. The binding scorecorresponds to the estimated half time of dissociation of complexescontaining the peptide at 37° C. at pH 6.5. Peptides with the highestbinding score are predicted to be the most tightly bound to HLA Class Ion the cell surface for the greatest period of time and thus representthe best immunogenic targets for T-cell recognition.

Actual binding of peptides to an HLA allele can be evaluated bystabilization of HLA expression on the antigen-processing defective cellline T2 (see, e.g., Xue et al., Prostate 30:73-8 (1997) and Peshwa etal., Prostate 36:129-38 (1998)). Immunogenicity of specific peptides canbe evaluated in vitro by stimulation of CD8+ cytotoxic T lymphocytes(CTL) in the presence of antigen presenting cells such as dendriticcells.

It is to be appreciated that every epitope predicted by the BIMAS site,Epimer™ and Epimatrix™ sites, or specified by the HLA class I or classII motifs available in the art or which become part of the art such asset forth in Table IV (or determined using World Wide Web site forSYFPEITHI, or BIMAS) are to be “applied” to a 282P1G3 protein inaccordance with the invention. As used in this context “applied” meansthat a 282P1G3 protein is evaluated, e.g., visually or by computer-basedpatterns finding methods, as appreciated by those of skill in therelevant art. Every subsequence of a 282P1G3 protein of 8, 9, 10, or 11amino acid residues that bears an HLA Class I motif, or a subsequence of9 or more amino acid residues that bear an HLA Class II motif are withinthe scope of the invention.

III.B.) Expression of 282P1G3-Related Proteins

In an embodiment described in the examples that follow, 282P1G3 can beconveniently expressed in cells (such as 293T cells) transfected with acommercially available expression vector such as a CMV-driven expressionvector encoding 282P1G3 with a C-terminal 6×His and MYC tag(pcDNA3.1/mycHIS, Invitrogen or Tag5, GenHunter Corporation, NashvilleTenn.). The Tag5 vector provides an IgGK secretion signal that can beused to facilitate the production of a secreted 282P1G3 protein intransfected cells. The secreted HIS-tagged 282P1G3 in the culture mediacan be purified, e.g., using a nickel column using standard techniques.

III.C.) Modifications of 282P1G3-Related Proteins

Modifications of 282P1G3-related proteins such as covalent modificationsare included within the scope of this invention. One type of covalentmodification includes reacting targeted amino acid residues of a 282P1G3polypeptide with an organic derivatizing agent that is capable ofreacting with selected side chains or the N- or C-terminal residues of a282P1G3 protein. Another type of covalent modification of a 282P1G3polypeptide included within the scope of this invention comprisesaltering the native glycosylation pattern of a protein of the invention.Another type of covalent modification of 282P1G3 comprises linking a282P1G3 polypeptide to one of a variety of nonproteinaceous polymers,e.g., polyethylene glycol (PEG), polypropylene glycol, orpolyoxyalkylenes, in the manner set forth in U.S. Pat. No. 4,640,835;4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The 282P1G3-related proteins of the present invention can also bemodified to form a chimeric molecule comprising 282P1G3 fused toanother, heterologous polypeptide or amino acid sequence. Such achimeric molecule can be synthesized chemically or recombinantly. Achimeric molecule can have a protein of the invention fused to anothertumor-associated antigen or fragment thereof. Alternatively, a proteinin accordance with the invention can comprise a fusion of fragments of a282P1G3 sequence (amino or nucleic acid) such that a molecule is createdthat is not, through its length, directly homologous to the amino ornucleic acid sequences shown in FIG. 2 or FIG. 3. Such a chimericmolecule can comprise multiples of the same subsequence of 282P1G3. Achimeric molecule can comprise a fusion of a 282P1G3-related proteinwith a polyhistidine epitope tag, which provides an epitope to whichimmobilized nickel can selectively bind, with cytokines or with growthfactors. The epitope tag is generally placed at the amino- orcarboxyl-terminus of a 282P1G3 protein. In an alternative embodiment,the chimeric molecule can comprise a fusion of a 282P1G3-related proteinwith an immunoglobulin or a particular region of an immunoglobulin. Fora bivalent form of the chimeric molecule (also referred to as an“immunoadhesin”), such a fusion could be to the Fc region of an IgGmolecule. The Ig fusions preferably include the substitution of asoluble (transmembrane domain deleted or inactivated) form of a 282P1G3polypeptide in place of at least one variable region within an Igmolecule. In a preferred embodiment, the immunoglobulin fusion includesthe hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of anIgG1 molecule. For the production of immunoglobulin fusions see, e.g.,U.S. Pat. No. 5,428,130 issued Jun. 27, 1995.

II.D.) Uses of 282P1G3-Related Proteins

The proteins of the invention have a number of different specific uses.As 282P1G3 is highly expressed in prostate and other cancers,282P1G3-related proteins are used in methods that assess the status of282P1G3 gene products in normal versus cancerous tissues, therebyelucidating the malignant phenotype. Typically, polypeptides fromspecific regions of a 282P1G3 protein are used to assess the presence ofperturbations (such as deletions, insertions, point mutations etc.) inthose regions (such as regions containing one or more motifs). Exemplaryassays utilize antibodies or T cells targeting 282P1G3-related proteinscomprising the amino acid residues of one or more of the biologicalmotifs contained within a 282P1G3 polypeptide sequence in order toevaluate the characteristics of this region in normal versus canceroustissues or to elicit an immune response to the epitope. Alternatively,282P1G3-related proteins that contain the amino acid residues of one ormore of the biological motifs in a 282P1G3 protein are used to screenfor factors that interact with that region of 282P1G3.

282P1G3 protein fragments/subsequences are particularly useful ingenerating and characterizing domain-specific antibodies (e.g.,antibodies recognizing an extracellular or intracellular epitope of a282P1G3 protein), for identifying agents or cellular factors that bindto 282P1G3 or a particular structural domain thereof, and in varioustherapeutic and diagnostic contexts, including but not limited todiagnostic assays, cancer vaccines and methods of preparing suchvaccines.

Proteins encoded by the 282P1G3 genes, or by analogs, homologs orfragments thereof, have a variety of uses, including but not limited togenerating antibodies and in methods for identifying ligands and otheragents and cellular constituents that bind to a 282P1G3 gene product.Antibodies raised against a 282P1G3 protein or fragment thereof areuseful in diagnostic and prognostic assays, and imaging methodologies inthe management of human cancers characterized by expression of 282P1G3protein, such as those listed in Table I. Such antibodies can beexpressed intracellularly and used in methods of treating patients withsuch cancers. 282P1G3-related nucleic acids or proteins are also used ingenerating HTL or CTL responses.

Various immunological assays useful for the detection of 282P1G3proteins are used, including but not limited to various types ofradioimmunoassays, enzyme-linked immunosorbent assays (ELISA),enzyme-linked immunofluorescent assays (ELIFA), immunocytochemicalmethods, and the like. Antibodies can be labeled and used asimmunological imaging reagents capable of detecting 282P1G3-expressingcells (e.g., in radioscintigraphic imaging methods). 282P1G3 proteinsare also particularly useful in generating cancer vaccines, as furtherdescribed herein.

IV.) 282P1G3 Antibodies

Another aspect of the invention provides antibodies that bind to282P1G3-related proteins. Preferred antibodies specifically bind to a282P1G3-related protein and do not bind (or bind weakly) to peptides orproteins that are not 282P1G3-related proteins under physiologicalconditions. In this context, examples of physiological conditionsinclude: 1) phosphate buffered saline; 2) Tris-buffered salinecontaining 25 mM Tris and 150 mM NaCl; or normal saline (0.9% NaCl); 4)animal serum such as human serum; or, 5) a combination of any of 1)through 4); these reactions preferably taking place at pH 7.5,alternatively in a range of pH 7.0 to 8.0, or alternatively in a rangeof pH 6.5 to 8.5; also, these reactions taking place at a temperaturebetween 4° C. to 37° C. For example, antibodies that bind 282P1G3 canbind 282P1G3-related proteins such as the homologs or analogs thereof.

282P1G3 antibodies of the invention are particularly useful in cancer(see, e.g., Table I) diagnostic and prognostic assays, and imagingmethodologies. Similarly, such antibodies are useful in the treatment,diagnosis, and/or prognosis of other cancers, to the extent 282P1G3 isalso expressed or overexpressed in these other cancers. Moreover,intracellularly expressed antibodies (e.g., single chain antibodies) aretherapeutically useful in treating cancers in which the expression of282P1G3 is involved, such as advanced or metastatic prostate cancers.

The invention also provides various immunological assays useful for thedetection and quantification of 282P1G3 and mutant 282P1G3-relatedproteins. Such assays can comprise one or more 282P1G3 antibodiescapable of recognizing and binding a 282P1G3-related protein, asappropriate. These assays are performed within various immunologicalassay formats well known in the art, including but not limited tovarious types of radioimmunoassays, enzyme-linked immunosorbent assays(ELISA), enzyme-linked immunofluorescent assays (ELIFA), and the like.

Immunological non-antibody assays of the invention also comprise T cellimmunogenicity assays (inhibitory or stimulatory) as well as majorhistocompatibility complex (MHC) binding assays.

In addition, immunological imaging methods capable of detecting prostatecancer and other cancers expressing 282P1G3 are also provided by theinvention, including but not limited to radioscintigraphic imagingmethods using labeled 282P1G3 antibodies. Such assays are clinicallyuseful in the detection, monitoring, and prognosis of 282P1G3 expressingcancers such as prostate cancer.

282P1G3 antibodies are also used in methods for purifying a282P1G3-related protein and for isolating 282P1G3 homologues and relatedmolecules. For example, a method of purifying a 282P1G3-related proteincomprises incubating a 282P1G3 antibody, which has been coupled to asolid matrix, with a lysate or other solution containing a282P1G3-related protein under conditions that permit the 282P1G3antibody to bind to the 282P1G3-related protein; washing the solidmatrix to eliminate impurities; and eluting the 282P1G3-related proteinfrom the coupled antibody. Other uses of 282P1G3 antibodies inaccordance with the invention include generating anti-idiotypicantibodies that mimic a 282P1G3 protein.

Various methods for the preparation of antibodies are well known in theart. For example, antibodies can be prepared by immunizing a suitablemammalian host using a 282P1G3-related protein, peptide, or fragment, inisolated or immunoconjugated form (Antibodies: A Laboratory Manual, CSHPress, Eds., Harlow, and Lane (1988); Harlow, Antibodies, Cold SpringHarbor Press, NY (1989)). In addition, fusion proteins of 282P1G3 canalso be used, such as a 282P1G3 GST-fusion protein. In a particularembodiment, a GST fusion protein comprising all or most of the aminoacid sequence of FIG. 2 or FIG. 3 is produced, then used as an immunogento generate appropriate antibodies. In another embodiment, a282P1G3-related protein is synthesized and used as an immunogen.

In addition, naked DNA immunization techniques known in the art are used(with or without purified 282P1G3-related protein or 282P1G3 expressingcells) to generate an immune response to the encoded immunogen (forreview, see Donnelly et al., 1997, Ann. Rev. Immunol. 15: 617-648).

The amino acid sequence of a 282P1G3 protein as shown in FIG. 2 or FIG.3 can be analyzed to select specific regions of the 282P1G3 protein forgenerating antibodies. For example, hydrophobicity and hydrophilicityanalyses of a 282P1G3 amino acid sequence are used to identifyhydrophilic regions in the 282P1G3 structure. Regions of a 282P1G3protein that show immunogenic structure, as well as other regions anddomains, can readily be identified using various other methods known inthe art, such as Chou-Fasman, Garnier-Robson, Kyte-Doolitle, Eisenberg,Karplus-Schultz or Jameson-Wolf analysis. Hydrophilicity profiles can begenerated using the method of Hopp, T. P. and Woods, K. R., 1981, Proc.Natl. Acad. Sci. U.S.A. 78:3824-3828. Hydropathicity profiles can begenerated using the method of Kyte, J. and Doolittle, R. F., 1982, J.Mol. Biol. 157:105-132. Percent (%) Accessible Residues profiles can begenerated using the method of Janin J., 1979, Nature 277:491-492.Average Flexibility profiles can be generated using the method ofBhaskaran R., Ponnuswamy P. K., 1988, Int. J. Pept. Protein Res.32:242-255. Beta-turn profiles can be generated using the method ofDeleage, G., Roux B., 1987, Protein Engineering 1:289-294. Thus, eachregion identified by any of these programs or methods is within thescope of the present invention. Methods for the generation of 282P1G3antibodies are further illustrated by way of the examples providedherein. Methods for preparing a protein or polypeptide for use as animmunogen are well known in the art. Also well known in the art aremethods for preparing immunogenic conjugates of a protein with acarrier, such as BSA, KLH or other carrier protein. In somecircumstances, direct conjugation using, for example, carbodiimidereagents are used; in other instances linking reagents such as thosesupplied by Pierce Chemical Co., Rockford, Ill., are effective.Administration of a 282P1G3 immunogen is often conducted by injectionover a suitable time period and with use of a suitable adjuvant, as isunderstood in the art. During the immunization schedule, titers ofantibodies can be taken to determine adequacy of antibody formation.

282P1G3 monoclonal antibodies can be produced by various means wellknown in the art. For example, immortalized cell lines that secrete adesired monoclonal antibody are prepared using the standard hybridomatechnology of Kohler and Milstein or modifications that immortalizeantibody-producing B cells, as is generally known. Immortalized celllines that secrete the desired antibodies are screened by immunoassay inwhich the antigen is a 282P1G3-related protein. When the appropriateimmortalized cell culture is identified, the cells can be expanded andantibodies produced either from in vitro cultures or from ascites fluid.

The antibodies or fragments of the invention can also be produced, byrecombinant means. Regions that bind specifically to the desired regionsof a 282P1G3 protein can also be produced in the context of chimeric orcomplementarity-determining region (CDR) grafted antibodies of multiplespecies origin. Humanized or human 282P1G3 antibodies can also beproduced, and are preferred for use in therapeutic contexts. Methods forhumanizing murine and other non-human antibodies, by substituting one ormore of the non-human antibody CDRs for corresponding human antibodysequences, are well known (see for example, Jones et al., 1986, Nature321: 522-525; Riechmann et al., 1988, Nature 332: 323-327; Verhoeyen etal., 1988, Science 239: 1534-1536). See also, Carter et al., 1993, Proc.Natl. Acad. Sci. USA 89: 4285 and Sims et al., 1993, J. Immunol. 151:2296.

Methods for producing fully human monoclonal antibodies include phagedisplay and transgenic methods (for review, see Vaughan et al., 1998,Nature Biotechnology 16: 535-539). Fully human 282P1G3 monoclonalantibodies can be generated using cloning technologies employing largehuman Ig gene combinatorial libraries (i.e., phage display) (Griffithsand Hoogenboom, Building an in vitro immune system: human antibodiesfrom phage display libraries. In: Protein Engineering of AntibodyMolecules for Prophylactic and Therapeutic Applications in Man, Clark,M. (Ed.), Nottingham Academic, pp 45-64 (1993); Burton and Barbas, HumanAntibodies from combinatorial libraries. Id., pp 65-82). Fully human282P1G3 monoclonal antibodies can also be produced using transgenic miceengineered to contain human immunoglobulin gene loci as described in PCTPatent Application WO98/24893, Kucherlapati and Jakobovits et al.,published Dec. 3, 1997 (see also, Jakobovits, 1998, Exp. Opin. Invest.Drugs 7(4): 607-614; U.S. Pat. No. 6,162,963 issued 19 Dec. 2000; U.S.Pat. No. 6,150,584 issued 12 Nov. 2000; and, U.S. Pat. No. 6,114,598issued 5 Sep. 2000). This method avoids the in vitro manipulationrequired with phage display technology and efficiently produces highaffinity authentic human antibodies.

Reactivity of 282P1G3 antibodies with a 282P1G3-related protein can beestablished by a number of well known means, including Western blot,immunoprecipitation, ELISA, and FACS analyses using, as appropriate,282P1G3-related proteins, 282P1G3-expressing cells or extracts thereof.A 282P1G3 antibody or fragment thereof can be labeled with a detectablemarker or conjugated to a second molecule. Suitable detectable markersinclude, but are not limited to, a radioisotope, a fluorescent compound,a bioluminescent compound, chemiluminescent compound, a metal chelatoror an enzyme. Further, bi-specific antibodies specific for two or more282P1G3 epitopes are generated using methods generally known in the art.Homodimeric antibodies can also be generated by cross-linking techniquesknown in the art (e.g., Wolff et al., Cancer Res. 53: 2560-2565).

V.) 282P1G3 Cellular Immune Responses

The mechanism by which T cells recognize antigens has been delineated.Efficacious peptide epitope vaccine compositions of the invention inducea therapeutic or prophylactic immune responses in very broad segments ofthe world-wide population. For an understanding of the value andefficacy of compositions of the invention that induce cellular immuneresponses, a brief review of immunology-related technology is provided.

A complex of an HLA molecule and a peptidic antigen acts as the ligandrecognized by HLA-restricted T cells (Buus, S. et al., Cell 47:1071,1986; Babbitt, B. P. et al., Nature 317:359, 1985; Townsend, A. andBodmer, H., Annu. Rev. Immunol. 7:601, 1989; Germain, R. N., Annu. Rev.Immunol. 11:403, 1993). Through the study of single amino acidsubstituted antigen analogs and the sequencing of endogenously bound,naturally processed peptides, critical residues that correspond tomotifs required for specific binding to HLA antigen molecules have beenidentified and are set forth in Table IV (see also, e.g., Southwood, etal., J. Immunol. 160:3363, 1998; Rammensee, et al., Immunogenetics41:178, 1995; Rammensee et al., SYFPEITHI, access via the World WideWeb; Sette, A. and Sidney, J. Cuff. Opin. Immunol. 10:478, 1998;Engelhard, V. H., Curr. Opin. Immunol. 6:13, 1994; Sette, A. and Grey,H. M., Curr. Opin. Immunol. 4:79, 1992; Sinigaglia, F. and Hammer, J.Curr. Biol. 6:52, 1994; Ruppert et al., Cell 74:929-937, 1993; Kondo etal., J. Immunol. 155:4307-4312, 1995; Sidney et al., J. Immunol.157:3480-3490, 1996; Sidney et al., Human Immunol. 45:79-93, 1996;Selte, A. and Sidney, J. Immunogenetics 1999 November; 50(3-4):201-12,Review).

Furthermore, x-ray crystallographic analyses of HLA-peptide complexeshave revealed pockets within the peptide binding cleft/groove of HLAmolecules which accommodate, in an allele-specific mode, residues borneby peptide ligands; these residues in turn determine the HLA bindingcapacity of the peptides in which they are present. (See, e.g., Madden,D. R. Annu. Rev. Immunol. 13:587, 1995; Smith, et al., Immunity 4:203,1996; Fremont et al., Immunity 8:305, 1998; Stern et al., Structure2:245, 1994; Jones, E. Y. Curr. Opin. Immunol. 9:75, 1997; Brown, J. H.et al., Nature 364:33, 1993; Guo, H. C. et al., Proc. Natl. Acad. Sci.USA 90:8053, 1993; Guo, H. C. et al., Nature 360:364, 1992; Silver, M.L. et al., Nature 360:367, 1992; Matsumura, M. et al., Science 257:927,1992; Madden et al., Cell 70:1035, 1992; Fremont, D. H. et al., Science257:919, 1992; Saper, M. A., Bjorkman, P. J. and Wiley, D. C., J. Mol.Biol. 219:277, 1991.)

Accordingly, the definition of class I and class II allele-specific HLAbinding motifs, or class I or class II supermotifs allows identificationof regions within a protein that are correlated with binding toparticular HLA antigen(s).

Thus, by a process of HLA motif identification, candidates forepitope-based vaccines have been identified; such candidates can befurther evaluated by HLA-peptide binding assays to determine bindingaffinity and/or the time period of association of the epitope and itscorresponding HLA molecule. Additional confirmatory work can beperformed to select, amongst these vaccine candidates, epitopes withpreferred characteristics in terms of population coverage, and/orimmunogenicity.

Various strategies can be utilized to evaluate cellular immunogenicity,including:

1) Evaluation of primary T cell cultures from normal individuals (see,e.g., Wentworth, P. A. et al., Mol. Immunol. 32:603, 1995; Celis, E. etal., Proc. Natl. Acad. Sci. USA 91:2105, 1994; Tsai, V. et al., J.Immunol. 158:1796, 1997; Kawashima, I. et al., Human Immunol. 59:1,1998). This procedure involves the stimulation of peripheral bloodlymphocytes (PBL) from normal subjects with a test peptide in thepresence of antigen presenting cells in vitro over a period of severalweeks. T cells specific for the peptide become activated during thistime and are detected using, e.g., a lymphokine- or ⁵¹Cr-release assayinvolving peptide sensitized target cells.

2) Immunization of HLA transgenic mice (see, e.g., Wentworth, P. A. etal., J. Immunol. 26:97, 1996; Wentworth, P. A. et al., Int. Immunol.8:651, 1996; Alexander, J. et al., J. Immunol. 159:4753, 1997). Forexample, in such methods peptides in incomplete Freund's adjuvant areadministered subcutaneously to HLA transgenic mice. Several weeksfollowing immunization, splenocytes are removed and cultured in vitro inthe presence of test peptide for approximately one week.Peptide-specific T cells are detected using, e.g., a ⁵¹ Cr-release assayinvolving peptide sensitized target cells and target cells expressingendogenously generated antigen.

3) Demonstration of recall T cell responses from immune individuals whohave been either effectively vaccinated and/or from chronically illpatients (see, e.g., Rehermann, B. et al., J. Exp. Med. 181:1047, 1995;Doolan, D. L. et al., Immunity 7:97, 1997; Bertoni, R. et al., J. Clin.Invest. 100:503, 1997; Threlkeld, S. C. et al., J. Immunol. 159:1648,1997; Diepolder, H. M. et al., J. Virol. 71:6011, 1997). Accordingly,recall responses are detected by culturing PBL from subjects that havebeen exposed to the antigen due to disease and thus have generated animmune response “naturally”, or from patients who were vaccinatedagainst the antigen. PBL from subjects are cultured in vitro for 1-2weeks in the presence of test peptide plus antigen presenting cells(APC) to allow activation of “memory” T cells, as compared to “naive” Tcells. At the end of the culture period, T cell activity is detectedusing assays including ⁵¹Cr release involving peptide-sensitizedtargets, T cell proliferation, or lymphokine release.

VI.) 282P1G3 Transgenic Animals

Nucleic acids that encode a 282P1G3-related protein can also be used togenerate either transgenic animals or “knock out” animals that, in turn,are useful in the development and screening of therapeutically usefulreagents. In accordance with established techniques, cDNA encoding282P1G3 can be used to clone genomic DNA that encodes 282P1G3. Thecloned genomic sequences can then be used to generate transgenic animalscontaining cells that express DNA that encode 282P1G3. Methods forgenerating transgenic animals, particularly animals such as mice orrats, have become conventional in the art and are described, forexample, in U.S. Pat. No. 4,736,866 issued 12 Apr. 1988, and U.S. Pat.No. 4,870,009 issued 26 Sep. 1989. Typically, particular cells would betargeted for 282P1G3 transgene incorporation with tissue-specificenhancers.

Transgenic animals that include a copy of a transgene encoding 282P1G3can be used to examine the effect of increased expression of DNA thatencodes 282P1G3. Such animals can be used as tester animals for reagentsthought to confer protection from, for example, pathological conditionsassociated with its overexpression. In accordance with this aspect ofthe invention, an animal is treated with a reagent and a reducedincidence of a pathological condition, compared to untreated animalsthat bear the transgene, would indicate a potential therapeuticintervention for the pathological condition.

Alternatively, non-human homologues of 282P1G3 can be used to constructa 282P1G3 “knock out” animal that has a defective or altered geneencoding 282P1G3 as a result of homologous recombination between theendogenous gene encoding 282P1G3 and altered genomic DNA encoding282P1G3 introduced into an embryonic cell of the animal. For example,cDNA that encodes 282P1G3 can be used to clone genomic DNA encoding282P1G3 in accordance with established techniques. A portion of thegenomic DNA encoding 282P1G3 can be deleted or replaced with anothergene, such as a gene encoding a selectable marker that can be used tomonitor integration. Typically, several kilobases of unaltered flankingDNA (both at the 5′ and 3′ ends) are included in the vector (see, e.g.,Thomas and Capecchi, Cell, 51:503 (1987) for a description of homologousrecombination vectors). The vector is introduced into an embryonic stemcell line (e.g., by electroporation) and cells in which the introducedDNA has homologously recombined with the endogenous DNA are selected(see, e.g., Li et al., Cell, 69:915 (1992)). The selected cells are theninjected into a blastocyst of an animal (e.g., a mouse or rat) to formaggregation chimeras (see, e.g., Bradley, in Teratocarcinomas andEmbryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL,Oxford, 1987), pp. 113-152). A chimeric embryo can then be implantedinto a suitable pseudopregnant female foster animal, and the embryobrought to term to create a “knock out” animal. Progeny harboring thehomologously recombined DNA in their germ cells can be identified bystandard techniques and used to breed animals in which all cells of theanimal contain the homologously recombined DNA. Knock out animals can becharacterized, for example, for their ability to defend against certainpathological conditions or for their development of pathologicalconditions due to absence of a 282P1G3 polypeptide.

VII.) Methods for the Detection of 282P1G3

Another aspect of the present invention relates to methods for detecting282P1G3 polynucleotides and 282P1G3-related proteins, as well as methodsfor identifying a cell that expresses 282P1G3. The expression profile of282P1G3 makes it a diagnostic marker for metastasized disease.Accordingly, the status of 282P1G3 gene products provides informationuseful for predicting a variety of factors including susceptibility toadvanced stage disease, rate of progression, and/or tumoraggressiveness. As discussed in detail herein, the status of 282P1G3gene products in patient samples can be analyzed by a variety protocolsthat are well known in the art including immunohistochemical analysis,the variety of Northern blotting techniques including in situhybridization, RT-PCR analysis (for example on laser capturemicro-dissected samples), Western blot analysis and tissue arrayanalysis.

More particularly, the invention provides assays for the detection of282P1G3 polynucleotides in a biological sample, such as serum, bone,prostate, and other tissues, urine, semen, cell preparations, and thelike. Detectable 282P1G3 polynucleotides include, for example, a 282P1G3gene or fragment thereof, 282P1G3 mRNA, alternative splice variant282P1G3 mRNAs, and recombinant DNA or RNA molecules that contain a282P1G3 polynucleotide. A number of methods for amplifying and/ordetecting the presence of 282P1G3 polynucleotides are well known in theart and can be employed in the practice of this aspect of the invention.

In one embodiment, a method for detecting a 282P1G3 mRNA in a biologicalsample comprises producing cDNA from the sample by reverse transcriptionusing at least one primer; amplifying the cDNA so produced using a282P1G3 polynucleotides as sense and antisense primers to amplify282P1G3 cDNAs therein; and detecting the presence of the amplified282P1G3 cDNA. Optionally, the sequence of the amplified 282P1G3 cDNA canbe determined.

In another embodiment, a method of detecting a 282P1G3 gene in abiological sample comprises first isolating genomic DNA from the sample;amplifying the isolated genomic DNA using 282P1G3 polynucleotides assense and antisense primers; and detecting the presence of the amplified282P1G3 gene. Any number of appropriate sense and antisense probecombinations can be designed from a 282P1G3 nucleotide sequence (see,e.g., FIG. 2) and used for this purpose.

The invention also provides assays for detecting the presence of a282P1G3 protein in a tissue or other biological sample such as serum,semen, bone, prostate, urine, cell preparations, and the like. Methodsfor detecting a 282P1G3-related protein are also well known and include,for example, immunoprecipitation, immunohistochemical analysis, Westernblot analysis, molecular binding assays, ELISA, ELIFA and the like. Forexample, a method of detecting the presence of a 282P1G3-related proteinin a biological sample comprises first contacting the sample with a282P1G3 antibody, a 282P1G3-reactive fragment thereof, or a recombinantprotein containing an antigen-binding region of a 282P1G3 antibody; andthen detecting the binding of 282P1G3-related protein in the sample.

Methods for identifying a cell that expresses 282P1G3 are also withinthe scope of the invention. In one embodiment, an assay for identifyinga cell that expresses a 282P1G3 gene comprises detecting the presence of282P1G3 mRNA in the cell. Methods for the detection of particular mRNAsin cells are well known and include, for example, hybridization assaysusing complementary DNA probes (such as in situ hybridization usinglabeled 282P1G3 riboprobes, Northern blot and related techniques) andvarious nucleic acid amplification assays (such as RT-PCR usingcomplementary primers specific for 282P1G3, and other amplification typedetection methods, such as, for example, branched DNA, SISBA, TMA andthe like). Alternatively, an assay for identifying a cell that expressesa 282P1G3 gene comprises detecting the presence of 282P1G3-relatedprotein in the cell or secreted by the cell. Various methods for thedetection of proteins are well known in the art and are employed for thedetection of 282P1G3-related proteins and cells that express282P1G3-related proteins.

282P1G3 expression analysis is also useful as a tool for identifying andevaluating agents that modulate 282P1G3 gene expression. For example,282P1G3 expression is significantly upregulated in prostate cancer, andis expressed in cancers of the tissues listed in Table I. Identificationof a molecule or biological agent that inhibits 282P1G3 expression orover-expression in cancer cells is of therapeutic value. For example,such an agent can be identified by using a screen that quantifies282P1G3 expression by RT-PCR, nucleic acid hybridization or antibodybinding.

VII.) Methods for Monitoring the Status of 282P1G3-Related Genes andTheir Products

Oncogenesis is known to be a multistep process where cellular growthbecomes progressively dysregulated and cells progress from a normalphysiological state to precancerous and then cancerous states (see,e.g., Alers et al., Lab Invest. 77(5): 437-438 (1997) and Isaacs et al.,Cancer Surv. 23: 19-32 (1995)). In this context, examining a biologicalsample for evidence of dysregulated cell growth (such as aberrant282P1G3 expression in cancers) allows for early detection of suchaberrant physiology, before a pathologic state such as cancer hasprogressed to a stage that therapeutic options are more limited and orthe prognosis is worse. In such examinations, the status of 282P1G3 in abiological sample of interest can be compared, for example, to thestatus of 282P1G3 in a corresponding normal sample (e.g. a sample fromthat individual or alternatively another individual that is not affectedby a pathology). An alteration in the status of 282P1G3 in thebiological sample (as compared to the normal sample) provides evidenceof dysregulated cellular growth. In addition to using a biologicalsample that is not affected by a pathology as a normal sample, one canalso use a predetermined normative value such as a predetermined normallevel of mRNA expression (see, e.g., Grever et al., J. Comp. Neurol.1996 Dec. 9; 376(2): 306-14 and U.S. Pat. No. 5,837,501) to compare282P1G3 status in a sample.

The term “status” in this context is used according to its art acceptedmeaning and refers to the condition or state of a gene and its products.Typically, skilled artisans use a number of parameters to evaluate thecondition or state of a gene and its products. These include, but arenot limited to the location of expressed gene products (including thelocation of 282P1G3 expressing cells) as well as the level, andbiological activity of expressed gene products (such as 282P1G3 mRNA,polynucleotides and polypeptides). Typically, an alteration in thestatus of 282P1G3 comprises a change in the location of 282P1G3 and/or282P1G3 expressing cells and/or an increase in 282P1G3 mRNA and/orprotein expression.

282P1G3 status in a sample can be analyzed by a number of means wellknown in the art, including without limitation, immunohistochemicalanalysis, in situ hybridization, RT-PCR analysis on laser capturemicro-dissected samples, Western blot analysis, and tissue arrayanalysis. Typical protocols for evaluating the status of a 282P1G3 geneand gene products are found, for example in Ausubel et al. eds., 1995,Current Protocols In Molecular Biology, Units 2 (Northern Blotting), 4(Southern Blotting), 15 (Immunoblotting) and 18 (PCR Analysis). Thus,the status of 282P1G3 in a biological sample is evaluated by variousmethods utilized by skilled artisans including, but not limited togenomic Southern analysis (to examine, for example perturbations in a282P1G3 gene), Northern analysis and/or PCR analysis of 282P1G3 mRNA (toexamine, for example alterations in the polynucleotide sequences orexpression levels of 282P1G3 mRNAs), and, Western and/orimmunohistochemical analysis (to examine, for example alterations inpolypeptide sequences, alterations in polypeptide localization within asample, alterations in expression levels of 282P1G3 proteins and/orassociations of 282P1G3 proteins with polypeptide binding partners).Detectable 282P1G3 polynucleotides include, for example, a 282P1G3 geneor fragment thereof, 282P1G3 mRNA, alternative splice variants, 282P1G3mRNAs, and recombinant DNA or RNA molecules containing a 282P1G3polynucleotide.

The expression profile of 282P1G3 makes it a diagnostic marker for localand/or metastasized disease, and provides information on the growth oroncogenic potential of a biological sample. In particular, the status of282P1G3 provides information useful for predicting susceptibility toparticular disease stages, progression, and/or tumor aggressiveness. Theinvention provides methods and assays for determining 282P1G3 status anddiagnosing cancers that express 282P1G3, such as cancers of the tissueslisted in Table I. For example, because 282P1G3 mRNA is so highlyexpressed in prostate and other cancers relative to normal prostatetissue, assays that evaluate the levels of 282P1G3 mRNA transcripts orproteins in a biological sample can be used to diagnose a diseaseassociated with 282P1G3 dysregulation, and can provide prognosticinformation useful in defining appropriate therapeutic options.

The expression status of 282P1G3 provides information including thepresence, stage and location of dysplastic, precancerous and cancerouscells, predicting susceptibility to various stages of disease, and/orfor gauging tumor aggressiveness. Moreover, the expression profile makesit useful as an imaging reagent for metastasized disease. Consequently,an aspect of the invention is directed to the various molecularprognostic and diagnostic methods for examining the status of 282P1G3 inbiological samples such as those from individuals suffering from, orsuspected of suffering from a pathology characterized by dysregulatedcellular growth, such as cancer.

As described above, the status of 282P1G3 in a biological sample can beexamined by a number of well-known procedures in the art. For example,the status of 282P1G3 in a biological sample taken from a specificlocation in the body can be examined by evaluating the sample for thepresence or absence of 282P1G3 expressing cells (e.g. those that express282P1G3 mRNAs or proteins). This examination can provide evidence ofdysregulated cellular growth, for example, when 282P1G3-expressing cellsare found in a biological sample that does not normally contain suchcells (such as a lymph node), because such alterations in the status of282P1G3 in a biological sample are often associated with dysregulatedcellular growth. Specifically, one indicator of dysregulated cellulargrowth is the metastases of cancer cells from an organ of origin (suchas the prostate) to a different area of the body (such as a lymph node).In this context, evidence of dysregulated cellular growth is importantfor example because occult lymph node metastases can be detected in asubstantial proportion of patients with prostate cancer, and suchmetastases are associated with known predictors of disease progression(see, e.g., Murphy et al., Prostate 42(4): 315-317 (2000); Su et al.,Semin. Surg. Oncol. 18(1): 17-28 (2000) and Freeman et al., J Urol 1995August 154(2 Pt 1):474-8).

In one aspect, the invention provides methods for monitoring 282P1G3gene products by determining the status of 282P1G3 gene productsexpressed by cells from an individual suspected of having a diseaseassociated with dysregulated cell growth (such as hyperplasia or cancer)and then comparing the status so determined to the status of 282P1G3gene products in a corresponding normal sample. The presence of aberrant282P1G3 gene products in the test sample relative to the normal sampleprovides an indication of the presence of dysregulated cell growthwithin the cells of the individual.

In another aspect, the invention provides assays useful in determiningthe presence of cancer in an individual, comprising detecting asignificant increase in 282P1G3 mRNA or protein expression in a testcell or tissue sample relative to expression levels in the correspondingnormal cell or tissue. The presence of 282P1G3 mRNA can, for example, beevaluated in tissues including but not limited to those listed in TableI. The presence of significant 282P1G3 expression in any of thesetissues is useful to indicate the emergence, presence and/or severity ofa cancer, since the corresponding normal tissues do not express 282P1G3mRNA or express it at lower levels.

In a related embodiment, 282P1G3 status is determined at the proteinlevel rather than at the nucleic acid level. For example, such a methodcomprises determining the level of 282P1G3 protein expressed by cells ina test tissue sample and comparing the level so determined to the levelof 282P1G3 expressed in a corresponding normal sample. In oneembodiment, the presence of 282P1G3 protein is evaluated, for example,using immunohistochemical methods. 282P1G3 antibodies or bindingpartners capable of detecting 282P1G3 protein expression are used in avariety of assay formats well known in the art for this purpose.

In a further embodiment, one can evaluate the status of 282P1G3nucleotide and amino acid sequences in a biological sample in order toidentify perturbations in the structure of these molecules. Theseperturbations can include insertions, deletions, substitutions and thelike. Such evaluations are useful because perturbations in thenucleotide and amino acid sequences are observed in a large number ofproteins associated with a growth dysregulated phenotype (see, e.g.,Marrogi et al., 1999, J. Cutan. Pathol. 26(8):369-378). For example, amutation in the sequence of 282P1G3 may be indicative of the presence orpromotion of a tumor. Such assays therefore have diagnostic andpredictive value where a mutation in 282P1G3 indicates a potential lossof function or increase in tumor growth.

A wide variety of assays for observing perturbations in nucleotide andamino acid sequences are well known in the art. For example, the sizeand structure of nucleic acid or amino acid sequences of 282P1G3 geneproducts are observed by the Northern, Southern, Western, PCR and DNAsequencing protocols discussed herein. In addition, other methods forobserving perturbations in nucleotide and amino acid sequences such assingle strand conformation polymorphism analysis are well known in theart (see, e.g., U.S. Pat. No. 5,382,510 issued 7 Sep. 1999, and U.S.Pat. No. 5,952,170 issued 17 Jan. 1995).

Additionally, one can examine the methylation status of a 282P1G3 genein a biological sample. Aberrant demethylation and/or hypermethylationof CpG islands in gene 5′ regulatory regions frequently occurs inimmortalized and transformed cells, and can result in altered expressionof various genes. For example, promoter hypermethylation of the pi-classglutathione S-transferase (a protein expressed in normal prostate butnot expressed in >90% of prostate carcinomas) appears to permanentlysilence transcription of this gene and is the most frequently detectedgenomic alteration in prostate carcinomas (De Marzo et al., Am. J.Pathol. 155(6): 1985-1992 (1999)). In addition, this alteration ispresent in at least 70% of cases of high-grade prostatic intraepithelialneoplasia (PIN) (Brooks et al., Cancer Epidemiol. Biomarkers Prev.,1998, 7:531-536). In another example, expression of the LAGE-I tumorspecific gene (which is not expressed in normal prostate but isexpressed in 25-50% of prostate cancers) is induced by deoxy-azacytidinein lymphoblastoid cells, suggesting that tumoral expression is due todemethylation (Lethe et al., Int. J. Cancer 76(6): 903-908 (1998)). Avariety of assays for examining methylation status of a gene are wellknown in the art. For example, one can utilize, in Southernhybridization approaches, methylation-sensitive restriction enzymes thatcannot cleave sequences that contain methylated CpG sites to assess themethylation status of CpG islands. In addition, MSP (methylationspecific PCR) can rapidly profile the methylation status of all the CpGsites present in a CpG island of a given gene. This procedure involvesinitial modification of DNA by sodium bisulfite (which will convert allunmethylated cytosines to uracil) followed by amplification usingprimers specific for methylated versus unmethylated DNA. Protocolsinvolving methylation interference can also be found for example inCurrent Protocols In Molecular Biology, Unit 12, Frederick M. Ausubel etal. eds., 1995.

Gene amplification is an additional method for assessing the status of282P1G3. Gene amplification is measured in a sample directly, forexample, by conventional Southern blotting or Northern blotting toquantitate the transcription of mRNA (Thomas, 1980, Proc. Natl. Acad.Sci. USA, 77:5201-5205), dot blotting (DNA analysis), or in situhybridization, using an appropriately labeled probe, based on thesequences provided herein. Alternatively, antibodies are employed thatrecognize specific duplexes, including DNA duplexes, RNA duplexes, andDNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turnare labeled and the assay carried out where the duplex is bound to asurface, so that upon the formation of duplex on the surface, thepresence of antibody bound to the duplex can be detected.

Biopsied tissue or peripheral blood can be conveniently assayed for thepresence of cancer cells using for example, Northern, dot blot or RT-PCRanalysis to detect 282P1G3 expression. The presence of RT-PCRamplifiable 282P1G3 mRNA provides an indication of the presence ofcancer. RT-PCR assays are well known in the art. RT-PCR detection assaysfor tumor cells in peripheral blood are currently being evaluated foruse in the diagnosis and management of a number of human solid tumors.In the prostate cancer field, these include RT-PCR assays for thedetection of cells expressing PSA and PSM (Verkaik et al., 1997, Urol.Res. 25:373-384; Ghossein et al., 1995, J. Clin. Oncol. 13:1195-2000;Heston et al., 1995, Clin. Chem. 41:1687-1688).

A further aspect of the invention is an assessment of the susceptibilitythat an individual has for developing cancer. In one embodiment, amethod for predicting susceptibility to cancer comprises detecting282P1G3 mRNA or 282P1G3 protein in a tissue sample, its presenceindicating susceptibility to cancer, wherein the degree of 282P1G3 mRNAexpression correlates to the degree of susceptibility. In a specificembodiment, the presence of 282P1G3 in prostate or other tissue isexamined, with the presence of 282P1G3 in the sample providing anindication of prostate cancer susceptibility (or the emergence orexistence of a prostate tumor). Similarly, one can evaluate theintegrity 282P1G3 nucleotide and amino acid sequences in a biologicalsample, in order to identify perturbations in the structure of thesemolecules such as insertions, deletions, substitutions and the like. Thepresence of one or more perturbations in 282P1G3 gene products in thesample is an indication of cancer susceptibility (or the emergence orexistence of a tumor).

The invention also comprises methods for gauging tumor aggressiveness.In one embodiment, a method for gauging aggressiveness of a tumorcomprises determining the level of 282P1G3 mRNA or 282P1G3 proteinexpressed by tumor cells, comparing the level so determined to the levelof 282P1G3 mRNA or 282P1G3 protein expressed in a corresponding normaltissue taken from the same individual or a normal tissue referencesample, wherein the degree of 282P1G3 mRNA or 282P1G3 protein expressionin the tumor sample relative to the normal sample indicates the degreeof aggressiveness. In a specific embodiment, aggressiveness of a tumoris evaluated by determining the extent to which 282P1G3 is expressed inthe tumor cells, with higher expression levels indicating moreaggressive tumors. Another embodiment is the evaluation of the integrityof 282P1G3 nucleotide and amino acid sequences in a biological sample,in order to identify perturbations in the structure of these moleculessuch as insertions, deletions, substitutions and the like. The presenceof one or more perturbations indicates more aggressive tumors.

Another embodiment of the invention is directed to methods for observingthe progression of a malignancy in an individual over time. In oneembodiment, methods for observing the progression of a malignancy in anindividual over time comprise determining the level of 282P1G3 mRNA or282P1G3 protein expressed by cells in a sample of the tumor, comparingthe level so determined to the level of 282P1G3 mRNA or 282P1G3 proteinexpressed in an equivalent tissue sample taken from the same individualat a different time, wherein the degree of 282P1G3 mRNA or 282P1G3protein expression in the tumor sample over time provides information onthe progression of the cancer. In a specific embodiment, the progressionof a cancer is evaluated by determining 282P1G3 expression in the tumorcells over time, where increased expression over time indicates aprogression of the cancer. Also, one can evaluate the integrity 282P1G3nucleotide and amino acid sequences in a biological sample in order toidentify perturbations in the structure of these molecules such asinsertions, deletions, substitutions and the like, where the presence ofone or more perturbations indicates a progression of the cancer.

The above diagnostic approaches can be combined with any one of a widevariety of prognostic and diagnostic protocols known in the art. Forexample, another embodiment of the invention is directed to methods forobserving a coincidence between the expression of 282P1G3 gene and282P1G3 gene products (or perturbations in 282P1G3 gene and 282P1G3 geneproducts) and a factor that is associated with malignancy, as a meansfor diagnosing and prognosticating the status of a tissue sample. A widevariety of factors associated with malignancy can be utilized, such asthe expression of genes associated with malignancy (e.g. PSA, PSCA andPSM expression for prostate cancer etc.) as well as gross cytologicalobservations (see, e.g., Bocking et al., 1984, Anal. Quant. Cytol.6(2):74-88; Epstein, 1995, Hum. Pathol. 26(2):223-9; Thorson et al.,1998, Mod. Pathol. 11(6):543-51; Baisden et al., 1999, Am. J. Surg.Pathol. 23(8):918-24). Methods for observing a coincidence between theexpression of 282P1G3 gene and 282P1G3 gene products (or perturbationsin 282P1G3 gene and 282P1G3 gene products) and another factor that isassociated with malignancy are useful, for example, because the presenceof a set of specific factors that coincide with disease providesinformation crucial for diagnosing and prognosticating the status of atissue sample.

In one embodiment, methods for observing a coincidence between theexpression of 282P1G3 gene and 282P1G3 gene products (or perturbationsin 282P1G3 gene and 282P1G3 gene products) and another factor associatedwith malignancy entails detecting the overexpression of 282P1G3 mRNA orprotein in a tissue sample, detecting the overexpression of PSA mRNA orprotein in a tissue sample (or PSCA or PSM expression), and observing acoincidence of 282P1G3 mRNA or protein and PSA mRNA or proteinoverexpression (or PSCA or PSM expression). In a specific embodiment,the expression of 282P1G3 and PSA mRNA in prostate tissue is examined,where the coincidence of 282P1G3 and PSA mRNA overexpression in thesample indicates the existence of prostate cancer, prostate cancersusceptibility or the emergence or status of a prostate tumor.

Methods for detecting and quantifying the expression of 282P1G3 mRNA orprotein are described herein, and standard nucleic acid and proteindetection and quantification technologies are well known in the art.Standard methods for the detection and quantification of 282P1G3 mRNAinclude in situ hybridization using labeled 282P1G3 riboprobes, Northernblot and related techniques using 282P1G3 polynucleotide probes, RT-PCRanalysis using primers specific for 282P1G3, and other amplificationtype detection methods, such as, for example, branched DNA, SISBA, TMAand the like. In a specific embodiment, semi-quantitative RT-PCR is usedto detect and quantify 282P1G3 mRNA expression. Any number of primerscapable of amplifying 282P1G3 can be used for this purpose, includingbut not limited to the various primer sets specifically describedherein. In a specific embodiment, polyclonal or monoclonal antibodiesspecifically reactive with the wild-type 282P1G3 protein can be used inan immunohistochemical assay of biopsied tissue.

IX.) Identification of Molecules that Interact with 282P1G3

The 282P1G3 protein and nucleic acid sequences disclosed herein allow askilled artisan to identify proteins, small molecules and other agentsthat interact with 282P1G3, as well as pathways activated by 282P1G3 viaany one of a variety of art accepted protocols. For example, one canutilize one of the so-called interaction trap systems (also referred toas the “two-hybrid assay”). In such systems, molecules interact andreconstitute a transcription factor which directs expression of areporter gene, whereupon the expression of the reporter gene is assayed.Other systems identify protein-protein interactions in vivo throughreconstitution of a eukaryotic transcriptional activator, see, e.g.,U.S. Pat. No. 5,955,280 issued 21 Sep. 1999, U.S. Pat. No. 5,925,523issued 20 Jul. 1999, U.S. Pat. No. 5,846,722 issued 8 Dec. 1998 and U.S.Pat. No. 6,004,746 issued 21 Dec. 1999. Algorithms are also available inthe art for genome-based predictions of protein function (see, e.g.,Marcotte, et al., Nature 402: 4 Nov. 1999, 83-86).

Alternatively one can screen peptide libraries to identify moleculesthat interact with 282P1G3 protein sequences. In such methods, peptidesthat bind to 282P1G3 are identified by screening libraries that encode arandom or controlled collection of amino acids. Peptides encoded by thelibraries are expressed as fusion proteins of bacteriophage coatproteins, the bacteriophage particles are then screened against the282P1G3 protein(s).

Accordingly, peptides having a wide variety of uses, such astherapeutic, prognostic or diagnostic reagents, are thus identifiedwithout any prior information on the structure of the expected ligand orreceptor molecule. Typical peptide libraries and screening methods thatcan be used to identify molecules that interact with 282P1G3 proteinsequences are disclosed for example in U.S. Pat. No. 5,723,286 issued 3Mar. 1998 and U.S. Pat. No. 5,733,731 issued 31 Mar. 1998.

Alternatively, cell lines that express 282P1G3 are used to identifyprotein-protein interactions mediated by 282P1G3. Such interactions canbe examined using immunoprecipitation techniques (see, e.g., Hamilton B.J., et al. Biochem. Biophys. Res. Commun. 1999, 261:646-51). 282P1G3protein can be immunoprecipitated from 282P1G3-expressing cell linesusing anti-282P1G3 antibodies. Alternatively, antibodies against His-tagcan be used in a cell line engineered to express fusions of 282P1G3 anda His-tag (vectors mentioned above). The immunoprecipitated complex canbe examined for protein association by procedures such as Westernblotting, ³⁵S-methionine labeling of proteins, protein microsequencing,silver staining and two-dimensional gel electrophoresis.

Small molecules and ligands that interact with 282P1G3 can be identifiedthrough related embodiments of such screening assays. For example, smallmolecules can be identified that interfere with protein function,including molecules that interfere with 282P1G3's ability to mediatephosphorylation and de-phosphorylation, interaction with DNA or RNAmolecules as an indication of regulation of cell cycles, secondmessenger signaling or tumorigenesis. Similarly, small molecules thatmodulate 282P1G3-related ion channel, protein pump, or cellcommunication functions are identified and used to treat patients thathave a cancer that expresses 282P1G3 (see, e.g., Hille, B., IonicChannels of Excitable Membranes 2^(nd) Ed., Sinauer Assoc., Sunderland,Mass., 1992). Moreover, ligands that regulate 282P1G3 function can beidentified based on their ability to bind 282P1G3 and activate areporter construct. Typical methods are discussed for example in U.S.Pat. No. 5,928,868 issued 27 Jul. 1999, and include methods for forminghybrid ligands in which at least one ligand is a small molecule. In anillustrative embodiment, cells engineered to express a fusion protein of282P1G3 and a DNA-binding protein are used to co-express a fusionprotein of a hybrid ligand/small molecule and a cDNA librarytranscriptional activator protein. The cells further contain a reportergene, the expression of which is conditioned on the proximity of thefirst and second fusion proteins to each other, an event that occursonly if the hybrid ligand binds to target sites on both hybrid proteins.Those cells that express the reporter gene are selected and the unknownsmall molecule or the unknown ligand is identified. This method providesa means of identifying modulators, which activate or inhibit 282P1G3.

An embodiment of this invention comprises a method of screening for amolecule that interacts with a 282P1G3 amino acid sequence shown in FIG.2 or FIG. 3, comprising the steps of contacting a population ofmolecules with a 282P1G3 amino acid sequence, allowing the population ofmolecules and the 282P1G3 amino acid sequence to interact underconditions that facilitate an interaction, determining the presence of amolecule that interacts with the 282P1G3 amino acid sequence, and thenseparating molecules that do not interact with the 282P1G3 amino acidsequence from molecules that do. In a specific embodiment, the methodfurther comprises purifying, characterizing and identifying a moleculethat interacts with the 282P1G3 amino acid sequence. The identifiedmolecule can be used to modulate a function performed by 282P1G3. In apreferred embodiment, the 282P1G3 amino acid sequence is contacted witha library of peptides.

X)) Therapeutic Methods and Compositions

The identification of 282P1G3 as a protein that is normally expressed ina restricted set of tissues, but which is also expressed in cancers suchas those listed in Table I, opens a number of therapeutic approaches tothe treatment of such cancers.

Of note, targeted antitumor therapies have been useful even when thetargeted protein is expressed on normal tissues, even vital normal organtissues. A vital organ is one that is necessary to sustain life, such asthe heart or colon. A non-vital organ is one that can be removedwhereupon the individual is still able to survive. Examples of non-vitalorgans are ovary, breast, and prostate.

For example, Herceptin®) is an FDA approved pharmaceutical that has asits active ingredient an antibody which is immunoreactive with theprotein variously known as HER2, HER2/neu, and erb-b-2. It is marketedby Genentech and has been a commercially successful antitumor agent.Herceptin sales reached almost $400 million in 2002. Herceptin is atreatment for HER2 positive metastatic breast cancer. However, theexpression of HER2 is not limited to such tumors. The same protein isexpressed in a number of normal tissues. In particular, it is known thatHER2/neu is present in normal kidney and heart, thus these tissues arepresent in all human recipients of Herceptin. The presence of HER2/neuin normal kidney is also confirmed by Latif, Z., et al., B.J.U.International (2002) 89:5-9. As shown in this article (which evaluatedwhether renal cell carcinoma should be a preferred indication foranti-HER2 antibodies such as Herceptin) both protein and mRNA areproduced in benign renal tissues. Notably, HER2/neu protein was stronglyoverexpressed in benign renal tissue.

Despite the fact that HER2/neu is expressed in such vital tissues asheart and kidney, Herceptin is a very useful, FDA approved, andcommercially successful drug. The effect of Herceptin on cardiac tissue,i.e., “cardiotoxicity,” has merely been a side effect to treatment. Whenpatients were treated with Herceptin alone, significant cardiotoxicityoccurred in a very low percentage of patients.

Of particular note, although kidney tissue is indicated to exhibitnormal expression, possibly even higher expression than cardiac tissue,kidney has no appreciable Herceptin side effect whatsoever. Moreover, ofthe diverse array of normal tissues in which HER2 is expressed, there isvery little occurrence of any side effect. Only cardiac tissue hasmanifested any appreciable side effect at all. A tissue such as kidney,where HER2/neu expression is especially notable, has not been the basisfor any side effect.

Furthermore, favorable therapeutic effects have been found for antitumortherapies that target epidermal growth factor receptor (EGFR). EGFR isalso expressed in numerous normal tissues. There have been very limitedside effects in normal tissues following use of anti-EGFR therapeutics.

Thus, expression of a target protein in normal tissue, even vital normaltissue, does not defeat the utility of a targeting agent for the proteinas a therapeutic for certain tumors in which the protein is alsooverexpressed.

Accordingly, therapeutic approaches that inhibit the activity of a282P1G3 protein are useful for patients suffering from a cancer thatexpresses 282P1G3. These therapeutic approaches generally fall into twoclasses. One class comprises various methods for inhibiting the bindingor association of a 282P1G3 protein with its binding partner or withother proteins. Another class comprises a variety of methods forinhibiting the transcription of a 282P1G3 gene or translation of 282P1G3mRNA.

X.A.) Anti-Cancer Vaccines

The invention provides cancer vaccines comprising a 282P1G3-relatedprotein or 282P1G3-related nucleic acid. In view of the expression of282P1G3, cancer vaccines prevent and/or treat 282P1G3-expressing cancerswith minimal or no effects on non-target tissues. The use of a tumorantigen in a vaccine that generates humoral and/or cell-mediated immuneresponses as anti-cancer therapy is well known in the art and has beenemployed in prostate cancer using human PSMA and rodent PAP immunogens(Hodge et al., 1995, Int. J. Cancer 63:231-237; Fong et al., 1997, J.Immunol. 159:3113-3117).

Such methods can be readily practiced by employing a 282P1G3-relatedprotein, or a 282P1G3-encoding nucleic acid molecule and recombinantvectors capable of expressing and presenting the 282P1G3 immunogen(which typically comprises a number of antibody or T cell epitopes).Skilled artisans understand that a wide variety of vaccine systems fordelivery of immunoreactive epitopes are known in the art (see, e.g.,Heryin et al., Ann Med 1999 Feb. 31(1):66-78; Maruyama et al., CancerImmunol Immunother 2000 June 49(3):123-32) Briefly, such methods ofgenerating an immune response (e.g. humoral and/or cell-mediated) in amammal, comprise the steps of: exposing the mammal's immune system to animmunoreactive epitope (e.g. an epitope present in a 282P1G3 proteinshown in FIG. 3 or analog or homolog thereof) so that the mammalgenerates an immune response that is specific for that epitope (e.g.generates antibodies that specifically recognize that epitope). In apreferred method, a 282P1G3 immunogen contains a biological motif, seee.g., Tables VIII-XXI and XXII-XLIX, or a peptide of a size range from282P1G3 indicated in FIG. 5, FIG. 6, FIG. 7, FIG. 8, and FIG. 9.

The entire 282P1G3 protein, immunogenic regions or epitopes thereof canbe combined and delivered by various means. Such vaccine compositionscan include, for example, lipopeptides (e.g., Vitiello, A. et al., J.Clin. Invest. 95:341, 1995), peptide compositions encapsulated inpoly(DL-lactide-co-glycolide) (“PLG”) microspheres (see, e.g., Eldridge,et al., Molec. Immunol. 28:287-294, 1991: Alonso et al., Vaccine12:299-306, 1994; Jones et al., Vaccine 13:675-681, 1995), peptidecompositions contained in immune stimulating complexes (ISCOMS) (see,e.g., Takahashi et al., Nature 344:873-875, 1990; Hu et al., Clin ExpImmunol. 113:235-243, 1998), multiple antigen peptide systems (MAPs)(see e.g., Tam, J. P., Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413, 1988;Tam, J. P., J. Immunol. Methods 196:17-32, 1996), peptides formulated asmultivalent peptides; peptides for use in ballistic delivery systems,typically crystallized peptides, viral delivery vectors (Perkus, M. E.et al., In: Concepts in vaccine development, Kaufmann, S. H. E., ed., p.379, 1996; Chakrabarti, S. et al., Nature 320:535, 1986; Hu, S. L. etal., Nature 320:537, 1986; Kieny, M.-P. et al., AIDS Bio/Technology4:790, 1986; Top, F. H. et al., J. Infect. Dis. 124:148, 1971; Chanda,P. K. et al., Virology 175:535, 1990), particles ofviral or syntheticorigin (e.g., Kofler, N. et al., J. Immunol. Methods. 192:25, 1996;Eldridge, J. H. et al., Sem. Hematol. 30:16, 1993; Falo, L. D., Jr. etal., Nature Med. 7:649, 1995), adjuvants (Warren, H. S., Vogel, F. R.,and Chedid, L. A. Annu. Rev. Immunol. 4:369, 1986; Gupta, R. K. et al.,Vaccine 11:293, 1993), liposomes (Reddy, R. et al., J. Immunol.148:1585, 1992; Rock, K. L., Immunol. Today 17:131, 1996), or, naked orparticle absorbed cDNA (Ulmer, J. B. et al., Science 259:1745, 1993;Robinson, H. L., Hunt, L. A., and Webster, R. G., Vaccine 11:957, 1993;Shiver, J. W. et al., In: Concepts in vaccine development, Kaufmann, S.H. E., ed., p. 423, 1996; Cease, K. B., and Berzofsky, J. A., Annu. Rev.Immunol. 12:923, 1994 and Eldridge, J. H. et al., Sem. Hematol. 30:16,1993). Toxin-targeted delivery technologies, also known as receptormediated targeting, such as those of Avant Immunotherapeutics, Inc.(Needham, Mass.) may also be used.

In patients with 282P1G3-associated cancer, the vaccine compositions ofthe inventon can also be used in conjunction with other treatments usedfor cancer, e.g., surgery, chemotherapy, drug therapies, radiationtherapies, etc. including use in combination with immune adjuvants suchas IL-2, IL-12, GM-CSF, and the like.

Cellular Vaccines:

CTL epitopes can be determined using specific algorithms to identifypeptides within 282P1G3 protein that bind corresponding HLA alleles (seee.g., Table IV; Epimer™ and Epimatrix™, Brown University, and BIMAS;SYFPEITHI on the World Wide Web. In a preferred embodiment, a 282P1G3immunogen contains one or more amino acid sequences identified usingtechniques well known in the art, such as the sequences shown in TablesVIII-XXI and XXII-XLIX or a peptide of 8, 9, 10 or 11 amino acidsspecified by an HLA Class I motif/supermotif (e.g., Table IV (A), TableIV (D), or Table IV (E)) and/or a peptide of at least 9 amino acids thatcomprises an HLA Class II motif/supermotif (e.g., Table IV (B) or TableIV (C)). As is appreciated in the art, the HLA Class I binding groove isessentially closed ended so that peptides of only a particular sizerange can fit into the groove and be bound, generally HLA Class Iepitopes are 8, 9, 10, or 11 amino acids long. In contrast, the HLAClass II binding groove is essentially open ended; therefore a peptideof about 9 or more amino acids can be bound by an HLA Class II molecule.Due to the binding groove differences between HLA Class I and 11, HLAClass I motifs are length specific, i.e., position two of a Class Imotif is the second amino acid in an amino to carboxyl direction of thepeptide. The amino acid positions in a Class II motif are relative onlyto each other, not the overall peptide, Le., additional amino acids canbe attached to the amino and/or carboxyl termini of a motif-bearingsequence. HLA Class II epitopes are often 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acids long, or longer than25 amino acids.

Antibody-Based Vaccines

A wide variety of methods for generating an immune response in a mammalare known in the art (for example as the first step in the generation ofhybridomas). Methods of generating an immune response in a mammalcomprise exposing the mammal's immune system to an immunogenic epitopeon a protein (e.g. a 282P1G3 protein) so that an immune response isgenerated. A typical embodiment consists of a method for generating animmune response to 282P1G3 in a host, by contacting the host with asufficient amount of at least one 282P1G3 B cell or cytotoxic T-cellepitope or analog thereof; and at least one periodic interval thereafterre-contacting the host with the 282P1G3 B cell or cytotoxic T-cellepitope or analog thereof. A specific embodiment consists of a method ofgenerating an immune response against a 282P1G3-related protein or aman-made multiepitopic peptide comprising: administering 282P1G3immunogen (e.g. a 282P1G3 protein or a peptide fragment thereof, a282P1G3 fusion protein or analog etc.) in a vaccine preparation to ahuman or another mammal. Typically, such vaccine preparations furthercontain a suitable adjuvant (see, e.g., U.S. Pat. No. 6,146,635) or auniversal helper epitope such as a PADRE™ peptide (Epimmune Inc., SanDiego, Calif.; see, e.g., Alexander et al., J. Immunol. 2000 164(3);164(3): 1625-1633; Alexander et al., Immunity 1994 1(9): 751-761 andAlexander et al., Immunol. Res. 1998 18(2): 79-92). An alternativemethod comprises generating an immune response in an individual againsta 282P1G3 immunogen by: administering in vivo to muscle or skin of theindividual's body a DNA molecule that comprises a DNA sequence thatencodes a 282P1G3 immunogen, the DNA sequence operatively linked toregulatory sequences which control the expression of the DNA sequence;wherein the DNA molecule is taken up by cells, the DNA sequence isexpressed in the cells and an immune response is generated against theimmunogen (see, e.g., U.S. Pat. No. 5,962,428). Optionally a geneticvaccine facilitator such as anionic lipids; saponins; lectins;estrogenic compounds; hydroxylated lower alkyls; dimethyl sulfoxide; andurea is also administered. In addition, an antiidiotypic antibody can beadministered that mimics 282P1G3, in order to generate a response to thetarget antigen.

Nucleic Acid Vaccines:

Vaccine compositions of the invention include nucleic acid-mediatedmodalities. DNA or RNA that encode protein(s) of the invention can beadministered to a patient. Genetic immunization methods can be employedto generate prophylactic or therapeutic humoral and cellular immuneresponses directed against cancer cells expressing 282P1G3. Constructscomprising DNA encoding a 282P1G3-related protein/immunogen andappropriate regulatory sequences can be injected directly into muscle orskin of an individual, such that the cells of the muscle or skin take-upthe construct and express the encoded 282P1G3 protein/immunogen.Alternatively, a vaccine comprises a 282P1G3-related protein. Expressionof the 282P1G3-related protein immunogen results in the generation ofprophylactic or therapeutic humoral and cellular immunity against cellsthat bear a 282P1G3 protein. Various prophylactic and therapeuticgenetic immunization techniques known in the art can be used (forreview, see information and references published at Internet addressgenweb.com). Nucleic acid-based delivery is described, for instance, inWolff et. al., Science 247:1465 (1990) as well as U.S. Pat. Nos.5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO98/04720. Examples of DNA-based delivery technologies include “nakedDNA”, facilitated (bupivicaine, polymers, peptide-mediated) delivery,cationic lipid complexes, and particle-mediated (“gene gun”) orpressure-mediated delivery (see, e.g., U.S. Pat. No. 5,922,687).

For therapeutic or prophylactic immunization purposes, proteins of theinvention can be expressed via viral or bacterial vectors. Various viralgene delivery systems that can be used in the practice of the inventioninclude, but are not limited to, vaccinia, fowlpox, canarypox,adenovirus, influenza, poliovirus, adeno-associated virus, lentvirus,and sindbis virus (see, e.g., Restifo, 1996, Curr. Opin. Immunol.8:658-663; Tsang et al J. Natl. Cancer Inst. 87:982-990 (1995)).Non-viral delivery systems can also be employed by introducing naked DNAencoding a 282P1G3-related protein into the patient (e.g.,intramuscularly or intradermally) to induce an anti-tumor response.

Vaccinia virus is used, for example, as a vector to express nucleotidesequences that encode the peptides of the invention. Upon introductioninto a host, the recombinant vaccinia virus expresses the proteinimmunogenic peptide, and thereby elicits a host immune response.Vaccinia vectors and methods useful in immunization protocols aredescribed in, e.g., U.S. Pat. No. 4,722,848. Another vector is BCG(Bacille Calmette Guerin). BCG vectors are described in Stover et al.,Nature 351:456-460 (1991). A wide variety of other vectors useful fortherapeutic administration or immunization of the peptides of theinvention, e.g. adeno and adeno-associated virus vectors, retroviralvectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, andthe like, will be apparent to those skilled in the art from thedescription herein.

Thus, gene delivery systems are used to deliver a 282P1G3-relatednucleic acid molecule. In one embodiment, the full-length human 282P1G3cDNA is employed. In another embodiment, 282P1G3 nucleic acid moleculesencoding specific cytotoxic T lymphocyte (CTL) and/or antibody epitopesare employed.

Ex Vivo Vaccines

Various ex vivo strategies can also be employed to generate an immuneresponse. One approach involves the use of antigen presenting cells(APCs) such as dendritic cells (DC) to present 282P1G3 antigen to apatient's immune system. Dendritic cells express MHC class I and 11molecules, B7 co-stimulator, and IL-12, and are thus highly specializedantigen presenting cells. In prostate cancer, autologous dendritic cellspulsed with peptides of the prostate-specific membrane antigen (PSMA)are being used in a Phase I clinical trial to stimulate prostate cancerpatients' immune systems (Tjoa et al., 1996, Prostate 28:65-69; Murphyet al., 1996, Prostate 29:371-380). Thus, dendritic cells can be used topresent 282P1G3 peptides to T cells in the context of MHC class I or 11molecules. In one embodiment, autologous dendritic cells are pulsed with282P1G3 peptides capable of binding to MHC class I and/or class IImolecules. In another embodiment, dendritic cells are pulsed with thecomplete 282P1G3 protein. Yet another embodiment involves engineeringthe overexpression of a 282P1G3 gene in dendritic cells using variousimplementing vectors known in the art, such as adenovirus (Arthur etal., 1997, Cancer Gene Ther. 4:17-25), retrovirus (Henderson et al.,1996, Cancer Res. 56:3763-3770), lentivirus, adeno-associated virus, DNAtransfection (Ribas et al., 1997, Cancer Res. 57:2865-2869), ortumor-derived RNA transfection (Ashley et al., 1997, J. Exp. Med.186:1177-1182). Cells that express 282P1G3 can also be engineered toexpress immune modulators, such as GM-CSF, and used as immunizingagents.

X.B.) 282P1G3 as a Target for Antibody-based Therapy

282P1G3 is an attractive target for antibody-based therapeuticstrategies. A number of antibody strategies are known in the art fortargeting both extracellular and intracellular molecules (see, e.g.,complement and ADCC mediated killing as well as the use of intrabodies).Because 282P1G3 is expressed by cancer cells of various lineagesrelative to corresponding normal cells, systemic administration of282P1G3-immunoreactive compositions are prepared that exhibit excellentsensitivity without toxic, non-specific and/or non-target effects causedby binding of the immunoreactive composition to non-target organs andtissues. Antibodies specifically reactive with domains of 282P1G3 areuseful to treat 282P1G3-expressing cancers systemically, either asconjugates with a toxin or therapeutic agent, or as naked antibodiescapable of inhibiting cell proliferation or function.

282P1G3 antibodies can be introduced into a patient such that theantibody binds to 282P1G3 and modulates a function, such as aninteraction with a binding partner, and consequently mediatesdestruction of the tumor cells and/or inhibits the growth of the tumorcells. Mechanisms by which such antibodies exert a therapeutic effectcan include complement-mediated cytolysis, antibody-dependent cellularcytotoxicity, modulation of the physiological function of 282P1G3,inhibition of ligand binding or signal transduction pathways, modulationof tumor cell differentiation, alteration of tumor angiogenesis factorprofiles, and/or apoptosis.

Those skilled in the art understand that antibodies can be used tospecifically target and bind immunogenic molecules such as animmunogenic region of a 282P1G3 sequence shown in FIG. 2 or FIG. 3. Inaddition, skilled artisans understand that it is routine to conjugateantibodies to cytotoxic agents (see, e.g., Slevers et al. Blood 93:113678-3684 (Jun. 1, 1999)). When cytotoxic and/or therapeutic agents aredelivered directly to cells, such as by conjugating them to antibodiesspecific for a molecule expressed by that cell (e.g. 282P1G3), thecytotoxic agent will exert its known biological effect (i.e.cytotoxicity) on those cells.

A wide variety of compositions and methods for using antibody-cytotoxicagent conjugates to kill cells are known in the art. In the context ofcancers, typical methods entail administering to an animal having atumor a biologically effective amount of a conjugate comprising aselected cytotoxic and/or therapeutic agent linked to a targeting agent(e.g. an anti-282P1G3 antibody) that binds to a marker (e.g. 282P1G3)expressed, accessible to binding or localized on the cell surfaces. Atypical embodiment is a method of delivering a cytotoxic and/ortherapeutic agent to a cell expressing 282P1G3, comprising conjugatingthe cytotoxic agent to an antibody that immunospecifically binds to a282P1G3 epitope, and, exposing the cell to the antibody-agent conjugate.Another illustrative embodiment is a method of treating an individualsuspected of suffering from metastasized cancer, comprising a step ofadministering parenterally to said individual a pharmaceuticalcomposition comprising a therapeutically effective amount of an antibodyconjugated to a cytotoxic and/or therapeutic agent.

Cancer immunotherapy using anti-282P1G3 antibodies can be done inaccordance with various approaches that have been successfully employedin the treatment of other types of cancer, including but not limited tocolon cancer (Arlen et al., 1998, Crit. Rev. Immunol. 18:133-138),multiple myeloma (Ozaki et al., 1997, Blood 90:3179-3186, Tsunenari etal., 1997, Blood 90:2437-2444), gastric cancer (Kasprzyk et al., 1992,Cancer Res. 52:2771-2776), B-cell lymphoma (Funakoshi et al., 1996, J.Immunother. Emphasis Tumor Immunol. 19:93-101), leukemia (Zhong et al.,1996, Leuk. Res. 20:581-589), colorectal cancer (Moun et al., 1994,Cancer Res. 54:6160-6166; Velders et al., 1995, Cancer Res.55:4398-4403), and breast cancer (Shepard et al., 1991, J. Clin.Immunol. 11:117-127). Some therapeutic approaches involve conjugation ofnaked antibody to a toxin or radioisotope, such as the conjugation ofY⁹¹ or I¹³¹ to anti-CD20 antibodies (e.g., Zevalin™, IDECPharmaceuticals Corp. or Bexxar™, Coulter Pharmaceuticals), while othersinvolve co-administration of antibodies and other therapeutic agents,such as Herceptin™ (trastuzumab) with paclitaxel (Genentech, Inc.). Theantibodies can be conjugated to a therapeutic agent. To treat prostatecancer, for example, 282P1G3 antibodies can be administered inconjunction with radiation, chemotherapy or hormone ablation. Also,antibodies can be conjugated to a toxin such as calicheamicin (e.g.,Mylotarg™, Wyeth-Ayerst, Madison, N.J., a recombinant humanized IgG₄kappa antibody conjugated to antitumor antibiotic calicheamicin) or amaytansinoid (e.g., taxane-based Tumor-Activated Prodrug, TAP, platform,ImmunoGen, Cambridge, Mass., also see e.g., U.S. Pat. No. 5,416,064).

Although 282P1G3 antibody therapy is useful for all stages of cancer,antibody therapy can be particularly appropriate in advanced ormetastatic cancers. Treatment with the antibody therapy of the inventionis indicated for patients who have received one or more rounds ofchemotherapy. Alternatively, antibody therapy of the invention iscombined with a chemotherapeutic or radiation regimen for patients whohave not received chemotherapeutic treatment. Additionally, antibodytherapy can enable the use of reduced dosages of concomitantchemotherapy, particularly for patients who do not tolerate the toxicityof the chemotherapeutic agent very well. Fan et al. (Cancer Res.53:4637-4642, 1993), Prewett et al. (International J. of Onco.9:217-224, 1996), and Hancock et al. (Cancer Res. 51:4575-4580, 1991)describe the use of various antibodies together with chemotherapeuticagents.

Although 282P1G3 antibody therapy is useful for all stages of cancer,antibody therapy can be particularly appropriate in advanced ormetastatic cancers. Treatment with the antibody therapy of the inventionis indicated for patients who have received one or more rounds ofchemotherapy. Alternatively, antibody therapy of the invention iscombined with a chemotherapeutic or radiation regimen for patients whohave not received chemotherapeutic treatment. Additionally, antibodytherapy can enable the use of reduced dosages of concomitantchemotherapy, particularly for patients who do not tolerate the toxicityof the chemotherapeutic agent very well.

Cancer patients can be evaluated for the presence and level of 282P1G3expression, preferably using immunohistochemical assessments of tumortissue, quantitative 282P1G3 imaging, or other techniques that reliablyindicate the presence and degree of 282P1G3 expression.Immunohistochemical analysis of tumor biopsies or surgical specimens ispreferred for this purpose. Methods for immunohistochemical analysis oftumor tissues are well known in the art.

Anti-282P1G3 monoclonal antibodies that treat prostate and other cancersinclude those that initiate a potent immune response against the tumoror those that are directly cytotoxic. In this regard, anti-282P1G3monoclonal antibodies (mAbs) can elicit tumor cell lysis by eithercomplement-mediated or antibody-dependent cell cytotoxicity (ADCC)mechanisms, both of which require an intact Fc portion of theimmunoglobulin molecule for interaction with effector cell Fc receptorsites on complement proteins. In addition, anti-282P1G3 mAbs that exerta direct biological effect on tumor growth are useful to treat cancersthat express 282P1G3. Mechanisms by which directly cytotoxic mAbs actinclude: inhibition of cell growth, modulation of cellulardifferentiation, modulation of tumor angiogenesis factor profiles, andthe induction of apoptosis. The mechanism(s) by which a particularanti-282P1G3 mAb exerts an anti-tumor effect is evaluated using anynumber of in vitro assays that evaluate cell death such as ADCC, ADMMC,complement-mediated cell lysis, and so forth, as is generally known inthe art.

In some patients, the use of murine or other non-human monoclonalantibodies, or human/mouse chimeric mAbs can induce moderate to strongimmune responses against the non-human antibody. This can result inclearance of the antibody from circulation and reduced efficacy. In themost severe cases, such an immune response can lead to the extensiveformation of immune complexes which, potentially, can cause renalfailure. Accordingly, preferred monoclonal antibodies used in thetherapeutic methods of the invention are those that are either fullyhuman or humanized and that bind specifically to the target 282P1G3antigen with high affinity but exhibit low or no antigenicity in thepatient.

Therapeutic methods of the invention contemplate the administration ofsingle anti-282P1G3 mAbs as well as combinations, or cocktails, ofdifferent mAbs. Such mAb cocktails can have certain advantages inasmuchas they contain mAbs that target different epitopes, exploit differenteffector mechanisms or combine directly cytotoxic mAbs with mAbs thatrely on immune effector functionality. Such mAbs in combination canexhibit synergistic therapeutic effects. In addition, anti-282P1G3 mAbscan be administered concomitantly with other therapeutic modalities,including but not limited to various chemotherapeutic agents,androgen-blockers, immune modulators (e.g., IL-2, GM-CSF), surgery orradiation. The anti-282P1G3 mAbs are administered in their “naked” orunconjugated form, or can have a therapeutic agent(s) conjugated tothem.

Anti-282P1G3 antibody formulations are administered via any routecapable of delivering the antibodies to a tumor cell. Routes ofadministration include, but are not limited to, intravenous,intraperitoneal, intramuscular, intratumor, intradermal, and the like.Treatment generally involves repeated administration of the anti-282P1G3antibody preparation, via an acceptable route of administration such asintravenous injection (IV), typically at a dose in the range of about0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 15, 20, or 25 mg/kg body weight. In general, doses in the range of10-1000 mg mAb per week are effective and well tolerated.

Based on clinical experience with the Herceptin™ mAb in the treatment ofmetastatic breast cancer, an initial loading dose of approximately 4mg/kg patient body weight IV, followed by weekly doses of about 2 mg/kgIV of the anti-282P1G3 mAb preparation represents an acceptable dosingregimen. Preferably, the initial loading dose is administered as a90-minute or longer infusion. The periodic maintenance dose isadministered as a 30 minute or longer infusion, provided the initialdose was well tolerated. As appreciated by those of skill in the art,various factors can influence the ideal dose regimen in a particularcase. Such factors include, for example, the binding affinity and halflife of the Ab or mAbs used, the degree of 282P1G3 expression in thepatient, the extent of circulating shed 282P1G3 antigen, the desiredsteady-state antibody concentration level, frequency of treatment, andthe influence of chemotherapeutic or other agents used in combinationwith the treatment method of the invention, as well as the health statusof a particular patient.

Optionally, patients should be evaluated for the levels of 282P1G3 in agiven sample (e.g. the levels of circulating 282P1G3 antigen and/or282P1G3 expressing cells) in order to assist in the determination of themost effective dosing regimen, etc. Such evaluations are also used formonitoring purposes throughout therapy, and are useful to gaugetherapeutic success in combination with the evaluation of otherparameters (for example, urine cytology and/or ImmunoCyt levels inbladder cancer therapy, or by analogy, serum PSA levels in prostatecancer therapy).

Anti-idiotypic anti-282P1G3 antibodies can also be used in anti-cancertherapy as a vaccine for inducing an immune response to cells expressinga 282P1G3-related protein. In particular, the generation ofanti-idiotypic antibodies is well known in the art; this methodology canreadily be adapted to generate anti-idiotypic anti-282P1G3 antibodiesthat mimic an epitope on a 282P1G3-related protein (see, for example,Wagner et al., 1997, Hybridoma 16: 33-40; Foon et al., 1995, J. Clin.Invest. 96:334-342; Herlyn et al., 1996, Cancer Immunol. Immunother.43:65-76). Such an anti-idiotypic antibody can be used in cancer vaccinestrategies.

X.C.) 282P1G3 as a Target for Cellular Immune Responses

Vaccines and methods of preparing vaccines that contain animmunogenically effective amount of one or more HLA-binding peptides asdescribed herein are further embodiments of the invention. Furthermore,vaccines in accordance with the invention encompass compositions of oneor more of the claimed peptides. A peptide can be present in a vaccineindividually. Alternatively, the peptide can exist as a homopolymercomprising multiple copies of the same peptide, or as a heteropolymer ofvarious peptides. Polymers have the advantage of increased immunologicalreaction and, where different peptide epitopes are used to make up thepolymer, the additional ability to induce antibodies and/or CTLs thatreact with different antigenic determinants of the pathogenic organismor tumor-related peptide targeted for an immune response. Thecomposition can be a naturally occurring region of an antigen or can beprepared, e.g., recombinantly or by chemical synthesis.

Carriers that can be used with vaccines of the invention are well knownin the art, and include, e.g., thyroglobulin, albumins such as humanserum albumin, tetanus toxoid, polyamino acids such as poly L-lysine,poly L-glutamic acid, influenza, hepatitis B virus core protein, and thelike. The vaccines can contain a physiologically tolerable (i.e.,acceptable) diluent such as water, or saline, preferably phosphatebuffered saline. The vaccines also typically include an adjuvant.Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate,aluminum hydroxide, or alum are examples of materials well known in theart. Additionally, as disclosed herein, CTL responses can be primed byconjugating peptides of the invention to lipids, such astripalmitoyl-5-glycerylcysteinlyseryl-serine (P3CSS). Moreover, anadjuvant such as a syntheticcytosine-phosphorothiolated-guanine-containing (CpG) oligonucleotideshas been found to increase CTL responses 10- to 100-fold. (see, e.g.Davila and Celis, J. Immunol. 165:539-547 (2000))

Upon immunization with a peptide composition in accordance with theinvention, via injection, aerosol, oral, transdermal, transmucosal,intrapleural, intrathecal, or other suitable routes, the immune systemof the host responds to the vaccine by producing large amounts of CTLsand/or HTLs specific for the desired antigen. Consequently, the hostbecomes at least partially immune to later development of cells thatexpress or overexpress 282P1G3 antigen, or derives at least sometherapeutic benefit when the antigen was tumor-associated.

In some embodiments, it may be desirable to combine the class I peptidecomponents with components that induce or facilitate neutralizingantibody and or helper T cell responses directed to the target antigen.A preferred embodiment of such a composition comprises class I and classII epitopes in accordance with the invention. An alternative embodimentof such a composition comprises a class I and/or class II epitope inaccordance with the invention, along with a cross reactive HTL epitopesuch as PADRE™ (Epimmune, San Diego, Calif.) molecule (described e.g.,in U.S. Pat. No. 5,736,142).

A vaccine of the invention can also include antigen-presenting cells(APC), such as dendritic cells (DC), as a vehicle to present peptides ofthe invention. Vaccine compositions can be created in vitro, followingdendritic cell mobilization and harvesting, whereby loading of dendriticcells occurs in vitro. For example, dendritic cells are transfected,e.g., with a minigene in accordance with the invention, or are pulsedwith peptides. The dendritic cell can then be administered to a patientto elicit immune responses in vivo. Vaccine compositions, either DNA- orpeptide-based, can also be administered in vivo in combination withdendritic cell mobilization whereby loading of dendritic cells occurs invivo.

Preferably, the following principles are utilized when selecting anarray of epitopes for inclusion in a polyepitopic composition for use ina vaccine, or for selecting discrete epitopes to be included in avaccine and/or to be encoded by nucleic acids such as a minigene. It ispreferred that each of the following principles be balanced in order tomake the selection. The multiple epitopes to be incorporated in a givenvaccine composition may be, but need not be, contiguous in sequence inthe native antigen from which the epitopes are derived.

1.) Epitopes are selected which, upon administration, mimic immuneresponses that have been observed to be correlated with tumor clearance.For HLA Class I this includes 3-4 epitopes that come from at least onetumor associated antigen (TAA). For HLA Class II a similar rationale isemployed; again 3-4 epitopes are selected from at least one TAA (see,e.g., Rosenberg et al., Science 278:1447-1450). Epitopes from one TAAmay be used in combination with epitopes from one or more additional TMsto produce a vaccine that targets tumors with varying expressionpatterns of frequently-expressed TMs.

2.) Epitopes are selected that have the requisite binding affinityestablished to be correlated with immunogenicity: for HLA Class I anIC₅₀ of 500 nM or less, often 200 nM or less; and for Class II an IC₅₀of 1000 nM or less.

3.) Sufficient supermotif bearing-peptides, or a sufficient array ofallele-specific motif-bearing peptides, are selected to give broadpopulation coverage. For example, it is preferable to have at least 80%population coverage. A Monte Carlo analysis, a statistical evaluationknown in the art, can be employed to assess the breadth, or redundancyof, population coverage.

4.) When selecting epitopes from cancer-related antigens it is oftenuseful to select analogs because the patient may have developedtolerance to the native epitope.

5.) Of particular relevance are epitopes referred to as “nestedepitopes.” Nested epitopes occur where at least two epitopes overlap ina given peptide sequence. A nested peptide sequence can comprise B cell,HLA class I and/or HLA class II epitopes. When providing nestedepitopes, a general objective is to provide the greatest number ofepitopes per sequence. Thus, an aspect is to avoid providing a peptidethat is any longer than the amino terminus of the amino terminal epitopeand the carboxyl terminus of the carboxyl terminal epitope in thepeptide. When providing a multi-epitopic sequence, such as a sequencecomprising nested epitopes, it is generally important to screen thesequence in order to insure that it does not have pathological or otherdeleterious biological properties.

6.) If a polyepitopic protein is created, or when creating a minigene,an objective is to generate the smallest peptide that encompasses theepitopes of interest. This principle is similar, if not the same as thatemployed when selecting a peptide comprising nested epitopes. However,with an artificial polyepitopic peptide, the size minimization objectiveis balanced against the need to integrate any spacer sequences betweenepitopes in the polyepitopic protein. Spacer amino acid residues can,for example, be introduced to avoid junctional epitopes (an epitoperecognized by the immune system, not present in the target antigen, andonly created by the man-made juxtaposition of epitopes), or tofacilitate cleavage between epitopes and thereby enhance epitopepresentation. Junctional epitopes are generally to be avoided becausethe recipient may generate an immune response to that non-nativeepitope. Of particular concern is a junctional epitope that is a“dominant epitope.” A dominant epitope may lead to such a zealousresponse that immune responses to other epitopes are diminished orsuppressed.

7.) Where the sequences of multiple variants of the same target proteinare present, potential peptide epitopes can also be selected on thebasis of their conservancy. For example, a criterion for conservancy maydefine that the entire sequence of an HLA class I binding peptide or theentire 9-mer core of a class II binding peptide be conserved in adesignated percentage of the sequences evaluated for a specific proteinantigen.

X.C.1. Minigene Vaccines

A number of different approaches are available which allow simultaneousdelivery of multiple epitopes. Nucleic acids encoding the peptides ofthe invention are a particularly useful embodiment of the invention.Epitopes for inclusion in a minigene are preferably selected accordingto the guidelines set forth in the previous section. A preferred meansof administering nucleic acids encoding the peptides of the inventionuses minigene constructs encoding a peptide comprising one or multipleepitopes of the invention.

The use of multi-epitope minigenes is described below and in, Ishioka etal., J. Immunol. 162:3915-3925, 1999; An, L. and Whitton, J. L., J.Virol. 71:2292, 1997; Thomson, S. A. et al., J. Immunol. 157:822, 1996;Whitton, J. L. et al., J. Virol. 67:348, 1993; Hanke, R. et al., Vaccine16:426, 1998. For example, a multi-epitope DNA plasmid encodingsupermotif and/or motif-bearing epitopes derived 282P1G3, the PADRESuniversal helper T cell epitope or multiple HTL epitopes from 282P1G3(see e.g., Tables VIII-XXI and XXII to XLIX), and an endoplasmicreticulum-translocating signal sequence can be engineered. A vaccine mayalso comprise epitopes that are derived from other TAAs.

The immunogenicity of a multi-epitopic minigene can be confirmed intransgenic mice to evaluate the magnitude of CTL induction responsesagainst the epitopes tested. Further, the immunogenicity of DNA-encodedepitopes in vivo can be correlated with the in vitro responses ofspecific CTL lines against target cells transfected with the DNAplasmid. Thus, these experiments can show that the minigene serves toboth: 1.) generate a CTL response and 2.) that the induced CTLsrecognized cells expressing the encoded epitopes.

For example, to create a DNA sequence encoding the selected epitopes(minigene) for expression in human cells, the amino acid sequences ofthe epitopes may be reverse translated. A human codon usage table can beused to guide the codon choice for each amino acid. Theseepitope-encoding DNA sequences may be directly adjoined, so that whentranslated, a continuous polypeptide sequence is created. To optimizeexpression and/or immunogenicity, additional elements can beincorporated into the minigene design. Examples of amino acid sequencesthat can be reverse translated and included in the minigene sequenceinclude: HLA class I epitopes, HLA class II epitopes, antibody epitopes,a ubiquitination signal sequence, and/or an endoplasmic reticulumtargeting signal. In addition, HLA presentation of CTL and HTL epitopesmay be improved by including synthetic (e.g. poly-alanine) ornaturally-occurring flanking sequences adjacent to the CTL or HTLepitopes; these larger peptides comprising the epitope(s) are within thescope of the invention.

The minigene sequence may be converted to DNA by assemblingoligonucleotides that encode the plus and minus strands of the minigene.Overlapping oligonucleotides (30-100 bases long) may be synthesized,phosphorylated, purified and annealed under appropriate conditions usingwell known techniques. The ends of the oligonucleotides can be joined,for example, using T4 DNA ligase. This synthetic minigene, encoding theepitope polypeptide, can then be cloned into a desired expressionvector.

Standard regulatory sequences well known to those of skill in the artare preferably included in the vector to ensure expression in the targetcells. Several vector elements are desirable: a promoter with adown-stream cloning site for minigene insertion; a polyadenylationsignal for efficient transcription termination; an E. coli origin ofreplication; and an E. coli selectable marker (e.g. ampicillin orkanamycin resistance). Numerous promoters can be used for this purpose,e.g., the human cytomegalovirus (hCMV) promoter. See, e.g., U.S. Pat.Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.

Additional vector modifications may be desired to optimize minigeneexpression and immunogenicity. In some cases, introns are required forefficient gene expression, and one or more synthetic ornaturally-occurring introns could be incorporated into the transcribedregion of the minigene. The inclusion of mRNA stabilization sequencesand sequences for replication in mammalian cells may also be consideredfor increasing minigene expression.

Once an expression vector is selected, the minigene is cloned into thepolylinker region downstream of the promoter. This plasmid istransformed into an appropriate E. coli strain, and DNA is preparedusing standard techniques. The orientation and DNA sequence of theminigene, as well as all other elements included in the vector, areconfirmed using restriction mapping and DNA sequence analysis. Bacterialcells harboring the correct plasmid can be stored as a master cell bankand a working cell bank.

In addition, immunostimulatory sequences (ISSs or CpGs) appear to play arole in the immunogenicity of DNA vaccines. These sequences may beincluded in the vector, outside the minigene coding sequence, if desiredto enhance immunogenicity.

In some embodiments, a bi-cistronic expression vector which allowsproduction of both the minigene-encoded epitopes and a second protein(included to enhance or decrease immunogenicity) can be used. Examplesof proteins or polypeptides that could beneficially enhance the immuneresponse if co-expressed include cytokines (e.g., IL-2, IL-12, GM-CSF),cytokine-inducing molecules (e.g., LelF), costimulatory molecules, orfor HTL responses, pan-DR binding proteins (PADRE™, Epimmune, San Diego,Calif.). Helper (HTL) epitopes can be joined to intracellular targetingsignals and expressed separately from expressed CTL epitopes; thisallows direction of the HTL epitopes to a cell compartment differentthan that of the CTL epitopes. If required, this could facilitate moreefficient entry of HTL epitopes into the HLA class II pathway, therebyimproving HTL induction. In contrast to HTL or CTL induction,specifically decreasing the immune response by co-expression ofimmunosuppressive molecules (e.g. TGF-β) may be beneficial in certaindiseases.

Therapeutic quantities of plasmid DNA can be produced for example, byfermentation in E. coli, followed by purification. Aliquots from theworking cell bank are used to inoculate growth medium, and grown tosaturation in shaker flasks or a bioreactor according to well-knowntechniques. Plasmid DNA can be purified using standard bioseparationtechnologies such as solid phase anion-exchange resins supplied byQIAGEN, Inc. (Valencia, Calif.). If required, supercoiled DNA can beisolated from the open circular and linear forms using gelelectrophoresis or other methods.

Purified plasmid DNA can be prepared for injection using a variety offormulations. The simplest of these is reconstitution of lyophilized DNAin sterile phosphate-buffer saline (PBS). This approach, known as “nakedDNA,” is currently being used for intramuscular (IM) administration inclinical trials. To maximize the immunotherapeutic effects of minigeneDNA vaccines, an alternative method for formulating purified plasmid DNAmay be desirable. A variety of methods have been described, and newtechniques may become available. Cationic lipids, glycolipids, andfusogenic liposomes can also be used in the formulation (see, e.g., asdescribed by WO 93/24640; Mannino & Gould-Fogerite, BioTechniques 6(7):682 (1988); U.S. Pat. No. 5,279,833; WO 91/06309; and Felgner, et al.,Proc. Nat'l Acad. Sci. USA 84:7413 (1987). In addition, peptides andcompounds referred to collectively as protective, interactive,non-condensing compounds (PINC) could also be complexed to purifiedplasmid DNA to influence variables such as stability, intramusculardispersion, or trafficking to specific organs or cell types.

Target cell sensitization can be used as a functional assay forexpression and HLA class I presentation of minigene-encoded CTLepitopes. For example, the plasmid DNA is introduced into a mammaliancell line that is suitable as a target for standard CTL chromium releaseassays. The transfection method used will be dependent on the finalformulation. Electroporation can be used for “naked” DNA, whereascationic lipids allow direct in vitro transfection. A plasmid expressinggreen fluorescent protein (GFP) can be co-transfected to allowenrichment of transfected cells using fluorescence activated cellsorting (FACS). These cells are then chromium-51 (⁵¹Cr) labeled and usedas target cells for epitope-specific CTL lines; cytolysis, detected by⁵¹Cr release, indicates both production of, and HLA presentation of,minigene-encoded CTL epitopes. Expression of HTL epitopes may beevaluated in an analogous manner using assays to assess HTL activity.

In vivo immunogenicity is a second approach for functional testing ofminigene DNA formulations. Transgenic mice expressing appropriate humanHLA proteins are immunized with the DNA product. The dose and route ofadministration are formulation dependent (e.g., IM for DNA in PBS,intraperitoneal (i.p.) for lipid-complexed DNA). Twenty-one days afterimmunization, splenocytes are harvested and restimulated for one week inthe presence of peptides encoding each epitope being tested. Thereafter,for CTL effector cells, assays are conducted for cytolysis ofpeptide-loaded, ⁵¹Cr-labeled target cells using standard techniques.Lysis of target cells that were sensitized by HLA loaded with peptideepitopes, corresponding to minigene-encoded epitopes, demonstrates DNAvaccine function for in vivo induction of CTLs. Immunogenicity of HTLepitopes is confirmed in transgenic mice in an analogous manner.

Alternatively, the nucleic acids can be administered using ballisticdelivery as described, for instance, in U.S. Pat. No. 5,204,253. Usingthis technique, particles comprised solely of DNA are administered. In afurther alternative embodiment, DNA can be adhered to particles, such asgold particles.

Minigenes can also be delivered using other bacterial or viral deliverysystems well known in the art, e.g., an expression construct encodingepitopes of the invention can be incorporated into a viral vector suchas vaccinia.

X.C.2. Combinations of CTL Peptides with Helper Peptides

Vaccine compositions comprising CTL peptides of the invention can bemodified, e.g., analoged, to provide desired attributes, such asimproved serum half life, broadened population coverage or enhancedimmunogenicity.

For instance, the ability of a peptide to induce CTL activity can beenhanced by linking the peptide to a sequence which contains at leastone epitope that is capable of inducing a T helper cell response.Although a CTL peptide can be directly linked to a T helper peptide,often CTL epitope/HTL epitope conjugates are linked by a spacermolecule. The spacer is typically comprised of relatively small, neutralmolecules, such as amino acids or amino acid mimetics, which aresubstantially uncharged under physiological conditions. The spacers aretypically selected from, e.g., Ala, Gly, or other neutral spacers ofnonpolar amino acids or neutral polar amino acids. It will be understoodthat the optionally present spacer need not be comprised of the sameresidues and thus may be a hetero- or homo-oligomer. When present, thespacer will usually be at least one or two residues, more usually threeto six residues and sometimes 10 or more residues. The CTL peptideepitope can be linked to the T helper peptide epitope either directly orvia a spacer either at the amino or carboxy terminus of the CTL peptide.The amino terminus of either the immunogenic peptide or the T helperpeptide may be acylated.

In certain embodiments, the T helper peptide is one that is recognizedby T helper cells present in a majority of a genetically diversepopulation. This can be accomplished by selecting peptides that bind tomany, most, or all of the HLA class II molecules. Examples of such aminoacid bind many HLA Class II molecules include sequences from antigenssuch as tetanus toxoid at positions 830-843 (QYIKANSKFIGITE; SEQ ID NO:37), Plasmodium falciparum circumsporozoite (CS) protein at positions378-398 (DIEKKIAKMEKASSVFNWNS; SEQ ID NO: 38), and Streptococcus 18 kDprotein at positions 116-131 (GAVDSILGGVATYGAA; SEQ ID NO: 39). Otherexamples include peptides bearing a DR 1-4-7 supermotif, or either ofthe DR3 motifs.

Alternatively, it is possible to prepare synthetic peptides capable ofstimulating T helper lymphocytes, in a loosely HLA-restricted fashion,using amino acid sequences not found in nature (see, e.g., PCTpublication WO 95/07707). These synthetic compounds calledPan-DR-binding epitopes (e.g., PADRE™, Epimmune, Inc., San Diego,Calif.) are designed, most preferably, to bind most HLA-DR (human HLAclass II) molecules. For instance, a pan-DR-binding epitope peptidehaving the formula: aKXVAAWTLKAa (SEQ ID NO: 40), where “X” is eithercyclohexylalanine, phenylalanine, or tyrosine, and a is either D-alanineor L-alanine, has been found to bind to most HLA-DR alleles, and tostimulate the response of T helper lymphocytes from most individuals,regardless of their HLA type. An alternative of a pan-DR binding epitopecomprises all “L” natural amino acids and can be provided in the form ofnucleic acids that encode the epitope.

HTL peptide epitopes can also be modified to alter their biologicalproperties. For example, they can be modified to include D-amino acidsto increase their resistance to proteases and thus extend their serumhalf life, or they can be conjugated to other molecules such as lipids,proteins, carbohydrates, and the like to increase their biologicalactivity. For example, a T helper peptide can be conjugated to one ormore palmitic acid chains at either the amino or carboxyl termini.

X.C.3. Combinations of CTL Peptides with T Cell Priming Agents

In some embodiments it may be desirable to include in the pharmaceuticalcompositions of the invention at least one component which primes Blymphocytes or T lymphocytes. Lipids have been identified as agentscapable of priming CTL in vivo. For example, palmitic acid residues canbe attached to the ε- and α-amino groups of a lysine residue and thenlinked, e.g., via one or more linking residues such as Gly, Gly-Gly-,Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidatedpeptide can then be administered either directly in a micelle orparticle, incorporated into a liposome, or emulsified in an adjuvant,e.g., incomplete Freund's adjuvant. In a preferred embodiment, aparticularly effective immunogenic composition comprises palmitic acidattached to ε- and α-amino groups of Lys, which is attached via linkage,e.g., Ser-Ser, to the amino terminus of the immunogenic peptide.

As another example of lipid priming of CTL responses, E. colilipoproteins, such as tripalmitoyl-S-glycerylcysteinlyseryl-serine(P3CSS) can be used to prime virus specific CTL when covalently attachedto an appropriate peptide (see, e.g., Deres, et al., Nature 342:561,1989). Peptides of the invention can be coupled to P3CSS, for example,and the lipopeptide administered to an individual to prime specificallyan immune response to the target antigen. Moreover, because theinduction of neutralizing antibodies can also be primed withP3CSS-conjugated epitopes, two such compositions can be combined to moreeffectively elicit both humoral and cell-mediated responses.

X.C.4. Vaccine Compositions Comprising DC Pulsed with CTL and/or HTLPeptides

An embodiment of a vaccine composition in accordance with the inventioncomprises ex vivo administration of a cocktail of epitope-bearingpeptides to PBMC, or isolated DC therefrom, from the patient's blood. Apharmaceutical to facilitate harvesting of DC can be used, such asProgenipoietin™ (Pharmacia-Monsanto, St. Louis, Mo.) or GM-CSF/IL-4.After pulsing the DC with peptides and prior to reinfusion intopatients, the DC are washed to remove unbound peptides. In thisembodiment, a vaccine comprises peptide-pulsed DCs which present thepulsed peptide epitopes complexed with HLA molecules on their surfaces.

The DC can be pulsed ex vivo with a cocktail of peptides, some of whichstimulate CTL responses to 282P1G3. Optionally, a helper T cell (HTL)peptide, such as a natural or artificial loosely restricted HLA Class IIpeptide, can be included to facilitate the CTL response. Thus, a vaccinein accordance with the invention is used to treat a cancer whichexpresses or overexpresses 282P1G3.

X.D. Adoptive Immunotherapy

Antigenic 282P1G3-related peptides are used to elicit a CTL and/or HTLresponse ex vivo, as well. The resulting CTL or HTL cells, can be usedto treat tumors in patients that do not respond to other conventionalforms of therapy, or will not respond to a therapeutic vaccine peptideor nucleic acid in accordance with the invention. Ex vivo CTL or HTLresponses to a particular antigen are induced by incubating in tissueculture the patient's, or genetically compatible, CTL or HTL precursorcells together with a source of antigen-presenting cells (APC), such asdendritic cells, and the appropriate immunogenic peptide. After anappropriate incubation time (typically about 7-28 days), in which theprecursor cells are activated and expanded into effector cells, thecells are infused back into the patient, where they will destroy (CTL)or facilitate destruction (HTL) of their specific target cell (e.g., atumor cell). Transfected dendritic cells may also be used as antigenpresenting cells.

X.E. Administration of Vaccines for Therapeutic or Prophylactic Purposes

Pharmaceutical and vaccine compositions of the invention are typicallyused to treat and/or prevent a cancer that expresses or overexpresses282P1G3. In therapeutic applications, peptide and/or nucleic acidcompositions are administered to a patient in an amount sufficient toelicit an effective B cell, CTL and/or HTL response to the antigen andto cure or at least partially arrest or slow symptoms and/orcomplications. An amount adequate to accomplish this is defined as“therapeutically effective dose.” Amounts effective for this use willdepend on, e.g., the particular composition administered, the manner ofadministration, the stage and severity of the disease being treated, theweight and general state of health of the patient, and the judgment ofthe prescribing physician.

For pharmaceutical compositions, the immunogenic peptides of theinvention, or DNA encoding them, are generally administered to anindividual already bearing a tumor that expresses 282P1G3. The peptidesor DNA encoding them can be administered individually or as fusions ofone or more peptide sequences. Patients can be treated with theimmunogenic peptides separately or in conjunction with other treatments,such as surgery, as appropriate.

For therapeutic use, administration should generally begin at the firstdiagnosis of 282P1G3-associated cancer. This is followed by boostingdoses until at least symptoms are substantially abated and for a periodthereafter. The embodiment of the vaccine composition (i.e., including,but not limited to embodiments such as peptide cocktails, polyepitopicpolypeptides, minigenes, or TAA-specific CTLs or pulsed dendritic cells)delivered to the patient may vary according to the stage of the diseaseor the patient's health status. For example, in a patient with a tumorthat expresses 282P1G3, a vaccine comprising 282P1G3-specific CTL may bemore efficacious in killing tumor cells in patient with advanced diseasethan alternative embodiments.

It is generally important to provide an amount of the peptide epitopedelivered by a mode of administration sufficient to stimulateeffectively a cytotoxic T cell response; compositions which stimulatehelper T cell responses can also be given in accordance with thisembodiment of the invention.

The dosage for an initial therapeutic immunization generally occurs in aunit dosage range where the lower value is about 1, 5, 50, 500, or 1,000μg and the higher value is about 10,000; 20,000; 30,000; or 50,000 μg.Dosage values for a human typically range from about 500 μg to about50,000 μg per 70 kilogram patient. Boosting dosages of between about 1.0μg to about 50,000 μg of peptide pursuant to a boosting regimen overweeks to months may be administered depending upon the patient'sresponse and condition as determined by measuring the specific activityof CTL and HTL obtained from the patient's blood. Administration shouldcontinue until at least clinical symptoms or laboratory tests indicatethat the neoplasia, has been eliminated or reduced and for a periodthereafter. The dosages, routes of administration, and dose schedulesare adjusted in accordance with methodologies known in the art.

In certain embodiments, the peptides and compositions of the presentinvention are employed in serious disease states, that is,life-threatening or potentially life threatening situations. In suchcases, as a result of the minimal amounts of extraneous substances andthe relative nontoxic nature of the peptides in preferred compositionsof the invention, it is possible and may be felt desirable by thetreating physician to administer substantial excesses of these peptidecompositions relative to these stated dosage amounts.

The vaccine compositions of the invention can also be used purely asprophylactic agents. Generally the dosage for an initial prophylacticimmunization generally occurs in a unit dosage range where the lowervalue is about 1, 5, 50, 500, or 1000 μg and the higher value is about10,000; 20,000; 30,000; or 50,000 μg. Dosage values for a humantypically range from about 500 μg to about 50,000 μg per 70 kilogrampatient. This is followed by boosting dosages of between about 1.0 μg toabout 50,000 μg of peptide administered at defined intervals from aboutfour weeks to six months after the initial administration of vaccine.The immunogenicity of the vaccine can be assessed by measuring thespecific activity of CTL and HTL obtained from a sample of the patient'sblood.

The pharmaceutical compositions for therapeutic treatment are intendedfor parenteral, topical, oral, nasal, intrathecal, or local (e.g. as acream or topical ointment) administration. Preferably, thepharmaceutical compositions are administered parentally, e.g.,intravenously, subcutaneously, intradermally, or intramuscularly. Thus,the invention provides compositions for parenteral administration whichcomprise a solution of the immunogenic peptides dissolved or suspendedin an acceptable carrier, preferably an aqueous carrier.

A variety of aqueous carriers may be used, e.g., water, buffered water,0.8% saline, 0.3% glycine, hyaluronic acid and the like. Thesecompositions may be sterilized by conventional, well-known sterilizationtechniques, or may be sterile filtered. The resulting aqueous solutionsmay be packaged for use as is, or lyophilized, the lyophilizedpreparation being combined with a sterile solution prior toadministration.

The compositions may contain pharmaceutically acceptable auxiliarysubstances as required to approximate physiological conditions, such aspH-adjusting and buffering agents, tonicity adjusting agents, wettingagents, preservatives, and the like, for example, sodium acetate, sodiumlactate, sodium chloride, potassium chloride, calcium chloride, sorbitanmonolaurate, triethanolamine oleate, etc.

The concentration of peptides of the invention in the pharmaceuticalformulations can vary widely, i.e., from less than about 0.1%, usuallyat or at least about 2% to as much as 20% to 50% or more by weight, andwill be selected primarily by fluid volumes, viscosities, etc., inaccordance with the particular mode of administration selected.

A human unit dose form of a composition is typically included in apharmaceutical composition that comprises a human unit dose of anacceptable carrier, in one embodiment an aqueous carrier, and isadministered in a volume/quantity that is known by those of skill in theart to be used for administration of such compositions to humans (see,e.g., Remington's Pharmaceutical Sciences, 17^(th) Edition, A. Gennaro,Editor, Mack Publishing Co., Easton, Pa., 1985). For example a peptidedose for initial immunization can be from about 1 to about 50,000 μg,generally 100-5,000 μg, for a 70 kg patient. For example, for nucleicacids an initial immunization may be performed using an expressionvector in the form of naked nucleic acid administered IM (or SC or ID)in the amounts of 0.5-5 mg at multiple sites. The nucleic acid (0.1 to1000 μg) can also be administered using a gene gun. Following anincubation period of 3-4 weeks, a booster dose is then administered. Thebooster can be recombinant fowlpox virus administered at a dose of 5-10⁷to 5×10⁹ pfu.

For antibodies, a treatment generally involves repeated administrationof the anti-282P1G3 antibody preparation, via an acceptable route ofadministration such as intravenous injection (IV), typically at a dosein the range of about 0.1 to about 10 mg/kg body weight. In general,doses in the range of 10-500 mg mAb per week are effective and welltolerated. Moreover, an initial loading dose of approximately 4 mg/kgpatient body weight IV, followed by weekly doses of about 2 mg/kg IV ofthe anti-282P1G3 mAb preparation represents an acceptable dosingregimen. As appreciated by those of skill in the art, various factorscan influence the ideal dose in a particular case. Such factors include,for example, half life of a composition, the binding affinity of an Ab,the immunogenicity of a substance, the degree of 282P1G3 expression inthe patient, the extent of circulating shed 282P1G3 antigen, the desiredsteady-state concentration level, frequency of treatment, and theinfluence of chemotherapeutic or other agents used in combination withthe treatment method of the invention, as well as the health status of aparticular patient. Non-limiting preferred human unit doses are, forexample, 500 μg-1 mg, 1 mg-50 mg, 50 mg-100 mg, 100 mg-200 mg, 200mg-300 mg, 400 mg-500 mg, 500 mg-600 mg, 600 mg-700 mg, 700 mg-800 mg,800 mg-900 mg, 900 mg-1 g, or 1 mg-700 mg. In certain embodiments, thedose is in a range of 2-5 mg/kg body weight, e.g., with follow on weeklydoses of 1-3 mg/kg; 0.5 mg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mg/kg bodyweight followed, e.g., in two, three or four weeks by weekly doses;0.5-10 mg/kg body weight, e.g., followed in two, three or four weeks byweekly doses; 225, 250, 275, 300, 325, 350, 375, 400 mg m² of body areaweekly; 1-600 mg m² of body area weekly; 225-400 mg m² of body areaweekly; these does can be followed by weekly doses for 2, 3, 4, 5, 6, 7,8, 9, 19, 11, 12 or more weeks.

In one embodiment, human unit dose forms of polynucleotides comprise asuitable dosage range or effective amount that provides any therapeuticeffect. As appreciated by one of ordinary skill in the art a therapeuticeffect depends on a number of factors, including the sequence of thepolynucleotide, molecular weight of the polynucleotide and route ofadministration. Dosages are generally selected by the physician or otherhealth care professional in accordance with a variety of parametersknown in the art, such as severity of symptoms, history of the patientand the like. Generally, for a polynucleotide of about 20 bases, adosage range may be selected from, for example, an independentlyselected lower limit such as about 0.1, 0.25, 0.5, 1, 2, 5, 10, 20, 30,40, 50, 60, 70, 80, 90, 100, 200, 300, 400 or 500 mg/kg up to anindependently selected upper limit, greater than the lower limit, ofabout 60, 80, 100, 200, 300, 400, 500, 750, 1000, 1500, 2000, 3000,4000, 5000, 6000, 7000, 8000, 9000 or 10,000 mg/kg. For example, a dosemay be about any of the following: 0.1 to 100 mg/kg, 0.1 to 50 mg/kg,0.1 to 25 mg/kg, 0.1 to 10 mg/kg, 1 to 500 mg/kg, 100 to 400 mg/kg, 200to 300 mg/kg, 1 to 100 mg/kg, 100 to 200 mg/kg, 300 to 400 mg/kg, 400 to500 mg/kg, 500 to 1000 mg/kg, 500 to 5000 mg/kg, or 500 to 10,000 mg/kg.Generally, parenteral routes of administration may require higher dosesof polynucleotide compared to more direct application to the nucleotideto diseased tissue, as do polynucleotides of increasing length.

In one embodiment, human unit dose forms of T-cells comprise a suitabledosage range or effective amount that provides any therapeutic effect.As appreciated by one of ordinary skill in the art, a therapeutic effectdepends on a number of factors. Dosages are generally selected by thephysician or other health care professional in accordance with a varietyof parameters known in the art, such as severity of symptoms, history ofthe patient and the like. A dose may be about 10⁴ cells to about 10⁶cells, about 10⁶ cells to about 10⁸ cells, about 10⁸ to about 10¹¹cells, or about 10⁸ to about 5×10¹⁰ cells. A dose may also about 10⁶cells/m² to about 10¹⁰ cells/m², or about 10⁶ cells/m² to about 10⁸cells/m².

Proteins(s) of the invention, and/or nucleic acids encoding theprotein(s), can also be administered via liposomes, which may also serveto: 1) target the proteins(s) to a particular tissue, such as lymphoidtissue; 2) to target selectively to diseases cells; or, 3) to increasethe half-life of the peptide composition. Liposomes include emulsions,foams, micelles, insoluble monolayers, liquid crystals, phospholipiddispersions, lamellar layers and the like. In these preparations, thepeptide to be delivered is incorporated as part of a liposome, alone orin conjunction with a molecule which binds to a receptor prevalent amonglymphoid cells, such as monoclonal antibodies which bind to the CD45antigen, or with other therapeutic or immunogenic compositions. Thus,liposomes either filled or decorated with a desired peptide of theinvention can be directed to the site of lymphoid cells, where theliposomes then deliver the peptide compositions. Liposomes for use inaccordance with the invention are formed from standard vesicle-forminglipids, which generally include neutral and negatively chargedphospholipids and a sterol, such as cholesterol. The selection of lipidsis generally guided by consideration of, e.g., liposome size, acidlability and stability of the liposomes in the blood stream. A varietyof methods are available for preparing liposomes, as described in, e.g.,Szoka, et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), and U.S. Pat.Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.

For targeting cells of the immune system, a ligand to be incorporatedinto the liposome can include, e.g., antibodies or fragments thereofspecific for cell surface determinants of the desired immune systemcells. A liposome suspension containing a peptide may be administeredintravenously, locally, topically, etc. in a dose which varies accordingto, inter alia, the manner of administration, the peptide beingdelivered, and the stage of the disease being treated.

For solid compositions, conventional nontoxic solid carriers may be usedwhich include, for example, pharmaceutical grades of mannitol, lactose,starch, magnesium stearate, sodium saccharin, talcum, cellulose,glucose, sucrose, magnesium carbonate, and the like. For oraladministration, a pharmaceutically acceptable nontoxic composition isformed by incorporating any of the normally employed excipients, such asthose carriers previously listed, and generally 10-95% of activeingredient, that is, one or more peptides of the invention, and morepreferably at a concentration of 25%-75%.

For aerosol administration, immunogenic peptides are preferably suppliedin finely divided form along with a surfactant and propellant. Typicalpercentages of peptides are about 0.01%-20% by weight, preferably about1%-10%. The surfactant must, of course, be nontoxic, and preferablysoluble in the propellant. Representative of such agents are the estersor partial esters of fatty acids containing from about 6 to 22 carbonatoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic,linolenic, olesteric and oleic acids with an aliphatic polyhydricalcohol or its cyclic anhydride. Mixed esters, such as mixed or naturalglycerides may be employed. The surfactant may constitute about 0.1%-20%by weight of the composition, preferably about 0.25-5%. The balance ofthe composition is ordinarily propellant. A carrier can also beincluded, as desired, as with, e.g., lecithin for intranasal delivery.

XI.) Diagnostic and Prognostic Embodiments of 282P1G3.

As disclosed herein, 282P1G3 polynucleotides, polypeptides, reactivecytotoxic T cells (CTL), reactive helper T cells (HTL) andanti-polypeptide antibodies are used in well known diagnostic,prognostic and therapeutic assays that examine conditions associatedwith dysregulated cell growth such as cancer, in particular the cancerslisted in Table I (see, e.g., both its specific pattern of tissueexpression as well as its overexpression in certain cancers as describedfor example in the Example entitled “Expression analysis of 282P1G3 innormal tissues, and patient specimens”).

282P1G3 can be analogized to a prostate associated antigen PSA, thearchetypal marker that has been used by medical practitioners for yearsto identify and monitor the presence of prostate cancer (see, e.g.,Merrill et al., J. Urol. 163(2): 503-5120 (2000); Polascik et al., J.Urol. August; 162(2):293-306 (1999) and Fortier et al., J. Nat. CancerInst. 91(19): 1635-1640(1999)). A variety of other diagnostic markersare also used in similar contexts including p53 and K-ras (see, e.g.,Tulchinsky et al., Int J Mol Med 1999 Jul. 4(1):99-102 and Minimoto etal., Cancer Detect Prev 2000; 24(1):1-12). Therefore, this disclosure of282P1G3 polynucleotides and polypeptides (as well as 282P1G3polynucleotide probes and anti-282P1G3 antibodies used to identify thepresence of these molecules) and their properties allows skilledartisans to utilize these molecules in methods that are analogous tothose used, for example, in a variety of diagnostic assays directed toexamining conditions associated with cancer.

Typical embodiments of diagnostic methods which utilize the 282P1G3polynucleotides, polypeptides, reactive T cells and antibodies areanalogous to those methods from well-established diagnostic assays,which employ, e.g., PSA polynucleotides, polypeptides, reactive T cellsand antibodies. For example, just as PSA polynucleotides are used asprobes (for example in Northern analysis, see, e.g., Sharief et al.,Biochem. Mol. Biol. Int. 33(3):567-74(1994)) and primers (for example inPCR analysis, see, e.g., Okegawa et al., J. Urol. 163(4): 1189-1190(2000)) to observe the presence and/or the level of PSA mRNAs in methodsof monitoring PSA overexpression or the metastasis of prostate cancers,the 282P1G3 polynucleotides described herein can be utilized in the sameway to detect 282P1G3 overexpression or the metastasis of prostate andother cancers expressing this gene. Alternatively, just as PSApolypeptides are used to generate antibodies specific for PSA which canthen be used to observe the presence and/or the level of PSA proteins inmethods to monitor PSA protein overexpression (see, e.g., Stephan etal., Urology 55(4):560-3 (2000)) or the metastasis of prostate cells(see, e.g., Alanen et al., Pathol. Res. Pract. 192(3):233-7 (1996)), the282P1G3 polypeptides described herein can be utilized to generateantibodies for use in detecting 282P1G3 overexpression or the metastasisof prostate cells and cells of other cancers expressing this gene.

Specifically, because metastases involves the movement of cancer cellsfrom an organ of origin (such as the lung or prostate gland etc.) to adifferent area of the body (such as a lymph node), assays which examinea biological sample for the presence of cells expressing 282P1G3polynucleotides and/or polypeptides can be used to provide evidence ofmetastasis. For example, when a biological sample from tissue that doesnot normally contain 282P1G3-expressing cells (lymph node) is found tocontain 282P1G3-expressing cells such as the 282P1G3 expression seen inLAPC4 and LAPC9, xenografts isolated from lymph node and bonemetastasis, respectively, this finding is indicative of metastasis.

Alternatively 282P1G3 polynucleotides and/or polypeptides can be used toprovide evidence of cancer, for example, when cells in a biologicalsample that do not normally express 282P1G3 or express 282P1G3 at adifferent level are found to express 282P1G3 or have an increasedexpression of 282P1G3 (see, e.g., the 282P1G3 expression in the cancerslisted in Table I and in patient samples etc. shown in the accompanyingFigures). In such assays, artisans may further wish to generatesupplementary evidence of metastasis by testing the biological samplefor the presence of a second tissue restricted marker (in addition to282P1G3) such as PSA, PSCA etc. (see, e.g., Alanen et al., Pathol. Res.Pract. 192(3): 233-237 (1996)).

The use of immunohistochemistry to identify the presence of a 282P1G3polypeptide within a tissue section can indicate an altered state ofcertain cells within that tissue. It is well understood in the art thatthe ability of an antibody to localize to a polypeptide that isexpressed in cancer cells is a way of diagnosing presence of disease,disease stage, progression and/or tumor aggressiveness. Such an antibodycan also detect an altered distribution of the polypeptide within thecancer cells, as compared to corresponding non-malignant tissue.

The 282P1G3 polypeptide and immunogenic compositions are also useful inview of the phenomena of altered subcellular protein localization indisease states. Alteration of cells from normal to diseased state causeschanges in cellular morphology and is often associated with changes insubcellular protein localization/distribution. For example, cellmembrane proteins that are expressed in a polarized manner in normalcells can be altered in disease, resulting in distribution of theprotein in a non-polar manner over the whole cell surface.

The phenomenon of altered subcellular protein localization in a diseasestate has been demonstrated with MUC1 and Her2 protein expression by useof immunohistochemical means. Normal epithelial cells have a typicalapical distribution of MUC1, in addition to some supranuclearlocalization of the glycoprotein, whereas malignant lesions oftendemonstrate an apolar staining pattern (Diaz et al, The Breast Journal,7; 40-45 (2001); Zhang et al, Clinical Cancer Research, 4; 2669-2676(1998): Cao, et al, The Journal of Histochemistry and Cytochemistry, 45:1547-1557 (1997)). In addition, normal breast epithelium is eithernegative for Her2 protein or exhibits only a basolateral distributionwhereas malignant cells can express the protein over the whole cellsurface (De Potter, et al, International Journal of Cancer, 44; 969-974(1989): McCormick, et al, 117; 935-943 (2002)). Alternatively,distribution of the protein may be altered from a surface onlylocalization to include diffuse cytoplasmic expression in the diseasedstate. Such an example can be seen with MUC1 (Diaz, et al, The BreastJournal, 7: 40-45 (2001)).

Alteration in the localization/distribution of a protein in the cell, asdetected by immunohistochemical methods, can also provide valuableinformation concerning the favorability of certain treatment modalities.This last point is illustrated by a situation where a protein may beintracellular in normal tissue, but cell surface in malignant cells; thecell surface location makes the cells favorably amenable toantibody-based diagnostic and treatment regimens. When such analteration of protein localization occurs for 282P1G3, the 282P1G3protein and immune responses related thereto are very useful.Accordingly, the ability to determine whether alteration of subcellularprotein localization occurred for 24P4C12 make the 282P1G3 protein andimmune responses related thereto very useful. Use of the 282P1G3compositions allows those skilled in the art to make importantdiagnostic and therapeutic decisions.

Immunohistochemical reagents specific to 282P1G3 are also useful todetect metastases of tumors expressing 282P1G3 when the polypeptideappears in tissues where 282P1G3 is not normally produced.

Thus, 282P1G3 polypeptides and antibodies resulting from immuneresponses thereto are useful in a variety of important contexts such asdiagnostic, prognostic, preventative and/or therapeutic purposes knownto those skilled in the art.

Just as PSA polynucleotide fragments and polynucleotide variants areemployed by skilled artisans for use in methods of monitoring PSA,282P1G3 polynucleotide fragments and polynucleotide variants are used inan analogous manner. In particular, typical PSA polynucleotides used inmethods of monitoring PSA are probes or primers which consist offragments of the PSA cDNA sequence. Illustrating this, primers used toPCR amplify a PSA polynucleotide must include less than the whole PSAsequence to function in the polymerase chain reaction. In the context ofsuch PCR reactions, skilled artisans generally create a variety ofdifferent polynucleotide fragments that can be used as primers in orderto amplify different portions of a polynucleotide of interest or tooptimize amplification reactions (see, e.g., Caetano-Anolles, G.Biotechniques 25(3): 472-476, 478-480 (1998); Robertson et al., MethodsMol. Biol. 98:121-154 (1998)). An additional illustration of the use ofsuch fragments is provided in the Example entitled “Expression analysisof 282P1G3 in normal tissues, and patient specimens,” where a 282P1G3polynucleotide fragment is used as a probe to show the expression of282P1G3 RNAs in cancer cells. In addition, variant polynucleotidesequences are typically used as primers and probes for the correspondingmRNAs in PCR and Northern analyses (see, e.g., Sawai et al., FetalDiagn. Ther. 1996 Nov.-Dec. 11 (6):407-13 and Current Protocols InMolecular Biology, Volume 2, Unit 2, Frederick M. Ausubel et al. eds.,1995)). Polynucleotide fragments and variants are useful in this contextwhere they are capable of binding to a target polynucleotide sequence(e.g., a 282P1G3 polynucleotide shown in FIG. 2 or variant thereof)under conditions of high stringency.

Furthermore, PSA polypeptides which contain an epitope that can berecognized by an antibody or T cell that specifically binds to thatepitope are used in methods of monitoring PSA. 282P1G3 polypeptidefragments and polypeptide analogs or variants can also be used in ananalogous manner. This practice of using polypeptide fragments orpolypeptide variants to generate antibodies (such as anti-PSA antibodiesor T cells) is typical in the art with a wide variety of systems such asfusion proteins being used by practitioners (see, e.g., CurrentProtocols In Molecular Biology, Volume 2, Unit 16, Frederick M. Ausubelet al. eds., 1995). In this context, each epitope(s) functions toprovide the architecture with which an antibody or T cell is reactive.Typically, skilled artisans create a variety of different polypeptidefragments that can be used in order to generate immune responsesspecific for different portions of a polypeptide of interest (see, e.g.,U.S. Pat. No. 5,840,501 and U.S. Pat. No. 5,939,533). For example it maybe preferable to utilize a polypeptide comprising one of the 282P1G3biological motifs discussed herein or a motif-bearing subsequence whichis readily identified by one of skill in the art based on motifsavailable in the art. Polypeptide fragments, variants or analogs aretypically useful in this context as long as they comprise an epitopecapable of generating an antibody or T cell specific for a targetpolypeptide sequence (e.g. a 282P1G3 polypeptide shown in FIG. 3).

As shown herein, the 282P1G3 polynucleotides and polypeptides (as wellas the 282P1G3 polynucleotide probes and anti-282P1G3 antibodies or Tcells used to identify the presence of these molecules) exhibit specificproperties that make them useful in diagnosing cancers such as thoselisted in Table I. Diagnostic assays that measure the presence of282P1G3 gene products, in order to evaluate the presence or onset of adisease condition described herein, such as prostate cancer, are used toidentify patients for preventive measures or further monitoring, as hasbeen done so successfully with PSA. Moreover, these materials satisfy aneed in the art for molecules having similar or complementarycharacteristics to PSA in situations where, for example, a definitediagnosis of metastasis of prostatic origin cannot be made on the basisof a test for PSA alone (see, e.g., Alanen et al., Pathol. Res. Pract.192(3): 233-237 (1996)), and consequently, materials such as 282P1G3polynucleotides and polypeptides (as well as the 282P1G3 polynucleotideprobes and anti-282P1G3 antibodies used to identify the presence ofthese molecules) need to be employed to confirm a metastases ofprostatic origin.

Finally, in addition to their use in diagnostic assays, the 282P1G3polynucleotides disclosed herein have a number of other utilities suchas their use in the identification of oncogenetic associated chromosomalabnormalities in the chromosomal region to which the 282P1G3 gene maps(see the Example entitled “Chromosomal Mapping of 282P1G3” below).Moreover, in addition to their use in diagnostic assays, the282P1G3-related proteins and polynucleotides disclosed herein have otherutilities such as their use in the forensic analysis of tissues ofunknown origin (see, e.g., Takahama K Forensic Sci Int 1996 Jun. 28;80(1-2): 63-9).

Additionally, 282P1G3-related proteins or polynucleotides of theinvention can be used to treat a pathologic condition characterized bythe over-expression of 282P1G3. For example, the amino acid or nucleicacid sequence of FIG. 2 or FIG. 3, or fragments of either, can be usedto generate an immune response to a 282P1G3 antigen. Antibodies or othermolecules that react with 282P1G3 can be used to modulate the functionof this molecule, and thereby provide a therapeutic benefit.

XII.) Inhibition of 282P1G3 Protein Function

The invention includes various methods and compositions for inhibitingthe binding of 282P1G3 to its binding partner or its association withother protein(s) as well as methods for inhibiting 282P1G3 function.

XII.A.) Inhibition of 282P1G3 with Intracellular Antibodies

In one approach, a recombinant vector that encodes single chainantibodies that specifically bind to 282P1G3 are introduced into 282P1G3expressing cells via gene transfer technologies. Accordingly, theencoded single chain anti-282P1G3 antibody is expressed intracellularly,binds to 282P1G3 protein, and thereby inhibits its function. Methods forengineering such intracellular single chain antibodies are well known.Such intracellular antibodies, also known as “intrabodies”, arespecifically targeted to a particular compartment within the cell,providing control over where the inhibitory activity of the treatment isfocused. This technology has been successfully applied in the art (forreview, see Richardson and Marasco, 1995, TIBTECH vol. 13). Intrabodieshave been shown to virtually eliminate the expression of otherwiseabundant cell surface receptors (see, e.g., Richardson et al., 1995,Proc. Natl. Acad. Sci. USA 92: 3137-3141; Beerli et al., 1994, J. Biol.Chem. 289: 23931-23936; Deshane et al, 1994, Gene Ther. 1: 332-337).

Single chain antibodies comprise the variable domains of the heavy andlight chain joined by a flexible linker polypeptide, and are expressedas a single polypeptide. Optionally, single chain antibodies areexpressed as a single chain variable region fragment joined to the lightchain constant region. Well-known intracellular trafficking signals areengineered into recombinant polynucleotide vectors encoding such singlechain antibodies in order to target precisely the intrabody to thedesired intracellular compartment. For example, intrabodies targeted tothe endoplasmic reticulum (ER) are engineered to incorporate a leaderpeptide and, optionally, a C-terminal ER retention signal, such as theKDEL amino acid motif. Intrabodies intended to exert activity in thenucleus are engineered to include a nuclear localization signal. Lipidmoieties are joined to intrabodies in order to tether the intrabody tothe cytosolic side of the plasma membrane. Intrabodies can also betargeted to exert function in the cytosol. For example, cytosolicintrabodies are used to sequester factors within the cytosol, therebypreventing them from being transported to their natural cellulardestination.

In one embodiment, intrabodies are used to capture 282P1G3 in thenucleus, thereby preventing its activity within the nucleus. Nucleartargeting signals are engineered into such 282P1G3 intrabodies in orderto achieve the desired targeting. Such 282P1G3 intrabodies are designedto bind specifically to a particular 282P1G3 domain. In anotherembodiment, cytosolic intrabodies that specifically bind to a 282P1G3protein are used to prevent 282P1G3 from gaining access to the nucleus,thereby preventing it from exerting any biological activity within thenucleus (e.g., preventing 282P1G3 from forming transcription complexeswith other factors).

In order to specifically direct the expression of such intrabodies toparticular cells, the transcription of the intrabody is placed under theregulatory control of an appropriate tumor-specific promoter and/orenhancer. In order to target intrabody expression specifically toprostate, for example, the PSA promoter and/or promoter/enhancer can beutilized (See, for example, U.S. Pat. No. 5,919,652 issued 6 Jul. 1999).

XII.B.) Inhibition of 282P1G3 with Recombinant Proteins

In another approach, recombinant molecules bind to 282P1G3 and therebyinhibit 282P1G3 function. For example, these recombinant moleculesprevent or inhibit 282P1G3 from accessing/binding to its bindingpartner(s) or associating with other protein(s). Such recombinantmolecules can, for example, contain the reactive part(s) of a 282P1G3specific antibody molecule. In a particular embodiment, the 282P1G3binding domain of a 282P1G3 binding partner is engineered into a dimericfusion protein, whereby the fusion protein comprises two 282P1G3 ligandbinding domains linked to the Fc portion of a human IgG, such as humanIgG1. Such IgG portion can contain, for example, the C_(H)2 and C_(H)3domains and the hinge region, but not the C_(H)1 domain. Such dimericfusion proteins are administered in soluble form to patients sufferingfrom a cancer associated with the expression of 282P1G3, whereby thedimeric fusion protein specifically binds to 282P1G3 and blocks 282P1G3interaction with a binding partner. Such dimeric fusion proteins arefurther combined into multimeric proteins using known antibody linkingtechnologies.

XII.C.) Inhibition of 282P1G3 Transcription or Translation

The present invention also comprises various methods and compositionsfor inhibiting the transcription of the 282P1G3 gene. Similarly, theinvention also provides methods and compositions for inhibiting thetranslation of 282P1G3 mRNA into protein.

In one approach, a method of inhibiting the transcription of the 282P1G3gene comprises contacting the 282P1G3 gene with a 282P1G3 antisensepolynucleotide. In another approach, a method of inhibiting 282P1G3 mRNAtranslation comprises contacting a 282P1G3 mRNA with an antisensepolynucleotide. In another approach, a 282P1G3 specific ribozyme is usedto cleave a 282P1G3 message, thereby inhibiting translation. Suchantisense and ribozyme based methods can also be directed to theregulatory regions of the 282P1G3 gene, such as 282P1G3 promoter and/orenhancer elements. Similarly, proteins capable of inhibiting a 282P1G3gene transcription factor are used to inhibit 282P1G3 mRNAtranscription. The various polynucleotides and compositions useful inthe aforementioned methods have been described above. The use ofantisense and ribozyme molecules to inhibit transcription andtranslation is well known in the art.

Other factors that inhibit the transcription of 282P1G3 by interferingwith 282P1G3 transcriptional activation are also useful to treat cancersexpressing 282P1G3. Similarly, factors that interfere with 282P1G3processing are useful to treat cancers that express 282P1G3. Cancertreatment methods utilizing such factors are also within the scope ofthe invention.

XII.D.) General Considerations for Therapeutic Strategies

Gene transfer and gene therapy technologies can be used to delivertherapeutic polynucleotide molecules to tumor cells synthesizing 282P1G3(i.e., antisense, ribozyme, polynucleotides encoding intrabodies andother 282P1G3 inhibitory molecules). A number of gene therapy approachesare known in the art. Recombinant vectors encoding 282P1G3 antisensepolynucleotides, ribozymes, factors capable of interfering with 282P1G3transcription, and so forth, can be delivered to target tumor cellsusing such gene therapy approaches.

The above therapeutic approaches can be combined with any one of a widevariety of surgical, chemotherapy or radiation therapy regimens. Thetherapeutic approaches of the invention can enable the use of reduceddosages of chemotherapy (or other therapies) and/or less frequentadministration, an advantage for all patients and particularly for thosethat do not tolerate the toxicity of the chemotherapeutic agent well.

The anti-tumor activity of a particular composition (e.g., antisense,ribozyme, intrabody), or a combination of such compositions, can beevaluated using various in vitro and in vivo assay systems. In vitroassays that evaluate therapeutic activity include cell growth assays,soft agar assays and other assays indicative of tumor promotingactivity, binding assays capable of determining the extent to which atherapeutic composition will inhibit the binding of 282P1G3 to a bindingpartner, etc.

In vivo, the effect of a 282P1G3 therapeutic composition can beevaluated in a suitable animal model. For example, xenogenic prostatecancer models can be used, wherein human prostate cancer explants orpassaged xenograft tissues are introduced into immune compromisedanimals, such as nude or SCID mice (Klein et al., 1997, Nature Medicine3: 402-408). For example, PCT Patent Application WO98/16628 and U.S.Pat. No. 6,107,540 describe various xenograft models of human prostatecancer capable of recapitulating the development of primary tumors,micrometastasis, and the formation of osteoblastic metastasescharacteristic of late stage disease. Efficacy can be predicted usingassays that measure inhibition of tumor formation, tumor regression ormetastasis, and the like.

In vivo assays that evaluate the promotion of apoptosis are useful inevaluating therapeutic compositions. In one embodiment, xenografts fromtumor bearing mice treated with the therapeutic composition can beexamined for the presence of apoptotic foci and compared to untreatedcontrol xenograft-bearing mice. The extent to which apoptotic foci arefound in the tumors of the treated mice provides an indication of thetherapeutic efficacy of the composition.

The therapeutic compositions used in the practice of the foregoingmethods can be formulated into pharmaceutical compositions comprising acarrier suitable for the desired delivery method. Suitable carriersinclude any material that when combined with the therapeutic compositionretains the anti-tumor function of the therapeutic composition and isgenerally non-reactive with the patient's immune system. Examplesinclude, but are not limited to, any of a number of standardpharmaceutical carriers such as sterile phosphate buffered salinesolutions, bacteriostatic water, and the like (see, generally,Remington's Pharmaceutical Sciences 16^(th) Edition, A. Osal., Ed.,1980).

Therapeutic formulations can be solubilized and administered via anyroute capable of delivering the therapeutic composition to the tumorsite. Potentially effective routes of administration include, but arenot limited to, intravenous, parenteral, intraperitoneal, intramuscular,intratumor, intradermal, intraorgan, orthotopic, and the like. Apreferred formulation for intravenous injection comprises thetherapeutic composition in a solution of preserved bacteriostatic water,sterile unpreserved water, and/or diluted in polyvinylchloride orpolyethylene bags containing 0.9% sterile Sodium Chloride for Injection,USP. Therapeutic protein preparations can be lyophilized and stored assterile powders, preferably under vacuum, and then reconstituted inbacteriostatic water (containing for example, benzyl alcoholpreservative) or in sterile water prior to injection.

Dosages and administration protocols for the treatment of cancers usingthe foregoing methods will vary with the method and the target cancer,and will generally depend on a number of other factors appreciated inthe art.

XIII.) Identification, Characterization and Use of Modulators of 282P1G3

Methods to Identify and Use Modulators

In one embodiment, screening is performed to identify modulators thatinduce or suppress a particular expression profile, suppress or inducespecific pathways, preferably generating the associated phenotypethereby. In another embodiment, having identified differentiallyexpressed genes important in a particular state; screens are performedto identify modulators that alter expression of individual genes, eitherincrease or decrease. In another embodiment, screening is performed toidentify modulators that alter a biological function of the expressionproduct of a differentially expressed gene. Again, having identified theimportance of a gene in a particular state, screens are performed toidentify agents that bind and/or modulate the biological activity of thegene product.

In addition, screens are done for genes that are induced in response toa candidate agent. After identifying a modulator (one that suppresses acancer expression pattern leading to a normal expression pattern, or amodulator of a cancer gene that leads to expression of the gene as innormal tissue) a screen is performed to identify genes that arespecifically modulated in response to the agent. Comparing expressionprofiles between normal tissue and agent-treated cancer tissue revealsgenes that are not expressed in normal tissue or cancer tissue, but areexpressed in agent treated tissue, and vice versa. These agent-specificsequences are identified and used by methods described herein for cancergenes or proteins. In particular these sequences and the proteins theyencode are used in marking or identifying agent-treated cells. Inaddition, antibodies are raised against the agent-induced proteins andused to target novel therapeutics to the treated cancer tissue sample.

Modulator-Related Identification and Screening Assays:

Gene Expression-Related Assays

Proteins, nucleic acids, and antibodies of the invention are used inscreening assays. The cancer-associated proteins, antibodies, nucleicacids, modified proteins and cells containing these sequences are usedin screening assays, such as evaluating the effect of drug candidates ona “gene expression profile,” expression profile of polypeptides oralteration of biological function. In one embodiment, the expressionprofiles are used, preferably in conjunction with high throughputscreening techniques to allow monitoring for expression profile genesafter treatment with a candidate agent (e.g., Davis, G F, et al., J BiolScreen 7:69 (2002); Zlokarnik, et al., Science 279:84-8 (1998); Heid,Genome Res 6:986-94, 1996).

The cancer proteins, antibodies, nucleic acids, modified proteins andcells containing the native or modified cancer proteins or genes areused in screening assays. That is, the present invention comprisesmethods for screening for compositions which modulate the cancerphenotype or a physiological function of a cancer protein of theinvention. This is done on a gene itself or by evaluating the effect ofdrug candidates on a “gene expression profile” or biological function.In one embodiment, expression profiles are used, preferably inconjunction with high throughput screening techniques to allowmonitoring after treatment with a candidate agent, see Zlokamik, supra.

A variety of assays are executed directed to the genes and proteins ofthe invention. Assays are run on an individual nucleic acid or proteinlevel. That is, having identified a particular gene as up regulated incancer, test compounds are screened for the ability to modulate geneexpression or for binding to the cancer protein of the invention.“Modulation” in this context includes an increase or a decrease in geneexpression. The preferred amount of modulation will depend on theoriginal change of the gene expression in normal versus tissueundergoing cancer, with changes of at least 10%, preferably 50%, morepreferably 100-300%, and in some embodiments 300-1000% or greater. Thus,if a gene exhibits a 4-fold increase in cancer tissue compared to normaltissue, a decrease of about four-fold is often desired; similarly, a10-fold decrease in cancer tissue compared to normal tissue a targetvalue of a 10-fold increase in expression by the test compound is oftendesired. Modulators that exacerbate the type of gene expression seen incancer are also useful, e.g., as an upregulated target in furtheranalyses.

The amount of gene expression is monitored using nucleic acid probes andthe quantification of gene expression levels, or, alternatively, a geneproduct itself is monitored, e.g., through the use of antibodies to thecancer protein and standard immunoassays. Proteomics and separationtechniques also allow for quantification of expression.

Expression Monitoring to Identify Compounds that Modify Gene Expression

In one embodiment, gene expression monitoring, i.e., an expressionprofile, is monitored simultaneously for a number of entities. Suchprofiles will typically involve one or more of the genes of FIG. 2. Inthis embodiment, e.g., cancer nucleic acid probes are attached tobiochips to detect and quantify cancer sequences in a particular cell.Alternatively, PCR can be used. Thus, a series, e.g., wells of amicrotiter plate, can be used with dispensed primers in desired wells. APCR reaction can then be performed and analyzed for each well.

Expression monitoring is performed to identify compounds that modify theexpression of one or more cancer-associated sequences, e.g., apolynucleotide sequence set out in FIG. 2. Generally, a test modulatoris added to the cells prior to analysis. Moreover, screens are alsoprovided to identify agents that modulate cancer, modulate cancerproteins of the invention, bind to a cancer protein of the invention, orinterfere with the binding of a cancer protein of the invention and anantibody or other binding partner.

In one embodiment, high throughput screening methods involve providing alibrary containing a large number of potential therapeutic compounds(candidate compounds). Such “combinatorial chemical libraries” are thenscreened in one or more assays to identify those library members(particular chemical species or subclasses) that display a desiredcharacteristic activity. The compounds thus identified can serve asconventional “lead compounds,” as compounds for screening, or astherapeutics.

In certain embodiments, combinatorial libraries of potential modulatorsare screened for an ability to bind to a cancer polypeptide or tomodulate activity. Conventionally, new chemical entities with usefulproperties are generated by identifying a chemical compound (called a“lead compound”) with some desirable property or activity, e.g.,inhibiting activity, creating variants of the lead compound, andevaluating the property and activity of those variant compounds. Often,high throughput screening (HTS) methods are employed for such ananalysis.

As noted above, gene expression monitoring is conveniently used to testcandidate modulators (e.g., protein, nucleic acid or small molecule).After the candidate agent has been added and the cells allowed toincubate for a period, the sample containing a target sequence to beanalyzed is, e.g., added to a biochip.

If required, the target sequence is prepared using known techniques. Forexample, a sample is treated to lyse the cells, using known lysisbuffers, electroporation, etc., with purification and/or amplificationsuch as PCR performed as appropriate. For example, an in vitrotranscription with labels covalently attached to the nucleotides isperformed. Generally, the nucleic acids are labeled with biotin-FITC orPE, or with cy3 or cy5.

The target sequence can be labeled with, e.g., a fluorescent, achemiluminescent, a chemical, or a radioactive signal, to provide ameans of detecting the target sequence's specific binding to a probe.The label also can be an enzyme, such as alkaline phosphatase orhorseradish peroxidase, which when provided with an appropriatesubstrate produces a product that is detected. Alternatively, the labelis a labeled compound or small molecule, such as an enzyme inhibitor,that binds but is not catalyzed or altered by the enzyme. The label alsocan be a moiety or compound, such as, an epitope tag or biotin whichspecifically binds to streptavidin. For the example of biotin, thestreptavidin is labeled as described above, thereby, providing adetectable signal for the bound target sequence. Unbound labeledstreptavidin is typically removed prior to analysis.

As will be appreciated by those in the art, these assays can be directhybridization assays or can comprise “sandwich assays”, which includethe use of multiple probes, as is generally outlined in U.S. Pat. Nos.5,681,702; 5,597,909; 5,545,730; 5,594,117; 5,591,584; 5,571,670;5,580,731; 5,571,670; 5,591,584; 5,624,802; 5,635,352; 5,594,118;5,359,100; 5,124, 246; and 5,681,697. In this embodiment, in general,the target nucleic acid is prepared as outlined above, and then added tothe biochip comprising a plurality of nucleic acid probes, underconditions that allow the formation of a hybridization complex.

A variety of hybridization conditions are used in the present invention,including high, moderate and low stringency conditions as outlinedabove. The assays are generally run under stringency conditions whichallow formation of the label probe hybridization complex only in thepresence of target. Stringency can be controlled by altering a stepparameter that is a thermodynamic variable, including, but not limitedto, temperature, formamide concentration, salt concentration, chaotropicsalt concentration pH, organic solvent concentration, etc. Theseparameters may also be used to control non-specific binding, as isgenerally outlined in U.S. Pat. No. 5,681,697. Thus, it can be desirableto perform certain steps at higher stringency conditions to reducenon-specific binding.

The reactions outlined herein can be accomplished in a variety of ways.Components of the reaction can be added simultaneously, or sequentially,in different orders, with preferred embodiments outlined below. Inaddition, the reaction may include a variety of other reagents. Theseinclude salts, buffers, neutral proteins, e.g. albumin, detergents, etc.which can be used to facilitate optimal hybridization and detection,and/or reduce nonspecific or background interactions. Reagents thatotherwise improve the efficiency of the assay, such as proteaseinhibitors, nuclease inhibitors, anti-microbial agents, etc., may alsobe used as appropriate, depending on the sample preparation methods andpurity of the target. The assay data are analyzed to determine theexpression levels of individual genes, and changes in expression levelsas between states, forming a gene expression profile.

Biological Activity-Related Assays

The invention provides methods identify or screen for a compound thatmodulates the activity of a cancer-related gene or protein of theinvention. The methods comprise adding a test compound, as definedabove, to a cell comprising a cancer protein of the invention. The cellscontain a recombinant nucleic acid that encodes a cancer protein of theinvention. In another embodiment, a library of candidate agents istested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence orprevious or subsequent exposure of physiological signals, e.g. hormones,antibodies, peptides, antigens, cytokines, growth factors, actionpotentials, pharmacological agents including chemotherapeutics,radiation, carcinogenics, or other cells (i.e., cell-cell contacts). Inanother example, the determinations are made at different stages of thecell cycle process. In this way, compounds that modulate genes orproteins of the invention are identified. Compounds with pharmacologicalactivity are able to enhance or interfere with the activity of thecancer protein of the invention. Once identified, similar structures areevaluated to identify critical structural features of the compound.

In one embodiment, a method of modulating (e.g., inhibiting) cancer celldivision is provided; the method comprises administration of a cancermodulator. In another embodiment, a method of modulating (e.g.,inhibiting) cancer is provided; the method comprises administration of acancer modulator. In a further embodiment, methods of treating cells orindividuals with cancer are provided; the method comprisesadministration of a cancer modulator.

In one embodiment, a method for modulating the status of a cell thatexpresses a gene of the invention is provided. As used herein statuscomprises such art-accepted parameters such as growth, proliferation,survival, function, apoptosis, senescence, location, enzymatic activity,signal transduction, etc. of a cell. In one embodiment, a cancerinhibitor is an antibody as discussed above. In another embodiment, thecancer inhibitor is an antisense molecule. A variety of cell growth,proliferation, and metastasis assays are known to those of skill in theart, as described herein.

High Throughput Screening to Identify Modulators

The assays to identify suitable modulators are amenable to highthroughput screening. Preferred assays thus detect enhancement orinhibition of cancer gene transcription, inhibition or enhancement ofpolypeptide expression, and inhibition or enhancement of polypeptideactivity.

In one embodiment, modulators evaluated in high throughput screeningmethods are proteins, often naturally occurring proteins or fragments ofnaturally occurring proteins. Thus, e.g., cellular extracts containingproteins, or random or directed digests of proteinaceous cellularextracts, are used. In this way, libraries of proteins are made forscreening in the methods of the invention. Particularly preferred inthis embodiment are libraries of bacterial, fungal, viral, and mammalianproteins, with the latter being preferred, and human proteins beingespecially preferred. Particularly useful test compound will be directedto the class of proteins to which the target belongs, e.g., substratesfor enzymes, or ligands and receptors.

Use of Soft Agar Growth and Colony Formation to Identify andCharacterize Modulators

Normal cells require a solid substrate to attach and grow. When cellsare transformed, they lose this phenotype and grow detached from thesubstrate. For example, transformed cells can grow in stirred suspensionculture or suspended in semi-solid media, such as semi-solid or softagar. The transformed cells, when transfected with tumor suppressorgenes, can regenerate normal phenotype and once again require a solidsubstrate to attach to and grow. Soft agar growth or colony formation inassays are used to identify modulators of cancer sequences, which whenexpressed in host cells, inhibit abnormal cellular proliferation andtransformation. A modulator reduces or eliminates the host cells'ability to grow suspended in solid or semisolid media, such as agar.

Techniques for soft agar growth or colony formation in suspension assaysare described in Freshney, Culture of Animal Cells a Manual of BasicTechnique (3rd ed., 1994). See also, the methods section of Garkavtsevet al. (1996), supra.

Evaluation of Contact Inhibition and Growth Density Limitation toIdentify and Characterize Modulators

Normal cells typically grow in a flat and organized pattern in cellculture until they touch other cells. When the cells touch one another,they are contact inhibited and stop growing. Transformed cells, however,are not contact inhibited and continue to grow to high densities indisorganized foci. Thus, transformed cells grow to a higher saturationdensity than corresponding normal cells. This is detectedmorphologically by the formation of a disoriented monolayer of cells orcells in foci. Alternatively, labeling index with (3H)-thymidine atsaturation density is used to measure density limitation of growth,similarly an MTT or Alamar blue assay will reveal proliferation capacityof cells and the ability of modulators to affect same. See Freshney(1994), supra. Transformed cells, when transfected with tumor suppressorgenes, can regenerate a normal phenotype and become contact inhibitedand would grow to a lower density.

In this assay, labeling index with ³H)-thymidine at saturation densityis a preferred method of measuring density limitation of growth.Transformed host cells are transfected with a cancer-associated sequenceand are grown for 24 hours at saturation density in non-limiting mediumconditions. The percentage of cells labeling with (3H)-thymidine isdetermined by incorporated cpm.

Contact independent growth is used to identify modulators of cancersequences, which had led to abnormal cellular proliferation andtransformation. A modulator reduces or eliminates contact independentgrowth, and returns the cells to a normal phenotype.

Evaluation of Growth Factor or Serum Dependence to Identify andCharacterize Modulators

Transformed cells have lower serum dependence than their normalcounterparts (see, e.g., Temin, J. Natl. Cancer Inst. 37:167-175 (1966);Eagle et al., J. Exp. Med 131:836-879 (1970)); Freshney, supra. This isin part due to release of various growth factors by the transformedcells. The degree of growth factor or serum dependence of transformedhost cells can be compared with that of control. For example, growthfactor or serum dependence of a cell is monitored in methods to identifyand characterize compounds that modulate cancer-associated sequences ofthe invention.

Use of Tumor-Specific Marker Levels to Identify and CharacterizeModulators

Tumor cells release an increased amount of certain factors (hereinafter“tumor specific markers”) than their normal counterparts. For example,plasminogen activator (PA) is released from human glioma at a higherlevel than from normal brain cells (see, e.g., Gullino, Angiogenesis,Tumor Vascularization, and Potential Interference with Tumor Growth, inBiological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)).Similarly, Tumor Angiogenesis Factor (TAF) is released at a higher levelin tumor cells than their normal counterparts. See, e.g., Folkman,Angiogenesis and Cancer, Sem Cancer Biol. (1992)), while bFGF isreleased from endothelial tumors (Ensoli, B et al.).

Various techniques which measure the release of these factors aredescribed in Freshney (1994), supra. Also, see, Unkless et al., J. Biol.Chem. 249:4295-4305 (1974); Strickland & Beers, J. Biol. Chem.251:5694-5702 (1976); Whur et al., Br. J. Cancer 42:305 312 (1980);Gullino, Angiogenesis, Tumor Vascularization, and Potential Interferencewith Tumor Growth, in Biological Responses in Cancer, pp. 178-184(Mihich (ed.) 1985); Freshney, Anticancer Res. 5:111-130 (1985). Forexample, tumor specific marker levels are monitored in methods toidentify and characterize compounds that modulate cancer-associatedsequences of the invention.

Invasiveness into Matrigel to Identify and Characterize Modulators

The degree of invasiveness into Matrigel or an extracellular matrixconstituent can be used as an assay to identify and characterizecompounds that modulate cancer associated sequences. Tumor cells exhibita positive correlation between malignancy and invasiveness of cells intoMatrigel or some other extracellular matrix constituent. In this assay,tumorigenic cells are typically used as host cells. Expression of atumor suppressor gene in these host cells would decrease invasiveness ofthe host cells. Techniques described in Cancer Res. 1999; 59:6010;Freshney (1994), supra, can be used. Briefly, the level of invasion ofhost cells is measured by using filters coated with Matrigel or someother extracellular matrix constituent. Penetration into the gel, orthrough to the distal side of the filter, is rated as invasiveness, andrated histologically by number of cells and distance moved, or byprelabeling the cells with 1251 and counting the radioactivity on thedistal side of the filter or bottom of the dish. See, e.g., Freshney(1984), supra.

Evaluation of Tumor Growth In Vivo to Identify and CharacterizeModulators

Effects of cancer-associated sequences on cell growth are tested intransgenic or immune-suppressed organisms. Transgenic organisms areprepared in a variety of art-accepted ways. For example, knock-outtransgenic organisms, e.g., mammals such as mice, are made, in which acancer gene is disrupted or in which a cancer gene is inserted.Knock-out transgenic mice are made by insertion of a marker gene orother heterologous gene into the endogenous cancer gene site in themouse genome via homologous recombination. Such mice can also be made bysubstituting the endogenous cancer gene with a mutated version of thecancer gene, or by mutating the endogenous cancer gene, e.g., byexposure to carcinogens.

To prepare transgenic chimeric animals, e.g., mice, a DNA construct isintroduced into the nuclei of embryonic stem cells. Cells containing thenewly engineered genetic lesion are injected into a host mouse embryo,which is re-implanted into a recipient female. Some of these embryosdevelop into chimeric mice that possess germ cells some of which arederived from the mutant cell line. Therefore, by breeding the chimericmice it is possible to obtain a new line of mice containing theintroduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288(1989)). Chimeric mice can be derived according to U.S. Pat. No.6,365,797, issued 2 Apr. 2002; U.S. Pat. No. 6,107,540 issued 22 Aug.2000; Hogan et al., Manipulating the Mouse Embryo: A laboratory Manual,Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and EmbryonicStem Cells: A Practical Approach, Robertson, ed., IRL Press, Washington,D.C., (1987).

Alternatively, various immune-suppressed or immune-deficient hostanimals can be used. For example, a genetically athymic “nude” mouse(see, e.g., Giovanella et al., J. Natl. Cancer Inst. 52:921 (1974)), aSCID mouse, a thymectornized mouse, or an irradiated mouse (see, e.g.,Bradley et al., Br. J. Cancer 38:263 (1978); Selby et al., Br. J. Cancer41:52 (1980)) can be used as a host. Transplantable tumor cells(typically about 10⁶ cells) injected into isogenic hosts produceinvasive tumors in a high proportion of cases, while normal cells ofsimilar origin will not. In hosts which developed invasive tumors, cellsexpressing cancer-associated sequences are injected subcutaneously ororthotopically. Mice are then separated into groups, including controlgroups and treated experimental groups) e.g. treated with a modulator).After a suitable length of time, preferably 4-8 weeks, tumor growth ismeasured (e.g., by volume or by its two largest dimensions, or weight)and compared to the control. Tumors that have statistically significantreduction (using, e.g., Student's T test) are said to have inhibitedgrowth.

In Vitro Assays to Identify and Characterize Modulators

Assays to identify compounds with modulating activity can be performedin vitro. For example, a cancer polypeptide is first contacted with apotential modulator and incubated for a suitable amount of time, e.g.,from 0.5 to 48 hours. In one embodiment, the cancer polypeptide levelsare determined in vitro by measuring the level of protein or mRNA. Thelevel of protein is measured using immunoassays such as Westernblotting, ELISA and the like with an antibody that selectively binds tothe cancer polypeptide or a fragment thereof. For measurement of mRNA,amplification, e.g., using PCR, LCR, or hybridization assays, e.g.,Northern hybridization, RNAse protection, dot blotting, are preferred.The level of protein or mRNA is detected using directly or indirectlylabeled detection agents, e.g., fluorescently or radioactively labelednucleic acids, radioactively or enzymatically labeled antibodies, andthe like, as described herein.

Alternatively, a reporter gene system can be devised using a cancerprotein promoter operably linked to a reporter gene such as luciferase,green fluorescent protein, CAT, or P-gal. The reporter construct istypically transfected into a cell. After treatment with a potentialmodulator, the amount of reporter gene transcription, translation, oractivity is measured according to standard techniques known to those ofskill in the art (Davis G F, supra; Gonzalez, J. & Negulescu, P. Curr.Opin. Biotechnol. 1998: 9:624).

As outlined above, in vitro screens are done on individual genes andgene products. That is, having identified a particular differentiallyexpressed gene as important in a particular state, screening ofmodulators of the expression of the gene or the gene product itself isperformed.

In one embodiment, screening for modulators of expression of specificgene(s) is performed. Typically, the expression of only one or a fewgenes is evaluated. In another embodiment, screens are designed to firstfind compounds that bind to differentially expressed proteins. Thesecompounds are then evaluated for the ability to modulate differentiallyexpressed activity. Moreover, once initial candidate compounds areidentified, variants can be further screened to better evaluatestructure activity relationships.

Binding Assays to Identify and Characterize Modulators

In binding assays in accordance with the invention, a purified orisolated gene product of the invention is generally used. For example,antibodies are generated to a protein of the invention, and immunoassaysare run to determine the amount and/or location of protein.Alternatively, cells comprising the cancer proteins are used in theassays.

Thus, the methods comprise combining a cancer protein of the inventionand a candidate compound such as a ligand, and determining the bindingof the compound to the cancer protein of the invention. Preferredembodiments utilize the human cancer protein; animal models of humandisease of can also be developed and used. Also, other analogousmammalian proteins also can be used as appreciated by those of skill inthe art. Moreover, in some embodiments variant or derivative cancerproteins are used.

Generally, the cancer protein of the invention, or the ligand, isnon-diffusibly bound to an insoluble support. The support can, e.g., beone having isolated sample receiving areas (a microtiter plate, anarray, etc.). The insoluble supports can be made of any composition towhich the compositions can be bound, is readily separated from solublematerial, and is otherwise compatible with the overall method ofscreening. The surface of such supports can be solid or porous and ofany convenient shape.

Examples of suitable insoluble supports include microtiter plates,arrays, membranes and beads. These are typically made of glass, plastic(e.g., polystyrene), polysaccharide, nylon, nitrocellulose, or Teflon™,etc. Microtiter plates and arrays are especially convenient because alarge number of assays can be carried out simultaneously, using smallamounts of reagents and samples. The particular manner of binding of thecomposition to the support is not crucial so long as it is compatiblewith the reagents and overall methods of the invention, maintains theactivity of the composition and is nondiffusable. Preferred methods ofbinding include the use of antibodies which do not sterically blockeither the ligand binding site or activation sequence when attaching theprotein to the support, direct binding to “sticky” or ionic supports,chemical crosslinking, the synthesis of the protein or agent on thesurface, etc. Following binding of the protein or ligand/binding agentto the support, excess unbound material is removed by washing. Thesample receiving areas may then be blocked through incubation withbovine serum albumin (BSA), casein or other innocuous protein or othermoiety.

Once a cancer protein of the invention is bound to the support, and atest compound is added to the assay. Alternatively, the candidatebinding agent is bound to the support and the cancer protein of theinvention is then added. Binding agents include specific antibodies,non-natural binding agents identified in screens of chemical libraries,peptide analogs, etc.

Of particular interest are assays to identify agents that have a lowtoxicity for human cells. A wide variety of assays can be used for thispurpose, including proliferation assays, cAMP assays, labeled in vitroprotein-protein binding assays, electrophoretic mobility shift assays,immunoassays for protein binding, functional assays (phosphorylationassays, etc.) and the like.

A determination of binding of the test compound (ligand, binding agent,modulator, etc.) to a cancer protein of the invention can be done in anumber of ways. The test compound can be labeled, and binding determineddirectly, e.g., by attaching all or a portion of the cancer protein ofthe invention to a solid support, adding a labeled candidate compound(e.g., a fluorescent label), washing off excess reagent, and determiningwhether the label is present on the solid support. Various blocking andwashing steps can be utilized as appropriate.

In certain embodiments, only one of the components is labeled, e.g., aprotein of the invention or ligands labeled. Alternatively, more thanone component is labeled with different labels, e.g., I¹²⁵, for theproteins and a fluorophor for the compound. Proximity reagents, e.g.,quenching or energy transfer reagents are also useful.

Competitive Binding to Identify and Characterize Modulators

In one embodiment, the binding of the “test compound” is determined bycompetitive binding assay with a “competitor.” The competitor is abinding moiety that binds to the target molecule (e.g., a cancer proteinof the invention). Competitors include compounds such as antibodies,peptides, binding partners, ligands, etc. Under certain circumstances,the competitive binding between the test compound and the competitordisplaces the test compound. In one embodiment, the test compound islabeled. Either the test compound, the competitor, or both, is added tothe protein for a time sufficient to allow binding. Incubations areperformed at a temperature that facilitates optimal activity, typicallybetween four and 40° C. Incubation periods are typically optimized,e.g., to facilitate rapid high throughput screening; typically betweenzero and one hour will be sufficient. Excess reagent is generallyremoved or washed away. The second component is then added, and thepresence or absence of the labeled component is followed, to indicatebinding.

In one embodiment, the competitor is added first, followed by the testcompound. Displacement of the competitor is an indication that the testcompound is binding to the cancer protein and thus is capable of bindingto, and potentially modulating, the activity of the cancer protein. Inthis embodiment, either component can be labeled. Thus, e.g., if thecompetitor is labeled, the presence of label in the post-test compoundwash solution indicates displacement by the test compound.Alternatively, if the test compound is labeled, the presence of thelabel on the support indicates displacement.

In an alternative embodiment, the test compound is added first, withincubation and washing, followed by the competitor. The absence ofbinding by the competitor indicates that the test compound binds to thecancer protein with higher affinity than the competitor. Thus, if thetest compound is labeled, the presence of the label on the support,coupled with a lack of competitor binding, indicates that the testcompound binds to and thus potentially modulates the cancer protein ofthe invention.

Accordingly, the competitive binding methods comprise differentialscreening to identity agents that are capable of modulating the activityof the cancer proteins of the invention. In this embodiment, the methodscomprise combining a cancer protein and a competitor in a first sample.A second sample comprises a test compound, the cancer protein, and acompetitor. The binding of the competitor is determined for bothsamples, and a change, or difference in binding between the two samplesindicates the presence of an agent capable of binding to the cancerprotein and potentially modulating its activity. That is, if the bindingof the competitor is different in the second sample relative to thefirst sample, the agent is capable of binding to the cancer protein.

Alternatively, differential screening is used to identify drugcandidates that bind to the native cancer protein, but cannot bind tomodified cancer proteins. For example the structure of the cancerprotein is modeled and used in rational drug design to synthesize agentsthat interact with that site, agents which generally do not bind tosite-modified proteins. Moreover, such drug candidates that affect theactivity of a native cancer protein are also identified by screeningdrugs for the ability to either enhance or reduce the activity of suchproteins.

Positive controls and negative controls can be used in the assays.Preferably control and test samples are performed in at least triplicateto obtain statistically significant results. Incubation of all samplesoccurs for a time sufficient to allow for the binding of the agent tothe protein. Following incubation, samples are washed free ofnon-specifically bound material and the amount of bound, generallylabeled agent determined. For example, where a radiolabel is employed,the samples can be counted in a scintillation counter to determine theamount of bound compound.

A variety of other reagents can be included in the screening assays.These include reagents like salts, neutral proteins, e.g. albumin,detergents, etc. which are used to facilitate optimal protein-proteinbinding and/or reduce non-specific or background interactions. Alsoreagents that otherwise improve the efficiency of the assay, such asprotease inhibitors, nuclease inhibitors, anti-microbial agents, etc.,can be used. The mixture of components is added in an order thatprovides for the requisite binding.

Use of Polynucleotides to Down-Regulate or Inhibit a Protein of theInvention.

Polynucleotide modulators of cancer can be introduced into a cellcontaining the target nucleotide sequence by formation of a conjugatewith a ligand-binding molecule, as described in WO 91/04753. Suitableligand-binding molecules include, but are not limited to, cell surfacereceptors, growth factors, other cytokines, or other ligands that bindto cell surface receptors. Preferably, conjugation of the ligand bindingmolecule does not substantially interfere with the ability of the ligandbinding molecule to bind to its corresponding molecule or receptor, orblock entry of the sense or antisense oligonucleotide or its conjugatedversion into the cell. Alternatively, a polynucleotide modulator ofcancer can be introduced into a cell containing the target nucleic acidsequence, e.g., by formation of a polynucleotide-lipid complex, asdescribed in WO 90/10448. It is understood that the use of antisensemolecules or knock out and knock in models may also be used in screeningassays as discussed above, in addition to methods of treatment.

Inhibitory and Antisense Nucleotides

In certain embodiments, the activity of a cancer-associated protein isdown-regulated, or entirely inhibited, by the use of antisensepolynucleotide or inhibitory small nuclear RNA (snRNA), i.e., a nucleicacid complementary to, and which can preferably hybridize specificallyto, a coding mRNA nucleic acid sequence, e.g., a cancer protein of theinvention, mRNA, or a subsequence thereof. Binding of the antisensepolynucleotide to the mRNA reduces the translation and/or stability ofthe mRNA.

In the context of this invention, antisense polynucleotides can comprisenaturally occurring nucleotides, or synthetic species formed fromnaturally occurring subunits or their close homologs. Antisensepolynucleotides may also have altered sugar moieties or inter-sugarlinkages. Exemplary among these are the phosphorothioate and othersulfur containing species which are known for use in the art. Analogsare comprised by this invention so long as they function effectively tohybridize with nucleotides of the invention. See, e.g., IsisPharmaceuticals, Carlsbad, Calif.; Sequitor, Inc., Natick, Mass.

Such antisense polynucleotides can readily be synthesized usingrecombinant means, or can be synthesized in vitro. Equipment for suchsynthesis is sold by several vendors, including Applied Biosystems. Thepreparation of other oligonucleotides such as phosphorothioates andalkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or senseoligonucleotides. Sense oligonucleotides can, e.g., be employed to blocktranscription by binding to the anti-sense strand. The antisense andsense oligonucleotide comprise a single stranded nucleic acid sequence(either RNA or DNA) capable of binding to target mRNA (sense) or DNA(antisense) sequences for cancer molecules. Antisense or senseoligonucleotides, according to the present invention, comprise afragment generally at least about 12 nucleotides, preferably from about12 to 30 nucleotides. The ability to derive an antisense or a senseoligonucleotide, based upon a cDNA sequence encoding a given protein isdescribed in, e.g., Stein &Cohen (Cancer Res. 48:2659 (1988 and van derKrol et al. (BioTechniques 6:958 (1988)).

Ribozymes

In addition to antisense polynucleotides, ribozymes can be used totarget and inhibit transcription of cancer-associated nucleotidesequences. A ribozyme is an RNA molecule that catalytically cleavesother RNA molecules. Different kinds of ribozymes have been described,including group I ribozymes, hammerhead ribozymes, hairpin ribozymes,RNase P, and axhead ribozymes (see, e.g., Castanotto et al., Adv. inPharmacology 25: 289-317 (1994) for a general review of the propertiesof different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampelet al., Nucl. Acids Res. 18:299-304 (1990); European Patent PublicationNo. 0360257; U.S. Pat. No. 5,254,678. Methods of preparing are wellknown to those of skill in the art (see, e.g., WO 94/26877; Ojwang etal, Proc. Nat. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al., HumanGene Therapy 1:39-45 (1994); Leavitt et al., Proc. Natl. Acad. Sci. USA92:699-703 (1995); Leavitt et al., Human Gene Therapy 5: 1151-120(1994); and Yamada et al., Virology 205: 121-126 (1994)).

Use of Modulators in Phenotypic Screening

In one embodiment, a test compound is administered to a population ofcancer cells, which have an associated cancer expression profile. By“administration” or “contacting” herein is meant that the modulator isadded to the cells in such a manner as to allow the modulator to actupon the cell, whether by uptake and intracellular action, or by actionat the cell surface. In some embodiments, a nucleic acid encoding aproteinaceous agent (i.e., a peptide) is put into a viral construct suchas an adenoviral or retroviral construct, and added to the cell, suchthat expression of the peptide agent is accomplished, e.g., PCTUS97/01019. Regulatable gene therapy systems can also be used. Once themodulator has been administered to the cells, the cells are washed ifdesired and are allowed to incubate under preferably physiologicalconditions for some period. The cells are then harvested and a new geneexpression profile is generated. Thus, e.g., cancer tissue is screenedfor agents that modulate, e.g., induce or suppress, the cancerphenotype. A change in at least one gene, preferably many, of theexpression profile indicates that the agent has an effect on canceractivity. Similarly, altering a biological function or a signalingpathway is indicative of modulator activity. By defining such asignature for the cancer phenotype, screens for new drugs that alter thephenotype are devised. With this approach, the drug target need not beknown and need not be represented in the original gene/proteinexpression screening platform, nor does the level of transcript for thetarget protein need to change. The modulator inhibiting function willserve as a surrogate marker

As outlined above, screens are done to assess genes or gene products.That is, having identified a particular differentially expressed gene asimportant in a particular state, screening of modulators of either theexpression of the gene or the gene product itself is performed.

Use of Modulators to Affect Peptides of the Invention

Measurements of cancer polypeptide activity, or of the cancer phenotypeare performed using a variety of assays. For example, the effects ofmodulators upon the function of a cancer polypeptide(s) are measured byexamining parameters described above. A physiological change thataffects activity is used to assess the influence of a test compound onthe polypeptides of this invention. When the functional outcomes aredetermined using intact cells or animals, a variety of effects can beassesses such as, in the case of a cancer associated with solid tumors,tumor growth, tumor metastasis, neovascularization, hormone release,transcriptional changes to both known and uncharacterized geneticmarkers (e.g., by Northern blots), changes in cell metabolism such ascell growth or pH changes, and changes in intracellular secondmessengers such as cGNIP.

Methods of Identifying Characterizing Cancer-Associated Sequences

Expression of various gene sequences is correlated with cancer.Accordingly, disorders based on mutant or variant cancer genes aredetermined. In one embodiment, the invention provides methods foridentifying cells containing variant cancer genes, e.g., determining thepresence of, all or part, the sequence of at least one endogenous cancergene in a cell. This is accomplished using any number of sequencingtechniques. The invention comprises methods of identifying the cancergenotype of an individual, e.g., determining all or part of the sequenceof at least one gene of the invention in the individual. This isgenerally done in at least one tissue of the individual, e.g., a tissueset forth in Table I, and may include the evaluation of a number oftissues or different samples of the same tissue. The method may includecomparing the sequence of the sequenced gene to a known cancer gene,i.e., a wild-type gene to determine the presence of family members,homologies, mutations or variants. The sequence of all or part of thegene can then be compared to the sequence of a known cancer gene todetermine if any differences exist. This is done using any number ofknown homology programs, such as BLAST, Bestfit, etc. The presence of adifference in the sequence between the cancer gene of the patient andthe known cancer gene correlates with a disease state or a propensityfor a disease state, as outlined herein.

In a preferred embodiment, the cancer genes are used as probes todetermine the number of copies of the cancer gene in the genome. Thecancer genes are used as probes to determine the chromosomallocalization of the cancer genes. Information such as chromosomallocalization finds use in providing a diagnosis or prognosis inparticular when chromosomal abnormalities such as translocations, andthe like are identified in the cancer gene locus.

XIV.) Kits/Articles of Manufacture

For use in the laboratory, prognostic, prophylactic, diagnostic andtherapeutic applications described herein, kits are within the scope ofthe invention. Such kits can comprise a carrier, package, or containerthat is compartmentalized to receive one or more containers such asvials, tubes, and the like, each of the container(s) comprising one ofthe separate elements to be used in the method, along with a label orinsert comprising instructions for use, such as a use described herein.For example, the container(s) can comprise a probe that is or can bedetectably labeled. Such probe can be an antibody or polynucleotidespecific for a protein or a gene or message of the invention,respectively. Where the method utilizes nucleic acid hybridization todetect the target nucleic acid, the kit can also have containerscontaining nucleotide(s) for amplification of the target nucleic acidsequence. Kits can comprise a container comprising a reporter, such as abiotin-binding protein, such as avidin or streptavidin, bound to areporter molecule, such as an enzymatic, fluorescent, or radioisotopelabel; such a reporter can be used with, e.g., a nucleic acid orantibody. The kit can include all or part of the amino acid sequences inFIG. 2 or FIG. 3 or analogs thereof, or a nucleic acid molecule thatencodes such amino acid sequences.

The kit of the invention will typically comprise the container describedabove and one or more other containers associated therewith thatcomprise materials desirable from a commercial and user standpoint,including buffers, diluents, filters, needles, syringes; carrier,package, container, vial and/or tube labels listing contents and/orinstructions for use, and package inserts with instructions for use.

A label can be present on or with the container to indicate that thecomposition is used for a specific therapy or non-therapeuticapplication, such as a prognostic, prophylactic, diagnostic orlaboratory application, and can also indicate directions for either invivo or in vitro use, such as those described herein. Directions and orother information can also be included on an insert(s) or label(s) whichis included with or on the kit. The label can be on or associated withthe container. A label a can be on a container when letters, numbers orother characters forming the label are molded or etched into thecontainer itself; a label can be associated with a container when it ispresent within a receptacle or carrier that also holds the container,e.g., as a package insert. The label can indicate that the compositionis used for diagnosing, treating, prophylaxing or prognosing acondition, such as a neoplasia of a tissue set forth in Table I.

The terms “kit” and “article of manufacture” can be used as synonyms.

In another embodiment of the invention, an article(s) of manufacturecontaining compositions, such as amino acid sequence(s), smallmolecule(s), nucleic acid sequence(s), and/or antibody(s), e.g.,materials useful for the diagnosis, prognosis, prophylaxis and/ortreatment of neoplasias of tissues such as those set forth in Table I isprovided. The article of manufacture typically comprises at least onecontainer and at least one label. Suitable containers include, forexample, bottles, vials, syringes, and test tubes. The containers can beformed from a variety of materials such as glass, metal or plastic. Thecontainer can hold amino acid sequence(s), small molecule(s), nucleicacid sequence(s), cell population(s) and/or antibody(s). In oneembodiment, the container holds a polynucleotide for use in examiningthe mRNA expression profile of a cell, together with reagents used forthis purpose. In another embodiment a container comprises an antibody,binding fragment thereof or specific binding protein for use inevaluating protein expression of 282P1G3 in cells and tissues, or forrelevant laboratory, prognostic, diagnostic, prophylactic andtherapeutic purposes; indications and/or directions for such uses can beincluded on or with such container, as can reagents and othercompositions or tools used for these purposes. In another embodiment, acontainer comprises materials for eliciting a cellular or humoral immuneresponse, together with associated indications and/or directions. Inanother embodiment, a container comprises materials for adoptiveimmunotherapy, such as cytotoxic T cells (CTL) or helper T cells (HTL),together with associated indications and/or directions; reagents andother compositions or tools used for such purpose can also be included.

The container can alternatively hold a composition that is effective fortreating, diagnosis, prognosing or prophylaxing a condition and can havea sterile access port (for example the container can be an intravenoussolution bag or a vial having a stopper pierceable by a hypodermicinjection needle). The active agents in the composition can be anantibody capable of specifically binding 282P1G3 and modulating thefunction of 282P1G3.

The article of manufacture can further comprise a second containercomprising a pharmaceutically-acceptable buffer, such asphosphate-buffered saline, Ringer's solution and/or dextrose solution.It can further include other materials desirable from a commercial anduser standpoint, including other buffers, diluents, filters, stirrers,needles, syringes, and/or package inserts with indications and/orinstructions for use.

EXAMPLES

Various aspects of the invention are further described and illustratedby way of the several examples that follow, none of which are intendedto limit the scope of the invention.

Example 1 SSH-Generated Isolation of cDNA Fragment of the 282P1G3 Gene

To isolate genes that are over-expressed in pancreatic cancer we usedthe Suppression Subtractive Hybridization (SSH) procedure using cDNAderived from pancreatic cancer tissues. The 282P1G3 SSH cDNA sequencewas derived from pancreatic tumor minus cDNAs derived from normalpancreas. The 282P1G3 cDNA was identified as highly expressed in thepancreas cancer.

Materials and Methods

Human Tissues:

The patient cancer and normal tissues were purchased from differentsources such as the NDRI (Philadelphia, Pa.). mRNA for some normaltissues were purchased from Clontech, Palo Alto, Calif.

RNA Isolation:

Tissues were homogenized in Trizol reagent (Life Technologies, GibcoBRL) using 10 ml/g tissue isolate total RNA. Poly A RNA was purifiedfrom total RNA using Qiagen's Oligotex mRNA Mini and Midi kits. Totaland mRNA were quantified by spectrophotometric analysis (O.D. 260/280nm) and analyzed by gel electrophoresis.

Oligonucleotides:

The following HPLC purified oligonucleotides were used:

DPNCDN (cDNA synthesis primer): (SEQ ID NO: 41) 5′TTTTGATCAAGCTT₃₀3′Adaptor 1: (SEQ ID NO: 42)5′CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGGCAG3′ (SEQ ID NO: 43)3′GGCCCGTCCTAG5′ Adaptor 2: (SEQ ID NO: 44)5′GTAATACGACTCACTATAGGGCAGCGTGGTCGCGGCCGAG3′ (SEQ ID NO: 45)3′CGGCTCCTAG5′ PCR primer 1: (SEQ ID NO: 46) 5′CTAATACGACTCACTATAGGGC3′Nested primer (NP)1: (SEQ ID NO: 47) 5′TCGAGCGGCCGCCCGGGCAGGA3′ Nestedprimer (NP)2: (SEQ ID NO: 48) 5′AGCGTGGTCGCGGCCGAGGA3′

Suppression Subtractive Hybridization:

Suppression Subtractive Hybridization (SSH) was used to identify cDNAscorresponding to genes that may be differentially expressed in pancreascancer. The SSH reaction utilized cDNA from pancreas cancer and normaltissues.

The gene 282P1G3 sequence was derived from pancreas cancer minus normalpancreas cDNA subtraction. The SSH DNA sequence (FIG. 1) was identified.

The cDNA derived from normal pancreas mixed with a pool of 9 normaltissues was used as the source of the “driver” cDNA, while the cDNA frompancreas cancer was used as the source of the “tester” cDNA. Doublestranded cDNAs corresponding to tester and driver cDNAs were synthesizedfrom 2 μg of poly(A), RNA isolated from the relevant xenograft tissue,as described above, using CLONTECH's PCR-Select cDNA Subtraction Kit and1 ng of oligonucleotide DPNCDN as primer. First- and second-strandsynthesis were carried out as described in the Kit's user manualprotocol (CLONTECH Protocol No. PT1117-1, Catalog No. K1804-1). Theresulting cDNA was digested with Dpn II for 3 hrs at 37° C. DigestedcDNA was extracted with phenol/chloroform (1:1) and ethanolprecipitated.

Driver cDNA was generated by combining in a 1:1 ratio Dpn II digestedcDNA from normal pancreas with a mix of digested cDNAs derived from thenine normal tissues: stomach, skeletal muscle, lung, brain, liver,kidney, pancreas, small intestine, and heart.

Tester cDNA was generated by diluting 1 μl of Dpn II digested cDNA fromthe relevant tissue source (see above) (400 ng) in 5 μl of water. Thediluted cDNA (2 μl, 160 ng) was then ligated to 2 μl of Adaptor 1 andAdaptor 2 (10 μM), in separate ligation reactions, in a total volume of10 μl at 16° C. overnight, using 400 u of T4 DNA ligase (CLONTECH).Ligation was terminated with 1 μl of 0.2 M EDTA and heating at 72° C.for 5 min.

The first hybridization was performed by adding 1.5 μl (600 ng) ofdriver cDNA to each of two tubes containing 1.5 μl (20 ng) Adaptor 1-and Adaptor 2-ligated tester cDNA. In a final volume of 4 μl, thesamples were overlaid with mineral oil, denatured in an MJ Researchthermal cycler at 98° C. for 1.5 minutes, and then were allowed tohybridize for 8 hrs at 68° C. The two hybridizations were then mixedtogether with an additional 1 μl of fresh denatured driver cDNA and wereallowed to hybridize overnight at 68° C. The second hybridization wasthen diluted in 200 μl of 20 mM Hepes, pH 8.3, 50 mM NaCl, 0.2 mM EDTA,heated at 70° C. for 7 min. and stored at −20° C.

PCR Amplification, Cloning and Sequencing of Gene Fragments Generatedfrom SSH:

To amplify gene fragments resulting from SSH reactions, two PCRamplifications were performed. In the primary PCR reaction 1 μl of thediluted final hybridization mix was added to 1 μl of PCR primer 1 (10μM), 0.5 μl dNTP mix (10 μM), 2.5 μl 10× reaction buffer (CLONTECH) and0.5 μl 50× Advantage cDNA polymerase Mix (CLONTECH) in a final volume of25 μl. PCR 1 was conducted using the following conditions: 75° C. for 5min., 94° C. for 25 sec., then 27 cycles of 94° C. for 10 sec, 66° C.for 30 sec, 72° C. for 1.5 min. Five separate primary PCR reactions wereperformed for each experiment. The products were pooled and diluted 1:10with water. For the secondary PCR reaction, 1 μl from the pooled anddiluted primary PCR reaction was added to the same reaction mix as usedfor PCR 1, except that primers NP1 and NP2 (10 μM) were used instead ofPCR primer 1. PCR 2 was performed using 10-12 cycles of 94° C. for 10sec, 68° C. for 30 sec, and 72° C. for 1.5 minutes. The PCR productswere analyzed using 2% agarose gel electrophoresis.

The PCR products were inserted into pCR2.1 using the T/A vector cloningkit (Invitrogen). Transformed E. coli were subjected to blue/white andampicillin selection. White colonies were picked and arrayed into 96well plates and were grown in liquid culture overnight. To identifyinserts, PCR amplification was performed on 1 μl of bacterial cultureusing the conditions of PCR1 and NP1 and NP2 as primers. PCR productswere analyzed using 2% agarose gel electrophoresis.

Bacterial clones were stored in 20% glycerol in a 96 well format.Plasmid DNA was prepared, sequenced, and subjected to nucleic acidhomology searches of the GenBank, dBest, and NCI-CGAP databases.

RT-PCR Expression Analysis:

First strand cDNAs can be generated from 1 μg of mRNA with oligo(dT)12-18 priming using the Gibco-BRL Superscript Preamplificationsystem. The manufacturer's protocol was used which included anincubation for 50 min at 42° C. with reverse transcriptase followed byRNAse H treatment at 37° C. for 20 min. After completing the reaction,the volume can be increased to 200 μl with water prior to normalization.First strand cDNAs from 16 different normal human tissues can beobtained from Clontech.

Normalization of the first strand cDNAs from multiple tissues wasperformed by using the primers 5′atatcgccgcgctcgtcgtcgacaa3′ (SEQ ID NO:49) and 5′agccacacgcagctcattgtagaagg 3′ (SEQ ID NO: 50) toamplify-actin. First strand cDNA (5 μl) were amplified in a total volumeof 50 μl containing 0.4 μM primers, 0.2 μM each dNTPs, 1×PCR buffer(Clontech, 10 mM Tris-HCL, 1.5 mM MgCl2, 50 mM KCl, pH8.3) and 1×Klentaq DNA polymerase (Clontech). Five μl of the PCR reaction can beremoved at 18, 20, and 22 cycles and used for agarose gelelectrophoresis. PCR was performed using an MJ Research thermal cyclerunder the following conditions: Initial denaturation can be at 94° C.for 15 sec, followed by a 18, 20, and 22 cycles of 94° C. for 15, 65° C.for 2 min, 72° C. for 5 sec. A final extension at 72° C. was carried outfor 2 min. After agarose gel electrophoresis, the band intensities ofthe 283 bp β-actin bands from multiple tissues were compared by visualinspection. Dilution factors for the first strand cDNAs were calculatedto result in equal β-actin band intensities in all tissues after 22cycles of PCR. Three rounds of normalization can be required to achieveequal band intensities in all tissues after 22 cycles of PCR.

To determine expression levels of the 282P1G3 gene, 5 μl of normalizedfirst strand cDNA were analyzed by PCR using 26, and 30 cycles ofamplification. Semi-quantitative expression analysis can be achieved bycomparing the PCR products at cycle numbers that give light bandintensities. The primers used for RT-PCR were designed using the 282P1G3SSH sequence and are listed below:

282P1G3.1 5′-TAAGGTCTCAGCTGTAAACCAAAAG-3′ (SEQ ID NO: 51) 282P1G3.25′-CTGTTTTAAGATTGTTGGAACCTGT-3′ (SEQ ID NO: 52)

A typical RT-PCR expression analysis is shown in FIG. 14. First strandcDNA was prepared from vital pool 1 (liver, lung and kidney), vital pool2 (pancreas, colon and stomach), normal pancreas, ovary cancer pool, andpancreas cancer pool. Normalization was performed by PCR using primersto actin and GAPDH. Semi-quantitative PCR, using primers to 282P1G3, wasperformed at 26 and 30 cycles of amplification. Expression of 282P1G3was detected in ovary cancer pool, pancreas cancer pool vital pool 1,but not in vital pool 2 nor in normal pancreas.

Example 2 Isolation of Full Length 282P1G3 Encoding cDNA

The 282P1G3 SSH cDNA sequence was derived from a subtraction consistingof pancreas cancer minus a normal pancreas. The SSH cDNA sequence of 321bp (FIG. 1) was designated 282P1G3.

282P1G3 v.2 of 3464 bp was cloned from a pool of normal tissue cDNAlibrary, revealing an ORF of 1171 amino acids (FIG. 2 and FIG. 3). Othervariants of 282P1G3 were also identified and these are listed in FIG. 2and FIG. 3.

282P1G3 v.1, v.9, v.10, v.11, v.24 and v.25 proteins are 1224 aminoacids in length and differ from each other by one amino acid as shown inFIG. 11. 282P1G3 v.12 through v.23, v.26 and v.27 are SNP variants andcode for the same protein as 282P1G3 v.1. 282P1G3 v.2, v.3, v.4, v.5,v.6, v.7, and v.8 are splice variants of 282P1G3 v.1 and code forproteins of 1171, 893, 1117, 1208, 1183, 1236, and 1195 amino acids,respectively. 282P1G3 v.28 is a splice variant identified by the 282P1G3SSH, and deletes the second exon of v.1.

282P1G3 v.1 shows 99% identity over 7650 nucleotides to cell adhesionmolecule with homology to L1CAM (close homolog of L1) (CHL1), accessionnumber NM_(—)006614. It is a neural recognition molecule that may beinvolved in signal transduction pathways. 282P1G3 v.2 is a novel splicevariant of 282P1G3 and has not been previously described.

Example 3 Chromosomal Mapping of 282P1G3

Chromosomal localization can implicate genes in disease pathogenesis.Several chromosome mapping approaches are available includingfluorescent in situ hybridization (FISH), human/hamster radiation hybrid(RH) panels (Walter et al., 1994; Nature Genetics 7:22; ResearchGenetics, Huntsville Ala.), human-rodent somatic cell hybrid panels suchas is available from the Cornell Institute (Camden, N.J.), and genomicviewers utilizing BLAST homologies to sequenced and mapped genomicclones (NCBI, Bethesda, Md.).

282P1G3 maps to chromosome 3p26.1 using 282P1G3 sequence and the NCBIBLAST tool located on the World Wide Web.

Example 4 Expression Analysis of 282P1G3 in Normal Tissues and PatientSpecimens

Expression analysis by RT-PCR demonstrated that 282P1G3 is stronglyexpressed in pancreas cancer and ovary cancer patient specimens (FIG.14). First strand cDNA was prepared from (A) vital pool 1 (liver, lungand kidney), vital pool 2 (pancreas, colon and stomach), normalpancreas, ovary cancer pool, and pancreas cancer pool; (B) normalstomach, normal brain, normal heart, normal liver, normal skeletalmuscle, normal testis, normal prostate, normal bladder, normal kidney,normal colon, normal lung, normal pancreas, and a pool of cancerspecimens from pancreas cancer patients, ovary cancer patients, andcancer metastasis specimens. Normalization was performed by PCR usingprimers to actin. Semi-quantitative PCR, using primers to 282P1G3, wasperformed at 26 and 30 cycles of amplification. (A) Expression of282P1G3 was detected in ovary cancer pool, pancreas cancer pool vitalpool 1, but not in vital pool 2 nor in normal pancreas. (B) Samples wererun on an agarose gel, and PCR products were quantitated using theAlphalmager software. Results show strong expression in pancreas cancer,ovary cancer, cancer metastasis, and normal brain compared to all othernormal tissues tested.

Extensive expression of 282P1G3 in normal tissues is shown in FIG. 15.Two multiple tissue northern blots (Clontech) both with 2 μg ofmRNA/lane were probed with the 282P1G3 sequence. Size standards inkilobases (kb) are indicated on the side. Results show expression of anapproximately 9-10 kb transcript in normal but not in any other normaltissue tested.

Expression of 282P1G3 in pancreas cancer patient specimens is shown inFIG. 16. RNA was extracted from pancreas cancer cell lines (CL), normalpancreas (N), and pancreas cancer patient tumor (T). Northern blots with10 μg of total RNA were probed with the 282P1G3 SSH fragment. Sizestandards in kilobases are on the side. Results show expression of282P1G3 in pancreas cancer patient tumor specimen but not in the celllines nor in the normal pancreas.

Expression of 282P1G3 was also detected in ovary cancer patientspecimens (FIG. 17). RNA was extracted from ovary cancer cell lines(CL), normal ovary (N), and ovary cancer patient tumor (T). Northernblots with 10 μg of total RNA were probed with the 282P1G3 DNA probe.Size standards in kilobases are on the side. Results show expression of282P1G3 in ovary cancer patient tumor specimen but not in the cell linesnor in the normal ovary.

FIG. 18 shows expression of 282P1G3 in lymphoma cancer patientspecimens. RNA was extracted from peripheral blood lymphocytes, cordblood isolated from normal individuals, and from lymphoma patient cancerspecimens. Northern blots with 10 μg of total RNA were probed with the282P1G3 sequence. Size standards in kilobases are on the side. Resultsshow expression of 282P1G3 in lymphoma patient specimens but not in thenormal blood cells tested.

The restricted expression of 282P1G3 in normal tissues and theexpression detected in cancer patient specimens suggest that 282P1G3 isa potential therapeutic target and a diagnostic marker for humancancers.

Example 5 Transcript Variants of 282P1G3

Transcript variants are variants of mature mRNA from the same gene whicharise by alternative transcription or alternative splicing. Alternativetranscripts are transcripts from the same gene but start transcriptionat different points. Splice variants are mRNA variants spliceddifferently from the same transcript. In eukaryotes, when a multi-exongene is transcribed from genomic DNA, the initial RNA is spliced toproduce functional mRNA, which has only exons and is used fortranslation into an amino acid sequence. Accordingly, a given gene canhave zero to many alternative transcripts and each transcript can havezero to many splice variants. Each transcript variant has a unique exonmakeup, and can have different coding and/or non-coding (5′ or 3′ end)portions, from the original transcript. Transcript variants can code forsimilar or different proteins with the same or a similar function or canencode proteins with different functions, and can be expressed in thesame tissue at the same time, or in different tissues at the same time,or in the same tissue at different times, or in different tissues atdifferent times. Proteins encoded by transcript variants can havesimilar or different cellular or extracellular localizations, e.g.,secreted versus intracellular.

Transcript variants are identified by a variety of art-accepted methods.For example, alternative transcripts and splice variants are identifiedby full-length cloning experiment, or by use of full-length transcriptand EST sequences. First, all human ESTs were grouped into clusterswhich show direct or indirect identity with each other. Second, ESTs inthe same cluster were further grouped into sub-clusters and assembledinto a consensus sequence. The original gene sequence is compared to theconsensus sequence(s) or other full-length sequences. Each consensussequence is a potential splice variant for that gene. Even when avariant is identified that is not a full-length clone, that portion ofthe variant is very useful for antigen generation and for furthercloning of the full-length splice variant, using techniques known in theart.

Moreover, computer programs are available in the art that identifytranscript variants based on genomic sequences. Genomic-based transcriptvariant identification programs include FgenesH (A. Salamov and V.Solovyev, “Ab initio gene finding in Drosophila genomic DNA,” GenomeResearch. 2000 April; 10(4):516-22); Grail and GenScan on the World WideWeb. For a general discussion of splice variant identification protocolssee., e.g., Southan, C., A genomic perspective on human proteases, FEBSLett. 2001 Jun. 8; 498(2-3):214-8; de Souza, S. J., et al.,Identification of human chromosome 22 transcribed sequences with ORFexpressed sequence tags, Proc. Natl Acad Sci USA. 2000 Nov. 7;97(23):12690-3.

To further confirm the parameters of a transcript variant, a variety oftechniques are available in the art, such as full-length cloning,proteomic validation, PCR-based validation, and 5′ RACE validation, etc.(see e.g., Proteomic Validation: Brennan, S. O., et al., Albumin bankspeninsula: a new termination variant characterized by electrospray massspectrometry, Biochem Biophys Acta. 1999 Aug. 17; 1433(1-2):321-6;Ferranti P, et al., Differential splicing of pre-messenger RNA producesmultiple forms of mature caprine alpha(s1)-casein, Eur J. Biochem. 1997Oct. 1; 249(1):1-7. For PCR-based Validation: Wellmann S, et al.,Specific reverse transcription-PCR quantification of vascularendothelial growth factor (VEGF) splice variants by LightCyclertechnology, Clin Chem. 2001 April; 47(4):654-60; Jia, H. P., et al.,Discovery of new human beta-defensins using a genomics-based approach,Gene. 2001 Jan. 24; 263(1-2):211-8. For PCR-based and 5′ RACEValidation: Brigle, K. E., et al., Organization of the murine reducedfolate carrier gene and identification of variant splice forms, BiochemBiophys Acta. 1997 Aug. 7; 1353(2): 191-8).

It is known in the art that genomic regions are modulated in cancers.When the genomic region to which a gene maps is modulated in aparticular cancer, the alternative transcripts or splice variants of thegene are modulated as well. Disclosed herein is that 282P1G03 has aparticular expression profile related to cancer. Alternative transcriptsand splice variants of 282P1G03 may also be involved in cancers in thesame or different tissues, thus serving as tumor-associatedmarkers/antigens.

Using the full-length gene and EST sequences, eight additionaltranscript variants were identified, designated as 282P1G03 v.2, v.3,v.4, v.5, v.6, v.7, v.8 and v.28. The boundaries of exons in theoriginal transcript, 282P1G03 v.1 were shown in Table LI. FIG. 12 showsthe structures of the transcript variants. Theoretically, each differentcombination of exons in spatial order (aligned on the genomic sequence),e.g. exons 2, 3, 5, 7, and 9-28 of v. 1, is a potential splice variant.

Tables LII(a)-(h) through LV(a)-(h) are set forth on avariant-by-variant bases. Tables LII(a)-(h) show the nucleotide sequenceof the transcript variant. Tables LIII(a)-(h) show the alignment of thetranscript variant with nucleic acid sequence of 282P1G03 v.1. TablesLIV(a)-(h) show the amino acid translation of the transcript variant forthe identified reading frame orientation. Tables LV(a)-(h) displayalignments of the amino acid sequence encoded by the splice variant withthat of 282P1G03 v. 1.

Example 6 Single Nucleotide Polymorphisms of 282P1G3

A Single Nucleotide Polymorphism (SNP) is a single base pair variationin a nucleotide sequence at a specific location. At any given point ofthe genome, there are four possible nucleotide base pairs: A/T, C/G, G/Cand T/A. Genotype refers to the specific base pair sequence of one ormore locations in the genome of an individual. Haplotype refers to thebase pair sequence of more than one location on the same DNA molecule(or the same chromosome in higher organisms), often in the context ofone gene or in the context of several tightly linked genes. SNP thatoccurs on a cDNA is called cSNP. This cSNP may change amino acids of theprotein encoded by the gene and thus change the functions of theprotein. Some SNP cause inherited diseases; others contribute toquantitative variations in phenotype and reactions to environmentalfactors including diet and drugs among individuals. Therefore, SNPand/or combinations of alleles (called haplotypes) have manyapplications, including diagnosis of inherited diseases, determinationof drug reactions and dosage, identification of genes responsible fordiseases, and analysis of the genetic relationship between individuals(P. Nowotny, J. M. Kwon and A. M. Goate, “SNP analysis to dissect humantraits,” Curr. Opin. Neurobiol. 2001 October; 11(5):637-641; M.Pirmohamed and B. K. Park, “Genetic susceptibility to adverse drugreactions,” Trends Pharmacol. Sci. 2001 June; 22(6):298-305; J. H.Riley, C. J. Allan, E. Lai and A. Roses, “The use of single nucleotidepolymorphisms in the isolation of common disease genes,”Pharmacogenomics. 2000 February; 1(1):39-47; R. Judson, J. C. Stephensand A. Windemuth, “The predictive power of haplotypes in clinicalresponse,” Pharmacogenomics. 2000 February; 1(1):15-26).

SNP are identified by a variety of art-accepted methods (P. Bean, “Thepromising voyage of SNP target discovery,” Am. Clin. Lab. 2001October-November; 20(9):18-20; K. M. Weiss, “In search of humanvariation,” Genome Res. 1998 July; 8(7):691-697; M. M. She, “Enablinglarge-scale pharmacogenetic studies by high-throughput mutationdetection and genotyping technologies,” Clin. Chem. 2001 February;47(2):164-172). For example, SNP can be identified by sequencing DNAfragments that show polymorphism by gel-based methods such asrestriction fragment length polymorphism (RFLP) and denaturing gradientgel electrophoresis (DGGE). They can also be discovered by directsequencing of DNA samples pooled from different individuals or bycomparing sequences from different DNA samples. With the rapidaccumulation of sequence data in public and private databases, one candiscover SNP by comparing sequences using computer programs (Z. Gu, L.Hillier and P. Y. Kwok, “Single nucleotide polymorphism hunting incyberspace,” Hum. Mutat. 1998; 12(4):221-225). SNP can be verified andgenotype or haplotype of an individual can be determined by a variety ofmethods including direct sequencing and high throughput microarrays (P.Y. Kwok, “Methods for genotyping single nucleotide polymorphisms,” Annu.Rev. Genomics Hum. Genet. 2001; 2:235-258; M. Kokoris, K. Dix, K.Moynihan, J. Mathis, B. Erwin, P. Grass, B. Hines and A. Duesterhoeft,“High-throughput SNP genotyping with the Masscode system,” Mol. Diagn.2000 December; 5(4):329-340).

Using the methods described above, 19 SNP were identified in theoriginal transcript, 282P1G03 v.1, at positions 320 (c/t), 668 (c/t),1178 (a/g), 3484 (c/t), 4615 (g/a), 4636 (−/t), 5078 (c/t), 5530 (t/a),5812 (c/t), 6114 (a/g), 6229 (c/t), 6383 (g/a), 6626 (c/t), 6942 (c/t),7085 (c/t), 2684 (a/g), 3864 (t/c), 5768 (t/c) and 6125 (c/t). Thetranscripts or proteins with alternative allele were designated asvariant 282P1G03 v.9 through v.25, as shown in FIG. 10. FIG. 11 showsthe schematic alignment of protein variants, corresponding to nucleotidevariants. Nucleotide variants that code for the same amino acid sequenceas v.1 are not shown in FIG. 11. These alleles of the SNP, though shownseparately here, can occur in different combinations (haplotypes) and inany one of the transcript variants (such as 282P1G03 v.2) that containsthe site of the SNP.

Example 7 Production of Recombinant 282P1G3 in Prokaryotic Systems

To express recombinant 282P1G3 and 282P1G3 variants in prokaryoticcells, the full or partial length 282P1G3 and 282P1G3 variant cDNAsequences are cloned into any one of a variety of expression vectorsknown in the art. One or more of the following regions of 282P1G3variants are expressed: the full length sequence presented in FIGS. 2and 3, or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from282P1G3, variants, or analogs thereof.

A. In vitro Transcription and Translation Constructs:

pCRII: To generate 282P1G3 sense and ant-sense RNA probes for RNA insitu investigations, pCRII constructs (Invitrogen, Carlsbad Calif.) aregenerated encoding either all or fragments of the 282P1G3 cDNA. ThepCR11 vector has Sp6 and T7 promoters flanking the insert to drive thetranscription of 282P1G3 RNA for use as probes in RNA in situhybridization experiments. These probes are used to analyze the cell andtissue expression of 282P1G3 at the RNA level. Transcribed 282P1G3 RNArepresenting the cDNA amino acid coding region of the 282P1G3 gene isused in in vitro translation systems such as the TnT™ CoupledReticulolysate System (Promega, Corp., Madison, Wis.) to synthesize282P1G3 protein.

B. Bacterial Constructs:

pGEX Constructs: To generate recombinant 282P1G3 proteins in bacteriathat are fused to the Glutathione S-transferase (GST) protein, all orparts of the 282P1G3 cDNA protein coding sequence are cloned into thepGEX family of GST-fusion vectors (Amersham Pharmacia Biotech,Piscataway, N.J.). These constructs allow controlled expression ofrecombinant 282P1G3 protein sequences with GST fused at theamino-terminus and a six histidine epitope (6×His) at thecarboxyl-terminus. The GST and 6×His tags permit purification of therecombinant fusion protein from induced bacteria with the appropriateaffinity matrix and allow recognition of the fusion protein withanti-GST and anti-His antibodies. The 6×His tag is generated by adding 6histidine codons to the cloning primer at the 3′ end, e.g., of the openreading frame (ORF). A proteolytic cleavage site, such as thePreScission™ recognition site in pGEX-6P-1, may be employed such that itpermits cleavage of the GST tag from 282P1G3-related protein. Theampicillin resistance gene and pBR322 origin permits selection andmaintenance of the pGEX plasmids in E. coli.

pMAL Constructs: To generate, in bacteria, recombinant 282P1G3 proteinsthat are fused to maltose-binding protein (MBP), all or parts of the282P1G3 cDNA protein coding sequence are fused to the MBP gene bycloning into the pMAL-c2X and pMAL-p2X vectors (New England Biolabs,Beverly, Mass.). These constructs allow controlled expression ofrecombinant 282P1G3 protein sequences with MBP fused at theamino-terminus and a 6×His epitope tag at the carboxyl-terminus. The MBPand 6×His tags permit purification of the recombinant protein frominduced bacteria with the appropriate affinity matrix and allowrecognition of the fusion protein with anti-MBP and anti-His antibodies.The 6×His epitope tag is generated by adding 6 histidine codons to the3′ cloning primer. A Factor Xa recognition site permits cleavage of thepMAL tag from 282P1G3. The pMAL-c2X and pMAL-p2X vectors are optimizedto express the recombinant protein in the cytoplasm or periplasmrespectively. Periplasm expression enhances folding of proteins withdisulfide bonds.

pET Constructs: To express 282P1G3 in bacterial cells, all or parts ofthe 282P1G3 cDNA protein coding sequence are cloned into the pET familyof vectors (Novagen, Madison, Wis.). These vectors allow tightlycontrolled expression of recombinant 282P1G3 protein in bacteria withand without fusion to proteins that enhance solubility, such as NusA andthioredoxin (Trx), and epitope tags, such as 6×His and S-Tag™ that aidpurification and detection of the recombinant protein. For example,constructs are made utilizing pET NusA fusion system 43.1 such thatregions of the 282P1G3 protein are expressed as amino-terminal fusionsto NusA.

C. Yeast Constructs:

pESC Constructs: To express 282P1G3 in the yeast species Saccharomycescerevisiae for generation of recombinant protein and functional studies,all or parts of the 282P1G3 cDNA protein coding sequence are cloned intothe pESC family of vectors each of which contain 1 of 4 selectablemarkers, HIS3, TRP1, LEU2, and URA3 (Stratagene, La Jolla, Calif.).These vectors allow controlled expression from the same plasmid of up to2 different genes or cloned sequences containing either Flag™ or Mycepitope tags in the same yeast cell. This system is useful to confirmprotein-protein interactions of 282P1G3. In addition, expression inyeast yields similar post-translational modifications, such asglycosylations and phosphorylations that are found when expressed ineukaryotic cells.

pESP Constructs: To express 282P1G3 in the yeast species Saccharomycespombe, all or parts of the 282P1G3 cDNA protein coding sequence arecloned into the pESP family of vectors. These vectors allow controlledhigh level of expression of a 282P1G3 protein sequence that is fused ateither the amino terminus or at the carboxyl terminus to GST which aidspurification of the recombinant protein. A Flag epitope tag allowsdetection of the recombinant protein with anti-Flag™ antibody.

Example 8 Production of Recombinant 282P1G3 in Higher Eukaryotic Systems

A. Mammalian Constructs:

To express recombinant 282P1G3 in eukaryotic cells, the full or partiallength 282P1G3 cDNA sequences were cloned into any one of a variety ofexpression vectors known in the art. One or more of the followingregions of 282P1G3 were expressed in these constructs, amino acids 1 to1224, or any 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, 25, 26, 27, 28, 29, 30 or more contiguous amino acids from282P1G3 v.1, and v.9 through v.25; amino acids 1 to 1171, 1 to 893, 1 to1117, 1 to 1208, 1 to 1183, 1 to 1236, 1 to 1195 of v.2, v.3, v.4, v.5,v.6, v.7, and v.8 respectively; or any 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or morecontiguous amino acids from 282P1G3 variants, or analogs thereof.

The constructs can be transfected into any one of a wide variety ofmammalian cells such as 293T cells. Transfected 293T cell lysates can beprobed with the anti-282P1G3 polyclonal serum, described herein.

pcDNA4/HisMax Constructs: To express 282P1G3 in mammalian cells, a282P1G3 ORF, or portions thereof, of 282P1G3 are cloned intopcDNA4/HisMax Version A (Invitrogen, Carlsbad, Calif.). Proteinexpression is driven from the cytomegalovirus (CMV) promoter and theSP16 translational enhancer. The recombinant protein has Xpress™ and sixhistidine (6×His) epitopes fused to the amino-terminus. ThepcDNA4/HisMax vector also contains the bovine growth hormone (BGH)polyadenylation signal and transcription termination sequence to enhancemRNA stability along with the SV40 origin for episomal replication andsimple vector rescue in cell lines expressing the large T antigen. TheZeocin resistance gene allows for selection of mammalian cellsexpressing the protein and the ampicillin resistance gene and ColE1origin permits selection and maintenance of the plasmid in E. coli.

pcDNA3.1/MycHis Constructs: To express 282P1G3 in mammalian cells, a282P1G3 ORF, or portions thereof, of 282P1G3 with a consensus Kozaktranslation initiation site is cloned into pcDNA3.1/MycHis Version A(Invitrogen, Carlsbad, Calif.). Protein expression is driven from thecytomegalovirus (CMV) promoter. The recombinant proteins have the mycepitope and 6×His epitope fused to the carboxyl-terminus. ThepcDNA3.1/MycHis vector also contains the bovine growth hormone (BGH)polyadenylation signal and transcription termination sequence to enhancemRNA stability, along with the SV40 origin for episomal replication andsimple vector rescue in cell lines expressing the large T antigen. TheNeomycin resistance gene can be used, as it allows for selection ofmammalian cells expressing the protein and the ampicillin resistancegene and ColE1 origin permits selection and maintenance of the plasmidin E. coli.

The complete ORF of 282P1G3 v.2 was cloned into the pcDNA3.1/MycHisconstruct to generate 282P1G3.pcDNA3.1/MycHis. FIG. 19 shows expressionof 282P1G3.pcDNA3.1/MycHis following transfection into 293T cells. 293Tcells were transfected with either 282P1G3.pcDNA3.1/MycHis orpcDNA3.1/MycHis vector control. Forty hours later, cell lysates werecollected. Samples were run on an SDS-PAGE acrylamide gel, blotted andstained with anti-his antibody. The blot was developed using the ECLchemiluminescence kit and visualized by autoradiography. Results showexpression of 282P1G3 from the 282P1G3.pcDNA3.1/MycHis construct in thelysates of transfected cells.

pcDNA3.1/CT-GFP-TOPO Construct: To express 282P1G3 in mammalian cellsand to allow detection of the recombinant proteins using fluorescence, a282P1G3 ORF, or portions thereof, with a consensus Kozak translationinitiation site are cloned into pcDNA3.1/CT-GFP-TOPO (Invitrogen, CA).Protein expression is driven from the cytomegalovirus (CMV) promoter.The recombinant proteins have the Green Fluorescent Protein (GFP) fusedto the carboxyl-terminus facilitating non-invasive, in vivo detectionand cell biology studies. The pcDNA3.1CT-GFP-TOPO vector also containsthe bovine growth hormone (BGH) polyadenylation signal and transcriptiontermination sequence to enhance mRNA stability along with the SV40origin for episomal replication and simple vector rescue in cell linesexpressing the large T antigen. The Neomycin resistance gene allows forselection of mammalian cells that express the protein, and theampicillin resistance gene and ColE1 origin permits selection andmaintenance of the plasmid in E. coli. Additional constructs with anamino-terminal GFP fusion are made in pcDNA3.1/NT-GFP-TOPO spanning theentire length of a 282P1G3 protein.

PAPtag: A 282P1G3 ORF, or portions thereof, is cloned into pAPtag-5(GenHunter Corp. Nashville, Tenn.). This construct generates an alkalinephosphatase fusion at the carboxyl-terminus of a 282P1G3 protein whilefusing the IgGκ signal sequence to the amino-terminus. Constructs arealso generated in which alkaline phosphatase with an amino-terminal IgGκsignal sequence is fused to the amino-terminus of a 282P1G3 protein. Theresulting recombinant 282P1G3 proteins are optimized for secretion intothe media of transfected mammalian cells and can be used to identifyproteins such as ligands or receptors that interact with 282P1G3proteins. Protein expression is driven from the CMV promoter and therecombinant proteins also contain myc and 6×His epitopes fused at thecarboxyl-terminus that facilitates detection and purification. TheZeocin resistance gene present in the vector allows for selection ofmammalian cells expressing the recombinant protein and the ampicillinresistance gene permits selection of the plasmid in E. coli.

pTag5: A 282P1G3 ORF, or portions thereof, were cloned into pTag-5. Thisvector is similar to pAPtag but without the alkaline phosphatase fusion.This construct generates 282P1G3 protein with an amino-terminal IgGκsignal sequence and myc and 6×His epitope tags at the carboxyl-terminusthat facilitate detection and affinity purification. The resultingrecombinant 282P1G3 protein is optimized for secretion into the media oftransfected mammalian cells, and is used as immunogen or ligand toidentify proteins such as ligands or receptors that interact with the282P1G3 proteins. Protein expression is driven from the CMV promoter.The Zeocin resistance gene present in the vector allows for selection ofmammalian cells expressing the protein, and the ampicillin resistancegene permits selection of the plasmid in E. coli.

The extracellular domain, amino acids 26-1043, of 282P1G3 v.2 was clonedinto the pTag5 construct to generate 282P1G3.pTag5. FIG. 20 showsexpression and secretion of the extracellular domain of 282P1G3following 282P1G3.pTag5 vector transfection into 293T cells. 293T cellswere transfected with 282P1G3.pTag5 construct. Forty hours later,supernatant as well as cell lysates were collected. Samples were run onan SDS-PAGE acrylamide gel, blotted and stained with anti-his antibody.The blot was developed using the ECL chemiluminescence kit andvisualized by autoradiography. Results show expression and secretion of282P1G3 from the 282P1G3.pTag5 transfected cells.

PsecFc: A 282P1G3 ORF, or portions thereof, is also cloned into psecFc.The psecFc vector was assembled by cloning the human immunoglobulin G1(IgG) Fc (hinge, CH2, CH3 regions) into pSecTag2 (Invitrogen,California). This construct generates an IgG1 Fc fusion at thecarboxyl-terminus of the 282P1G3 proteins, while fusing the IgGK signalsequence to N-terminus. 282P1G3 fusions utilizing the murine IgG1 Fcregion are also used. The resulting recombinant 282P1G3 proteins areoptimized for secretion into the media of transfected mammalian cells,and can be used as immunogens or to identify proteins such as ligands orreceptors that interact with 282P1G3 protein. Protein expression isdriven from the CMV promoter. The hygromycin resistance gene present inthe vector allows for selection of mammalian cells that express therecombinant protein, and the ampicillin resistance gene permitsselection of the plasmid in E. coli.

pSRα Constructs: To generate mammalian cell lines that express 282P1G3constitutively, 282P1G3 ORF, or portions thereof, of 282P1G3 were clonedinto pSRα constructs. Amphotropic and ecotropic retroviruses weregenerated by transfection of pSRα constructs into the 293T-10A1packaging line or co-transfection of pSRα and a helper plasmid(containing deleted packaging sequences) into the 293 cells,respectively. The retrovirus is used to infect a variety of mammaliancell lines, resulting in the integration of the cloned gene, 282P1G3,into the host cell-lines. Protein expression is driven from a longterminal repeat (LTR). The Neomycin resistance gene present in thevector allows for selection of mammalian cells that express the protein,and the ampicillin resistance gene and ColE1 origin permit selection andmaintenance of the plasmid in E. coli. The retroviral vectors canthereafter be used for infection and generation of various cell linesusing, for example, PC3, NIH 3T3, TsuPr1, 293 or rat-1 cells.

Additional pSRα constructs are made that fuse an epitope tag such as theFLAG™ tag to the carboxyl-terminus of 282P1G3 sequences to allowdetection using anti-Flag antibodies. For example, the FLAG™ sequence 5′gat tac aag gat gac gac gat aag 3′ (SEQ ID NO: 53) is added to cloningprimer at the 3′ end of the ORF. Additional pSRα constructs are made toproduce both amino-terminal and carboxyl-terminal GFP and myc/6×Hisfusion proteins of the full-length 282P1G3 proteins.

Additional Viral Vectors: Additional constructs are made forviral-mediated delivery and expression of 282P1G3. High virus titerleading to high level expression of 282P1G3 is achieved in viraldelivery systems such as adenoviral vectors and herpes amplicon vectors.A 282P1G3 coding sequences or fragments thereof are amplified by PCR andsubcloned into the AdEasy shuttle vector (Stratagene). Recombination andvirus packaging are performed according to the manufacturer'sinstructions to generate adenoviral vectors. Alternatively, 282P1G3coding sequences or fragments thereof are cloned into the HSV-1 vector(Imgenex) to generate herpes viral vectors. The viral vectors arethereafter used for infection of various cell lines such as PC3, NIH3T3, 293 or rat-1 cells.

Regulated Expression Systems: To control expression of 282P1G3 inmammalian cells, coding sequences of 282P1G3, or portions thereof, arecloned into regulated mammalian expression systems such as the T-RexSystem (Invitrogen), the GeneSwitch System (Invitrogen) and thetightly-regulated Ecdysone System (Sratagene). These systems allow thestudy of the temporal and concentration dependent effects of recombinant282P1G3. These vectors are thereafter used to control expression of282P1G3 in various cell lines such as PC3, NIH 3T3, 293 or rat-1 cells.

B. Baculovirus Expression Systems

To generate recombinant 282P1G3 proteins in a baculovirus expressionsystem, 282P1G3 ORF, or portions thereof, are cloned into thebaculovirus transfer vector pBlueBac 4.5 (Invitrogen), which provides aHis-tag at the N-terminus. Specifically, pBlueBac-282P1G3 isco-transfected with helper plasmid pBac-N-Blue (Invitrogen) into SF9(Spodoptera frugiperda) insect cells to generate recombinant baculovirus(see Invitrogen instruction manual for details). Baculovirus is thencollected from cell supernatant and purified by plaque assay.

Recombinant 282P1G3 protein is then generated by infection of HighFiveinsect cells (Invitrogen) with purified baculovirus. Recombinant 282P1G3protein can be detected using anti-282P1G3 or anti-His-tag antibody.282P1G3 protein can be purified and used in various cell-based assays oras immunogen to generate polyclonal and monoclonal antibodies specificfor 282P1G3.

Example 9 Antigenicity Profiles and Secondary Structure

FIG. 5(A-C), FIG. 6(A-C), FIG. 7(A-C), FIG. 8(A-C), and FIG. 9(A-C)depict graphically five amino acid profiles of 282P1G3 variants 1, 3,and 7, each assessment available by accessing the ProtScale websitelocated on the World Wide Web at (.expasy.ch/cgi-bin/protscale.pl) onthe ExPasy molecular biology server.

These profiles: FIG. 5(A-C), Hydrophilicity, (Hopp T. P., Woods K. R.,1981. Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828); FIG. 6(A-C),Hydropathicity, (Kyte J., Doolittle R. F., 1982. J. Mol. Biol.157:105-132); FIG. 7(A-C), Percentage Accessible Residues (Janin J.,1979 Nature 277:491-492); FIG. 8(A-C), Average Flexibility, (BhaskaranR., and Ponnuswamy P. K., 1988. Int. J. Pept. Protein Res. 32:242-255);FIG. 9(A-C), Beta-turn (Deleage, G., Roux B. 1987 Protein Engineering1:289-294); and optionally others available in the art, such as on theProtScale website, were used to identify antigenic regions of each ofthe 282P1G3 variant proteins. Each of the above amino acid profiles of282P1G3 variants were generated using the following ProtScale parametersfor analysis: 1) A window size of 9; 2) 100% weight of the window edgescompared to the window center; and, 3) amino acid profile valuesnormalized to lie between 0 and 1.

Hydrophilicity (FIG. 5), Hydropathicity (FIG. 6) and PercentageAccessible Residues (FIG. 7) profiles were used to determine stretchesof hydrophilic amino acids (i.e., values greater than 0.5 on theHydrophilicity and Percentage Accessible Residues profile, and valuesless than 0.5 on the Hydropathicity profile). Such regions are likely tobe exposed to the aqueous environment, be present on the surface of theprotein, and thus available for immune recognition, such as byantibodies.

Average Flexibility (FIG. 8) and Beta-turn (FIG. 9) profiles determinestretches of amino acids (i.e., values greater than 0.5 on the Beta-turnprofile and the Average Flexibility profile) that are not constrained insecondary structures such as beta sheets and alpha helices. Such regionsare also more likely to be exposed on the protein and thus accessible toimmune recognition, such as by antibodies.

Antigenic sequences of the 282P1G3 variant proteins indicated, e.g., bythe profiles set forth in FIG. 5(A-C), FIG. 6(A-C), FIG. 7(A-C), FIG.8(A-C), and/or FIG. 9(A-C) are used to prepare immunogens, eitherpeptides or nucleic acids that encode them, to generate therapeutic anddiagnostic anti-282P1G3 antibodies. The immunogen can be any 5, 6, 7, 8,9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30,35, 40, 45, 50 or more than 50 contiguous amino acids, or thecorresponding nucleic acids that encode them, from the 282P1G3 proteinvariants listed in FIGS. 2 and 3, In particular, peptide immunogens ofthe invention can comprise, a peptide region of at least 5 amino acidsof FIGS. 2 and 3 in any whole number increment that includes an aminoacid position having a value greater than 0.5 in the Hydrophilicityprofiles of FIG. 5; a peptide region of at least 5 amino acids of FIGS.2 and 3 in any whole number increment that includes an amino acidposition having a value less than 0.5 in the Hydropathicity profile ofFIG. 6; a peptide region of at least 5 amino acids of FIGS. 2 and 3 inany whole number increment that includes an amino acid position having avalue greater than 0.5 in the Percent Accessible Residues profiles ofFIG. 7; a peptide region of at least 5 amino acids of FIGS. 2 and 3 inany whole number increment that includes an amino acid position having avalue greater than 0.5 in the Average Flexibility profiles on FIG. 8;and, a peptide region of at least 5 amino acids of FIGS. 2 and 3 in anywhole number increment that includes an amino acid position having avalue greater than 0.5 in the Beta-turn profile of FIG. 9. Peptideimmunogens of the invention can also comprise nucleic acids that encodeany of the forgoing.

All immunogens of the invention, peptide or nucleic acid, can beembodied in human unit dose form, or comprised by a composition thatincludes a pharmaceutical excipient compatible with human physiology.

The secondary structure of 282P1G3 protein variants 1 through 8, namelythe predicted presence and location of alpha helices, extended strands,and random coils, is predicted from the primary amino acid sequenceusing the HNN—Hierarchical Neural Network method (Guermeur, 1997,accessed from the ExPasy molecular biology server located on the WorldWide Web at (.expasy.ch/tools/). The analysis indicates that 282P1G3variant 1 is composed of 15.77% alpha helix, 26.14% extended strand, and58.09% random coil (FIG. 13A). Variant 2 is composed of 14.86% alphahelix, 26.39% extended strand, and 58.75% random coil (FIG. 13B).Variant 3 is composed of 14.00% alpha helix, 29.34% extended strand, and56.66% random coil (FIG. 13C). Variant 4 is composed of 15.94% alphahelix, 26.14% extended strand, and 57.92% random coil (FIG. 13D).Variant 5 is composed of 15.73% alpha helix, 26.32% extended strand, and57.95% random coil (FIG. 13E). Variant 6 is composed of 16.99% alphahelix, 25.36% extended strand, and 57.65% random coil (FIG. 13F).Variant 7 is composed of 15.78% alpha helix, 26.13% extended strand, and58.09% random coil (FIG. 13G). Variant 8 is composed of 16.99% alphahelix, 25.36% extended strand, and 57.66% random coil (FIG. 13H).

Analysis for the potential presence of transmembrane domains in the282P1G3 variant proteins was carried out using a variety oftransmembrane prediction algorithms accessed from the ExPasy molecularbiology server located on the World Wide Web at (.expasy.ch/tools/).Shown graphically in FIG. 13I and 13J are the results of analysis ofvariant 1 depicting the presence and location of 1 transmembrane domainusing the TMpred program (FIG. 13I) and 1 transmembrane domain using theTMHMM program (FIG. 13J). Shown graphically in FIGS. 13K and 13L are theresults of analysis of variant 2 depicting the presence and location of1 transmembrane domains using the TMpred program (FIG. 13K) and 1transmembrane domain using the TMHMM program (FIG. 13L). Showngraphically in FIGS. 13M and 13N are the results of analysis of variant3 depicting no transmembrane domain using both the TMpred program (FIG.13M) and TMHMM program (FIG. 13N). Shown graphically in FIG. 13O and 13Pare the results of analysis of variant 4 depicting the presence andlocation of 1 transmembrane domain using the TMpred program (FIG. 13O)and 1 transmembrane domain using the TMHMM program (FIG. 13P). Showngraphically in FIGS. 13Q and 13R are the results of analysis of variant5 depicting the presence and location of 1 transmembrane domain usingthe TMpred program (FIG. 13Q) and 1 transmembrane domain using the TMHMMprogram (FIG. 13R). Shown graphically in FIGS. 13S and 13T are theresults of analysis of variant 6 depicting the presence and location of1 transmembrane domain using the TMpred program (FIG. 13S) and 1transmembrane domain using the TMHMM program (FIG. 13T). Showngraphically in FIGS. 13U and 13V are the results of analysis of variant7 depicting the presence and location of 1 transmembrane domain usingthe TMpred program (FIG. 13U) and 1 transmembrane domain using the TMHMMprogram (FIG. 13V). Shown graphically in FIGS. 13W and 13X are theresults of analysis of variant 8 depicting the presence and location of1 transmembrane domain using the TMpred program (FIG. 13W) and 1transmembrane domain using the TMHMM program (FIG. 13X). The results ofeach program, namely the amino acids encoding the transmembrane domainsare summarized in Table VI.

Example 10 Generation of 282P1G3 Polyclonal Antibodies

Polyclonal antibodies can be raised in a mammal, for example, by one ormore injections of an immunizing agent and, if desired, an adjuvant.Typically, the immunizing agent and/or adjuvant will be injected in themammal by multiple subcutaneous or intraperitoneal injections. Inaddition to immunizing with a full length 282P1G3 protein variant,computer algorithms are employed in design of immunogens that, based onamino acid sequence analysis contain characteristics of being antigenicand available for recognition by the immune system of the immunized host(see the Example entitled “Antigenicity Profiles and SecondaryStructure”). Such regions would be predicted to be hydrophilic,flexible, in beta-turn conformations, and be exposed on the surface ofthe protein (see, e.g., FIG. 5(A-C), FIG. 6(A & C), FIG. 7(A-C), FIG.8(A-C), or FIG. 9(A-C) for amino acid profiles that indicate suchregions of 282P1G3 protein variants).

For example, recombinant bacterial fusion proteins or peptidescontaining hydrophilic, flexible, beta-turn regions of 282P1G3 proteinvariants are used as antigens to generate polyclonal antibodies in NewZealand White rabbits or monoclonal antibodies as described in Example11. For example, in 282P1G3 variant 1, such regions include, but are notlimited to, amino acids 57-75, amino acids 131-135, amino acids 210-265,amino acids 550-588, and amino acids 662-688. In sequence unique tovariant 3, such regions include, but are not limited to, amino acids855-872 and amino acids 856-886. In sequence specific for variant 7,such regions include, but are not limited to, amino acids 345-356. It isuseful to conjugate the immunizing agent to a protein known to beimmunogenic in the mammal being immunized. Examples of such immunogenicproteins include, but are not limited to, keyhole limpet hemocyanin(KLH), serum albumin, bovine thyroglobulin, and soybean trypsininhibitor. In one embodiment, a peptide encoding amino acids 57-75 of282P1G3 variant 1 was conjugated to KLH and used to immunize a rabbit.Alternatively the immunizing agent may include all or portions of the282P1G3 variant proteins, analogs or fusion proteins thereof. Forexample, the 282P1G3 variant 1 amino acid sequence can be fused usingrecombinant DNA techniques to any one of a variety of fusion proteinpartners that are well known in the art, such asglutathione-5-transferase (GST) and HIS tagged fusion proteins. Inanother embodiment, amino acids 26-265 of 282P1G3 variant 1 was fused toGST using recombinant techniques and the pGEX expression vector,expressed, purified and used to immunize a rabbit. Such fusion proteinsare purified from induced bacteria using the appropriate affinitymatrix.

Other recombinant bacterial fusion proteins that may be employed includemaltose binding protein, LacZ, thioredoxin, NusA, or an immunoglobulinconstant region (see the section entitled “Production of 282P1G3 inProkaryotic Systems” and Current Protocols In Molecular Biology, Volume2, Unit 16, Frederick M. Ausubul et al. eds., 1995; Linsley, P. S.,Brady, W., Urnes, M., Grosmaire, L., Damle, N., and Ledbetter, L. (1991)J.Exp. Med. 174, 561-566).

In addition to bacterial derived fusion proteins, mammalian expressedprotein antigens are also used. These antigens are expressed frommammalian expression vectors such as the Tag5 and Fc-fusion vectors (seethe section entitled “Production of Recombinant 282P1G3 in EukaryoticSystems”), and retains post-translational modifications such asglycosylations found in native protein. In one embodiment, amino acids26-1,043 of variant 2, encoding the extracellular domain, was clonedinto the Tag5 mammalian secretion vector, and expressed in 293T cells.The recombinant protein is purified by metal chelate chromatography fromtissue culture supernatants of 293T cells stably expressing therecombinant vector. The purified Tag5 282P1G3 protein is then used asimmunogen.

During the immunization protocol, it is useful to mix or emulsify theantigen in adjuvants that enhance the immune response of the hostanimal. Examples of adjuvants include, but are not limited to, completeFreund's adjuvant (CFA) and MPL-TDM adjuvant (monophosphoryl Lipid A,synthetic trehalose dicorynomycolate).

In a typical protocol, rabbits are initially immunized subcutaneouslywith up to 200 μg, typically 100-200 μg, of fusion protein or peptideconjugated to KLH mixed in complete Freund's adjuvant (CFA). Rabbits arethen injected subcutaneously every two weeks with up to 200 μg,typically 100-200 μg, of the immunogen in incomplete Freund's adjuvant(IFA). Test bleeds are taken approximately 7-10 days following eachimmunization and used to monitor the titer of the antiserum by ELISA.

To test reactivity and specificity of immune serum, such as the rabbitserum derived from immunization with the Tag5-282P1G3 variant 2 protein,the full-length 282P1G3 variant 1 cDNA is cloned into pcDNA 3.1 myc-hisexpression vector (Invitrogen, see the Example entitled “Production ofRecombinant 282P1G3 in Eukaryotic Systems”). After transfection of theconstructs into 293T cells, cell lysates are probed with theanti-282P1G3 serum and with anti-His antibody (See FIG. 19; Santa CruzBiotechnologies, Santa Cruz, Calif.) to determine specific reactivity todenatured 282P1G3 protein using the Western blot technique. In addition,the immune serum is tested by fluorescence microscopy, flow cytometryand immunoprecipitation against 293T and other recombinant282P1G3-expressing cells to determine specific recognition of nativeprotein. Western blot, immunoprecipitation, fluorescent microscopy, andflow cytometric techniques using cells that endogenously express 282P1G3are also carried out to test reactivity and specificity.

Anti-serum from rabbits immunized with 282P1G3 variant fusion proteins,such as GST and MBP fusion proteins, are purified by depletion ofantibodies reactive to the fusion partner sequence by passage over anaffinity column containing the fusion partner either alone or in thecontext of an irrelevant fusion protein. For example, antiserum derivedfrom a GST-282P1G3 variant 1 fusion protein is first purified by passageover a column of GST protein covalently coupled to AffiGel matrix(BioRad, Hercules, Calif.). The antiserum is then affinity purified bypassage over a column composed of a MBP-282P1G3 fusion proteincovalently coupled to Affigel matrix. The serum is then further purifiedby protein G affinity chromatography to isolate the IgG fraction. Serafrom other His-tagged antigens and peptide immunized rabbits as well asfusion partner depleted sera are affinity purified by passage over acolumn matrix composed of the original protein immunogen or freepeptide.

Example 11 Generation of 282P1G3 Monoclonal Antibodies (mAbs)

In one embodiment, therapeutic mAbs to 282P1G3 variants comprise thosethat react with epitopes specific for each variant protein or specificto sequences in common between the variants that would disrupt ormodulate the biological function of the 282P1G3 variants, for examplethose that would disrupt the interaction with ligands and bindingpartners. Immunogens for generation of such mAbs include those designedto encode or contain the entire 282P1G3 protein variant sequence,regions of the 282P1G3 protein variants predicted to be antigenic fromcomputer analysis of the amino acid sequence (see, e.g., FIG. 5(A-C),FIG. 6(A-C), FIG. 7(A-C), FIG. 8(A-C), or FIG. 9(A-C), and the Exampleentitled “Antigenicity Profiles and Secondary Structure”). Immunogensinclude peptides, recombinant bacterial proteins, and mammalianexpressed Tag 5 proteins and human and murine IgG FC fusion proteins. Inaddition, cells engineered to express high levels of a respective282P1G3 variant, such as 293T-282P1G3 variant 1 or 300.19-282P1G3variant 1 murine Pre-B cells, are used to immunize mice.

To generate mAbs to a 282P1G3 variant, mice are first immunizedintraperitoneally (IP) with, typically, 10-50 μg of protein immunogen or10⁷ 282P1G3-expressing cells mixed in complete Freund's adjuvant. Miceare then subsequently immunized IP every 2-4 weeks with, typically,10-50 μg of protein immunogen or 10⁷ cells mixed in incomplete Freund'sadjuvant. Alternatively, MPL-TDM adjuvant is used in immunizations. Inaddition to the above protein and cell-based immunization strategies, aDNA-based immunization protocol is employed in which a mammalianexpression vector encoding a 282P1G3 variant sequence is used toimmunize mice by direct injection of the plasmid DNA. For example, aminoacids 26-1,043 of variant 2 was cloned into the Tag5 mammalian secretionvector and the recombinant vector will then be used as immunogen. Inanother example the same amino acids are cloned into an Fc-fusionsecretion vector in which the 282P1G3 variant 2 sequence is fused at theamino-terminus to an IgK leader sequence and at the carboxyl-terminus tothe coding sequence of the human or murine IgG Fc region. Thisrecombinant vector is then used as immunogen. The plasmid immunizationprotocols are used in combination with purified proteins expressed fromthe same vector and with cells expressing the respective 282P1G3variant.

During the immunization protocol, test bleeds are taken 7-10 daysfollowing an injection to monitor titer and specificity of the immuneresponse. Once appropriate reactivity and specificity is obtained asdetermined by ELISA, Western blotting, immunoprecipitation, fluorescencemicroscopy, and flow cytometric analyses, fusion and hybridomageneration is then carried out with established procedures well known inthe art (see, e.g., Harlow and Lane, 1988).

In one embodiment for generating 282P1G3 monoclonal antibodies, aTag5-282P1G3 variant 2 antigen encoding amino acids 26-1,043, wasexpressed (FIG. 20) and then purified from stably transfected 293Tcells. Balb C mice are initially immunized intraperitoneally with 25 μgof the Tag5-282P1G3 variant 2 protein mixed in complete Freund'sadjuvant. Mice are subsequently immunized every two weeks with 25 μg ofthe antigen mixed in incomplete Freund's adjuvant for a total of threeimmunizations. ELISA using the Tag5 antigen determines the titer ofserum from immunized mice. Reactivity and specificity of serum to fulllength 282P1G3 variant 2 protein is monitored by Western blotting,immunoprecipitation and flow cytometry using 293T cells transfected withan expression vector encoding the 282P1G3 variant 2 cDNA (see e.g., theExample entitled “Production of Recombinant 282P1G3 in EukaryoticSystems” and FIG. 19). Other recombinant 282P1G3 variant 2-expressingcells or cells endogenously expressing 282P1G3 variant 2 are also used.Mice showing the strongest reactivity are rested and given a finalinjection of Tag5 antigen in PBS and then sacrificed four days later.The spleens of the sacrificed mice are harvested and fused to SPO/2myeloma cells using standard procedures (Harlow and Lane, 1988).Supernatants from HAT selected growth wells are screened by ELISA,Western blot, immunoprecipitation, fluorescent microscopy, and flowcytometry to identify 282P1G3 specific antibody-producing clones.

To generate monoclonal antibodies that are specific for each 282P1G3variant protein, immunogens are designed to encode sequences unique foreach variant. For example, peptides or recombinant protein antigens(i.e. Tag5 fusion proteins) encompassing the unique sequence derivedfrom alternate exon usage in splice variants 2, 3, 4, 5, 6, and 7 areused as immunogens. In one embodiment, a Tag5 protein encoding aminoacids 838-893 unique to 282P1G3 variant 3 is produced, purified, andused as immunogen to derive monoclonal antibodies specific to 282P1G3variant 3. In another embodiment, an antigenic peptide composed of aminoacids 1025-1037 of 282P1G3 variant 2 is coupled to KLH and used asimmunogen. In another embodiment, an antigenic peptide composed of aminoacids 817-829 of 282P1G3 variant 4 is coupled to KLH and used asimmunogen. In another embodiment, an antigenic peptide composed of aminoacids 220-232 of 282P1G3 variant 5 is coupled to KLH and used asimmunogen. In another embodiment, an antigenic peptide composed of aminoacids 122-134 of 282P1G3 variant 6 is coupled to KLH and used asimmunogen. In another embodiment, an antigenic peptide composed of aminoacids 339-362 of 282P1G3 variant 7 is coupled to KLH and used asimmunogen. Hybridoma supernatants are then screened on the respectiveantigen and then further screened on cells expressing the specificvariant and cross-screened on cells expressing the other variants toderive variant-specific monoclonal antibodies.

The binding affinity of a 282P1G3 variant monoclonal antibody isdetermined using standard technologies. Affinity measurements quantifythe strength of antibody to epitope binding and are used to help definewhich 282P1G3 variant monoclonal antibodies preferred for diagnostic ortherapeutic use, as appreciated by one of skill in the art. The BIAcoresystem (Uppsala, Sweden) is a preferred method for determining bindingaffinity. The BIAcore system uses surface plasmon resonance (SPR,Welford K. 1991, Opt. Quant. Elect. 23:1; Morton and Myszka, 1998,Methods in Enzymology 295: 268) to monitor biomolecular interactions inreal time. BIAcore analysis conveniently generates association rateconstants, dissociation rate constants, equilibrium dissociationconstants, and affinity constants.

Example 12 HLA Class I and Class II Binding Assays

HLA class I and class II binding assays using purified HLA molecules areperformed in accordance with disclosed protocols (e.g., PCT publicationsWO 94/20127 and WO 94/03205; Sidney et al., Current Protocols inImmunology 18.3.1 (1998); Sidney, et al., J. Immunol. 154:247 (1995);Sette, et al., Mol. Immunol. 31:813 (1994)). Briefly, purified MHCmolecules (5 to 500 nM) are incubated with various unlabeled peptideinhibitors and 1-10 nM ¹²⁵I-radiolabeled probe peptides as described.Following incubation, MHC-peptide complexes are separated from freepeptide by gel filtration and the fraction of peptide bound isdetermined. Typically, in preliminary experiments, each MHC preparationis titered in the presence of fixed amounts of radiolabeled peptides todetermine the concentration of HLA molecules necessary to bind 10-20% ofthe total radioactivity. All subsequent inhibition and direct bindingassays are performed using these HLA concentrations.

Since under these conditions [label]<[HLA] and IC₅₀≧[HLA], the measuredIC₅₀ values are reasonable approximations of the true KD values. Peptideinhibitors are typically tested at concentrations ranging from 120 μg/mlto 1.2 ng/ml, and are tested in two to four completely independentexperiments. To allow comparison of the data obtained in differentexperiments, a relative binding figure is calculated for each peptide bydividing the IC₅₀ of a positive control for inhibition by the IC₅₀ foreach tested peptide (typically unlabeled versions of the radiolabeledprobe peptide). For database purposes, and inter-experiment comparisons,relative binding values are compiled. These values can subsequently beconverted back into IC₅₀ nM values by dividing the IC₅₀ nM of thepositive controls for inhibition by the relative binding of the peptideof interest. This method of data compilation is accurate and consistentfor comparing peptides that have been tested on different days, or withdifferent lots of purified MHC.

Binding assays as outlined above may be used to analyze HLA supermotifand/or HLA motif-bearing peptides (see Table IV).

Example 13 Identification of HLA Supermotif- and Motif-Bearing CTLCandidate Epitopes

HLA vaccine compositions of the invention can include multiple epitopes.The multiple epitopes can comprise multiple HLA supermotifs or motifs toachieve broad population coverage. This example illustrates theidentification and confirmation of supermotif- and motif-bearingepitopes for the inclusion in such a vaccine composition. Calculation ofpopulation coverage is performed using the strategy described below.

Computer Searches and Algorithms for Identification of Supermotif and/orMotif-bearing Epitopes

The searches performed to identify the motif-bearing peptide sequencesin the Example entitled “Antigenicity Profiles” and Tables VIII-XXI andXXII-XLIX employ the protein sequence data from the gene product of282P1G3 set forth in FIGS. 2 and 3, the specific search peptides used togenerate the tables are listed in Table VII.

Computer searches for epitopes bearing HLA Class I or Class IIsupermotifs or motifs are performed as follows. All translated 282P1G3protein sequences are analyzed using a text string search softwareprogram to identify potential peptide sequences containing appropriateHLA binding motifs; such programs are readily produced in accordancewith information in the art in view of known motif/supermotifdisclosures. Furthermore, such calculations can be made mentally.

Identified A2-, A3-, and DR-supermotif sequences are scored usingpolynomial algorithms to predict their capacity to bind to specificHLA-Class I or Class II molecules. These polynomial algorithms accountfor the impact of different amino acids at different positions, and areessentially based on the premise that the overall affinity (or ΔG) ofpeptide-HLA molecule interactions can be approximated as a linearpolynomial function of the type:“ΔG”=a _(1i) ×a _(2i) ×a _(3i) . . . ×a _(ni)

where a_(ji) is a coefficient which represents the effect of thepresence of a given amino acid (j) at a given position (i) along thesequence of a peptide of n amino acids. The crucial assumption of thismethod is that the effects at each position are essentially independentof each other (i.e., independent binding of individual side-chains).When residue j occurs at position i in the peptide, it is assumed tocontribute a constant amount j_(i) to the free energy of binding of thepeptide irrespective of the sequence of the rest of the peptide.

The method of derivation of specific algorithm coefficients has beendescribed in Gulukota et al., J. Mol. Biol. 267:1258-126, 1997; (seealso Sidney et al., Human Immunol. 45:79-93, 1996; and Southwood et al.,J. Immunol. 160:3363-3373, 1998). Briefly, for all i positions, anchorand non-anchor alike, the geometric mean of the average relative binding(ARB) of all peptides carrying j is calculated relative to the remainderof the group, and used as the estimate of j_(i). For Class II peptides,if multiple alignments are possible, only the highest scoring alignmentis utilized, following an iterative procedure. To calculate an algorithmscore of a given peptide in a test set, the ARB values corresponding tothe sequence of the peptide are multiplied. If this product exceeds achosen threshold, the peptide is predicted to bind. Appropriatethresholds are chosen as a function of the degree of stringency ofprediction desired.

Selection of HLA-A2 Supertype Cross-reactive Peptides

Protein sequences from 282P1G3 are scanned utilizing motifidentification software, to identify 8-, 9-10- and 11-mer sequencescontaining the HLA-A2-supermotif main anchor specificity. Typically,these sequences are then scored using the protocol described above andthe peptides corresponding to the positive-scoring sequences aresynthesized and tested for their capacity to bind purified HLA-A*0201molecules in vitro (HLA-A*0201 is considered a prototype A2 supertypemolecule).

These peptides are then tested for the capacity to bind to additionalA2-supertype molecules (A*0202, A*0203, A*0206, and A*6802). Peptidesthat bind to at least three of the five A2-supertype alleles tested aretypically deemed A2-supertype cross-reactive binders. Preferred peptidesbind at an affinity equal to or less than 500 nM to three or more HLA-A2supertype molecules.

Selection of HLA-A3 Supermotif-bearing Epitopes

The 282P1G3 protein sequence(s) scanned above is also examined for thepresence of peptides with the HLA-A3-supermotif primary anchors.Peptides corresponding to the HLA A3 supermotif-bearing sequences arethen synthesized and tested for binding to HLA-A*0301 and HLA-A*1101molecules, the molecules encoded by the two most prevalent A3-supertypealleles. The peptides that bind at least one of the two alleles withbinding affinities of ≦500 nM, often ≦200 nM, are then tested forbinding cross-reactivity to the other common A3-supertype alleles (e.g.,A*3101, A*3301, and A*6801) to identify those that can bind at leastthree of the five HLA-A3-supertype molecules tested.

Selection of HLA-B7 Supermotif Bearing Epitopes

The 282P1G3 protein(s) scanned above is also analyzed for the presenceof 8-, 9-10-, or 11-mer peptides with the HLA-B7-supermotif.Corresponding peptides are synthesized and tested for binding toHLA-B*0702, the molecule encoded by the most common B7-supertype allele(i.e., the prototype B7 supertype allele). Peptides binding B*0702 withIC₅₀ of ≦500 nM are identified using standard methods. These peptidesare then tested for binding to other common B7-supertype molecules(e.g., B*3501, B*5101, B*5301, and B*5401). Peptides capable of bindingto three or more of the five B7-supertype alleles tested are therebyidentified.

Selection of A1 and A24 Motif-bearing Epitopes

To further increase population coverage, HLA-A1 and -A24 epitopes canalso be incorporated into vaccine compositions. An analysis of the282P1G3 protein can also be performed to identify HLA-A1- andA24-motif-containing sequences.

High affinity and/or cross-reactive binding epitopes that bear othermotif and/or supermotifs are identified using analogous methodology.

Example 14 Confirmation of Immunogenicity

Cross-reactive candidate CTL A2-supermotif-bearing peptides that areidentified as described herein are selected to confirm in vitroimmunogenicity. Confirmation is performed using the followingmethodology:

Target Cell Lines for Cellular Screening:

The 0.221A2.1 cell line, produced by transferring the HLA-A2.1 gene intothe HLA-A, -B, -C null mutant human B-lymphoblastoid cell line 721.221,is used as the peptide-loaded target to measure activity ofHLA-A2.1-restricted CTL. This cell line is grown in RPMI-1640 mediumsupplemented with antibiotics, sodium pyruvate, nonessential amino acidsand 10% (v/v) heat inactivated FCS. Cells that express an antigen ofinterest, or transfectants comprising the gene encoding the antigen ofinterest, can be used as target cells to confirm the ability ofpeptide-specific CTLs to recognize endogenous antigen.

Primary CTL Induction Cultures:

Generation of Dendritic Cells (DC): PBMCs are thawed in RPMI with 30μg/ml DNAse, washed twice and resuspended in complete medium (RPMI-1640plus 5% AB human serum, non-essential amino acids, sodium pyruvate,L-glutamine and penicillin/streptomycin). The monocytes are purified byplating 10×10⁶ PBMC/well in a 6-well plate. After 2 hours at 37° C., thenon-adherent cells are removed by gently shaking the plates andaspirating the supernatants. The wells are washed a total of three timeswith 3 ml RPMI to remove most of the non-adherent and loosely adherentcells. Three ml of complete medium containing 50 ng/ml of GM-CSF and1,000 U/ml of IL-4 are then added to each well. TNFα is added to the DCson day 6 at 75 ng/ml and the cells are used for CTL induction cultureson day 7.

Induction of CTL with DC and Peptide: CD8+ T-cells are isolated bypositive selection with Dynal immunomagnetic beads (Dynabeads® M-450)and the detacha-bead® reagent. Typically about 200-250×10⁶ PBMC areprocessed to obtain 24×10⁶ CD8+ T-cells (enough for a 48-well plateculture). Briefly, the PBMCs are thawed in RPMI with 30 μg/ml DNAse,washed once with PBS containing 1% human AB serum and resuspended inPBS/1% AB serum at a concentration of 20×10⁶ cells/ml. The magneticbeads are washed 3 times with PBS/AB serum, added to the cells (140 μlbeads/20×10⁶ cells) and incubated for 1 hour at 4° C. with continuousmixing. The beads and cells are washed 4× with PBS/AB serum to removethe nonadherent cells and resuspended at 100×10⁶ cells/ml (based on theoriginal cell number) in PBS/AB serum containing 100 μl/ml detacha-bead®reagent and 30 μg/ml DNAse. The mixture is incubated for 1 hour at roomtemperature with continuous mixing. The beads are washed again withPBS/AB/DNAse to collect the CD8+ T-cells. The DC are collected andcentrifuged at 1300 rpm for 5-7 minutes, washed once with PBS with 1%BSA, counted and pulsed with 40 μg/ml of peptide at a cell concentrationof 1-2×10⁶/ml in the presence of 3 μg/ml β₂-microglobulin for 4 hours at20° C. The DC are then irradiated (4,200 rads), washed 1 time withmedium and counted again.

Setting up induction cultures: 0.25 ml cytokine-generated DC (at 1×10⁵cells/ml) are co-cultured with 0.25 ml of CD8+ T-cells (at 2×10⁶cell/ml) in each well of a 48-well plate in the presence of 10 ng/ml ofIL-7. Recombinant human IL-10 is added the next day at a finalconcentration of 10 ng/ml and rhuman IL-2 is added 48 hours later at 10IU/ml.

Restimulation of the induction cultures with peptide-pulsed adherentcells: Seven and fourteen days after the primary induction, the cellsare restimulated with peptide-pulsed adherent cells. The PBMCs arethawed and washed twice with RPMI and DNAse. The cells are resuspendedat 5×10⁶ cells/ml and irradiated at −4200 rads. The PBMCs are plated at2×10⁶ in 0.5 ml complete medium per well and incubated for 2 hours at37° C. The plates are washed twice with RPMI by tapping the plate gentlyto remove the nonadherent cells and the adherent cells pulsed with 10μg/ml of peptide in the presence of 3 μg/ml β₂ microglobulin in 0.25 mlRPMI/5% AB per well for 2 hours at 37° C. Peptide solution from eachwell is aspirated and the wells are washed once with RPMI. Most of themedia is aspirated from the induction cultures (CD8+ cells) and broughtto 0.5 ml with fresh media. The cells are then transferred to the wellscontaining the peptide-pulsed adherent cells. Twenty four hours laterrecombinant human IL-10 is added at a final concentration of 10 ng/mland recombinant human IL2 is added the next day and again 2-3 days laterat 50 IU/ml (Tsai et al., Critical Reviews in Immunology 18(1-2):65-75,1998). Seven days later, the cultures are assayed for CTL activity in a⁵¹Cr release assay. In some experiments the cultures are assayed forpeptide-specific recognition in the in situ IFNγ ELISA at the time ofthe second restimulation followed by assay of endogenous recognition 7days later. After expansion, activity is measured in both assays for aside-by-side comparison.

Measurement of CTL Lytic Activity by ⁵¹Cr Release.

Seven days after the second restimulation, cytotoxicity is determined ina standard (5 hr) ⁵¹Cr release assay by assaying individual wells at asingle E:T. Peptide-pulsed targets are prepared by incubating the cellswith 10 μg/ml peptide overnight at 37° C.

Adherent target cells are removed from culture flasks with trypsin-EDTA.Target cells are labeled with 200 μCi of ⁵¹Cr sodium chromate (Dupont,Wilmington, Del.) for 1 hour at 37° C. Labeled target cells areresuspended at 106 per ml and diluted 1:10 with K562 cells at aconcentration of 3.3×10⁶/ml (an NK-sensitive erythroblastoma cell lineused to reduce non-specific lysis). Target cells (100 μl) and effectors(100 μl) are plated in 96 well round-bottom plates and incubated for 5hours at 37° C. At that time, 100 μl of supernatant are collected fromeach well and percent lysis is determined according to the formula:[(cpm of the test sample−cpm of the spontaneous ⁵¹Cr releasesample)/(cpm of the maximal ⁵¹Cr release sample−cpm of the spontaneous⁵¹Cr release sample)]×100.

Maximum and spontaneous release are determined by incubating the labeledtargets with 1% Triton X-100 and media alone, respectively. A positiveculture is defined as one in which the specific lysis(sample-background) is 10% or higher in the case of individual wells andis 15% or more at the two highest E:T ratios when expanded cultures areassayed.

In situ Measurement of Human IFNγ Production as an Indicator ofPeptide-Specific and Endogenous Recognition

Immulon 2 plates are coated with mouse anti-human IFNγ monoclonalantibody (4 μg/ml 0.1M NaHCO₃, pH8.2) overnight at 4° C. The plates arewashed with Ca²⁺, Mg²⁺-free PBS/0.05% Tween 20 and blocked with PBS/10%FCS for two hours, after which the CTLs (100 μl/well) and targets (100μl/well) are added to each well, leaving empty wells for the standardsand blanks (which received media only). The target cells, eitherpeptide-pulsed or endogenous targets, are used at a concentration of1×10⁶ cells/ml. The plates are incubated for 48 hours at 37° C. with 5%CO₂.

Recombinant human IFN-gamma is added to the standard wells starting at400 pg or 1200 pg/100 microliter/well and the plate incubated for twohours at 37° C. The plates are washed and 100 μl of biotinylated mouseanti-human IFN-gamma monoclonal antibody (2 microgram/ml in PBS/3%FCS/0.05% Tween 20) are added and incubated for 2 hours at roomtemperature. After washing again, 100 microliter HRP-streptavidin(1:4000) are added and the plates incubated for one hour at roomtemperature. The plates are then washed 6× with wash buffer, 100microliter/well developing solution (TMB 1:1) are added, and the platesallowed to develop for 5-15 minutes. The reaction is stopped with 50microliter/well 1M H₃PO₄ and read at OD450. A culture is consideredpositive if it measured at least 50 pg of IFN-gamma/well abovebackground and is twice the background level of expression.

CTL Expansion.

Those cultures that demonstrate specific lytic activity againstpeptide-pulsed targets and/or tumor targets are expanded over a two weekperiod with anti-CD3. Briefly, 5×10⁴ CD8+ cells are added to a T25 flaskcontaining the following: 1×10⁶ irradiated (4,200 rad) PBMC (autologousor allogeneic) per ml, 2×10⁵ irradiated (8,000 rad) EBV-transformedcells per ml, and OKT3 (anti-CD3) at 30 ng per ml in RPMI-1640containing 10% (v/v) human AB serum, non-essential amino acids, sodiumpyruvate, 25 μM 2-mercaptoethanol, L-glutamine andpenicillin/streptomycin. Recombinant human IL2 is added 24 hours laterat a final concentration of 200 IU/ml and every three days thereafterwith fresh media at 50 IU/ml. The cells are split if the cellconcentration exceeds 1×10⁶/ml and the cultures are assayed between days13 and 15 at E:T ratios of 30, 10, 3 and 1:1 in the ⁵¹Cr release assayor at 1×10⁶/ml in the in situ IFNγ assay using the same targets asbefore the expansion.

Cultures are expanded in the absence of anti-CD3+ as follows. Thosecultures that demonstrate specific lytic activity against peptide andendogenous targets are selected and 5×10⁴ CD8+ cells are added to a T25flask containing the following: 1×10⁶ autologous PBMC per ml which havebeen peptide-pulsed with 10 μg/ml peptide for two hours at 37° C. andirradiated (4,200 rad); 2×10⁵ irradiated (8,000 rad) EBV-transformedcells per ml RPMI-1640 containing 10% (v/v) human AB serum,non-essential AA, sodium pyruvate, 25 mM 2-ME, L-glutamine andgentamicin.

Immunogenicity of A2 Supermotif-bearing Peptides

A2-supermotif cross-reactive binding peptides are tested in the cellularassay for the ability to induce peptide-specific CTL in normalindividuals. In this analysis, a peptide is typically considered to bean epitope if it induces peptide-specific CTLs in at least individuals,and preferably, also recognizes the endogenously expressed peptide.

Immunogenicity can also be confirmed using PBMCs isolated from patientsbearing a tumor that expresses 282P1G3. Briefly, PBMCs are isolated frompatients, re-stimulated with peptide-pulsed monocytes and assayed forthe ability to recognize peptide-pulsed target cells as well astransfected cells endogenously expressing the antigen.

Evaluation of A*03/A11 Immunogenicity

HLA-A3 supermotif-bearing cross-reactive binding peptides are alsoevaluated for immunogenicity using methodology analogous for that usedto evaluate the immunogenicity of the HLA-A2 supermotif peptides.

Evaluation of B7 Immunogenicity

Immunogenicity screening of the B7-supertype cross-reactive bindingpeptides identified as set forth herein are confirmed in a manneranalogous to the confirmation of A2- and A3-supermotif-bearing peptides.

Peptides bearing other supermotifs/motifs, e.g., HLA-A1, HLA-A24 etc.are also confirmed using similar methodology.

Example 15 Implementation of the Extended Supermotif to Improve theBinding Capacity of Native Epitopes by Creating Analogs

HLA motifs and supermotifs (comprising primary and/or secondaryresidues) are useful in the identification and preparation of highlycross-reactive native peptides, as demonstrated herein. Moreover, thedefinition of HLA motifs and supermotifs also allows one to engineerhighly cross-reactive epitopes by identifying residues within a nativepeptide sequence which can be analoged to confer upon the peptidecertain characteristics, e.g. greater cross-reactivity within the groupof HLA molecules that comprise a supertype, and/or greater bindingaffinity for some or all of those HLA molecules. Examples of analogingpeptides to exhibit modulated binding affinity are set forth in thisexample.

Analoging at Primary Anchor Residues

Peptide engineering strategies are implemented to further increase thecross-reactivity of the epitopes. For example, the main anchors ofA2-supermotif-bearing peptides are altered, for example, to introduce apreferred L, I, V, or M at position 2, and I or V at the C-terminus.

To analyze the cross-reactivity of the analog peptides, each engineeredanalog is initially tested for binding to the prototype A2 supertypeallele A*0201, then, if A*0201 binding capacity is maintained, forA2-supertype cross-reactivity.

Alternatively, a peptide is confirmed as binding one or all supertypemembers and then analoged to modulate binding affinity to any one (ormore) of the supertype members to add population coverage.

The selection of analogs for immunogenicity in a cellular screeninganalysis is typically further restricted by the capacity of the parentwild type (WT) peptide to bind at least weakly, i.e., bind at an IC₅₀ of5000 nM or less, to three of more A2 supertype alleles. The rationalefor this requirement is that the WT peptides must be presentendogenously in sufficient quantity to be biologically relevant.Analoged peptides have been shown to have increased immunogenicity andcross-reactivity by T cells specific for the parent epitope (see, e.g.,Parkhurst et al., J. Immunol. 157:2539, 1996; and Pogue et al., Proc.Natl. Acad. Sci. USA 92:8166, 1995).

In the cellular screening of these peptide analogs, it is important toconfirm that analog-specific CTLs are also able to recognize thewild-type peptide and, when possible, target cells that endogenouslyexpress the epitope.

Analoging of HLA-A3 and B7-Supermotif-bearing Peptides

Analogs of HLA-A3 supermotif-bearing epitopes are generated usingstrategies similar to those employed in analoging HLA-A2supermotif-bearing peptides. For example, peptides binding to 3/5 of theA3-supertype molecules are engineered at primary anchor residues topossess a preferred residue (V, S, M, or A) at position 2.

The analog peptides are then tested for the ability to bind A*03 andA*11 (prototype A3 supertype alleles). Those peptides that demonstrate≦500 nM binding capacity are then confirmed as having A3-supertypecross-reactivity.

Similarly to the A2- and A3-motif bearing peptides, peptides binding 3or more B7-supertype alleles can be improved, where possible, to achieveincreased cross-reactive binding or greater binding affinity or bindinghalf life. B7 supermotif-bearing peptides are, for example, engineeredto possess a preferred residue (V, I, L, or F) at the C-terminal primaryanchor position, as demonstrated by Sidney et al. (J. Immunol.157:3480-3490, 1996).

Analoging at primary anchor residues of other motif and/orsupermotif-bearing epitopes is performed in a like manner.

The analog peptides are then be confirmed for immunogenicity, typicallyin a cellular screening assay. Again, it is generally important todemonstrate that analog-specific CTLs are also able to recognize thewild-type peptide and, when possible, targets that endogenously expressthe epitope.

Analoging at Secondary Anchor Residues

Moreover, HLA supermotifs are of value in engineering highlycross-reactive peptides and/or peptides that bind HLA molecules withincreased affinity by identifying particular residues at secondaryanchor positions that are associated with such properties. For example,the binding capacity of a B7 supermotif-bearing peptide with an Fresidue at position 1 is analyzed. The peptide is then analoged to, forexample, substitute L for F at position 1. The analoged peptide isevaluated for increased binding affinity, binding half life and/orincreased cross-reactivity. Such a procedure identifies analogedpeptides with enhanced properties.

Engineered analogs with sufficiently improved binding capacity orcross-reactivity can also be tested for immunogenicity inHLA-B7-transgenic mice, following for example, IFA immunization orlipopeptide immunization. Analoged peptides are additionally tested forthe ability to stimulate a recall response using PBMC from patients with282P1G3-expressing tumors.

Other Analoging Strategies

Another form of peptide analoging, unrelated to anchor positions,involves the substitution of a cysteine with α-amino butyric acid. Dueto its chemical nature, cysteine has the propensity to form disulfidebridges and sufficiently alter the peptide structurally so as to reducebinding capacity. Substitution of α-amino butyric acid for cysteine notonly alleviates this problem, but has been shown to improve binding andcrossbinding capabilities in some instances (see, e.g., the review bySette et al., In: Persistent Viral Infections, Eds. R. Ahmed and 1.Chen, John Wiley & Sons, England, 1999).

Thus, by the use of single amino acid substitutions, the bindingproperties and/or cross-reactivity of peptide ligands for HLA supertypemolecules can be modulated.

Example 16 Identification and Confirmation of 282P1G3-Derived Sequenceswith HLA-DR Binding Motifs

Peptide epitopes bearing an HLA class II supermotifor motif areidentified and confirmed as outlined below using methodology similar tothat described for HLA Class I peptides.

Selection of HLA-DR-Supermotif-bearing Epitopes.

To identify 282P1G3-derived, HLA class II HTL epitopes, a 282P1G3antigen is analyzed for the presence of sequences bearing anHLA-DR-motif or supermotif. Specifically, 15-mer sequences are selectedcomprising a DR-supermotif, comprising a 9-mer core, and three-residueN- and C-terminal flanking regions (15 amino acids total).

Protocols for predicting peptide binding to DR molecules have beendeveloped (Southwood et al., J. Immunol. 160:3363-3373, 1998). Theseprotocols, specific for individual DR molecules, allow the scoring, andranking, of 9-mer core regions. Each protocol not only scores peptidesequences for the presence of DR-supermotif primary anchors (i.e., atposition 1 and position 6) within a 9-mer core, but additionallyevaluates sequences for the presence of secondary anchors. Usingallele-specific selection tables (see, e.g., Southwood et al., ibid.),it has been found that these protocols efficiently select peptidesequences with a high probability of binding a particular DR molecule.Additionally, it has been found that performing these protocols intandem, specifically those for DR1, DR4w4, and DR7, can efficientlyselect DR cross-reactive peptides.

The 282P1G3-derived peptides identified above are tested for theirbinding capacity for various common HLA-DR molecules. All peptides areinitially tested for binding to the DR molecules in the primary panel:DR1, DR4w4, and DR7. Peptides binding at least two of these three DRmolecules are then tested for binding to DR2w2 β1, DR2w2 β2, DR6w19, andDR9 molecules in secondary assays. Finally, peptides binding at leasttwo of the four secondary panel DR molecules, and thus cumulatively atleast four of seven different DR molecules, are screened for binding toDR4w15, DR5w11, and DR8w2 molecules in tertiary assays. Peptides bindingat least seven of the ten DR molecules comprising the primary,secondary, and tertiary screening assays are considered cross-reactiveDR binders. 282P1G3-derived peptides found to bind common HLA-DR allelesare of particular interest.

Selection of DR3 Motif Peptides

Because HLA-DR3 is an allele that is prevalent in Caucasian, Black, andHispanic populations, DR3 binding capacity is a relevant criterion inthe selection of HTL epitopes. Thus, peptides shown to be candidates mayalso be assayed for their DR3 binding capacity. However, in view of thebinding specificity of the DR3 motif, peptides binding only to DR3 canalso be considered as candidates for inclusion in a vaccine formulation.

To efficiently identify peptides that bind DR3, target 282P1G3 antigensare analyzed for sequences carrying one of the two DR3-specific bindingmotifs reported by Geluk et al. (J. Immunol. 152:5742-5748, 1994). Thecorresponding peptides are then synthesized and confirmed as having theability to bind DR3 with an affinity of 1 μM or better, i.e., less than1 μM. Peptides are found that meet this binding criterion and qualify asHLA class II high affinity binders.

DR3 binding epitopes identified in this manner are included in vaccinecompositions with DR supermotif-bearing peptide epitopes.

Similarly to the case of HLA class I motif-bearing peptides, the classII motif-bearing peptides are analoged to improve affinity orcross-reactivity. For example, aspartic acid at position 4 of the 9-mercore sequence is an optimal residue for DR3 binding, and substitutionfor that residue often improves DR 3 binding.

Example 17 Immunogenicity of 282P1G3-derived HTL Epitopes

This example determines immunogenic DR supermotif- and DR3 motif-bearingepitopes among those identified using the methodology set forth herein.

Immunogenicity of HTL epitopes are confirmed in a manner analogous tothe determination of immunogenicity of CTL epitopes, by assessing theability to stimulate HTL responses and/or by using appropriatetransgenic mouse models. Immunogenicity is determined by screening for:1.) in vitro primary induction using normal PBMC or 2.) recall responsesfrom patients who have 282P1G3-expressing tumors.

Example 18 Calculation of Phenotypic Frequencies of HLA-supertypes inVarious Ethnic Backgrounds to Determine Breadth of Population Coverage

This example illustrates the assessment of the breadth of populationcoverage of a vaccine composition comprised of multiple epitopescomprising multiple supermotifs and/or motifs.

In order to analyze population coverage, gene frequencies of HLA allelesare determined. Gene frequencies for each HLA allele are calculated fromantigen or allele frequencies utilizing the binomial distributionformulae gf=1-(SQRT(1-af)) (see, e.g., Sidney et al., Human Immunol.45:79-93, 1996). To obtain overall phenotypic frequencies, cumulativegene frequencies are calculated, and the cumulative antigen frequenciesderived by the use of the inverse formula [af=1−(1−Cgf)²].

Where frequency data is not available at the level of DNA typing,correspondence to the serologically defined antigen frequencies isassumed. To obtain total potential supertype population coverage nolinkage disequilibrium is assumed, and only alleles confirmed to belongto each of the supertypes are included (minimal estimates). Estimates oftotal potential coverage achieved by inter-loci combinations are made byadding to the A coverage the proportion of the non-A covered populationthat could be expected to be covered by the B alleles considered (e.g.,total=A+B*(1−A)). Confirmed members of the A3-like supertype are A3,A11, A31, A*3301, and A*6801. Although the A3-like supertype may alsoinclude A34, A66, and A*7401, these alleles were not included in overallfrequency calculations. Likewise, confirmed members of the A2-likesupertype family are A*0201, A*0202, A*0203, A*0204, A*0205, A*0206,A*0207, A*6802, and A*6901. Finally, the B7-like supertype-confirmedalleles are: B7, B*3501-03, B51, B*5301, B*5401, B*5501-2, B*5601,B*6701, and B*7801 (potentially also B*1401, B*3504-06, B*4201, andB*5602).

Population coverage achieved by combining the A2-, A3- and B7-supertypesis approximately 86% in five major ethnic groups. Coverage may beextended by including peptides bearing the A1 and A24 motifs. Onaverage, A1 is present in 12% and A24 in 29% of the population acrossfive different major ethnic groups (Caucasian, North American Black,Chinese, Japanese, and Hispanic). Together, these alleles arerepresented with an average frequency of 39% in these same ethnicpopulations. The total coverage across the major ethnicities when A1 andA24 are combined with the coverage of the A2-, A3- and B7-supertypealleles is >95%, see, e.g., Table IV (G). An analogous approach can beused to estimate population coverage achieved with combinations of classII motif-bearing epitopes.

Immunogenicity studies in humans (e.g., Bertoni et al., J. Clin. Invest.100:503, 1997; Doolan et al., Immunity 7:97, 1997; and Threlkeld et al.,J. Immunol. 159:1648, 1997) have shown that highly cross-reactivebinding peptides are almost always recognized as epitopes. The use ofhighly cross-reactive binding peptides is an important selectioncriterion in identifying candidate epitopes for inclusion in a vaccinethat is immunogenic in a diverse population.

With a sufficient number of epitopes (as disclosed herein and from theart), an average population coverage is predicted to be greater than 95%in each of five major ethnic populations. The game theory Monte Carlosimulation analysis, which is known in the art (see e.g., Osborne, M. J.and Rubinstein, A. “A course in game theory” MIT Press, 1994), can beused to estimate what percentage of the individuals in a populationcomprised of the Caucasian, North American Black, Japanese, Chinese, andHispanic ethnic groups would recognize the vaccine epitopes describedherein. A preferred percentage is 90%. A more preferred percentage is95%.

Example 19 CTL Recognition of Endogenously Processed Antigens afterPriming

This example confirms that CTL induced by native or analoged peptideepitopes identified and selected as described herein recognizeendogenously synthesized, i.e., native antigens.

Effector cells isolated from transgenic mice that are immunized withpeptide epitopes, for example HLA-A2 supermotif-bearing epitopes, arere-stimulated in vitro using peptide-coated stimulator cells. Six dayslater, effector cells are assayed for cytotoxicity and the cell linesthat contain peptide-specific cytotoxic activity are furtherre-stimulated. An additional six days later, these cell lines are testedfor cytotoxic activity on ⁵¹Cr labeled Jurkat-A2.1/K^(b) target cells inthe absence or presence of peptide, and also tested on ⁵¹Cr labeledtarget cells bearing the endogenously synthesized antigen, i.e. cellsthat are stably transfected with 282P1G3 expression vectors.

The results demonstrate that CTL lines obtained from animals primed withpeptide epitope recognize endogenously synthesized 282P1G3 antigen. Thechoice of transgenic mouse model to be used for such an analysis dependsupon the epitope(s) that are being evaluated. In addition toHLA-A*0201/K^(b) transgenic mice, several other transgenic mouse modelsincluding mice with human A11, which may also be used to evaluate A3epitopes, and B7 alleles have been characterized and others (e.g.,transgenic mice for HLA-A1 and A24) are being developed. HLA-DR1 andHLA-DR3 mouse models have also been developed, which may be used toevaluate HTL epitopes.

Example 20 Activity Of CTL-HTL Conjugated Epitopes in Transgenic Mice

This example illustrates the induction of CTLs and HTLs in transgenicmice, by use of a 282P1G3-derived CTL and HTL peptide vaccinecompositions. The vaccine composition used herein comprise peptides tobe administered to a patient with a 282P1G3-expressing tumor. Thepeptide composition can comprise multiple CTL and/or HTL epitopes. Theepitopes are identified using methodology as described herein. Thisexample also illustrates that enhanced immunogenicity can be achieved byinclusion of one or more HTL epitopes in a CTL vaccine composition; sucha peptide composition can comprise an HTL epitope conjugated to a CTLepitope. The CTL epitope can be one that binds to multiple HLA familymembers at an affinity of 500 nM or less, or analogs of that epitope.The peptides may be lipidated, if desired.

Immunization procedures: Immunization of transgenic mice is performed asdescribed (Alexander et al., J. Immunol. 159:4753-4761, 1997). Forexample, A2/K^(b) mice, which are transgenic for the human HLA A2.1allele and are used to confirm the immunogenicity of HLA-A*0201 motif-or HLA-A2 supermotif-bearing epitopes, and are primed subcutaneously(base of the tail) with a 0.1 ml of peptide in Incomplete Freund'sAdjuvant, or if the peptide composition is a lipidated CTL/HTLconjugate, in DMSO/saline, or if the peptide composition is apolypeptide, in PBS or Incomplete Freund's Adjuvant. Seven days afterpriming, splenocytes obtained from these animals are restimulated withsyngenic irradiated LPS-activated lymphoblasts coated with peptide.

Cell lines: Target cells for peptide-specific cytotoxicity assays areJurkat cells transfected with the HLA-A2.1/K^(b) chimeric gene (e.g.,Vitiello et al., J. Exp. Med. 173:1007, 1991)

In vitro CTL activation: One week after priming, spleen cells (30×10⁶cells/flask) are co-cultured at 37° C. with syngeneic, irradiated (3000rads), peptide coated lymphoblasts (10×10⁶ cells/flask) in 10 ml ofculture medium/T25 flask. After six days, effector cells are harvestedand assayed for cytotoxic activity.

Assay for cytotoxic activity: Target cells (1.0 to 1.5×10⁶) areincubated at 37° C. in the presence of 200 μl of ⁵¹Cr. After 60 minutes,cells are washed three times and resuspended in R10 medium. Peptide isadded where required at a concentration of 1 μg/ml. For the assay, 10⁴⁵¹Cr-labeled target cells are added to different concentrations ofeffector cells (final volume of 200 μl) in U-bottom 96-well plates.After a six hour incubation period at 37° C., a 0.1 ml aliquot ofsupernatant is removed from each well and radioactivity is determined ina Micromedic automatic gamma counter. The percent specific lysis isdetermined by the formula: percent specific release=100×(experimentalrelease−spontaneous release)/(maximum release−spontaneous release). Tofacilitate comparison between separate CTL assays run under the sameconditions, % ⁵¹Cr release data is expressed as lytic units/10⁶ cells.One lytic unit is arbitrarily defined as the number of effector cellsrequired to achieve 30% lysis of 10,000 target cells in a six hour ⁵¹Crrelease assay. To obtain specific lytic units/10⁶, the lytic units/10⁶obtained in the absence of peptide is subtracted from the lyticunits/10⁶ obtained in the presence of peptide. For example, if 30% ⁵¹Crrelease is obtained at the effector (E): target (T) ratio of 50:1 (i.e.,5×10⁵ effector cells for 10,000 targets) in the absence of peptide and5:1 (i.e., 5×10⁴ effector cells for 10,000 targets) in the presence ofpeptide, the specific lytic units would be:[(1/50,000)−(1/500,000)]×10⁶=18 LU.

The results are analyzed to assess the magnitude of the CTL responses ofanimals injected with the immunogenic CTL/HTL conjugate vaccinepreparation and are compared to the magnitude of the CTL responseachieved using, for example, CTL epitopes as outlined above in theExample entitled “Confirmation of Immunogenicity.” Analyses similar tothis may be performed to confirm the immunogenicity of peptideconjugates containing multiple CTL epitopes and/or multiple HTLepitopes. In accordance with these procedures, it is found that a CTLresponse is induced, and concomitantly that an HTL response is inducedupon administration of such compositions.

Example 21 Selection of CTL and HTL Epitopes for Inclusion in a282P1G3-specific Vaccine

This example illustrates a procedure for selecting peptide epitopes forvaccine compositions of the invention. The peptides in the compositioncan be in the form of a nucleic acid sequence, either single or one ormore sequences (i.e., minigene) that encodes peptide(s), or can besingle and/or polyepitopic peptides.

The following principles are utilized when selecting a plurality ofepitopes for inclusion in a vaccine composition. Each of the followingprinciples is balanced in order to make the selection.

Epitopes are selected which, upon administration, mimic immune responsesthat are correlated with 282P1G3 clearance. The number of epitopes useddepends on observations of patients who spontaneously clear 282P1G3. Forexample, if it has been observed that patients who spontaneously clear282P1G3-expressing cells generate an immune response to at least three(3) epitopes from 282P1G3 antigen, then at least three epitopes shouldbe included for HLA class I. A similar rationale is used to determineHLA class II epitopes.

Epitopes are often selected that have a binding affinity of an IC₅₀ of500 nM or less for an HLA class I molecule, or for class II, an IC₅₀ of1000 nM or less; or HLA Class I peptides with high binding scores fromthe BIMAS web site on the World Wide Web.

In order to achieve broad coverage of the vaccine through out a diversepopulation, sufficient supermotif bearing peptides, or a sufficientarray of allele-specific motif bearing peptides, are selected to givebroad population coverage. In one embodiment, epitopes are selected toprovide at least 80% population coverage. A Monte Carlo analysis, astatistical evaluation known in the art, can be employed to assessbreadth, or redundancy, of population coverage.

When creating polyepitopic compositions, or a minigene that encodessame, it is typically desirable to generate the smallest peptidepossible that encompasses the epitopes of interest. The principlesemployed are similar, if not the same, as those employed when selectinga peptide comprising nested epitopes. For example, a protein sequencefor the vaccine composition is selected because it has maximal number ofepitopes contained within the sequence, i.e., it has a highconcentration of epitopes. Epitopes may be nested or overlapping (i.e.,frame shifted relative to one another). For example, with overlappingepitopes, two 9-mer epitopes and one 10-mer epitope can be present in a10 amino acid peptide. Each epitope can be exposed and bound by an HLAmolecule upon administration of such a peptide. A multi-epitopic,peptide can be generated synthetically, recombinantly, or via cleavagefrom the native source. Alternatively, an analog can be made of thisnative sequence, whereby one or more of the epitopes comprisesubstitutions that alter the cross-reactivity and/or binding affinityproperties of the polyepitopic peptide. Such a vaccine composition isadministered for therapeutic or prophylactic purposes. This embodimentprovides for the possibility that an as yet undiscovered aspect ofimmune system processing will apply to the native nested sequence andthereby facilitate the production of therapeutic or prophylactic immuneresponse-inducing vaccine compositions. Additionally such an embodimentprovides for the possibility of motif-bearing epitopes for an HLA makeupthat is presently unknown. Furthermore, this embodiment (absent thecreating of any analogs) directs the immune response to multiple peptidesequences that are actually present in 282P1G3, thus avoiding the needto evaluate any junctional epitopes. Lastly, the embodiment provides aneconomy of scale when producing nucleic acid vaccine compositions.Related to this embodiment, computer programs can be derived inaccordance with principles in the art, which identify in a targetsequence, the greatest number of epitopes per sequence length.

A vaccine composition comprised of selected peptides, when administered,is safe, efficacious, and elicits an immune response similar inmagnitude to an immune response that controls or clears cells that bearor overexpress 282P1G3.

Example 22 Construction of “Minigene” Multi-Epitope DNA Plasmids

This example discusses the construction of a minigene expressionplasmid. Minigene plasmids may, of course, contain variousconfigurations of B cell, CTL and/or HTL epitopes or epitope analogs asdescribed herein.

A minigene expression plasmid typically includes multiple CTL and HTLpeptide epitopes. In the present example, HLA-A2, -A3, -B7supermotif-bearing peptide epitopes and HLA-A1 and -A24 motif-bearingpeptide epitopes are used in conjunction with DR supermotif-bearingepitopes and/or DR3 epitopes. HLA class I supermotif or motif-bearingpeptide epitopes derived 282P1G3, are selected such that multiplesupermotifs/motifs are represented to ensure broad population coverage.Similarly, HLA class II epitopes are selected from 282P1G3 to providebroad population coverage, i.e. both HLA DR-1-4-7 supermotif-bearingepitopes and HLA DR-3 motif-bearing epitopes are selected for inclusionin the minigene construct. The selected CTL and HTL epitopes are thenincorporated into a minigene for expression in an expression vector.

Such a construct may additionally include sequences that direct the HTLepitopes to the endoplasmic reticulum. For example, the li protein maybe fused to one or more HTL epitopes as described in the art, whereinthe CLIP sequence of the li protein is removed and replaced with an HLAclass II epitope sequence so that HLA class II epitope is directed tothe endoplasmic reticulum, where the epitope binds to an HLA class IImolecules.

This example illustrates the methods to be used for construction of aminigene-bearing expression plasmid. Other expression vectors that maybe used for minigene compositions are available and known to those ofskill in the art.

The minigene DNA plasmid of this example contains a consensus Kozaksequence and a consensus murine kappa Ig-light chain signal sequencefollowed by CTL and/or HTL epitopes selected in accordance withprinciples disclosed herein. The sequence encodes an open reading framefused to the Myc and His antibody epitope tag coded for by the pcDNA 3.1Myc-His vector.

Overlapping oligonucleotides that can, for example, average about 70nucleotides in length with 15 nucleotide overlaps, are synthesized andHPLC-purified. The oligonucleotides encode the selected peptide epitopesas well as appropriate linker nucleotides, Kozak sequence, and signalsequence. The final multiepitope minigene is assembled by extending theoverlapping oligonucleotides in three sets of reactions using PCR. APerkin/Elmer 9600 PCR machine is used and a total of 30 cycles areperformed using the following conditions: 95° C. for 15 sec, annealingtemperature (5° below the lowest calculated Tm of each primer pair) for30 sec, and 72° C. for 1 min.

For example, a minigene is prepared as follows. For a first PCRreaction, 5 μg of each of two oligonucleotides are annealed andextended: In an example using eight oligonucleotides, i.e., four pairsof primers, oligonucleotides 1+2, 3+4, 5+6, and 7+8 are combined in 100μl reactions containing Pfu polymerase buffer (1x=10 mM KCL, 10 mM(NH4)₂SO₄, 20 mM Tris-chloride, pH 8.75, 2 mM MgSO₄, 0.1% Triton X-100,100 μg/ml BSA), 0.25 mM each dNTP, and 2.5 U of Pfu polymerase. Thefull-length dimer products are gel-purified, and two reactionscontaining the product of 1+2 and 3+4, and the product of 5+6 and 7+8are mixed, annealed, and extended for 10 cycles. Half of the tworeactions are then mixed, and 5 cycles of annealing and extensioncarried out before flanking primers are added to amplify the full lengthproduct. The full-length product is gel-purified and cloned intopCR-blunt (Invitrogen) and individual clones are screened by sequencing.

Example 23 The Plasmid Construct and the Degree to which it InducesImmunogenicity

The degree to which a plasmid construct, for example a plasmidconstructed in accordance with the previous Example, is able to induceimmunogenicity is confirmed in vitro by determining epitope presentationby APC following transduction or transfection of the APC with anepitope-expressing nucleic acid construct. Such a study determines“antigenicity” and allows the use of human APC. The assay determines theability of the epitope to be presented by the APC in a context that isrecognized by a T cell by quantifying the density of epitope-HLA class Icomplexes on the cell surface. Quantitation can be performed by directlymeasuring the amount of peptide eluted from the APC (see, e.g., Sijts etal., J. Immunol. 156:683-692, 1996; Demotz et al., Nature 342:682-684,1989); or the number of peptide-HLA class I complexes can be estimatedby measuring the amount of lysis or lymphokine release induced bydiseased or transfected target cells, and then determining theconcentration of peptide necessary to obtain equivalent levels of lysisor lymphokine release (see, e.g., Kageyama et al., J. Immunol.154:567-576, 1995).

Alternatively, immunogenicity is confirmed through in vivo injectionsinto mice and subsequent in vitro assessment of CTL and HTL activity,which are analyzed using cytotoxicity and proliferation assays,respectively, as detailed e.g., in Alexander et al., Immunity 1:751-761,1994.

For example, to confirm the capacity of a DNA minigene constructcontaining at least one HLA-A2 supermotif peptide to induce CTLs invivo, HLA-A2.1/Kb transgenic mice, for example, are immunizedintramuscularly with 100 μg of naked cDNA. As a means of comparing thelevel of CTLs induced by cDNA immunization, a control group of animalsis also immunized with an actual peptide composition that comprisesmultiple epitopes synthesized as a single polypeptide as they would beencoded by the minigene.

Splenocytes from immunized animals are stimulated twice with each of therespective compositions (peptide epitopes encoded in the minigene or thepolyepitopic peptide), then assayed for peptide-specific cytotoxicactivity in a ⁵¹Cr release assay. The results indicate the magnitude ofthe CTL response directed against the A2-restricted epitope, thusindicating the in vivo immunogenicity of the minigene vaccine andpolyepitopic vaccine.

It is, therefore, found that the minigene elicits immune responsesdirected toward the HLA-A2 supermotif peptide epitopes as does thepolyepitopic peptide vaccine. A similar analysis is also performed usingother HLA-A3 and HLA-B7 transgenic mouse models to assess CTL inductionby HLA-A3 and HLA-B7 motif or supermotif epitopes, whereby it is alsofound that the minigene elicits appropriate immune responses directedtoward the provided epitopes.

To confirm the capacity of a class II epitope-encoding minigene toinduce HTLs in vivo, DR transgenic mice, or for those epitopes thatcross react with the appropriate mouse MHC molecule, I-A^(b)-restrictedmice, for example, are immunized intramuscularly with 100 μg of plasmidDNA. As a means of comparing the level of HTLs induced by DNAimmunization, a group of control animals is also immunized with anactual peptide composition emulsified in complete Freund's adjuvant.CD4+ T cells, i.e. HTLs, are purified from splenocytes of immunizedanimals and stimulated with each of the respective compositions(peptides encoded in the minigene). The HTL response is measured using a³H-thymidine incorporation proliferation assay, (see, e.g., Alexander etal. Immunity 1:751-761, 1994). The results indicate the magnitude of theHTL response, thus demonstrating the in vivo immunogenicity of theminigene.

DNA minigenes, constructed as described in the previous Example, canalso be confirmed as a vaccine in combination with a boosting agentusing a prime boost protocol. The boosting agent can consist ofrecombinant protein (e.g., Barnett et al., Aids Res. and HumanRetroviruses 14, Supplement 3:S299-S309, 1998) or recombinant vaccinia,for example, expressing a minigene or DNA encoding the complete proteinof interest (see, e.g., Hanke et al., Vaccine 16:439-445, 1998; Sedegahet al., Proc. Natl. Acad. Sci USA 95:7648-53, 1998; Hanke and McMichael,Immunol. Letters 66:177-181, 1999; and Robinson et al., Nature Med.5:526-34, 1999).

For example, the efficacy of the DNA minigene used in a prime boostprotocol is initially evaluated in transgenic mice. In this example,A2.1/K^(b) transgenic mice are immunized IM with 100 μg of a DNAminigene encoding the immunogenic peptides including at least one HLA-A2supermotif-bearing peptide. After an incubation period (ranging from 3-9weeks), the mice are boosted IP with 10⁷ pfu/mouse of a recombinantvaccinia virus expressing the same sequence encoded by the DNA minigene.Control mice are immunized with 100 μg of DNA or recombinant vacciniawithout the minigene sequence, or with DNA encoding the minigene, butwithout the vaccinia boost. After an additional incubation period of twoweeks, splenocytes from the mice are immediately assayed forpeptide-specific activity in an ELISPOT assay. Additionally, splenocytesare stimulated in vitro with the A2-restricted peptide epitopes encodedin the minigene and recombinant vaccinia, then assayed forpeptide-specific activity in an alpha, beta and/or gamma IFN ELISA.

It is found that the minigene utilized in a prime-boost protocol elicitsgreater immune responses toward the HLA-A2 supermotif peptides than withDNA alone. Such an analysis can also be performed using HLA-AL 1 orHLA-B7 transgenic mouse models to assess CTL induction by HLA-A3 orHLA-B7 motif or supermotif epitopes. The use of prime boost protocols inhumans is described below in the Example entitled “Induction of CTLResponses Using a Prime Boost Protocol.”

Example 24 Peptide Compositions for Prophylactic Uses

Vaccine compositions of the present invention can be used to prevent282P1G3 expression in persons who are at risk for tumors that bear thisantigen. For example, a polyepitopic peptide epitope composition (or anucleic acid comprising the same) containing multiple CTL and HTLepitopes such as those selected in the above Examples, which are alsoselected to target greater than 80% of the population, is administeredto individuals at risk for a 282P1G3-associated tumor.

For example, a peptide-based composition is provided as a singlepolypeptide that encompasses multiple epitopes. The vaccine is typicallyadministered in a physiological solution that comprises an adjuvant,such as Incomplete Freunds Adjuvant. The dose of peptide for the initialimmunization is from about 1 to about 50,000 μg, generally 100-5,000 μg,for a 70 kg patient. The initial administration of vaccine is followedby booster dosages at 4 weeks followed by evaluation of the magnitude ofthe immune response in the patient, by techniques that determine thepresence of epitope-specific CTL populations in a PBMC sample.Additional booster doses are administered as required. The compositionis found to be both safe and efficacious as a prophylaxis against282P1G3-associated disease.

Alternatively, a composition typically comprising transfecting agents isused for the administration of a nucleic acid-based vaccine inaccordance with methodologies known in the art and disclosed herein.

Example 25 Polyepitopic Vaccine Compositions Derived from Native 282P1G3Sequences

A native 282P1G3 polyprotein sequence is analyzed, preferably usingcomputer algorithms defined for each class I and/or class II supermotifor motif, to identify “relatively short” regions of the polyprotein thatcomprise multiple epitopes. The “relatively short” regions arepreferably less in length than an entire native antigen. This relativelyshort sequence that contains multiple distinct or overlapping, “nested”epitopes can be used to generate a minigene construct. The construct isengineered to express the peptide, which corresponds to the nativeprotein sequence. The “relatively short” peptide is generally less than250 amino acids in length, often less than 100 amino acids in length,preferably less than 75 amino acids in length, and more preferably lessthan 50 amino acids in length. The protein sequence of the vaccinecomposition is selected because it has maximal number of epitopescontained within the sequence, i.e., it has a high concentration ofepitopes. As noted herein, epitope motifs may be nested or overlapping(i.e., frame shifted relative to one another). For example, withoverlapping epitopes, two 9-mer epitopes and one 10-mer epitope can bepresent in a 10 amino acid peptide. Such a vaccine composition isadministered for therapeutic or prophylactic purposes.

The vaccine composition will include, for example, multiple CTL epitopesfrom 282P1G3 antigen and at least one HTL epitope. This polyepitopicnative sequence is administered either as a peptide or as a nucleic acidsequence which encodes the peptide. Alternatively, an analog can be madeof this native sequence, whereby one or more of the epitopes comprisesubstitutions that alter the cross-reactivity and/or binding affinityproperties of the polyepitopic peptide.

The embodiment of this example provides for the possibility that an asyet undiscovered aspect of immune system processing will apply to thenative nested sequence and thereby facilitate the production oftherapeutic or prophylactic immune response-inducing vaccinecompositions. Additionally, such an embodiment provides for thepossibility of motif-bearing epitopes for an HLA makeup(s) that ispresently unknown. Furthermore, this embodiment (excluding an analogedembodiment) directs the immune response to multiple peptide sequencesthat are actually present in native 282P1G3, thus avoiding the need toevaluate any junctional epitopes. Lastly, the embodiment provides aneconomy of scale when producing peptide or nucleic acid vaccinecompositions.

Related to this embodiment, computer programs are available in the artwhich can be used to identify in a target sequence, the greatest numberof epitopes per sequence length.

Example 26 Polyepitopic Vaccine Compositions from Multiple Antigens

The 282P1G3 peptide epitopes of the present invention are used inconjunction with epitopes from other target tumor-associated antigens,to create a vaccine composition that is useful for the prevention ortreatment of cancer that expresses 282P1G3 and such other antigens. Forexample, a vaccine composition can be provided as a single polypeptidethat incorporates multiple epitopes from 282P1G3 as well astumor-associated antigens that are often expressed with a target cancerassociated with 282P1G3 expression, or can be administered as acomposition comprising a cocktail of one or more discrete epitopes.Alternatively, the vaccine can be administered as a minigene constructor as dendritic cells which have been loaded with the peptide epitopesin vitro.

Example 27 Use of Peptides to Evaluate an Immune Response

Peptides of the invention may be used to analyze an immune response forthe presence of specific antibodies, CTL or HTL directed to 282P1G3.Such an analysis can be performed in a manner described by Ogg et al.,Science 279:2103-2106, 1998. In this Example, peptides in accordancewith the invention are used as a reagent for diagnostic or prognosticpurposes, not as an immunogen.

In this example highly sensitive human leukocyte antigen tetramericcomplexes (“tetramers”) are used for a cross-sectional analysis of, forexample, 282P1G3 HLA-A*0201-specific CTL frequencies from HLAA*0201-positive individuals at different stages of disease or followingimmunization comprising a 282P1G3 peptide containing an A*0201 motif.Tetrameric complexes are synthesized as described (Musey et al., N.Engl. J. Med. 337:1267, 1997). Briefly, purified HLA heavy chain (A*0201in this example) and β2-microglobulin are synthesized by means of aprokaryotic expression system. The heavy chain is modified by deletionof the transmembrane-cytosolic tail and COOH-terminal addition of asequence containing a BirA enzymatic biotinylation site. The heavychain, β2-microglobulin, and peptide are refolded by dilution. The 45-kDrefolded product is isolated by fast protein liquid chromatography andthen biotinylated by BirA in the presence of biotin (Sigma, St. Louis,Mo.), adenosine 5′ triphosphate and magnesium.Streptavidin-phycoerythrin conjugate is added in a 1:4 molar ratio, andthe tetrameric product is concentrated to 1 mg/ml. The resulting productis referred to as tetramer-phycoerythrin.

For the analysis of patient blood samples, approximately one millionPBMCs are centrifuged at 300 g for 5 minutes and resuspended in 50 μl ofcold phosphate-buffered saline. Tri-color analysis is performed with thetetramer-phycoerythrin, along with anti-CD8-Tricolor, and anti-CD38. ThePBMCs are incubated with tetramer and antibodies on ice for 30 to 60 minand then washed twice before formaldehyde fixation. Gates are applied tocontain >99.98% of control samples. Controls for the tetramers includeboth A*0201-negative individuals and A*0201-positive non-diseaseddonors. The percentage of cells stained with the tetramer is thendetermined by flow cytometry. The results indicate the number of cellsin the PBMC sample that contain epitope-restricted CTLs, thereby readilyindicating the extent of immune response to the 282P1G3 epitope, andthus the status of exposure to 282P1G3, or exposure to a vaccine thatelicits a protective or therapeutic response.

Example 28 Use of Peptide Epitopes to Evaluate Recall Responses

The peptide epitopes of the invention are used as reagents to evaluate Tcell responses, such as acute or recall responses, in patients. Such ananalysis may be performed on patients who have recovered from282P1G3-associated disease or who have been vaccinated with a 282P1G3vaccine.

For example, the class I restricted CTL response of persons who havebeen vaccinated may be analyzed. The vaccine may be any 282P1G3 vaccine.PBMC are collected from vaccinated individuals and HLA typed.Appropriate peptide epitopes of the invention that, optimally, bearsupermotifs to provide cross-reactivity with multiple HLA supertypefamily members, are then used for analysis of samples derived fromindividuals who bear that HLA type.

PBMC from vaccinated individuals are separated on Ficoll-Histopaquedensity gradients (Sigma Chemical Co., St. Louis, Mo.), washed threetimes in HBSS (GIBCO Laboratories), resuspended in RPMI-1640 (GIBCOLaboratories) supplemented with L-glutamine (2 mM), penicillin (50U/ml), streptomycin (50 μg/ml), and Hepes (10 mM) containing 10%heat-inactivated human AB serum (complete RPMI) and plated usingmicroculture formats. A synthetic peptide comprising an epitope of theinvention is added at 10 μg/ml to each well and HBV core 128-140 epitopeis added at 1 μg/ml to each well as a source of T cell help during thefirst week of stimulation.

In the microculture format, 4×10⁵ PBMC are stimulated with peptide in 8replicate cultures in 96-well round bottom plate in 100 μl/well ofcomplete RPMI. On days 3 and 10, 100 μl of complete RPMI and 20 U/mlfinal concentration of rlL-2 are added to each well. On day 7 thecultures are transferred into a 96-well flat-bottom plate andrestimulated with peptide, rIL-2 and 10⁵ irradiated (3,000 rad)autologous feeder cells. The cultures are tested for cytotoxic activityon day 14. A positive CTL response requires two or more of the eightreplicate cultures to display greater than 10% specific ⁵¹Cr release,based on comparison with non-diseased control subjects as previouslydescribed (Rehermann, et al., Nature Med. 2:1104, 1108, 1996; Rehermannet al., J. Clin. Invest. 97:1655-1665, 1996; and Rehermann et al. J.Clin. Invest. 98:1432-1440, 1996).

Target cell lines are autologous and allogeneic EBV-transformed B-LCLthat are either purchased from the American Society forHistocompatibility and Immunogenetics (ASH I, Boston, Mass.) orestablished from the pool of patients as described (Guilhot, et al. J.Virol. 66:2670-2678, 1992).

Cytotoxicity assays are performed in the following manner. Target cellsconsist of either allogeneic HLA-matched or autologous EBV-transformed Blymphoblastoid cell line that are incubated overnight with the syntheticpeptide epitope of the invention at 10 μM, and labeled with 100 μCi of⁵¹Cr (Amersham Corp., Arlington Heights, Ill.) for 1 hour after whichthey are washed four times with HBSS.

Cytolytic activity is determined in a standard 4-h, split well ⁵¹Crrelease assay using U-bottomed 96 well plates containing 3,000targets/well. Stimulated PBMC are tested at effector/target (E/T) ratiosof 20-50:1 on day 14. Percent cytotoxicity is determined from theformula: 100×[(experimental release−spontaneous release)/maximumrelease−spontaneous release)]. Maximum release is determined by lysis oftargets by detergent (2% Triton X-100; Sigma Chemical Co., St. Louis,Mo.). Spontaneous release is <25% of maximum release for allexperiments.

The results of such an analysis indicate the extent to whichHLA-restricted CTL populations have been stimulated by previous exposureto 282P1G3 or a 282P1G3 vaccine.

Similarly, Class II restricted HTL responses may also be analyzed.Purified PBMC are cultured in a 96-well flat bottom plate at a densityof 1.5×10⁵ cells/well and are stimulated with 10 μg/ml synthetic peptideof the invention, whole 282P1G3 antigen, or PHA. Cells are routinelyplated in replicates of 4-6 wells for each condition. After seven daysof culture, the medium is removed and replaced with fresh mediumcontaining 10 U/ml IL-2. Two days later, 1 μCi ³H-thymidine is added toeach well and incubation is continued for an additional 18 hours.Cellular DNA is then harvested on glass fiber mats and analyzed for³H-thymidine incorporation. Antigen-specific T cell proliferation iscalculated as the ratio of ³H-thymidine incorporation in the presence ofantigen divided by the ³H-thymidine incorporation in the absence ofantigen.

Example 29 Induction Of Specific CTL Response in Humans

A human clinical trial for an immunogenic composition comprising CTL andHTL epitopes of the invention is set up as an IND Phase I, doseescalation study and carried out as a randomized, double-blind,placebo-controlled trial. Such a trial is designed, for example, asfollows:

A total of about 27 individuals are enrolled and divided into 3 groups:

Group I: 3 subjects are injected with placebo and 6 subjects areinjected with 5 μg of peptide composition;

Group II: 3 subjects are injected with placebo and 6 subjects areinjected with 50 μg peptide composition;

Group III: 3 subjects are injected with placebo and 6 subjects areinjected with 500 μg of peptide composition.

After 4 weeks following the first injection, all subjects receive abooster inoculation at the same dosage.

The endpoints measured in this study relate to the safety andtolerability of the peptide composition as well as its immunogenicity.Cellular immune responses to the peptide composition are an index of theintrinsic activity of this the peptide composition, and can therefore beviewed as a measure of biological efficacy. The following summarize theclinical and laboratory data that relate to safety and efficacyendpoints.

Safety: The incidence of adverse events is monitored in the placebo anddrug treatment group and assessed in terms of degree and reversibility.

Evaluation of Vaccine Efficacy: For evaluation of vaccine efficacy,subjects are bled before and after injection. Peripheral bloodmononuclear cells are isolated from fresh heparinized blood byFicoll-Hypaque density gradient centrifugation, aliquoted in freezingmedia and stored frozen. Samples are assayed for CTL and HTL activity.

The vaccine is found to be both safe and efficacious.

Example 30 Phase II Trials in Patients Expressing 282P1G3

Phase II trials are performed to study the effect of administering theCTL-HTL peptide compositions to patients having cancer that expresses282P1G3. The main objectives of the trial are to determine an effectivedose and regimen for inducing CTLs in cancer patients that express282P1G3, to establish the safety of inducing a CTL and HTL response inthese patients, and to see to what extent activation of CTLs improvesthe clinical picture of these patients, as manifested, e.g., by thereduction and/or shrinking of lesions. Such a study is designed, forexample, as follows:

The studies are performed in multiple centers. The trial design is anopen-label, uncontrolled, dose escalation protocol wherein the peptidecomposition is administered as a single dose followed six weeks later bya single booster shot of the same dose. The dosages are 50, 500 and5,000 micrograms per injection. Drug-associated adverse effects(severity and reversibility) are recorded.

There are three patient groupings. The first group is injected with 50micrograms of the peptide composition and the second and third groupswith 500 and 5,000 micrograms of peptide composition, respectively. Thepatients within each group range in age from 21-65 and represent diverseethnic backgrounds. All of them have a tumor that expresses 282P1G3.

Clinical manifestations or antigen-specific T-cell responses aremonitored to assess the effects of administering the peptidecompositions. The vaccine composition is found to be both safe andefficacious in the treatment of 282P1G3-associated disease.

Example 31 Induction of CTL Responses Using a Prime Boost Protocol

A prime boost protocol similar in its underlying principle to that usedto confirm the efficacy of a DNA vaccine in transgenic mice, such asdescribed above in the Example entitled “The Plasmid Construct and theDegree to Which It Induces Immunogenicity,” can also be used for theadministration of the vaccine to humans. Such a vaccine regimen caninclude an initial administration of, for example, naked DNA followed bya boost using recombinant virus encoding the vaccine, or recombinantprotein/polypeptide or a peptide mixture administered in an adjuvant.

For example, the initial immunization may be performed using anexpression vector, such as that constructed in the Example entitled“Construction of “Minigene” Multi-Epitope DNA Plasmids” in the form ofnaked nucleic acid administered IM (or SC or ID) in the amounts of 0.5-5mg at multiple sites. The nucleic acid (0.1 to 1000 μg) can also beadministered using a gene gun. Following an incubation period of 3-4weeks, a booster dose is then administered. The booster can berecombinant fowlpox virus administered at a dose of 5-10⁷ to 5×10⁹ pfu.An alternative recombinant virus, such as an MVA, canarypox, adenovirus,or adeno-associated virus, can also be used for the booster, or thepolyepitopic protein or a mixture of the peptides can be administered.For evaluation of vaccine efficacy, patient blood samples are obtainedbefore immunization as well as at intervals following administration ofthe initial vaccine and booster doses of the vaccine. Peripheral bloodmononuclear cells are isolated from fresh heparinized blood byFicoll-Hypaque density gradient centrifugation, aliquoted in freezingmedia and stored frozen. Samples are assayed for CTL and HTL activity.

Analysis of the results indicates that a magnitude of responsesufficient to achieve a therapeutic or protective immunity against282P1G3 is generated.

Example 32 Administration of Vaccine Compositions Using Dendritic Cells(DC)

Vaccines comprising peptide epitopes of the invention can beadministered using APCs, or professional APCs such as DC. In thisexample, peptide-pulsed DC are administered to a patient to stimulate aCTL response in vivo. In this method, dendritic cells are isolated,expanded, and pulsed with a vaccine comprising peptide CTL and HTLepitopes of the invention. The dendritic cells are infused back into thepatient to elicit CTL and HTL responses in vivo. The induced CTL and HTLthen destroy or facilitate destruction, respectively, of the targetcells that bear the 282P1G3 protein from which the epitopes in thevaccine are derived.

For example, a cocktail of epitope-comprising peptides is administeredex vivo to PBMC, or isolated DC therefrom. A pharmaceutical tofacilitate harvesting of DC can be used, such as Progenipoietin™(Monsanto, St. Louis, Mo.) or GM-CSF/IL-4. After pulsing the DC withpeptides, and prior to reinfusion into patients, the DC are washed toremove unbound peptides.

As appreciated clinically, and readily determined by one of skill basedon clinical outcomes, the number of DC reinfused into the patient canvary (see, e.g., Nature Med. 4:328, 1998; Nature Med. 2:52, 1996 andProstate 32:272, 1997). Although 2-50×10⁶ DC per patient are typicallyadministered, larger number of DC, such as 10⁷ or 10⁸ can also beprovided. Such cell populations typically contain between 50-90% DC.

In some embodiments, peptide-loaded PBMC are injected into patientswithout purification of the DC. For example, PBMC generated aftertreatment with an agent such as Progenipoietin™ are injected intopatients without purification of the DC. The total number of PBMC thatare administered often ranges from 10⁸ to 10¹⁰. Generally, the celldoses injected into patients is based on the percentage of DC in theblood of each patient, as determined, for example, by immunofluorescenceanalysis with specific anti-DC antibodies. Thus, for example, ifProgenipoietin™ mobilizes 2% DC in the peripheral blood of a givenpatient, and that patient is to receive 5×10⁶ DC, then the patient willbe injected with a total of 2.5×10⁸ peptide-loaded PBMC. The percent DCmobilized by an agent such as Progenipoietin™ is typically estimated tobe between 2-10%, but can vary as appreciated by one of skill in theart.

Ex Vivo Activation of CTL/HTL Responses

Alternatively, ex vivo CTL or HTL responses to 282P1G3 antigens can beinduced by incubating, in tissue culture, the patient's, or geneticallycompatible, CTL or HTL precursor cells together with a source of APC,such as DC, and immunogenic peptides. After an appropriate incubationtime (typically about 7-28 days), in which the precursor cells areactivated and expanded into effector cells, the cells are infused intothe patient, where they will destroy (CTL) or facilitate destruction(HTL) of their specific target cells, i.e., tumor cells.

Example 33 An Alternative Method of Identifying and ConfirmingMotif-Bearing Peptides

Another method of identifying and confirming motif-bearing peptides isto elute them from cells bearing defined MHC molecules. For example, EBVtransformed B cell lines used for tissue typing have been extensivelycharacterized to determine which HLA molecules they express. In certaincases these cells express only a single type of HLA molecule. Thesecells can be transfected with nucleic acids that express the antigen ofinterest, e.g. 282P1G3. Peptides produced by endogenous antigenprocessing of peptides produced as a result of transfection will thenbind to HLA molecules within the cell and be transported and displayedon the cell's surface. Peptides are then eluted from the HLA moleculesby exposure to mild acid conditions and their amino acid sequencedetermined, e.g., by mass spectral analysis (e.g., Kubo et al., J.Immunol. 152:3913, 1994). Because the majority of peptides that bind aparticular HLA molecule are motif-bearing, this is an alternativemodality for obtaining the motif-bearing peptides correlated with theparticular HLA molecule expressed on the cell.

Alternatively, cell lines that do not express endogenous HLA moleculescan be transfected with an expression construct encoding a single HLAallele. These cells can then be used as described, i.e., they can thenbe transfected with nucleic acids that encode 282P1G3 to isolatepeptides corresponding to 282P1G3 that have been presented on the cellsurface. Peptides obtained from such an analysis will bear motif(s) thatcorrespond to binding to the single HLA allele that is expressed in thecell.

As appreciated by one in the art, one can perform a similar analysis ona cell bearing more than one HLA allele and subsequently determinepeptides specific for each HLA allele expressed. Moreover, one of skillwould also recognize that means other than transfection, such as loadingwith a protein antigen, can be used to provide a source of antigen tothe cell.

Example 34 Complementary Polynucleotides

Sequences complementary to the 282P1G3-encoding sequences, or any partsthereof, are used to detect, decrease, or inhibit expression ofnaturally occurring 282P1G3. Although use of oligonucleotides comprisingfrom about 15 to 30 base pairs is described, essentially the sameprocedure is used with smaller or with larger sequence fragments.Appropriate oligonucleotides are designed using, e.g., OLIGO 4.06software (National Biosciences) and the coding sequence of 282P1G3. Toinhibit transcription, a complementary oligonucleotide is designed fromthe most unique 5′ sequence and used to prevent promoter binding to thecoding sequence. To inhibit translation, a complementary oligonucleotideis designed to prevent ribosomal binding to a 282P1G3-encodingtranscript.

Example 35 Purification of Naturally-occurring or Recombinant 282P1G3Using 282P1G3-Specific Antibodies

Naturally occurring or recombinant 282P1G3 is substantially purified byimmunoaffinity chromatography using antibodies specific for 282P1G3. Animmunoaffinity column is constructed by covalently coupling anti-282P1G3antibody to an activated chromatographic resin, such as CNBr-activatedSEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin isblocked and washed according to the manufacturer's instructions.

Media containing 282P1G3 are passed over the immunoaffinity column, andthe column is washed under conditions that allow the preferentialabsorbance of 282P1G3 (e.g., high ionic strength buffers in the presenceof detergent). The column is eluted under conditions that disruptantibody/282P1G3 binding (e.g., a buffer of pH 2 to pH 3, or a highconcentration of a chaotrope, such as urea or thiocyanate ion), andGCR.P is collected.

Example 36 Identification of Molecules which Interact with 282P1G3

282P1G3, or biologically active fragments thereof, are labeled with 1211 Bolton-Hunter reagent. (See, e.g., Bolton et al. (1973) Biochem. J.133:529.) Candidate molecules previously arrayed in the wells of amulti-well plate are incubated with the labeled 282P1G3, washed, and anywells with labeled 282P1G3 complex are assayed. Data obtained usingdifferent concentrations of 282P1G3 are used to calculate values for thenumber, affinity, and association of 282P1G3 with the candidatemolecules.

Example 37 In Vivo Assay for 282P1G3 Tumor Growth Promotion

The effect of the 282P1G3 protein on tumor cell growth is evaluated invivo by evaluating tumor development and growth of cells expressing orlacking 282P1G3. For example, SCID mice are injected subcutaneously oneach flank with 1×10⁶ of either 3T3, ovarian (e.g. PA-1 cells),pancreatic (e.g. Panc-1 cells) or lymphoma (e.g. Daudi cells) cancercell lines containing tkNeo empty vector or 282P1G3. At least twostrategies may be used: (1) Constitutive 282P1G3 expression underregulation of a promoter such as a constitutive promoter obtained fromthe genomes of viruses such as polyoma virus, fowlpox virus (UK2,211,504 published 5 Jul. 1989), adenovirus (such as Adenovirus 2),bovine papilloma virus, avian sarcoma virus, cytomegalovirus, aretrovirus, hepatitis-B virus and Simian Virus 40 (SV40), or fromheterologous mammalian promoters, e.g., the actin promoter or animmunoglobulin promoter, provided such promoters are compatible with thehost cell systems, and (2) Regulated expression under control of aninducible vector system, such as ecdysone, tetracycline, etc., providedsuch promoters are compatible with the host cell systems. Tumor volumeis then monitored by caliper measurement at the appearance of palpabletumors and followed over time to determine if 282P1G3-expressing cellsgrow at a faster rate and whether tumors produced by 282P1G3-expressingcells demonstrate characteristics of altered aggressiveness (e.g.enhanced metastasis, vascularization, reduced responsiveness tochemotherapeutic drugs).

Additionally, mice can be implanted with 1×10⁵ of the same cellsorthotopically to determine if 282P1G3 has an effect on local growth inthe pancreas, and whether 282P1G3 affects the ability of the cells tometastasize, specifically to lymph nodes, and bone (Miki, T et al.,Oncol Res. 2001; 12:209; Fu X et al., Int J Cancer. 1991, 49:938). Theeffect of 282P1G3 on bone tumor formation and growth may be assessed byinjecting tumor cells intratibially.

The assay is also useful to determine the 282P1G3 inhibitory effect ofcandidate therapeutic compositions, such as, 282P1G3 intrabodies,282P1G3 antisense molecules and ribozymes.

Example 38 282P1G3 Monoclonal Antibody-mediated Inhibition of Tumors inVivo

The significant expression of 282P1G3 in cancer tissues and surfacelocalization, together with its restrictive expression in normal tissuesmakes 282P1G3 a good target for antibody therapy. Similarly, 282P1G3 isa target for T cell-based immunotherapy. Thus, the therapeutic efficacyof anti-282P1G3 mAbs in human cancer xenograft mouse models, includingovarian, pancreatic or lymphoma and other -282P1G3 cancers listed inTable I, is evaluated by using recombinant cell lines such asPa-1-282P1G3, Panc1-282P1G3, Daudi-282P1G3, and 3T3-282P1G3 (see, e.g.,Kaighn, M. E., et al., Invest Urol, 1979. 17(1): 16-23), as well ashuman xenograft models (Saffran et al. PNAS 1999, 10:1073-1078).

Antibody efficacy on tumor growth and metastasis formation is studied,e.g., in a mouse orthotopic ovary, pancreas, or blood cancer xenograftmodels. The antibodies can be unconjugated, as discussed in thisExample, or can be conjugated to a therapeutic modality, as appreciatedin the art. Anti-282P1G3 mAbs inhibit formation of tumors in mousexenografts. Anti-282P1G3 mAbs also retard the growth of establishedorthotopic tumors and prolonged survival of tumor-bearing mice. Theseresults indicate the utility of anti-282P1G3 mAbs in the treatment oflocal and advanced stages several solid tumors. (See, e.g., Saffran, D.,et al., PNAS 10:1073-1078 or on the World Wide Web.

Administration of the anti-282P1G3 mAbs led to retardation ofestablished orthotopic tumor growth and inhibition of metastasis todistant sites, resulting in a significant prolongation in the survivalof tumor-bearing mice. These studies indicate that 282P1G3 as anattractive target for immunotherapy and demonstrate the therapeuticpotential of anti-282P1G3 mAbs for the treatment of local and metastaticcancer. This example indicates that unconjugated 282P1G3 monoclonalantibodies are effective to inhibit the growth of human pancreatic,ovarian and lymphomas tumor xenografts grown in SCID mice; accordingly acombination of such efficacious monoclonal antibodies is also effective.

Tumor Inhibition Using Multiple Unconjugated 282P1G3 mAbs

Materials and Methods:

282P1G3 Monoclonal Antibodies:

Monoclonal antibodies are raised against 282P1G3 as described in theExample entitled “Generation of 282P1G3 Monoclonal Antibodies (mAbs).”The antibodies are characterized by ELISA, Western blot, FACS, andimmunoprecipitation for their capacity to bind 282P1G3. Epitope mappingdata for the anti-282P1G3 mAbs, as determined by ELISA and Westernanalysis, recognize epitopes on the 282P1G3 protein. Immunohistochemicalanalysis of cancer tissues and cells with these antibodies is performed.

The monoclonal antibodies are purified from ascites or hybridoma tissueculture supernatants by Protein-G Sepharose chromatography, dialyzedagainst PBS, filter sterilized, and stored at −20° C. Proteindeterminations are performed by a Bradford assay (Bio-Rad, Hercules,Calif.). A therapeutic monoclonal antibody or a cocktail comprising amixture of individual monoclonal antibodies is prepared and used for thetreatment of mice receiving subcutaneous or orthotopic injections ofPC3, UM-UC3, CaKi and A427 tumor xenografts.

Cell Lines and Xenografts

The cancer cell lines PA-1, Panc1, Daudi cell lines, as well as thefibroblast line NIH 3T3 (American Type Culture Collection) aremaintained in DMEM supplemented with L-glutamine and 10% FBS.

PA1-282P1G3, Panc1-282P1G3, Daudi-282P1G3 and 3T3-282P1G3 cellpopulations are generated by retroviral gene transfer as described inHubert, R. S., et al., Proc Natl Acad Sci USA, 1999. 96(25): 14523.

Human patient-derived xenografts are passaged in 6- to 8-week-old maleICR-severe combined immunodeficient (SCID) mice (Taconic Farms) by s.c.trocar implant (Craft, N., et al., Nat Med. 1999, 5:280). Single-cellsuspensions of tumor cells are prepared as described in Craft, et al.

Xenograft Mouse Models.

Subcutaneous (s.c.) tumors are generated by injection of 2×10 6 cancercells mixed at a 1:1 dilution with Matrigel (Collaborative Research) inthe right flank of male SCID mice. To test antibody efficacy on tumorformation, i.e. antibody injections are started on the same day astumor-cell injections. As a control, mice are injected with eitherpurified mouse IgG (ICN) or PBS; or a purified monoclonal antibody thatrecognizes an irrelevant antigen not expressed in human cells. Inpreliminary studies, no difference is found between mouse IgG or PBS ontumor growth. Tumor sizes are determined by caliper measurements, andthe tumor volume is calculated as length×width×height. Mice withSubcutaneous tumors greater than 1.5 cm in diameter are sacrificed.

Orthotopic injections are performed under anesthesia by usingketamine/xylazine. Following tumor implantation, the mice are segregatedinto groups for the appropriate treatments, with anti-282P1G3 or controlmAbs being injected i.p. To monitor tumor growth, mice are palpated andblood is collected on a weekly basis to measure hCG levels.

Anti-282P1G3 mAbs Inhibit Growth of 282P1G3-Expressing Xenograft-CancerTumors

The effect of anti-282P1G3 mAbs on tumor formation is tested by usingcell line (e.g. PA-1, Panc1, Daudi and 3T3) and patient-derived tumororthotopic models. As compared with the s.c. tumor model, the orthotopicmodel, which requires injection of tumor cells directly in the mouseorgan results in a local tumor growth, development of metastasis indistal sites, deterioration of mouse health, and subsequent death(Saffran, D., et al., PNAS supra). The features make the orthotopicmodel more representative of human disease progression and allowed us tofollow the therapeutic effect of mAbs on clinically relevant end points.

A major advantage of the orthotopic cancer models is the ability tostudy the development of metastases. Formation of metastasis in micebearing established orthotopic tumors is studies by IHC analysis on lungsections using an antibody against a tumor-specific cell-surface proteinsuch as anti-CK20 for prostate cancer (Lin S et al., Cancer Detect Prev.2001; 25:202).

Another advantage of xenograft cancer models is the ability to studyneovascularization and angiogenesis. Tumor growth is partly dependent onnew blood vessel development. Although the capillary system anddeveloping blood network is of host origin, the initiation andarchitecture of the neovasculature is regulated by the xenograft tumor(Davidoff A M et al., Clin Cancer Res. 2001; 7:2870; Solesvik O et al.,Eur J Cancer Clin Oncol. 1984, 20:1295). The effect of antibody andsmall molecule on neovascularization is studied in accordance withprocedures known in the art, such as by IHC analysis of tumor tissuesand their surrounding microenvironment.

Mice bearing established orthotopic tumors are administered 1000 μpinjections of either anti-282P1G3 mAb or PBS over a 4-week period. Micein both groups are allowed to establish a high tumor burden, to ensure ahigh frequency of metastasis formation in mouse lungs. Mice then arekilled and their bladders, livers, bone and lungs are analyzed for thepresence of tumor cells by IHC analysis. These studies demonstrate abroad anti-tumor efficacy of anti-282P1G3 antibodies on initiation andprogression of prostate cancer in xenograft mouse models. Anti-282P1G3antibodies inhibit tumor formation of tumors as well as retarding thegrowth of already established tumors and prolong the survival of treatedmice. Moreover, anti-282P1G3 mAbs demonstrate a dramatic inhibitoryeffect on the spread of local prostate tumor to distal sites, even inthe presence of a large tumor burden. Thus, anti-282P1G3 mAbs areefficacious on major clinically relevant end points (tumor growth),prolongation of survival, and health.

Example 39 Therapeutic and Diagnostic Use of Anti-282P1G3 Antibodies inHumans

Anti-282P1G3 monoclonal antibodies are safely and effectively used fordiagnostic, prophylactic, prognostic and/or therapeutic purposes inhumans. Western blot and immunohistochemical analysis of cancer tissuesand cancer xenografts with anti-282P1G3 mAb show strong extensivestaining in carcinoma but significantly lower or undetectable levels innormal tissues. Detection of 282P1G3 in carcinoma and in metastaticdisease demonstrates the usefulness of the mAb as a diagnostic and/orprognostic indicator. Anti-282P1G3 antibodies are therefore used indiagnostic applications such as immunohistochemistry of kidney biopsyspecimens to detect cancer from suspect patients.

As determined by flow cytometry, anti-282P1G3 mAb specifically binds tocarcinoma cells. Thus, anti-282P1G3 antibodies are used in diagnosticwhole body imaging applications, such as radioimmunoscintigraphy andradioimmunotherapy, (see, e.g., Potamianos S., et. al. Anticancer Res20(2A):925-948 (2000)) for the detection of localized and metastaticcancers that exhibit expression of 282P1G3. Shedding or release of anextracellular domain of 282P1G3 into the extracellular milieu, such asthat seen for alkaline phosphodiesterase B10 (Meerson, N. R., Hepatology27:563-568 (1998)), allows diagnostic detection of 282P1G3 byanti-282P1G3 antibodies in serum and/or urine samples from suspectpatients.

Anti-282P1G3 antibodies that specifically bind 282P1G3 are used intherapeutic applications for the treatment of cancers that express282P1G3. Anti-282P1G3 antibodies are used as an unconjugated modalityand as conjugated form in which the antibodies are attached to one ofvarious therapeutic or imaging modalities well known in the art, such asa prodrugs, enzymes or radioisotopes. In preclinical studies,unconjugated and conjugated anti-282P1G3 antibodies are tested forefficacy of tumor prevention and growth inhibition in the SCID mousecancer xenograft models, e.g., kidney cancer models AGS-K3 and AGS-K6,(see, e.g., the Example entitled “282P1G3 Monoclonal Antibody-mediatedInhibition of Bladder and Lung Tumors In Vivo”). Either conjugated andunconjugated anti-282P1G3 antibodies are used as a therapeutic modalityin human clinical trials either alone or in combination with othertreatments as described in following Examples.

Example 40 Human Clinical Trials for the Treatment and Diagnosis ofHuman Carcinomas through use of Human Anti-282P1G3 Antibodies In vivo

Antibodies are used in accordance with the present invention whichrecognize an epitope on 282P1G3, and are used in the treatment ofcertain tumors such as those listed in Table I. Based upon a number offactors, including 282P1G3 expression levels, tumors such as thoselisted in Table I are presently preferred indications. In connectionwith each of these indications, three clinical approaches aresuccessfully pursued.

I.) Adjunctive therapy: In adjunctive therapy, patients are treated withanti-282P1G3 antibodies in combination with a chemotherapeutic orantineoplastic agent and/or radiation therapy. Primary cancer targets,such as those listed in Table I, are treated under standard protocols bythe addition anti-282P1G3 antibodies to standard first and second linetherapy. Protocol designs address effectiveness as assessed by reductionin tumor mass as well as the ability to reduce usual doses of standardchemotherapy. These dosage reductions allow additional and/or prolongedtherapy by reducing dose-related toxicity of the chemotherapeutic agent.Anti-282P1G3 antibodies are utilized in several adjunctive clinicaltrials in combination with the chemotherapeutic or antineoplastic agentsadriamycin (advanced prostrate carcinoma), cisplatin (advanced head andneck and lung carcinomas), taxol (breast cancer), and doxorubicin(preclinical).

II.) Monotherapy: In connection with the use of the anti-282P1G3antibodies in monotherapy of tumors, the antibodies are administered topatients without a chemotherapeutic or antineoplastic agent. In oneembodiment, monotherapy is conducted clinically in end stage cancerpatients with extensive metastatic disease. Patients show some diseasestabilization. Trials demonstrate an effect in refractory patients withcancerous tumors.

III.) Imaging Agent: Through binding a radionuclide (e.g., iodine oryttrium (I¹³¹, Y⁹⁰) to anti-282P1G3 antibodies, the radiolabeledantibodies are utilized as a diagnostic and/or imaging agent. In such arole, the labeled antibodies localize to both solid tumors, as well as,metastatic lesions of cells expressing 282P1G3. In connection with theuse of the anti-282P1G3 antibodies as imaging agents, the antibodies areused as an adjunct to surgical treatment of solid tumors, as both apre-surgical screen as well as a post-operative follow-up to determinewhat tumor remains and/or returns. In one embodiment, a (¹¹¹In)-282P1G3antibody is used as an imaging agent in a Phase I human clinical trialin patients having a carcinoma that expresses 282P1G3 (by analogy see,e.g., Divgi et al. J. Natl. Cancer Inst. 83:97-104 (1991)). Patients arefollowed with standard anterior and posterior gamma camera. The resultsindicate that primary lesions and metastatic lesions are identified.

Dose and Route of Administration

As appreciated by those of ordinary skill in the art, dosingconsiderations can be determined through comparison with the analogousproducts that are in the clinic. Thus, anti-282P1G3 antibodies can beadministered with doses in the range of 5 to 400 mg/m², with the lowerdoses used, e.g., in connection with safety studies. The affinity ofanti-282P1G3 antibodies relative to the affinity of a known antibody forits target is one parameter used by those of skill in the art fordetermining analogous dose regimens. Further, anti-282P1G3 antibodiesthat are fully human antibodies, as compared to the chimeric antibody,have slower clearance; accordingly, dosing in patients with such fullyhuman anti-282P1G3 antibodies can be lower, perhaps in the range of 50to 300 mg/m², and still remain efficacious. Dosing in mg/m², as opposedto the conventional measurement of dose in mg/kg, is a measurement basedon surface area and is a convenient dosing measurement that is designedto include patients of all sizes from infants to adults.

Three distinct delivery approaches are useful for delivery ofanti-282P1G3 antibodies. Conventional intravenous delivery is onestandard delivery technique for many tumors. However, in connection withtumors in the peritoneal cavity, such as tumors of the ovaries, biliaryduct, other ducts, and the like, intraperitoneal administration mayprove favorable for obtaining high dose of antibody at the tumor and toalso minimize antibody clearance. In a similar manner, certain solidtumors possess vasculature that is appropriate for regional perfusion.Regional perfusion allows for a high dose of antibody at the site of atumor and minimizes short term clearance of the antibody.

Clinical Development Plan (CDP)

Overview: The CDP follows and develops treatments of anti-282P1G3antibodies in connection with adjunctive therapy, monotherapy, and as animaging agent. Trials initially demonstrate safety and thereafterconfirm efficacy in repeat doses. Trails are open label comparingstandard chemotherapy with standard therapy plus anti-282P1G3antibodies. As will be appreciated, one criteria that can be utilized inconnection with enrollment of patients is 282P1G3 expression levels intheir tumors as determined by biopsy.

As with any protein or antibody infusion-based therapeutic, safetyconcerns are related primarily to (i) cytokine release syndrome, i.e.,hypotension, fever, shaking, chills; (ii) the development of animmunogenic response to the material (i.e., development of humanantibodies by the patient to the antibody therapeutic, or HAHAresponse); and, (iii) toxicity to normal cells that express 282P1G3.Standard tests and follow-up are utilized to monitor each of thesesafety concerns. Anti-282P1G3 antibodies are found to be safe upon humanadministration.

Example 41 Human Clinical Trial Adjunctive Therapy with HumanAnti-282P1G3 Antibody and Chemotherapeutic Agent

A phase I human clinical trial is initiated to assess the safety of sixintravenous doses of a human anti-282P1G3 antibody in connection withthe treatment of a solid tumor, e.g., a cancer of a tissue listed inTable I. In the study, the safety of single doses of anti-282P1G3antibodies when utilized as an adjunctive therapy to an antineoplasticor chemotherapeutic agent as defined herein, such as, withoutlimitation: cisplatin, topotecan, doxorubicin, adriamycin, taxol, or thelike, is assessed. The trial design includes delivery of six singledoses of an anti-282P1G3 antibody with dosage of antibody escalatingfrom approximately about 25 mg/m ² to about 275 mg/m² over the course ofthe treatment in accordance with the following schedule:

Day 0 Day 7 Day 14 Day 21 Day 28 Day 35 mAb Dose 25 mg/m² 75 mg/m² 125mg/m² 175 mg/m² 225 mg/m² 275 mg/m² Chemotherapy + + + + + + (standarddose)

Patients are closely followed for one-week following each administrationof antibody and chemotherapy. In particular, patients are assessed forthe safety concerns mentioned above: (i) cytokine release syndrome,i.e., hypotension, fever, shaking, chills; (ii) the development of animmunogenic response to the material (i.e., development of humanantibodies by the patient to the human antibody therapeutic, or HAHAresponse); and, (iii) toxicity to normal cells that express 282P1G3.Standard tests and follow-up are utilized to monitor each of thesesafety concerns. Patients are also assessed for clinical outcome, andparticularly reduction in tumor mass as evidenced by MRI or otherimaging.

The anti-282P1G3 antibodies are demonstrated to be safe and efficacious,Phase II trials confirm the efficacy and refine optimum dosing.

Example 42 Human Clinical Trial: Monotherapy with Human Anti-282P1G3Antibody

Anti-282P1G3 antibodies are safe in connection with the above-discussedadjunctive trial, a Phase II human clinical trial confirms the efficacyand optimum dosing for monotherapy. Such trial is accomplished, andentails the same safety and outcome analyses, to the above-describedadjunctive trial with the exception being that patients do not receivechemotherapy concurrently with the receipt of doses of anti-282P1G3antibodies.

Example 43 Human Clinical Trial: Diagnostic Imaging with Anti-282P1G3Antibody

Once again, as the adjunctive therapy discussed above is safe within thesafety criteria discussed above, a human clinical trial is conductedconcerning the use of anti-282P1G3 antibodies as a diagnostic imagingagent. The protocol is designed in a substantially similar manner tothose described in the art, such as in Divgi et al. J. Natl. CancerInst. 83:97-104 (1991). The antibodies are found to be both safe andefficacious when used as a diagnostic modality.

Example 44 Comparison of 282P1G3 to Known Sequences

The human 282P1G3 protein exhibit a high degree of homology to a knownhuman protein, cell adhesion molecule with homology to Li CAM precursor(gi 27894376), also known Close Homolog of L1 (CHL1) or CALL. Human CHL1shows 99% identity to 282P1G3 at the protein level (FIG. 4A). The mousehomolog of 282P1G3 has been identified as murine CHL1 (gi 6680936), andshows 82% identity and 89% homology to 282P1G3 (FIG. 4B). CHL1 has beenreported to regulate neuronal development by altering cell adhesion andaxonal projections (Montag-Sallaz M et al., Mol. Cell. Biol. 2002,22:7967). In addition, CHL1 was found to play a role in neurite growthand survival (Dong L et al., J. Neurosci. Res, 2002; Chaisuksunt V etal., J. Comp. Neurol 2000, 425:382). Mutations in CHL1 have beenassociated with schizophrenia and metal disorders (Sakurai et al., MolPsychiatry 2002, 7:412; We H et al., Hum Genet 1998, 103:355).

The prototype member of the 282P1G3 family, 282P1G3v.1, is a 1224 aminoacids protein. Initial bioinformatics analysis using topology predictionprograms suggested that 191P2D14 may contain 2 transmembranes based onhydrophobicity profile. However, the first hydrophobic domain wasidentified as a signal sequence, rendering 191P2D12 a singletransmembrane protein.

The 282P1G3 gene has several variants, including 5 SNP represented by282P1G3 v.9, v.10, v.11, v.24 and v.25. In addition, several splicevariants have been identified, including deletion variants such as282P1G3 v.2, v.4, v.5 and v.6, as well as insertion mutants such as282P1G3 v.7 and v.8, and a splice variant at aa 838 of 282P1G3 v.1,namely 282P1G3 v.3.

Motif analysis revealed the presence of several protein functionalmotifs in the 282P1G3 protein (Table L). Six immunoglobulin domains havebeen identified in addition to four fibronectin type III repeats.Immunoglobulin domains are found in numerous proteins and participate inprotein-protein such including protein-ligand interactions (Weismann etal., J Mol Med 2000, 78:247). In addition, Ig-domains function in celladhesion, allowing the interaction of leukocytes and blood-born cellswith the endothelium (Wang and Springer, Immunol Rev 1998, 163:197).Fibronectin type III repeats are 100 amino acid domains with bindingsites for various molecules, including DNA, heparin, basement membraneand cell surface proteins (Kimizuka et al., J Biol. Chem. 1991,266:3045; Yokosaki et al., J Biol. Chem. 1998, 273:11423). The majorityfor proteins containing fibronectin III motifs participate in cellsurface binding, binding to specific substrates including heparin,collagen, DNA, actin and fibrin, or are involved in binding tofibronectin receptors. Fibronectins have been reported to function inwound healing; cell adhesion, cell differentiation, cell migration andtumour metastasis (Bloom et al., Mol Biol Cell. 1999, 10:1521; Brodt P.Cancer Met Rev 1991, 10:23). The motifs found in 282P1G3 as well as itssimilarity to CHL1 indicate that 282P1G3 can participate in tumor growthand progression by enhancing the initial stages of tumorigenesis,including tumor establishment and tumor growth, by allowing adhesion tobasement membranes and surrounding cells, by mediating cell migrationand metastasis.

Accordingly, when 282P1G3 functions as a regulator of tumorestablishment, tumor formation, tumor growth, survival or cellsignaling, 282P1G3 is used for therapeutic, diagnostic, prognosticand/or preventative purposes. In addition, when a molecule, such as asplice variant or SNP of 282P1G3 is expressed in cancerous tissues, suchas those listed in Table I, they are used for therapeutic, diagnostic,prognostic and/or preventative purposes.

Example 45 Regulation of Transcription

The cell surface localization of 282P1G3 coupled to the presence ofIg-domains within its sequence indicate that 282P1G3 modulates signaltransduction and the transcriptional regulation of eukaryotic genes.Regulation of gene expression is confirmed, e.g., by studying geneexpression in cells expressing or lacking 282P1G3. For this purpose, twotypes of experiments are performed.

In the first set of experiments, RNA from parental and282P1G3-expressing cells are extracted and hybridized to commerciallyavailable gene arrays (Clontech) (Smid-Koopman E et al. Br J Cancer.2000. 83:246). Resting cells as well as cells treated with FBS, androgenor growth factors are compared. Differentially expressed genes areidentified in accordance with procedures known in the art. Thedifferentially expressed genes are then mapped to biological pathways(Chen K et al. Thyroid. 2001. 11:41.).

In the second set of experiments, specific transcriptional pathwayactivation is evaluated using commercially available (Stratagene)luciferase reporter constructs including: NFkB-luc, SRE-luc, ELK1-luc,ARE-luc, p53-luc, and CRE-luc. These transcriptional reporters containconsensus binding sites for known transcription factors that liedownstream of well-characterized signal transduction pathways, andrepresent a good tool to ascertain pathway activation and screen forpositive and negative modulators of pathway activation.

Thus, 282P1G3 plays a role in gene regulation, and it is used as atarget for diagnostic, prognostic, preventative and/or therapeuticpurposes.

Example 46 Identification and Confirmation of Potential SignalTransduction Pathways

Many mammalian proteins have been reported to interact with signalingmolecules and to participate in regulating signaling pathways. (J.Neurochem. 2001; 76:217-223). Immunoglobulin-like molecules inparticular has been associated with several tyrpsine kinases includingLyc, Blk, syk (Tamir and Cambier, Oncogene. 1998, 17:1353), the MAPKsignaling cascade that control cell mitogenesis and calcium flux (VilenJ et al., J Immunol 1997, 159:231; Jiang F, Jia Y, Cohen I. Blood. 2002,99:3579). In addition, the 282P1G3 protein contains severalphosphorylation sites (see Table VI) indicating an association withspecific signaling cascades. Using immunoprecipitation and Westernblotting techniques, proteins are identified that associate with 282P1G3and mediate signaling events. Several pathways known to play a role incancer biology can be regulated by 282P1G3, including phospholipidpathways such as P13K, AKT, etc, adhesion and migration pathways,including FAK, Rho, Rac-1, catenin, etc, as well as mitogenic/survivalcascades such as ERK, p38, etc (Cell Growth Differ. 2000, 11:279; JBiol. Chem. 1999, 274:801; Oncogene. 2000, 19:3003, J. Cell Biol. 1997,138:913.).). In order to determine whether expression of 282P1G3 issufficient to regulate specific signaling pathways not otherwise activein resting cancer cells, the effect of 282P1G3 on the activation of thesignaling cascade is investigated in the cancer cell lines PA-1, Panc1and Daudi. Cancer cells stably expressing 282P1G3 or neo are stimulatedwith growth factor, FBS or other activating molecules. Whole celllysates are analyzed by western blotting.

To confirm that 282P1G3 directly or indirectly activates known signaltransduction pathways in cells, luciferase (luc) based transcriptionalreporter assays are carried out in cells expressing individual genes.These transcriptional reporters contain consensus-binding sites forknown transcription factors that lie downstream of well-characterizedsignal transduction pathways. The reporters and examples of theseassociated transcription factors, signal transduction pathways, andactivation stimuli are listed below.

1. NFkB-luc, NFkB/Rel; Ik-kinase/SAPK; growth/apoptosis/stress

2. SRE-luc, SRF/TCF/ELK1; MAPK/SAPK; growth/differentiation

3. AP-1-luc, FOS/JUN; MAPK/SAPK/PKC; growth/apoptosis/stress

4. ARE-luc, androgen receptor; steroids/MAPK;growth/differentiation/apoptosis

5. p53-luc, p53; SAPK; growth/differentiation/apoptosis

6. CRE-luc, CREB/ATF2; PKA/p38; growth/apoptosis/stress

7. TCF-luc, TCF/Lef; -catenin, Adhesion/invasion

Gene-mediated effects can be assayed in cells showing mRNA expression.Luciferase reporter plasmids can be introduced by lipid-mediatedtransfection (TFX-50, Promega). Luciferase activity, an indicator ofrelative transcriptional activity, is measured by incubation of cellextracts with luciferin substrate and luminescence of the reaction ismonitored in a luminometer.

Signaling pathways activated by 282P1G3 are mapped and used for theidentification and validation of therapeutic targets. When 282P1G3 isinvolved in cell signaling, it is used as target for diagnostic,prognostic, preventative and/or therapeutic purposes.

Example 47 Involvement in Tumor Progression

Based on the role of Ig-domains and fibronectin motifs in cell growthand signal transduction, the 282P1G3 gene can contribute to the growth,invasion and transformation of cancer cells. The role of 282P1G3 intumor growth is confirmed in a variety of primary and transfected celllines including prostate cell lines, as well as NIH 3T3 cells engineeredto stably express 282P1G3. Parental cells lacking 282P1G3 and cellsexpressing 282P1G3 are evaluated for cell growth using a well-documentedproliferation assay (Fraser S P, Grimes J A, Djamgoz M B. Prostate.2000; 44:61, Johnson D E, Ochieng J, Evans S L. Anticancer Drugs. 1996,7:288).

To confirm the role of 282P1G3 in the transformation process, its effectin colony forming assays is investigated. Parental NIH-3T3 cells lacking282P1G3 are compared to NIH-3T3 cells expressing 282P1G3, using a softagar assay under stringent and more permissive conditions (Song Z. etal. Cancer Res. 2000; 60:6730).

To confirm the role of 282P1G3 in invasion and metastasis of cancercells, a well-established assay is used, e.g., a Transwell Insert Systemassay (Becton Dickinson) (Cancer Res. 1999; 59:6010). Control cells,including prostate, breast and kidney cell lines lacking 282P1G3 arecompared to cells expressing 282P1G3. Cells are loaded with thefluorescent dye, calcein, and plated in the top well of the Transwellinsert coated with a basement membrane analog. Invasion is determined byfluorescence of cells in the lower chamber relative to the fluorescenceof the entire cell population.

282P1G3 can also play a role in cell cycle and apoptosis. Parental cellsand cells expressing 282P1G3 are compared for differences in cell cycleregulation using a well-established BrdU assay (Abdel-Malek Z A. J CellPhysiol. 1988, 136:247). In short, cells are grown under both optimal(full serum) and limiting (low serum) conditions are labeled with BrdUand stained with anti-BrdU Ab and propidium iodide. Cells are analyzedfor entry into the G1, S, and G2M phases of the cell cycle.Alternatively, the effect of stress on apoptosis is evaluated in controlparental cells and cells expressing 282P1G3, including normal and tumorprostate cells. Engineered and parental cells are treated with variouschemotherapeutic agents, such as etoposide, taxol, etc, and proteinsynthesis inhibitors, such as cycloheximide. Cells are stained withannexin V-FITC and cell death is measured by FACS analysis. Themodulation of cell death by 282P1G3 can play a critical role inregulating tumor progression and tumor load.

When 282P1G3 plays a role in cell growth, transformation, invasion orapoptosis, it is used as a target for diagnostic, prognostic,preventative and/or therapeutic purposes.

Example 48 Involvement in Angiogenesis

Angiogenesis or new capillary blood vessel formation is necessary fortumor growth (Hanahan D, Folkman J. Cell. 1996, 86:353; Folkman J.Endocrinology. 1998 139:441). Based on the effect of fibronectins ontumor cell adhesion and their interaction with endothelial cells,282P1G3 plays a role in angiogenesis (Mareel and Leroy: Physiol Rev,83:337; DeFouw L et al., Microvasc Res 2001, 62:263). Several assayshave been developed to measure angiogenesis in vitro and in vivo, suchas the tissue culture assays endothelial cell tube formation andendothelial cell proliferation. Using these assays as well as in vitroneo-vascularization, the role of 282P1G3 in angiogenesis, enhancement orinhibition, is confirmed.

For example, endothelial cells engineered to express 282P1G3 areevaluated using tube formation and proliferation assays. The effect of282P1G3 is also confirmed in animal models in vivo. For example, cellseither expressing or lacking 282P1G3 are implanted subcutaneously inimmunocompromised mice. Endothelial cell migration and angiogenesis areevaluated 5-15 days later using immunohistochemistry techniques. 282P1G3affects angiogenesis, and it is used as a target for diagnostic,prognostic, preventative and/or therapeutic purposes.

Example 49 Involvement in Protein-Protein Interactions

Ig-domains and fibronectin motifs have been shown to mediate interactionwith other proteins, including cell surface protein. Usingimmunoprecipitation techniques as well as two yeast hybrid systems,proteins are identified that associate with 282P1G3. Immunoprecipitatesfrom cells expressing 282P1G3 and cells lacking 282P1G3 are compared forspecific protein-protein associations.

Studies are performed to confirm the extent of association of 282P1G3with effector molecules, such as nuclear proteins, transcriptionfactors, kinases, phosphates etc. Studies comparing 282P1G3 positive and282P1G3 negative cells as well as studies comparing unstimulated/restingcells and cells treated with epithelial cell activators, such ascytokines, growth factors, androgen and anti-integrin Ab reveal uniqueinteractions.

In addition, protein-protein interactions are confirmed using two yeasthybrid methodology (Curr. Opin. Chem. Biol. 1999, 3:64). A vectorcarrying a library of proteins fused to the activation domain of atranscription factor is introduced into yeast expressing a282P1G3-DNA-binding domain fusion protein and a reporter construct.Protein-protein interaction is detected by colorimetric reporteractivity. Specific association with effector molecules and transcriptionfactors directs one of skill to the mode of action of 282P1G3, and thusidentifies therapeutic, prognostic, preventative and/or diagnostictargets for cancer. This and similar assays are also used to identifyand screen for small molecules that interact with 282P1G3.

Thus, it is found that 282P1G3 associates with proteins and smallmolecules. Accordingly, 282P1G3 and these proteins and small moleculesare used for diagnostic, prognostic, preventative and/or therapeuticpurposes.

Example 50 Involvement of 282P1G3 in Cell-cell Communication

Cell-cell communication is essential in maintaining organ integrity andhomeostasis, both of which become deregulated during tumor formation andprogression. Based on the presence of a fibronectin motif in 282P1G3, amotif known to be involved in cell interaction and cell-cell adhesion,282P1G3 can regulate cell communication. Intercellular communicationscan be measured using two types of assays (J. Biol. Chem. 2000,275:25207). In the first assay, cells loaded with a fluorescent dye areincubated in the presence of unlabeled recipient cells and the cellpopulations are examined under fluorescent microscopy. This qualitativeassay measures the exchange of dye between adjacent cells. In the secondassay system, donor and recipient cell populations are treated as aboveand quantitative measurements of the recipient cell population areperformed by FACS analysis. Using these two assay systems, cellsexpressing 282P1G3 are compared to controls that do not express 282P1G3,and it is found that 282P1G3 enhances cell communications. Smallmolecules and/or antibodies that modulate cell-cell communicationmediated by 282P1G3 are used as therapeutics for cancers that express282P1G3. When 282P1G3 functions in cell-cell communication and smallmolecule transport, it is used as a target or marker for diagnostic,prognostic, preventative and/or therapeutic purposes.

Throughout this application, various website data content, publications,patent applications and patents are referenced. (Websites are referencedby their Uniform Resource Locator, or on the World Wide Web.) Thedisclosures of each of these references are hereby incorporated byreference herein in their entireties.

The present invention is not to be limited in scope by the embodimentsdisclosed herein, which are intended as single illustrations ofindividual aspects of the invention, and any that are functionallyequivalent are within the scope of the invention. Various modificationsto the models and methods of the invention, in addition to thosedescribed herein, will become apparent to those skilled in the art fromthe foregoing description and teachings, and are similarly intended tofall within the scope of the invention. Such modifications or otherembodiments can be practiced without departing from the true scope andspirit of the invention.

TABLES:

TABLE I Tissues that Express 282P1G3: a. Malignant Tissues PancreasOvary Lymph node

TABLE II Amino Acid Abbreviations SINGLE LETTER THREE LETTER FULL NAME FPhe phenylalanine L Leu leucine S Ser serine Y Tyr tyrosine C Cyscysteine W Trp tryptophan P Pro proline H His histidine Q Gln glutamineR Arg arginine I Ile isoleucine M Met methionine T Thr threonine N Asnasparagine K Lys lysine V Val valine A Ala alanine D Asp aspartic acid EGlu glutamic acid G Gly glycine

TABLE III Amino Acid Substitution Matrix Adapted from the GCG Software9.0 BLOSUM62 amino acid substitution matrix (block substitution matrix).The higher the value, the more likely a substitution is found inrelated, natural proteins. (See world wide web URLikp.unibe.ch/manual/blosum62.html) A C D E F G H I K L M N P Q R S T V WY . 4 0 −2 −1 −2 0 −2 −1 −1 −1 −1 −2 −1 −1 −1 1 0 0 −3 −2 A 9 −3 −4 −2−3 −3 −1 −3 −1 −1 −3 −3 −3 −3 −1 −1 −1 −2 −2 C 6 2 −3 −1 −1 −3 −1 −4 −31 −1 0 −2 0 −1 −3 −4 −3 D 5 −3 −2 0 −3 1 −3 −2 0 −1 2 0 0 −1 −2 −3 −2 E6 −3 −1 0 −3 0 0 −3 −4 −3 −3 −2 −2 −1 1 3 F 6 −2 −4 −2 −4 −3 0 −2 −2 −20 −2 −3 −2 −3 G 8 −3 −1 −3 −2 1 −2 0 0 −1 −2 −3 −2 2 H 4 −3 2 1 −3 −3 −3−3 −2 −1 3 −3 −1 I 5 −2 −1 0 −1 1 2 0 −1 −2 −3 −2 K 4 2 −3 −3 −2 −2 −2−1 1 −2 −1 L 5 −2 −2 0 −1 −1 −1 1 −1 −1 M 6 −2 0 0 1 0 −3 −4 −2 N 7 −1−2 −1 −1 −2 −4 −3 P 5 1 0 −1 −2 −2 −1 Q 5 −1 −1 −3 −3 −2 R 4 1 −2 −3 −2S 5 0 −2 −2 T 4 −3 −1 V 11 2 W 7 Y

TABLE IV HLA Class I/II Motifs/Supermotifs TABLE IV (A): HLA Class ISupermotifs/Motifs POSITION 2 (Primary Anchor) POSITION 3 (PrimaryAnchor) POSITION C Terminus (Primary Anchor) SUPERMOTIF A1 TI LVMS FWYA2 LIVM ATQ IV MATL A3 VSMA TLI RK A24 YF WIVLMT FI YWLM B7 P VILF MWYAB27 RHK FYL WMIVA B44 E D FWYLIMVA B58 ATS FWY LIVMA B62 QL IVMP FWYMIVLA MOTIFS A1 TSM Y A1 DE AS Y A2.1 LM VQIAT V LIMAT A3 LMVISATF CGDKYR HFA A11 VTMLISAGN CDF K RYH A24 YFW M FLIW A*3101 MVT ALIS R KA*3301 MVALF IST RK A*6801 AVT MSLI RK SUPERMOTIF B*0702 P LMF WYAIVB*3501 P LMFWY IVA B51 P LIVF WYAM B*5301 P IMFWY ALV B*5401 P ATIVLMFWY Bolded residues are preferred, italicized residues are lesspreferred: A peptide is considered motif-bearing if it has primaryanchors at each primary anchor position for a motif or supermotif asspecified in the above table. TABLE IV (B): HLA Class II Supermotif 1 69 W, F, Y, V, I, L A, V, I, L, P, C, S, T A, V, I, L, C, S, T, M, YTABLE IV (C): HLA Class II Motifs MOTIFS 1° anchor 1 2 3 4 5 1° anchor 67 8 9 DR4 preferred FMYLIVW M T I VSTCPALIM MH MH deleterious W R WDEDR1 preferred MFLIVWY PAMQ VMATSPLIC M AVM deleterious C CH FD CWD GDE DDR7 preferred MFLIVWY M W A IVMSACTPL M IV deleterious C G GRD N G DR3MOTIFS 1° anchor 1 2 3 1° anchor 4 5 1° anchor 6 Motif a preferredLIVMFY D Motif b preferred LIVMFAY DNQEST KRH DR Supermotif MFLIVWYVMSTACPLI Italicized residues indicate less preferred or “tolerated”residues TABLE IV (D): HLA Class I Supermotifs SUPER- POSITION: MOTIFS 12 3 4 5 6 7 8 C-terminus A1 1° Anchor 1° Anchor TILVMS FWY A2 1° Anchor1° Anchor LIVMATQ LIVMAT A3 Preferred 1° Anchor YFW YFW YFW P 1° AnchorVSMATLI (4/5) (3/5) (4/5) (4/5) RK deleterious DE (3/5); DE P (5/5)(4/5) A24 1° Anchor 1° Anchor YFWIVLMT FIYWLM B7 Preferred FWY (5/5) 1°Anchor FWY FWY 1° Anchor LIVM (3/5) P (4/5) (3/5) VILFMWYA deleteriousDE (3/5); DE G QN DE P(5/5); (3/5) (4/5) (4/5) (4/5) G(4/5); A(3/5);QN(3/5) B27 1° Anchor 1° Anchor RHK FYLWMIVA B44 1° Anchor 1° Anchor EDFWYLIMVA B58 1° Anchor 1° Anchor ATS FWYLIVMA B62 1° Anchor 1° AnchorQLIVMP FWYMIVLA Italicized residues indicate less preferred or“tolerated” residues TABLE IV (E): HLA Class I Motifs POSITION 9 or C- 12 3 4 5 6 7 8 C-terminus terminus A1 preferred GFYW 1° Anchor DEA YFW PDEQN YFW 1° Anchor 9-mer STM Y deleterious DE RHKLIVMP A G A A1preferred GRHK ASTCLIVM 1° Anchor GSTC ASTC LIVM DE 1° Anchor 9-mer DEASY deleterious A RHKDEPYFW DE PQN RHK PG GP A1 preferred YFW 1° AnchorDEAQN A YFWQN PASTC GDE P 1° Anchor 10- STM Y mer deleterious GPRHKGLIVM DE RHK QNA RHKYFW RHK A A1 preferred YFW STCLIVM 1° Anchor AYFW PG G YFW 1° Anchor 10- DEAS Y mer deleterious RHK RHKDEPYFW P G PRHKQN A2.1 preferred YFW 1° Anchor YFW STC YFW A P 1° Anchor 9-mer LMIVQATVLIMAT deleterious DEP DERKH RKH DERKH POSITION: C- 1 2 3 4 5 6 7 8 9Terminus A2.1 preferred AYFW 1° Anchor LVIM G G FYWL 1° Anchor 10-LMIVQAT VIM VLIMAT mer deleterious DEP DE RKHA P RKH DERKHRKH A3preferred RHK 1° Anchor YFW PRHKYF A YFW P 1° Anchor LMVISATFCGD WKYRHFA deleterious DEP DE A11 preferred A 1° Anchor YFW YFW A YFW YFW P1° Anchor VTLMISAGNCD KRYH F deleterious DEP A G A24 preferred YFWRHK 1°Anchor STC YFW YFW 1° Anchor 9-mer YFWM FLIW deleterious DEG DE G QNPDERHKG AQN A24 Preferred 1° Anchor P YFWP P 1° Anchor 10- YFWM FLIW merDeleterious GDE QN RHK DE A QN DEA POSITION 9 or C- 1 2 3 4 5 6 7 8C-terminus terminus A3101 Preferred RHK 1° Anchor YFW P YFW YFW AP 1°Anchor MVTALIS RK Deleterious DEP DE ADE DE DE DE A3301 Preferred 1°Anchor YFW AYFW 1° Anchor MVALFIST RK Deleterious GP DE A6801 PreferredYFWSTC 1° Anchor YFWLIV YFW P 1° Anchor AVTMSLI M RK deleterious GP DEGRHK A B0702 Preferred RHKFWY 1° Anchor RHK RHK RHK RHK PA 1° Anchor PLMFWYAI V deleterious DEQNP DEP DE DE GDE QN DE B3501 Preferred FWYLIVM1° Anchor FWY FWY 1° Anchor P LMFWYIV A deleterious AGP G G B51Preferred LIVMFWY 1° Anchor FWY STC FWY G FWY 1° Anchor P LIVFWYA Mdeleterious AGPDER DE G DEQN GDE HKSTC B5301 preferred LIVMFWY 1° AnchorFWY STC FWY LIVMFWYFWY 1° Anchor P IMFWYAL V deleterious AGPQN G RHKQNDE B5401 preferred FWY 1° Anchor FWYLIVM LIVM ALIVM FWYA 1° Anchor P PATIVLMF WY deleterious GPQNDE GDESTC RHKDE DE QNDGE DE TABLE IV (F):Summary of HLA-supertypes Overall phenotypic frequencies ofHLA-supertypes in different ethnic populations Specificity Phenotypicfrequency Supertype Position 2 C-Terminus Caucasian N.A. Black JapaneseChinese Hispanic Average B7 P AILMVFWY 43.2 55.1 57.1 43.0 49.3 49.5 A3AILMVST RK 37.5 42.1 45.8 52.7 43.1 44.2 A2 AILMVT AILMVT 45.8 39.0 42.445.9 43.0 42.2 A24 YF (WIVLMT) FI (YWLM) 23.9 38.9 58.6 40.1 38.3 40.0B44 E (D) FWYLIMVA 43.0 21.2 42.9 39.1 39.0 37.0 A1 TI (LVMS) FWY 47.116.1 21.8 14.7 26.3 25.2 B27 RHK FYL (WMI) 28.4 26.1 13.3 13.9 35.3 23.4B62 QL (IVMP) FWY (MIV) 12.6 4.8 36.5 25.4 11.1 18.1 B58 ATS FWY (LIV)10.0 25.1 1.6 9.0 5.9 10.3 TABLE IV (G): Calculated population coverageafforded by different HLA-supertype combinations Phenotypic frequencyHLA-supertypes Caucasian N.A Blacks Japanese Chinese Hispanic AverageA2, A3 and B7 83.0 86.1 87.5 88.4 86.3 86.2 A2, A3, B7, A24, B44 99.598.1 100.0 99.5 99.4 99.3 and A1 99.9 99.6 100.0 99.8 99.9 99.8 A2, A3,B7, A24, B44, A1, B27, B62, and B58 Motifs indicate the residuesdefining supertype specificites. The motifs incorporate residuesdetermined on the basis of published data to be recognized by multiplealleles within the supertype. Residues within brackets are additionalresidues also predicted to be tolerated by multiple alleles within thesupertype.

TABLE V Frequently Occurring Motifs avrg. % Name identity DescriptionPotential Function zf-C2H2 34% Zinc finger, C2H2 type Nucleicacid-binding protein functions as transcription factor, nuclear locationprobable cytochrome_b_N 68% Cytochrome b(N- membrane bound oxidase,generate superoxide terminal)/b6/petB Ig 19% Immunoglobulin domaindomains are one hundred amino acids long and include a conservedintradomain disulfide bond. WD40 18% WD domain, G-beta repeat tandemrepeats of about 40 residues, each containing a Trp-Asp motif. Functionin signal transduction and protein interaction PDZ 23% PDZ domain mayfunction in targeting signaling molecules to sub-membranous sites LRR28% Leucine Rich Repeat short sequence motifs involved inprotein-protein interactions Pkinase 23% Protein kinase domain conservedcatalytic core common to both serine/threonine and tyrosine proteinkinases containing an ATP binding site and a catalytic site PH 16% PHdomain pleckstrin homology involved in intracellular signaling or asconstituents of the cytoskeleton EGF 34% EGF-like domain 30-40amino-acid long found in the extracellular domain of membrane-boundproteins or in secreted proteins Rvt 49% Reverse transcriptase(RNA-dependent DNA polymerase) Ank 25% Ank repeat Cytoplasmic protein,associates integral membrane proteins to the cytoskeleton Oxidored_q132% NADH- membrane associated. Involved in proton translocation acrossthe Ubiquinone/plastoquinone membrane (complex I), various chains Efhand24% EF hand calcium-binding domain, consists of a 12 residue loopflanked on both sides by a 12 residue alpha-helical domain Rvp 79%Retroviral aspartyl Aspartyl or acid proteases, centered on a catalyticaspartyl residue protease Collagen 42% Collagen triple helix repeatextracellular structural proteins involved in formation of connective(20 copies) tissue. The sequence consists of the G-X-Y and thepolypeptide chains forms a triple helix. Fn3 20% Fibronectin type IIIdomain Located in the extracellular ligand-binding region of receptorsand is about 200 amino acid residues long with two pairs of cysteinesinvolved in disulfide bonds 7tm_1 19% 7 transmembrane receptor sevenhydrophobic transmembrane regions, with the N-terminus (rhodopsinfamily) located extracellularly while the C-terminus is cytoplasmic.Signal through G proteins

TABLE VI Motifs and Post-translational Modifications of 282P1G3N-glycosylation site 87-90 NNSG (SEQ ID NO: 54) 231-234 NDSS (SEQ ID NO:55) 315-318 NVSY (SEQ ID NO: 56) 410-413 NHTA (SEQ ID NO: 57) 492-495NGTL (SEQ ID NO: 58) 498-501 NRTT (SEQ ID NO: 59) 529-532 NATK (SEQ IDNO: 60) 578-581 NGTE (SEQ ID NO: 61) 591-594 NLTI (SEQ ID NO: 62)596-599 NVTL (SEQ ID NO: 63) 641-644 NRSV (SEQ ID NO: 64) 657-660 NISE(SEQ ID NO: 65) 783-786 NHTL (SEQ ID NO: 66) 838-841 NSTL (SEQ ID NO:67) 961-964 NLTG (SEQ ID NO: 68) 973-976 NDTY (SEQ ID NO: 69) 985-988NITT (SEQ ID NO: 70) 1000-1003 NATT (SEQ ID NO: 71) 1042-1045 NLTQ (SEQID NO: 72) 1071-1074 NDSI (SEQ ID NO: 73) 1213-1216 NGSS (SEQ ID NO: 74)Tyrosine sulfation site 817-831 TLYSGEDYPDTAPVI (SEQ ID NO: 75)1083-1097 GREYAGLYDDISTQG (SEQ ID NO: 76) 1145-1159 KDETFGEYSDSDEKP (SEQID NO: 77) 1176-1190 SADSLVEYGEGDHGL (SEQ ID NO: 78) cAMP- andcGMP-dependent protein kinase phosphorylation site 684-687 KKTT (SEQ IDNO: 79) Pkinase C phosphorylation site 91-93 TFR 112-114 SNK 183-185 SQK226-228 SLK 245-247 SIK 310-312 TLK 350-352 TKK 377-379 TIK 536-538 SPK563-565 SLK 637-639 SER 643-645 SVR 766-768 TWK 785-787 TLR 1002-1004TTK 1044-1046 TQK 1128-1130 SVK 1143-1145 SVK 1163-1165 SLR Caseinkinase II phosphorylation site 198-201 SRND (SEQ ID NO: 80) 235-238 SSTE(SEQ ID NO: 81) 260-263 SGSE (SEQ ID NO: 82) 317-320 SYQD (SEQ ID NO:83) 385-388 SPVD (SEQ ID NO: 84) 500-503 TTEE (SEQ ID NO: 85) 501-504TEED (SEQ ID NO: 86) 554-557 SKCD (SEQ ID NO: 87) 598-601 TLED (SEQ IDNO: 88) 611-614 TALD (SEQ ID NO: 89) 615-618 SAAD (SEQ ID NO: 90)623-626 TVLD (SEQ ID NO: 91) 809-812 SGPD (SEQ ID NO: 92) 820-823 SGED(SEQ ID NO: 93) 870-873 SLLD (SEQ ID NO: 94) 1027-1030 TLGE (SEQ ID NO:95) 1128-1131 SVKE (SEQ ID NO: 96) 1143-1146 SVKD (SEQ ID NO: 97)1148-1151 TFGE (SEQ ID NO: 98) 1153-1156 SDSD (SEQ ID NO: 99) 1179-1182SLVE (SEQ ID NO: 100) Tyrosine kinase phosphorylation site 480-487KPL.EGRRY (SEQ ID NO: 101) N-myristoylation site 116-121 GIAMSE (SEQ IDNO: 102) 240-245 GSKANS (SEQ ID NO: 103) 261-266 GSESSI (SEQ ID NO: 104)322-327 GNYRCT (SEQ ID NO: 105) 364-369 GILLCE (SEQ ID NO: 106) 424-429GTILAN (SEQ ID NO: 107) 506-511 GSYSCW (SEQ ID NO: 108) 579-584 GTEDGR(SEQ ID NO: 109) 589-594 GANLTI (SEQ ID NO: 110) 603-608 GIYCCS (SEQ IDNO: 111) 651-656 GADHNS (SEQ ID NO: 112) 888-893 GQRNSG (SEQ ID NO: 113)893-898 GMVPSL (SEQ ID NO: 114) 960-965 GNLTGY (SEQ ID NO: 115)1040-1045 GVNLTQ (SEQ ID NO: 116) 1101-1106 GLMCAI (SEQ ID NO: 117)1124-1129 GGKYSV (SEQ ID NO: 118) 1162-1167 GSLRSL (SEQ ID NO: 119)1195-1200 GSFIGA (SEQ ID NO: 120) 1199-1204 GAYAGS (SEQ ID NO: 121)1208-1213 GSVESN (SEQ ID NO: 122) 1214-1219 GSSTAT (SEQ ID NO: 123)Amidation site 483-486 EGRR (SEQ ID NO: 124) 682-685 QGKK (SEQ ID NO:125)

TABLE VII Search Peptides v.1 ORF: 272-3946 9-mers, 10-mers and 15-mers(SEQ ID NO: 126) MEPLLLGRGL IVYLMFLLLK FSKAIEIPSS VQQVPTIIKQ SKVQVAFPFDEYFQIECEAK 60 GNPEPTFSWT KDGNPFYFTD HRIIPSNNSG TFRIPNEGHI SHFQGKYRCFASNKLGIAMS 120 EEIEFIVPSV PKLPKEKIDP LEVEEGDPIV LPCNPPKGLP PLHIYWMNIELEHIEQDERV 180 YMSQKGDLYF ANVEEKDSRN DYCCFAAFPR LRTIVQKMPM KLTVNSLKHANDSSSSTEIG 240 SKANSIKQRK PKLLLPPTES GSESSITILK GEILLLECFA EGLPTPQVDWNKIGGDLPKG 300 RETKENYGKT LKIENVSYQD KGNYRCTASN FLGTATHDFH VIVEEPPRWTKKPQSAVYST 360 GSNGILLCEA EGEPQPTIKW RVNGSPVDNH PFAGDVVFPR EISFTNLQPNHTAVYQCEAS 420 NVHGTILANA NIDVVDVRPL IQTKDGENYA TVVGYSAFLH CEFFASPEAVVSWQKVEEVK 480 PLEGRRYHIY ENGTLQINRT TEEDAGSYSC WVENAIGKTA VTANLDIRNATKLRVSPKNP 540 RIPKLHMLEL HCESKCDSHL KHSLKLSWSK DGEAFEINGT EDGRIIIDGANLTISNVTLE 600 DQGIYCCSAH TALDSAADIT QVTVLDVPDP PENLHLSERQ NRSVRLTWEAGADHNSNISE 660 YIVEFEGNKE EPGRWEELTR VQGKKTTVIL PLAPFVRYQF RVIAVNEVGRSQPSQPSDHH 720 ETPPAAPDRN PQNIRVQASQ PKEMIIKWEP LKSMEQNGPG LEYRVTWKPQGAPVEWEEET 780 VTNHTLRVMT PAVYAPYDVK VQAINQLGSG PDPQSVTLYS GEDYPDTAPVIHGVDVINST 840 LVKVTWSTVP KDRVHGRLKG YQINWWKTKS LLDGRTHPKE VNILRFSGQRNSGMVPSLDA 900 FSEFHLTVLA YNSKGAGPES EPYIFQTPEG VPEQPTFLKV IKVDKDTATLSWGLPKKLNG 960 NLTGYLLQYQ IINDTYEIGE LNDINITTPS KPSWHLSNLN ATTKYKFYLRACTSQGCGKP 1020 ITEESSTLGE GSKGIGKISG VNLTQKTHPI EVFEPGAEHI VRLMTKNWGDNDSIFQDVIE 1080 TRGREYAGLY DDISTQGWFI GLMCAIALLT LLLLTVCFVK RNRGGKYSVKEKEDLHPDPE 1140 IQSVKDETFG EYSDSDEKPL KGSLRSLNRD MQPTESADSL VEYGEGDHGLFSEDGSFIGA 1200 YAGSKEKGSV ESNGSSTATF PLRA 1224 v.2 ORF: 272-3787 9-mersaa 125-141 FIVPSVPKFPKEKIDPL (SEQ ID NO: 127) aa 295-311GDLPKGREAKENYGKTL (SEQ ID NO: 128) aa 1024-1040 ESSTLGEGKYAGLYDDI (SEQID NO: 129) 10-mers aa 124-142 EFIVPSVPKFPKEKIDPLE (SEQ ID NO: 130) aa294-312 GGDLPKGREAKENYGKTLK (SEQ ID NO: 131) aa 1023-1041EESSTLGEGKYAGLYDDIS (SEQ ID NO: 132) 15-mers aa 119-147MSEEIEFIVPSVPKFPKEKIDPLEVEEGD (SEQ ID NO: 133) aa 289-317DWNKIGGDLPKGREAKENYGKTLKIENVS (SEQ ID NO: 134) aa 1018-1046GKPITEESSTLGEGKYAGLYDDISTQGWF (SEQ ID NO: 135) v.3 ORF: 272...2953 Frame+2 9-mers aa 830-848 VIHGVDVINTTYVSN TTYVSNATGSPQ PSIFICSKEQ ELSYRNRNMLAEDFIQKSTS CNYVEKSSTF (SEQ ID NO: 136) FKI 10-mers aa 829-849PVIHGVDVINTTYVSN TTYVSNATGSPQ PSIFICSKEQ ELSYRNRNML AEDFIQKSTSCNYVEKSSTF (SEQ ID NO: 137) FKI 15-mers aa 824-854 YPDTAPVIHGVDVINTTYVSNTTYVSNATGSPQ PSIFICSKEQ ELSYRNRNML AEDFIQKSTS (SEQ ID NO: 138)CNYVEKSSTF FKI v.4 ORF: 272...3625 Frame +2 9-mers aa 816-832VTLYSGEDLPEQPTFLK (SEQ ID NO: 139) 10-mers aa 815-833SVTLYSGEDLPEQPTFLKV (SEQ ID NO: 140) 15-mers aa 810-838GPDPQSVTLYSGEDLPEQPTFLKVIKVDK (SEQ ID NO: 141) v.5 ORF: 272...3898 Frame+2 9-mers aa 219-235 PMKLTVNSSNSIKQRKP (SEQ ID NO: 142) 10-mers aa218-236 MPMKLTVNSSNSIKQRKPK (SEQ ID NO: 143) 15-mers aa 213-241TIVQKMPMKLTVNSSNSIKQRKPKLLLPP (SEQ ID NO: 144) v.6 ORF: 272...3823 Frame+2 9-mers aa 121-137 EEIEFIVPKLEHIEQDE (SEQ ID NO: 145) 10-mers aa122-139 SEEIEFIVPKLEHIEQDER (SEQ ID NO: 146) 15-mers aa 115-143LGIAMSEEIEFIVPKLEHIEQDERVYMSQ (SEQ ID NO: 147) v.7 ORF: 272...3982 Frame+2 9-mers aa 337-364 HDFHVIVEDNISHELFTLHPEPPRWTKK (SEQ ID NO: 148) 10mers aa 336-365 THDFHVIVEDNISHELFTLHPEPPRWTKKP (SEQ ID NO: 149) 15-mersaa 331-370 FLGTATHDFHVIVEDNISHELFTLHPEPPRWTKKPQSAVY (SEQ ID NO: 150)Tables VIII-XXI:

TABLE VIII Start Subsequence Score V1-HLA-A1-9mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 500 TTEEDAGSY 112.500 919ESEPYIFQT 67.500 173 HIEQDERVY 45.000 1078 VIETRGREY 45.000 371EGEPQPTIK 45.000 931 VPEQPTFLK 22.500 524 NLDIRNATK 20.000 760 GLEYRVTWK18.000 547 MLELHCESK 18.000 579 GTEDGRIII 11.250 871 LLDGRTHPK 10.000343 VEEPPRWTK 9.000 1191 FSEDGSFIG 6.750 119 MSEEIEFIV 6.750 78FTDHRIIPS 6.250 145 EGDPIVLPC 6.250 721 ETPPAAPDR 5.000 915 GAGPESEPY5.000 396 VVFPREISF 5.000 168 NIELEHIEQ 4.500 598 TLEDQGIYC 4.500 917GPESEPTIF 4.500 149 IVLPCNPPK 4.000 1154 DSDEKPLKG 3.750 434 VVDVRPLIQ2.500 948 ATLSWGLPK 2.500 961 NLTGYLLQY 2.500 287 QVDWNKIGG 2.500 789MTPAVYAPY 2.500 586 IIDGANLTI 2.500 810 GPDPQSVTL 2.500 236 STEIGSKAN2.250 1021 ITEESSTLG 2.250 V1-HLA-A1-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 3; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 1183 YGEGDHGLF 2.250 62 NPEPTFSWT 2.250 416QCEASNVHG 1.800 142 EVEEGDPIV 1.800 122 EIEFIVPSV 1.800 1175 ESADSLVEY1.500 261 GSESSITIL 1.350 901 FSEFHLTVL 1.350 627 VPDPPENLH 1.250 1144VKDETFGEY 1.250 1136 HPDPEIQSV 1.250 816 VTLYSGEDY 1.250 70 TKDGNPFYF1.250 597 VTLEDQGIY 1.250 157 KGLPPLHIY 1.250 571 DGEAFEING 1.125 270KGEILLLEC 1.125 978 IGELNDINI 1.125 1112 LLLTVCFVK 1.000 137 KIDPLEVEE1.000 616 AADITQVTV 1.000 45 VAFPFDEYF 1.000 835 DVINSTLVK 1.000 279FAEGLPTPQ 0.900 369 EAEGEPQPT 0.900 54 QIECEAKGN 0.900 342 IVEEPPRWT0.900 192 NVEEKDSRN 0.900 753 SMEQNGPGL 0.900 511 WVENAIGKT 0.900 1056WVENAIGKT 0.900 1056 GAEHIVRLM 0.900 551 HCESKCDSH 0.900 367 LCEAEGEPQ0.900 V1-HLA-A1-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 3;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 1180 LVEYGEGDH 0.900 275 LLECFAEGL 0.900 24 AIEIPSSVQ 0.900 1209SVESNGSST 0.900 738 ASQPKEMII 0.750 316 CSYQDKGNY 0.750 1152 YSDSDEKPL0.750 199 RNDYCCFAA 0.625 1068 WGDNDSIFQ 0.625 44 QVAFPFDEY 0.500 99HISHFQGKY 0.500 1000 NATTKYKFY 0.500 158 GLPPLHIYW 0.500 117 IAMSEEIEF0.500 392 FAGDVVFPR 0.500 1176 SADSLVEYG 0.500 612 ALDSAADIT 0.500 651GADHNSNIS 0.500 875 RTHPKEVNI 0.500 833 GVDVINSTL 0.500 202 YCCFAAFPR0.500 897 SLDAFSEFH 0.500 906 LTVLAYNSK 0.500 986 ITTPSKPSW 0.500 555KCDSHLKHS 0.500 893 GMVPSLDAF 0.500 957 KLNGNLTGY 0.500 689 ILPLAPFVR0.500 853 RVHGRLKGY 0.500 13 YLMFLLLKF 0.500 929 EGVPEQPTF 0.500 1052VFEPGAEHI 0.450 213 TIVQKMPMK 0.400 V1-HLA-A1-9mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 949 TLSWGLPKK 0.400V2-HLA-A1-9mers-(SET 1-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 1 FIVPSVPKF 2.000 3 VPSVPKFPK 0.250 5 SVPKFPKEK 0.020 4 PSVPKFPKE0.003 2 IVPSVPKFP 0.001 6 VPKFPKEKI 0.000 9 FPKEKIDPL 0.000 7 PKFPKEKID0.000 8 KFPKEKIDP 0.000 V2-HLA-A1-9mers-(SET 2)-282P1G3 Each peptide isa portion of SEQ ID NO: 5; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 9 AKENYGKTL 0.045 6 GREAKENYG 0.045 2DLPKGREAK 0.020 5 KGREAKENY 0.013 1 GDLPKGREA 0.005 7 REAKENYGK 0.002 8EAKENYGKT 0.001 3 LPKGREAKE 0.000 V2-HLA-A1-9mers-(SET2)-282P1G3 Eachpeptide is a portion of SEQ ID NO: 5; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 4 PKGREAKEN 0.000V2-HLA-A1-9mers-(SET3)-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 2 SSTLGEGKY 0.750 5 LGEGKYAGL 0.450 1 ESSTLGEGK 0.300 3 STLGEGKYA0.025 4 TLGEGKYAG 0.020 6 GEGKYAGLY 0.003 9 KYAGLYDDI 0.001 7 EGKYAGLYD0.000 8 GKYAGLYDD 0.000 V3-HLA-A1-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 7; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 4 GVDVINTTY 25.000 36 EQELSYRNR 1.350 10TTYVSNTTY 1.250 55 STSCNYVEK 1.000 46 MLAEDFIQK 1.000 47 LAEDFIQKS 0.90060 YVEKSSTFF 0.900 34 SKEQELSYR 0.450 V3-HLA-A1-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 7; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 33 CSKEQELSY 0.375 23TGSPQPSIF 0.250 25 SPQPSIFIC 0.125 24 GSPQPSIFI 0.075 22 ATGSPQPSI 0.05027 QPSIFICSK 0.050 16 TTYVSNATG 0.050 13 VSNTTYVSN 0.030 15 NTTYVSNAT0.025 48 AEDFIQKST 0.025 45 NMLAEDFIQ 0.025 9 NTTYVSNTT 0.025 1VIHGVDVIN 0.020 7 VINTTYVSN 0.020 12 YVSNTTYVS 0.020 6 DVINTTYVS 0.02019 VSNATGSPQ 0.015 56 TSCNYVEKS 0.015 29 SIFICSKEQ 0.010 21 NATGSPQPS0.010 57 SCNYVEKSS 0.010 38 ELSTRNRNM 0.010 31 FICSKEQEL 0.010 52IQKSTSCNY 0.007 61 VEKSSTFFK 0.005 59 NYVEKSSTF 0.005 43 NRNMLAEDF 0.00554 KSTSCNYVE 0.003 3 HGVDVINTT 0.003 44 RNMLAEDFI 0.003 8 INTIYVSNT0.003 58 CNYVEKSST 0.003 14 SNTTYVSNA 0.003 62 EKSSTFFKI 0.003V3-HLA-A1-9mers-282-P1G3 Each peptide is a portion of SEQ ID NO: 7; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight. 2IHGVDVINT 0.003 39 LSYRNRNML 0.002 51 FIQKSTSCN 0.001 18 YVSNATGSP 0.00132 ICSKEQELS 0.001 35 KEQELSYRN 0.001 26 PQPSIFICS 0.001 37 QELSYRNRN0.001 20 SNATGSPQP 0.001 5 VDVINTTYV 0.001 49 EDFIQKSTS 0.001 11TYVSNTTYV 0.001 50 DFIQKSTSC 0.001 53 QKSTSCNYV 0.001 17 TYVSNATGS 0.00140 SYRNRNMLA 0.000 28 PSIFICSKE 0.000 42 RNRNMLAED 0.000 30 IFICSKEQE0.000 41 YRNRNMLAE 0.000 V4-HLA-A1-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 9; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 9 LPEQPTFLK 22.500 7 EDLPEQPTF 0.100 4YSGEDLPEQ 0.030 6 GEDLPEQPT 0.025 1 VTLTSGEDL 0.025 5 SGEDLPEQP 0.022V4-HLA-A1-9mers-282-P1G3 Each peptide is a portion of SEQ ID NO: 9; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight. 8DLPEQPTFL 0.010 2 TLYSGEDLP 0.001 3 LYSGEDLPE 0.000V5-HLA-A1-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight. 8SSNSIKQRK 0.300 5 TVNSSNSIK 0.200 7 NSSNSIKQR 0.150 4 LTVNSSNSI 0.025 6VNSSNSIKQ 0.013 3 KLTVNSSNS 0.010 2 MKLTVNSSN 0.001 9 SNSIKQRKP 0.000 1PMKLTVNSS 0.000 V6-HLA-A1-9mers-282P1G3 Each peptide is a portion of SEQID NO: 13; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 2 EIEFIVPKL 1.800 5 FIVPKLEHI 0.100 9 KLIHIEQDE 0.090 1EEIEFIVPK 0.020 4 EFIVPKLEH 0.003 7 VPKLEHIEQ 0.001V6-HLA-A1-9mers-282-P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 6 IVPKLEHIE 0.000 3 IEFIVPKLE 0.000 8 PKLEHIEQD 0.000V7-HLA-A1-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight. 19HPEPPRWTK 45.000 16 FTLHPEPPR 0.500 17 TLHPEPPRW 0.200 6 IVEDNISHE 0.0905 VIVEDNISH 0.050 10 NISHELFTL 0.050 7 VEDNISHEL 0.025 12 SHELFTLHP0.022 11 ISHELFTLH 0.015 9 DNISHELFT 0.013 20 PEPPRWTKK 0.010 4HVIVEDNIS 0.010 8 EDNISHELF 0.005 14 ELFTLHPEP 0.002 2 DFHVIVEDN 0.00118 LHPEPPRWT 0.001 3 FHVIVEDNI 0.001 1 HDFHVIVED 0.000 15 LFTLHPEPP0.000 13 HELFTLHPE 0.000

TABLE IX V1-HLA-A1-10mers-282P1G3 Each peptide is a portion of SEQ IDNO: 3; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. Start Subsequence Score 261 GSESSITILK 135.000 810 GPDPQSVTLY62.500 62 NPEPTFSWTK 45.000 1152 YSDSDEKPLK 30.000 1136 HPDPEIQSVK25.000 1028 LGEGSKGIGK 22.500 312 KIENVSYQDK 18.000 342 IVEEPPRWTK18.000 738 ASQPKEMIIK 15.000 371 EGEPQPTIKW 11.250 406 NLQPNHTAVY 10.000343 VEEPPRWTKK 9.000 170 ELEHIEQDER 9.000 658 ISEYIVEFEG 6.750 1191FSEDGSFIGA 6.750 627 VPDPPENLHL 6.250 788 VMTPAVYAPY 5.000 688VILPLAPFVR 5.000 137 KIDPLEVEEG 5.000 1056 GAEHIVRLMT 4.500 481PLEGRRYHIY 4.500 236 STEIGSKANS 4.500 1149 FGEYSDSDEK 4.500 466SPEAVVSWQK 4.500 475 KVEEVKPLEG 4.500 142 EVEEGDPIVL 4.500 901FSEFHLTVLA 2.700 434 VVDVRPLIQT 2.500 897 SLDAFSEFHL 2.500 78 FTDHRIIPSN2.500 145 EGDPIVLPCN 2.500 4 LLLGRGLIVY 2.500 199 RNDYCCFAAF 2.500 612ALDSAADITQ 2.500 500 TTEEDAGSYS 2.250 747 KWEPLKSMEQ 2.250 270KGEILLLECF 2.250 369 EAEGEPQPTI 1.800 279 FAEGLPTPQV 1.800 460HCEFFASPEA 1.800 173 HIEQDERVYM 1.800 24 AIEIPSSVQQ 1.800 300 GRETKENYGK1.800 598 TLEDQGIYCC 1.800 919 ESEPYIFQTP 1.350 636 LSERQNRSVR 1.3501192 SEDGSFIGAY 1.250 499 RTTEEDAGSY 1.250 917 GPESEPYIFQ 1.125 1021ITEESSTLGE 1.125 1183 YGEGDHGLFS 1.125 579 GTEDGRIIID 1.125 931VPEQPTFLKV 1.125 930 GVPEQPTFLK 1.000 948 ATLSWGLPKK 1.000 1111LLLLTVCFVK 1.000 212 RTIVQKMPMK 1.000 11 IVYLMFLLLK 1.000 126 IVPSVPKLPK1.000 689 ILPLAPFVRY 1.000 30 SVQQVPTIIK 1.000 624 VLDVPDPPEN 1.000 947TATLSWGLPK 1.000 1078 VIETRGREYA 0.900 511 WVENAIGKTA 0.900 1180LVEYGEGDHG 0.900 416 QCEASNVHGT 0.900 547 MLELHCESKC 0.900 551HCESKCDSHL 0.900 303 TKENYGKTLK 0.900 675 WEELTRVQGK 0.900 1209SVESNGSSTA 0.900 996 LSNLNATTKY 0.750 1154 DSDEKPLKGS 0.750 1075FQDVIETRGR 0.750 119 MSEEIEFIVP 0.675 824 YPDTAPVIHG 0.625 960GNLTGYLLQY 0.625 431 NIDVVDVRPL 0.500 616 AADITQVTVL 0.500 586IIDGANLTIS 0.500 847 STVPKDRVHG 0.500 395 DVVFPREISF 0.500 524NLDIRNATKL 0.500 555 KCDSHLKHSL 0.500 833 GVDVINSTLV 0.500 686TTVILPLAPF 0.500 596 NVTLEDQGIY 0.500 14 LMFLLLKFSK 0.500 315 NVSYQDKGNY0.500 815 SVTLYSGEDY 0.500 478 EVKPLEGRRY 0.500 440 LIQTKDGENY 0.500 283LPTPQVDWNK 0.500 116 GIAMSEEIEF 0.500 1077 DVIETRGREY 0.500 1109LTLLLLTVCF 0.500 1134 DLHPDPEIQS 0.500 445 DGENYATVVG 0.450 669KEEPGRWEEL 0.450 V2-HLA-A1-10mers-(SET 1)-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. Start Subsequence Score 3 IVPSVPKFPK 1.000 5PSVPKFPKEK 0.300 1 EFIVPSVPKF 0.010 2 FIVPSVPKFP 0.010 6 SVPKFPKEKI0.001 4 VPSVPKFPKE 0.001 8 PKFPKEKIDP 0.000 10 FPKEKIDPLE 0.000 9KFPKEKIDPL 0.000 7 VPKFPKEKID 0.000 V2-HLA-A1-10mers-(SET 2)-282P1G3Each peptide is a portion of SEQ ID NO: 5; each start position isspecified, the length of peptide is 10 amino acids, and the end positionfor each peptide is the start position plus nine. Start SubsequenceScore 5 LGEGKYAGLY 11.250 1 ESSTLGEGKY 0.750 3 STLGEGKYAG 0.050 4TLGEGKYAGL 0.020 2 SSTLGEGKYA 0.015 8 GKYAGLYDDI 0.001 7 EGKYAGLYDD0.000 6 GEGKYAGLYD 0.000 V2-HLA-A1-10mers-(SET 3)-282P1G3 Each peptideis a portion of SEQ ID NO: 5; each start position is specified, thelength of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. Start Subsequence Score 6LGEGKYAGLY 11.250 2 ESSTLGEGKY 0.750 4 STLGEGKYAG 0.050 5 TLGEGKYAGL0.020 3 SSTLGEGKYA 0.015 1 EESSTLGEGK 0.010 10 KYAGLYDDIS 0.001 9GKYAGLYDDI 0.001 8 EGKYAGLYDD 0.000 7 GEGKYAGLYD 0.000V3-HLA-A1-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7; eachstart position is specified, the length of peptide is 10 amino acids,and the end position for each peptide is the start position plus nine.Start Subsequence Score 61 YVEKSSTFFK 9.000 10 NTTYVSNTTY 1.250 48LAEDFIQKST 0.900 55 KSTSCNYVEK 0.600 46 NMLAEDFIQK 0.500 5 GVDVINTTYV0.500 33 ICSKEQELSY 0.250 23 ATGSPQPSIF 0.250 37 EQELSYRNRN 0.135 26SPQPSIFICS 0.125 4 HGVDVINTTY 0.125 24 TGSPQPSIFI 0.125 35 SKEQELSYRN0.090 25 GSPQPSIFIC 0.075 52 FIQKSTSCNY 0.050 16 NTTYVSNATG 0.050 2VIHGVDVINT 0.050 49 AEDFIQKSTS 0.025 56 STSCNYVEKS 0.025 11 TTYVSNTTYV0.025 17 TTYVSNATGS 0.025 59 CNYVEKSSTF 0.025 13 YVSNTTYVSN 0.020 22NATGSPQPSI 0.020 7 DVINTTYVSN 0.020 34 CSKEQELSYR 0.015 14 VSNTTYVSNA0.015 57 TSCNYVEKSS 0.015 45 RNMLAEDFIQ 0.013 47 MLAEDFIQKS 0.010 32FICSKEQELS 0.010 58 SCNYVEKSST 0.010 8 VINTTYVSNT 0.010 19 YVSNATGSPQ0.010 39 ELSYRNRNML 0.010 40 LSYRNRNMLA 0.008 60 NYVEKSSTFF 0.005 36KEQELSYRNR 0.005 20 VSNATGSPQP 0.003 27 PQPSIFICSK 0.003 15 SNTTYVSNAT0.003 43 RNRNMLAEDF 0.003 9 INTTYVSNTT 0.003 21 SNATGSPQPS 0.003 1PVIHGVDVIN 0.002 29 PSIFICSKEQ 0.002 12 TYVSNTTYVS 0.001 30 SIFICSKEQE0.001 6 VDVINTTYVS 0.001 31 IFICSKEQEL 0.001 38 QELSYRNRNM 0.001 3IHGVDVINTT 0.001 51 DFIQKSTSCN 0.001 50 EDFIQKSTSC 0.001 44 NRNMLAEDFI0.001 62 VEKSSTFFKI 0.000 28 QPSIFICSKE 0.000 53 IQKSTSCNYV 0.000 54QKSTSCNYVE 0.000 18 TYVSNATGSP 0.000 41 SYRNRNMLAE 0.000 42 YRNRNMLAED0.000 V4-HLA-A1-10mers-282P1G3 Each peptide is a portion of SEQ ID NO:9; each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. Start Subsequence Score 10 LPEQPTFLKV 1.125 9 DLPEQPTFLK 1.000 7GEDLPEQPTF 0.500 6 SGEDLPEQPT 0.225 1 SVTLYSGEDL 0.010 8 EDLPEQPTFL0.005 3 TLYSGEDLPE 0.005 2 VTLYSGEDLP 0.003 5 YSGEDLPEQP 0.002 4LYSGEDLPEQ 0.001 V5-HLA-A1-10mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 11; each start position is specified, the length of peptideis 10 amino acids, and the end position for each peptide is the startposition plus nine. Start Subsequence Score 5 LTVNSSNSIK 0.500 8NSSNSIKQRK 0.300 10 SNSIKQRKPK 0.050 6 TVNSSNSIKQ 0.050 7 VNSSNSIKQR0.025 4 KLTVNSSNSI 0.010 9 SSNSIKQRKP 0.002 3 MKLTVNSSNS 0.001 1MPMKLTVNSS 0.000 2 PMKLTVNSSN 0.000

TABLE X V1-HLA-A0201-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 3; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Start Subsequence Score 1111 LLLLTVCFV 5534.148 688VILPLAPFV 330.846 1108 LLTLLLLTV 271.948 9 GLIVYLMFL 270.234 17LLLKFSKAI 249.365 118 AMSEEIEFI 191.488 1101 GLMCAIALL 181.794 4LLLGRGLIV 179.368 16 FLLLKFSKA 160.655 426 ILANANIDV 118.238 923YIFQTPEGV 79.757 406 NLQPNHTAV 69.552 10 LIVYLMFLL 66.613 1107 ALLTLLLLT63.417 840 TLVKVTWST 55.890 1027 TLGEGSKGI 42.774 930 GVPEQPTFL 42.15147 FPFDEYFQI 41.346 166 WMNIELEHI 39.062 836 VINSTLVKV 37.393 125FIVPSVPKL 31.077 591 NLTISNVTL 21.362 11 IVYLMFLLL 19.320 544 KLHMLELHC17.388 1166 SLNRDMQPT 17.140 23 KAIEIPSSV 13.862 103 FQGKYRCFA 12.744267 TILKGEILL 10.868 1042 NLTQKTHPI 10.433 451 TVVGYSAFL 10.281 1001ATTKYKFYL 9.465 967 LQYQIINDT 9.453 1102 LMCAIALLT 9.149 787 RVMTPAVYA8.846 1073 SIFQDVIET 8.720 908 VLAYNSKGA 8.446 471 VSWQKVEEV 7.220 598TLEDQGIYC 7.170 585 IIIDGANLT 7.142 335 ATHDFHVIV 6.171 680 RVQGKKTTV6.086 780 TVTNHTLRV 6.086 333 GTATHDFHV 5.603 785 TLRVMTPAV 5.286 1092DISTQGWFI 4.438 275 LLECFAEGL 4.328 1106 IALLTLLLL 4.292 14 LMFLLLKFS4.282 458 FLHCEFFAS 3.778 619 ITQVTVLDV 3.777 174 IEQDERVYM 3.703 1033KGIGKISGV 3.655 274 LLLECFAEG 3.651 774 VEWEEETVT 3.437 603 GIYCCSAHT3.279 214 IVQKMPMKL 3.178 1105 AIALLTLLL 2.937 584 RIIIDGANL 2.937 268ILKGEILLL 2.923 13 YLMFLLLKF 2.917 942 KVDKDTATL 2.617 1053 FEPGAEHIV2.551 980 ELNDINITT 2.291 939 KVIKVDKDT 2.282 429 NANIDVVDV 2.222 589GANLTISNV 2.222 611 TALDSAADI 2.198 976 YEIGELNDI 2.146 444 KDGENYATV2.079 863 INWWKTKSL 1.968 950 LSWGLPKKL 1.968 83 IIPSNNSGT 1.742 26EIPSSVQQV 1.650 916 AGPESEPYI 1.536 970 QIINDTYEI 1.435 819 YSGEDYPDT1.376 280 AEGLPTPQV 1.352 1099 FIGLMCAIA 1.288 185 KGDLYFANV 1.208 374PQPTIKWRV 1.164 991 KPSWHLSNL 1.123 988 TPSKPSWHL 1.046 272 EILLLECFA1.043 846 WSTVPKDRV 1.023 753 SMEQNGPGL 0.987 203 CCFAAFPRL 0.980 586IIDGANLTI 0.975 1066 KNWGDNDSI 0.969 252 KLLLPPTES 0.965 743 EMIIKWEPL0.964 318 YQDKGNYRC 0.927 746 IKWEPLKSM 0.918 534 RVSPKNPRI 0.913 596NVTLEDQGI 0.913 1100 IGLMCAIAL 0.877 210 RLRTIVQKM 0.868 736 VQASQPKEM0.856 370 AEGEPQPTI 0.832 1214 GSSTATFPL 0.809 427 LANANIDVV 0.759V2-HLA-A201-9mers-(SET 1)-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Start Subsequence Score 1 FIVPSVPKF 2.000 3 VPSVPKFPK 0.2505 SVPKFPKEK 0.020 4 PSVPKFPKE 0.003 2 IVPSVPKFP 0.001 6 VPKFPKEKI 0.0009 FPKEKIDPL 0.000 7 PKFPKEKID 0.000 8 KFPKEKIDP 0.000V2-HLA-A201-9mers-(SET 2)-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Start Subsequence Score 1 GDLPKGREA 0.005 9 AKENYGKTL 0.0022 DLPKGREAK 0.001 7 REAKENYGK 0.000 5 KGREAKENY 0.000 8 EAKENYGKT 0.0003 LPKGREAKE 0.000 6 GREAKENYG 0.000 4 PKGREAKEN 0.000V2-HLA-A201-9mers-(SET 3)-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Start Subsequence Score 3 STLGEGKYA 1.404 4 TLGEGKYAG 0.3065 LGEGKYAGL 0.023 9 KYAGLYDDI 0.004 6 GEGKYAGLY 0.000 8 GKYAGLYDD 0.0002 SSTLGEGKY 0.000 1 ESSTLGEGK 0.000 7 EGKYAGLYD 0.000V3-HLA-A201-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 31 FICSKEQEL 13.512 5 VDVINTTYV 0.903 39LSYRNRNML 0.759 44 RNMLAEDFI 0.679 53 QKSTSCNYV 0.531 24 GSPQPSIFI 0.37546 MLAEDFIQK 0.197 8 INTTYVSNT 0.190 25 SPQPSIFIC 0.177 58 CNYVEKSST0.156 22 ATGSPQPSI 0.145 9 NTTYVSNTT 0.104 15 NTTYVSNAT 0.104 45NMLAEDFIQ 0.095 14 SNTTYVSNA 0.075 38 ELSYRNRNM 0.075 48 AEDFIQKST 0.05811 TYVSNTTYV 0.053 51 FIQKSTSCN 0.047 7 VINTTYVSN 0.026 35 KEQELSYRN0.021 2 IHGVDVINT 0.020 3 HGVDVINTT 0.016 12 YVSNTTYVS 0.012 62EKSSTFFKI 0.012 60 YVEKSSTFF 0.011 29 SIFICSKEQ 0.008 1 VIHGVDVIN 0.00737 QELSYRNRN 0.005 47 LAEDFIQKS 0.004 10 TTYVSNTTY 0.003 16 TTYVSNATG0.003 4 GVDVINTTY 0.003 13 VSNTTYVSN 0.001 21 NATGSPQPS 0.001 27QPSIFICSK 0.001 18 YVSNATGSP 0.001 61 VEKSSTFFK 0.001 56 TSCNYVEKS 0.00157 SCNYVEKSS 0.000 52 IQKSTSCNY 0.000 32 ICSKEQELS 0.000 26 PQPSIFICS0.000 55 STSCNYVEK 0.000 50 DFIQKSTSC 0.000 6 DVINTTYVS 0.000 23TGSPQPSIF 0.000 19 VSNATGSPQ 0.000 54 KSTSCNYVE 0.000 20 SNATGSPQP 0.00033 CSKEQELSY 0.000 40 SYRNRNMLA 0.000 59 NYVEKSSTF 0.000 49 EDFIQKSTS0.000 41 YRNRNMLAE 0.000 42 RNRNMLAED 0.000 34 SKEQELSYR 0.000 17TYVSNATGS 0.000 30 IFICSKEQE 0.000 43 NRNMLAEDF 0.000 36 EQELSYRNR 0.00028 PSIFICSKE 0.000 V4-HLA-A0201-9mers-282P1G3 Each peptide is a portionof SEQ ID NO: 9; each start position is specified, the length of peptideis 9 amino acids, and the end position for each peptide is the startposition plus eight. Start Subsequence Score 8 DLPEQPTFL 36.129 1VTLYSGEDL 0.914 6 GEDLPEQPT 0.058 2 TLYSGEDLP 0.023 4 YSGEDLPEQ 0.004 9LPEQPTFLK 0.000 7 EDLPEQPTF 0.000 5 SGEDLPEQP 0.000 3 LYSGEDLPE 0.000V5-HLA-A0201-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 3 KLTVNSSNS 0.261 4 LTVNSSNSI 0.246 2MKLTVNSSN 0.001 5 TVNSSNSIK 0.001 7 NSSNSIKQR 0.000 6 VNSSNSIKQ 0.000 8SSNSIKQRK 0.000 1 PMKLTVNSS 0.000 9 SNSIKQRKP 0.000V6-HLA-A0201-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 5 FIVPKLEHI 7.437 2 EIEFIVPKL 0.032 9KLEHIEQDE 0.003 3 IEFIVPKLE 0.002 6 IVPKLEHIE 0.001 1 EEIEFIVPK 0.001 8PKLEHIEQD 0.000 7 VPKLEHIEQ 0.000 4 EFIVPKLEH 0.000V7-HLA-A0201-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 10 NISHELFTL 39.184 7 VEDNISHEL 0.282 17TLHPEPPRW 0.075 5 VIVEDNISH 0.071 18 LHPEPPRWT 0.040 9 DNISHELFT 0.020 3FHVIVEDNI 0.016 11 ISHELFTLH 0.006 14 ELFTLHPEP 0.004 16 FTLHPEPPR 0.0046 IVEDNISHE 0.001 4 HVIVEDNIS 0.000 13 HELFTLHPE 0.000 20 PEPPRWTKK0.000 15 LFTLHPEPP 0.000 1 HDFHVIVED 0.000 2 DFHVIVEDN 0.000 8 EDNISHELF0.000 12 SHELFTLHP 0.000 19 HPEPPRWTK 0.000

TABLE XI V6-HLA-A1-10mers-282P1G3 Each peptide is a portion of SEQ IDNO: 13; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. Start Subsequence Score 10 KLEHIEQDER 9.000 1 SEEIEFIVPK1.800 3 EIEFIVPKLE 0.090 6 FIVPKLEHIE 0.010 7 IVPKLEHIEQ 0.005 4IEFIVPKLEH 0.003 2 EEIEFIVPKL 0.001 5 EFIVPKLEHI 0.001 8 VPKLEHIEQD0.000 9 PKLEHIEQDE 0.000 V7-HLA-A1-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 15; each start position is specified, the lengthof peptide is 10 amino acids, and the end position for each peptide isthe start position plus nine. Start Subsequence Score 20 HPEPPRWTKK45.000 7 IVEDNISHEL 0.900 8 VEDNISHELF 0.250 18 TLHPEPPRWT 0.100 5HVIVEDNISH 0.050 17 FTLHPEPPRW 0.050 10 DNISHELFTL 0.013 19 LHPEPPRWTK0.010 16 LFTLHPEPPR 0.010 11 NISHELFTLH 0.010 12 ISHELFTLHP 0.007 1THDFHVIVED 0.005 13 SHELFTLHPE 0.005 9 EDNISHELFT 0.003 15 ELFTLHPEPP0.001 6 VIVEDNISHE 0.001 2 HDFHVIVEDN 0.001 4 FHVIVEDNIS 0.001 3DFHVIVEDNI 0.001 14 HELFTLHPEP 0.000 21 PEPPRWTKKP 0.000V1-HLA-A0201-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 3;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. Start Subsequence Score 1110 TLLLLTVCFV 3255.381 274 LLLECFAEGL1025.804 16 FLLLKFSKAI 674.752 1107 ALLTLLLLTV 591.888 118 AMSEEIEFIV489.752 5 LLGRGLIVYL 459.398 9 GLIVYLMFLL 284.974 1189 GLFSEDGSFI212.307 840 TLVKVTWSTV 118.238 132 KLPKEKIDPL 84.264 158 GLPPLHIYWM62.845 1102 LMCAIALLTL 60.325 426 ILANANIDVV 54.634 957 KLNGNLTGYL53.459 396 VVFPREISFT 51.883 897 SLDAFSEFHL 49.561 221 KLTVNSLKHA 39.992150 VLPCNPPKGL 36.316 425 TILANANIDV 35.385 687 TVILPLAPFV 33.472 966LLQYQIINDT 29.137 1101 GLMCAIALLT 27.572 267 TILKGEILLL 24.997 949TLSWGLPKKL 21.362 792 AVYAPYDVKV 19.475 413 AVYQCEASNV 19.475 114KLGIAMSEEI 17.892 13 YLMFLLLKFS 16.044 765 VTWKPQGAPV 13.630 1099FIGLMCAIAL 13.512 470 VVSWQKVEEV 11.660 585 IIIDGANLTI 9.999 597VTLEDQGIYC 9.787 693 APFVRYQFRV 9.743 36 TIIKQSKVQV 9.563 10 LIVYLMFLLL9.488 1000 NATTKYKFYL 9.465 524 NLDIRNATKL 8.545 456 SAFLHCEFFA 8.1441108 LLTLLLLTVC 7.964 341 VIVEEPPRWT 7.856 752 KSMEQNGPGL 7.404 859KGYQINWWKT 6.947 541 RIPKLHMLEL 6.756 1105 AIALLTLLLL 6.756 8 RGLIVYLMFL6.527 117 IAMSEEIEFI 5.649 25 IEIPSSVQQV 5.288 969 YQIINDTYEI 4.866 441IQTKDGENYA 4.710 742 KEMIIKWEPL 4.481 332 LGTATHDFHV 4.477 615SAADITQVTV 3.961 141 LEVEEGDPIV 3.865 480 KPLEGRRYHI 3.616 598TLEDQGIYCC 2.998 1034 GIGKISGVNL 2.937 213 TIVQKMPMKL 2.937 862QINWWKTKSL 2.937 356 AVYSTGSNGI 2.921 839 STLVKVTWST 2.872 953GLPKKLNGNL 2.777 214 IVQKMPMKLT 2.550 461 CEFFASPEAV 2.452 833GVDVINSTLV 2.434 3 PLLLGRGLIV 2.321 512 VENAIGKTAV 2.299 565 KLSWSKDGEA2.260 1181 VEYGEGDHGL 2.260 987 TTPSKPSWHL 2.225 603 GIYCCSAHTA 2.186 61GNPEPTFSWT 2.084 795 APYDVKVQAI 2.055 1100 IGLMCAIALL 2.017 218MPMKLTVNSL 2.017 863 INWWKTKSLL 1.968 635 HLSERQNRSV 1.939 1172QPTESADSLV 1.861 1171 MQPTESADSL 1.804 1008 YLRACTSQGC 1.737 405TNLQPNHTAV 1.680 618 DITQVTVLDV 1.650 836 VINSTLVKVT 1.643 1043LTQKTHPIEV 1.642 450 ATVVGYSAFL 1.632 907 TVLAYNSKGA 1.608 681VQGKKTTVIL 1.510 334 TATHDFHVIV 1.505 1106 IALLTLLLLT 1.497 206AAFPRLRTIV 1.465 452 VVGYSAFLHC 1.404 378 IKWRVNGSPV 1.363 181YMSQKGDLYF 1.362 202 YCCFAAFPRL 1.219 171 LEHIEQDERV 1.127 1113LLTVCFVKRN 1.107 835 DVINSTLVKV 1.050 934 QPTFLKVIKV 1.044 428ANANIDVVDV 1.044 82 RIIPSNNSGT 1.025 V2-HLA-A0201-10mers-(SET 1)-282P1G3Each peptide is a portion of SEQ ID NO: 5; each start position isspecified, the length of peptide is 10 amino acids, and the end positionfor each peptide is the start position plus nine. Start SubsequenceScore 6 SVPKFPKEKI 0.447 9 KFPKEKIDPL 0.059 2 FIVPSVPKFP 0.052 3IVPSVPKFPK 0.013 4 VPSVPKFPKE 0.000 10 FPKEKIDPLE 0.000 1 EFIVPSVPKF0.000 5 PSVPKFPKEK 0.000 7 VPKFPKEKID 0.000 8 PKFPKEKIDP 0.000V2-HLA-A0201-10mers-(SET 2)-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. Start Subsequence Score 4 TLGEGKYAGL 131.379 2 SSTLGEGKYA0.178 8 GKYAGLYDDI 0.034 3 STLGEGKYAG 0.004 6 GEGKYAGLYD 0.002 5LGEGKYAGLY 0.000 1 ESSTLGEGKY 0.000 7 EGKYAGLYDD 0.000V2-HLA-A0201-10mers-(SET 3)282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. Start Subsequence Score 5 TLGEGKYAGL 131.379 3 SSTLGEGKYA0.178 9 GKYAGLYDDI 0.034 4 STLGEGKYAG 0.004 7 GEGKYAGLYD 0.002 1EESSTLGEGK 0.000 10 KYAGLYDDIS 0.000 6 LGEGKYAGLY 0.000 2 ESSTLGEGKY0.000 8 EGKYAGLYDD 0.000 V3-HLA-A0201-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 7; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. Start Subsequence Score 11 TTYVSNTTYV 17.002 5GVDVINTTYV 13.389 47 MLAEDFIQKS 4.540 8 VINTTYVSNT 4.006 2 VIHGVDVINT4.006 53 IQKSTSCNYV 2.308 39 ELSYRNRNML 1.602 24 TGSPQPSIFI 0.375 25GSPQPSIFIC 0.177 40 LSYRNRNMLA 0.176 22 NATGSPQPSI 0.145 62 VEKSSTFFKI0.133 14 VSNTTYVSNA 0.127 9 INTTYVSNTT 0.083 46 NMLAEDFIQK 0.076 38QELSYRNRNM 0.071 15 SNTTYVSNAT 0.049 58 SCNYVEKSST 0.049 52 FIQKSTSCNY0.047 48 LAEDFIQKST 0.046 13 YVSNTTYVSN 0.045 31 IFICSKEQEL 0.025 32FICSKEQELS 0.023 3 IHGVDVINTT 0.020 61 YVEKSSTFFK 0.012 19 YVSNATGSPQ0.006 44 NRNMLAEDFI 0.004 30 SIFICSKEQE 0.004 17 TTYVSNATGS 0.003 50EDFIQKSTSC 0.002 59 CNYVEKSSTF 0.002 36 KEQELSYRNR 0.001 56 STSCNYVEKS0.001 10 NTTYVSNTTY 0.001 16 NTTYVSNATG 0.001 26 SPQPSIFICS 0.001 45RNMLAEDFIQ 0.001 33 ICSKEQELSY 0.001 7 DVINTTYVSN 0.001 49 AEDFIQKSTS0.001 55 KSTSCNYVEK 0.001 57 TSCNYVEKSS 0.000 21 SNATGSPQPS 0.000 23ATGSPQPSIF 0.000 27 PQPSIFICSK 0.000 60 NYVEKSSTFF 0.000 34 CSKEQELSYR0.000 20 VSNATGSPQP 0.000 28 QPSIFICSKE 0.000 6 VDVINTTYVS 0.000 4HGVDVINTTY 0.000 1 PVIHGVDVIN 0.000 37 EQELSYRNRN 0.000 42 YRNRNMLAED0.000 43 RNRNMLAEDF 0.000 54 QKSTSCNYVE 0.000 35 SKEQELSYRN 0.000 12TYVSNTTYVS 0.000 51 DFIQKSTSCN 0.000 29 PSIFICSKEQ 0.000 41 SYRNRNMLAE0.000 18 TYVSNATGSP 0.000 V4-HLA-0201-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 9; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. Start Subsequence Score 1 SVTLYSGEDL 0.916 10LPEQPTFLKV 0.094 3 TLYSGEDLPE 0.048 8 EDLPEQPTFL 0.045 9 DLPEQPTFLK0.027 6 SGEDLPEQPT 0.013 5 YSGEDLPEQP 0.001 2 VTLYSGEDLP 0.001 7GEDLPEQPTF 0.001 4 LYSGEDLPEQ 0.000 V5-HLA-0201-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 11; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. Start Subsequence Score 4KLTVNSSNSI 36.515 1 MPMKLTVNSS 0.007 6 TVNSSNSIKQ 0.001 3 MKLTVNSSNS0.001 7 VNSSNSIKQR 0.000 5 LTVNSSNSIK 0.000 10 SNSIKQRKPK 0.000 8NSSNSIKQRK 0.000 2 PMKLTVNSSN 0.000 9 SSNSIKQRKP 0.000V6-HLA-0201-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. Start Subsequence Score 2 EEIEFIVPKL 0.294 4 IEFIVPKLEH 0.009 6FIVPKLEHIE 0.004 7 IVPKLEHIEQ 0.002 10 KLEHIEQDER 0.002 5 EFIVPKLEHI0.001 1 SEEIEFIVPK 0.000 3 EIEFIVPKLE 0.000 9 PKLEHIEQDE 0.000 8VPKLEHIEQD 0.000 V7-HLA-0201-10mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 15; each start position is specified, the length of peptideis 10 amino acids, and the end position for each peptide is thestart_position plus nine. Start Subsequence Score 18 TLHPEPPRWT 8.197 7IVEDNISHEL 0.834 10 DNISHELFTL 0.140 6 VIVEDNISHE 0.033 11 NISHELFTLH0.019 17 FTLHPEPPRW 0.018 9 EDNISHELFT 0.004 12 ISHELFTLHP 0.003 15ELFTLHPEPP 0.002 19 LHPEPPRWTK 0.001 8 VEDNISHELF 0.000 3 DFHVIVEDNI0.000 5 HVIVEDNISH 0.000 4 FHVIVEDNIS 0.000 14 HELFTLHPEP 0.000 16LFTLHPEPPR 0.000 2 HDFHVIVEDN 0.000 1 THDFHVIVED 0.000 21 PEPPRWTKKP0.000 13 SHELFTLHPE 0.000 20 HPEPPRWTKK 0.000

TABLE XII V1-HLA-A3-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 3; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Start Subsequence Score 760 GLEYRVTWK 180.000 1112 LLLTVCFVK135.000 961 NLTGYLLQY 54.000 937 FLKVIKVDK 30.000 949 TLSWGLPKK 30.000871 LLDGRTHPK 30.000 957 KLNGNLTGY 27.000 9 GLIVYLMFL 24.300 893GMVPSLDAF 20.250 524 NLDIRNATK 20.000 547 MLELHCESK 20.000 792 AVYAPYDVK15.000 5 LLGRGLIVY 12.000 1113 LLTVCFVKR 12.000 689 ILPLAPFVR 12.000 998NLNATTKYK 10.000 744 MIIKWEPLK 9.000 1189 GLFSEDGSF 9.000 13 YLMFLLLKF9.000 948 ATLSWGLPK 9.000 843 KVTWSTVPK 6.000 296 DLPKGRETK 6.000 213TIVQKMPMK 4.500 149 IVLPCNPPK 4.500 661 YIVEFEGNK 4.050 1101 GLMCAIALL4.050 181 YMSQKGDLY 4.000 310 TLKIENVSY 4.000 396 VVFPREISF 3.000 1110TLLLLTVCF 3.000 530 ATKLRVSPK 3.000 268 ILKGEILLL 2.700 677 ELTRVQGKK2.700 331 FLGTATHDF 2.000 11 IVYLMFLLL 1.800 275 LLECFAEGL 1.800 857RLKGYQINW 1.800 739 SQPKEMIIK 1.800 44 QVAFPFDEY 1.800 835 DVINSTLVK1.800 31 VQQVPTIIK 1.800 158 GLPPLHIYW 1.800 1197 FIGAYAGSK 1.800 1002TTKYKFYLR 1.800 906 LTVLAYNSK 1.500 1199 GAYAGSKEK 1.500 859 KGYQINWWK1.350 118 AMSEEIEFI 1.350 17 LLLKFSKAI 1.350 436 DVRPLIQTK 1.350 657NISEYIVEF 1.350 861 YQINWWKTK 1.350 221 KLTVNSLKH 1.200 544 KLHMLELHC1.200 129 SVPKLPKEK 1.000 166 WMNIELEHI 0.900 931 VPEQPTFLK 0.900 4LLLGRGLIV 0.900 1111 LLLLTVCFV 0.900 1150 GEYSDSDEK 0.900 867 KTKSLLDGR0.900 282 GLPTPQVDW 0.900 210 RLRTIVQKM 0.900 242 KANSIKQRK 0.900 16FLLLKFSKA 0.900 1094 STQGWFIGL 0.810 840 TLVKVTWST 0.675 687 TVILPLAPF0.675 520 AVTANLDIR 0.600 163 HIYWMNIEL 0.600 591 NLTISNVTL 0.600 983DINITTPSK 0.600 1108 LLTLLLLTV 0.600 1042 NLTQKTHPI 0.600 127 VPSVPKLPK0.600 897 SLDAFSEFH 0.600 1118 FVKRNRGGK 0.600 74 NPFYFTDHR 0.600 340HVIVEEPPR 0.600 536 SPKNPRIPK 0.600 753 SMEQNGPGL 0.600 882 NILRFSGQR0.540 392 FAGDVVFPR 0.540 562 HSLKLSWSK 0.450 284 PTPQVDWNK 0.450 853RVHGRLKGY 0.450 45 VAFPFDEYF 0.450 1027 TLGEGSKGI 0.450 1088 GLYDDISTQ0.450 1107 ALLTLLLLT 0.450 125 FIVPSVPKL 0.405 10 LIVYLMFLL 0.405 451TVVGYSAFL 0.405 343 VEEPPRWTK 0.405 702 VIAVNEVGR 0.400 426 ILANANIDV0.400 598 TLEDQGIYC 0.400 161 PLHIYWMNI 0.360 99 HISHFQGKY 0.360 458FLHCEFFAS 0.360 V2-HLA-A3-9mers-(SET 1)-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. Start Subsequence Score 5 SVPKFPKEK 3.000 1FIVPSVPKF 1.350 3 VPSVPKFPK 0.900 9 FPKEKIDPL 0.013 6 VPKFPKEKI 0.009 2IVPSVPKFP 0.002 8 KFPKEKIDP 0.000 4 PSVPKFPKE 0.000 7 PKFPKEKID 0.000V2-HLA-A3-9mers-(SET 2)-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 2 DLPKGREAK 6.000 7 REAKENYGK 0.180 5KGREAKENY 0.018 9 AKENYGKTL 0.001 3 LPKGREAKE 0.000 1 GDLPKGREA 0.000 8EAKENYGKT 0.000 6 GREAKENYG 0.000 4 PKGREAKEN 0.000 V2-HLA-A3-9mers-(SET3)-282P1G3 Each peptide is a portion of SEQ ID NO: 5; each startposition is specified, the length of peptide is 9 amino acids, and theend position for each peptide is the start position plus eight. StartSubsequence Score 4 TLGEGKYAG 0.090 6 GEGKYAGLY 0.032 1 ESSTLGEGK 0.0303 STLGEGKYA 0.011 2 SSTLGEGKY 0.006 9 KYAGLYDDI 0.003 8 GKYAGLYDD 0.0015 LGEGKYAGL 0.001 7 EGKYAGLYD 0.000 V3-A3-9mers-282P1G3 Each peptide isa portion of SEQ ID NO: 7; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. Start Subsequence Score 46 MLAEDFIQK180.000 4 GVDVINTTY 1.800 10 TTYVSNTTY 1.000 55 STSCNYVEK 1.000 27QPSIFICSK 0.900 60 YVEKSSTFF 0.200 61 VEKSSTFFK 0.180 52 IQKSTSCNY 0.12045 NMLAEDFIQ 0.090 33 CSKEQELSY 0.060 31 FICSKEQEL 0.060 22 ATGSPQPSI0.045 24 GSPQPSIFI 0.027 39 LSYRNRNML 0.015 25 SPQPSIFIC 0.013 12YVSNTTYVS 0.012 15 NTTYVSNAT 0.007 9 NTTYVSNTT 0.007 34 SKEQELSYR 0.00638 ELSYRNRNM 0.006 6 DVINTTYVS 0.005 29 SIFICSKEQ 0.005 16 TTYVSNATG0.005 59 NYVEKSSTF 0.005 1 VIHGVDVIN 0.005 14 SNTTYVSNA 0.004 36EQELSYRNR 0.004 23 TGSPQPSIF 0.003 43 NRNMLAEDF 0.002 51 FIQKSTSCN 0.0027 VINTTYVSN 0.002 44 RNMLAEDFI 0.002 8 INTTYVSNT 0.002 56 TSCNYVEKS0.002 47 LAEDFIQKS 0.002 62 EKSSTFFKI 0.002 26 PQPSIFICS 0.001 58CNYVEKSST 0.001 54 KSTSCNYVE 0.001 35 KEQELSYRN 0.001 21 NATGSPQPS 0.00118 YVSNATGSP 0.001 2 IHGVDVINT 0.001 32 ICSKEQELS 0.000 40 SYRNRNMLA0.000 3 HGVDVINTT 0.000 5 VDVINTTYV 0.000 11 TYVSNTTYV 0.000 57SCNYVEKSS 0.000 37 QELSYRNRN 0.000 48 AEDFIQKST 0.000 53 QKSTSCNYV 0.00019 VSNATGSPQ 0.000 13 VSNTTYVSN 0.000 50 DFIQKSTSC 0.000 42 RNRNMLAED0.000 17 TYVSNATGS 0.000 41 YRNRNMLAE 0.000 49 EDFIQKSTS 0.000 20SNATGSPQP 0.000 30 IFICSKEQE 0.000 28 PSIFICSKE 0.000V4-HLA-A3-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 9; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight.Start Subsequence Score 9 LPEQPTFLK 0.900 8 DLPEQPTFL 0.270 2 TLYSGEDLP0.100 1 VTLYSGEDL 0.045 7 EDLPEQPTF 0.001 6 GEDLPEQPT 0.001 4 YSGEDLPEQ0.000 3 LYSGEDLPE 0.000 5 SGEDLPEQP 0.000 V5-HLA-A3-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 11; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. Start Subsequence Score 5TVNSSNSIK 2.000 8 SSNSIKQRK 0.150 3 KLTVNSSNS 0.120 4 LTVNSSNSI 0.045 7NSSNSIKQR 0.015 1 PMKLTVNSS 0.012 6 VNSSNSIKQ 0.000 2 MKLTVNSSN 0.000 9SNSIKQRKP 0.000 V6-HLA-A3-9mers-282P1G3 Each peptide is a portion of SEQID NO: 13; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Start Subsequence Score 5 FIVPKLEHI 0.203 1 EEIEFIVPK 0.1829 KLEHIEQDE 0.090 2 EIEFIVPKL 0.081 6 IVPKLEHIE 0.002 7 VPKLEHIEQ 0.0004 EFIVPKLEH 0.000 3 IEFIVPKLE 0.000 8 PKLEHIEQD 0.000V7-HLA-A3-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight.Start Subsequence Score 19 HPEPPRWTK 1.350 16 FTLHPEPPR 0.450 17TLHPEPPRW 0.300 10 NISHELFTL 0.270 5 VIVEDNISH 0.090 14 ELFTLHPEP 0.03020 PEPPRWTKK 0.009 4 HVIVEDNIS 0.006 11 ISHELFTLH 0.005 6 IVEDNISHE0.003 7 VEDNISHEL 0.003 3 FHVIVEDNI 0.001 8 EDNISHELF 0.001 1 HDFHVIVED0.000 9 DNISHELFT 0.000 13 HELTLHPE 0.000 12 SHELFTLHP 0.000 2 DFHVIVEDN0.000 18 LHPEPPRWT 0.000 15 LFTLHPEPP 0.000

TABLE XIII V1-HLA-A3-10mers-282P1G3 Each peptide is a portion of SEQ IDNO: 3; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. Start Subsequence Score 14 LMFLLLKFSK 300.000 1111 LLLLTVCFVK135.000 11 IVYLMFLLLK 90.000 187 DLYFANVEEK 90.000 546 HMLELHCESK 45.000930 GVPEQPTFLK 40.500 870 SLLDGRTHPK 30.000 743 EMIIKWEPLK 27.000 4LLLGRGLIVY 27.000 995 HLSNLNATTK 20.000 905 HLTVLAYNSK 20.000 532KLRVSPKNPR 18.000 1112 LLLTVCFVKR 18.000 689 ILPLAPFVRY 18.000 342IVEEPPRWTK 13.500 1037 KISGVNLTQK 13.500 9 GLIVYLMFLL 12.150 788VMTPAVYAPY 9.000 1189 GLFSEDGSFI 9.000 312 KIENVSYQDK 6.000 30SVQQVPTIIK 6.000 406 NLQPNHTAVY 6.000 126 IVPSVPKLPK 6.000 998NLNATTKYKF 6.000 1073 SIFQDVIETR 4.500 274 LLLECFAEGL 4.050 158GLPPLHIYWM 4.050 633 NLHLSERQNR 4.000 181 YMSQKGDLYF 4.000 785TLRVMTPAVY 4.000 33 QVPTIIKQSK 3.000 219 PMKLTVNSLK 3.000 62 NPEPTFSWTK2.700 132 KLPKEKIDPL 2.700 688 VILPLAPFVR 2.700 212 RTIVQKMPMK 2.250 948ATLSWGLPKK 2.250 509 SCWVENAIGK 2.000 733 NIRVQASQPK 2.000 1102LMCAIALLTL 1.800 11001 ATTKYKFYLR 1.800 897 SLDAFSEFHL 1.800 114KLGIAMSEEI 1.800 1101 GLMCAIALLT 1.350 118 AMSEEIEFIV 1.350 691PLAPFVRYQF 1.350 16 FLLLKFSKAI 1.350 283 LPTPQVDWNK 1.350 18 LLKFSKAIEI1.200 170 ELEHIEQDER 1.200 848 TVPKDRVHGR 1.200 116 GIAMSEEIEF 1.200 947TATLSWGLPK 1.200 105 GKYRCFASNK 0.900 967 LQYQIINDTY 0.900 5 LLGRGLIVYL0.900 488 HIYENGTLQI 0.900 466 SPEAVVSWQK 0.900 598 TLEDQGIYCC 0.900 261GSESSITILK 0.900 1107 ALLTLLLLTV 0.900 292 KIGGDLPKGR 0.900 1110TLLLLTVCFV 0.900 309 KTLKIENVSY 0.900 957 KLNGNLTGYL 0.810 43 VQVAFPFDEY0.810 471 VSWQKVEEVK 0.750 844 VTWSTVPKDR 0.750 481 PLEGRRYHIY 0.600 524NLDIRNATKL 0.600 44 QVAFPFDEYF 0.600 529 NATKLRVSPK 0.600 701 RVIAVNEVGR0.600 238 EIGSKANSIK 0.600 810 GPDPQSVTLY 0.540 10 LIVYLMFLLL 0.540 953GLPKKLNGNL 0.540 738 ASQPKEMIIK 0.450 857 RLKGYQINWW 0.450 221KLTVNSLKHA 0.450 123 IEFIVPSVPK 0.450 1088 GLYDDISTQG 0.450 150VLPCNPPKGL 0.450 1136 HPDPEIQSVK 0.450 440 LIQTKDGENY 0.400 815SVTLYSGEDY 0.400 559 HLKHSLKLSW 0.400 902 SEFHLTVLAY 0.360 1143SVKDETFGEY 0.360 686 TTVILPLAPF 0.338 960 GNLTGYLLQY 0.324 148PIVLPCNPPK 0.300 1108 LLTLLLLTVC 0.300 356 AVYSTGSNGI 0.300 426ILANANIDVV 0.300 817 TLYSGEDYPD 0.300 535 VSPKNPRIPK 0.300 69 WTKDGNPFYF0.300 840 TLVKVTWSTV 0.300 603 GIYCCSAHTA 0.300 V2-HLA-A3-10mers-(SET1)-282P1G3 Each peptide is a portion of SEQ ID NO: 5; each startposition is specified, the length of peptide is 10 amino acids, and theend position for each peptide is the start position plus nine. StartSubsequence Score 3 IVPSVPKFPK 9.000 6 SVPKFPKEKI 0.090 5 PSVPKFPKEK0.034 2 FIVPSVPKFP 0.003 9 KFPKEKIDPL 0.003 1 EFIVPSVPKF 0.003 4VPSVPKFPKE 0.001 10 FPKEKIDPLE 0.000 7 VPKFPKEKID 0.000 8 PKFPKEKIDP0.000 V2-HLA-A3-10mers-(SET 2)-282P1G3 Each peptide is a portion of SEQID NO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. Start Subsequence Score 4 TLGEGKYAGL 0.900 8 GKYAGLYDDI 0.0093 STLGEGKYAG 0.007 5 LGEGKYAGLY 0.005 1 ESSTLGEGKY 0.002 2 SSTLGEGKYA0.001 6 GEGKYAGLYD 0.000 7 EGKYAGLYDD 0.000 V2-HLA-A3-10mers-(SET3)-282P1G3 Each peptide is a portion of SEQ ID NO: 5; each startposition is specified, the length of peptide is 10 amino acids, and theend position for each peptide is the start position plus nine. StartSubsequence Score 5 TLGEGKYAGL 0.900 1 EESSTLGEGK 0.018 9 GKYAGLYDDI0.009 4 STLGEGKYAG 0.007 6 LGEGKYAGLY 0.005 2 ESSTLGEGKY 0.002 10KYAGLYDDIS 0.001 3 SSTLGEGKYA 0.001 7 GEGKYAGLYD 0.000 8 GEGKYAGLYD0.000 V3-HLA-A3-10mers-282P1G3 Each peptide is a portion of SEQ ID NO:7; each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. Start Subsequence Score 46 NMLAEDFIQK 180.000 61 YVEKSSTFFK 6.00052 FIQKSTSCNY 0.400 55 KSTSCNYVEK 0.300 47 MLAEDFIQKS 0.270 27PQPSIFICSK 0.270 10 NTTYVSNTTY 0.200 39 ELSYRNRNML 0.180 23 ATGSPQPSIF0.100 8 VINTTYVSNT 0.090 2 VIHGVDVINT 0.090 33 ICSKEQELSY 0.080 5GVDVINTTYV 0.060 11 TTYVSNTTYV 0.050 34 CSKEQELSYR 0.045 59 CNYVEKSSTF0.020 56 STSCNYVEKS 0.018 62 VEKSSTFFKI 0.016 25 GSPQPSIFIC 0.013 22NATGSPQPSI 0.013 30 SIFICSKEQE 0.010 17 TTYVSNATGS 0.010 40 LSYRNRNMLA0.010 4 HGVDVINTTY 0.009 14 VSNTTYVSNA 0.009 53 IQKSTSCNYV 0.006 26SPQPSIFICS 0.005 36 KEQELSYRNR 0.005 60 NYVEKSSTFF 0.005 32 FICSKEQELS0.004 43 RNRNMLAEDF 0.004 24 TGSPQPSIFI 0.003 19 YVSNATGSPQ 0.002 13YVSNTTYVSN 0.002 16 NTTYVSNATG 0.001 58 SCNYVEKSST 0.001 31 IFICSKEQEL0.001 7 DVINTTYVSN 0.001 48 LAEDFIQKST 0.001 44 NRNMLAEDFI 0.001 37EQELSYRNRN 0.001 1 PVIHGVDVIN 0.000 28 QPSIFICSKE 0.000 15 SNTTYVSNAT0.000 9 INTTYVSNTT 0.000 50 EDFIQKSTSC 0.000 3 IHGVDVINTT 0.000 45RNMLAEDFIQ 0.000 12 TYVSNTTYVS 0.000 6 VDVINTTYVS 0.000 57 TSCNYVEKSS0.000 49 AEDFIQKSTS 0.000 20 VSNATGSPQP 0.000 38 QELSYRNRNM 0.000 21SNATGSPQPS 0.000 35 SKEQELSYRN 0.000 54 QKSTSCNYVE 0.000 41 SYRNRNMLAE0.000 42 YRNRNMLAED 0.000 18 TYVSNATGSP 0.000 51 DFIQKSTSCN 0.000 29PSIFICSKEQ 0.000 V4-HLA-A3-10mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 9; each start position is specified, the length of peptide is10 amino acids, and the end position for each peptide is the startposition plus nine. Start Subsequence Score 9 DLPEQPTFLK 40.500 3TLYSGEDLPE 0.200 1 SVTLYSGEDL 0.060 7 GEDLPEQPTF 0.018 10 LPEQPTFLKV0.012 2 VTLYSGEDLP 0.002 8 EDLPEQPTFL 0.000 6 SGEDLPEQPT 0.000 5YSGEDLPEQP 0.000 4 LYSGEDLPEQ 0.000 V5-HLA-A3-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 11; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. Start Subsequence Score 4KLTVNSSNSI 1.800 5 LTVNSSNSIK 1.500 8 NSSNSIKQRK 0.150 10 SNSIKQRKPK0.020 7 VNSSNSIKQR 0.006 6 TVNSSNSIKQ 0.004 2 PMKLTVNSSN 0.003 1MPMKLTVNSS 0.002 3 MKLTVNSSNS 0.000 9 SSNSIKQRKP 0.000V6-HLA-A3-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. Start Subsequence Score 10 KLEHIEQDER 12.000 1 SEEIEFIVPK 0.270 4IEFIVPKLEH 0.009 2 EEIEFIVPKL 0.005 6 FIVPKLEHIE 0.005 7 IVPKLEHIEQ0.004 3 EIEFIVPKLE 0.000 5 EFIVPKLEHI 0.000 8 VPKLEHIEQD 0.000 9PKLEHIEQDE 0.000 V7-HLA-A3-10mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 15; each start position is specified, the length of peptideis 10 amino acids, and the end position for each peptide is the startposition plus nine. Start Subsequence Score 20 HPEPPRWTKK 0.300 19LHPEPPRWTK 0.135 7 IVEDNISHEL 0.090 11 NISHELFTLH 0.060 5 HVIVEDNISH0.060 15 ELFTLHPEPP 0.030 18 TLHPEPPRWT 0.022 17 FTLHPEPPRW 0.015 6VIVEDNISHE 0.007 16 LFTLHPEPPR 0.006 8 VEDNISHELF 0.006 10 DNISHELFTL0.002 12 ISHELFTLHP 0.001 2 HDFHVIVEDN 0.000 3 DFHVIVEDNI 0.000 14HELFTLHPEP 0.000 4 FHVIVEDNIS 0.000 9 EDNISHELFT 0.000 1 THDFHVIVED0.000 13 SHELFTLHPE 0.000 21 PEPPRWTKKP 0.000

TABLE XIV V1-HLA-A1101-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 3; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Start Subsequence Score 843 KVTWSTVPK 6.000 792 AVYAPYDVK4.000 149 IVLPCNPPK 3.000 948 ATLSWGLPK 3.000 1118 FVKRNRGGK 2.000 835DVINSTLVK 1.800 1112 LLLTVCFVK 1.800 906 LTVLAYNSK 1.500 739 SQPKEMIIK1.200 760 GLEYRVTWK 1.200 12 VYLMFLLLK 1.200 106 KYRCFASNK 1.200 31VQQVPTIIK 1.200 129 SVPKLPKEK 1.000 530 ATKLRVSPK 1.000 15 MFLLLKFSK0.900 188 LYFANVEEK 0.800 1199 GAYAGSKEK 0.600 436 DVRPLIQTK 0.600 340HVIVEEPPR 0.600 744 MIIKWEPLK 0.600 931 VPEQPTFLK 0.600 242 KANSIKQRK0.600 661 YIVEFEGNK 0.600 867 KTKSLLDGR 0.600 213 TIVQKMPMK 0.600 861YQINWWKTK 0.450 127 VPSVPKLPK 0.400 536 SPKNPRIPK 0.400 871 LLDGRTHPK0.400 937 FLKVIKVDK 0.400 547 MLELHCESK 0.400 524 NLDIRNATK 0.400 520AVTANLDIR 0.400 1002 TTKYKFYLR 0.400 949 TLSWGLPKK 0.400 1197 FIGAYAGSK0.400 1150 GEYSDSDEK 0.360 301 RETKENYGK 0.360 1029 GEGSKGIGK 0.360 859KGYQINWWK 0.240 689 ILPLAPFVR 0.240 34 VPTIIKQSK 0.200 52 YFQIECEAK0.200 934 QPTFLKVIK 0.200 1011 ACTSQGCGK 0.200 998 NLNATTKYK 0.200 284PTPQVDWNK 0.209 304 KENYGKTLK 0.180 787 RVMTPAVYA 0.120 983 DINITTPSK0.120 262 SESSITILK 0.120 478 EVKPLEGRR 0.120 392 FAGDVVFPR 0.120 343VEEPPRWTK 0.120 296 DLPKGRETK 0.120 882 NILRFSGQR 0.120 202 YCCFAAFPR0.120 677 ELTRVQGKK 0.120 98 GHISHFQGK 0.090 333 GTATHDFHV 0.090 212RTIVQKMPM 0.090 779 ETVTNHTLR 0.090 124 EFIVPSVPK 0.090 702 VIAVNEVGR0.080 74 NPFYFTDHR 0.080 11 IVYLMFLLL 0.080 877 HPKEVNILR 0.080 1113LLTVCFVKR 0.080 396 VVFPREISF 0.080 693 APFVRYQFR 0.080 317 SYQDKGNYR0.080 562 HSLKLSWSK 0.060 291 NKIGGDLPK 0.060 510 CWVENAIGK 0.060 680RVQGKKTTV 0.060 764 RVTWKPQGA 0.060 942 KVDKDTATL 0.060 721 ETPPAAPDR0.060 534 RVSPKNPRI 0.060 930 GVPEQPTFL 0.060 833 GVDVINSTL 0.060 313IENVSYQDK 0.060 452 VVGYSAFLH 0.060 579 GTEDGRIII 0.060 424 GTILANANI0.045 1115 TVCFVKRNR 0.040 780 TVTNHTLRV 0.040 214 IVQKMPMKL 0.040 849VPKDRVHGR 0.040 1074 IFQDVIETR 0.040 9 GLIVYLMFL 0.036 247 KQRKPKLLL0.036 734 IRVQASQPK 0.030 220 MKLTVNSLK 0.030 1124 GGKYSVKEK 0.030 685KTTVILPLA 0.030 687 TVILPLAPF 0.030 1001 ATTKYKFYL 0.030 875 RTHPKEVNI0.030 V2-HLA-A1101-9mers-(SET 1)-282P1G3 Each peptide is a portion ofSEQ ID NO: 5; each start position is specified, the length of peptide is9 amino acids, and the end position for each peptide is the startposition plus eight. Start Subsequence Score 5 SVPKFPKEK 1.000 3VPSVPKFPK 0.600 1 FIVPSVPKF 0.006 6 VPKFPKEKI 0.002 9 FPKEKIDPL 0.002 8KFPKEKIDP 0.001 2 IVPSVPKFP 0.001 4 PSVPKFPKE 0.000 7 PKFPKEKID 0.000V2-HLA-A1101-9mers-(SET 2)-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Start Subsequence Score 7 REAKENYGK 0.360 2 DLPKGREAK 0.1205 KGREAKENY 0.001 3 LPKGREAKE 0.000 9 AKENYGKTL 0.000 1 GDLPKGREA 0.0006 GREAKENYG 0.000 8 EAKENYGKT 0.000 4 PKGREAKEN 0.000V2-HLA-A1101-9mers-(SET 3)-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Start Subsequence Score 9 KYAGLYDDI 0.012 3 STLGEGKYA 0.0071 ESSTLGEGK 0.006 6 GEGKYAGLY 0.002 4 TLGEGKYAG 0.001 8 GKYAGLYDD 0.0005 LGEGKYAGL 0.000 2 SSTLGEGKY 0.000 7 EGKYAGLYD 0.000V3-HLA-A1101-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 55 STSCNYVEK 1.000 46 MLAEDFIQK 0.800 27QPSIFICSK 0.200 61 VEKSSTFFK 0.180 4 GVDVINTTY 0.060 60 YVEKSSTFF 0.02010 TTYVSNTTY 0.020 22 ATGSPQPSI 0.010 40 SYRNRNMLA 0.008 52 IQKSTSCNY0.006 59 NYVEKSSTF 0.006 11 TYVSNTTYV 0.006 12 YVSNTTYVS 0.004 31FICSKEQEL 0.004 34 SKEQELSYR 0.004 36 EQELSYRNR 0.004 44 RNMLAEDFI 0.00218 YVSNATGSP 0.002 16 TTYVSNATG 0.002 45 NMLAEDFIQ 0.002 6 DVINTTYVS0.002 24 GSPQPSIFI 0.001 9 NTTYVSNTT 0.001 15 NTTYVSNAT 0.001 25SPQPSIFIC 0.001 17 TYVSNATGS 0.001 33 CSKEQELSY 0.000 39 LSYRNRNML 0.00051 FIQKSTSCN 0.000 14 SNTTYVSNA 0.000 7 VINTTYVSN 0.000 1 VIHGVDVIN0.000 29 SIFICSKEQ 0.000 35 KEQELSYRN 0.000 30 IFICSKEQE 0.000 5VDVINTTYV 0.000 47 LAEDFIQKS 0.000 43 NRNMLAEDF 0.000 32 ICSKEQELS 0.00023 TGSPQPSIF 0.000 53 QKSTSCNYV 0.000 21 NATGSPQPS 0.000 62 EKSSTFFKI0.000 26 PQPSIFICS 0.000 42 RNRNMLAED 0.000 54 KSTSCNYVE 0.000 38ELSYRNRNM 0.000 57 SCNYVEKSS 0.000 37 QELSYRNRN 0.000 50 DFIQKSTSC 0.00058 CNYVEKSST 0.000 20 SNATGSPQP 0.000 2 IHGVDVINT 0.000 8 INTTYVSNT0.000 41 YRNRNMLAE 0.000 3 HGVDVINTT 0.000 48 AEDFIQKST 0.000 13VSNTTYVSN 0.000 19 VSNATGSPQ 0.000 56 TSCNYVEKS 0.000 49 EDFIQKSTS 0.00028 PSIFICSKE 0.000 V4-HLA-A1101-9mers-282P1G3 Each peptide is a portionof SEQ ID NO: 9; each start position is specified, the length of peptideis 9 amino acids, and the end position for each peptide is the startposition plus eight. Start Subsequence Score 9 LPEQPTFLK 0.600 1VTLYSGEDL 0.015 8 DLPEQPTFL 0.001 3 LYSGEDLPE 0.001 2 TLYSGEDLP 0.001 6GEDLPEQPT 0.000 7 EDLPEQPTF 0.000 4 YSGEDLPEQ 0.000 5 SGEDLPEQP 0.000V5-HLA-A1101-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 5 TVNSSNSIK 2.000 8 SSNSIKQRK 0.020 4LTVNSSNSI 0.015 7 NSSNSIKQR 0.002 3 KLTVNSSNS 0.001 6 VNSSNSIKQ 0.000 1PMKLTVNSS 0.000 2 MKLTVNSSN 0.000 9 SNSIKQRKP 0.000V6-HLA-A1101-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 1 EEIEFIVPK 0.027 5 FIVPKLEHI 0.006 6IVPKLEHIE 0.002 4 EFIVPKLEH 0.002 9 KLEHIEQDE 0.001 2 EIEFIVPKL 0.001 7VPKLEHIEQ 0.000 3 IEFIVPKLE 0.000 8 PKLEHIEQD 0.000V7-HLA-A1101-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 19 HPEPPRWTK 0.400 16 FTLHPEPPR 0.300 5VIVEDNISH 0.012 10 NISHELFTL 0.012 20 PEPPRWTKK 0.006 17 TLHPEPPRW 0.0044 HVIVEDNIS 0.003 6 IVEDNISHE 0.002 7 VEDNISHEL 0.001 3 FHVIVEDNI 0.00014 ELFTLHPEP 0.000 11 ISHELFTLH 0.000 15 LFTLHPEPP 0.000 13 HELFTLHPE0.000 2 DFHVIVEDN 0.000 8 EDNISHELF 0.000 1 HDFHVIVED 0.000 12 SHELFTLHP0.000 9 DNISHELFT 0.000 18 LHPEPPRWL 0.000

TABLE XV V1-HLA-A1101-10mers-282P1G3 Each peptide is a portion of SEQ IDNO: 3; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. Start Subsequence Score 930 GVPEQPTFLK 18.000 11 IVYLMFLLLK8.000 212 RTIVQKMPMK 4.500 342 IVEEPPRWTK 4.000 126 IVPSVPKLPK 4.000 30SVQQVPTIIK 4.000 14 LMFLLLKFSK 2.400 33 QVPTIIKQSK 2.000 1111 LLLLTVCFVK1.800 701 RVIAVNEVGR 1.800 948 ATLSWGLPKK 1.500 1037 KISGVNLTQK 1.200312 KIENVSYQDK 1.200 509 SCWVENAIGK 0.800 1010 RACTSQGCGK 0.600 870SLLDGRTHPK 0.600 860 GYQINWWKTK 0.600 546 HMLELHCESK 0.600 1001ATTKYKFYLR 0.400 995 HLSNLNATTK 0.400 733 NIRVQASQPK 0.400 848TVPKDRVHGR 0.400 947 TATLSWGLPK 0.400 283 LPTPQVDWNK 0.400 466SPEAVVSWQK 0.400 905 HLTVLAYNSK 0.400 62 NPEPTFSWTK 0.400 688 VILPLAPFVR0.360 1196 SFIGAYAGSK 0.300 936 TFLKVIKVDK 0.300 1117 CFVKRNRGGK 0.30051 EYFQIECEAK 0.240 532 KLRVSPKNPR 0.240 187 DLYFANVEEK 0.240 1136HPDPEIQSVK 0.200 208 FPRLRTIVQK 0.200 529 NATKLRVSPK 0.200 844VTWSTVPKDR 0.200 933 EQPTFLKVIK 0.180 660 EYIVEFEGNK 0.180 743EMIIKWEPLK 0.180 1073 SIFQDVIETR 0.160 1121 RNRGGKYSVK 0.120 105GKYRCFASNK 0.120 561 KHSLKLSWSK 0.120 300 GRETKENYGK 0.120 261GSESSITILK 0.120 123 IEFIVPSVPK 0.120 292 KIGGDLPKGR 0.120 238EIGSKANSIK 0.120 1112 LLLTVCFVKR 0.120 1057 AEHIVRLMTK 0.120 179RVYMSQKGDL 0.120 295 GDLPKGRETK 0.090 451 TVVGYSAFLH 0.090 939KVIKVDKDTA 0.090 290 WNKIGGDLPK 0.080 633 NLHLSERQNR 0.080 201DYCCFAAFPR 0.072 523 ANLDIRNATK 0.060 834 VDVINSTLVK 0.060 148PIVLPCNPPK 0.060 519 TAVTANLDIR 0.060 680 RVQGKKTTVI 0.060 552CESKCDSHLK 0.060 370 AEGEPQPTIK 0.060 381 RVNGSPVDNH 0.060 833GVDVINSTLV 0.060 518 KTAVTANLDI 0.060 343 VEEPPRWTKK 0.060 90 GTFRIPNEGH0.060 675 WEELTRVQGK 0.060 9 GLIVYLMFLL 0.054 309 KTLKIENVSY 0.045 692LAPFVRYQFR 0.040 99 HISHFQGKYR 0.040 535 VSPKNPRIPK 0.040 858 LKGYQINWWK0.040 738 ASQPKEMIIK 0.040 471 VSWQKVEEVK 0.040 356 AVYSTGSNGI 0.040 429NANIDVVDVR 0.040 219 PMKLTVNSLK 0.040 84 IPSNNSGTFR 0.040 792 AVYAPYDVKV0.040 1028 LGEGSKGIGK 0.040 190 FANVEEKDSR 0.040 726 APDRNPQNIR 0.040413 AVYQCEASNV 0.040 639 RQNRSVRLTW 0.036 755 EQNGPGLEYR 0.036 842VKVTWSTVPK 0.030 435 VDVRPLIQTK 0.030 982 NDINITTPSK 0.030 791PAVYAPYDVK 0.030 997 SNLNATTKYK 0.030 1123 RGGKYSVKEK 0.030 340HVIVEEPPRW 0.030 735 RVQASQPKEM 0.030 499 RTTEEDAGSY 0.030V2-HLA-A1101-10mers-(SET 1)-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. Start Subsequence Score 3 IVPSVPKFPK 6.000 6 SVPKFPKEKI 0.0209 KFPKEKIDPL 0.006 5 PSVPKFPKEK 0.002 1 EFIVPSVPKF 0.001 2 FIVPSVPKFP0.000 10 FPKEKIDPLE 0.000 4 VPSVPKFPKE 0.000 7 VPKFPKEKID 0.000 8PKFPKEKIDP 0.000 V2-HLA-A1101-10mers-(SET 2)-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. Start Subsequence Score 4 TLGEGKYAGL 0.004 3STLGEGKYAG 0.003 8 GKYAGLYDDI 0.001 6 GEGKYAGLYD 0.000 5 LGEGKYAGLY0.000 2 SSTLGEGKYA 0.000 1 ESSTLGEGKY 0.000 7 EGKYAGLYDD 0.000V2-HLA-A1101-10mers-(SET 3)-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. Start Subsequence Score 1 EESSTLGEGK 0.018 5 TLGEGKYAGL 0.0044 STLGEGKYAG 0.003 9 GKYAGLYDDI 0.001 10 KYAGLYDDIS 0.001 7 GEGKYAGLYD0.000 6 LGEGKYAGLY 0.000 3 SSTLGEGKYA 0.000 2 ESSTLGEGKY 0.000 8EGKYAGLYDD 0.000 V3-HLA-A1101-10mers-282P1G3 Each peptide is a portionof SEQ ID NO: 7; each start position is specified, the length of peptideis 10 amino acids, and the end position for each peptide is the startposition plus nine. Start Subsequence Score 61 YVEKSSTFFK 6.000 46NMLAEDFIQK 1.200 55 KSTSCNYVEK 0.060 27 PQPSIFICSK 0.060 5 GVDVINTTYV0.060 11 TTYVSNTTYV 0.020 10 NTTYVSNTTY 0.010 23 ATGSPQPSIF 0.010 60NYVEKSSTFF 0.006 53 IQKSTSCNYV 0.006 33 ICSKEQELSY 0.004 34 CSKEQELSYR0.004 52 FIQKSTSCNY 0.004 36 KEQELSYRNR 0.004 31 IFICSKEQEL 0.003 22NATGSPQPSI 0.002 17 TTYVSNATGS 0.002 19 YVSNATGSPQ 0.002 13 YVSNTTYVSN0.002 62 VEKSSTFFKI 0.002 12 TYVSNTTYVS 0.001 43 RNRNMLAEDF 0.001 39ELSYRNRNML 0.001 56 STSCNYVEKS 0.001 16 NTTYVSNATG 0.001 7 DVINTTYVSN0.001 30 SIFICSKEQE 0.001 41 SYRNRNMLAE 0.001 2 VIHGVDVINT 0.001 59CNYVEKSSTF 0.001 40 LSYRNRNMLA 0.001 45 RNMLAEDFIQ 0.001 18 TYVSNATGSP0.001 47 MLAEDFIQKS 0.000 24 TGSPQPSIFI 0.000 8 VINTTYVSNT 0.000 32FICSKEQELS 0.000 26 SPQPSIFICS 0.000 4 HGVDVINTTY 0.000 1 PVIHGVDVIN0.000 44 NRNMLAEDFI 0.000 28 QPSIFICSKE 0.000 58 SCNYVEKSST 0.000 14VSNTTYVSNA 0.000 25 GSPQPSIFIC 0.000 37 EQELSYRNRN 0.000 48 LAEDFIQKST0.000 51 DFIQKSTSCN 0.000 38 QELSYRNRNM 0.000 6 VDVINTTYVS 0.000 49AEDFIQKSTS 0.000 54 QKSTSCNYVE 0.000 9 INTTYVSNTT 0.000 21 SNATGSPQPS0.000 35 SKEQELSYRN 0.000 15 SNTTYVSNAT 0.000 20 VSNATGSPQP 0.000 3IHGVDVINTT 0.000 42 YRNRNMLAED 0.000 50 EDFIQKSTSC 0.000 57 TSCNYVEKSS0.000 29 PSIFICSKEQ 0.000 V4-HLA-A1101-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 9; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. Start Subsequence Score 9 DLPEQPTFLK 0.360 1SVTLYSGEDL 0.020 10 LPEQPTFLKV 0.004 7 GEDLPEQPTF 0.002 3 TLYSGEDLPE0.002 2 VTLYSGEDLP 0.002 4 LYSGEDLPEQ 0.000 8 EDLPEQPTFL 0.000 6SGEDLPEQPT 0.000 5 YSGEDLPEQP 0.000 V5-HLA-A1101-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 11; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. Start Subsequence Score 5LTVNSSNSIK 1.500 8 NSSNSIKQRK 0.020 10 SNSIKQRKPK 0.020 4 KLTVNSSNSI0.012 6 TVNSSNSIKQ 0.004 7 VNSSNSIKQR 0.004 1 MPMKLTVNSS 0.000 2PMKLTVNSSN 0.000 3 MKLTVNSSNS 0.000 9 SSNSIKQRKP 0.000V6-HLA-A1101-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. Start Subsequence Score 10 KLEHIEQDER 0.240 1 SEEIEFIVPK 0.060 7IVPKLEHIEQ 0.004 4 IEFIVPKLEH 0.002 5 EFIVPKLEHI 0.001 6 FIVPKLEHIE0.001 2 EEIEFIVPKL 0.000 8 VPKLEHIEQD 0.000 3 EIEFIVPKLE 0.000 9PKLEHIEQDE 0.000 V7-HLA-A1101-10mers-282P1G3 Each peptide is a portionof SEQ ID NO: 15; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. Start Subsequence Score 20 HPEPPRWTKK 0.200 5HVIVEDNISH 0.060 16 LFTLHPEPPR 0.040 19 LHPEPPRWTK 0.040 7 IVEDNISHEL0.020 17 FTLHPEPPRW 0.015 11 NISHELFTLH 0.004 6 VIVEDNISHE 0.001 8VEDNISHELF 0.001 3 DFHVIVEDNI 0.001 10 DNISHELFTL 0.001 15 ELFTLHPEPP0.000 14 HELFTLHPEP 0.000 18 TLHPEPPRWT 0.000 12 ISHELFTLHP 0.000 2HDFHVIVEDN 0.000 4 FHVIVEDNIS 0.000 13 SHELFTLHPE 0.000 1 THDFHVIVED0.000 9 EDNISHELFT 0.000 21 PEPPRWTKKP 0.000

TABLE XVI V1-HLA-A24-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 3; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Start Subsequence Score 180 VYMSQKGDL 300.000 1182 EYGEGDHGL240.000 323 NYRCTASNF 100.000 823 DYPDTAPVI 90.000 964 GYLLQYQII 90.000489 IYENGTLQI 75.000 1085 EYAGLYDDI 60.000 357 VYSTGSNGI 60.000 76FYFTDHRII 50.000 102 HFQGKYRCF 15.000 697 RYQFRVIAV 15.000 584 RIIIDGANL12.000 486 RYHIYENGT 12.000 968 QYQIINDTY 10.500 1004 KYKFYLRAC 10.0001052 VFEPGAEHI 9.000 1098 WFIGLMCAI 9.000 660 EYIVEFEGN 9.000 8RGLIVYLMF 8.400 289 DWNKIGGDL 8.400 860 GYQINWWKT 8.250 991 KPSWHLSNL8.000 942 KVDKDTATL 8.000 247 KQRKPKLLL 8.000 890 RNSGMVPSL 8.000 125FIVPSVPKL 7.920 51 EYFQIECEA 7.700 414 VYQCEASNV 7.500 10 LIVYLMFLL7.200 2 EPLLLGRGL 7.200 1094 STQGWFIGL 7.200 1104 CAIALLTLL 7.200 626DVPDPPENL 7.200 930 GVPEQPTFL 7.200 448 NYATVVGYS 7.000 793 VYAPYDVKV6.600 214 IVQKMPMKL 6.600 1100 IGLMCAIAL 6.000 451 TVVGYSAFL 6.000 1101GLMCAIALL 6.000 1190 LFSEDGSFI 6.000 9 GLIVYLMEL 6.000 154 NPPKGLPPL6.000 796 PYDVKVQAI 6.000 419 ASNVHGTIL 6.000 959 NGNLTGYLL 6.000 275LLECFAEGL 6.000 261 GSESSITIL 6.000 267 TILKGEILL 6.000 753 SMEQNGPGL6.000 901 FSEFHLTVL 6.000 743 EMIIKWEPL 6.000 266 ITILKGEIL 6.000 1127YSVKEKEDL 6.000 1106 IALLTLLLL 6.000 833 GVDVINSTL 5.600 39 KQSKVQVAF5.600 950 LSWGLPKKL 5.280 507 SYSCWVENA 5.000 109 CFASNKLGI 5.000 604IYCCSAHTA 5.000 1172 QPTESADSL 4.800 946 DTATLSWGL 4.800 958 LNGNLTGYL4.800 133 LPKEKIDPL 4.800 11 IVYLMFLLL 4.800 203 CCFAAFPRL 4.800 6LGRGLIVYL 4.800 810 GPDPQSVTL 4.800 1105 AIALLTLLL 4.800 954 LPKKLNGNL4.800 245 SIKQRKPKL 4.400 163 HIYWMNIEL 4.400 542 IPKLHMLEL 4.400 692LAPFVRYQF 4.200 359 STGSNGILL 4.000 358 YSTGSNGIL 4.000 1103 MCAIALLTL4.000 1152 YSDSDEKPL 4.900 1001 ATTKYKFYL 4.000 864 NWWKTKSLL 4.000 151LPCNPPKGL 4.000 1035 IGKISGVNL 4.000 591 NLTISNVTL 4.000 682 QGKKTTVIL4.000 1214 GSSTATFPL 4.000 863 INWWKTKSL 4.000 268 ILKGEILLL 4.000 605YCCSAHTAL 4.000 988 TPSKPSWHL 4.000 13 YLMFLLLKF 3.960 893 GMVPSLDAF3.600 1110 TLLLLTVCF 3.600 929 EGVPEQPTF 3.600 117 IAMSEEIEF 3.300 384GSPVDNHPF 3.000 1183 YGEGDHGLF 3.000 450 ATVVGYSAF 3.000 687 TVILPLAPF3.000 917 GPESEPYIF 3.000 V2-HLA-A24-9mers-(SET 1)-282P1G3 Each peptideis a portion of SEQ ID NO: 5; each start position is specified, thelength of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. Start Subsequence Score 9FPKEKIDPL 4.800 1 FIVPSVPKF 3.960 6 VPKFPKEKI 1.100 8 KFPKEKIPD 0.150 2IVPSVPKFP 0.021 5 SVPKFPKEK 0.017 3 VPSVPKFPK 0.010 4 PSVPKFPKE 0.002 7PKFPKEKID 0.000 V2-HLA-A24-9mers-(SET 2)-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. Start Subsequence Score 9 AKENYGKTL 0.600 5KGREAKENY 0.240 8 EAKENYGKT 0.132 1 GDLPKGREA 0.020 2 DLPKGREAK 0.015 3LPKGREAKE 0.011 7 REAKENYGK 0.002 6 GREAKENYG 0.002 4 PKGREAKEN 0.001V2-HLA-A24-9mers-(SET 3)-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 9 KYAGLYDDI 120.000 5 LGEGKYAGL 6.000 3STLGEGKYA 0.150 2 SSTLGEGKY 0.110 1 ESSTLGEGK 0.012 4 TLGEGKYAG 0.012 6GEGKYAGLY 0.010 7 EGKYAGLYD 0.010 8 GKYAGLYDD 0.001V3-HLA-A24-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight.Start Subsequence Score 59 NYVEKSSTF 180.000 17 TYVSNATGS 7.500 11TYVSNTTYV 7.500 31 FICSKEQEL 5.280 40 SYRNRNMLA 5.000 39 LSYRNRNML 4.80060 YVEKSSTFF 3.000 44 RNMLAEDFI 3.000 23 TGSPQPSIF 2.400 24 GSPQPSIFI1.500 22 ATGSPQPSI 1.000 50 DFIQKSTSC 0.750 38 ELSYRNRNM 0.500 43NRNMLAEDF 0.360 3 HGVDVINTT 0.302 47 LAEDFIQKS 0.238 57 SCNYVEKSS 0.21025 SPQPSIFIC 0.180 15 NTTYVSNAT 0.168 9 NTTYVSNTT 0.168 51 FIQKSTSCN0.150 13 VSNTTYVSN 0.150 6 DVINTTYVS 0.150 7 VINTTYVSN 0.150 1 VIHGVDVIN0.140 4 GVDVINTTY 0.140 62 EKSSTFFKI 0.132 33 CSKEQELSY 0.120 21NATGSPQPS 0.120 56 TSCNYVEKS 0.110 10 TTYVSNTTY 0.100 14 SNTTYVSNA 0.10032 ICSKEQELS 0.100 8 INTTYVSNT 0.100 12 YVSNTTYVS 0.100 52 IQKSTSCNY0.100 58 CNYVEKSST 0.100 30 IFICSKEQE 0.075 35 KEQELSYRN 0.043 26PQPSIFICS 0.025 42 RNRNMLAED 0.022 54 KSTSCNYVE 0.020 37 QELSYRNRN 0.01819 VSNATGSPQ 0.015 36 EQELSYRNR 0.015 45 NMLAEDFIQ 0.015 5 VDVINTTYV0.015 46 MLAEDFIQK 0.014 48 AEDFIQKST 0.014 53 QKSTSCNYV 0.012 55STSCNYVEK 0.011 29 SIFICSKEQ 0.011 2 IHGVDVINT 0.010 16 TTYVSNATG 0.01020 SNATGSPQP 0.010 27 QPSIFICSK 0.010 18 YVSNATGSP 0.010 49 EDFIQKSTS0.010 28 PSIFICSKE 0.002 34 SKEQELSYR 0.002 41 YRNRNMLAE 0.002 61VEKSSTFFK 0.001 V4-HLA-A24-9mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 9; each start position is specified, the length of peptide is9 amino acids, and the end position for each peptide is the startposition plus eight. Start Subsequence Score 8 DLPEQPTFL 7.200 1VTLYSGEDL 6.000 3 LYSGEDLPE 0.500 7 EDLPEQPTF 0.360 5 SGEDLPEQP 0.022 9LPEQPTFLK 0.015 4 YSGEDLPEQ 0.013 6 GEDLPEQPT 0.012 2 TLYSGEDLP 0.010V5-HLA-A24-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 4 LTVNSSNSI 1.800 3 KLTVNSSNS 0.200 8SSNSIKQRK 0.025 2 MKLTVNSSN 0.021 5 TVNSSNSIK 0.015 1 PMKLTVNSS 0.012 6VNSSNSIKQ 0.011 9 SNSIKQRKP 0.011 7 NSSNSIKQR 0.010V6-HLA-A24-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 2 EIEFIVPKL 9.240 5 FIVPKLEHI 1.800 4EFIVPKLEH 0.083 9 KLEHIEQDE 0.050 6 IVPKLEHIE 0.018 7 VPKLEHIEQ 0.011 1EEIEFIVPK 0.002 3 IEFIVPKLE 0.001 8 PKLEHIEQD 0.000V7-HLA-A24-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Start Subsequence Score 10 NISHELFTL 4.000 2 DFHVIVEDN 0.700 7VEDNISHEL 0.616 8 EDNISHELF 0.300 3 FHVIVEDNI 0.210 4 HVIVEDNIS 0.180 9DNISHELFT 0.150 17 TLHPEPPRW 0.120 15 LFTLHPEPP 0.050 18 LHPEPPRWT 0.0186 IVEDNISHE 0.018 5 VIVEDNISH 0.018 19 HPEPPRWTK 0.018 11 ISHELFTLH0.017 16 FTLHPEPPR 0.015 14 ELFTLHPEP 0.013 7 HDFHVIVED 0.002 13HELFTLHPE 0.002 12 SHELFTLHP 0.002 20 PEPPRWTKK 0.000

TABLE XVII Start Subsequence Score V1-HLA-A24-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 3; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 106 KYRCFASNKL 528.000 1126KYSVKEKEDL 400.000 486 RYHIYENGTL 400.000 323 NYRCTASNFL 240.000 1151EYSDSDEKPL 240.000 357 VYSTGSNGIL 200.000 604 IYCCSAHTAL 200.000 12VYLMFLLLKF 198.000 454 GYSAFLHCEF 132.000 1182 EYGEGDHGLF 120.000 975TYEIGELNDI 90.000 507 SYSCWVENAI 84.000 124 EFIVPSVPKL 33.000 900AFSEFHLTVL 24.000 697 RYQFRVIAVN 21.000 330 NFLGTATHDF 15.000 752KSMEQNGPGL 14.400 957 KLNGNLTGYL 14.400 541 RIPKLHMLEL 13.200 1019KPITEESSTL 12.000 1158 KPLKGSLRSL 12.000 132 KLPKEKIDPL 12.000 8RGLIVYLMFL 12.000 1004 KYKFYLRACT 12.000 875 RTHPKEVNIL 11.520 832HGVDVINSTL 10.080 555 KCDSHLKHSL 9.600 489 IYENGTLQIN 9.000 317SYQDKGNYRC 9.000 179 RVYMSQKGDL 8.000 180 VYMSQKGDLY 7.500 964GYLLQYQIIN 7.500 46 AFPFDEYFQI 7.500 1089 LYDDISTQGW 7.200 153CNPPKGLPPL 7.200 9 GLIVYLMFLL 7.200 929 EGVPEQPTFL 7.200 218 MPMKLTVNSL7.200 953 GLPKKLNGNL 7.200 274 LLLECFAEGL 7.200 142 EVEEGDPIVL 7.200 10LIVYLMFLLL 7.200 809 SGPDPQSVTL 7.200 270 KGEILLLECF 7.200 1104CAIALLTLLL 7.200 448 NYATVVGYSA 7.000 849 VPKDRVHGRL 6.720 213TIVQKMPMKL 6.600 306 NYGKTLKIEN 6.600 244 NSIKQRKPKL 6.600 1100IGLMCAIALL 6.000 551 HCESKCDSHL 6.000 590 ANLTISNVTL 6.000 266ITILKGEILL 6.000 267 TILKGEILLL 6.000 150 VLPCNPPKGL 6.000 987TTPSKPSWHL 6.000 862 QINWWKTKSL 6.000 1171 MQPTESADSL 6.000 450ATVVGYSAFL 6.000 398 FPREISFTNL 5.760 516 IGKTAVTANL 5.600 949TLSWGLPKKL 5.280 1200 AYAGSKEKGS 5.000 818 LYSGEDYPDT 5.000 885RFSGQRNSGM 5.000 91 TFRIPNEGHI 5.000 1085 EYAGLYDDIS 5.000 260SGSESSITIL 4.800 798 DVKVQAINQL 4.800 627 VPDPPENLHL 4.800 1093ISTQGWFIGL 4.800 302 ETKENYGKTL 4.800 202 YCCFAAFPRL 4.800 5 LLGRGLIVYL4.800 1103 MCAIALLTLL 4.800 199 RNDYCCFAAF 4.800 536 SPKNPRIPKL 4.400557 DSHLKHSLKL 4.400 972 INDTYEIGEL 4.400 524 NLDIRNATKL 4.400 681VQGKKTTVIL 4.000 245 SIKQRKPKLL 4.000 539 NPRIPKLHML 4.000 1034GIGKISGVNL 4.000 1105 AIALLTLLLL 4.000 431 NIDVVDVRPL 4.000 863INWWKTKSLL 4.000 1099 FIGLMCAIAL 4.000 1102 LMCAIALLTL 4.000 1213NGSSTATFPL 4.000 1054 EPGAEHIVRL 4.000 958 LNGNLTGYLL 4.000 897SLDAFSEFHL 4.000 1066 KNWGDNDSIF 4.000 418 EASNVHGTIL 4.000 1000NATTKYKFYL 4.000 358 YSTGSNGILL 4.000 1080 ETRGREYAGL 4.000 616AADITQVTVL 4.000 V2-HLA-A24-10mers-(SET 1)-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 9 KFPKEKIDPL 60.000 1 EFIVPSVPKF 16.500 6SVPKFPKEKI 1.650 2 FIVPSVPKFP 0.025 10 FPKEKIDPLE 0.017 3 IVPSVPKFPK0.015 4 VPSVPKFPKE 0.013 7 VPKFPKEKID 0.010 5 PSVPKFPKEK 0.002 8PKFPKEKIDP 0.000 V2-HLA-A24-10mers-(SET 2)-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 4 TLGEGKYAGL 4.800 5 LGEGKYAGLY 0.150 8GKYAGLYDDI 0.120 1 ESSTLGEGKY 0.110 2 SSTLGEGKYA 0.100 3 STLGEGKYAG0.015 7 EGKYAGLYDD 0.010 6 GEGKYAGLYD 0.001 V2-HLA-A24-10mers-(SET3)-282P1G3 Each peptide is a portion of SEQ ID NO: 5; each startposition is specified, the length of peptide is 10 amino acids, and theend position for each peptide is the start position plus nine. 10KYAGLYDDIS 10.000 5 TLGEGKYAGL 4.800 6 LGEGKYAGLY 0.150 9 GKYAGLYDDI0.120 2 ESSTLGEGKY 0.110 3 SSTLGEGKYA 0.100 4 STLGEGKYAG 0.015 8EGKYAGLYDD 0.010 1 EESSTLGEGK 0.001 7 GEGKYAGLYD 0.001V3-HLA-A24-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 60 NYVEKSSTFF 180.000 31 IFICSKEQEL 39.600 12 TYVSNTTYVS 7.500 43RNRNMLAEDF 4.800 39 ELSYRNRNML 4.800 23 ATGSPQPSIF 2.000 59 CNYVEKSSTF2.000 24 TGSPQPSIFI 1.200 22 NATGSPQPSI 1.000 51 DFIQKSTSCN 0.750 18TYVSNATGSP 0.750 41 SYRNRNMLAE 0.500 26 SPQPSIFICS 0.302 4 HGVDVINTTY0.252 48 LAEDFIQKST 0.252 37 EQELSYRNRN 0.180 15 SNTTYVSNAT 0.168 9INTTYVSNTT 0.168 47 MLAEDFIQKS 0.158 25 GSPQPSIFIC 0.150 8 VINTTYVSNT0.150 14 VSNTTYVSNA 0.150 7 DVINTTYVSN 0.150 44 NRNMLAEDFI 0.150 52FIQKSTSCNY 0.150 58 SCNYVEKSST 0.150 57 TSCNYVEKSS 0.140 62 VEKSSTFFKI0.132 53 IQKSTSCNYV 0.120 21 SNATGSPQPS 0.120 56 STSCNYVEKS 0.110 17TTYVSNATGS 0.100 10 NTTYVSNTTY 0.100 2 VIHGVDVINT 0.100 5 GVDVINTTYV0.100 11 TTYVSNTTYV 0.100 32 FICSKEQELS 0.100 33 ICSKEQELSY 0.100 13YVSNTTYVSN 0.100 40 LSYRNRNMLA 0.100 38 QELSYRNRNM 0.075 45 RNMLAEDFIQ0.030 55 KSTSCNYVEK 0.022 1 PVIHGVDVIN 0.021 35 SKEQELSYRN 0.018 46NMLAEDFIQK 0.018 3 IHGVDVINTT 0.017 28 QPSIFICSKE 0.015 20 VSNATGSPQP0.015 6 VDVINTTYVS 0.015 61 YVEKSSTFFK 0.015 34 CSKEQELSYR 0.012 50EDFIQKSTSC 0.010 49 AEDFIQKSTS 0.010 16 NTTYVSNATG 0.010 19 YVSNATGSPQ0.010 30 SIFICSKEQE 0.010 36 KEQELSYRNR 0.004 29 PSIFICSKEQ 0.002 42YRNRNMLAED 0.002 27 PQPSIFICSK 0.002 54 QKSTSCNYVE 0.001V4-HLA-A24-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 9;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 1 SVTLYSGEDL 4.000 8 EDLPEQPTFL 0.720 4 LYSGEDLPEQ 0.550 6SGEDLPEQPT 0.216 7 GEDLPEQPTF 0.200 10 LPEQPTFLKV 0.198 9 DLPEQPTFLK0.018 2 VTLYSGEDLP 0.015 5 YSGEDLPEQP 0.014 3 TLYSGEDLPE 0.010V5-HLA-A24-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 4 KLTVNSSNSI 2.400 1 MPMKLTVNSS 0.180 8 NSSNSIKQRK 0.017 6TVNSSNSIKQ 0.017 9 SSNSIKQRKP 0.017 3 MKLTVNSSNS 0.015 5 LTVNSSNSIK0.015 2 PMKLTVNSSN 0.014 7 VNSSNSIKQR 0.010 10 SNSIKQRKPK 0.010V6-HLA-A24-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 5 EFIVPKLEHI 7.500 2 EEIEFIVPKL 1.109 10 KLEHIEQDER 0.033 6FIVPKLEHIE 0.022 3 EIEFIVPKLE 0.021 7 IVPKLEHIEQ 0.017 8 VPKLEHIEQD0.010 1 SEEIEFIVPK 0.002 4 IEFIVPKLEH 0.001 9 PKLEHIEQDE 0.000V7-HLA-A24-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 7 IVEDNISHEL 11.088 3 DFHVIVEDNI 7.000 10 DNISHELFTL 6.000 8VEDNISHELF 0.200 17 FTLHPEPPRW 0.150 18 TLHPEPPRWT 0.120 16 LFTLHPEPPR0.050 20 HPEPPRWTKK 0.020 4 FHVIVEDNIS 0.018 6 VIVEDNISHE 0.018 5HVIVEDNISH 0.015 9 EDNISHELFT 0.015 11 NISHELFTLH 0.014 2 HDFHVIVEDN0.014 12 ISHELFTLHP 0.012 15 ELFTLHPEPP 0.010 14 HELFTLHPEP 0.002 19LHPEPPRWTK 0.002 1 THDFHVIVED 0.002 13 SHELFTLHPE 0.002 21 PEPPRWTKKP0.000

TABLE XVIII Start Subsequence Score V1-HLA-B7-9mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 539 NPRIPKLHM 300.000 151LPCNPPKGL 120.000 988 TPSKPSWHL 120.000 2 EPLLLGRGL 80.000 133 LPKEKIDPL80.000 991 KPSWHLSNL 80.000 1172 QPTESADSL 80.000 542 IPKLHMLEL 80.000954 LPKKLNGNL 80.000 154 NPPKGLPPL 80.000 247 KQRKPKLLL 60.000 6LGRGLIVYL 40.000 626 DVPDPPENL 30.000 810 GPDPQSVTL 24.000 695 FVRYQFRVI20.000 11 IVYLMFLLL 20.000 214 IVQKMPMKL 20.000 930 GVPEQPTFL 20.000 451TVVGYSAFL 20.000 159 LPPLHIYWM 20.000 1106 IALLTLLLL 12.000 1101GLMCAIALL 12.000 1001 ATTKYKFYL 12.000 130 VPKLPKEKI 12.000 828APVIHGVDV 12.000 1105 AIALLTLLL 12.000 1104 CAIALLTLL 12.000 419ASNVHGTIL 12.000 1163 SLRSLNRDM 10.000 210 RLRTIVQKM 10.000 285TPQVDWNKI 8.000 47 FPFDEYFQI 8.000 726 APDRNPQNI 7.200 833 GVDVINSTL6.000 772 APVEWEEET 6.000 942 KVDKDTATL 6.000 795 APYDVKVQA 6.000 1100IGLMCAIAL 4.000 398 FPREISFTN 4.000 863 INWWKTKSL 4.000 267 TILKGEILL4.000 9 GLIVYLMFL 4.000 946 DTATLSWGL 4.000 591 NLTISNVTL 4.000 10LIVYLMFLL 4.000 268 ILKGEILLL 4.000 1127 YSVKEKEDL 4.000 950 LSWGLPKKL4.000 266 ITILKGEIL 4.000 1214 GSSTATFPL 4.000 203 CCFAAFPRL 4.000 1103MCAIALLTL 4.000 959 NGNLTGYLL 4.000 358 YSTGSNGIL 4.000 605 YCCSAHTAL4.000 743 EMIIKWEPL 4.000 584 RIIIDGANL 4.000 125 FIVPSVPKL 4.000 163HIYWMNIEL 4.000 890 RNSGMVPSL 4.000 1094 STQGWFIGL 4.000 359 STGSNGILL4.000 1035 IGKISGVNL 4.000 682 QGKKTTVIL 4.000 245 SIKQRKPKL 4.000 958LNGNLTGYL 4.000 855 HGRLKGYQI 4.000 206 AAFPRLRTI 3.600 730 NPQNIRVQA3.000 111 ASNKLGIAM 3.000 433 DVVDVRPLI 3.000 787 RVMTPAVYA 2.250 250KPKLLLPPT 2.000 758 GPGLEYRVT 2.000 352 KPQSAVYST 2.000 208 FPRLRTIVQ2.000 596 NVTLEDQGI 2.000 534 RVSPKNPRI 2.000 30 SVQQVPTII 2.000 785TLRVMTPAV 2.000 385 SPVDNHPFA 2.000 671 EPGRWEELT 2.000 873 DGRTHPKEV2.000 1019 KPITEESST 2.000 1121 RNRGGKYSV 2.000 737 QASQPKEMI 1.800 753SMEQNGPGL 1.200 334 TATHDFHVI 1.200 916 AGPESEPYI 1.200 118 AMSEEIEFI1.200 519 TAVTANLDI 1.200 180 VYMSQKGDL 1.200 261 GSESSITIL 1.200 738ASQPKEMII 1.200 650 AGADHNSNI 1.200 611 TALDSAADI 1.200 901 FSEFHLTVL1.200 1152 YSDSDEKPL 1.200 218 MPMKLTVNS 1.200 418 EASNVHGTI 1.200V2-HLA-B7-9mers-(SET 1)-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 9 FPKEKIDPL 80.000 6 VPKFPKEKI 12.000 3 VPSVPKFPK 0.300 5SVPKFPKEK 0.050 2 IVPSVPKFP 0.050 1 FIVPSVPKF 0.020 4 PSVPKFPKE 0.001 8KFPKEKIDP 0.001 7 PKFPKEKID 0.000 V2-HLA-B7-9mers-(SET 2)-282P1G3 Eachpeptide is a portion of SEQ ID NO: 5; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 9 AKENYGKTL 0.360 8 EAKENYGKT0.300 5 KGREAKENY 0.200 3 LPKGREAKE 0.200 2 DLPKGREAK 0.015 1 GDLPKGREA0.010 7 REAKENYGK 0.001 6 GREAKENYG 0.000 4 PKGREAKEN 0.000V2-HLA-B7-9mers-(SET 3)-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 5 LGEGKYAGL 1.200 3 STLGEGKYA 0.100 9 KYAGLYDDI 0.040 2 SSTLGEGKY0.020 7 EGKYAGLYD 0.010 1 ESSTLGEGK 0.010 4 TLGEGKYAG 0.010 6 GEGKYAGLY0.002 8 GKYAGLYDD 0.001 V3-HLA-B7-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 7; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 39 LSYRNRNML 6.000 31 FICSKEQEL 4.000 25SPQPSIFIC 2.000 22 ATGSPQPSI 1.800 44 RNMLAEDFI 1.200 38 ELSYRNRNM 1.00024 GSPQPSIFI 0.600 27 QPSIFICSK 0.200 8 INTTYVSNT 0.100 15 NTTYVSNAT0.100 3 HGVDVINTT 0.100 12 YVSNTTYVS 0.100 58 CNYVEKSST 0.100 42RNRNMLAED 0.100 6 DVINTTYVS 0.100 40 SYRNRNMLA 0.100 14 SNTTYVSNA 0.1009 NTTYVSNTT 0.100 21 NATGSPQPS 0.060 18 YVSNATGSP 0.050 62 EKSSTFFKI0.040 60 YVEKSSTFF 0.030 4 GVDVINTTY 0.030 10 TTYVSNTTY 0.020 32ICSKEQELS 0.020 56 TSCNYVEKS 0.020 5 VDVINTTYV 0.020 13 VSNTTYVSN 0.02051 FIQKSTSCN 0.020 53 QKSTSCNYV 0.020 33 CSKEQELSY 0.020 1 VIHGVDVIN0.020 57 SCNYVEKSS 0.020 23 TGSPQPSIF 0.020 7 VINTTYVSN 0.020 52IQKSTSCNY 0.020 11 TYVSNTTYV 0.020 47 LAEDFIQKS 0.018 16 TTYVSNATG 0.0102 IHGVDVINT 0.010 46 MLAEDFIQK 0.010 45 NMLAEDFIQ 0.010 19 VSNATGSPQ0.010 20 SNATGSPQP 0.010 54 KSTSCNYVE 0.010 50 DFIQKSTSC 0.010 29SIFICSKEQ 0.010 55 STSCNYVEK 0.010 48 AEDFIQKST 0.009 37 QELSYRNRN 0.00336 EQELSYRNR 0.003 59 NYVEKSSTF 0.002 26 PQPSIFICS 0.002 43 NRNMLAEDF0.002 35 KEQELSYRN 0.002 17 TYVSNATGS 0.002 49 EDFIQKSTS 0.002 61VEKSSTFFK 0.001 28 PSIFICSKE 0.001 41 YRNRNMLAE 0.001 30 IFICSKEQE 0.00134 SKEQELSYR 0.000 V4-HLA-B7-9mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 9; each start position is specified, the length of peptide is9 amino acids, and the end position for each peptide is the startposition plus eight. 1 VTLYSGEDL 4.000 8 DLPEQPTFL 4.000 9 LPEQPTFLK0.090 4 YSGEDLPEQ 0.010 2 TLYSGEDLP 0.010 6 GEDLPEQPT 0.004 5 SGEDLPEQP0.003 7 EDLPEQPTF 0.002 3 LYSGEDLPE 0.001 V5-HLA-B7-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 11; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 4 LTVNSSNSI 0.400 5 TVNSSNSIK0.050 3 KLTVNSSNS 0.020 8 SSNSIKQRK 0.010 6 VNSSNSIKQ 0.010 7 NSSNSIKQR0.010 9 SNSIKQRKP 0.010 2 MKLTVNSSN 0.002 1 PMKLTVNSS 0.002V6-HLA-B7-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight. 2EIEFIVPKL 1.200 5 FIVPKLEHI 0.400 7 VPKLEHIEQ 0.200 6 IVPKLEHIE 0.050 9KLEHIEQDE 0.003 4 EFIVPKLEH 0.002 3 IEFIVPKLE 0.001 1 EEIEFIVPK 0.001 8PKLEHIEQD 0.000 V7-HLA-B7-9mers-282P1G3 Each peptide is a portion of SEQID NO: 15; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 10 NISHELFTL 4.000 19 HPEPPRWTK 0.135 7 VEDNISHEL 0.120 4HVIVEDNIS 0.100 9 DNISHELFT 0.100 3 FHVIVEDNI 0.040 17 TLHPEPPRW 0.02016 FTLHPEPPR 0.015 6 IVEDNISHE 0.015 18 LHPEPPRWT 0.015 11 ISHELFTLH0.010 14 ELFTLHPEP 0.010 5 VIVEDNISH 0.010 8 EDNISHELF 0.002 2 DFHVIVEDN0.002 13 HELFTLHPE 0.001 1 HDFHVIVED 0.001 15 LFTLHPEPP 0.001 12SHELFTLHP 0.000 20 PEPPRWTKK 0.000

TABLE XIX Start Subsequence Score V1-HLA-B7-10mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 398 FPREISFTNL 800.000 539NPRIPKLHML 800.000 218 MPMKLTVNSL 240.000 1054 EPGAEHIVRL 80.000 1158KPLKGSLRSL 80.000 849 VPKDRVHGRL 80.000 536 SPKNPRIPKL 80.000 1019KPITEESSTL 80.000 1080 ETRGREYAGL 40.000 828 APVIHGVDVI 24.000 627VPDPPENLHL 24.000 795 APYDVKVQAI 24.000 798 DVKVQAINQL 20.000 179RVYMSQKGDL 20.000 1105 AIALLTLLLL 12.000 693 APFVRYQFRV 12.000 752KSMEQNGPGL 12.000 450 ATVVGYSAFL 12.000 772 APVEWEEETV 12.000 1000NATTKYKFYL 12.000 480 KPLEGRRYHI 12.000 590 ANLTISNVTL 12.000 418EASNVHGTIL 12.000 2 EPLLLGRGLI 12.000 1104 CAIALLTLLL 12.000 616AADITQVTVL 10.800 6 LGRGLIVYLM 10.000 74 NPFYFTDHRI 8.000 695 FVRYQFRVIA7.500 356 AVYSTGSNGI 6.000 150 VLPCNPPKGL 6.000 142 EVEEGDPIVL 6.000 987TTPSKPSWHL 6.000 643 SVRLTWEAGA 5.000 735 RVQASQPKEM 5.000 780TVTNHTLRVM 5.000 863 INWWKTKSLL 4.000 790 TPAVYAPYDV 4.000 1034GIGKISGVNL 4.000 266 ITILKGEILL 4.000 1103 MCAIALLTLL 4.000 9 GLIVYLMFLL4.000 953 GLPKKLNGNL 4.000 323 NYRCTASNFL 4.000 106 KYRCFASNKL 4.000 862QINWWKTKSL 4.000 274 LLLECFAEGL 4.000 541 RIPKLHMLEL 4.000 260SGSESSITIL 4.000 949 TLSWGLPKKL 4.000 213 TIVQKMPMKL 4.000 557DSHLKHSLKL 4.000 957 KLNGNLTGYL 4.000 1102 LMCAIALLTL 4.000 1093ISTQGWFIGL 4.000 934 QPTFLKVIKV 4.000 132 KLPKEKIDPL 4.000 5 LLGRGLIVYL4.000 8 RGLIVYLMFL 4.000 832 HGVDVINSTL 4.000 1099 FIGLMCAIAL 4.000 267TILKGEILLL 4.000 929 EGVPEQPTFL 4.000 516 IGKTAVTANL 4.000 202YCCFAAFPRL 4.000 473 WQKVEEVKPL 4.000 244 NSIKQRKPKL 4.000 373EPQPTIKWRV 4.000 1171 MQPTESADSL 4.000 302 ETKENYGKTL 4.000 681VQGKKTTVIL 4.000 1213 NGSSTATFPL 4.000 1100 IGLMCAIALL 4.000 809SGPDPQSVTL 4.000 958 LNGNLTGYLL 4.000 358 YSTGSNGILL 4.000 637SERQNRSVRL 4.000 153 CNPPKGLPPL 4.000 875 RTHPKEVNIL 4.000 1172QPTESADSLV 4.000 265 SITILKGEIL 4.000 245 SIKQRKPKLL 4.000 34 VPTIIKQSKV4.000 10 LIVYLMFLLL 4.000 725 AAPDRNPQNI 3.600 117 IAMSEEIEFI 3.600 110FASNKLGIAM 3.000 792 AVYAPYDVKV 3.000 413 AVYQCEASNV 3.000 129SVPKLPKEKI 3.000 206 AAFPRLRTIV 2.700 1048 HPIEVFEPGA 2.000 680RVQGKKTTVI 2.000 27 IPSSVQQVPT 2.000 526 DIRNATKLRV 2.000 408 QPNHTAVYQC2.000 1051 EVFEPGAEHI 2.000 954 LPKKLNGNLT 2.000 208 FPRLRTIVQK 2.000538 KNPRIPKLHM 1.500 V2-HLA-B7-10mers-(SET 1)-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 6 SVPKFPKEKI 3.000 9 KFPKEKIDPL 0.400 7VPKFPKEKID 0.200 4 VPSVPKFPKE 0.200 10 FPKEKIDPLE 0.200 3 IVPSVPKFPK0.075 2 FIVPSVPKFP 0.010 1 EFIVPSVPKF 0.002 5 PSVPKFPKEK 0.001 8PKFPKEKIDP 0.000 V2-HLA-B7-10mers-(SET 2)-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 4 TLGEGKYAGL 4.000 2 SSTLGEGKYA 0.100 8GKYAGLYDDI 0.040 1 ESSTLGEGKY 0.020 3 STLGEGKYAG 0.010 7 EGKYAGLYDD0.010 5 LGEGKYAGLY 0.006 6 GEGKYAGLYD 0.001 V2-HLA-B7-10mers-(SET3)-282P1G3 Each peptide is a portion of SEQ ID NO: 5; each startposition is specified, the length of peptide is 10 amino acids, and theend position for each peptide is the start position plus nine. 5TLGEGKYAGL 4.000 3 SSTLGEGKYA 0.100 9 GKYAGLYDDI 0.040 2 ESSTLGEGKY0.020 4 STLGEGKYAG 0.010 8 EGKYAGLYDD 0.010 6 LGEGKYAGLY 0.006 10KYAGLYDDIS 0.002 7 GEGKYAGLYD 0.001 1 EESSTLGEGK 0.001V3-HLA-B7-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7; eachstart position is specified, the length of peptide is 10 amino acids,and the end position for each peptide is the start position plus nine.39 ELSYRNRNML 6.000 22 NATGSPQPSI 1.800 24 TGSPQPSIFI 0.600 31IFICSKEQEL 0.400 26 SPQPSIFICS 0.400 5 GVDVINTTYV 0.300 53 IQKSTSCNYV0.200 28 QPSIFICSKE 0.200 11 TTYVSNTTYV 0.200 43 RNRNMLAEDF 0.200 8VINTTYVSNT 0.100 15 SNTTYVSNAT 0.100 58 SCNYVEKSST 0.100 38 QELSYRNRNM0.100 9 INTTYVSNTT 0.100 14 VSNTTYVSNA 0.100 7 DVINTTYVSN 0.100 2VIHGVDVINT 0.100 25 GSPQPSIFIC 0.100 40 LSYRNRNMLA 0.100 13 YVSNTTYVSN0.100 48 LAEDFIQKST 0.090 23 ATGSPQPSIF 0.060 19 YVSNATGSPQ 0.050 62VEKSSTFFKI 0.040 44 NRNMLAEDFI 0.040 45 RNMLAEDFIQ 0.030 17 TTYVSNATGS0.020 47 MLAEDFIQKS 0.020 10 NTTYVSNTTY 0.200 32 FICSKEQELS 0.020 59CNYVEKSSTF 0.020 21 SNATGSPQPS 0.020 52 FIQKSTSCNY 0.020 56 STSCNYVEKS0.020 4 HGVDVINTTY 0.020 57 TSCNYVEKSS 0.020 33 ICSKEQELSY 0.020 61YVEKSSTFFK 0.015 16 NTTYVSNATG 0.010 1 PVIHGVDVIN 0.010 20 VSNATGSPQP0.010 41 SYRNRNMLAE 0.010 34 CSKEQELSYR 0.010 30 SIFICSKEQE 0.010 50EDFIQKSTSC 0.010 55 KSTSCNYVEK 0.010 3 IHGVDVINTT 0.010 46 NMLAEDFIQK0.010 37 EQELSYRNRN 0.009 60 NYVEKSSTFF 0.002 51 DFIQKSTSCN 0.002 12TYVSNTTYVS 0.002 6 VDVINTTYVS 0.002 49 AEDFIQKSTS 0.002 36 KEQELSYRNR0.001 29 PSIFICSKEQ 0.001 54 QKSTSCNYVE 0.001 27 PQPSIFICSK 0.001 42YRNRNMLAED 0.001 18 TYVSNATGSP 0.001 35 SKEQELSYRN 0.001V4-HLA-B7-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 9; eachstart position is specified, the length of peptide is 10 amino acids,and the end position for each peptide is the start position plus nine. 1SVTLYSGEDL 20.000 10 LPEQPTFLKV 1.200 8 EDLPEQPTFL 0.400 6 SGEDLPEQPT0.045 9 DLPEQPTFLK 0.015 3 TLYSGEDLPE 0.010 5 YSGEDLPEQP 0.010 2VTLYSGEDLP 0.010 4 LYSGEDLPEQ 0.001 7 GEDLPEQPTF 0.001V5-HLA-B7-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 1 MPMKLTVNSS 1.200 4 KLTVNSSNSI 0.400 6 TVNSSNSIKQ 0.050 10SNSIKQRKPK 0.015 7 VNSSNSIKQR 0.010 8 NSSNSIKQRK 0.010 9 SSNSIKQRKP0.010 5 LTVNSSNSIK 0.010 2 PMKLTVNSSN 0.002 3 MKLTVNSSNS 0.002V6-HLA-B7-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 2 EEIEFIVPKL 0.400 8 VPKLEHIEQD 0.200 7 IVPKLEHIEQ 0.050 5EFIVPKLEHI 0.040 6 FIVPKLEHIE 0.010 10 KLEHIEQDER 0.003 3 EIEFIVPKLE0.003 4 IEFIVPKLEH 0.002 1 SEEIEFIVPK 0.000 9 PKLEHIEQDE 0.000V7-HLA-B7-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 7 IVEDNISHEL 6.000 10 DNISHELFTL 4.000 18 TLHPEPPRWT 0.150 20HPEPPRWTKK 0.060 5 HVIVEDNISH 0.050 3 DFHVIVEDNI 0.040 17 FTLHPEPPRW0.020 6 VIVEDNISHE 0.010 15 ELFTLHPEPP 0.010 11 NISHELFTLH 0.010 12ISHELFTLHP 0.010 9 EDNISHELFT 0.010 19 LHPEPPRWTK 0.002 2 HDFHVIVEDN0.002 4 FHVIVEDNIS 0.002 16 LFTLHPEPPR 0.002 14 HELFTLHPEP 0.001 8VEDNISHELF 0.001 13 SHELFTLHPE 0.000 1 THDFHVIVED 0.000 21 PEPPRWTKKP0.000

TABLE XX Start Subsequence Score V1-HLA-B3501-9mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 539 NPRIPKLHM 120.000 133LPKEKIDPL 120.000 740 QPKEMIIKW 60.000 542 IPKLHMLEL 60.000 954LPKKLNGNL 60.000 991 KPSWHLSNL 40.000 159 LPPLHIYWM 40.000 690 LPLAPFVRY40.000 1172 QPTESADSL 40.000 130 VPKLPKEKI 24.000 299 KGRETKENY 24.0001082 RGREYAGLY 24.000 47 FPFDEYFQI 24.000 197 DSRNDYCCF 22.500 151LPCNPPKGL 20.000 1175 ESADSLVEY 20.000 390 HPFAGDVVF 20.000 2 EPLLLGRGL20.000 988 TPSKPSWHL 20.000 154 NPPKGLPPL 20.000 768 KPQGAPVEW 20.000 84IPSNNSGTF 20.000 316 VSYQDKGNY 15.000 285 TPQVDWNKI 12.000 398 FPREISFTN12.000 250 KPKLLLPPT 12.000 69 WTKDGNPFY 12.000 210 RLRTIVQKM 12.000 111ASNKLGIAM 10.000 886 FSGQRNSGM 10.000 917 GPESEPYIF 9.000 915 GAGPESEPY9.000 310 TLKIENVSY 9.000 1127 YSVKEKEDL 7.500 384 GSPVDNHPF 7.500 1000NATTKYKFY 6.000 1019 KPITEESST 6.000 810 GPDPQSVTL 6.000 597 VTLEDQGIY6.000 1163 SLRSLNRDM 6.000 247 KQRKPKLLL 6.000 1214 GSSTATFPL 5.000 950LSWGLPKKL 5.000 455 YSAFLHCEF 5.000 465 ASPEAVVSW 5.000 182 MSQKGDLYF5.000 358 YSTGSNGIL 5.000 419 ASNVHGTIL 5.000 667 GNKEEPGRW 4.500 117IAMSEEIEF 4.500 268 ILKGEILLL 4.500 1158 KPLKGSLRS 4.000 385 SPVDNHPFA4.000 853 RVHGRLKGY 4.000 957 KLNGNLTGY 4.000 828 APVIHGVDV 4.000 352KPQSAVYST 4.000 795 APYDVKVQA 4.000 157 KGLPPLHIY 4.000 772 APVEWEEET4.000 629 DPPENLHLS 4.000 212 RTIVQKMPM 4.000 1104 CAIALLTLL 3.000 682QGKKTTVIL 3.000 692 LAPFVRYQF 3.000 45 VAFPFDEYF 3.000 441 IQTKDGENY3.000 1106 IALLTLLLL 3.000 6 LGRGLIVYL 3.000 1035 IGKISGVNL 3.000 857RLKGYQINW 3.000 456 SAFLHCEFF 3.000 758 GPGLEYRVT 3.000 584 RIIIDGANL3.000 245 SIKQRKPKL 3.000 838 NSTLVKVTW 2.500 726 APDRNPQNI 2.400 611ITALDSAADI 2.400 23 KAIEIPSSV 2.400 1152 YSDSDEKPL 2.250 5 LLGRGLIVY2.000 997 SNLNATTKY 2.000 738 ASQPKEMII 2.000 722 TPPAAPDRN 2.000 181YMSQKGDLY 2.000 657 NISEYIVEF 2.000 812 DPQSVTLYS 2.000 890 RNSGMVPSL2.000 626 DVPDPPENL 2.000 39 KQSKVQVAF 2.000 44 QVAFPFDEY 2.000 730NPQNIRVQA 2.000 283 LPTPQVDWN 2.000 508 YSCWVENAI 2.000 8 RGLIVYLMF2.000 99 HISHFQGKY 2.000 736 VQASQPKEM 2.000 447 ENYATVVGY 2.000 755EQNGPGLEY 2.000 1013 TSQGCGKPI 2.000 V2-HLA-B3501-9mers-(SET 1)-282P1G3Each peptide is a portion of SEQ ID NO: 5; each start position isspecified, the length of peptide is 9 amino acids, and the end positionfor each peptide is the start position plus eight. 9 FPKEKIDPL 120.000 6VPKFPKEKI 24.000 1 FIVPSVPKF 1.000 3 VPSVPKFPK 0.200 5 SVPKFPKEK 0.010 2IVPSVPKFP 0.010 4 PSVPKFPKE 0.005 8 KFPKEKIDP 0.003 7 PKFPKEKID 0.000V2-B3501-9mers-(SET 2)-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 5 KGREAKENY 24.000 8 EAKENYGKT 1.800 3 LPKGREAKE 0.600 9AKENYGKTL 0.030 1 GDLPKGREA 0.010 2 DLPKGREAK 0.010 7 REAKENYGK 0.003 4PKGREAKEN 0.002 6 GREAKENYG 0.000 V2-B3501-9mers-(SET 3)-282P1G3 Eachpeptide is a portion of SEQ ID NO: 5; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 2 SSTLGEGKY 10.000 5 LGEGKYAGL0.300 6 GEGKYAGLY 0.200 3 STLGEGKYA 0.150 9 KYAGLYDDI 0.080 1 ESSTLGEGK0.050 7 EGKYAGLYD 0.030 4 TLGEGKYAG 0.020 8 GKYAGLYDD 0.001V3-B3501-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight. 33CSKEQELSY 60.00 52 IQKSTSCNY 6.000 39 LSYRNRNML 5.000 10 TTYVSNTTY 2.00024 GSPQPSIFI 2.000 25 SPQPSIFIC 2.000 38 ELSYRNRNM 2.000 31 FICSKEQEL1.000 23 TGSPQPSIF 1.000 44 RNMLAEDFI 0.800 4 GVDVINTTY 0.600 56TSCNYVEKS 0.500 13 VSNTTYVSN 0.500 22 ATGSPQPSI 0.400 60 YVEKSSTFF 0.30021 NATGSPQPS 0.300 59 NYVEKSSTF 0.200 3 HGVDVINTT 0.200 27 QPSIFICSK0.200 47 LAEDFIQKS 0.180 32 ICSKEQELS 0.150 58 CNYVEKSST 0.150 9NTTYVSNTT 0.100 7 VINTTYVSN 0.100 54 KSTSCNYVE 0.100 15 NTTYVSNAT 0.1008 INTTYVSNT 0.100 12 YVSNTTYVS 0.100 51 FIQKSTSCN 0.100 43 NRNMLAEDF0.100 57 SCNYVEKSS 0.100 1 VIHGVDVIN 0.100 14 SNTTYVSNA 0.100 6DVINTTYVS 0.100 42 RNRNMLAED 0.060 19 VSNATGSPQ 0.050 35 KEQELSYRN 0.04062 EKSSTFFKI 0.040 46 MLAEDFIQK 0.030 40 SYRNRNMLA 0.030 5 VDVINTTYV0.020 11 TYVSNTTYV 0.020 53 QKSTSCNYV 0.020 2 IHGVDVINT 0.015 45NMLAEDFIQ 0.015 26 PQPSIFICS 0.010 49 EDFIQKSTS 0.010 16 TTYVSNATG 0.01037 QELSYRNRN 0.010 55 STSCNYVEK 0.010 17 TYVSNATGS 0.010 29 SIFICSKEQ0.010 18 YVSNATGSP 0.010 20 SNATGSPQP 0.010 50 DFIQKSTSC 0.010 28PSIFICSKE 0.005 61 VEKSSTFFK 0.003 48 AEDFIQKST 0.003 36 EQELSYRNR 0.00330 IFICSKEQE 0.001 41 YRNRNMLAE 0.001 34 SKEQELSYR 0.000V4-HLA-B3501-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 9;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 8 DLPEQPTFL 2.000 1 VTLYSGEDL 1.000 7 EDLPEQPTF 0.150 4 YSGEDLPEQ0.150 9 LPEQPTFLK 0.060 2 TLYSGEDLP 0.010 5 SGEDLPEQP 0.006 6 GEDLPEQPT0.003 3 LYSGEDLPE 0.002 V5-HLA-B3501 -9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 11; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 4 LTVNSSNSI 0.400 3 KLTVNSSNS 0.200 8SSNSIKQRK 0.050 7 NSSNSIKQR 0.050 1 PMKLTVNSS 0.030 9 SNSIKQRKP 0.010 6VNSSNSIKQ 0.010 2 MKLTVNSSN 0.010 5 TVNSSNSIK 0.010V6-HLA-B3501-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 7 VPKLEHIEQ 0.900 5 FIVPKLEHI 0.400 2 EIEFIVPKL 0.300 6 IVPKLEHIE0.010 9 KLEHIEQDE 0.006 1 EEIEFIVPK 0.002 4 EFIVPKLEH 0.001 3 IEFIVPKLE0.001 8 PKLEHIEQD 0.000 V7-HLA-B3501-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 15; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 10 NISHELFTL 1.500 17 TLHPEPPRW 0.750 4HVIVEDNIS 0.150 11 ISHELFTLH 0.100 8 EDNISHELF 0.100 9 DNISHELFT 0.10019 HPEPPRWTK 0.060 3 FHVIVEDNI 0.040 5 VIVEDNISH 0.030 7 VEDNISHEL 0.03018 LHPEPPRWT 0.020 2 DFHVIVEDN 0.010 16 FTLHPEPPR 0.010 14 ELFTLHPEP0.010 6 IVEDNISHE 0.006 13 HELFTLHPE 0.001 1 HDFHVIVED 0.001 15LFTLHPEPP 0.001 12 SHELFTLHP 0.000 20 PEPPRWTKK 0.000

TABLE XXI Start Subsequence Score V1-HLA-B35-10mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 398 FPREISFTNL 120.000 849VPKDRVHGRL 120.000 877 HPKEVNILRF 120.000 539 NPRIPKLHML 60.000 1019KPITEESSTL 60.000 536 SPKNPRIPKL 60.000 1158 KPLKGSLRSL 40.000 94IPNEGHISHF 40.000 480 KPLEGRRYHI 32.000 218 MPMKLTVNSL 20.000 1054EPGAEHIVRL 20.000 895 VPSLDAFSEF 20.000 752 KSMEQNGPGL 20.000 568WSKDGEAFEI 18.000 795 APYDVKVQAI 16.000 40 QSKVQVAFPF 15.000 1143SVKDETFGEY 12.000 810 GPDPQSVTLY 12.000 499 RTTEEDAGSY 12.000 772APVEWEEETV 12.000 996 LSNLNATTKY 10.000 758 GPGLEYRVTW 10.000 1162GSLRSLNRDM 10.000 297 LPKGRETKEN 9.000 58 EAKGNPEPTF 9.000 478EVKPLEGRRY 9.000 627 VPDPPENLHL 9.000 828 APVIHGVDVI 8.000 74 NPFYFTDHRI8.000 1172 QPTESADSLV 8.000 2 EPLLLGRGLI 8.000 566 LSWSKDGEAF 7.500 67FSWTKDGNPF 7.500 110 FASNKLGIAM 6.000 309 KTLKIENVSY 6.000 349WTKKPQSAVY 6.000 69 WTKDGNPFYF 6.000 785 TLRVMTPAVY 6.000 6 LGRGLIVYLM6.000 302 ETKENYGKTL 6.000 954 LPKKLNGNLT 6.000 1118 FVKRNRGGKY 6.000745 IIKWEPLKSM 6.000 914 KGAGPESEPY 6.000 1121 ESNGSSTATF 5.000 244NSIKQRKPKL 5.000 455 YSAFLHCEFF 5.000 557 DSHLKHSLKL 5.000 358YSTGSNGILL 5.000 1093 ISTQGWFIGL 5.000 473 WQKVEEVKPL 4.500 1080ETRGREYAGL 4.500 934 QPTFLKVIKV 4.000 735 RVQASQPKEM 4.000 1077DVIETRGREY 4.000 991 KPSWHLSNLN 4.000 693 APFVRYQFRV 4.000 373EPQPTIKWRV 4.000 34 VPTIIKQSKV 4.000 1048 HPIEVFEPGA 4.000 538KNPRIPKLHM 4.000 790 TPAVYAPYDV 4.000 440 LIQTKDGENY 3.000 315NVSYQDKGNY 3.000 449 YATVVGYSAF 3.000 916 AGPESEPYIF 3.000 516IGKTAVTANL 3.000 1203 GSKEKGSVES 3.000 798 DVKVQAINQL 3.000 1000NATTKYKFYL 3.000 1044 TQKTHPIEVF 3.000 418 EASNVHGTIL 3.000 596NVTLEDQGIY 3.000 875 RTHPKEVNIL 3.000 857 RLKGYQINWW 3.000 1104CAIALLTLLL 3.000 245 SIKQRKPKLL 3.000 725 AAPDRNPQNI 2.400 155PPKGLPPLHI 2.400 21 FSKAIEIPSS 2.250 274 LLLECFAEGL 2.000 159 LPPLHIYWMN2.000 957 KLNGNLTGYL 2.000 132 KLPKEKIDPL 2.000 43 VQVAFPFDEY 2.000 29SSVQQVPTII 2.000 264 SSITILKGEI 2.000 988 TPSKPSWHLS 2.000 260SGSESSITIL 2.000 689 ILPLAPFVRY 2.000 158 GLPPLHIYWM 2.000 780TVTNHTLRVM 2.000 4 LLLGRGLIVY 2.000 960 GNLTGYLLQY 2.000 967 LQYQIINDTY2.000 255 LPPTESGSES 2.000 730 NPQNIRVQAS 2.000 788 VMTPAVYAPY 2.000 8RGLIVYLMFL 2.000 406 NLQPNHTAVY 2.000 V2-HLA-B3501-10mers-(SET1)-282P1G3 Each peptide is a portion of SEQ ID NO: 5; each startposition is specified, the length of peptide is 10 amino acids, and theend position for each peptide is the start position plus nine. 10FPKEKIDPLE 1.200 7 VPKFPKEKID 0.600 6 SVPKFPKEKI 0.400 4 VPSVPKFPKE0.200 9 KFPKEKIDPL 0.200 1 EFIVPSVPKF 0.100 3 IVPSVPKFPK 0.010 2FIVPSVPKFP 0.010 5 PSVPKFPKEK 0.005 8 PKFPKEKIDP 0.000V2-HLA-B3501-10mers-(SET 2)-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 1 ESSTLGEGKY 10.000 4 TLGEGKYAGL 2.000 2 SSTLGEGKYA 0.750 5LGEGKYAGLY 0.600 8 GKYAGLYDDI 0.040 7 EGKYAGLYDD 0.030 3 STLGEGKYAG0.010 6 GEGKYAGLYD 0.001 V2-HLA-B3501-10mers-(SET 3)-282P1G3 Eachpeptide is a portion of SEQ ID NO: 5; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 2 ESSTLGEGKY 10.000 5TLGEGKYAGL 2.000 3 SSTLGEGKYA 0.750 6 LGEGKYAGLY 0.600 9 GKYAGLYDDI0.040 8 EGKYAGLYDD 0.030 10 KYAGLYDDIS 0.020 4 STLGEGKYAG 0.010 7GEGKYAGLYD 0.001 1 EESSTLGEGK 0.001 V3-HLA-B3501-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 7; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 43 RNRNMLAEDF 6.000 4HGVDVINTTY 4.000 52 FIQKSTSCNY 2.000 26 SPQPSIFICS 2.000 33 ICSKEQELSY2.000 10 NTTYVSNTTY 2.000 22 NATGSPQPSI 1.200 39 ELSYRNRNML 1.000 59CNYVEKSSTF 1.000 23 ATGSPQPSIF 1.000 53 IQKSTSCNYV 0.600 14 VSNTTYVSNA0.500 40 LSYRNRNMLA 0.500 57 TSCNYVEKSS 0.500 25 GSPQPSIFIC 0.500 34CSKEQELSYR 0.450 24 TGSPQPSIFI 0.400 60 NYVEKSSTFF 0.200 28 QPSIFICSKE0.200 11 TTYVSNTTYV 0.200 47 MLAEDFIQKS 0.200 38 QELSYRNRNM 0.200 48LAEDFIQKST 0.180 32 FICSKEQELS 0.150 58 SCNYVEKSST 0.150 2 VIHGVDVINT0.150 62 VEKSSTFFKI 0.120 9 INTTYVSNTT 0.100 31 IFICSKEQEL 0.100 7DVINTTYVSN 0.100 13 YVSNTTYVSN 0.100 17 TTYVSNATGS 0.100 21 SNATGSPQPS0.100 55 KSTSCNYVEK 0.100 56 STSCNYVEKS 0.100 8 VINTTYVSNT 0.100 15SNTTYVSNAT 0.100 5 GVDVINTTYV 0.060 20 VSNATGSPQP 0.050 44 NRNMLAEDFI0.040 45 RNMLAEDFIQ 0.030 37 EQELSYRNRN 0.030 46 NMLAEDFIQK 0.015 19YVSNATGSPQ 0.010 51 DFIQKSTSCN 0.010 1 PVIHGVDVIN 0.010 30 SIFICSKEQE0.010 16 NTTYVSNATG 0.010 6 VDVINTTYVS 0.010 12 TYVSNTTYVS 0.010 3IHGVDVINTT 0.010 50 EDFIQKSTSC 0.010 29 PSIFICSKEQ 0.005 36 KEQELSYRNR0.004 41 SYRNRNMLAE 0.003 49 AEDFIQKSTS 0.003 35 SKEQELSYRN 0.003 61YVEKSSTFFK 0.003 54 QKSTSCNYVE 0.001 42 YRNRNMLAED 0.001 27 PQPSIFICSK0.001 18 TYVSNATGSP 0.001 V4-HLA-B35-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 9; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 10 LPEQPTFLKV 1.200 1 SVTLYSGEDL 1.000 8EDLPEQPTFL 0.100 5 YSGEDLPEQP 0.100 6 SGEDLPEQPT 0.060 7 GEDLPEQPTF0.045 9 DLPEQPTFLK 0.020 3 TLYSGEDLPE 0.015 2 VTLYSGEDLP 0.010 4LYSGEDLPEQ 0.002 V5-HLA-B35-10mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 11; each start position is specified, the length of peptideis 10 amino acids, and the end position for each peptide is the startposition plus nine. 1 MPMKLTVNSS 2.000 4 KLTVNSSNSI 0.800 8 NSSNSIKQRK0.050 9 SSNSIKQRKP 0.050 2 PMKLTVNSSN 0.030 6 TVNSSNSIKQ 0.010 10SNSIKQRKPK 0.010 3 MKLTVNSSNS 0.010 7 VNSSNSIKQR 0.010 5 LTVNSSNSIK0.010 V6-HLA-B35-10mers-282P1G3 Each peptide is a portion of SEQ ID NO:13; each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 8 VPKLEHIEQD 0.600 2 EEIEFIVPKL 0.200 5 EFIVPKLEHI 0.040 7IVPKLEHIEQ 0.015 6 FIVPKLEHIE 0.010 10 KLEHIEQDER 0.009 3 EIEFIVPKLE0.003 4 IEFIVPKLEH 0.001 1 SEEIEFIVPK 0.000 9 PKLEHIEQDE 0.000V7-HLA-B35-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 10 DNISHELFTL 1.500 17 FTLHPEPPRW 0.750 7 IVEDNISHEL 0.600 18TLHPEPPRWT 0.100 12 ISHELFTLHP 0.100 20 HPEPPRWTKK 0.060 3 DFHVIVEDNI0.040 8 VEDNISHELF 0.030 6 VIVEDNISHE 0.020 4 FHVIVEDNIS 0.015 5HVIVEDNISH 0.015 15 ELFTLHPEPP 0.010 11 NISHELFTLH 0.010 2 HDFHVIVEDN0.010 9 EDNISHELFT 0.010 19 LHPEPPRWTK 0.002 16 LFTLHPEPPR 0.001 14HELFTLHPEP 0.001 13 SHELFTLHPE 0.000 1 THDFHVIVED 0.000 21 PEPPRWTKKP0.000Tables XXII-XLIX:

TABLE XXII Pos 123456789 score HLA-V1-A1-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 3; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 500 TTEEDAGSY 31 1144 VKDETFGEY 29 1078VIETRGREY 27 173 HIEQDERVY 26 69 WTKDGNPFY 24 755 EQNGPGLEY 24 961NLTGYLLQY 24 5 LLGRGLIVY 23 579 GTEDGRIII 23 789 MTPAVYAPY 23 816VTLYSGEDY 23 350 TKKPQSAVY 22 597 VTLEDQGIY 22 903 EFHLTVLAY 22 1154DSDEKPLKG 22 78 FTDHRIIPS 21 145 EGDPIVLPC 21 120 SEEIEFIVP 20 157KGLPPLHIY 20 181 YMSQKGDLY 20 236 STEIGSKAN 20 316 VSYQDKGNY 20 1192SEDGSFIGA 20 44 QVAFPFDEY 19 690 LPLAPFVRY 19 915 GAGPESEPY 19 919ESEPYIFQT 19 997 SNLNATTKY 19 1119 VKRNRGGKY 19 1175 ESADSLVEY 19 257PTESGSESS 18 489 IYENGTLQI 18 586 IIDGANLTI 18 598 TLEDQGIYC 18 627VPDPPENLH 18 811 PDPQSVTLY 18 975 TYEIGELND 18 1021 ITEESSTLG 18 1082RGREYAGLY 18 1173 PTESADSLV 18 62 NPEPTFSWT 17 99 HISHFQGKY 17 143VEEGDPIVL 17 310 TLKIENVSY 17 343 VEEPPRWTK 17 434 VVDVRPLIQ 17 476VEEVKPLEG 17 479 VKPLEGRRY 17 636 LSERQNRSV 17 669 KEEPGRWEE 17 957KLNGNLTGY 17 1052 VFEPGAEHI 17 1083 GREYAGLYD 17 1129 VKEKEDLHP 17 1191FSEDGSFIG 17 194 EEKDSRNDY 16 270 KGEILLLEC 16 336 THDFHVIVE 16 371EGEPQPTIK 16 393 AGDVVFPRE 16 407 LQPNHTAVY 16 441 IQTKDGENY 16 447ENYATVVGY 16 630 PPENLHLSE 16 786 LRVMTPAVY 16 810 GPDPQSVTL 16 853RVHGRLKGY 16 878 PKEVNILRF 16 901 FSEFHLTVL 16 944 DKDTATLSW 16 968QYQIINDTY 16 1022 TEESSTLGE 16 1094 STQGWFIGL 16 1152 YSDSDEKPL 16 49FDEYFQIEC 15 299 KGRETKENY 15 318 YQDKGNYRC 15 326 CTASNFLGT 15 359STGSNGILL 15 466 SPEAVVSWQ 15 482 LEGRRYHIY 15 580 TEDGRIIID 15 653DHNSNISEY 15 658 ISEYIVEFE 15 747 KWEPLKSME 15 932 PEQPTFLKV 15 972INDTYEIGE 15 1000 NATTKYKFY 15 1183 YGEGDHGLF 15 1193 EDGSFIGAY 15HLA-V2-(SET1)-A1-9mers-(SET1)-282P1G3 Each peptide is a portion of SEQID NO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 4 PSVPKFPKE 13 1 FIVPSVPKF 8HLA-V2-(SET2)-A1-9mers-(SET2)-282P1G3 Each peptide is a portion of SEQID NO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 5 KGREAKENY 15 9 AKENYGKTL 13 6 GREAKENYG 10HLA-V2-(SET3)-A1-9mers-(SET3)-282P1G3 Each peptide is a portion of SEQID NO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 2 SSTLGEGKY 25 6 GEGKYAGLY 18 HLA-V3-A1-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 7; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 33 CSKEQELSY 27 4 GVDVINTTY 2610 TTYVSNTTY 22 52 IQKSTSCNY 15 HLA-V4-A1-9mers-282P1G3 Each peptide isa portion of SEQ ID NO: 9; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 9 LPEQPTFLK 13 5 SGEDLPEQP 12 6 GEDLPEQPT11 1 VTLYSGEDL 8 3 LYSGEDLPE 7 4 YSGEDLPEQ 6 HLA-V5-A1-9mers-282P1G3Each peptide is a portion of SEQ ID NO: 11; each start position isspecified, the length of peptide is 9 amino acids, and the end positionfor each peptide is the start position plus eight. 6 VNSSNSIKQ 7 4LTVNSSNSI 6 8 SSNSIKQRK 6 7 NSSNSIKQR 4 9 SNSIKQRKP 4 2 MKLTVNSSN 3HLA-V6-A1-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight. 2EIEFIVPKL 13 9 KLEHIEQDE 11 4 EFIVPKLEH 7 HLA-V7-A1-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 15; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 12 SHELFTLHP 18 19 HPEPPRWTK16 7 VEDNISHEL 11 6 IVEDNISHE 10 11 ISHELFTLH 9 16 FTLHPEPPR 8

TABLE XXIII V1-HLA-A0201-9mers-282P1G3 Each peptide is a portion of SEQID NO: 3; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Pos 1108 123456789 score 9 LLTLLLLTV 29 125 GLIVYLMFL 28 268FIVPSVPKL 28 836 ILKGEILLL 28 1101 VINSTLVKV 28 1111 GLMCAIALL 28 4LLLLTVCFV 28 1105 LLLGRGLIV 27 688 AIALLTLLL 26 118 VILPLAPFV 25 426AMSEEIEFI 24 785 ILANANIDV 24 1107 TLRVMTPAV 24 1159 ALLTLLLLT 24 17PLKGSLRSL 24 206 LLLKFSKAI 23 275 AAFPRLRTI 23 406 LLECFAEGL 23 586NLQPNHTAV 23 591 IIDGANLTI 23 826 NLTISNVTL 23 970 DTAPVIHGV 23 1106QIINDTYEI 23 245 IALLTLLLL 23 267 SIKQRKPKL 22 584 TILKGEILL 22 923RIIIDGANL 22 1027 YIFQTPEGV 22 6 TLGEGSKGI 22 23 LGRGLIVYL 21 37KAIEIPSSV 21 163 IIKQSKVQV 21 166 HIYWMNIEL 21 219 WMNIELEHI 21 253PMKLTVNSL 21 427 LLLPPTESG 21 429 LANANIDVV 21 619 NANIDVVDV 21 753ITQVTVLDV 21 942 SMEQNGPGL 21 1033 KVDKDTATL 21 1042 KGIGKISGV 21 1073NLTQKTHPI 21 1104 SIFQDVIET 21 10 CAIALLTLL 21 13 LIVYLMFLL 20 16YLMFLLLKF 20 122 FLLLKFSKA 20 210 EIEFIVPSV 20 265 RLRTIVQKM 20 274SITILKGEI 20 335 LLLECFAEG 20 585 ATHDFHVIV 20 589 IIIDGANLT 20 616GANLTISNV 20 793 AADITQVTV 20 3 VYAPYDVKV 20 26 PLLLGRGLI 19 266EIPSSVQQV 19 451 ITILKGEIL 19 471 TVVGYSAFL 19 657 VSWQKVEEV 19 680NISEYIVEF 19 890 RVQGKKTTV 19 935 RNSGMVPSL 19 949 PTFLKVIKV 19 957TLSWGLPKK 19 976 KLNGNLTGY 19 995 YEIGELNDI 19 1088 HLSNLNATT 19 1094GLYDDISTQ 19 1103 STQGWFIGL 19 5 MCAIALLTL 19 11 LLGRGLIVY 18 133IVYLMFLLL 18 214 LPKEKIDPL 18 292 IVQKMPMKL 18 515 KIGGDLPKG 18 617AIGKTAVTA 18 673 ADITQVTVL 18 700 GRWEELTRV 18 743 FRVIAVNEV 18 840EMIIKWEPL 18 900 TLVKVTWST 18 953 AFSEFHLTV 18 1020 GLPKKLNGN 18 1136PITEESSTL 18 29 HPDPEIQSV 18 154 SSVQQVPTI 17 238 NPPKGLPPL 17 333EIGSKANSI 17 424 GTATHDFHV 17 444 GTILANANI 17 481 KDGENYATV 17 514PLEGRRYHI 17 537 NAIGKTAVT 17 540 PKNPRIPKL 17 558 PRIPKLHML 17 611SHLKHSLKL 17 810 TALDSAADI 17 829 GPDPQSVTL 17 833 PVIHGVDVI 17 841GVDVINSTL 17 863 LVKVTWSTV 17 870 INWWKTKSL 17 871 SLLDGRTHP 17 875LLDGRTHPK 17 930 RTHPKEVNI 17 946 GVPEQPTFL 17 950 DTATLSWGL 17 961LSWGLPKKL 17 1055 NLTGYLLQY 17 1110 PGAEHIVRL 17 1121 TLLLLTVCF 17 1163RNRGGKYSV 17 1166 SLRSLNRDM 17 35 SLNRDMQPT 17 137 PTIIKQSKV 16 161KIDPLEVEE 16 216 PLHIYWMNI 16 252 QKMPMKLTV 16 280 KLLLPPTES 16 359AEGLPTPQV 16 366 STGSNGILL 16 370 LLCEAEGEP 16 432 AEGEPQPTI 16 463IDVVDVRPL 16 525 FFASPEAVV 16 534 LDIRNATKL 16 603 RVSPKNPRI 16 608GIYCCSAHT 16 612 SAHTALDSA 16 691 ALDSAADIT 16 780 PLAPFVRYQ 16 788TVTNHTLRV 16 799 VMTPAVYAP 16 893 VKVQAINQL 16 908 GMVPSLDAF 16 1001VLAYNSKGA 16 1179 ATTKYKFYL 16 14 SLVEYGEGD 16 82 LMFLLLKFS 15 83RIIPSNNSG 15 86 IIPSNNSGT 15 142 SNNSGTFRI 15 254 EVEEGDPIV 15 273LLPPTESGS 15 308 ILLLECFAE 15 327 GKTLKIENV 15 349 TASNFLGTA 15 364WTKKPQSAV 15 365 GILLCEAEG 15 474 ILLCEAEGE 15 487 QKVEEVKPL 15 546YHIYENGTL 15 579 HMLELHCES 15 614 GTEDGRIII 15 615 DSAADITQV 15 626SAADITQVT 15 684 DVPDPPENL 15 746 KKTTVILPL 15 808 IKWEPLKSM 15 876GSGPDPQSV 15 926 THPKEVNIL 15 958 QTPEGVPEQ 15 965 LNGNLTGYL 15 966YLLQYQIIN 15 980 LLQYQIIND 15 991 ELNDINITT 15 1092 KPSWHLSNL 15 1099DISTQGWFI 15 1100 FIGLMCAIA 15 1102 IGLMCAIAL 15 1113 LMCAIALLT 15 19LLTVCFVKR 15 30 LKFSKAIEI 14 107 SVQQVPTII 14 110 YRCFASNKL 14 115FASNKLGIA 14 150 LGIAMSEEI 14 158 VLPCNPPKG 14 185 GLPPLHIYW 14 217KGDLYFANV 14 260 KMPMKLTVN 14 261 SGSESSITI 14 282 GSESSITIL 14 305GLPTPQVDW 14 331 ENYGKTLKI 14 489 FLGTATHDF 14 504 IYENGTLQI 14 517DAGSYSCWV 14 524 GKTAVTANL 14 527 NLDIRNATK 14 542 IRNATKLRV 14 556IPKLHMLEL 14 569 CDSHLKHSL 14 697 SKDGEAFEI 14 702 RYQFRVIAV 14 757VIAVNEVGR 14 781 NGPGLEYRV 14 822 VTNHTLRVM 14 828 EDYPDTAPV 14 940APVIHGVDV 14 973 VIKVDKDTA 14 1008 NDTYEIGEL 14 1036 YLRACTSQG 14 1037GKISGVNLT 14 1053 KISGVNLTQ 14 1066 FEPGAEHIV 14 1098 KNWGDNDSI 14 1112WFIGLMCAI 14 1189 LLLTVCFVK 14 1202 GLFSEDGSF 14 1216 AGSKEKGSV 14V2-(SET1)-HLA-A0201-9mers-(SET1)-282P1G3 Each peptide is a portion ofSEQ ID NO: 5; each start position is specified, the length of peptide is9 amino acids, and the end position for each peptide is the startposition plus eight. Pos 123456789 score 1 FIVPSVPKF 18 9 FPKEKIDPL 17 6VPKFPKEKI 10 5 SVPKFPKEK 8 V2-(SET2)-HLA-A0201-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 5; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. Pos 123456789 score 9AKENYGKTL 13 1 GDLPKGREA 12 2 DLPKGREAK 12 8 EAKENYGKT 8 3 LPKGREAKE 7V2-(SET3)-HLA-A0201-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Pos 123456789 score 5 LGEGKYAGL 17 4 TLGEGKYAG 16 9KYAGLYDDI 14 3 STLGEGKYA 13 8 GKYAGLYDD 9 V3-HLA-A0201-9mers-282P1G3Each peptide is a portion of SEQ ID NO: 7; each start position isspecified, the length of peptide is 9 amino acids, and the end positionfor each peptide is the start position plus eight. Pos 123456789 score31 FICSKEQEL 22 22 ATGSPQPSI 18 7 VINTTYVSN 14 39 LSYRNRNML 14 46MLAEDFIQK 14 1 VIHGVDVIN 13 5 VDVINTTYV 13 47 LAEDFIQKS 13 3 HGVDVINTT12 11 TYVSNTTYV 12 29 SIFICSKEQ 12 51 FIQKSTSCN 11 53 QKSTSCNYV 11 2IHGVDVINT 10 8 INTTYVSNT 10 14 SNTTYVSNA 10 18 YVSNATGSP 10 24 GSPQPSIFI10 38 ELSYRNRNM 10 45 NMLAEDFIQ 10 55 STSCNYVEK 10V4-HLA-A0201-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 9;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Pos 123456789 score 8 DLPEQPTFL 21 1 VTLYSGEDL 16 2 TLYSGEDLP 134 YSGEDLPEQ 11 V5-HLA-A0201-9mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 11; each start position is specified, the length of peptideis 9 amino acids, and the end position for each peptide is the startposition plus eight. Pos 123456789 score 4 LTVNSSNSI 17 1 PMKLTVNSS 11 3KLTVNSSNS 10 V6-HLA-A0201-9mers-282P1G3 Each peptide is a portion of SEQID NO: 13; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. Pos 123456789 score 5 FIVPKLEHI 24 2 EIEFIVPKL 20V7-HLA-A0201-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. Pos 123456789 score 10 NISHELFTL 24 7 VEDNISHEL 14 5 VIVEDNISH 1317 TLHPEPPRW 13 14 ELFTLHPEP 12

TABLE XXIV Pos 123456789 score V1-HLA-A0203-9mers-282P1G3NoResultsFound. V2-(SET1)HLA-A0203-9mers-282P1G3 NoResultsFound.V2-(SET2)-HLA-A0203-9mers-282P1G3 NoResultsFound.V2-(SET3)-HLA-A0203-9mers-282P1G3 NoResultsFound.V3-HLA-A0203-9mers-282P1G3 NoResultsFound.V4-HLA-A0203-9mers-(SET2)-282P1G3 NoResultsFound.V5-HLA-A0203-9mers-(SET2)-282P1G3 NoResultsFound.V6-HLA-A0203-9mers-(SET2)-282P1G3 NoResultsFound.V7-HLA-A0203-9mers-(SET2)-282P1G3 NoResultsFound.

TABLE XXV Pos 123456789 score V1-HLA-A3-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 3; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 792 AVYAPYDVK 33 835 DVINSTLVK 31 436DVRPLIQTK 30 524 NLDIRNATK 30 149 IVLPCNPPK 27 296 DLPKGRETK 27 843KVTWSTVPK 27 1112 LLLTVCFVK 27 1118 FVKRNRGGK 26 1197 FIGAYAGSK 26 5LLGRGLIVY 25 677 ELTRVQGKK 25 937 FLKVIKVDK 25 310 TLKIENVSY 24 701RVIAVNEVG 24 760 GLEYRVTWK 24 853 RVHGRLKGY 24 871 LLDGRTHPK 24 961NLTGYLLQY 24 356 AVYSTGSNG 23 547 MLELHCESK 23 4 LLLGRGLIV 22 106KYRCFASNK 22 129 SVPKLPKEK 22 209 PRLRTIVQK 22 413 AVYQCEASN 22 515AIGKTAVTA 22 584 RIIIDGANL 22 680 RVQGKKTTV 22 689 ILPLAPFVR 22 949TLSWGLPKK 22 957 KLNGNLTGY 22 998 NLNATTKYK 22 1088 GLYDDISTQ 22 381RVNGSPVDN 21 396 VVFPREISF 21 687 TVILPLAPF 21 744 MIIKWEPLK 21 787RVMTPAVYA 21 882 NILRFSGQR 21 948 ATLSWGLPK 21 983 DINITTPSK 21 1008YLRACTSQG 21 1037 KISGVNLTQ 21 1051 EVFEPGAEH 21 1110 TLLLLTVCF 21 11VYLMFLLL 20 82 RIIPSNNSG 20 213 TIVQKMPMK 20 221 KLTVNSLKH 20 291NKIGGDLPK 20 530 ATKLRVSPK 20 661 YIVEFEGNK 20 704 AVNEVGRSQ 20 733NIRVQASQP 20 942 KVDKDTATL 20 1058 EHIVRLMTK 20 1122 NRGGKYSVK 20 24AIEIPSSVQ 19 44 QVAFPFDEY 19 177 DERVYMSQK 19 478 EVKPLEGRR 19 520AVTANLDIR 19 585 IIIDGANLT 19 586 IIDGANLTI 19 591 NLTISNVTL 19 645RLTWEAGAD 19 829 PVIHGVDVI 19 851 KDRVHGRLK 19 996 LSNLNATTK 19 1040GVNLTQKTH 19 1078 VIETRGREY 19 1209 SVESNGSST 19 37 IIKQSKVQV 18 137KIDPLEVEE 18 173 HIEQDERVY 18 179 RVYMSQKGD 18 187 DLYFANVEE 18 252KLLLPPTES 18 268 ILKGEILLL 18 343 VEEPPRWTK 18 534 RVSPKNPRI 18 841LVKVTWSTV 18 859 KGYQINWWK 18 861 YQINWWKTK 18 870 SLLDGRTHP 18 883ILRFSGQRN 18 995 HLSNLNATT 18 1082 RGREYAGLY 18 1107 ALLTLLLLT 18 1108LLTLLLLTV 18 1113 LLTVCFVKR 18 1128 SVKEKEDLH 18 1137 PDPEIQSVK 18 1199GAYAGSKEK 18 3 PLLLGRGLI 17 13 YLMFLLLKF 17 16 FLLLKFSKA 17 114KLGIAMSEE 17 124 EFIVPSVPK 17 210 RLRTIVQKM 17 253 LLLPPTESG 17 340HVIVEEPPR 17 350 TKKPQSAVY 17 365 ILLCEAEGE 17 452 VVGYSAFLH 17 469AVVSWQKVE 17 488 HIYENGTLQ 17 494 TLQINRTTE 17 532 KLRVSPKNP 17 657NISEYIVEF 17 695 FVRYQFRVI 17 702 VIAVNEVGR 17 803 AINQLGSGP 17 833GVDVINSTL 17 857 RLKGYQINW 17 869 KSLLDGRTH 17 897 SLDAFSEFH 17 907TVLAYNSKG 17 939 KVIKVDKDT 17 1006 KFYLRACTS 17 1025 SSTLGEGSK 17 1180LVEYGEGDH 17 1189 GLFSEDGSF 17 8 RGLIVYLMF 16 93 RIPNEGHIS 16 220MKLTVNSLK 16 254 LLPPTESGS 16 273 ILLLECFAE 16 274 LLLECFAEG 16 304KENYGKTLK 16 312 KIENVSYQD 16 344 EEPPRWTKK 16 390 HPFAGDVVF 16 421NVHGTILAN 16 430 ANIDVVDVR 16 434 VVDVRPLIQ 16 447 ENYATVVGY 16 472SWQKVEEVK 16 526 DIRNATKLR 16 544 KLHMLELHC 16 563 SLKLSWSKD 16 612ALDSAADIT 16 621 QVTVLDVPD 16 637 SERQNRSVR 16 643 SVRLTWEAG 16 688VILPLAPFV 16 735 RVQASQPKE 16 764 RVTWKPQGA 16 795 APYDVKVQA 16 817TLYSGEDYP 16 934 QPTFLKVIK 16 1011 ACTSQGCGK 16 1020 PITEESSTL 16 1038ISGVNLTQK 16 1060 IVRLMTKNW 16 1077 DVIETRGRE 16 1105 AIALLTLLL 16 1119VKRNRGGKY 16 V2-(SET1)HLA-A3-9mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 5; each start position is specified, the length of peptide is9 amino acids, and the end position for each peptide is the startposition plus eight. 5 SVPKFPKEK 22 1 FIVPSVPKF 15 2 IVPSVPKFP 14 3VPSVPKFPK 10 V2-(SET2)-HLA-A3-9mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 5; each start position is specified, the length of peptide is9 amino acids, and the end position for each peptide is the startposition plus eight. 2 DLPKGREAK 24 7 REAKENYGK 15 5 KGREAKENY 13 9AKENYGKTL 11 V2-(SET3)-HLA-A3-9mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 5; each start position is specified, the length of peptide is9 amino acids, and the end position for each peptide is the startposition plus eight. 4 TLGEGKYAG 14 1 ESSTLGEGK 13 2 SSTLGEGKY 11 6GEGKYAGLY 10 3 STLGEGKYA 8 8 GKYAGLYDD 8 7 EGKYAGLYD 7 5 LGEGKYAGL 6 9KYAGLYDDI 6 V3-HLA-A3-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 7; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 46 MLAEDFIQK 25 4 GVDVINTTY 21 6 DVINTTYVS 18 1 VIHGVDVIN 1510 TTYVSNTTY 15 12 YVSNTTYVS 15 27 QPSIFICSK 15 55 STSCNYVEK 15 60YVEKSSTFF 15 7 VINTTYVSN 14 18 YVSNATGSP 14 33 CSKEQELSY 13 59 NYVEKSSTF13 38 ELSYRNRNM 12 V4-HLA-A3-9mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 9; each start position is specified, the length of peptide is9 amino acids, and the end position for each peptide is the startposition plus eight. 2 TLYSGEDLP 16 7 EDLPEQPTF 13 8 DLPEQPTFL 13 9LPEQPTFLK 10 V5-HLA-A3-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 11; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 5 TVNSSNSIK 23 3 KLTVNSSNS 16 8 SSNSIKQRK 11V6-HLA-A3-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight. 1EEIEFIVPK 18 9 KLEHIEQDE 13 5 FIVPKLEHI 12 6 IVPKLEHIE 12 4 EFIVPKLEH 102 EIEFIVPKL 8 V7-HLA-A3-9mers-282P1G3 Each peptide is a portion of SEQID NO: 15; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 19 HPEPPRWTK 18 6 IVEDNISHE 16 20 PEPPRWTKK 16 5 VIVEDNISH15 17 TLHPEPPRW 14 4 HVIVEDNIS 13 10 NISHELFTL 12 14 ELFTLHPEP 10 11ISHELFTLH 8 779 ETVTNHTLR 23 835 DVINSTLVK 23 1147 ETFGEYSDS 23 125FIVPSVPKL 22 142 EVEEGDPIV 22 266 ITILKGEIL 22 395 DVVFPREIS 22 450ATVVGYSAF 22 755 EQNGPGLEY 22 833 GVDVINSTL 22 880 EVNILRFSG 22 1091DDISTQGWF 22 122 EIEFIVPSV 21 194 EEKDSRNDY 21 359 STGSNGILL 21 597VTLEDQGIY 21 707 EVGRSQPSQ 21 826 DTAPVIHGV 21 974 DTYEIGELN 21 2EPLLLGRGL 20 26 EIPSSVQQV 20 44 QVAFPFDEY 20 121 EEIEFIVPS 20 289DWNKIGGDL 20 573 EAFEINGTE 20 778 EETVTNHTL 20 930 GVPEQPTFL 20 1156DEKPLKGSL 20 1182 EYGEGDHGL 20 11 IVYLMFLLL 19 69 WTKDGNPFY 19 136EKIDPLEVE 19 214 IVQKMPMKL 19 540 PRIPKLHML 19 721 ETPPAAPDR 19 798DVKVQAINQ 19 816 VTLYSGEDY 19 935 PTFLKVIKV 19 942 KVDKDTATL 19 1058EHIVRLMTK 19 1080 ETRGREYAG 19 145 EGDPIVLPC 18 474 QKVEEVKPL 18 477EEVKPLEGR 18 592 LTISNVTLE 18 638 ERQNRSVRL 18 657 NISEYIVEF 18 670EEPGRWEEL 18 789 MTPAVYAPY 18 829 PVIHGVDVI 18 893 GMVPSLDAF 18 1094STQGWFIGL 18 10 LIVYLMFLL 17 33 QVPTIIKQS 17 175 EQDERVYMS 17 238EIGSKANSI 17 271 GEILLLECF 17 581 EDGRIIIDG 17 584 RIIIDGANL 17 799VKVQAINQL 17 961 NLTGYLLQY 17 977 EIGELNDIN 17 1001 ATTKYKFYL 17 1020PITEESSTL 17 1104 CAIALLTLL 17 9 GLIVYLMEL 16 51 EYFQIECEA 16 99HISHFQGKY 16 172 EHIEQDERV 16 197 DSRNDYCCF 16 222 LTVNSLKHA 16 263ESSITILKG 16 277 ECFAEGLPT 16 314 ENVSYQDKG 16 401 EISFTNLQP 16 421NVHGTILAN 16 432 IDVVDVRPL 16 511 WVENAIGKT 16 520 AVTANLDIR 16 617ADITQVTVL 16 622 VTVLDVPDP 16 686 TTVILPLAP 16 919 ESEPYIFQT 16 1023EESSTLGEG 16 1030 EGSKGIGKI 16 1114 LTVCFVKRN 16 1209 SVESNGSST 16 5LLGRGLIVY 15 13 YLMFLLLKF 15 35 PTIIKQSKV 15 133 LPKEKIDPL 15 144EEGDPIVLP 15 157 KGLPPLHIY 15 178 ERVYMSQKG 15 272 EILLLECFA 15 373EPQPTIKWR 15 462 EFFASPEAV 15 468 EAVVSWQKV 15 469 AVVSWQKVE 15 629DPPENLHLS 15 685 KTTVILPLA 15 847 STVPKDRVH 15 957 KLNGNLTGY 15 980ELNDINITT 15 1078 VIETRGREY 15 1140 EIQSVKDET 15 1185 EGDHGLFSE 15 1189GLFSEDGSF 15 90 GTFRIPNEG 14 124 EFIVPSVPK 14 173 HIEQDERVY 14 192NVEEKDSRN 14 223 TVNSLKHAN 14 245 SIKQRKPKL 14 267 TILKGEILL 14 338DFHVIVEEP 14 340 HVIVEEPPR 14 487 YHIYENGTL 14 525 LDIRNATKL 14 537PKNPRIPKL 14 576 EINGTEDGR 14 582 DGRIIIDGA 14 660 EYIVEFEGN 14 676EELTRVQGK 14 684 KKTTVILPL 14 701 RVIAVNEVG 14 704 AVNEVGRSQ 14 786LRVMTPAVY 14 811 PDPQSVTLY 14 839 STLVKVTWS 14 844 VTWSTVPKD 14 852DRVHGRLKG 14 867 KTKSLLDGR 14 878 PKEVNILRF 14 926 QTPEGVPEQ 14 933EQPTFLKVI 14 939 KVIKVDKDT 14 973 NDTYEIGEL 14 1055 PGAEHIVRL 14 1073SIFQDVIET 14 1103 MCAIALLTL 14 1105 AIALLTLLL 14 1128 SVKEKEDLH 14 6LGRGLIVYL 13 41 SKVQVAFPF 13 45 VAFPFDEYF 13 65 PTFSWTKDG 13 78FTDHRIIPS 13 95 PNEGHISHF 13 147 DPIVLPCNP 13 163 HIYWMNIEL 13 219PMKLTVNSL 13 261 GSESSITIL 13 268 ILKGEILLL 13 305 ENYGKTLKI 13 356AVYSTGSNG 13 456 SAFLHCEFF 13 530 ATKLRVSPK 13 614 DSAADITQV 13 618DITQVTVLD 13 619 ITQVTVLDV 13 677 ELTRVQGKK 13 775 EWEEETVTN 13 780TVTNHTLRV 13 815 SVTLYSGED 13 876 THPKEVNIL 13 890 RNSGMVPSL 13 899DAFSEFHLT 13 906 LTVLAYNSK 13 907 TVLAYNSKG 13 962 LTGYLLQYQ 13 968QYQIINDTY 13 983 DINITTPSK 13 991 KPSWHLSNL 13 1045 QKTHPIEVF 13 1082RGREYAGLY 13 1092 DISTQGWFI 13 1106 IALLTLLLL 13 1109 LTLLLLTVC 13 1119VKRNRGGKY 13 1144 VKDETFGEY 13 1154 DSDEKPLKG 13 1157 EKPLKGSLR 13 1159PLKGSLRSL 13

TABLE XXVI Pos 123456789 score V1-HLA-A26-9mers-282P1G3 Each peptide isa portion of SEQ ID NO: 3; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 626 DVPDPPENL 27 687 TVILPLAPF 27 1051EVFEPGAEH 27 1193 EDGSFIGAY 27 903 EFHLTVLAY 26 396 VVFPREISF 25 436DVRPLIQTK 25 653 DHNSNISEY 25 946 DTATLSWGL 25 1077 DVIETRGRE 25 1175ESADSLVEY 25 447 ENYATVVGY 24 853 RVHGRLKGY 24 929 EGVPEQPTF 24 302ETKENYGKT 23 433 DVVDVRPLI 23 451 TVVGYSAFL 23 478 EVKPLEGRR 23 500TTEEDAGSY 23 743 EMIIKWEPL 23 V2-(SET1)-HLA-A26-9mers-(SET1)-282P1G3Each peptide is a portion of SEQ ID NO: 5; each start position isspecified, the length of peptide is 9 amino acids, and the end positionfor each peptide is the start position plus eight. 1 FIVPSVPKF 22 9FPKEKIDPL 15 2 IVPSVPKFP 11 5 SVPKFPKEK 11V2-(SET2)-HLA-A26-9mers-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 8 EAKENYGKT 15 5 KGREAKENY 12 9 AKENYGKTL 10 2 DLPKGREAK 9V2-(SET3)-HLA-A26-9mers-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 2 SSTLGEGKY 14 1 ESSTLGEGK 12 7 EGKYAGLYD 12 6 GEGKYAGLY 11 3STLGEGKYA 10 5 LGEGKYAGL 9 V3-HLA-A26-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 7; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 4 GVDVINTTY 23 6 DVINTTYVS 22 10 TTYVSNTTY 2060 YVEKSSTFF 18 59 NYVEKSSTF 17 49 EDFIQKSTS 16 31 FICSKEQEL 14 33CSKEQELSY 14 50 DFIQKSTSC 14 18 YVSNATGSP 12 62 EKSSTFFKI 12 23TGSPQPSIF 11 52 IQKSTSCNY 11 V4-HLA-A26-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 9; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 7 EDLPEQPTF 20 8 DLPEQPTFL 18 1 VTLYSGEDL 17V5-HLA-A26-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 4 LTVNSSNSI 13 5 TVNSSNSIK 13 V6-HLA-A26-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 13; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 2 EIEFIVPKL 29 1 EEIEFIVPK 204 EFIVPKLEH 15 5 FIVPKLEHI 14 V7-HLA-A26-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 15; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 8 EDNISHELF 18 6 IVEDNISHE 17 10NISHELFTL 17 14 ELFTLHPEP 15 2 DFHVIVEDN 14 4 HVIVEDNIS 14 9 DNISHELFT14 5 VIVEDNISH 12 7 VEDNISHEL 10 1 HDFHVIVED 8 16 FTLHPEPPR 8

TABLE XXVII Pos 123456789 score V1-HLA-B0702-9mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 988 TPSKPSWHL 26 810 GPDPQSVTL24 151 LPCNPPKGL 23 154 NPPKGLPPL 23 539 NPRIPKLHM 23 542 IPKLHMLEL 23991 KPSWHLSNL 23 2 EPLLLGRGL 22 133 LPKEKIDPL 21 828 APVIHGVDV 21 954LPKKLNGNL 21 390 HPFAGDVVF 20 795 APYDVKVQA 20 1172 QPTESADSL 20 84IPSNNSGTF 19 130 VPKLPKEKI 19 247 KQRKPKLLL 19 250 KPKLLLPPT 19 726APDRNPQNI 19 730 NPQNIRVQA 19 62 NPEPTFSWT 18 127 VPSVPKLPK 18 352KPQSAVYST 18 385 SPVDNHPFA 18 671 EPGRWEELT 18 758 GPGLEYRVT 18 772APVEWEEET 18 1136 HPDPEIQSV 18 690 LPLAPFVRY 17 890 RNSGMVPSL 17 1019KPITEESST 17 6 LGRGLIVYL 16 47 FPFDEYFQI 16 159 LPPLHIYWM 16 285TPQVDWNKI 16 917 GPESEPYIF 16 1105 AIALLTLLL 16 218 MPMKLTVNS 15 268ILKGEILLL 15 536 SPKNPRIPK 15 617 ADITQVTVL 15 627 VPDPPENLH 15 712QPSQPSDHH 15 723 PPAAPDRNP 15 768 KPQGAPVEW 15 942 KVDKDTATL 15 11VYLMFLLL 14 27 IPSSVQQVP 14 208 FPRLRTIVQ 14 280 AEGLPTPQV 14 419ASNVHGTIL 14 451 TVVGYSAFL 14 682 QGKKTTVIL 14 684 KKTTVILPL 14 931VPEQPTFLK 14 1035 IGKISGVNL 14 1054 EPGAEHIVR 14 1158 KPLKGSLRS 14 1214GSSTATFPL 14 39 KQSKVQVAF 13 59 AKGNPEPTF 13 71 KDGNPFYFT 13 125FIVPSVPKL 13 143 VEEGDPIVL 13 155 PPKGLPPLH 13 203 CCFAAFPRL 13 205FAAFPRLRT 13 297 LPKGRETKE 13 346 PPRWTKKPQ 13 370 AEGEPQPTI 13 432IDVVDVRPL 13 517 GKTAVTANL 13 552 CESKCDSHL 13 558 SHLKHSLKL 13 584RIIIDGANL 13 626 DVPDPPENL 13 628 PDPPENLHL 13 638 ERQNRSVRL 13 670EEPGRWEEL 13 693 APFVRYQFR 13 787 RVMTPAVYA 13 812 DPQSVTLYS 13 824YPDTAPVIH 13 921 EPYIFQTPE 13 1001 ATTKYKFYL 13 1055 PGAEHIVRL 13 1094STQGWFIGL 13 1103 MCAIALLTL 13 1106 IALLTLLLL 13V2-(SET1)-HLA-B0702-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 9 FPKEKIDPL 21 6 VPKFPKEKI 19 3 VPSVPKFPK 16V2-(SET2)-HLA-B0702-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 3 LPKGREAKE 13 9 AKENYGKTL 13 1 GDLPKGREA 8V2-(SET3)-HLA-B0702-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 5 LGEGKYAGL 13 9 KYAGLYDDI 10 3 STLGEGKYA 9V3-HLA-B0702-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 22 ATGSPQPSI 13 27 QPSIFICSK 12 25 SPQPSIFIC 11 39 LSYRNRNML 1124 GSPQPSIFI 10 31 FICSKEQEL 10 62 EKSSTFFKI 10 2 IHGVDVINT 9 23TGSPQPSIF 9 38 ELSYRNRNM 9 44 RNMLAEDFI 9 48 AEDFIQKST 9 60 YVEKSSTFF 95 VDVINTTYV 8 8 INTTYVSNT 8 11 TYVSNTTYV 8 40 SYRNRNMLA 8 53 QKSTSCNYV 814 SNTTYVSNA 7 15 NTTYVSNAT 7 3 HGVDVINTT 6 9 NTTYVSNTT 6 43 NRNMLAEDF 658 CNYVEKSST 6 59 NYVEKSSTF 6 V4-HLA-B0702-9mers Each peptide is aportion of SEQ ID NO: 9; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 9 LPEQPTFLK 14 8 DLPEQPTFL 12 1 VTLYSGEDL 116 GEDLPEQPT 11 7 EDLPEQPTF 9 3 LYSGEDLPE 7 V5-HLA-B0702-9mers Eachpeptide is a portion of SEQ ID NO: 11; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 4 LTVNSSNSI 6 6 VNSSNSIKQ 2 7NSSNSIKQR 2 9 SNSIKQRKP 2 V6-HLA-B0702-9mers Each peptide is a portionof SEQ ID NO: 13; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 2 EIEFIVPKL 13 7 VPKLEHIEQ 10 5 FIVPKLEHI 7 4EFIVPKLEH 6 V7-HLA-B0702-9mers Each peptide is a portion of SEQ ID NO:15; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 19 HPEPPRWTK 15 10 NISHELFTL 12 7 VEDNISHEL 11 9 DNISHELFT 9 18LHPEPPRWT 9 8 EDNISHELF 7

TABLE XXVIII Pos 123456789 score V1-HLA-B08-9mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 133 LPKEKIDPL 39 245 SIKQRKPKL34 542 IPKLHMLEL 29 268 ILKGEILLL 28 954 LPKKLNGNL 27 849 VPKDRVHGR 261159 PLKGSLRSL 26 130 VPKLPKEKI 24 297 LPKGRETKE 24 855 HGRLKGYQI 241128 SVKEKEDLH 24 377 TIKWRVNGS 23 1203 GSKEKGSVE 23 208 FPRLRTIVQ 22219 PMKLTVNSL 22 238 EIGSKANSI 22 246 IKQRKPKLL 22 266 ITILKGEIL 22 743EMIIKWEPL 22 863 INWWKTKSL 22 1035 IGKISGVNL 22 1042 NLTQKTHPI 22 638ERQNRSVRL 21 670 EEPGRWEEL 21 682 QGKKTTVIL 21 1002 TTKYKFYLR 21 104QGKYRCFAS 20 248 QRKPKLLLP 20 481 PLEGRRYHI 20 530 ATKLRVSPK 20 540PRIPKLHML 20 865 WWKTKSLLD 20 877 HPKEVNILR 20 1156 DEKPLKGSL 20 2EPLLLGRGL 19 226 SLKHANDSS 19 537 PKNPRIPKL 19 563 SLKLSWSKD 19 740QPKEMIIKW 19 796 PYDVKVQAI 19 937 FLKVIKVDK 19V2-(SET1)-HLA-B08-9mers-(SET1)-282P1G3 Each peptide is a portion of SEQID NO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 9 FPKEKIDPL 40 6 VPKFPKEKI 23V2-(SET2)-HLA-B08-9mers-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 3 LPKGREAKE 24 8 EAKENYGKT 18 1 GDLPKGREA 12 6 GREAKENYG 11 9AKENYGKTL 11 V2-(SET3)-HLA-B08-9mers-282P1G3 Each peptide is a portionof SEQ ID NO: 5; each start position is specified, the length of peptideis 9 amino acids, and the end position for each peptide is the startposition plus eight. 5 LGEGKYAGL 20 7 EGKYAGLYD 13 4 TLGEGKYAG 9V3-HLA-B08-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7; eachstart position is specified, the length of peptide is 9 amino acids, andthe end position for each peptide is the start position plus eight. 31FICSKEQEL 26 38 ELSYRNRNM 18 59 NYVEKSSTF 18 40 SYRNRNMLA 17 33CSKEQELSY 12 V4-HLA-B08-9mers-282P1G3 Each peptide is a portion of SEQID NO: 9; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 8 DLPEQPTFL 18 1 VTLYSGEDL 12 7 EDLPEQPTF 8V5-HLA-B08-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 1 PMKLTVNSS 12 9 SNSIKQRKP 12 3 KLTVNSSNS 7 4 LTVNSSNSI 6V6-HLA-B08-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 5 FIVPKLEHI 21 7 VPKLEHIEQ 19 2 EIEFIVPKL 17V7-HLA-B08-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 10 NISHELFTL 14 7 VEDNISHEL 12 14 ELFTLHPEP 9 5 VIVEDNISH 8 8EDNISHELF 8 20 PEPPRWTKK 8 3 FHVIVEDNI 7 19 HPEPPRWTK 7 17 TLHPEPPRW 6

TABLE XXIX Pos 123456789 score V1-HLA-B1510-9mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 876 THPKEVNIL 23 487 YHIYENGTL22 558 SHLKHSLKL 21 1055 PGAEHIVRL 17 432 IDVVDVRPL 16 810 GPDPQSVTL 16101 SHFQGKYRC 15 143 VEEGDPIVL 15 638 ERQNRSVRL 15 6 LGRGLIVYL 14 125FIVPSVPKL 14 172 EHIEQDERV 14 214 IVQKMPMKL 14 268 ILKGEILLL 14 336THDFHVIVE 14 537 PKNPRIPKL 14 542 IPKLHMLEL 14 718 DHHETPPAA 14 719HHETPPAAP 14 753 SMEQNGPGL 14 831 IHGVDVINS 14 890 RNSGMVPSL 14 988TPSKPSWHL 14 1035 IGKISGVNL 14 2 EPLLLGRGL 13 154 NPPKGLPPL 13 203CCFAAFPRL 13 245 SIKQRKPKL 13 246 IKQRKPKLL 13 247 KQRKPKLLL 13 261GSESSITIL 13 267 TILKGEILL 13 303 TKENYGKTL 13 591 NLTISNVTL 13 617ADITQVTVL 13 626 DVPDPPENL 13 653 DHNSNISEY 13 670 EEPGRWEEL 13 682QGKKTTVIL 13 778 EETVTNHTL 13 833 GVDVINSTL 13 901 FSEFHLTVL 13 930GVPEQPTFL 13 1047 THPIEVFEP 13 1058 EHIVRLMTK 13 1100 IGLMCAIAL 13 1127YSVKEKEDL 13 1156 DEKPLKGSL 13 1159 PLKGSLRSL 13 1182 EYGEGDHGL 13 9GLIVYLMFL 12 11 IVYLMFLLL 12 133 LPKEKIDPL 12 151 LPCNPPKGL 12 174IEQDERVYM 12 266 ITILKGEIL 12 358 YSTGSNGIL 12 389 NHPFAGDVV 12 451TVVGYSAFL 12 474 QKVEEVKPL 12 540 PRIPKLHML 12 550 LHCESKCDS 12 552CESKCDSHL 12 556 CDSHLKHSL 12 605 YCCSAHTAL 12 628 PDPPENLHL 12 657NISEYIVEF 12 783 NHTLRVMTP 12 799 VKVQAINQL 12 850 PKDRVHGRL 12 863INWWKTKSL 12 864 NWWKTKSLL 12 878 PKEVNILRF 12 942 KVDKDTATL 12 950LSWGLPKKL 12 973 NDTYEIGEL 12 994 WHLSNLNAT 12 1001 ATTKYKFYL 12 1020PITEESSTL 12 1101 GLMCAIALL 12 1103 MCAIALLTL 12 1106 IALLTLLLL 12 1135LHPDPEIQS 12 1214 GSSTATFPL 12 10 LIVYLMFLL 11 39 KQSKVQVAF 11 80DHRIIPSNN 11 84 IPSNNSGTF 11 98 GHISHFQGK 11 107 YRCFASNKL 11 162LHIYWMNIE 11 163 HIYWMNIEL 11 180 VYMSQKGDL 11 219 PMKLTVNSL 11 228KHANDSSSS 11 275 LLECFAEGL 11 289 DWNKIGGDL 11 324 YRCTASNFL 11 359STGSNGILL 11 390 HPFAGDVVF 11 399 PREISFTNL 11 419 ASNVHGTIL 11 459LHCEFFASP 11 517 GKTAVTANL 11 525 LDIRNATKL 11 561 KHSLKLSWS 11 609AHTALDSAA 11 634 LHLSERQNR 11 684 KKTTVILPL 11 743 EMIIKWEPL 11 854VHGRLKGYQ 11 898 LDAFSEFHL 11 929 EGVPEQPTF 11 946 DTATLSWGL 11 954LPKKLNGNL 11 991 KPSWHLSNL 11 1056 GAEHIVRLM 11 1081 TRGREYAGL 11 1094STQGWFIGL 11 1105 AIALLTLLL 11 1141 IQSVKDETF 11 1152 YSDSDEKPL 11V2-(SET1)-HLA-B1510-9mers-(SET1)-282P1G3 Each peptide is a portion ofSEQ ID NO: 5; each start position is specified, the length of peptide is9 amino acids, and the end position for each peptide is the startposition plus eight. 9 FPKEKIDPL 12 1 FIVPSVPKF 10V2-(SET2)-HLA-B1510-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 9 AKENYGKTL 12 1 GDLPKGREA 6V2-(SET3)-HLA-B1510-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 5 LGEGKYAGL 12 4 TLGEGKYAG 5 V3-HLA-B1510-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 7; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 2 IHGVDVINT 14 39 LSYRNRNML 1223 TGSPQPSIF 11 31 FICSKEQEL 11 38 ELSYRNRNM 10 60 YVEKSSTFF 9 59NYVEKSSTF 8 43 NRNMLAEDF 6 V4-HLA-B1510-9mers-282P1G3 Each peptide is aportion of SEQ ID NO: 9; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 8 DLPEQPTFL 12 7 EDLPEQPTF 11 1 VTLYSGEDL 10V5-HLA-B1510-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 8 SSNSIKQRK 3 9 SNSIKQRKP 3 3 KLTVNSSNS 2 6 VNSSNSIKQ 2 7NSSNSIKQR 2 1 PMKLTVNSS 1 5 TVNSSNSIK 1 V6-HLA-B1510-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 13; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 2 EIEFIVPKL 14V7-HLA-B1510-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 18 LHPEPPRWT 15 10 NISHELFTL 12 7 VEDNISHEL 11 12 SHELFTLHP 11 3FHVIVEDNI 10 8 EDNISHELF 7 17 TLHPEPPRW 7

TABLE XXX Pos 123456789 score V1-HLA-B2705-9mers-282P1G3 Each peptide isa portion of SEQ ID NO: 3; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 209 PRLRTIVQK 27 7 GRGLIVYLM 25 399PREISFTNL 25 540 PRIPKLHML 25 734 IRVQASQPK 25 1122 NRGGKYSVK 25 107YRCFASNKL 24 533 LRVSPKNPR 24 638 ERQNRSVRL 24 324 YRCTASNFL 22 1081TRGREYAGL 22 786 LRVMTPAVY 21 673 GRWEELTRV 20 92 FRIPNEGHI 19 261GSESSITIL 19 301 RETKENYGK 19 485 RRYHIYENG 19 584 RIIIDGANL 19 856GRLKGYQIN 19 859 KGYQINWWK 19 884 LRFSGQRNS 19 890 RNSGMVPSL 19 1189GLFSEDGSF 19 1199 GAYAGSKEK 19 8 RGLIVYLMF 18 39 KQSKVQVAF 18 268ILKGEILLL 18 271 GEILLLECF 18 291 NKIGGDLPK 18 390 HPFAGDVVF 18 437VRPLIQTKD 18 484 GRRYHIYEN 18 558 SHLKHSLKL 18 562 HSLKLSWSK 18 799VKVQAINQL 18 6 LGRGLIVYL 17 9 GLIVYLMFL 17 81 HRIIPSNNS 17 125 FIVPSVPKL17 247 KQRKPKLLL 17 267 TILKGEILL 17 284 PTPQVDWNK 17 304 KENYGKTLK 17517 GKTAVTANL 17 525 LDIRNATKL 17 537 PKNPRIPKL 17 583 GRIIIDGAN 17 617ADITQVTVL 17 679 TRVQGKKTT 17 684 KKTTVILPL 17 709 GRSQPSQPS 17 810GPDPQSVTL 17 833 GVDVINSTL 17 893 GMVPSLDAF 17 929 EGVPEQPTF 17 1055PGAEHIVRL 17 1101 GLMCAIALL 17 1150 GEYSDSDEK 17 1161 KGSLRSLNR 17 15MFLLLKFSK 16 95 PNEGHISHF 16 106 KYRCFASNK 16 149 IVLPCNPPK 16 154NPPKGLPPL 16 182 MSQKGDLYF 16 191 ANVEEKDSR 16 203 CCFAAFPRL 16 210RLRTIVQKM 16 212 RTIVQKMPM 16 214 IVQKMPMKL 16 242 KANSIKQRK 16 245SIKQRKPKL 16 329 SNFLGTATH 16 380 WRVNGSPVD 16 396 VVFPREISF 16 424GTILANANI 16 430 ANIDVVDVR 16 436 DVRPLIQTK 16 491 ENGTLQINR 16 534RVSPKNPRI 16 657 NISEYIVEF 16 687 TVILPLAPF 16 760 GLEYRVTWK 16 852DRVHGRLKG 16 874 GRTHPKEVN 16 878 PKEVNILRF 16 930 GVPEQPTFL 16 942KVDKDTATL 16 949 TLSWGLPKK 16 954 LPKKLNGNL 16 991 KPSWHLSNL 16 1074IFQDVIETR 16 1104 CAIALLTLL 16 1106 IALLTLLLL 16 1124 GGKYSVKEK 16 1137PDPEIQSVK 16 11 IVYLMFLLL 15 13 YLMFLLLKF 15 41 SKVQVAFPF 15 45VAFPFDEYF 15 98 GHISHFQGK 15 124 EFIVPSVPK 15 133 LPKEKIDPL 15 157KGLPPLHIY 15 163 HIYWMNIEL 15 188 LYFANVEEK 15 213 TIVQKMPMK 15 220MKLTVNSLK 15 234 SSSTEIGSK 15 239 IGSKANSIK 15 241 SKANSIKQR 15 266ITILKGEIL 15 296 DLPKGRETK 15 300 GRETKENYG 15 316 VSYQDKGNY 15 344EEPPRWTKK 15 450 ATVVGYSAF 15 451 TVVGYSAFL 15 477 EEVKPLEGR 15 480KPLEGRRYH 15 487 YHIYENGTL 15 527 IRNATKLRV 15 634 LHLSERQNR 15 677ELTRVQGKK 15 696 VRYQFRVIA 15 728 DRNPQNIRV 15 744 MIIKWEPLK 15 792AVYAPYDVK 15 835 DVINSTLVK 15 853 RVHGRLKGY 15 875 RTHPKEVNI 15 876THPKEVNIL 15 917 GPESEPYIF 15 950 LSWGLPKKL 15 957 KLNGNLTGY 15 973NDTYEIGEL 15 988 TPSKPSWHL 15 996 LSNLNATTK 15 1020 PITEESSTL 15 1029GEGSKGIGK 15 1030 EGSKGIGKI 15 1035 IGKISGVNL 15 1038 ISGVNLTQK 15 1040GVNLTQKTH 15 1045 QKTHPIEVF 15 1051 EVFEPGAEH 15 1058 EHIVRLMTK 15 1100IGLMCAIAL 15 1110 TLLLLTVCF 15 1127 YSVKEKEDL 15 1159 PLKGSLRSL 15 2EPLLLGRGL 14 12 VYLMFLLLK 14 59 AKGNPEPTF 14 94 IPNEGHISH 14 117IAMSEEIEF 14 129 SVPKLPKEK 14 143 VEEGDPIVL 14 171 LEHIEQDER 14 178ERVYMSQKG 14 219 PMKLTVNSL 14 221 KLTVNSLKH 14 244 NSIKQRKPK 14 248QRKPKLLLP 14 299 KGRETKENY 14 305 ENYGKTLKI 14 323 NYRCTASNF 14 340HVIVEEPPR 14 343 VEEPPRWTK 14 347 PRWTKKPQS 14 358 YSTGSNGIL 14 373EPQPTIKWR 14 384 GSPVDNHPF 14 403 SFTNLQPNH 14 456 SAFLHCEFF 14 467PEAVVSWQK 14 472 SWQKVEEVK 14 474 QKVEEVKPL 14 478 EVKPLEGRR 14 510CWVENAIGK 14 530 ATKLRVSPK 14 542 IPKLHMLEL 14 552 CESKCDSHL 14 591NLTISNVTL 14 628 PDPPENLHL 14 631 PENLHLSER 14 637 SERQNRSVR 14 661YIVEFEGNK 14 666 EGNKEEPGR 14 690 LPLAPFVRY 14 693 APFVRYQFR 14 700FRVIAVNEV 14 727 PDRNPQNIR 14 739 SQPKEMIIK 14 756 QNGPGLEYR 14 763YRVTWKPQG 14 776 WEEETVTNH 14 811 PDPQSVTLY 14 843 KVTWSTVPK 14 864NWWKTKSLL 14 867 KTKSLLDGR 14 869 KSLLDGRTH 14 877 HPKEVNILR 14 882NILRFSGQR 14 896 PSLDAFSEF 14 901 FSEFHLTVL 14 906 LTVLAYNSK 14 915GAGPESEPY 14 948 ATLSWGLPK 14 963 TGYLLQYQI 14 997 SNLNATTKY 14 999LNATTKYKF 14 1001 ATTKYKFYL 14 1025 SSTLGEGSK 14 1061 VRLMTKNWG 14 1082RGREYAGLY 14 1083 GREYAGLYD 14 1091 DDISTQGWF 14 1105 AIALLTLLL 14 1112LLLTVCFVK 14 1115 TVCFVKRNR 14 1120 KRNRGGKYS 14 1141 IQSVKDETF 14 1156DEKPLKGSL 14 1172 QPTESADSL 14 1182 EYGEGDHGL 14 5 LLGRGLIVY 13 19LKFSKAIEI 13 34 VPTIIKQSK 13 63 PEPTFSWTK 13 68 SWTKDGNPF 13 73GNPFYFTDH 13 74 NPFYFTDHR 13 84 IPSNNSGTF 13 85 PSNNSGTFR 13 102HFQGKYRCF 13 111 ASNKLGIAM 13 127 VPSVPKLPK 13 159 LPPLHIYWM 13 200NDYCCFAAF 13 206 AAFPRLRTI 13 211 LRTIVQKMP 13 289 DWNKIGGDL 13 370AEGEPQPTI 13 371 EGEPQPTIK 13 419 ASNVHGTIL 13 432 IDVVDVRPL 13 441IQTKDGENY 13 524 NLDIRNATK 13 556 CDSHLKHSL 13 557 DSHLKHSLK 13 597VTLEDQGIY 13 626 DVPDPPENL 13 641 NRSVRLTWE 13 644 VRLTWEAGA 13 653DHNSNISEY 13 670 EEPGRWEEL 13 672 PGRWEELTR 13 676 EELTRVQGK 13 682QGKKTTVIL 13 689 ILPLAPFVR 13 692 LAPFVRYQF 13 721 ETPPAAPDR 13 743EMIIKWEPL 13 746 IKWEPLKSM 13 753 SMEQNGPGL 13 755 EQNGPGLEY 13 779ETVTNHTLR 13 847 STVPKDRVH 13 850 PKDRVHGRL 13 861 YQINWWKTK 13 863INWWKTKSL 13 889 QRNSGMVPS 13 931 VPEQPTFLK 13 934 QPTFLKVIK 13 937FLKVIKVDK 13 946 DTATLSWGL 13 961 NLTGYLLQY 13 976 YEIGELNDI 13 1054EPGAEHIVR 13 1056 GAEHIVRLM 13 1094 STQGWFIGL 13 1103 MCAIALLTL 13 1113LLTVCFVKR 13 1153 SDSDEKPLK 13 1157 EKPLKGSLR 13 1168 NRDMQPTES 13 1212SNGSSTATF 13 1214 GSSTATFPL 13 V2-(SET1)-HLA-B2705-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 5; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 1 FIVPSVPKF 17 9 FPKEKIDPL 155 SVPKFPKEK 13 3 VPSVPKFPK 12 6 VPKFPKEKI 10V2-(SET2)-HLA-B2705-9mers-(SET1)-282P1G3 Each peptide is a portion ofSEQ ID NO: 5; each start position is specified, the length of peptide is9 amino acids, and the end position for each peptide is the startposition plus eight. 7 REAKENYGK 19 6 GREAKENYG 15 2 DLPKGREAK 14 5KGREAKENY 14 9 AKENYGKTL 12 V2-(SET3)-HLA-B2705-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 5; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 5 LGEGKYAGL 14 6 GEGKYAGLY 142 SSTLGEGKY 13 1 ESSTLGEGK 11 9 KYAGLYDDI 11 8 GKYAGLYDD 9V3-HLA-B2705-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 43 NRNMLAEDF 22 4 GVDVINTTY 16 59 NYVEKSSTF 16 60 YVEKSSTFF 16 10TTYVSNTTY 15 34 SKEQELSYR 15 24 GSPQPSIFI 14 27 QPSIFICSK 14 36EQELSYRNR 14 39 LSYRNRNML 13 46 MLAEDFIQK 13 22 ATGSPQPSI 12 23TGSPQPSIF 12 31 FICSKEQEL 12 52 IQKSTSCNY 12 55 STSCNYVEK 12 33CSKEQELSY 11 38 ELSYRNRNM 11 41 YRNRNMLAE 11 44 RNMLAEDFI 11 61VEKSSTFFK 11 V4-HLA-B2705-9mers-282P1G3 Each peptide is a portion of SEQID NO: 9; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 7 EDLPEQPTF 18 1 VTLYSGEDL 13 8 DLPEQPTFL 13 9 LPEQPTFLK 13V5-HLA-B2705-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 7 NSSNSIKQR 15 8 SSNSIKQRK 14 5 TVNSSNSIK 13 4 LTVNSSNSI 11V6-HLA-B2705-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 1 EEIEFIVPK 17 2 EIEFIVPKL 15 4 EFIVPKLEH 14 5 FIVPKLEHI 10V7-HLA-B2705-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 20 PEPPRWTKK 15 16 FTLHPEPPR 14 19 HPEPPRWTK 14 5 VIVEDNISH 13 7VEDNISHEL 13 10 NISHELFTL 13 11 ISHELFTLH 13 8 EDNISHELF 11 3 FHVIVEDNI10 1 HDFHVIVED 9

TABLE XXXI Pos 123456789 score V1-HLA-2709-9mers-282P1G3 Each peptide isa portion of SEQ ID NO: 3; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 7 GRGLIVYLM 24 540 PRIPKLHML 22 638ERQNRSVRL 22 673 GRWEELTRV 22 399 PREISFTNL 21 527 IRNATKLRV 21 92FRIPNEGHI 20 107 YRCFASNKL 20 324 YRCTASNFL 20 700 FRVIAVNEV 20 728DRNPQNIRV 20 1081 TRGREYAGL 20 485 RRYHIYENG 18 584 RIIIDGANL 17 890RNSGMVPSL 16 8 RGLIVYLMF 15 517 GKTAVTANL 15 534 RVSPKNPRI 15 583GRIIIDGAN 15 810 GPDPQSVTL 15 856 GRLKGYQIN 15 875 RTHPKEVNI 15 9GLIVYLMFL 14 11 IVYLMFLLL 14 125 FIVPSVPKL 14 203 CCFAAFPRL 14 209PRLRTIVQK 14 210 RLRTIVQKM 14 261 GSESSITIL 14 432 IDVVDVRPL 14 484GRRYHIYEN 14 684 KKTTVILPL 14 833 GVDVINSTL 14 874 GRTHPKEVN 14 884LRFSGQRNS 14 1083 GREYAGLYD 14 1100 IGLMCAIAL 14 1106 IALLTLLLL 14 1189GLFSEDGSF 14 212 RTIVQKMPM 13 247 KQRKPKLLL 13 300 GRETKENYG 13 308GKTLKIENV 13 424 GTILANANI 13 558 SHLKHSLKL 13 617 ADITQVTVL 13 688VILPLAPFV 13 696 VRYQFRVIA 13 697 RYQFRVIAV 13 709 GRSQPSQPS 13 763YRVTWKPQG 13 808 GSGPDPQSV 13 893 GMVPSLDAF 13 917 GPESEPYIF 13 930GVPEQPTFL 13 942 KVDKDTATL 13 964 GYLLQYQII 13 991 KPSWHLSNL 13 1035IGKISGVNL 13 1056 GAEHIVRLM 13 1101 GLMCAIALL 13 1121 RNRGGKYSV 13 1214GSSTATFPL 13 2 EPLLLGRGL 12 19 LKFSKAIEI 12 23 KAIEIPSSV 12 81 HRIIPSNNS12 135 KEKIDPLEV 12 163 HIYWMNIEL 12 206 AAFPRLRTI 12 248 QRKPKLLLP 12266 ITILKGEIL 12 267 TILKGEILL 12 268 ILKGEILLL 12 271 GEILLLECF 12 347PRWTKKPQS 12 380 WRVNGSPVD 12 384 GSPVDNHPF 12 394 GDVVFPREI 12 474QKVEEVKPL 12 525 LDIRNATKL 12 533 LRVSPKNPR 12 537 PKNPRIPKL 12 542IPKLHMLEL 12 589 GANLTISNV 12 591 NLTISNVTL 12 628 PDPPENLHL 12 644VRLTWEAGA 12 680 RVQGKKTTV 12 734 IRVQASQPK 12 799 VKVQAINQL 12 822EDYPDTAPV 12 852 DRVHGRLKG 12 889 QRNSGMVPS 12 963 TGYLLQYQI 12 1001ATTKYKFYL 12 1055 PGAEHIVRL 12 1061 VRLMTKNWG 12 1105 AIALLTLLL 12 1120KRNRGGKYS 12 1152 YSDSDEKPL 12 1172 QPTESADSL 12 4 LLLGRGLIV 11 6LGRGLIVYL 11 10 LIVYLMELL 11 26 EIPSSVQQV 11 29 SSVQQVPTI 11 37IIKQSKVQV 11 39 KQSKVQVAF 11 45 VAFPFDEYF 11 47 FPFDEYFQI 11 75PFYFTDHRI 11 76 FYFTDHRII 11 122 EIEFIVPSV 11 143 VEEGDPIVL 11 154NPPKGLPPL 11 178 ERVYMSQKG 11 180 VYMSQKGDL 11 185 KGDLYFANV 11 211LRTIVQKMP 11 214 IVQKMPMKL 11 219 PMKLTVNSL 11 245 SIKQRKPKL 11 246IKQRKPKLL 11 275 LLECFAEGL 11 280 AEGLPTPQV 11 289 DWNKIGGDL 11 305ENYGKTLKI 11 333 GTATHDFHV 11 358 YSTGSNGIL 11 359 STGSNGILL 11 390HPFAGDVVF 11 396 VVFPREISF 11 419 ASNVHGTIL 11 429 NANIDVVDV 11 437VRPLIQTKD 11 451 TVVGYSAFL 11 487 YHIYENGTL 11 489 IYENGTLQI 11 498NRTTEEDAG 11 579 GTEDGRIII 11 605 YCCSAHTAL 11 611 TALDSAADI 11 619ITQVTVLDV 11 626 DVPDPPENL 11 679 TRVQGKKTT 11 682 QGKKTTVIL 11 743EMIIKWEPL 11 753 SMEQNGPGL 11 778 EETVTNHTL 11 780 TVTNHTLRV 11 786LRVMTPAVY 11 828 APVIHGVDV 11 850 PKDRVHGRL 11 863 INWWKTKSL 11 876THPKEVNIL 11 929 EGVPEQPTF 11 935 PTFLKVIKV 11 954 LPKKLNGNL 11 959NGNLTGYLL 11 970 QIINDTYEI 11 973 NDTYEIGEL 11 1020 PITEESSTL 11 1033KGIGKISGV 11 1066 KNWGDNDSI 11 1103 MCAIALLTL 11 1104 CAIALLTLL 11 1110TLLLLTVCF 11 1111 LLLLTVCFV 11 1127 YSVKEKEDL 11 1133 EDLHPDPEI 11 1156DEKPLKGSL 11 V2-(SET1)-HLA-B2709-9mers-282P1G3 Each peptide is a portionof SEQ ID NO: 5; each start position is specified, the length of peptideis 9 amino acids, and the end position for each peptide is the startposition plus eight. 1 FIVPSVPKF 12 9 FPKEKIDPL 10 6 VPKFPKEKI 8V2-(SET2)-HLA-B2709-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 6 GREAKENYG 13 9 AKENYGKTL 11 1 GDLPKGREA 6V2-(SET3)-HLA-B2709-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 5 LGEGKYAGL 10 9 KYAGLYDDI 10 8 GKYAGLYDD 6 6 GEGKYAGLY 4V3-HLA-B2709-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 43 NRNMLAEDF 19 39 LSYRNRNML 12 44 RNMLAEDFI 12 22 ATGSPQPSI 1124 GSPQPSIFI 11 31 FICSKEQEL 11 41 YRNRNMLAE 11 11 TYVSNTTYV 10 5VDVINTTYV 9 23 TGSPQPSIF 9 38 ELSYRNRNM 9 59 NYVEKSSTF 9 62 EKSSTFFKI 953 QKSTSCNYV 8 60 YVEKSSTFF 8 V4-HLA-B2709-9mers-282P1G3 Each peptide isa portion of SEQ ID NO: 9; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 1 VTLYSGEDL 12 7 EDLPEQPTF 12 8 DLPEQPTFL10 V5-HLA-B2709-9mers-282P1G3 Each peptide is a portion of SEQ ID NO:11; each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 4 LTVNSSNSI 9 3 KLTVNSSNS 4 V6-HLA-B2709-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 13; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 2 EIEFIVPKL 13 5 FIVPKLEHI 10V7-HLA-B2709-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 7 VEDNISHEL 11 3 FHVIVEDNI 10 10 NISHELFTL 10 8 EDNISHELF 8

TABLE XXXII Pos 123456789 score V1-HLA-B4402-9mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 194 EEKDSRNDY 25 271 GEILLLECF25 670 EEPGRWEEL 25 143 VEEGDPIVL 24 372 GEPQPTIKW 24 778 EETVTNHTL 24976 YEIGELNDI 24 482 LEGRRYHIY 23 1156 DEKPLKGSL 23 370 AEGEPQPTI 22 552CESKCDSHL 21 206 AAFPRLRTI 20 258 TESGSESSI 20 121 EEIEFIVPS 19 617ADITQVTVL 19 25 IEIPSSVQQ 18 141 LEVEEGDPI 18 144 EEGDPIVLP 18 344EEPPRWTKK 18 537 PKNPRIPKL 18 540 PRIPKLHML 18 157 KGLPPLHIY 17 396WFPREISF 17 525 LDIRNATKL 17 580 TEDGRIIID 17 903 EFHLTVLAY 17 1105AIALLTLLL 17 1193 EDGSFIGAY 17 262 SESSITILK 16 268 ILKGEILLL 16 280AEGLPTPQV 16 400 REISFTNLQ 16 465 ASPEAVVSW 16 657 NISEYIVEF 16 676EELTRVQGK 16 684 KKTTVILPL 16 810 GPDPQSVTL 16 893 GMVPSLDAF 16 902SEFHLTVLA 16 929 EGVPEQPTF 16 932 PEQPTFLKV 16 933 EQPTFLKVI 16 979GELNDINIT 16 1139 PEIQSVKDE 16 2 EPLLLGRGL 15 6 LGRGLIVYL 15 39KQSKVQVAF 15 45 VAFPFDEYF 15 59 AKGNPEPTF 15 92 FRIPNEGHI 15 118AMSEEIEFI 15 125 FIVPSVPKL 15 158 GLPPLHIYW 15 169 IELEHIEQD 15 246IKQRKPKLL 15 343 VEEPPRWTK 15 450 ATWGYSAF 15 575 FEINGTEDG 15 628PDPPENLHL 15 638 ERQNRSVRL 15 669 KEEPGRWEE 15 687 TVILPLAPF 15 726APDRNPQNI 15 740 QPKEMIIKW 15 743 EMIIKWEPL 15 777 EEETVTNHT 15 799VKVQAINQL 15 853 RVHGRLKGY 15 878 PKEVNILRF 15 879 KEVNILRFS 15 920SEPYIFQTP 15 950 LSWGLPKKL 15 961 NLTGYLLQY 15 997 SNLNATTKY 15 1030EGSKGIGKI 15 1057 AEHIVRLMT 15 1100 IGLMCAIAL 15 1101 GLMCAIALL 15 1104CAIALLTLL 15 1106 IALLTLLLL 15 1175 ESADSLVEY 15 1192 SEDGSFIGA 15 5LLGRGLIVY 14 9 GLIVYLMFL 14 11 IVYLMFLLL 14 13 YLMFLLLKF 14 70 TKDGNPFYF14 84 IPSNNSGTF 14 95 PNEGHISHF 14 120 SEEIEFIVP 14 123 IEFIVPSVP 14 151LPCNPPKGL 14 200 NDYCCFAAF 14 237 TEIGSKANS 14 266 ITILKGEIL 14 303TKENYGKTL 14 305 ENYGKTLKI 14 350 TKKPQSAVY 14 359 STGSNGILL 14 390HPFAGDVVF 14 407 LQPNHTAVY 14 447 ENYATVVGY 14 456 SAFLHCEFF 14 487YHIYENGTL 14 512 VENAIGKTA 14 558 SHLKHSLKL 14 567 SWSKDGEAF 14 572GEAFEINGT 14 599 LEDQGIYCC 14 637 SERQNRSVR 14 653 DHNSNISEY 14 663VEFEGNKEE 14 675 WEELTRVQG 14 720 HETPPAAPD 14 738 ASQPKEMII 14 755EQNGPGLEY 14 759 PGLEYRVTW 14 768 KPQGAPVEW 14 838 NSTLVKVTW 14 858LKGYQINWW 14 942 KVDKDTATL 14 944 DKDTATLSW 14 957 KLNGNLTGY 14 973NDTYEIGEL 14 1000 NATTKYKFY 14 1023 EESSTLGEG 14 1045 QKTHPIEVF 14 1055PGAEHIVRL 14 1060 IVRLMTKNW 14 1094 STQGWFIGL 14 1098 WFIGLMCAI 14 1110TLLLLTVCF 14 1132 KEDLHPDPE 14 1 MEPLLLGRG 13 17 LLLKFSKAI 13 50DEYFQIECE 13 63 PEPTFSWTK 13 96 NEGHISHFQ 13 133 LPKEKIDPL 13 135KEKIDPLEV 13 154 NPPKGLPPL 13 174 IEQDERVYM 13 203 CCFAAFPRL 13 219PMKLTVNSL 13 245 SIKQRKPKL 13 247 KQRKPKLLL 13 261 GSESSITIL 13 267TILKGEILL 13 282 GLPTPQVDW 13 331 FLGTATHDF 13 417 CEASNVHGT 13 418EASNVHGTI 13 419 ASNVHGTIL 13 446 GENYATVVG 13 474 QKVEEVKPL 13 477EEVKPLEGR 13 479 VKPLEGRRY 13 502 EEDAGSYSC 13 503 EDAGSYSCW 13 584RIIIDGANL 13 591 NLTISNVTL 13 626 DVPDPPENL 13 640 QNRSVRLTW 13 690LPLAPFVRY 13 692 LAPFVRYQF 13 706 NEVGRSQPS 13 742 KEMIIKWEP 13 754MEQNGPGLE 13 761 LEYRVTWKP 13 811 PDPQSVTLY 13 821 GEDYPDTAP 13 829PVIHGVDVI 13 833 GVDVINSTL 13 863 INWWKTKSL 13 876 THPKEVNIL 13 890RNSGMVPSL 13 896 PSLDAFSEF 13 915 GAGPESEPY 13 959 NGNLTGYLL 13 970QIINDTYEI 13 986 ITTPSKPSW 13 991 KPSWHLSNL 13 1001 ATTKYKFYL 13 1050IEVFEPGAE 13 1053 FEPGAEHIV 13 1067 NWGDNDSIF 13 1078 VIETRGREY 13 1091DDISTQGWF 13 1103 MCAIALLTL 13 1119 VKRNRGGKY 13 1130 KEKEDLHPD 13 1152YSDSDEKPL 13 1159 PLKGSLRSL 13 1174 TESADSLVE 13 1182 EYGEGDHGL 13 1205KEKGSVESN 13 1210 VESNGSSTA 13 1212 SNGSSTATF 13 1214 GSSTATFPL 13 3PLLLGRGLI 12 8 RGLIVYLMF 12 19 LKFSKAIEI 12 41 SKVQVAFPF 12 47 FPFDEYFQI12 61 GNPEPTFSW 12 68 SWTKDGNPF 12 76 FYFTDHRII 12 99 HISHFQGKY 12 102HFQGKYRCF 12 107 YRCFASNKL 12 117 IAMSEEIEF 12 173 HIEQDERVY 12 181YMSQKGDLY 12 214 IVQKMPMKL 12 238 EIGSKANSI 12 260 SGSESSITI 12 304KENYGKTLK 12 323 NYRCTASNF 12 324 YRCTASNFL 12 384 GSPVDNHPF 12 424GTILANANI 12 432 IDVVDVRPL 12 461 CEFFASPEA 12 476 VEEVKPLEG 12 489IYENGTLQI 12 490 YENGTLQIN 12 534 RVSPKNPRI 12 542 IPKLHMLEL 12 548LELHCESKC 12 556 CDSHLKHSL 12 569 SKDGEAFEI 12 586 IIDGANLTI 12 605YCCSAHTAL 12 631 PENLHLSER 12 648 WEAGADHNS 12 650 AGADHNSNI 12 682QGKKTTVIL 12 748 WEPLKSMEQ 12 753 SMEQNGPGL 12 786 LRVMTPAVY 12 796PYDVKVQAI 12 823 DYPDTAPVI 12 850 PKDRVHGRL 12 857 RLKGYQINW 12 864NWWKTKSLL 12 875 RTHPKEVNI 12 901 FSEFHLTVL 12 916 AGPESEPYI 12 918PESEPYIFQ 12 930 GVPEQPTFL 12 958 LNGNLTGYL 12 968 QYQIINDTY 12 999LNATTKYKF 12 1022 TEESSTLGE 12 1052 VFEPGAEHI 12 1079 IETRGREYA 12 1082RGREYAGLY 12 1090 YDDISTQGW 12 1141 IQSVKDETF 12 1144 VKDETFGEY 12 1183YGEGDHGLF 12 1184 GEGDHGLFS 12 1189 GLFSEDGSF 12V2-(SET1)-HLA-B4402-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 1 FIVPSVPKF 15 9 FPKEKIDPL 13 6 VPKFPKEKI 9 7 PKFPKEKID 7V2-(SET2)-HLA-B4402-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 9 AKENYGKTL 17 5 KGREAKENY 11 7 REAKENYGK 10V2-(SET3)-HLA-B4402-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 6 GEGKYAGLY 22 2 SSTLGEGKY 13 5 LGEGKYAGL 11 9 KYAGLYDDI 10V3-HLA-B4402-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 48 AEDFIQKST 17 23 TGSPQPSIF 15 39 LSYRNRNML 14 4 GVDVINTTY 13 37QELSYRNRN 13 62 EKSSTFFKI 13 43 NRNMLAEDF 12 59 NYVEKSSTF 12 10TTYVSNTTY 11 22 ATGSPQPSI 11 33 CSKEQELSY 11 35 KEQELSYRN 11 61VEKSSTFFK 11 24 GSPQPSIFI 10 31 FICSKEQEL 10 44 RNMLAEDFI 10 52IQKSTSCNY 10 60 YVEKSSTFF 10 V4-HLA-B4402-9mers-282P1G3 Each peptide isa portion of SEQ ID NO: 9; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 7 EDLPEQPTF 17 6 GEDLPEQPT 12 8 DLPEQPTFL12 1 VTLYSGEDL 11 V5-HLA-B4402-9mers-282P1G3 Each peptide is a portionof SEQ ID NO: 11; each start position is specified, the length ofpeptide is 9 amino acids, and the end position for each peptide is thestart position plus eight. 4 LTVNSSNSI 10 7 NSSNSIKQR 9 6 VNSSNSIKQ 4 9SNSIKQRKP 4 V6-HLA-B4402-9mers-282P1G3 Each peptide is a portion of SEQID NO: 13; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 1 EEIEFIVPK 19 3 IEFIVPKLE 16 2 EIEFIVPKL 15 5 FIVPKLEHI 12V7-HLA-B4402-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 7 VEDNISHEL 24 20 PEPPRWTKK 16 10 NISHELFTL 14 17 TLHPEPPRW 14 8EDNISHELF 13 13 HELFTLHPE 13

TABLE XXXIIII Pos 123456789 score V1-HLA-B5101-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 3; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 611 TALDSAADI 26 206 AAFPRLRTI25 334 TATHDFHVI 25 427 LANANIDVV 25 285 TPQVDWNKI 24 418 EASNVHGTI 24445 DGENYATVV 24 519 TAVTANLDI 24 47 FPFDEYFQI 23 130 VPKLPKEKI 23 504DAGSYSCWV 23 1106 IALLTLLLL 23 133 LPKEKIDPL 22 260 SGSESSITI 22 429NANIDVVDV 22 616 AADITQVTV 22 23 KAIEIPSSV 21 468 EAVVSWQKV 21 726APDRNPQNI 21 823 DYPDTAPVI 21 873 DGRTHPKEV 21 963 TGYLLQYQI 21 115LGIAMSEEI 20 139 DPLEVEEGD 20 151 LPCNPPKGL 20 154 NPPKGLPPL 20 578NGTEDGRII 20 589 GANLTISNV 20 737 QASQPKEMI 20 916 AGPESEPYI 20 954LPKKLNGNL 20 1030 EGSKGIGKI 20 1172 QPTESADSL 20 2 EPLLLGRGL 19 305ENYGKTLKI 19 542 IPKLHMLEL 19 791 PAVYAPYDV 19 794 YAPYDVKVQ 19 810GPDPQSVTL 19 828 APVIHGVDV 19 978 IGELNDINI 19 988 TPSKPSWHL 19 1104CAIALLTLL 19 1136 HPDPEIQSV 19 629 DPPENLHLS 18 650 AGADHNSNI 18 690LPLAPFVRY 18 757 NGPGLEYRV 18 795 APYDVKVQA 18 1100 IGLMCAIAL 18 6LGRGLIVYL 17 27 IPSSVQQVP 17 433 DVVDVRPLI 17 586 IIDGANLTI 17 681VQGKKTTVI 17 740 QPKEMIIKW 17 812 DPQSVTLYS 17 855 HGRLKGYQI 17 909LAYNSKGAG 17 933 EQPTFLKVI 17 991 KPSWHLSNL 17 1033 KGIGKISGV 17 1055PGAEHIVRL 17 1138 DPEIQSVKD 17 17 LLLKFSKAI 16 19 LKFSKAIEI 16 75PFYFTDHRI 16 185 KGDLYFANV 16 297 LPKGRETKE 16 390 HPFAGDVVF 16 392FAGDVVFPR 16 464 FASPEAVVS 16 514 NAIGKTAVT 16 573 EAFEINGTE 16 695FVRYQFRVI 16 877 HPKEVNILR 16 899 DAFSEFHLT 16 1035 IGKISGVNL 16 1199GAYAGSKEK 16 11 IVYLMFLLL 15 94 IPNEGHISH 15 147 DPIVLPCNP 15 208FPRLRTIVQ 15 375 QPTIKWRVN 15 398 FPREISFTN 15 466 SPEAVVSWQ 15 480KPLEGRRYH 15 508 YSCWVENAI 15 614 DSAADITQV 15 682 QGKKTTVIL 15 692LAPFVRYQF 15 703 IAVNEVGRS 15 722 TPPAAPDRN 15 728 DRNPQNIRV 15 824YPDTAPVIH 15 826 DTAPVIHGV 15 827 TAPVIHGVD 15 829 PVIHGVDVI 15 921EPYIFQTPE 15 927 TPEGVPEQP 15 935 PTFLKVIKV 15 976 YEIGELNDI 15 1048HPIEVFEPG 15 1054 EPGAEHIVR 15 1092 DISTQGWFI 15 1111 LLLLTVCFV 15 1158KPLKGSLRS 15 1202 AGSKEKGSV 15 4 LLLGRGLIV 14 29 SSVQQVPTI 14 30SVQQVPTII 14 64 EPTFSWTKD 14 76 FYFTDHRII 14 84 IPSNNSGTF 14 141LEVEEGDPI 14 159 LPPLHIYWM 14 255 LPPTESGSE 14 279 FAEGLPTPQ 14 283LPTPQVDWN 14 327 TASNFLGTA 14 345 EPPRWTKKP 14 370 AEGEPQPTI 14 449YATVVGYSA 14 453 VGYSAFLHC 14 527 IRNATKLRV 14 577 INGTEDGRI 14 615SAADITQVT 14 619 ITQVTVLDV 14 673 GRWEELTRV 14 749 EPLKSMEQN 14 758GPGLEYRVT 14 759 PGLEYRVTW 14 836 VINSTLVKV 14 849 VPKDRVHGR 14 887SGQRNSGMV 14 950 LSWGLPKKL 14 959 NGNLTGYLL 14 1000 NATTKYKFY 14 1027TLGEGSKGI 14 1071 NDSIFQDVI 14 1108 LLTLLLLTV 14 1190 LFSEDGSFI 14 1201YAGSKEKGS 14 62 NPEPTFSWT 13 74 NPFYFTDHR 13 110 FASNKLGIA 13 117IAMSEEIEF 13 118 AMSEEIEFI 13 143 VEEGDPIVL 13 156 PKGLPPLHI 13 163HIYWMNIEL 13 205 FAAFPRLRT 13 214 IVQKMPMKL 13 218 MPMKLTVNS 13 231NDSSSSTEI 13 238 EIGSKANSI 13 256 PPTESGSES 13 258 TESGSESSI 13 281EGLPTPQVD 13 357 VYSTGSNGI 13 373 EPQPTIKWR 13 388 DNHPFAGDV 13 389NHPFAGDVV 13 408 QPNHTAVYQ 13 438 RPLIQTKDG 13 471 VSWQKVEEV 13 489IYENGTLQI 13 522 TANLDIRNA 13 529 NATKLRVSP 13 534 RVSPKNPRI 13 539NPRIPKLHM 13 617 ADITQVTVL 13 626 DVPDPPENL 13 680 RVQGKKTTV 13 715QPSDHHETP 13 725 AAPDRNPQN 13 768 KPQGAPVEW 13 790 TPAVYAPYD 13 793VYAPYDVKV 13 796 PYDVKVQAI 13 841 LVKVTWSTV 13 900 AFSEFHLTV 13 923YIFQTPEGV 13 932 PEQPTFLKV 13 1013 TSQGCGKPI 13 1052 VFEPGAEHI 13 1056GAEHIVRLM 13 1066 KNWGDNDSI 13 1070 DNDSIFQDV 13 1086 YAGLYDDIS 13 3PLLLGRGLI 12 26 EIPSSVQQV 12 37 IIKQSKVQV 12 45 VAFPFDEYF 12 58EAKGNPEPT 12 72 DGNPFYFTD 12 92 FRIPNEGHI 12 125 FIVPSVPKL 12 127VPSVPKLPK 12 155 PPKGLPPLH 12 160 PPLHIYWMN 12 166 WMNIELEHI 12 190FANVEEKDS 12 216 QKMPMKLTV 12 229 HANDSSSST 12 346 PPRWTKKPQ 12 352KPQSAVYST 12 369 EAEGEPQPT 12 394 GDVVFPREI 12 426 ILANANIDV 12 444KDGENYATV 12 462 EFFASPEAV 12 463 FFASPEAVV 12 481 PLEGRRYHI 12 516IGKTAVTAN 12 525 LDIRNATKL 12 558 SHLKHSLKL 12 569 SKDGEAFEI 12 571DGEAFEING 12 579 GTEDGRIII 12 591 NLTISNVTL 12 608 SAHTALDSA 12 627VPDPPENLH 12 636 LSERQNRSV 12 649 EAGADHNSN 12 688 VILPLAPFV 12 700FRVIAVNEV 12 723 PPAAPDRNP 12 730 NPQNIRVQA 12 772 APVEWEEET 12 822EDYPDTAPV 12 875 RTHPKEVNI 12 876 THPKEVNIL 12 895 VPSLDAFSE 12 901FSEFHLTVL 12 947 TATLSWGLP 12 964 GYLLQYQII 12 1010 RACTSQGCG 12 1015QGCGKPITE 12 1042 NLTQKTHPI 12 1044 TQKTHPIEV 12 1133 EDLHPDPEI 12 1176SADSLVEYG 12 V2-HLA-B5101-9mers-(SET1)-282P1G3 Each peptide is a portionof SEQ ID NO: 5; each start position is specified, the length of peptideis 9 amino acids, and the end position for each peptide is the startposition plus eight. 6 VPKFPKEKI 23 9 FPKEKIDPL 21 3 VPSVPKFPK 11V2-(SET2)-HLA-B5101-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 3 LPKGREAKE 15 8 EAKENYGKT 14 9 AKENYGKTL 10 5 KGREAKENY 8V2-(SET3)-HLA-B5101-9mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 5 LGEGKYAGL 16 9 KYAGLYDDI 11 7 EGKYAGLYD 7V3-HLA-B5101-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 47 LAEDFIQKS 16 21 NATGSPQPS 14 62 EKSSTFFKI 14 3 HGVDVINTT 13 39LSYRNRNML 13 24 GSPQPSIFI 12 25 SPQPSIFIC 12 27 QPSIFICSK 11 53QKSTSCNYV 11 5 VDVINTTYV 10 10 TTYVSNTTY 10 11 TYVSNTTYV 10 22 ATGSPQPSI10 44 RNMLAEDFI 10 16 TTYVSNATG 9 6 DVINTTYVS 8 23 TGSPQPSIF 8 31FICSKEQEL 8 V4-HLA-B5101-9mers-282P1G3 Each peptide is a portion of SEQID NO: 9; each start position is specified, the length of peptide is 9amino acids, and the end position for each peptide is the start positionplus eight. 8 DLPEQPTFL 15 9 LPEQPTFLK 12 1 VTLYSGEDL 10 5 SGEDLPEQP 8V5-HLA-B5101-9mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 9 aminoacids, and the end position for each peptide is the start position pluseight. 4 LTVNSSNSI 14 2 MKLTVNSSN 7 V6-HLA-B5101-9mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 13; each start position is specified,the length of peptide is 9 amino acids, and the end position for eachpeptide is the start position plus eight. 5 FIVPKLEHI 14 7 VPKLEHIEQ 122 EIEFIVPKL 10 3 IEFIVPKLE 7 V7-HLA-B5101-9mers-282P1G3 Each peptide isa portion of SEQ ID NO: 15; each start position is specified, the lengthof peptide is 9 amino acids, and the end position for each peptide isthe start position plus eight. 3 FHVIVEDNI 13 19 HPEPPRWTK 12 10NISHELFTL 10 7 VEDNISHEL 7 18 LHPEPPRWT 7 2 DFHVIVEDN 6 11 ISHELFTLH 6

TABLE XXXIV Pos 1234567890 score V1-HLA-A1-10mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 810 GPDPQSVTLY 32 1192SEDGSFIGAY 28 193 VEEKDSRNDY 27 481 PLEGRRYHIY 27 902 SEFHLTVLAY 24 1173PTESADSLVE 23 4 LLLGRGLIVY 22 119 MSEEIEFIVP 22 309 KTLKIENVSY 22 349WTKKPQSAVY 22 627 VPDPPENLHL 22 754 MEQNGPGLEY 22 931 VPEQPTFLKV 22 1021ITEESSTLGE 22 1191 FSEDGSFIGA 22 406 NLQPNHTAVY 21 499 RTTEEDAGSY 21 919ESEPYIFQTP 21 960 GNLTGYLLQY 21 996 LSNLNATTKY 21 261 GSESSITILK 20 371EGEPQPTIKW 20 478 EVKPLEGRRY 20 579 GTEDGRIIID 20 788 VMTPAVYAPY 20 1143SVKDETFGEY 20 1183 YGEGDHGLFS 20 43 VQVAFPFDEY 19 180 VYMSQKGDLY 19 689ILPLAPFVRY 19 1118 FVKRNRGGKY 19 68 SWTKDGNPFY 18 236 STEIGSKANS 18 815SVTLYSGEDY 18 1056 GAEHIVRLMT 18 1152 YSDSDEKPLK 18 78 FTDHRIIPSN 17 98GHISHFQGKY 17 343 VEEPPRWTKK 17 500 TTEEDAGSYS 17 785 TLRVMTPAVY 17 824YPDTAPVIHG 17 901 FSEFHLTVLA 17 1081 TRGREYAGLY 17 134 PKEKIDPLEV 16 172EHIEQOERVY 16 257 PTESGSESSI 16 359 STGSNGILLC 16 440 LIQTKDGENY 16 446GENYATVVGY 16 475 KVEEVKPLEG 16 569 SKDGEAFEIN 16 612 ALDSAADITQ 16 636LSERQNRSVR 16 652 ADHNSNISEY 16 914 KGAGPESEPY 16 967 LQYQIINDTY 16 1028LGEGSKGIGK 16 1077 DVIETRGREY 16 137 KIDPLEVEEG 15 142 EVEEGDPIVL 15 156PKGLPPLHIY 15 298 PKGRETKENY 15 315 NVSYQDKGNY 15 434 VVDVRPLIQT 15 580TEDGRIIIDG 15 596 NVTLEDQGIY 15 651 GADHNSNISE 15 852 DRVHGRLKGY 15 956KKLNGNLTGY 15 999 LNATTKYKFY 15 1052 VFEPGAEHIV 15 1136 HPDPEIQSVK 151174 TESADSLVEY 15 V2-(SET1)-HLA-A1-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 5 PSVPKFPKEK 8 8 PKFPKEKIDP 8 4 VPSVPKFPKE 6 2FIVPSVPKFP 5 6 SVPKFPKEKI 4 1 EFIVPSVPKF 3 10 FPKEKIDPLE 3V2-(SET2)-HLA-A1-10mers-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 5 PKGREAKENY 15 10 AKENYGKTLK 13 1 GGDLPKGREA 11 7 GREAKENYGK 11V2-(SET3)-HLA-A1-10mers-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 6 LGEGKYAGLY 28 2 ESSTLGEGKY 21 V3-HLA-A1-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 7; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 10 NTTYVSNTTY 22 33 ICSKEQELSY21 4 HGVDVINTTY 16 52 FIQKSTSCNY 16 26 SPQPSIFICS 13 35 SKEQELSYRN 12 61YVEKSSTFFK 12 37 EQELSYRNRN 11 49 AEDFIQKSTS 11 56 STSCNYVEKS 11 5GVDVINTTYV 10 48 LAEDFIQKST 10 V4-HLA-A1-10mers-282P1G3 Each peptide isa portion of SEQ ID NO: 9; each start position is specified, the lengthof peptide is 10 amino acids, and the end position for each peptide isthe start position plus nine. 10 LPEQPTFLKV 21 6 SGEDLPEQPT 12 7GEDLPEQPTF 10 V5-HLA-A1-10mers-282P1G3 Each peptide is a portion of SEQID NO: 11; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 9 SSNSIKQRKP 8 5 LTVNSSNSIK 7 6 VNSSNSIKQ 6 8 NSSNSIKQRK 4 10SNSIKQRKPK 3 V6-HLA-A1-10mers-282P1G3 Each peptide is a portion of SEQID NO: 13; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 1 SEEIEFIVPK 12 3 EIEFIVPKLE 12 10 KLEHIEQDER 11 4 IEFIVPKLEH6 6 FIVPKLEHIE 5 V7-HLA-A1-10mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 15; each start position is specified, the length of peptideis 10 amino acids, and the end position for each peptide is the startposition plus nine. 20 HPEPPRWTKK 16 8 VEDNISHELF 13 13 SHELFTLHPE 12 1THDFHVIVED 10 7 IVEDNISHEL 10 12 ISHELFTLHP 10 17 FTLHPEPPRW 7

TABLE XXXV Pos 1234567890 score V1-HLA-A0201-10mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 1107 ALLTLLLLTV 31 5 LLGRGLIVYL28 426 ILANANIDVV 28 274 LLLECFAEGL 27 1102 LMCAIALLTL 27 1105AIALLTLLLL 27 1110 TLLLLTVCFV 26 132 KLPKEKIDPL 25 267 TILKGEILLL 25 585IIIDGANLTI 24 635 HLSERQNRSV 24 957 KLNGNLTGYL 24 9 GLIVYLMFLL 23 615SAADITQVTV 23 835 DVINSTLVKV 23 36 TIIKQSKVQV 22 118 AMSEEIEFIV 22 158GLPPLHIYWM 22 431 NIDVVDVRPL 22 524 NLDIRNATKL 22 840 TLVKVTWSTV 22 897SLDAFSEFHL 22 16 FLLLKFSKAI 21 114 KLGIAMSEEI 21 150 VLPCNPPKGL 21 470VVSWQKVEEV 21 541 RIPKLHMLEL 21 618 DITQVTVLDV 21 792 AVYAPYDVKV 21 875RTHPKEVNIL 21 949 TLSWGLPKKL 21 953 GLPKKLNGNL 21 1034 GIGKISGVNL 21 3PLLLGRGLIV 20 4 LLLGRGLIVY 20 10 LIVYLMFLLL 20 18 LLKFSKAIEI 20 25IEIPSSVQQV 20 205 FAAFPRLRTI 20 213 TIVQKMPMKL 20 425 TILANANIDV 20 428ANANIDVVDV 20 488 HIYENGTLQI 20 616 AADITQVTVL 20 862 QINWWKTKSL 20 966LLQYQIINDT 20 1099 FIGLMCAIAL 20 1100 IGLMCAIALL 20 1189 GLFSEDGSFI 20117 IAMSEEIEFI 19 206 AAFPRLRTIV 19 265 SITILKGEIL 19 1135 LHPDPEIQSV 191158 KPLKGSLRSL 19 121 EEIEFIVPSV 18 218 MPMKLTVNSL 18 245 SIKQRKPKLL 18260 SGSESSITIL 18 266 ITILKGEILL 18 268 ILKGEILLLE 18 273 ILLLECFAEG 18450 ATVVGYSAFL 18 526 DIRNATKLRV 18 536 SPKNPRIPKL 18 590 ANLTISNVTL 18745 IIKWEPLKSM 18 765 VTWKPQGAPV 18 784 HTLRVMTPAV 18 889 QRNSGMVPSL 18900 AFSEFHLTVL 18 965 YLLQYQIIND 18 972 INDTYEIGEL 18 1026 STLGEGSKGI 181043 LTQKTHPIEV 18 1112 LLLTVCFVKR 18 1201 YAGSKEKGSV 18 37 IIKQSKVQVA17 82 RIIPSNNSGT 17 137 KIDPLEVEEG 17 153 CNPPKGLPPL 17 221 KLTVNSLKHA17 253 LLLPPTESGS 17 279 FAEGLPTPQV 17 356 AVYSTGSNGI 17 413 AVYQCEASNV17 565 KLSWSKDGEA 17 603 GIYCCSAHTA 17 687 TVILPLAPFV 17 696 VRYQFRVIAV17 699 QFRVIAVNEV 17 795 APYDVKVQAI 17 798 DVKVQAINQL 17 809 SGPDPQSVTL17 836 VINSTLVKVT 17 871 LLDGRTHPKE 17 899 DAFSEFHLTV 17 941 IKVDKDTATL17 1032 SKGIGKISGV 17 1073 SIFQDVIETR 17 1101 GLMCAIALLT 17 1104CAIALLTLLL 17 1106 IALLTLLLLT 17 8 RGLIVYLMFL 16 17 LLKFSKAIE 16 22SKAIEIPSSV 16 124 EFIVPSVPKL 16 129 SVPKLPKEKI 16 254 LLPPTESGSE 16 326CTASNFLGTA 16 333 GTATHDFHVI 16 365 ILLCEAEGEP 16 396 VVFPREISFT 16 421NVHGTILANA 16 443 TKDGENYATV 16 514 NAIGKTAVTA 16 518 KTAVTANLDI 16 544KLHMLELHCE 16 576 EINGTEDGRI 16 586 IIDGANLTIS 16 610 HTALDSAADI 16 613LDSAADITQV 16 752 KSMEQNGPGL 16 772 APVEWEEETV 16 807 LGSGPDPQSV 16 827TAPVIHGVDV 16 857 RLKGYQINWW 16 870 SLLDGRTHPK 16 915 GAGPESEPYI 16 937FLKVIKVDKD 16 990 SKPSWHLSNL 16 1080 ETRGREYAGL 16 1094 STQGWFIGLM 161103 MCAIALLTLL 16 1166 SLNRDMQPTE 16 1181 VEYGEGDHGL 16 13 YLMFLLLKFS15 141 LEVEEGDPIV 15 162 LHIYWMNIEL 15 165 YWMNIELEHI 15 179 RVYMSQKGDL15 187 DLYFANVEEK 15 237 TEIGSKANSI 15 244 NSIKQRKPKL 15 252 KLLLPPTESG15 282 GLPTPQVDWN 15 307 YGKTLKIENV 15 334 TATHDFHVIV 15 341 VIVEEPPRWT15 458 FLHCEFFASP 15 464 FASPEAVVSW 15 515 AIGKTAVTAN 15 521 VTANLDIRNA15 539 NPRIPKLHML 15 583 GRIIIDGANL 15 584 RIIIDGANLT 15 588 DGANLTISNV15 598 TLEDQGIYCC 15 661 YIVEFEGNKE 15 683 GKKTTVILPL 15 702 VIAVNEVGRS15 725 AAPDRNPQNI 15 830 VIHGVDVINS 15 833 GVDVINSTLV 15 948 ATLSWGLPKK15 961 NLTGYLLQYQ 15 969 YQIINDTYEI 15 977 EIGELNDINI 15 980 ELNDINITTP15 1019 KPITEESSTL 15 1029 GEGSKGIGKI 15 1037 KISGVNLTQK 15 1108LLTLLLLTVC 15 1120 KRNRGGKYSV 15 V2-(SET1)-HLA-A0201-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 5; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 6 SVPKFPKEKI 16 9 KFPKEKIDPL 152 FIVPSVPKFP 10 V2-(SET2)-HLA-A0201-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 3 DLPKGREAKE 13 9 EAKENYGKTL 13 8 REAKENYGKT 81 GGDLPKGREA 7 2 GDLPKGREAK 6 V2-(SET3)-HLA-A0201-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 5; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 3 SSTLGEGKYA 10 4 STLGEGKYAG 95 TLGEGKYAGL 8 V3-HLA-A0201-10mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 7; each start position is specified, the length of peptide is10 amino acids, and the end position for each peptide is the startposition plus nine. 47 MLAEDFIQKS 20 2 VIHGVDVINT 19 8 VINTTYVSNT 18 39ELSYRNRNML 17 22 NATGSPQPSI 16 31 IFICSKEQEL 16 5 GVDVINTTYV 15 11TTYVSNTTYV 15 3 IHGVDVINTT 13 53 IQKSTSCNYV 12 56 STSCNYVEKS 12 30SIFICSKEQE 11 42 YRNRNMLAED 11 48 LAEDFIQKST 11 13 YVSNTTYVSN 10 14VSNTTYVSNA 10 24 TGSPQPSIFI 10 46 NMLAEDFIQK 10 62 VEKSSTFFKI 10 7DVINTTYVSN 9 32 FICSKEQELS 9 44 NRNMLAEDFI 9 52 FIQKSTSCNY 9V4-HLA-A0201-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 9;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 1 SVTLYSGEDL 15 10 LPEQPTFLKV 14 3 TLYSGEDLPE 12 4 LYSGEDLPEQ 11 8EDLPEQPTFL 11 9 DLPEQPTFLK 11 V5-HLA-A0201-10mers-282P1G3 Each peptideis a portion of SEQ ID NO: 11; each start position is specified, thelength of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 4 KLTVNSSNSI 21V6-HLA-A0201-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 2 EEIEFIVPKL 18 6 FIVPKLEHIE 12 10 KLEHIEQDER 12 5 EFIVPKLEHI 11 7IVPKLEHIEQ 8 V7-HLA-A0201-10mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 15; each start position is specified, the length of peptideis 10 amino acids, and the end position for each peptide is the startposition plus nine. 7 IVEDNISHEL 19 10 DNISHELFTL 7 18 TLHPEPPRWT 16 6VIVEDNISHE 15

TABLE XXXVI Pos 1234567890 score V1-HLA-A0203-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 3; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 198 SRNDYCCFAA 19 608SAHTALDSAA 19 717 SDHHETPPAA 19 421 NVHGTILANA 18 643 SVRLTWEAGA 18 1098WFIGLMCAIA 18 1193 EDGSFIGAYA 18 199 RNDYCCFAAF 17 609 AHTALDSAAD 17 718DHHETPPAAP 17 15 MFLLLKFSKA 10 37 IIKQSKVQVA 10 50 DEYFQIECEA 10 102HFQGKYRCFA 10 109 CFASNKLGIA 10 182 MSQKGDLYFA 10 197 DSRNDYCCFA 10 221KLTVNSLKHA 10 234 SSSTEIGSKA 10 271 GEILLLECFA 10 319 QDKGNYRCTA 10 326CTASNFLGTA 10 347 PRWTKKPQSA 10 361 GSNGILLCEA 10 384 GSPVDNHPFA 10 404FTNLQPNHTA 10 410 NHTAVYQCEA 10 419 ASNVHGTILA 10 441 IQTKOGENYA 10 448NYATVVGYSA 10 456 SAFLHCEFFA 10 460 HCEFFASPEA 10 496 QINRTTEEDA 10 506GSYSCWVENA 10 511 WVENAIGKTA 10 514 NAIGKTAVTA 10 521 VTANLDIRNA 10 565KLSWSKDGEA 10 581 EDGRIIIDGA 10 600 EDQGIYCCSA 10 603 GIYCCSAHTA 10 607CSAHTALDSA 10 641 NRSVRLTWEA 10 684 KKTTVILPLA 10 695 FVRYQFRVIA 10 716PSDHHETPPA 10 729 RNPQNIRVQA 10 763 YRVTWKPQGA 10 783 NHTLRVMTPA 10 786LRVMTPAVYA 10 794 YAPYDVKVQA 10 819 YSGEDYPDTA 10 891 NSGMVPSLDA 10 901FSEFHLTVLA 10 907 TVLAYNSKGA 10 939 KVIKVDKDTA 10 992 PSWHLSNLNA 10 1002TTKYKFYLRA 10 1048 HPIEVFEPGA 10 1078 VIETRGREYA 10 1096 QGWFIGLMCA 101168 NRDMQPTESA 10 1191 FSEDGSFIGA 10 1209 SVESNGSSTA 10 1215 SSTATFPLRA10 16 FLLLKFSKAI 9 38 IKQSKVQVAF 9 51 EYFQIECEAK 9 103 FQGKYRCFAS 9 110FASNKLGIAM 9 183 SQKGDLYFAN 9 222 LTVNSLKHAN 9 235 SSTEIGSKAN 9 272EILLLECFAE 9 320 DKGNYRCTAS 9 327 TASNFLGTAT 9 348 RWTKKPQSAV 9 362SNGILLCEAE 9 385 SPVDNHPFAG 9 405 TNLQPNHTAV 9 411 HTAVYQCEAS 9 420SNVHGTILAN 9 422 VHGTILANAN 9 442 QTKDGENYAT 9 449 YATVVGYSAF 9 457AFLHCEFFAS 9 461 CEFFASPEAV 9 497 INRTTEEDAG 9 507 SYSCWVENAI 9 512VENAIGKTAV 9 515 AIGKTAVTAN 9 522 TANLDIRNAT 9 566 LSWSKDGEAF 9 582OGRIIIDGAN 9 601 DQGIYCCSAH 9 604 IYCCSAHTAL 9 642 RSVRLTWEAG 9 644VRLTWEAGAD 9 685 KTTVILPLAP 9 696 VRYQFRVIAV 9 730 NPQNIRVQAS 9 764RVTWKPQGAP 9 784 HTLRVMTPAV 9 787 RVMTPAVYAP 9 795 APYDVKVQAI 9 820SGEDYPDTAP 9 892 SGMVPSLDAF 9 902 SEFHLTVLAY 9 908 VLAYNSKGAG 9 940VIKVDKDTAT 9 993 SWHLSNLNAT 9 1003 TKYKFYLRAC 9 1049 PIEVFPEGAE 9 1079IETRGREYAG 9 1097 GWFIGLMCAI 9 1099 FIGLMCAIAL 9 1169 RDMQPTESAD 9 1192SEDGSFIGAY 9 1194 DGSFIGAYAG 9 1210 VESNGSSTAT 9V2-(SET1)-HLA-A0203-10mers-282P1G3 NoResultsFound.V2-(SET2)HLA-A0203-10mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 1 GGDLPKGREA 10 2 GDLPKGREAK 9 3 DLPKGREAKE 8V2-(SET3)HLA-A0203-10mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 3 SSTLGEGKYA 10 4 STLGEGKYAG 9 5 TLGEGKYAGL 8V3-HLA-A0203-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 14 VSNTTYVSNA 10 40 LSYRNRNMLA 10 15 SNTTYVSNAT 9 41 SYRNRNMLAE 916 NTTYVSNATG 8 42 YRNRNMLAED 8 V4-HLA-A0203-10mers- NoResultsFound.V5-HLA-A0203-10mers- NoResultsFound. V6-HLA-A0203-10mers-NoResultsFound. V7-HLA-A0203-10mers- NoResultsFound.

TABLE XXXVII Pos 1234567890 score V1-A3-10mers-282P12G3 Each peptide isa portion of SEQ ID NO: 3; each start position is specified, the lengthof peptide is 10 amino acids, and the end position for each peptide isthe start position plus nine. 11 IVYLMFLLLK 30 995 HLSNLNATTK 29 342IVEEPPRWTK 28 701 RVIAVNEVGR 27 785 TLRVMTPAVY 27 1037 KISGVNLTQK 271111 LLLLTVCFVK 27 406 NLQPNHTAVY 26 1121 RNRGGKYSVK 26 126 IVPSVPKLPK25 4 LLLGRGLIVY 24 33 QVPTIIKQSK 24 187 DLYFANVEEK 24 645 RLTWEAGADH 24870 SLLDGRTHPK 24 1118 FVKRNRGGKY 24 105 GKYRCFASNK 23 413 AVYQCEASNV 23478 EVKPLEGRRY 23 523 ANLDIRNATK 23 689 ILPLAPFVRY 23 792 AVYAPYDVKV 231077 DVIETRGREY 23 312 KIENVSYQDK 22 688 VILPLAPFVR 22 691 PLAPFVRYQF 22905 HLTVLAYNSK 22 1107 ALLTLLLLTV 22 1196 SFIGAYAGSK 22 30 SVQQVPTIIK 2182 RIIPSNNSGT 21 176 QDERVYMSQK 21 208 FPRLRTIVQK 21 238 EIGSKANSIK 21585 IIIDGANLTI 21 680 RVQGKKTTVI 21 704 AVNEVGRSQP 21 733 NIRVQASQPK 21815 SVTLYSGEDY 21 930 GVPEQPTFLK 21 295 GDLPKGRETK 20 381 RVNGSPVDNH 20532 KLRVSPKNPR 20 707 EVGRSQPSQP 20 939 KVIKVDKDTA 20 1112 LLLTVCFVKR 201136 HPDPEIQSVK 20 1143 SVKDETFGEY 20 3 PLLLGRGLIV 19 24 AIEIPSSVQQ 1983 IPSNNSGTF 19 93 RIPNEGHISH 19 148 PIVLPCNPPK 19 179 RVYMSQKGDL 19 451TVVGYSAFLH 19 488 HIYENGTLQI 19 584 RIIIDGANLT 19 603 GIYCCSAHTA 19 1057AEHIVRLMTK 19 1088 GLYDDISTQG 19 36 TIIKQSKVQV 18 149 IVLPCNPPKG 18 210RLRTIVQKMP 18 212 RTIVQKMPMK 18 252 KLLLPPTESG 18 253 LLLPPTESGS 18 268ILKGEILLLE 18 273 ILLLECFAEG 18 292 KIGGDLPKGR 18 426 ILANANIDVV 18 475KVEEVKPLEG 18 481 PLEGRRYHIY 18 511 WVENAIGKTA 18 534 RVSPKNPRIP 18 596NVTLEDQGIY 18 643 SVRLTWEAGA 18 695 FVRYQFRVIA 18 800 KVQAINQLGS 18 834VDVINSTLVK 18 835 DVINSTLVKV 18 857 RLKGYQINWW 18 1166 SLNRDMQPTE 181209 SVESNGSSTA 18 5 LLGRGLIVYL 17 44 QVAFPFDEYF 17 62 NPEPTFSWTK 17 123IEFIVPSVPK 17 226 SLKHANDSSS 17 309 KTLKIENVSY 17 315 NVSYQDKGNY 17 322GNYRCTASNF 17 356 AVYSTGSNGI 17 435 VDVRPLIQTK 17 436 DVRPLIQTKD 17 440LIQTKDGENY 17 469 AVVSWQKVEE 17 499 RTTEEDAGSY 17 612 ALDSAADITQ 17 687TVILPLAPFV 17 732 QNIRVQASQP 17 735 RVQASQPKEM 17 829 PVIHGVDVIN 17 840TLVKVTWSTV 17 853 RVHGRLKGYQ 17 942 KVDKDTATLS 17 947 TATLSWGLPK 17 1010RACTSQGCGK 17 1060 IVRLMTKNWG 17 1073 SIFQDVIETR 17 1159 PLKGSLRSLN 171179 SLVEYGEGDH 17 122 EIEFIVPSVP 16 142 EVEEGDPIVL 16 254 LLPPTESGSE 16274 LLLECFAEGL 16 370 AEGEPQPTIK 16 395 DVVFPREISF 16 396 VVFPREISFT 16466 SPEAVVSWQK 16 514 NAIGKTAVTA 16 559 HLKHSLKLSW 16 561 KHSLKLSWSK 16633 NLHLSERQNR 16 677 ELTRVQGKKT 16 738 ASQPKEMIIK 16 764 RVTWKPQGAP 16841 LVKVTWSTVP 16 850 PKDRVHGRLK 16 882 NILRFSGQRN 16 936 TFLKVIKVDK 16957 KLNGNLTGYL 16 980 ELNDINITTP 16 982 NDINITTPSK 16 998 NLNATTKYKF 161101 GLMCAIALLT 16 1105 AIALLTLLLL 16 1108 LLTLLLLTVC 16 1128 SVKEKEDLHP16 1134 DLHPDPEIQS 16 1140 EIQSVKDETF 16 1163 SLRSLNRDMQ 16 1189GLFSEDGSFI 16 1197 FIGAYAGSKE 16 17 LLLKFSKAIE 15 37 IIKQSKVQVA 15 99HISHFQGKYR 15 219 PMKLTVNSLK 15 243 ANSIKQRKPK 15 290 WNKIGGDLPK 15 310TLKIENVSYQ 15 365 ILLCEAEGEP 15 421 NVHGTILANA 15 433 DVVDVRPLIQ 15 458FLHCEFFASP 15 520 AVTANLDIRN 15 524 NLDIRNATKL 15 526 DIRNATKLRV 15 541RIPKLHMLEL 15 546 HMLELHCESK 15 626 DVPDPPENLH 15 636 LSERQNRSVR 15 639RQNRSVRLTW 15 710 RSQPSQPSDH 15 744 MIIKWEPLKS 15 759 PGLEYRVTWK 15 773PVEWEEETVT 15 780 TVTNHTLRVM 15 787 RVMTPAVYAP 15 806 QLGSGPDPQS 15 860GYQINWWKTK 15 883 ILRFSGQRNS 15 894 MVPSLDAFSE 15 948 ATLSWGLPKK 15 1008YLRACTSQGC 15 1028 LGEGSKGIGK 15 1034 GIGKISGVNL 15 1062 RLMTKNWGDN 1516 FLLLKFSKAI 14 18 LLKFSKAIEI 14 23 KAIEIPSSVQ 14 42 KVQVAFBFDE 14 114KLGIAMSEEI 14 128 PSVPKLPKEK 14 137 KIDPLEVEEG 14 158 GLPPLHIYWM 14 170ELEHIEQDER 14 172 EHIEQDERVY 14 233 SSSSTEIGSK 14 328 ASNFLGTATH 14 331FLGTATHDFH 14 340 HVIVEEPPRW 14 343 VEEPPRWTKK 14 349 WTKKPQSAVY 14 364GILLCEAEGE 14 366 LLCEAEGEPQ 14 386 PVDNHPFAGD 14 439 PLIQTKDGEN 14 471VSWQKVEEVK 14 509 SCWVENAIGK 14 547 MLELHCESKC 14 565 KLSWSKDGEA 14 660EYIVEFEGNK 14 671 EPGRWEELTR 14 743 EMIIKWEPLK 14 791 PAVYAPYDVK 14 798DVKVQAINQL 14 817 TLYSGEDYPD 14 822 EDYPDTAPVI 14 842 VKVTWSTVPK 14 848TVPKDRVHGR 14 880 EVNILRFSGQ 14 907 TVLAYNSKGA 14 933 EQPTFLKVIK 14 960GNLTGYLLQY 14 967 LQYQIINDTY 14 970 QIINDTYEIG 14 986 ITTPSKPSWH 14 997SNLNATTKYK 14 1051 EVFEPGAEHI 14 1082 RGREYAGLYD 14 1123 RGGKYSVKEK 141156 DEKPLKGSLR 14 V2-(SET1)-HLA-A3-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 3 IVPSVPKFPK 22 5 PSVPKFPKEK 14 2 FIVPSVPKFP12 6 SVPKFPKEKI 11 V2-(SET2)-HLA-A3-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 2 GDLPKGREAK 17 10 AKENYGKTLK 15 3 DLPKGREAKE13 7 GREAKENYGK 12 V2-(SET3)-HLA-A3-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 5 TLGEGKYAGL 14 1 EESSTLGEGK 13 6 LGEGKYAGLY12 2 ESSTLGEGKY 7 4 STLGEGKYAG 6 7 GEGKYAGLYD 6 9 GKYAGLYDDI 6 10KYAGLYDDIS 6 V3-HLA-A3-10mers-282P1G3 Each peptide is a portion of SEQID NO: 7; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 7 DVINTTYVSN 20 61 YVEKSSTFFK 20 1 PVIHGVDVIN 17 13YVSNTTYVSN 17 19 YVSNATGSPQ 17 46 NMLAEDFIQK 17 55 KSTSCNYVEK 17 43RNRNMLAEDF 15 59 CNYVEKSSTF 15 52 FIQKSTSCNY 14 30 SIFICSKEQE 13 33ICSKEQELSY 13 4 HGVDVINTTY 12 27 PQPSIFICSK 12 39 ELSYRNRNML 12 47MLAEDFIQKS 12 5 GVDVINTTYV 11 8 VINTTYVSNT 11 10 NTTYVSNTTY 11 23ATGSPQPSIF 11 2 VIHGVDVINT 10 49 AEDFIQKSTS 10 34 CSKEQELSYR 9 41SYRNRNMLAE 9 V4-HLA-A3-10mers-282P1G3 Each peptide is a portion of SEQID NO: 9; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 9 DLPEQPTFLK 21 3 TLYSGEDLPE 17 1 SVTLYSGEDL 15V5-HLA-A3-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 4 KLTVNSSNSI 15 5 LTVNSSNSIK 14 10 SNSIKQRKPK 13 8 NSSNSIKQRK 11 6TVNSSNSIKQ 10 2 PMKLTVNSSN 7 7 VNSSNSIKQR 7 V6-HLA-A3-10mers-282P1G3Each peptide is a portion of SEQ ID NO: 13; each start position isspecified, the length of peptide is 10 amino acids, and the end positionfor each peptide is the start position plus nine. 10 KLEHIEQDER 17 1SEEIEFIVPK 16 7 IVPKLEHIEQ 12 6 FIVPKLEHIE 11 4 IEFIVPKLEH 10 3EIEFIVPKLE 9 V7-HLA-A3-10mers-282P1G3 Each peptide is a portion of SEQID NO: 15; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 5 HVIVEDNISH 19 19 LHPEPPRWTK 16 18 TLHPEPPRWT 15 20HPEPPRWTKK 14 7 IVEDNISHEL 13 11 NISHELFTLH 13 6 VIVEDNISHE 12 15ELFTLHPEPP 11

TABLE XXXVIII Pos 1234567890 score V1-HLA-A26-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 3; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 1077 DVIETRGREY 35 395DVVFPREISF 32 478 EVKPLEGRRY 32 142 EVEEGDPIVL 31 798 DVKVQAINQL 31 302ETKENYGKTL 30 124 EFIVPSVPKL 27 835 DVINSTLVKV 27 172 EHIEQDERVY 26 852DRVHGRLKGY 26 1051 EVFEPGAEHI 26 1080 ETRGREYAGL 26 686 TTVILPLAPF 25433 DVVDVRPLIQ 24 1140 EIQSVKDETF 24 499 RTTEEDAGSY 23 779 ETVTNHTLRV 23815 SVTLYSGEDY 23 929 EGVPEQPTFL 23 1118 FVKRNRGGKY 23 1143 SVKDETFGEY23 1147 ETFGEYSDSD 23 596 NVTLEDQGIY 22 707 EVGRSQPSQP 22 1054EPGAEHIVRL 22 121 EEIEFIVPSV 21 266 ITILKGEILL 21 315 NVSYQDKGNY 21 875RTHPKEVNIL 21 880 EVNILRFSGQ 21 902 SEFHLTVLAY 21 1182 EYGEGDHGLF 21 396VVFPREISFT 20 436 DVRPLIQTKD 20 450 ATVVGYSAFL 20 58 EAKGNPEPTF 19 179RVYMSQKGDL 19 277 ECFAEGLPTP 19 309 KTLKIENVSY 19 418 EASNVHGTIL 19 626DVPDPPENLH 19 721 ETPPAAPDRN 19 777 EEETVTNHTL 19 974 DTYEIGELND 19 1151EYSDSDEKPL 19 1211 ESNGSSTATF 19 44 QVAFPFDEYF 18 213 TIVQKMPMKL 18 267TILKGEILLL 18 349 WTKKPQSAVY 18 401 EISFTNLQPN 18 557 DSHLKHSLKL 18 618DITQVTVLDV 18 656 SNISEYIVEF 18 826 DTAPVIHGVD 18 987 TTPSKPSWHL 18 10LIVYLMFLLL 17 69 WTKDGNPFYF 17 98 GHISHFQGKY 17 573 EAFEINGTED 17 946DTATLSWGLP 17 977 EIGELNDINI 17 1072 DSIFQDVIET 17 1105 AIALLTLLLL 171192 SEDGSFIGAY 17 V2-(SET1)-HLA-A26-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 1 EFIVPSVPKF 27V2-(SET2)-HLA-A26-10mers-282P1G3 Each peptide is a portion of SEQ ID NO:5; each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 9 EAKENYGKTL 22 5 PKGREAKENY 10 V2-(SET3)-HLA-A26-10mers-282P1G3Each peptide is a portion of SEQ ID NO: 5; each start position isspecified, the length of peptide is 10 amino acids, and the end positionfor each peptide is the start position plus nine. 2 ESSTLGEGKY 22 8EGKYAGLYDD 14 1 EESSTLGEGK 12 5 TLGEGKYAGL 11 6 LGEGKYAGLY 11 4STLGEGKYAG 10 V3-HLA-A26-10mers-282P1G3 Each peptide is a portion of SEQID NO: 7; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 2 EEIEFIVPKL 29 5 EFIVPKLEHI 18 3 EIEFIVPKLE 14V4-HLA-A26-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 9;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 1 SVTLYSGEDL 21 8 EDLPEQPTFL 19 9 DLPEQPTFLK 10V5-HLA-A26-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 6 TVNSSNSIKQ 14 5 LTVNSSNSIK 13 7 VNSSNSIKQR 6V6-HLA-A26-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 2 EEIEFIVPKL 29 5 EFIVPKLEHI 18 3 EIEFIVPKLE 14V7-HLA-A26-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 10 DNISHELFTL 26 7 IVEDNISHEL 19 5 HVIVEDNISH 16 6 VIVEDNISHE 1515 ELFTLHPEPP 14

TABLE XXXIX Pos 1234567890 score V1-HLA-B0702-10mers-28P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 1054 EPGAEHIVRL 25 398FPREISFTNL 24 627 VPDPPENLHL 24 218 MPMKLTVNSL 23 27 IPSSVQQVPT 22 539NPRIPKLHML 22 1158 KPLKGSLRSL 22 536 SPKNPRIPKL 21 1019 KPITEESSTL 21155 PPKGLPPLHI 20 795 APYDVKVQAI 20 828 APVIHGVDVI 20 849 VPKDRVHGRL 20895 VPSLDAFSEF 19 927 TPEGVPEQPT 19 931 VPEQPTFLKV 19 2 EPLLLGRGLI 18373 EPQPTIKWRV 18 480 KPLEGRRYHI 18 693 APFVRYQFRV 18 772 APVEWEEETV 18877 HPKEVNILRF 18 94 IPNEGHISHF 17 790 TPAVYAPYDV 17 934 QPTFLKVIKV 17954 LPKKLNGNLT 17 1048 HPIEVFEPGA 17 34 VPTIIKQSKV 16 74 NPFYFTDHRI 16160 PPLHIYWMNI 16 616 AADITQVTVL 16 900 AFSEFHLTVL 16 1080 ETRGREYAGL 161172 QPTESADSLV 16 84 IPSNNSGTFR 15 390 HPFAGDVVFP 15 681 VQGKKTTVIL 151105 AIALLTLLLL 15 208 FPRLRTIVQK 14 418 EASNVHGTIL 14 450 ATVVGYSAFL 14541 RIPKLHMLEL 14 590 ANLTISNVTL 14 637 SERQNRSVRL 14 671 EPGRWEELTR 14715 QPSDHHETPP 14 723 PPAAPDRNPQ 14 758 GPGLEYRVTW 14 768 KPQGAPVEWE 14810 GPDPQSVTLY 14 929 EGVPEQPTFL 14 957 KLNGNLTGYL 14 1034 GIGKISGVNL 141104 CAIALLTLLL 14 1151 EYSDSDEKPL 14 1213 NGSSTATFPL 14 5 LLGRGLIVYL 1310 LIVYLMFLLL 13 106 KYRCFASNKL 13 124 EFIVPSVPKL 13 127 VPSVPKLPKE 13132 KLPKEKIDPL 13 153 CNPPKGLPPL 13 246 IKQRKPKLLL 13 260 SGSESSITIL 13267 TILKGEILLL 13 297 LPKGRETKEN 13 323 NYRCTASNFL 13 346 PPRWTKKPQS 13375 QPTIKWRVNG 13 431 NIDVVDVRPL 13 516 IGKTAVTANL 13 604 IYCCSAHTAL 13683 GKKTTVILPL 13 726 APDRNPQNIR 13 742 KEMIIKWEPL 13 752 KSMEQNGPGL 13875 RTHPKEVNIL 13 921 EPYIFQTPEG 13 941 IKVDKDTATL 13 988 TPSKPSWHLS 13991 KPSWHLSNLN 13 1102 LMCAIALLTL 13 1126 KYSVKEKEDL 13 1136 HPDPEIQSVK13 8 RGLIVYLMFL 12 64 EPTFSWTKDG 12 142 EVEEGDPIVL 12 154 NPPKGLPPLH 12202 YCCFAAFPRL 12 244 NSIKQRKPKL 12 250 KPKLLLPPTE 12 345 EPPRWTKKPQ 12357 VYSTGSNGIL 12 358 YSTGSNGILL 12 428 ANANIDVVDV 12 473 WQKVEEVKPL 12524 NLDIRNATKL 12 555 KCDSHLKHSL 12 557 DSHLKHSLKL 12 629 DPPENLHLSE 12669 KEEPGRWEEL 12 680 RVQGKKTTVI 12 690 LPLAPFVRYQ 12 712 QPSQPSDHHE 12730 NPQNIRVQAS 12 749 EPLKSMEQNG 12 809 SGPDPQSVTL 12 824 YPDTAPVIHG 12889 QRNSGMVPSL 12 897 SLDAFSEFHL 12 945 KDTATLSWGL 12 949 TLSWGLPKKL 12972 INDTYEIGEL 12 1093 ISTQGWFIGL 12 1099 FIGLMCAIAL 12 1100 IGLMCAIALL12 1103 MCAIALLTLL 12 1181 VEYGEGDHGL 12V2-(SET1)-HLA-B0702-10mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 9 KFPKEKIDPL 13 10 FPKEKIDPLE 11 7 VPKFPKEKID 10 1 EFIVPSVPKF9 6 SVPKFPKEKI 7 V2-(SET2)-HLA-B0702-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 4 LPKGREAKEN 12 9 EAKENYGKTL 11 8 REAKENYGKT 91 GGDLPKGREA 7 V2-(SET3)-HLA-B0702-10mers-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 10 amino acids, and the end position for each peptide is thestart position plus nine. 5 TLGEGKYAGL 12 9 GKYAGLYDDI 7 3 SSTLGEGKYA 6V3-HLA-B0702-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 7;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 7 DVINTTYVSN 23 10 NTTYVSNTTY 20 39 ELSYRNRNML 19 23 ATGSPQPSIF 184 HGVDVINTTY 16 50 EDFIQKSTSC 15 1 PVIHGVDVIN 14 52 FIQKSTSCNY 14 56STSCNYVEKS 14 60 NYVEKSSTFF 14 51 DFIQKSTSCN 13 19 YVSNATGSPQ 12 31IFICSKEQEL 12 33 ICSKEQELSY 11 13 YVSNTTYVSN 11V4-HLA-B0702-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 9;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 10 LPEQPTFLKV 19 8 EDLPEQPTFL 14 1 SVTLYSGEDL 10V5-HLA-B0702-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 1 MPMKLTVNSS 13 4 KLTVNSSNSI 7 V6-HLA-B0702-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 13; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 2 EEIEFIVPKL 13 8 VPKLEHIEQD 105 EFIVPKLEHI 7 V7-HLA-B0702-10mers-282P1G3 Each peptide is a portion ofSEQ ID NO: 15; each start position is specified, the length of peptideis 10 amino acids, and the end position for each peptide is the startposition plus nine. 20 HPEPPRWTKK 12 7 IVEDNISHEL 11 9 EDNISHELFT 10 10DNISHELFTL 10 8 VEDNISHELF 7 18 TLHPEPPRWT 7 3 DFHVIVEDNI 6

TABLE XL Pos 1234567890 score V1-HLA-B08-10mers-282P1G3 NoResultsFound.V2-(SET1)-HLA-B08-10mers-282P1G3 NoResultsFound.V2-(SET2)-HLA-B08-10mers-282P1G3 NoResultsFound.V2-(SET3)-HLA-B08-10mers-282P1G3 NoResultsFound.V3-HLA-B08-10mers-282P1G3 NoResultsFound. V4-HLA-B08-10mers-282P1G3NoResultsFound. V5-HLA-B08-10mers-282P1G3 NoResultsFound.V6-HLA-B08-10mers-282P1G3 NoResultsFound. V7-HLA-B08-10mers-282P1G3NoResultsFound.

TABLE XLI Pos 1234567890 score V1-HLA-B1510-10mers-282P1G3NoResultsFound. V2-(SET1)-HLA-B1510-10mers-282P1G3 NoResultsFound.V2-(SET2)-HLA-B1510-10mers-282P1G3 NoResultsFound.V2-(SET3)-HLA-B1510-10mers-282P1G3 NoResultsFound.V2-(SET3)-HLA-B1510-10mers-282P1G3 NoResultsFound.V3-HLA-B1510-10mers-(SET3)-282P1G3 NoResultsFound.V4-HLA-B1510-10mers-282P1G3 NoResultsFound. V5-HLA-B1510-10mers-282P1G3NoResultsFound. V6-HLA-B1510-10mers-282P1G3 NoResultsFound.V7-HLA-B1510-10mers-282P1G3 NoResultsFound.

TABLE XLII Pos 1234567890 score V1-HLA-B2705-10mers-282P1G3NoResultsFound. V2-(SET1)-HLA-B2705-10mers-282P1G3 NoResultsFound.V2-(SET2)-HLA-B2705-10mers-282P1G3 NoResultsFound.V2-(SET3)-HLA-B2705-10mers-282P1G3 NoResultsFound.V3-HLA-B2705-10mers-282P1G3 NoResultsFound. V4-HLA-B2705-10mers-282P1G3NoResultsFound. V5-HLA-B2705-10mers-282P1G3 NoResultsFound.V6-HLA-B2705-10mers-282P1G3 NoResultsFound. V7-HLA-B2705-10mers-282P1G3NoResultsFound.

TABLE XLIII Pos 1234567890 score V1-HLA-B2709-10mers-282P1G3NoResultsFound. V2-(SET1)-HLA-B2709-10mers-282P1G3 NoResultsFound.V2-(SET2)-HLA-B2709-10mers-282P1G3 NoResultsFound.V2-(SET3)-HLA-B2709-10mers-282P1G3 NoResultsFound.V3-HLA-B2709-10mers-282P1G3 NoResultsFound. V4-HLA-B2709-10mers-282P1G3NoResultsFound. V5-HLA-B2709-10mers-282P1G3 NoResultsFound.V6-HLA-B2709-10mers-282P1G3 NoResultsFound. V7-HLA-B2709-10mers-282P1G3NoResultsFound.

TABLE XLIV Pos 1234567890 score V1-HLA-B4402-10mers-282P1G3 Each peptideis a portion of SEQ ID NO: 3; each start position is specified, thelength of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 1192 SEDGSFIGAY 28 902SEFHLTVLAY 27 777 EEETVTNHTL 25 932 PEQPTFLKVI 25 237 TEIGSKANSI 24 669KEEPGRWEEL 24 1 MEPLLLGRGL 23 502 EEDAGSYSCW 23 1174 TESADSLVEY 23 193VEEKDSRNDY 22 304 KENYGKTLKI 22 446 GENYATVVGY 22 637 SERQNRSVRL 22 742KEMIIKWEPL 22 754 MEQNGPGLEY 22 1029 GEGSKGIGKI 22 1181 VEYGEGDHGL 22928 PEGVPEQPTF 21 1132 KEDLHPDPEI 21 344 EEPPRWTKKP 20 417 CEASNVHGTI 1925 IEIPSSVQQV 18 371 EGEPQPTIKW 18 656 SNISEYIVEF 18 1084 REYAGLYDDI 18124 EFIVPSVPKL 17 172 EHIEQDERVY 17 262 SESSITILKG 17 281 EGLPTPQVDW 17590 ANLTISNVTL 17 652 ADHNSNISEY 17 739 SQPKEMIIKW 17 1105 AIALLTLLLL 17121 EEIEFIVPSV 16 143 VEEGDPIVLP 16 157 KGLPPLHIYW 16 266 ITILKGEILL 16267 TILKGEILLL 16 280 AEGLPTPQVD 16 372 GEPQPTIKWR 16 383 NGSPVDNHPF 16406 NLQPNHTAVY 16 464 FASPEAVVSW 16 478 EVKPLEGRRY 16 536 SPKNPRIPKL 16580 TEDGRIIIDG 16 616 AADITQVTVL 16 810 GPDPQSVTLY 16 900 AFSEFHLTVL 16929 EGVPEQPTFL 16 1019 KPITEESSTL 16 1054 EPGAEHIVRL 16 1104 CAIALLTLLL16 1151 EYSDSDEKPL 16 4 LLLGRGLIVY 15 5 LLGRGLIVYL 15 60 KGNPEPTFSW 15120 SEEIEFIVPS 15 132 KLPKEKIDPL 15 142 EVEEGDPIVL 15 144 EEGDPIVLPC 15153 CNPPKGLPPL 15 244 NSIKQRKPKL 15 245 SIKQRKPKLL 15 260 SGSESSITIL 15302 ETKENYGKTL 15 330 NFLGTATHDF 15 400 REISFTNLQP 15 461 CEFFASPEAV 15627 VPDPPENLHL 15 670 EEPGRWEELT 15 676 EELTRVQGKK 15 683 GKKTTVILPL 15691 PLAPFVRYQF 15 795 APYDVKVQAI 15 798 DVKVQAINQL 15 809 SGPDPQSVTL 15822 EDYPDTAPVI 15 857 RLKGYQINWW 15 875 RTHPKEVNIL 15 892 SGMVPSLDAF 15916 AGPESEPYIF 15 918 PESEPYIFQT 15 949 TLSWGLPKKL 15 960 GNLTGYLLQY 15972 INDTYEIGEL 15 1044 TQKTHPIEVF 15 1057 AEHIVRLMTK 15 1099 FIGLMCAIAL15 1100 IGLMCAIALL 15 1211 ESNGSSTATF 15 2 EPLLLGRGLI 14 9 GLIVYLMFLL 1412 VYLMFLLLKF 14 16 FLLLKFSKAI 14 58 EAKGNPEPTF 14 98 GHISHFQGKY 14 101SHFQGKYRCF 14 150 VLPCNPPKGL 14 162 LHIYWMNIEL 14 199 RNDYCCFAAF 14 271GEILLLECFA 14 340 HVIVEEPPRW 14 343 VEEPPRWTKK 14 370 AEGEPQPTIK 14 389NHPFAGDVVF 14 393 AGDVVFPREI 14 418 EASNVHGTIL 14 431 NIDVVDVRPL 14 524NLDIRNATKL 14 575 FEINGTEDGR 14 585 IIIDGANLTI 14 625 LDVPDPPENL 14 639RQNRSVRLTW 14 689 ILPLAPFVRY 14 720 HETPPAAPDR 14 725 AAPDRNPQNI 14 758GPGLEYRVTW 14 837 INSTLVKVTW 14 877 HPKEVNILRF 14 956 KKLNGNLTGY 14 976YEIGELNDIN 14 979 GELNDINITT 14 1053 FEPGAEHIVR 14 1059 HIVRLMTKNW 141077 DVIETRGREY 14 1109 LTLLLLTVCF 14 1156 DEKPLKGSLR 14 1158 KPLKGSLRSL14 1210 VESNGSSTAT 14 10 LIVYLMFLLL 13 38 IKQSKVQVAF 13 46 AFPFDEYFQI 1363 PEPTFSWTKD 13 94 IPNEGHISHF 13 106 KYRCFASNKL 13 123 IEFIVPSVPK 13135 KEKIDPLEVE 13 156 PKGLPPLHIY 13 194 EEKDSRNDYC 13 196 KDSRNDYCCF 13218 MPMKLTVNSL 13 246 IKQRKPKLLL 13 264 SSITILKGEI 13 309 KTLKIENVSY 13358 YSTGSNGILL 13 450 ATVVGYSAFL 13 473 WQKVEEVKPL 13 507 SYSCWVENAI 13539 NPRIPKLHML 13 548 LELHCESKCD 13 552 CESKCDSHLK 13 555 KCDSHLKHSL 13557 DSHLKHSLKL 13 583 GRIIIDGANL 13 666 EGNKEEPGRW 13 748 WEPLKSMEQN 13761 LEYRVTWKPQ 13 767 WKPQGAPVEW 13 774 VEWEEETVTN 13 778 EETVTNHTLR 13788 VMTPAVYAPY 13 828 APVIHGVDVI 13 852 DRVHGRLKGY 13 862 QINWWKTKSL 13879 KEVNILRFSG 13 895 VPSLDAFSEF 13 941 IKVDKDTATL 13 943 VDKDTATLSW 13957 KLNGNLTGYL 13 990 SKPSWHLSNL 13 996 LSNLNATTKY 13 999 LNATTKYKFY 131023 EESSTLGEGS 13 1026 STLGEGSKGI 13 1051 EVFEPGAEHI 13 1079 IETRGREYAG13 1080 ETRGREYAGL 13 1081 TRGREYAGLY 13 1089 LYDDISTQGW 13 1102LMCAIALLTL 13 1139 PEIQSVKDET 13 1140 EIQSVKDETF 13 1143 SVKDETFGEY 131171 MQPTESADSL 13 1182 EYGEGDHGLF 13 1213 NGSSTATFPL 13V2-(SET1)-HLA-B4402-10mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 1 EFIVPSVPKF 17 9 KFPKEKIDPL 15 6 SVPKFPKEKI 11V2-(SET2)-HLA-B4402-10mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 9 EAKENYGKTL 15 5 PKGREAKENY 11 8 REAKENYGKT 11 2 GDLPKGREAK7 V2-(SET3)-HLA-B4402-10mers-282P1G3 Each peptide is a portion of SEQ IDNO: 5; each start position is specified, the length of peptide is 10amino acids, and the end position for each peptide is the start positionplus nine. 2 ESSTLGEGKY 15 1 EESSTLGEGK 13 6 LGEGKYAGLY 13 7 GEGKYAGLYD11 5 TLGEGKYAGL 10 9 GKYAGLYDDI 8 V3-HLA-B4402-10mers-282P1G3 Eachpeptide is a portion of SEQ ID NO: 7; each start position is specified,the length of peptide is 10 amino acids, and the end position for eachpeptide is the start position plus nine. 62 VEKSSTFFKI 20 39 ELSYRNRNML15 49 AEDFIQKSTS 15 23 ATGSPQPSIF 14 24 TGSPQPSIFI 13 31 IFICSKEQEL 13 4HGVDVINTTY 12 10 NTTYVSNTTY 12 33 ICSKEQELSY 12 36 KEQELSYRNR 12 38QELSYRNRNM 12 43 RNRNMLAEDF 12 59 CNYVEKSSTF 11 60 NYVEKSSTFF 11 22NATGSPQPSI 10 52 FIQKSTSCNY 10 44 NRNMLAEDFI 9V4-HLA-B4402-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 9;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 7 GEDLPEQPTF 23 8 EDLPEQPTFL 17 1 SVTLYSGEDL 12V5-HLA-B4402-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 11;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 4 KLTVNSSNSI 10 7 VNSSNSIKQR 7 10 SNSIKQRKPK 5V6-HLA-B4402-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 13;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 2 EEIEFIVPKL 27 1 SEEIEFIVPK 15 5 EFIVPKLEHI 14 4 IEFIVPKLEH 13V7-HLA-B4402-10mers-282P1G3 Each peptide is a portion of SEQ ID NO: 15;each start position is specified, the length of peptide is 10 aminoacids, and the end position for each peptide is the start position plusnine. 8 VEDNISHELF 23 21 PEPPRWTKKP 18 10 DNISHELFTL 15 7 IVEDNISHEL 1217 FTLHPEPPRW 12 14 HELFTLHPEP 11

TABLE XLV Pos 1234567890 score V1-HLA-B5101-10mers-282P1G3NoResultsFound. V2-(SET1)-HLA-B5101-10mers-282P1G3 NoResultsFound.V2-(SET2)-HLA-B5101-10mers-282P1G3 NoResultsFound.V2-(SET3)-HLA-B5101-10mers-282P1G3 NoResultsFound.V3-HLA-B5101-10mers-(SET3)-282P1G3 NoResultsFound.V4-HLA-B5101-10mers-282P1G3 NoResultsFound. V5-HLA-B5101-10mers-282P1G3NoResultsFound. V6-HLA-B5101-10mers-282P1G3 NoResultsFound.V7-HLA-B5101-10mers-282P1G3 NoResultsFound.

TABLE XLVI V1-DRB1-0101-15mers-282P1G3 Each peptide is a portion of SEQID NO: 3; each start position is specified, the length of peptide is 15amino acids, and the end position for each peptide is the start positionplus fourteen. Pos 123456789012345 score 263 ESSITILKGEILLLE 36 287QVDWNKIGGDLPKGR 36 920 SEPYIFQTPEGVPEQ 33 446 GENYATVVGYSAFLH 32 1032SKGIGKISGVNLTQK 32 1097 GWFIGLMCAIALLTL 31 120 SEEIEFIVPSVPKLP 29 522TANLDIRNATKLRVS 29 831 IHGVDVINSTLVKVT 29 13 YLMFLLLKFSKAIEI 28 470VVSWQKVEEVKPLEG 28 104 QGKYRCFASNKLGIA 27 127 VPSVPKLPKEKIDPL 27 461CEFFASPEAWSWQK 27 476 VEEVKPLEGRRYHIY 27 940 VIKVDKDTATLSWGL 27 981LNDINITTPSKPSWH 27 11 IVYLMFLLLKFSKAI 26 16 FLLLKFSKAIEIPSS 26 187DLYFANVEEKDSRND 26 272 EILLLECFAEGLPTP 26 321 KGNYRCTASNFLGTA 26 539NPRIPKLHMLELHCE 26 697 RYQFRVIAVNEVGRS 26 742 KEMIIKWEPLKSMEQ 26 748WEPLKSMEQNGPGLE 26 764 RVTWKPQGAPVEWEE 26 883 ILRFSGQRNSGMVPS 26 1083GREYAGLYDDISTQG 26 1096 QGWFIGLMCAIALLT 26 1 MEPLLLGRGLIVYLM 25 8RGLIVYLMFLLLKFS 25 78 FTDHRIIPSNNSGTF 25 112 SNKLGIAMSEEIEFI 25 138IDPLEVEEGDPIVLP 25 148 PIVLPCNPPKGLPPL 25 163 HIYWMNIELEHIEQD 25 208FPRLRTIVQKMPMKL 25 354 QSAVYSTGSNGILLC 25 401 EISFTNLQPNHTAVY 25 411HTAVYQCEASNVHGT 25 509 SCWVENAIGKTAVTA 25 581 EDGRIIIDGANLTIS 25 619ITQVTVLDVPDPPEN 25 675 WEELTRVQGKKTTVI 25 685 KTTVILPLAPFVRYQ 25 838NSTLVKVTWSTVPKD 25 905 HLTVLAYNSKGAGPE 25 993 SWHLSNLNATTKYKF 25 1049PIEVFEPGAEHIVRL 25 1103 MCAIALLTLLLLTVC 25 1108 LLTLLLLTVCFVKRN 25 14LMFLLLKFSKAIEIP 24 34 VPTIIKQSKVQVAFP 24 123 IEFIVPSVPKLPKEK 24 156PKGLPPLHIYWMNIE 24 178 ERVYMSQKGDLYFAN 24 205 FAAFPRLRTIVQKMP 24 211LRTIVQKMPMKLTVN 24 243 ANSIKQRKPKLLLPP 24 249 RKPKLLLPPTESGSE 24 328ASNFLGTATHDFHVI 24 336 THDFHVIVEEPPRWT 24 601 DQGIYCCSAHTALDS 24 693APFVRYQFRVIAVNE 24 702 VIAVNEVGRSQPSQP 24 745 IIKWEPLKSMEQNGP 24 750PLKSMEQNGPGLEYR 24 798 DVKVQAINQLGSGPD 24 800 KVQAINQLGSGPDPQ 24 801VQAINQLGSGPDPQS 24 839 STLVKVTWSTVPKDR 24 843 KVTWSTVPKDRVHGR 24 852DRVHGRLKGYQINWW 24 860 GYQINWWKTKSLLDG 24 892 SGMVPSLDAFSEFHL 24 937FLKVIKVDKDTATLS 24 947 TATLSWGLPKKLNGN 24 956 KKLNGNLTGYLLQYQ 24 975TYEIGELNDINITTP 24 978 IGELNDINITTPSKP 24 1003 TKYKFYLRACTSQGC 24 1057AEHIVRLMTKNWGDN 24 1087 AGLYDDISTQGWFIG 24 1105 AIALLTLLLLTVCFV 24 1187DHGLFSEDGSFIGAY 24 38 IKQSKVQVAFPFDEY 23 89 SGTFRIPNEGHISHF 23 144EEGDPIVLPCNPPKG 23 153 CNPPKGLPPLHIYWM 23 215 VQKMPMKLTVNSLKH 23 348RWTKKPQSAVYSTGS 23 351 KKPQSAVYSTGSNGI 23 416 QCEASNVHGTILANA 23 429NANIDVVDVRPLIQT 23 486 RYHIYENGTLQINRT 23 532 KLRVSPKNPRIPKLH 23 616AADITQVTVLDVPDP 23 678 LTRVQGKKTTVILPL 23 733 NIRVQASQPKEMIIK 23 758GPGLEYRVTWKPQGA 23 796 PYDVKVQAINQLGSG 23 955 PKKLNGNLTGYLLQY 23 1107ALLTLLLLTVCFVKR 23 1165 RSLNRDMQPTESADS 23 1168 NRDMQPTESADSLVE 23 1204SKEKGSVESNGSSTA 23 1207 KGSVESNGSSTATFP 23 27 IPSSVQQVPTIIKQS 22 81HRIIPSNNSGTFRIP 22 132 KLPKEKIDPLEVEEG 22 140 PLEVEEGDPIVLPCN 22 277ECFAEGLPTPQVDWN 22 376 PTIKWRVNGSPVDNH 22 468 EAWSWQKVEEVKPL 22 484GRRYHIYENGTLQIN 22 686 TTVILPLAPFVRYQF 22 705 VNEVGRSQPSQPSDH 22 706NEVGRSQPSQPSDHH 22 730 NPQNIRVQASQPKEM 22 731 PQNIRVQASQPKEMI 22 783NHTLRVMTPAVYAPY 22 825 PDTAPVIHGVDVINS 22 828 APVIHGVDVINSTLV 22 878PKEVNILRFSGQRNS 22 902 SEFHLTVLAYNSKGA 22 973 NDTYEIGELNDINIT 22 1100IGLMCAIALLTLLLL 22 1102 LMCAIALLTLLLLTV 22 1138 DPEIQSVKDETFGEY 22 346PPRWTKKPQSAVYST 21 391 PFAGDVVFPREISFT 21 431 NIDVVDVRPLIQTKD 21 529NATKLRVSPKNPRIP 21 641 NRSVRLTWEAGADHN 21 683 GKKTTVILPLAPFVR 21 881VNILRFSGQRNSGMV 21 889 QRNSGMVPSLDAFSE 21 1095 TQGWFIGLMCAIALL 21 1166SLNRDMQPTESADSL 21 1198 IGAYAGSKEKGSVES 21 10 LIVYLMFLLLKFSKA 20 18LLKFSKAIEIPSSVQ 20 28 PSSVQQVPTIIKQSK 20 44 QVAFPFDEYFQIECE 20 73GNPFYFTDHRIIPSN 20 109 CFASNKLGIAMSEEI 20 362 SNGILLCEAEGEPQP 20 421NVHGTILANANIDVV 20 434 VVDVRPLIQTKDGEN 20 473 WQKVEEVKPLEGRRY 20 572GEAFEINGTEDGRII 20 582 DGRIIIDGANLTISN 20 593 TISNVTLEDQGIYCC 20 684KKTTVILPLAPFVRY 20 692 LAPFVRYQFRVIAVN 20 782 TNHTLRVMTPAVYAP 20 908VLAYNSKGAGPESEP 20 928 PEGVPEQPTFLKVIK 20 966 LLQYQIINDTYEIGE 20 1039SGVNLTQKTHPIEVF 20 1117 CFVKRNRGGKYSVKE 20 32 QQVPTIIKQSKVQVA 19 75PFYFTDHRIIPSNNS 19 122 EIEFIVPSVPKLPKE 19 265 SITILKGEILLLECF 19 268ILKGEILLLECFAEG 19 377 TIKWRVNGSPVDNHP 19 455 YSAFLHCEFFASPEA 19 602QGIYCCSAHTALDSA 19 659 SEYIVEFEGNKEEPG 19 898 LDAFSEFHLTVLAYN 19 922PYIFQTPEGVPEQPT 19 932 PEQPTFLKVIKVDKD 19 952 WGLPKKLNGNLTGYL 19 1028LGEGSKGIGKISGVN 19 1038 ISGVNLTQKTHPIEV 19 1061 VRLMTKNWGDNDSIF 19 1106IALLTLLLLTVCFVK 19 1124 GGKYSVKEKEDLHPD 19 1149 FGEYSDSDEKPLKGS 19 4LLLGRGLIVYLMFLL 18 64 EPTFSWTKDGNPFYF 18 74 NPFYFTDHRIIPSNN 18 100ISHFQGKYRCFASNK 18 107 YRCFASNKLGIAMSE 18 114 KLGIAMSEEIEFIVP 18 130VPKLPKEKIDPLEVE 18 199 RNDYCCFAAFPRLRT 18 209 PRLRTIVQKMPMKLT 18 216QKMPMKLTVNSLKHA 18 219 PMKLTVNSLKHANDS 18 251 PKLLLPPTESGSESS 18 270KGEILLLECFAEGLP 18 300 GRETKENYGKTLKIE 18 355 SAVYSTGSNGILLCE 18 393AGDVVFPREISFTNL 18 452 VVGYSAFLHCEFFAS 18 460 HCEFFASPEAVVSWQ 18 492NGTLQINRTTEEDAG 18 505 AGSYSCWVENAIGKT 18 524 NLDIRNATKLRVSPK 18 542IPKLHMLELHCESKC 18 566 LSWSKDGEAFEINGT 18 574 AFEINGTEDGRIIID 18 645RLTWEAGADHNSNIS 18 672 PGRWEELTRVQGKKT 18 743 EMIIKWEPLKSMEQN 18 763YRVTWKPQGAPVEWE 18 778 EETVTNHTLRVMTPA 18 784 HTLRVMTPAVYAPYD 18 813PQSVTLYSGEDYPDT 18 862 QINWWKTKSLLDGRT 18 866 WKTKSLLDGRTHPKE 18 907TVLAYNSKGAGPESE 18 909 LAYNSKGAGPESEPY 18 934 QPTFLKVIKVDKDTA 18 951SWGLPKKLNGNLTGY 18 979 GELNDINITTPSKPS 18 996 LSNLNATTKYKFYLR 18 1006KFYLRACTSQGCGKP 18 1021 ITEESSTLGEGSKGI 18 1024 ESSTLGEGSKGIGKI 18 1050IEVFEPGAEHIVRLM 18 1116 VCFVKRNRGGKYSVK 18 1126 KYSVKEKEOLHPOPE 18 1161KGSLRSLNRDMQPTE 18 1180 LVEYGEGDHGLFSED 18 1194 DGSFIGAYAGSKEKG 18 6LGRGLIVYLMFLLLK 17 12 VYLMFLLLKFSKAIE 17 20 KFSKAIEIPSSVQQV 17 22SKAIEIPSSVQQVPT 17 35 PTIIKQSKVQVAFPF 17 42 KVQVAFPFDEYFQIE 17 49FDEYFQIECEAKGNP 17 90 GTFRIPNEGHISHFQ 17 97 EGHISHFQGKYRCFA 17 135KEKIDPLEVEEGDPI 17 150 VLPCNPPKGLPPLHI 17 171 LEHIEQDERVYMSQK 17 177DERVYMSQKGDLYFA 17 179 RVYMSQKGDLYFANV 17 212 RTIVQKMPMKLTVNS 17 221KLTVNSLKHANDSSS 17 222 LTVNSLKHANDSSSS 17 224 VNSLKHANDSSSSTE 17 232DSSSSTEIGSKANSI 17 240 GSKANSIKQRKPKLL 17 242 KANSIKQRKPKLLLP 17 269LKGEILLLECFAEGL 17 276 LECFAEGLPTPQVDW 17 290 WNKIGGDLPKGRETK 17 305ENYGKTLKIENVSYQ 17 326 CTASNFLGTATHDFH 17 356 AVYSTGSNGILLCEA 17 364GILLCEAEGEPQPTI 17 375 QPTIKWRVNGSPVDN 17 385 SPVDNHPFAGDVVFP 17 396VVFPREISFTNLQPN 17 442 QTKDGENYATVVGYS 17 449 YATVVGYSAFLHCEF 17 453VGYSAFLHCEFFASP 17 494 TLQINRTTEEDAGSY 17 510 CWVENAIGKTAVTAN 17 519TAVTANLDIRNATKL 17 561 KHSLKLSWSKDGEAF 17 575 FEINGTEDGRIIIDG 17 584RIIIDGANLTISNVT 17 608 SAHTALDSAADITQV 17 633 NLHLSERQNRSVRLT 17 643SVRLTWEAGADHNSN 17 700 FRVIAVNEVGRSQPS 17 740 QPKEMIIKWEPLKSM 17 761LEYRVTWKPQGAPVE 17 762 EYRVTWKPQGAPVEW 17 790 TPAVYAPYDVKVQAI 17 795APYDVKVQAINQLGS 17 802 QAINQLGSGPDPQSV 17 833 GVDVINSTLVKVTWS 17 836VINSTLVKVTWSTVP 17 891 NSGMVPSLDAFSEFH 17 903 EFHLTVLAYNSKGAG 17 943VDKDTATLSWGLPKK 17 961 NLTGYLLQYQIINDT 17 962 LTGYLLQYQIINDTY 17 967LQYQIINDTYEIGEL 17 1009 LRACTSQGCGKPITE 17 1010 RACTSQGCGKPITEE 17 1058EHIVRLMTKNWGDND 17 1072 DSIFQDVIETRGREY 17 1075 FQDVIETRGREYAGL 17 1076QDVIETRGREYAGLY 17 1154 DSDEKPLKGSLRSLN 17 1178 DSLVEYGEGDHGLFS 17 1188HGLFSEDGSFIGAYA 17 1195 GSFIGAYAGSKEKGS 17 1210 VESNGSSTATFPLRA 17V2-(SET1)-HLA-DRB1-0101-15mers-282P1G3 Each peptide is a portion of SEQID NO: 5; each start position is specified, the length of peptide is 15amino acids, and the end position for each peptide is the start positionplus fourteen. Pos 123456789012345 score 2 SEEIEFIVPSVPKFP 29 5IEFIVPSVPKFPKEK 24 14 KFPKEKIDPLEVEEG 22 12 VPKFPKEKIDPLEVE 20 4EIEFIVPSVPKFPKE 19 9 VPSVPKFPKEKIDPL 19 3 EEIEFIVPSVPKFPK 15 6EFIVPSVPKFPKEKI 14 V2-(SET2)-HLA-DRB1-0101-15mers-282P1G3 Each peptideis a portion of SEQ ID NO: 5; each start position is specified, thelength of peptide is 15 amino acids, and the end position for eachpeptide is the start position plus fourteen. Pos 123456789012345 score 4KIGGDLPKGREAKEN 18 12 GREAKENYGKTLKIE 18 2 WNKIGGDLPKGREAK 17 14EAKENYGKTLKIENV 16 6 GGDLPKGREAKENYG 11 7 GDLPKGREAKENYGK 11 3NKIGGDLPKGREAKE 8 V2-(SET3)-HLA-DRB1-0101-15mers-282P1G3 Each peptide isa portion of SEQ ID NO: 5; each start position is specified, the lengthof peptide is 15 amino acids, and the end position for each peptide isthe start position plus fourteen. Pos 123456789012345 score 13EGKYAGLYDDISTQG 26 6 EESSTLGEGKYAGLY 20 8 SSTLGEGKYAGLYDD 18 1GKPITEESSTLGEGK 16 V3-HLA-DRB1-0101-15mers-282P1G3 Each peptide is aportion of SEQ ID NO: 7; each start position is specified, the length ofpeptide is 15 amino acids, and the end position for each peptide is thestart position plus fourteen. Pos 123456789012345 score 8IHGVDVINTTYVSNT 29 15 NTTYVSNTTYVSNAT 25 21 NTTYVSNATGSPQPS 25 46SYRNRNMLAEDFIQK 24 2 PDTAPVIHGVDVINT 22 27 NATGSPQPSIFICSK 20 20SNTTYVSNATGSPQP 19 9 HGVDVINTTYVSNTT 18 34 PSIFICSKEQELSYR 18 47YRNRNMLAEDFIQKS 18 35 SIFICSKEQELSYRN 17 50 RNMLAEDFIQKSTSC 17 22TTYVSNATGSPQPSI 16 23 TYVSNATGSPQPSIF 16 42 EQELSYRNRNMLAED 16 53LAEDFIQKSTSCNYV 16 54 AEDFIQKSTSCNYVE 16 55 EDFIQKSTSCNYVEK 16 14INTTYVSNTTYVSNA 15 52 MLAEDFIQKSTSCNY 15 5 APVIHGVDVINTTYV 14 24YVSNATGSPQPSIFI 14 26 SNATGSPQPSIFICS 14 32 PQPSIFICSKEQELS 14 62TSCNYVEKSSTFFKI 14 V4-HLA-DRB1-0101-15mers-282P1G3 Each peptide is aportion of SEQ ID NO: 9; each start position is specified, the length ofpeptide is 15 amino acids, and the end position for each peptide is thestart position plus fourteen. Pos 123456789012345 score 4PQSVTLYSGEDLPEQ 26 12 GEDLPEQPTFLKVIK 20 3 DPQSVTLYSGEDLPE 15 11SGEDLPEQPTFLKVI 15 8 TLYSGEDLPEQPTFL 14 V5-HLA-DRB1-0101-15mers-282P1G3Each peptide is a portion of SEQ ID NO: 11; each start position isspecified, the length of peptide is 15 amino acids, and the end positionfor each peptide is the start position plus fourteen. Pos123456789012345 score 15 SNSIKQRKPKLLLPP 24 3 VQKMPMKLTVNSSNS 23 7PMKLTVNSSNSIKQR 23 6 MPMKLTVNSSNSIKQ 20 4 QKMPMKLTVNSSNSI 18 12VNSSNSIKQRKPKLL 17 14 SSNSIKQRKPKLLLP 17 9 KLTVNSSNSIKQRKP 16V6-HLA-DRB1-0101-15mers-282P1G3 Each peptide is a portion of SEQ ID NO:13; each start position is specified, the length of peptide is 15 aminoacids, and the end position for each peptide is the start position plusfourteen. Pos 123456789012345 score 6 SEEIEFIVPKLEHIE 22 10EFIVPKLEHIEQDER 19 8 EIEFIVPKLEHIEQD 18 2 GIAMSEEIEFIVPKL 16 3IAMSEEIEFIVPKLE 15 13 VPKLEHIEQDERVYM 15 14 PKLEHIEQDERVYMS 11V7-HLA-DRB1-0101-15mers-282P1G3 Each peptide is a portion of SEQ ID NO:15; each start position is specified, the length of peptide is 15 aminoacids, and the end position for each peptide is the start position plusfourteen. Pos 123456789012345 score 18 SHELFTLHPEPPRWT 30 6THDFHVIVEDNISHE 24 10 HVIVEDNISHELFTL 22 15 DNISHELFTLHPEPP 22 7HDFHVIVEDNISHEL 19 V7-HLA-DRB1-0101-15mers-282P1G3 Each peptide is aportion of SEQ ID NO: 15; each start position is specified, the lengthof peptide is 15 amino acids, and the end position for each peptide isthe start position plus fourteen. Pos 123456789012345 score 24LHPEPPRWTKKPQSA 16 21 LFTLHPEPPRWTKKP 15 11 VIVEDNISHELFTLH 14

TABLE XLVII Pos 123456789012345 score V1-HLA-DRB1-0301-15mers-282P1G3Each peptide is a portion of SEQ ID NO: 3; each start position isspecified, the length of peptide is 15 amino acids, and the end positionfor each peptide is the start position plus fourteen. 171LEHIEQDERVYMSQK 28 1132 KEDLHPDPEIQSVKD 28 66 TFSWTKDGNPFYFTD 26 114KLGIAMSEEIEFIVP 26 191 ANVEEKDSRNDYCCF 26 594 ISNVTLEDQGIYCCS 26 951SWGLPKKLNGNLTGY 26 1164 LRSLNRDMQPTESAD 26 177 DERVYMSQKGDLYFA 25 313IENVSYQDKGNYRCT 25 393 AGDVVFPREISFTNL 25 689 ILPLAPFVRYQFRVI 25 895VPSLDAFSEFHLTVL 25 996 LSNLNATTKYKFYLR 25 582 DGRIIIDGANLTISN 24 265SITILKGEILLLECF 23 938 LKVIKVDKDTATLSW 23 623 TVLDVPDPPENLHLS 22 2EPLLLGRGLIVYLMF 21 7 GRGLIVYLMFLLLKF 21 8 RGLIVYLMFLLLKFS 21 243ANSIKQRKPKLLLPP 21 272 EILLLECFAEGLPTP 21 290 WNKIGGDLPKGRETK 21 476VEEVKPLEGRRYHIY 21 687 TVILPLAPFVRYQFR 21 786 LRVMTPAVYAPYDVK 21 813PQSVTLYSGEDYPDT 21 940 VIKVDKDTATLSWGL 21 968 QYQIINDTYEIGELN 21 1032SKGIGKISGVNLTQK 21 1103 MCAIALLTLLLLTVC 21 3 PLLLGRGLIVYLMFL 20 15MFLLLKFSKAIEIPS 20 179 RVVMSQKGDLYFANV 20 211 LRTIVQKMPMKLTVN 20 263ESSITILKGEILLLE 20 404 FTNLQPNHTAVYQCE 20 631 PENLHLSERQNRSVR 20 748WEPLKSMEQNGPGLE 20 783 NHTLRVMTPAVYAPY 20 796 PYDVKVQAINQLGSG 20 846WSTVPKDRVHGRLKG 20 867 KTKSLLDGRTHPKEV 20 947 TATLSWGLPKKLNGN 20 1071NDSIFQDVIETRGRE 20 1075 FQDVIETRGREYAGL 20 1086 YAGLYDDISTQGWFI 20 1097GWFIGLMCAIALLTL 20 1116 VCFVKRNRGGKYSVK 20 1138 DPEIQSVKDETFGEY 20 1172QPTESADSLVEYGEG 20 1188 HGLFSEDGSFIGAYA 20 34 VPTIIKQSKVQVAFP 19 44QVAFPFDEYFQIECE 19 81 HRIIPSNNSGTFRIP 19 122 EIEFIVPSVPKLPKE 19 124EFIVPSVPKLPKEKI 19 130 VPKLPKEKIDPLEVE 19 140 PLEVEEGDPIVLPCN 19 148PIVLPCNPPKGLPPL 19 217 KMPMKLTVNSLKHAN 19 251 PKLLLPPTESGSESS 19 434VVDVRPLIQTKDGEN 19 438 RPLIQTKDGENYATV 19 439 PLIQTKDGENYATVV 19 467PEAVVSWQKVEEVKP 19 520 AVTANLDIRNATKLR 19 522 TANLDIRNATKLRVS 19 530ATKLRVSPKNPRIPK 19 539 NPRIPKLHMLELHCE 19 557 DSHLKHSLKLSWSKD 19 576EINGTEDGRIIIDGA 19 624 VLDVPDPPENLHLSE 19 641 NRSVRLTWEAGADHN 19 762EYRVTWKPQGAPVEW 19 860 GYQINWWKTKSLLDG 19 881 VNILRFSGQRNSGMV 19 893GMVPSLDAFSEFHLT 19 955 PKKLNGNLTGYLLQY 19 1058 EHIVRLMTKNWGDND 19 1100IGLMCAIALLTLLLL 19 1141 IQSVKDETFGEYSDS 19 1150 GEYSDSDEKPLKGSL 19 1157EKPLKGSLRSLNRDM 19 1177 ADSLVEYGEGDHGLF 19 12 VYLMFLLLKFSKAIE 18 24AIEIPSSVQQVPTII 18 42 KVQVAFPFDEYFQIE 18 80 DHRIIPSNNSGTFRI 18 127VPSVPKLPKEKIDPL 18 146 GDPIVLPCNPPKGLP 18 264 SSITILKGEILLLEC 18 307YGKTLKIENVSYQDK 18 328 ASNFLGTATHDFHVI 18 340 HVIVEEPPRWTKKPQ 18 363NGILLCEAEGEPQPT 18 389 NHPFAGDVVFPREIS 18 423 HGTILANANIDVVDV 18 429NANIDVVDVRPLIQT 18 430 ANIDVVDVRPLIQTK 18 479 VKPLEGRRYHIYENG 18 524NLDIRNATKLRVSPK 18 545 LHMLELHCESKCDSH 18 565 KLSWSKDGEAFEING 18 583GRIIIDGANLTISNV 18 588 DGANLTISNVTLEDQ 18 693 APFVRYQFRVIAVNE 18 699QFRVIAVNEVGRSQP 18 702 VIAVNEVGRSQPSQP 18 741 PKEMIIKWEPLKSME 18 806QLGSGPDPQSVTLYS 18 906 LTVLAYNSKGAGPES 18 977 EIGELNDINITTPSK 18 983DINITTPSKPSWHLS 18 1025 SSTLGEGSKGIGKIS 18 1064 MTKNWGDNDSIFQDV 18 1113LLTVCFVKRNRGGKY 18 1161 KGSLRSLNRDMQPTE 18 31 VQQVPTIIKQSKVQV 17 36TIIKQSKVQVAFPFD 17 52 YFQIECEAKGNPEPT 17 96 NEGHISHFQGKYRCF 17 116GIAMSEEIEFIVPSV 17 164 IYWMNIELEHIEQDE 17 168 NIELEHIEQDERVYM 17 208FPRLRTIVQKMPMKL 17 236 STEIGSKANSIKQRK 17 244 NSIKQRKPKLLLPPT 17 273ILLLECFAEGLPTPQ 17 294 GGDLPKGRETKENYG 17 375 QPTIKWRVNGSPVDN 17 547MLELHCESKCDSHLK 17 625 LDVPDPPENLHLSER 17 633 NLHLSERQNRSVRLT 17 647TWEAGADHNSNISEY 17 660 EYIVEFEGNKEEPGR 17 722 TPPAAPDRNPQNIRV 17 771GAPVEWEEETVTNHT 17 792 AVYAPYDVKVQAINQ 17 798 DVKVQAINQLGSGPD 17 851KDRVHGRLKGYQINW 17 898 LDAFSEFHLTVLAYN 17 921 EPYIFQTPEGVPEQP 17 934QPTFLKVIKVDKDTA 17 937 FLKVIKVDKDTATLS 17 1038 ISGVNLTQKTHPIEV 17 1076QDVIETRGREYAGLY 17 50 DEYFQIECEAKGNPE 16 56 ECEAKGNPEPTFSWT 16 74NPFYFTDHRIIPSNN 16 170 ELEHIEQDERVYMSQ 16 202 YCCFAAFPRLRTIVQ 16 242KANSIKQRKPKLLLP 16 283 LPTPQVDWNKIGGDL 16 460 HCEFFASPEAVVSWQ 16 494TLQINRTTEEDAGSY 16 553 ESKCDSHLKHSLKLS 16 969 YQIINDTYEIGELND 16 46AFPFDEYFQIECEAK 15 89 SGTFRIPNEGHISHF 15 160 PPLHIYWMNIELEHI 15 187DLYFANVEEKDSRND 15 270 KGEILLLECFAEGLP 15 296 DLPKGRETKENYGKT 15 355SAVYSTGSNGILLCE 15 381 RVNGSPVDNHPFAGD 15 484 GRRYHIYENGTLQIN 15 659SEYIVEFEGNKEEPG 15 662 IVEFEGNKEEPGRWE 15 830 VIHGVDVINSTLVKV 15 861YQINWWKTKSLLDGR 15 926 QTPEGVPEQPTFLKV 15 998 NLNATTKYKFYLRAC 15 1050IEVFEPGAEHIVRLM 15 1115 TVCFVKRNRGGKYSV 15 1124 GGKYSVKEKEDLHPD 15 1153SDSDEKPLKGSLRSL 15 1 MEPLLLGRGLIVYLM 14 10 LIVYLMFLLLKFSKA 14 14LMFLLLKFSKAIEIP 14 18 LLKFSKAIEIPSSVQ 14 100 ISHFQGKYRCFASNK 14 147DPIVLPCNPPKGLPP 14 215 VQKMPMKLTVNSLKH 14 221 KLTVNSLKHANDSSS 14 250KPKLLLPPTESGSES 14 271 GEILLLECFAEGLPT 14 336 THDFHVIVEEPPRWT 14 362SNGILLCEAEGEPQP 14 551 HCESKGDSHLKHSLK 14 742 KEMIIKWEPLKSMEQ 14 775EWEEETVTNHTLRVM 14 880 EVNILRFSGQRNSGM 14 883 ILRFSGQRNSGMVPS 14 891NSGMVPSLDAFSEFH 14 965 YLLQYQIINDTYEIG 14 1018 GKPITEESSTLGEGS 14 1072DSIFQDVIETRGREY 14 1088 GLYDDISTQGWFIGL 14 1105 AIALLTLLLLTVCFV 14 1110TLLLLTVCFVKRNRG 14 1126 KYSVKEKEDLHPDPE 14 1149 FGEYSDSDEKPLKGS 14 9GLIVYLMFLLLKFSK 13 13 YLMFLLLKFSKAIEI 13 35 PTIIKQSKVQVAFPF 13 123IEFIVPSVPKLPKEK 13 141 LEVEEGDPIVLPCNP 13 181 YMSQKGDLYFANVEE 13 266TILKGEILLLECFA 13 339 FHVIVEEPPRWTKKP 13 354 QSAVYSTGSNGILLC 13 449YATVVGYSAFLHCEF 13 473 WQKVEEVKPLEGRRY 13 486 RYHIYENGTLQINRT 13 544KLHMLELHCESKCDS 13 595 SNVTLEDQGIYCCSA 13 608 SAHTALDSAADITQV 13 621QVTVLDVPDPPENLH 13 685 KTTVILPLAPFVRYQ 13 686 TTVILPLAPFVRYQF 13 833GVDVINSTLVKVTWS 13 928 PEGVPEQPTFLKVIK 13 935 PTFLKVIKVDKDTAT 13 959NGNLTGYLLQYQIIN 13 963 TGYLLQYQIINDTYE 13 1098 WFIGLMCAIALLTLL 13 1106IALLTLLLLTVCFVK 13 1107 ALLTLLLLTVCFVKR 13 1108 LLTLLLLTVCFVKRN 13 1109LTLLLLTVCFVKRNR 13 1128 SVKEKEDLHPDPEIQ 13 1148 TFGEYSDSDEKPLKG 13 1168NRDMQPTESAOSLVE 13 V2-(SET1)-HLA-DRB1-0301-15mers-282P1G3 Each peptideis a portion of SEQ ID NO: 5; each start position is specified, thelength of peptide is 15 amino acids, and the end position for eachpeptide is the start position plus fourteen. 4 EIEFIVPSVPKFPKE 19 6EFIVPSVPKFPKEKI 18 9 VPSVPKFPKEKIDPL 18 12 VPKFPKEKIDPLEVE 17 5IEFIVPSVPKFPKEK 12 15 FPKEKIDPLEVEEGD 12 2 SEEIEFIVPSVPKFP 10V2-(SET2)-HLA-DRB1-0301-15mers-282P1G3 Each peptide is a portion of SEQID NO: 5; each start position is specified, the length of peptide is 15amino acids, and the end position for each peptide is the start positionplus fourteen. 2 WNKIGGDLPKGREAK 21 6 GGDLPKGREAKENYG 18 8DLPKGREAKENYGKT 15 5 IGGDLPKGREAKENY 11 9 LPKGREAKENYGKTL 10 12GREAKENYGKTLKIE 10 V2-(SET3)-HLA-DRB1-0301-15mers-282P1G3 Each peptideis a portion of SEQ ID NO: 5; each start position is specified, thelength of peptide is 15 amino acids, and the end position for eachpeptide is the start position plus fourteen. 8 SSTLGEGKYAGLYDD 21 5TEESSTLGEGKYAGL 16 1 GKPITEESSTLGEGK 14 15 KYAGLYDDISTQGWF 12 7ESSTLGEGKYAGLYD 10 V3-HLA-DRB1-0301-15mers-282P1G3 Each peptide is aportion of SEQ ID NO: 7; each start position is specified, the length ofpeptide is 15 amino acids, and the end position for each pepfide is thestart posifion plus fourteen. 34 PSIFICSKEQELSYR 25 42 EQELSYRNRNMLAED25 50 RNMLAEDFIQKSTSC 23 35 SIFICSKEQELSYRN 19 55 EDFIQKSTSCNYVEK 19 33QPSIFICSKEQELSY 17 13 VINTTYVSNTTYVSN 16 7 VIHGVDVINTTYVSN 15 36IFICSKEQELSYRNR 15 4 TAPVIHGVDVINTTY 12 10 GVDViNTTYVSNTTY 12 49NRNMLAEDFIQKSTS 12 V4-HLA-DRB1-0301-15mers-282P1G3 Each peptide is aportion of SEQ ID NO: 9; each start position is specified, the length ofpeptide is 15 amino acids, and the end position for each peptide is thestart position plus fourteen. 4 PQSVTLYSGEDLPEQ 21 10 YSGEDLPEQPTFLKV 166 SVTLYSGEDLPEQPT 13 12 GEDLPEQPTFLKVIK 13 8 TLYSGEDLPEQPTFL 12 11SGEDLPEQPTFLKVI 11 5 QSVTLYSGEDLPEQP 11 V5-HLA-DRB1-0301-15mers-282P1G3Each peptide is a portion of SEQ ID NO: 11; each start position isspecified, the length of peptide is 15 amino acids, and the end positionfor each peptide is the start position plus fourteen. 15 SNSIKQRKPKLLLPP21 5 KMPMKLTVNSSNSIK 18 14 SSNSIKQRKPKLLLP 16 3 VQKMPMKLTVNSSNS 14 7PMKLTVNSSNSIKQR 13 9 KLTVNSSNSIKQRKP 12

TABLE XLVIII Pos 123456789012345 score V2-(SET1)-HLA-0401-15mers-282P1G3Each peptide is a portion of SEQ ID NO: 5; each start position isspecified, the length of peptide is 15 amino acids, and the end positionfor each peptide is the start position plus fourteen. 12 VPKFPKEKIDPLEVE22 6 EFIVPSVPKFPKEKI 20 9 VPSVPKFPKEKIDPL 20 3 EEIEFIVPSVPKFPK 18 2SEEIEFIVPSVPKFP 14 1 MSEEIEFIVPSVPKF 12 14 KFPKEKIDPLEVEEG 12 4EIEFIVPSVPKFPKE 10 V2-(SET2)-HLA-0401-15mers-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 15 amino acids, and the end position for each peptide is thestart position plus fourteen. 2 WNKIGGDLPKGREAK 14 11 KGREAKENYGKTLKI 1214 EAKENYGKTLKIENV 12 6 GGDLPKGREAKENYG 8 5 IGGDLPKGREAKENY 7 10PKGREAKENYGKTLK 7 3 NKIGGDLPKGREAKE 6 4 KIGGDLPKGREAKEN 6 8DLPKGREAKENYGKT 6 9 LPKGREAKENYGKTL 6 12 GREAKENYGKTLKIE 6 13REAKENYGKTLKIEN 6 V2-(SET3)-HLA1-0401-15mers-282P1G3 Each peptide is aportion of SEQ ID NO: 5; each start position is specified, the length ofpeptide is 15 amino acids, and the end position for each peptide is thestart position plus fourteen. 13 EGKYAGLYDDISTQG 22 1 GKPITEESSTLGEGK 208 SSTLGEGKYAGLYDD 14 15 KYAGLYDDISTQGWF 12 V3-HLA-0401-15mers-282P1G3Each peptide is a portion of SEQ ID NO: 7; each start position isspecified, the length of peptide is 15 amino acids, and the end positionfor each peptide is the start position plus fourteen. 8 IHGVDVINTTYVSNT26 15 NTTYVSNTTYVSNAT 22 5 APVIHGVDVINTTYV 20 22 TTYVSNATGSPQPSI 20 49NRNMLAEDFIQKSTS 20 50 RNMLAEDFIQKSTSC 20 32 PQPSIFICSKEQELS 18 38ICSKEQELSYRNRNM 18 51 NMLAEDFIQKSTSCN 18 54 AEDFIQKSTSCNYVE 17 21NTTYVSNATGSPQPS 16 34 PSIFICSKEQELSYR 16 35 SIFICSKEQELSYRN 15 42EQELSYRNRNMLAED 15 4 TAPVIHGVDVINTTY 14 10 GVDVINTTYVSNTTY 14 11VDVINTTYVSNTTYV 14 16 TTYVSNTTYVSNATG 14 55 EDFIQKSTSCNYVEK 14 1YPDTAPVIHGVDVIN 12 2 PDTAPVIHGVDVINT 12 6 PVIHGVDVINTTYVS 12 7VIHGVDVINTTYVSN 12 9 HGVDVINTTYVSNTT 12 12 DVINTTYVSNTTYVS 12 13VINTTYVSNTTYVSN 12 14 INTTYVSNTTYVSNA 12 18 YVSNTTYVSNATGSP 12 19VSNTTYVSNATGSPQ 12 25 VSNATGSPQPSIFIC 12 27 NATGSPQPSIFICSK 12 30GSPQPSIFICSKEQE 12 40 SKEQELSYRNRNMLA 12 41 KEQELSYRNRNMLAE 12 43QELSYRNRNMLAEDF 12 47 YRNRNMLAEDFIQKS 12 48 RNRNMLAEDFIQKST 12 52MLAEDFIQKSTSCNY 12 61 STSCNYVEKSSTFFK 12 62 TSCNYVEKSSTFFKI 12V4-HLA-0401-15mers-282P1G3 Each peptide is a portion of SEQ ID NO: 9;each start position is specified, the length of peptide is 15 aminoacids, and the end position for each peptide is the start position plusfourteen. 7 VTLYSGEDLPEQPTF 22 12 GEDLPEQPTFLKVIK 20 4 PQSVTLYSGEDLPEQ14 3 DPQSVTLYSGEDLPE 12 9 LYSGEDLPEQPTFLK 12 11 SGEDLPEQPTFLKVI 12 15LPEQPTFLKVIKVDK 12 V5-HLA-0401-15mers-282P1G3 Each peptide is a portionof SEQ ID NO: 11; each start position is specified, the length ofpeptide is 15 amino acids, and the end position for each peptide is thestart position plus fourteen. 5 KMPMKLTVNSSNSIK 20 7 PMKLTVNSSNSIKQR 209 KLTVNSSNSIKQRKP 20 6 MPMKLTVNSSNSIKQ 18 3 VQKMPMKLTVNSSNS 15 4QKMPMKLTVNSSNSI 12 8 MKLTVNSSNSIKQRK 12 12 VNSSNSIKQRKPKLL 12 15SNSIKQRKPKLLLPP 9 V6-HLA-0401-15mers-282P1G3 Each peptide is a portionof SEQ ID NO: 13; each start position is specified, the length ofpeptide is 15 amino acids, and the end position for each peptide is thestart position plus fourteen. 10 EFIVPKLEHIEQDER 26 2 GIAMSEEIEFIVPKL 2013 VPKLEHIEQDERVYM 20 8 EIEFIVPKLEHIEQD 16 6 SEEIEFIVPKLEHIE 14 1LGIAMSEEIEFIVPK 12 4 AMSEEIEFIVPKLEH 12 5 MSEEIEFIVPKLEHI 12 14PKLEHIEQDERVYMS 12 V7-HLA-0401-15mers-282P1G3 Each peptide is a portionof SEQ ID NO: 15; each start position is specified, the length ofpeptide is 15 amino acids, and the end position for each peptide is thestart position plus fourteen. 6 THDFHVIVEDNISHE 22 8 DFHVIVEDNISHELF 2010 HVIVEDNISHELFTL 20 21 LFTLHPEPPRWTKKP 20 2 LGTATHDFHVIVEDN 18 9FHVIVEDNISHELFT 14 14 EDNISHELFTLHPEP 14 18 SHELFTLHPEPPRWT 14 5ATHDFHVIVEDNISH 12 7 HDFHVIVEDNISHEL 12 11 VIVEDNISHELFTLH 12 15DNISHELFTLHPEPP 12 22 FTLHPEPPRWTKKPQ 12 19 HELFTLHPEPPRWTK 10

TABLE XLIX Pos 123456789012345 score V1-HLA-DRB1-1101-15mers-282P1G3Each peptide is a portion of SEQ ID NO: 3; each start position isspecified, the length of peptide is 15 amino acids, and the end positionfor each peptide is the start position plus fourteen. 672PGRWEELTRVQGKKT 30 1113 LLTVCFVKRNRGGKY 28 74 NPFYFTDHRIIPSNN 26 702VIAVNEVGRSQPSQP 26 843 KVTWSTVPKDRVHGR 26 937 FLKVIKVDKDTATLS 26 1058EHIVRLMTKNWGDND 26 336 THDFHVIVEEPPRWT 25 760 GLEYRVTWKPQGAPV 25 100ISHFQGKYRCFASNK 24 446 GENYATVVGYSAFLH 24 934 QPTFLKVIKVDKDTA 24 949TLSWGLPKKLNGNLT 24 1072 DSIFQDVIETRGREY 24 13 YLMFLLLKFSKAIEI 23 287QVDWNKIGGDLPKGR 23 470 VVSWQKVEEVKPLEG 23 1083 GREYAGLYDDISTQG 23 1096QGWFIGLMCAIALLT 23 187 DLYFANVEEKDSRND 22 12 VYLMFLLLKFSKAIE 21 120SEEIEFIVPSVPKLP 21 127 VPSVPKLPKEKIDPL 21 619 ITQVTVLDVPDPPEN 21 693APFVRYQFRVIAVNE 21 1025 SSTLGEGSKGIGKIS 21 31 VQQVPTIIKQSKVQV 20 52YFQIECEAKGNPEPT 20 73 GNPFYFTDHRIIPSN 20 94 PNEGHISHFQGKYRI 20 124EFIVPSVPKLPKEKI 20 202 YCCFAAFPRLRTIVQ 20 208 FPRLRTIVQKMPMKL 20 221KLTVNSLKHANDSSS 20 547 MLELHCESKCDSHLK 20 739 SQPKEMIIKWEPLKS 20 877HPKEVNILRFSGQRN 20 906 LTVLAYNSKGAGPES 20 1029 GEGSKGIGKISGVNL 20 1038ISGVNLTQKTHPIEV 20 1076 QDVIETRGREYAGLY 20 1161 KGSLRSLNRDMQPTE 20 1124GGKYSVKEKEDLHPD 19 1180 LVEYGEGDHGLFSED 19 11 IVYLMFLLLKFSKAI 18 75PFYFTDHRIIPSNNS 18 135 KEKIDPLEVEEGDPI 18 304 KENYGKTLKIENVSY 18 401EISFTNLQPNHTAVY 18 452 VVGYSAFLHCEFFAS 18 473 WQKVEEVKPLEGRRY 18 602QGIYCCSAHTALDSA 18 748 WEPLKSMEQNGPGLE 18 798 DVKVQAINQLGSGPD 18 828APVIHGVDVINSTLV 18 978 IGELNDINITTPSKP 18 1002 TTKYKFYLRACTSQG 18 1115TVCFVKRNRGGKYSV 18 49 FDEYFQIECEAKGNP 17 50 DEYFQIECEAKGNPE 17 107YRCFASNKLGIAMSE 17 205 FAAFPRLRTIVQKMP 17 461 CEFFASPEAVVSWQK 17 697RYQFRVIAVNEVGRS 17 1040 GVNLTQKTHPIEVFE 17 1188 HGLFSEDGSFIGAYA 17 18LLKFSKAIEIPSSVQ 16 64 EPTFSWTKDGNPFYF 16 163 HIYWMNIELEHIEQD 16 209PRLRTIVQKMPMKLT 16 291 NKIGGDLPKGRETKE 16 373 EPQPTIKWRVNGSPV 16 392FAGDVVFPREISFTN 16 428 ANANIDVVDVRPLIQ 16 455 YSAFLHCEFFASPEA 16 524NLDIRNATKLRVSPK 16 572 GEAFEINGTEDGRII 16 645 RLTWEAGADHNSNIS 16 662IVEFEGNKEEPGRWE 16 689 ILPLAPFVRYQFRVI 16 745 IIKWEPLKSMEQNGP 16 792AVYAPYDVKVQAINQ 16 835 DVINSTLVKVTWSTV 16 849 VPKDRVHGRLKGYQI 16 863INWWKTKSLLDGRTH 16 966 LLQYQIINDTYEIGE 16 983 DINITTPSKPSWHLS 16 1005YKFYLRACTSQGCGK 16 1054 EPGAEHIVRLMTKNW 16 1087 AGLYDDISTQGWFIG 16 1198IGAYAGSKEKGSVES 16 15 MFLLLKFSKAIEIPS 15 24 AIEIPSSVQQVPTII 15 123IEFIVPSVPKLPKEK 15 149 IVLPCNPPKGLPPLH 15 219 PMKLTVNSLKHANDS 15 263ESSITILKGEILLLE 15 382 VNGSPVDNHPFAGDV 15 476 VEEVKPLEGRRYHIY 15 530ATKLRVSPKNPRIPK 15 554 SKCDSHLKHSLKLSW 15 661 YIVEFEGNKEEPGRW 15 675WEELTRVQGKKTTVI 15 682 QGKKTTVILPLAPFV 15 683 GKKTTVILPLAPFVR 15 700FRVIAVNEVGRSQPS 15 758 GPGLEYRVTWKPQGA 15 824 YPDTAPVIHGVDVIN 15 859KGYQINWWKTKSLLD 15 869 KSLLDGRTHPKEVNI 15 882 NILRFSGQRNSGMVP 15 903EFHLTVLAYNSKGAG 15 948 ATLSWGLPKKLNGNL 15 996 LSNLNATTKYKFYLR 15 1018GKPITEESSTLGEGS 15 1106 IALLTLLLLTVCFVK 15 1157 EKPLKGSLRSLNRDM 15 1197FIGAYAGSKEKGSVE 15 34 VPTIIKQSKVQVAFP 14 91 TFRIPNEGHISHFQG 14 129SVPKLPKEKIDPLEV 14 165 YWMNIELEHIEQDER 14 171 LEHIEQDERVYMSQK 14 177DERVYMSQKGDLYFA 14 186 GDLYFANVEEKDSRN 14 234 SSSTEIGSKANSIKQ 14 240GSKANSIKQRKPKLL 14 262 SESSITILKGEILLL 14 284 PTPQVDWNKIGGDLP 14 313IENVSYQDKGNYRCT 14 317 SYQDKGNYRCTASNF 14 329 SNFLGTATHDFHVIV 14 340HVIVEEPPRWTKKPQ 14 344 EEPPRWTKKPQSAVY 14 375 QPTIKWRVNGSPVDN 14 408QPNHTAVYQCEASNV 14 429 NANIDVVDVRPLIQT 14 467 PEAVVSWQKVEEVKP 14 491ENGTLQINRTTEEDA 14 510 CWVENAIGKTAVTAN 14 526 DIRNATKLRVSPKNP 14 532KLRVSPKNPRIPKLH 14 536 SPKNPRIPKLHMLEL 14 543 PKLHMLELHCESKCD 14 557DSHLKHSLKLSWSKD 14 616 AADITQVTVLDVPDP 14 631 PENLHLSERQNRSVR 14 656SNISEYIVEFEGNKE 14 712 QPSQPSDHHETPPAA 14 727 PDRNPQNIRVQASQP 14 762EYRVTWKPQGAPVEW 14 783 NHTLRVMTPAVYAPY 14 794 YAPYDVKVQAINQLG 14 831IHGVDVINSTLVKVT 14 836 VINSTLVKVTWSTVP 14 839 STLVKVTWSTVPKDR 14 845TWSTVPKDRVHGRLK 14 851 KDRVHGRLKGYQINW 14 867 KTKSLLDGRTHPKEV 14 921EPYIFQTPEGVPEQP 14 935 PTFLKVIKVDKDTAT 14 1128 SVKEKEDLHPDPEIQ 14V2-(SET2)-HLA-DRB1-1101-15mers-282P1G3 Each peptide is a portion of SEQID NO: 5; each start position is specified, the length of peptide is 15amino acids, and the end position for each peptide is the start positionplus fourteen. 3 NKIGGDLPKGREAKE 16 13 REAKENYGKTLKIEN 9 5IGGDLPKGREAKENY 8 8 DLPKGREAKENYGKT 8 1 DWNKIGGDLPKGREA 7 4KIGGDLPKGREAKEN 7 6 GGDLPKGREAKENYG 7V2-(SET3)-HLA-DRB1-1101-15mers-282P1G3 Each peptide is a portion of SEQID NO: 5; each start position is specified, the length of peptide is 15amino acids, and the end position for each peptide is the start positionplus fourteen. 13 EGKYAGLYDDISTQG 23 1 GKPITEESSTLGEGK 15 7ESSTLGEGKYAGLYD 14 V3-HLA-DRB1-1101-15mers-282P1G3 Each peptide is aportion of SEQ ID NO: 7; each start position is specified, the length ofpeptide is 15 amino acids, and the end position for each peptide is thestart position plus fourteen. 52 MLAEDFIQKSTSCNY 20 15 NTTYVSNTTYVSNAT17 21 NTTYVSNATGSPQPS 16 1 YPDTAPVIHGVDVIN 15 33 QPSIFICSKEQELSY 15 19VSNTTYVSNATGSPQ 14 42 EQELSYRNRNMLAED 14 61 STSCNYVEKSSTFFK 14 8IHGVDVINTTYVSNT 13 35 SIFICSKEQELSYRN 13 50 RNMLAEDFIQKSTSC 13 5APVIHGVDVINTTYV 12 34 PSIFICSKEQELSYR 10 40 SKEQELSYRNRNMLA 10 44ELSYRNRNMLAEDFI 10 54 AEDFIQKSTSCNYVE 10 4 TAPVIHGVDVINTTY 9V4-HLA-DRB1-1101-15mers-282P1G3 Each peptide is a portion of SEQ ID NO:9; each start position is specified, the length of peptide is 15 aminoacids, and the end position for each peptide is the start position plusfourteen. 1 GPDPQSVTLYSGEDL 12 7 VTLYSGEDLPEQPTF 10 15 LPEQPTFLKVIKVDK 94 PQSVTLYSGEDLPEQ 8 5 QSVTLYSGEDLPEQP 7 12 GEDLPEQPTFLKVIK 7 3DPQSVTLYSGEDLPE 6 6 SVTLYSGEDLPEQPT 6 8 TLYSGEDLPEQPTFL 6 9LYSGEDLPEQPTFLK 6 V5-HLA-DRB1-1101-15mers-282P1G3 Each peptide is aportion of SEQ ID NO: 11; each start position is specified, the lengthof peptide is 15 amino acids, and the end position for each peptide isthe start position plus fourteen. 12 VNSSNSIKQRKPKLL 14 3VQKMPMKLTVNSSNS 12 4 QKMPMKLTVNSSNSI 12 6 MPMKLTVNSSNSIKQ 12 11TVNSSNSIKQRKPKL 10 7 PMKLTVNSSNSIKQR 9 14 SSNSIKQRKPKLLLP 9 1TIVQKMPMKLTVNSS 8 5 KMPMKLTVNSSNSIK 8 13 NSSNSIKQRKPKLLL 8 2IVQKMPMKLTVNSSN 7 9 KLTVNSSNSIKQRKP 7 15 SNSIKQRKPKLLLPP 7V6-HLA-DRB1-1101-15mers-282P1G3 Each peptide is a portion of SEQ ID NO:13; each start position is specified, the length of peptide is 15 aminoacids, and the end position for each peptide is the start position plusfourteen. 10 EFIVPKLEHIEQDER 20 6 SEEIEFIVPKLEHIE 15 7 EEIEFIVPKLEHIEQ15 3 IAMSEEIEFIVPKLE 13 13 VPKLEHIEQDERVYM 12 8 EIEFIVPKLEHIEQD 11V7-HLA-DRB1-1101-15mers-282P1G3 Each peptide is a portion of SEQ ID NO:15; each start position is specified, the length of peptide is 15 aminoacids, and the end position for each peptide is the start position plusfourteen. 6 THDFHVIVEDNISHE 19 18 SHELFTLHPEPPRWT 19 11 VIVEDNISHELFTLH15 17 ISHELFTLHPEPPRW 14 26 PEPPRWTKKPQSAVY 14 7 HDFHVIVEDNISHEL 13 15DNISHELFTLHPEPP 12 19 HELFTLHPEPPRWTK 12 2 LGTATHDFHVIVEDN 11

TABLE L Protein Characteristics of 282P1G3 Bioinformatic 282P1G3 v.1Program Outcome ORF ORF finder Protein length 1224 aa Trans- TM Pred2TM, aa 6-25, 1098-1116 membrane HMMTop one TM, aa 1098-1117 regionSosui 2TM, aa 3-25, 1096-1118 TMHMM one TM, aa 1097-1119 Signal PeptideSignal P yes, cleave aa 24-25 pI pI/MW tool pI 5.54 Molecular pI/MW tool136.6 kD weight Localization PSORT 46% plasma membrane, 10% micobodyPSORT II 44% endoplasmic, 11% vacuolar Motifs Pfam Ig domain,Fibronectin type III repeat Prints Cadherin, Fibronectin type III repeatBlocks Fibronectin type III repeat Bioinformatic v.3 Program Outcome ORFORF finder Protein length 893 aa Trans- TM Pred one TM, aa 3-19,N-terminus in membrane HMMTop one TM, aa 1-25, N-terminus out regionSosui one TM, aa 3-25 TMHMM none Signal Peptide Signal P none pI pI/MWtool pI 5.49 Molecular pI/MW tool 100.2 kD weight Localization PSORT 78%secreted, 19% lysosomal PSORT II 52% nuclear, 17% mitochondreal MotifsPfam Ig domain, Fibronectin type III repeat Prints Cadherin, Fibronectintype III repeat Blocks Fibronectin type III repeat

TABLE LI Exon boundaries of transcript 282P1G03 v.1 Exon Number StartEnd Length 1 1 97 97 2 98 177 80 3 178 362 185 4 363 468 106 5 469 656188 6 657 779 123 7 780 950 171 8 951 998 48 9 999 1119 121 10 1120 1304185 11 1305 1436 132 12 1437 1577 141 13 1578 1689 112 14 1690 1906 21715 1907 2022 116 16 2023 2147 125 17 2148 2249 102 18 2250 2447 198 192448 2518 71 20 2519 2741 223 21 2742 2857 116 22 2858 3062 205 23 30633185 123 24 3186 3365 180 25 3366 3524 159 26 3525 3656 132 27 3657 372973 28 3730 7650 3921

TABLE LIIa Nucleotide sequence of transcript variant 282P1G03 v.2 (SEQID NO: 151) cggaccctgc gcgcccccgt cccggctccc ggccggctcg ggggagaaggcgcccgaggg 60 gaggcgccgg acagatcgcg tttcggaggc ggcgcaggtg ctgtaaactgcaaaccataa 120 tcctgtctta atactgcaaa caaatcatag tggaactaag gggaacttaatttactgttt 180 ccaggttaac taaggtctca gctgtaaacc aaaagtgaga ggagacattaagattttcat 240 tcttaccggg ttgtcttctt cctgaagagc aatggagccg cttttacttggaagaggact 300 aatcgtatat ctaatgttcc tcctgttaaa attctcaaaa gcaattgaaataccatcttc 360 agttcaacag gttccaacaa tcataaaaca gtcaaaagtc caagttgcctttcccttcga 420 tgagtatttt caaattgaat gtgaagctaa aggaaatcca gaaccaacattttcgtggac 480 taaggatggc aacccttttt atttcactga ccatcggata attccatcgaacaattcagg 540 aacattcagg atcccaaacg aggggcacat atctcacttt caagggaaataccgctgctt 600 tgcttcaaat aaactgggaa tcgctatgtc agaagaaata gaatttatagttccaagtgt 660 tccaaaattc ccaaaagaaa aaattgaccc tcttgaagtg gaggagggagatccaattgt 720 cctcccatgc aatcctccca aaggcctccc acctttacac atttattggatgaatattga 780 attagaacac atcgaacaag atgaaagagt atacatgagc caaaagggagatctatactt 840 cgcaaacgtg gaagaaaagg acagtcgcaa tgactactgt tgctttgctgcatttccaag 900 attaaggact attgtacaga aaatgccaat gaaactaaca gttaacagtttaaagcatgc 960 taatgactca agttcatcca cagaaattgg ttccaaggca aattccatcaagcaaagaaa 1020 acccaaactg ctgttgcctc ccactgagag tggcagtgag tcttcaattaccatcctcaa 1080 aggggaaatc ttgctgcttg agtgttttgc tgaaggcttg ccaactccacaggttgattg 1140 gaacaaaatt ggtggtgact taccaaaggg gagagaagca aaagaaaattatggcaagac 1200 tttgaagata gagaatgtct cctaccagga caaaggaaat tatcgctgcacagccagcaa 1260 tttcttggga acagccactc acgattttca cgttatagta gaagagcctcctcgctggac 1320 aaagaagcct cagagtgctg tgtatagcac cggaagcaat ggcatcttgttatgtgaggc 1380 tgaaggagaa cctcaaccca caatcaagtg gagagtcaat ggctccccagttgacaatca 1440 tccatttgct ggtgatgttg tcttccccag ggaaatcagt tttaccaaccttcaaccaaa 1500 tcatactgct gtgtaccagt gtgaagcctc aaatgtccat ggaactatccttgccaatgc 1560 caatattgat gttgtggatg tccgtccatt gatacaaacc aaagatggagaaaattacgc 1620 tacagtggtt gggtacagtg ctttcttaca ttgcgagttc tttgcttcacctgaggcagt 1680 cgtgtcctgg cagaaggtgg aagaagtgaa acccctggag ggcaggcggtatcatatcta 1740 tgaaaatggc acattgcaga tcaacagaac caccgaagaa gatgctgggtcttactcatg 1800 ttgggtagaa aatgctatag gaaaaactgc agtcacagcc aatttggatattagaaatgc 1860 tacaaaactt agagtttctc ctaagaatcc tcgtatcccc aaattgcatatgcttgaatt 1920 acattgtgaa agcaaatgtg actcacattt gaaacacagt ttgaagttgtcctggagtaa 1980 agatggagaa gcctttgaaa ttaatggcac agaagatggc aggataattattgatggagc 2040 taatttgacc atatctaatg taactttaga ggaccaaggt atttactgctgttcagctca 2100 tactgctcta gacagtgctg ccgatataac tcaagtaact gttcttgatgttccggatcc 2160 accagaaaac cttcacttgt ctgaaagaca gaacaggagt gttcggctgacctgggaagc 2220 tggagctgac cacaacagca atattagcga gtatattgtt gaatttgaaggaaacaaaga 2280 agagcctgga aggtgggagg aactgaccag agtccaagga aagaaaaccacagttatctt 2340 acctttggct ccatttgtga gataccagtt cagggtcata gccgtgaacgaagtagggag 2400 aagtcagcct agccagccgt cagaccatca tgaaacacca ccagcagctccagataggaa 2460 tccacaaaac ataagggttc aagcctctca acccaaggaa atgattataaagtgggagcc 2520 tttgaaatcc atggagcaga atggaccagg cctagagtac agagtgacctggaagccaca 2580 gggagcccca gtggagtggg aagaagaaac agtcacaaac cacacattgcgggtgatgac 2640 gcctgctgtc tatgcccctt atgatgtcaa ggtccaggct atcaatcaactaggatctgg 2700 gcctgaccct cagtcagtga ctctctattc tggagaagac tatcctgatacagctccagt 2760 gatccatggg gtggacgtta taaacagtac attagttaaa gttacctggtcaacagttcc 2820 aaaggacaga gtacatggac gtctgaaagg ctatcagata aattggtggaaaacaaaaag 2880 tctgttggat ggaagaacac atcccaaaga agtgaacatt ctaagattttcaggacaaag 2940 aaactctgga atggttcctt ccttagatgc ctttagtgaa tttcatttaacagtcttagc 3000 ctataactct aaaggagctg gtcctgaaag tgagccttat atatttcaaacaccagaagg 3060 agtacctgaa cagccaactt ttctaaaggt catcaaagtt gataaagacactgccacttt 3120 atcttgggga ctacctaaga aattaaatgg aaacttaact ggctatcttttgcaatatca 3180 gataataaat gacacctacg agattggaga attaaatgat attaacattacaactccatc 3240 aaagcccagc tggcacctct caaacctgaa tgcaactacc aagtacaaattctacttgag 3300 ggcttgcact tcacagggct gtggaaaacc gatcacggag gaaagctccaccttaggaga 3360 agggaaatat gctggtttat atgatgacat ctccactcaa ggctggtttattggactgat 3420 gtgtgcgatt gctcttctca cactactatt attaactgtt tgctttgtgaagaggaatag 3480 aggtggaaag tactcagtta aagaaaagga agatttgcat ccagacccagaaattcagtc 3540 agtaaaagat gaaacctttg gtgaatacag tgacagtgat gaaaagcctctcaaaggaag 3600 ccttcggtcc cttaataggg atatgcagcc tactgaaagt gctgacagcttagtcgaata 3660 cggagaggga gaccatggtc tcttcagtga agatggatca tttattggtgcctacgctgg 3720 atctaaggag aagggatctg ttgaaagcaa tggaagttct acagcaacttttccccttcg 3780 ggcataaaca caacatatgt aagcaacgct actggttcac cccaaccttccatatttatc 3840 tgttcaaagg agcaagaact ttcatatagg aatagaaaca tgctggccgaagatttcatc 3900 cagaagtcaa catcctgcaa ttatgttgaa aagagtagta ctttcttcaaaatataaaat 3960 gccaagcact tcaggcctat gttttgctta tattgttttc aggtgctcaaaatgcaaaac 4020 acaaaacaaa tcctgcattt agatacacct caactaaatc caaagtccccattcagtata 4080 ttccatattt gcctgatttt actattcggt gtgtttgcat agatgttgctacttggtggg 4140 tttttctccg tatgcacatt ggtatacagt ctctgagaac tggcttggtgactttgcttc 4200 actacaggtt aaaagaccat aagcaaactg gttatttaaa atgtaaaaaggaatatgaaa 4260 gtcttattaa aacacttcat tgaaaatata cagtctaaat ttattatttaaattttacta 4320 gcaaaagtct taggtgaaca atcaactagt atttgttgag ctcctatttgcccagagatg 4380 gtcatattta aacagaagta tacgtttttc agtttcaaca tgaatttttttatttctgtc 4440 agttatgaca tccacgagca tcactttttg tgtctgtttt tttttttttcttggactaaa 4500 ttcaactgca tggaagcggt ggtcagaagg ttgttttata cgagaacaggcagaaagtgc 4560 ccattgttca ggattctaat agctacatct acttaatatc ttcatttctaaattgactgc 4620 ttttaccttt ttctcatgtt tatataatgg tatgcttgca tatatttcatgaatacattg 4680 tacatattat gttaatattt acacaattta aaatatagat gtgttttattttgaagtgag 4740 aaaatgaaca ttaacaggca tgtttgtaca gctagaatat attagtaagatactgttttt 4800 cgtcattcca gagctacaac taataacacg aggttccaaa gctgaagactttgtataaag 4860 tatttgggtt ttgttcttgt attgctttct ttcaacagtt tcaaaataaaatatcataca 4920 aatattgagg gaaatgtttt catatttttc aaaataggtt tttattgttgaatgtacatc 4980 taccccagcc cctcaaaaga aaaactgttt acatagaaat tcctacacatacgtttgcgt 5040 atatgttatt ttaaacatct ttgtggtgag aattttttcc ccgatattctccttctgtca 5100 aagtcagaac aaattcaggg aatttatttt ctggcagttg tgctccagtccttttaaaat 5160 tgtacatgaa catgttttag aaacaatatg gaggatgatg catacatgtcggtcaagttc 5220 agcgctcgac attttatgga aagatttttt taaccttacc acgaaatacttaactactgt 5280 ttaagtgaat tgacttattt cactttagtt tttgaactgt gattattggtatactgttat 5340 atcctcaact tggatttatg gtaacccctt ttagttcatg gagaccaaaatttggggtat 5400 ttataatagt cagcgcagga atgcacatgg aatatctact tgtccttttgaacctcacga 5460 gtcatccaga atgtatagac aggaaaagca tgtcttattt aaaactgtaatttatgggct 5520 caggatctga ccgcagtccc gggagtaagc atttcaaagg gggaaggcagtgtggtccct 5580 accctgtgtg aatgtgagga tgtagacatc catcagtgca actcgagctccatcctcctc 5640 cgatttctaa ggctccagtt ttctggaggg acagtcatca tgttttgatttatctgggag 5700 aaaactgtgg tgcacagctt gtgaggaggg caaggttgtg acgttcgagcttagttctgg 5760 tgttattctg tctcctcttc tttgtcatca gccaaaacgt ggtttttaaagagagtcatg 5820 caggttagaa ataatgtcaa aaatatttag gaatttaata acctttaagtcagaaactaa 5880 aacaaatact gaaatattag ctcttcctac acttcgtgtt cccctttagctgcctgaaaa 5940 tcaagattgc tcctactcag atcttctgag tggctaaaac ttatggatatgaaaaatgag 6000 attgaatgat gactatgctt tgctatcatt gttacctttc ctcaatactatttggcaact 6060 actgggactc ttcagcacaa aaggaataga tctatgattg accctgattttaattgtgaa 6120 attatatgat tcatatattt tatgaatcag aataaccttc aaataaaataaatctaagtc 6180 ggttaaaatg gatttcatga ttttccctca gaaaatgagt aacggagtccacggcgtgca 6240 atggtaatta taaattggtg atgcttgttt gcaaattgcc cactcgtgataagtcaacag 6300 ccaatattta aaactttgtt cgttactggc tttaccctaa ctttctctagtctactgtca 6360 atatcatttt aatgtaattg attgtatata gtctcaagaa tggttggtgggcatgagttc 6420 ctagagaact gtccaagggt tgggaaaatc caaattctct tcctggctccagcactgatt 6480 ttgtacataa acattaggca ggttgcttaa cctttttatt tcaaactctctcaactctaa 6540 agtgctaata ataatctcag ttaccttatc tttgtcacag ggtgttcttttttatgaaga 6600 aaaatttgaa aatgataaaa gctaagatgc cttctaactt cataagcaaacctttaacta 6660 attatgtatc tgaaagtcac ccccacatac caactcaact tttttcctgtgaacacataa 6720 atatattttt atagaaaaac aaatctacat aaaataaatc tactgtttagtgagcagtat 6780 gacttgtaca tgccattgaa aattattaat cagaagaaaa ttaagcagggtctttgctat 6840 acaaaagtgt tttccactaa ttttgcatgc gtatttataa gaaaaatgtgaatttggtgg 6900 ttttattcta tcggtataaa ggcatcgata ttttagatgc acccgtgtttgtaaaaatgt 6960 agagcacaat ggaattatgc tggaagtctc aaataatatt tttttcctattttatactca 7020 tggaagagat aagctaaaga ggggacaata atgagaaatg ttggtgtgcttttctaagca 7080 tttaaaacat aattgccaat tgaaacccta aatatgttta cataccattaagatatgatt 7140 catgtaacaa tgttaaatta attataatgg gattgggttt gttatctgtggtagtatata 7200 tcctagtgtt cctatagtga aataagtagg gttcagccaa agctttctttgttttgtacc 7260 ttaaattgtt cgattacgtc atcaaaagag atgaaaggta tgtagaacaggttcacgtga 7320 ttaccttttt cttttggctt ggattaatat tcatagtaga actttataaaacgtgtttgt 7380 attgtaggtg gtgtttgtat tatgcttatg actatgtatg gtttgaaaatattttcatta 7440 tacatgaaat tcaactttcc aaataaaagt tctacttcat gtaatccaaa a7491

TABLE LIIIa Nucleotide sequence alignment of 282P1G03 v.1 (SEQ IDNO:152) and 282P1G03 v.2 (SEQ ID NO:153)

Note: Two SNP at 668 and 1178.

TABLE LIVa Peptide sequences of protein coded by 282P1G03 v.2 (SEQ IDNO: 154) MEPLLLGRGL IVYLMFLLLK FSKAIEIPSS VQQVPTIIKQ SKVQVAFPFDEYFQIECEAK 60 GNPEPTFSWT KDGNPFYFTD HRIIPSNNSG TFRIPNEGHI SHFQGKYRCFASNKLGIAMS 120 EEIEFIVPSV PKFPKEKIDP LEVEEGDPIV LPCNPPKGLP PLHIYWMNIELEHIEQDERV 180 YMSQKGDLYF ANVEEKDSRN DYCCFAAFPR LRTIVQKMPM KLTVNSLKHANDSSSSTEIG 240 SKANSIKQRK PKLLLPPTES GSESSITILK GEILLLECFA EGLPTPQVDWNKIGGDLPKG 300 REAKENYGKT LKIENVSYQD KGNYRCTASN FLGTATHDFH VIVEEPPRWTKKPQSAVYST 360 GSNGILLCEA EGEPQPTIKW RVNGSPVDNH PFAGDVVFPR EISFTNLQPNHTAVYQCEAS 420 NVHGTILANA NIDVVDVRPL IQTKDGENYA TVVGYSAFLH CEFFASPEAVVSWQKVEEVK 480 PLEGRRYHIY ENGTLQINRT TEEDAGSYSC WVENAIGKTA VTANLDIRNATKLRVSPKNP 540 RIPKLHMLEL HCESKCDSHL KHSLKLSWSK DGEAFEINGT EDGRIIIDGANLTISNVTLE 600 DQGIYCCSAH TALDSAADIT QVTVLDVPDP PENLHLSERQ NRSVRLTWEAGADHNSNISE 660 YIVEFEGNKE EPGRWEELTR VQGKKTTVIL PLAPFVRYQF RVIAVNEVGRSQPSQPSDHH 720 ETPPAAPDRN PQNIRVQASQ PKEMIIKWEP LKSMEQNGPG LEYRVTWKPQGAPVEWEEET 780 VTNHTLRVMT PAVYAPYDVK VQAINQLGSG PDPQSVTLYS GEDYPDTAPVIHGVDVINST 840 LVKVTWSTVP KDRVHGRLKG YQINWWKTKS LLDGRTHPKE VNILRFSGQRNSGMVPSLDA 900 FSEFHLTVLA YNSKGAGPES EPYIFQTPEG VPEQPTFLKV IKVDKDTATLSWGLPKKLNG 960 NLTGYLLQYQ IINDTYEIGE LNDINITTPS KPSWHLSNLN ATTKYKFYLRACTSQGCGKP 1020 ITEESSTLGE GKYAGLYDDI STQGWFIGLM CAIALLTLLL LTVCFVKRNRGGKYSVKEKE 1080 DLHPDPEIQS VKDETFGEYS DSDEKPLKGS LRSLNRDMQP TESADSLVEYGEGDHGLFSE 1140 DGSFIGAYAG SKEKGSVESN GSSTATFPLR A 1171

TABLE LVa Amino acid sequence alignment of 282P1G03 v.1 (SEQ ID NO:155)and 282P1G03 v.2 (SEQ ID NO:156)

TABLE LIIb Nucleotide sequence of transcript variant 282P1G03 v.3cggaccctgc gcgcccccgt cccggctccc ggccggctcg ggggagaagg cgcccgaggg 60gaggcgccgg acagatcgcg tttcggaggc ggcgcaggtg ctgtaaactg caaaccataa 120tcctgtctta atactgcaaa caaatcatag tggaactaag gggaacttaa tttactgttt 180ccaggttaac taaggtctca gctgtaaacc aaaagtgaga ggagacatta agattttcat 240tcttaccggg ttgtcttctt cctgaagagc aatggagccg cttttacttg gaagaggact 300aatcgtatat ctaatgttcc tcctgttaaa attctcaaaa gcaattgaaa taccatcttc 360agttcaacag gttccaacaa tcataaaaca gtcaaaagtc caagttgcct ttcccttcga 420tgagtatttt caaattgaat gtgaagctaa aggaaatcca gaaccaacat tttcgtggac 480taaggatggc aacccttttt atttcactga ccatcggata attccatcga acaattcagg 540aacattcagg atcccaaacg aggggcacat atctcacttt caagggaaat accgctgctt 600tgcttcaaat aaactgggaa tcgctatgtc agaagaaata gaatttatag ttccaagtgt 660tccaaaactc ccaaaagaaa aaattgaccc tcttgaagtg gaggagggag atccaattgt 720cctcccatgc aatcctccca aaggcctccc acctttacac atttattgga tgaatattga 780attagaacac atcgaacaag atgaaagagt atacatgagc caaaagggag atctatactt 840cgcaaacgtg gaagaaaagg acagtcgcaa tgactactgt tgctttgctg catttccaag 900attaaggact attgtacaga aaatgccaat gaaactaaca gttaacagtt taaagcatgc 960taatgactca agttcatcca cagaaattgg ttccaaggca aattccatca agcaaagaaa 1020acccaaactg ctgttgcctc ccactgagag tggcagtgag tcttcaatta ccatcctcaa 1080aggggaaatc ttgctgcttg agtgttttgc tgaaggcttg ccaactccac aggttgattg 1140gaacaaaatt ggtggtgact taccaaaggg gagagaaaca aaagaaaatt atggcaagac 1200tttgaagata gagaatgtct cctaccagga caaaggaaat tatcgctgca cagccagcaa 1260tttcttggga acagccactc acgattttca cgttatagta gaagagcctc ctcgctggac 1320aaagaagcct cagagtgctg tgtatagcac cggaagcaat ggcatcttgt tatgtgaggc 1380tgaaggagaa cctcaaccca caatcaagtg gagagtcaat ggctccccag ttgacaatca 1440tccatttgct ggtgatgttg tcttccccag ggaaatcagt tttaccaacc ttcaaccaaa 1500tcatactgct gtgtaccagt gtgaagcctc aaatgtccat ggaactatcc ttgccaatgc 1560caatattgat gttgtggatg tccgtccatt gatacaaacc aaagatggag aaaattacgc 1620tacagtggtt gggtacagtg ctttcttaca ttgcgagttc tttgcttcac ctgaggcagt 1680cgtgtcctgg cagaaggtgg aagaagtgaa acccctggag ggcaggcggt atcatatcta 1740tgaaaatggc acattgcaga tcaacagaac caccgaagaa gatgctgggt cttactcatg 1800ttgggtagaa aatgctatag gaaaaactgc agtcacagcc aatttggata ttagaaatgc 1860tacaaaactt agagtttctc ctaagaatcc tcgtatcccc aaattgcata tgcttgaatt 1920acattgtgaa agcaaatgtg actcacattt gaaacacagt ttgaagttgt cctggagtaa 1980agatggagaa gcctttgaaa ttaatggcac agaagatggc aggataatta ttgatggagc 2040taatttgacc atatctaatg taactttaga ggaccaaggt atttactgct gttcagctca 2100tactgctcta gacagtgctg ccgatataac tcaagtaact gttcttgatg ttccggatcc 2160accagaaaac cttcacttgt ctgaaagaca gaacaggagt gttcggctga cctgggaagc 2220tggagctgac cacaacagca atattagcga gtatattgtt gaatttgaag gaaacaaaga 2280agagcctgga aggtgggagg aactgaccag agtccaagga aagaaaacca cagttatctt 2340acctttggct ccatttgtga gataccagtt cagggtcata gccgtgaacg aagtagggag 2400aagtcagcct agccagccgt cagaccatca tgaaacacca ccagcagctc cagataggaa 2460tccacaaaac ataagggttc aagcctctca acccaaggaa atgattataa agtgggagcc 2520tttgaaatcc atggagcaga atggaccagg cctagagtac agagtgacct ggaagccaca 2580gggagcccca gtggagtggg aagaagaaac agtcacaaac cacacattgc gggtgatgac 2640gcctgctgtc tatgcccctt atgatgtcaa ggtccaggct atcaatcaac taggatctgg 2700gcctgaccct cagtcagtga ctctctattc tggagaagac tatcctgata cagctccagt 2760gatccatggg gtggacgtta taaacacaac atatgtaagc aacgctactg gttcacccca 2820accttccata tttatctgtt caaaggagca agaactttca tataggaata gaaacatgct 2880ggccgaagat ttcatccaga agtcaacatc ctgcaattat gttgaaaaga gtagtacttt 2940cttcaaaata taaaatgcca agcacttcag gcctatgttt tgcttatatt gttttcaggt 3000gctcaaaatg caaaacacaa aacaaatcct gcatttagat acacctcaac taaatccaaa 3060gtccccattc agtatattcc atatttgcct gattttacta ttcggtgtgt ttgcatagat 3120gttgctactt ggtgggtttt tctccgtatg cacattggta tacagtctct gagaactggc 3180ttggtgactt tgcttcacta caggttaaaa gaccataagc aaactggtta tttaaaatgt 3240aaaaaggaat atgaaagtct tattaaaaca cttcattgaa aatatacagt ctaaatttat 3300tatttaaatt ttactagcaa aagtcttagg tgaacaatca actagtattt gttgagctcc 3360tatttgccca gagatggtca tatttaaaca gaagtatacg tttttcagtt tcaacatgaa 3420tttttttatt tctgtcagtt atgacatcca cgagcatcac tttttgtgtc tgtttttttt 3480tttttcttgg actaaattca actgcatgga agcggtggtc agaaggttgt tttatacgag 3540aacaggcaga aagtgcccat tgttcaggat tctaatagct acatctactt aatatcttca 3600tttctaaatt gactgctttt acctttttct catgtttata taatggtatg cttgcatata 3660tttcatgaat acattgtaca tattatgtta atatttacac aatttaaaat atagatgtgt 3720tttattttga agtgagaaaa tgaacattaa caggcatgtt tgtacagcta gaatatatta 3780gtaagatact gtttttcgtc attccagagc tacaactaat aacacgaggt tccaaagctg 3840aagactttgt ataaagtatt tgggttttgt tcttgtattg ctttctttca acagtttcaa 3900aataaaatat catacaaata ttgagggaaa tgttttcata tttttcaaaa taggttttta 3960ttgttgaatg tacatctacc ccagcccctc aaaagaaaaa ctgtttacat agaaattcct 4020acacatacgt ttgcgtatat gttattttaa acatctttgt ggtgagaatt ttttccccga 4080tattctcctt ctgtcaaagt cagaacaaat tcagggaatt tattttctgg cagttgtgct 4140ccagtccttt taaaattgta catgaacatg ttttagaaac aatatggagg atgatgcata 4200catgtcggtc aagttcagcg ctcgacattt tatggaaaga tttttttaac cttaccacga 4260aatacttaac tactgtttaa gtgaattgac ttatttcact ttagtttttg aactgtgatt 4320attggtatac tgttatatcc tcaacttgga tttatggtaa ccccttttag ttcatggaga 4380ccaaaatttg gggtatttat aatagtcagc gcaggaatgc acatggaata tctacttgtc 4440cttttgaacc tcacgagtca tccagaatgt atagacagga aaagcatgtc ttatttaaaa 4500ctgtaattta tgggctcagg atctgaccgc agtcccggga gtaagcattt caaaggggga 4560aggcagtgtg gtccctaccc tgtgtgaatg tgaggatgta gacatccatc agtgcaactc 4620gagctccatc ctcctccgat ttctaaggct ccagttttct ggagggacag tcatcatgtt 4680ttgatttatc tgggagaaaa ctgtggtgca cagcttgtga ggagggcaag gttgtgacgt 4740tcgagcttag ttctggtgtt attctgtctc ctcttctttg tcatcagcca aaacgtggtt 4800tttaaagaga gtcatgcagg ttagaaataa tgtcaaaaat atttaggaat ttaataacct 4860ttaagtcaga aactaaaaca aatactgaaa tattagctct tcctacactt cgtgttcccc 4920tttagctgcc tgaaaatcaa gattgctcct actcagatct tctgagtggc taaaacttat 4980ggatatgaaa aatgagattg aatgatgact atgctttgct atcattgtta cctttcctca 5040atactatttg gcaactactg ggactcttca gcacaaaagg aatagatcta tgattgaccc 5100tgattttaat tgtgaaatta tatgattcat atattttatg aatcagaata accttcaaat 5160aaaataaatc taagtcggtt aaaatggatt tcatgatttt ccctcagaaa atgagtaacg 5220gagtccacgg cgtgcaatgg taattataaa ttggtgatgc ttgtttgcaa attgcccact 5280cgtgataagt caacagccaa tatttaaaac tttgttcgtt actggcttta ccctaacttt 5340ctctagtcta ctgtcaatat cattttaatg taattgattg tatatagtct caagaatggt 5400tggtgggcat gagttcctag agaactgtcc aagggttggg aaaatccaaa ttctcttcct 5460ggctccagca ctgattttgt acataaacat taggcaggtt gcttaacctt tttatttcaa 5520actctctcaa ctctaaagtg ctaataataa tctcagttac cttatctttg tcacagggtg 5580ttctttttta tgaagaaaaa tttgaaaatg ataaaagcta agatgccttc taacttcata 5640agcaaacctt taactaatta tgtatctgaa agtcaccccc acataccaac tcaacttttt 5700tcctgtgaac acataaatat atttttatag aaaaacaaat ctacataaaa taaatctact 5760gtttagtgag cagtatgact tgtacatgcc attgaaaatt attaatcaga agaaaattaa 5820gcagggtctt tgctatacaa aagtgttttc cactaatttt gcatgcgtat ttataagaaa 5880aatgtgaatt tggtggtttt attctatcgg tataaaggca tcgatatttt agatgcaccc 5940gtgtttgtaa aaatgtagag cacaatggaa ttatgctgga agtctcaaat aatatttttt 6000tcctatttta tactcatgga agagataagc taaagagggg acaataatga gaaatgttgg 6060tgtgcttttc taagcattta aaacataatt gccaattgaa accctaaata tgtttacata 6120ccattaagat atgattcatg taacaatgtt aaattaatta taatgggatt gggtttgtta 6180tctgtggtag tatatatcct agtgttccta tagtgaaata agtagggttc agccaaagct 6240ttctttgttt tgtaccttaa attgttcgat tacgtcatca aaagagatga aaggtatgta 6300gaacaggttc acgtgattac ctttttcttt tggcttggat taatattcat agtagaactt 6360tataaaacgt gtttgtattg taggtggtgt ttgtattatg cttatgacta tgtatggttt 6420gaaaatattt tcattataca tgaaattcaa ctttccaaat aaaagttcta cttcatgtaa 6480tccaaaa 6487

TABLE LIIIb Nucleotide sequence alignment of 282P1G03 v.1 (SEQ ID NO:158) and 282P1G03 v.3 (SEQ ID NO: 159)

TABLE LIVb Peptide seguences of protein coded by 282P1G03 v.3 (SEQ IDNO: 160) MEPLLLGRGL IVYLMFLLLK FSKAIEIPSS VQQVPTIIKQ SKVQVAFPFDEYFQIECEAK  60 GNPEPTFSWT KDGNPFYFTD HRIIPSNNSG TFRIPNEGHI SHFQGKYRCFASNKLGIANS 120 EEIEFIVPSV PKLPKEKIDP LEVEEGDPIV LPCNPPKGLP PLHIYWMNIELEHIEQDERV 180 YMSQKGDLYF ANVEEKDSRN DYCCFAAFPR LRTIVQKMPM KLTVNSLKHANDSSSSTEIG 240 SKANSIKQRK PKLLLPPTES GSESSITILK GEILLLECFA EGLPTPQVDWNKIGGDLPKG 300 RETKENYGKT LKIENVSYQD KGNYRCTASN FLGTATHDFH VIVEEPPRWTKKPQSAVYST 360 GSNGILLCEA EGEPQPTIKW RVNGSPVDNH PFAGDVVFPR EISFTNLQPNHTAVYQCEAS 420 NVHGTILANA NIDVVDVRPL IQTKDGENYA TVVGYSAFLH CEFFASPEAVVSWQKVEEVK 480 PLEGRRYHIY ENGTLQINRT TEEDAGSYSC WVENAIGKTA VTANLDIRNATKLRVSPKNP 540 RIPKLHMLEL HCESKCDSHL KHSLKLSWSK DGEAFEINGT EDGRIIIDGANLTISNVTLE 600 DQGIYCCSAH TALDSAADIT QVTVLDVPDP PENLHLSERQ NRSVRLTWEAGADHNSNISE 660 YIVEFEGNKE EPGRWEELTR VQGKKTTVIL PLAPFVRYQF RVIAVNEVGRSQPSQPSDHH 720 ETPPAAPDRN PQNIRVQASQ PKEMIIKWEP LKSMEQNGPG LEYRVTWKPQGAPVEWEEET 780 VTNHTLRVMT PAVYAPYDVK VQAINQLGSG PDPQSVTLYS GEDYPDTAPVIHGVDVINTT 840 YVSNATGSPQ PSIFICSKEQ ELSYRNRNML AEDFIQKSTS CNYVEKSSTFFKI        893

TABLE LVb Amino acid sequence alignment of 282P1G03 v.1 (SEQ ID NO: 161)and 282P1G03 v.3 (SEQ ID NO: 162)

TABLE LIIc Nucleotide sequence of transcript variant 282P1G03 v.4 (SEQID NO: 163) cggaccctgc gcgcccccgt cccggctccc ggccggctcg ggggagaaggcgcccgaggg   60 gaggcgccgg acagatcgcg tttcggaggc ggcgcaggtg ctgtaaactgcaaaccataa  120 tcctgtctta atactgcaaa caaatcatag tggaactaag gggaacttaatttactgttt  180 ccaggttaac taaggtctca gctgtaaacc aaaagtgaga ggagacattaagattttcat  240 tcttaccggg ttgtcttctt cctgaagagc aatggagccg cttttacttggaagaggact  300 aatcgtatat ctaatgttcc tcctgttaaa attctcaaaa gcaattgaaataccatcttc  360 agttcaacag gttccaacaa tcataaaaca gtcaaaagtc caagttgcctttcccttcga  420 tgagtatttt caaattgaat gtgaagctaa aggaaatcca gaaccaacattttcgtggac  480 taaggatggc aacccttttt atttcactga ccatcggata attccatcgaacaattcagg  540 aacattcagg atcccaaacg aggggcacat atctcacttt caagggaaataccgctgctt  600 tgcttcaaat aaactgggaa tcgctatgtc agaagaaata gaatttatagttccaagtgt  660 tccaaaactc ccaaaagaaa aaattgaccc tcttgaagtg gaggagggagatccaattgt  720 cctcccatgc aatcctccca aaggcctccc acctttacac atttattggatgaatattga  780 attagaacac atcgaacaag atgaaagagt atacatgagc caaaagggagatctatactt  840 cgcaaacgtg gaagaaaagg acagtcgcaa tgactactgt tgctttgctgcatttccaag  900 attaaggact attgtacaga aaatgccaat gaaactaaca gttaacagtttaaagcatgc  960 taatgactca agttcatcca cagaaattgg ttccaaggca aattccatcaagcaaagaaa 1020 acccaaactg ctgttgcctc ccactgagag tggcagtgag tcttcaattaccatcctcaa 1080 aggggaaatc ttgctgcttg agtgttttgc tgaaggcttg ccaactccacaggttgattg 1140 gaacaaaatt ggtggtgact taccaaaggg gagagaaaca aaagaaaattatggcaagac 1200 tttgaagata gagaatgtct cctaccagga caaaggaaat tatcgctgcacagccagcaa 1260 tttcttggga acagccactc acgattttca cgttatagta gaagagcctcctcgctggac 1320 aaagaagcct cagagtgctg tgtatagcac cggaagcaat ggcatcttgttatgtgaggc 1380 tgaaggagaa cctcaaccca caatcaagtg gagagtcaat ggctccccagttgacaatca 1440 tccatttgct ggtgatgttg tcttccccag ggaaatcagt tttaccaaccttcaaccaaa 1500 tcatactgct gtgtaccagt gtgaagcctc aaatgtccat ggaactatccttgccaatgc 1560 caatattgat gttgtggatg tccgtccatt gatacaaacc aaagatggagaaaattacgc 1620 tacagtggtt gggtacagtg ctttcttaca ttgcgagttc tttgcttcacctgaggcagt 1680 cgtgtcctgg cagaaggtgg aagaagtgaa acccctggag ggcaggcggtatcatatcta 1740 tgaaaatggc acattgcaga tcaacagaac caccgaagaa gatgctgggtcttactcatg 1800 ttgggtagaa aatgctatag gaaaaactgc agtcacagcc aatttggatattagaaatgc 1860 tacaaaactt agagtttctc ctaagaatcc tcgtatcccc aaattgcatatgcttgaatt 1920 acattgtgaa agcaaatgtg actcacattt gaaacacagt ttgaagttgtcctggagtaa 1980 agatggagaa gcctttgaaa ttaatggcac agaagatggc aggataattattgatggagc 2040 taatttgacc atatctaatg taactttaga ggaccaaggt atttactgctgttcagctca 2100 tactgctcta gacagtgctg ccgatataac tcaagtaact gttcttgatgttccggatcc 2160 accagaaaac cttcacttgt ctgaaagaca gaacaggagt gttcggctgacctgggaagc 2220 tggagctgac cacaacagca atattagcga gtatattgtt gaatttgaaggaaacaaaga 2280 agagcctgga aggtgggagg aactgaccag agtccaagga aagaaaaccacagttatctt 2340 acctttggct ccatttgtga gataccagtt cagggtcata gccgtgaacgaagtagggag 2400 aagtcagcct agccagccgt cagaccatca tgaaacacca ccagcagctccagataggaa 2460 tccacaaaac ataagggttc aagcctctca acccaaggaa atgattataaagtgggagcc 2520 tttgaaatcc atggagcaga atggaccagg cctagagtac agagtgacctggaagccaca 2580 gggagcccca gtggagtggg aagaagaaac agtcacaaac cacacattgcgggtgatgac 2640 gcctgctgtc tatgcccctt atgatgtcaa ggtccaggct atcaatcaactaggatctgg 2700 gcctgaccct cagtcagtga ctctctattc tggagaagac ttacctgaacagccaacttt 2760 tctaaaggtc atcaaagttg ataaagacac tgccacttta tcttggggactacctaagaa 2820 attaaatgga aacttaactg gctatctttt gcaatatcag ataataaatgacacctacga 2880 gattggagaa ttaaatgata ttaacattac aactccatca aagcccagctggcacctctc 2940 aaacctgaat gcaactacca agtacaaatt ctacttgagg gcttgcacttcacagggctg 3000 tggaaaaccg atcacggagg aaagctccac cttaggagaa gggagtaaaggtatcgggaa 3060 gatatcagga gtaaatctta ctcaaaagac tcacccaata gaggtatttgagccgggagc 3120 tgaacatata gttcgcctaa tgactaagaa ttggggcgat aacgatagcatttttcaaga 3180 tgtaattgag acaagaggga gagaatatgc tggtttatat gatgacatctccactcaagg 3240 ctggtttatt ggactgatgt gtgcgattgc tcttctcaca ctactattattaactgtttg 3300 ctttgtgaag aggaatagag gtggaaagta ctcagttaaa gaaaaggaagatttgcatcc 3360 agacccagaa attcagtcag taaaagatga aacctttggt gaatacagtgacagtgatga 3420 aaagcctctc aaaggaagcc ttcggtccct taatagggat atgcagcctactgaaagtgc 3480 tgacagctta gtcgaatacg gagagggaga ccatggtctc ttcagtgaagatggatcatt 3540 tattggtgcc tacgctggat ctaaggagaa gggatctgtt gaaagcaatggaagttctac 3600 agcaactttt ccccttcggg cataaacaca acatatgtaa gcaacgctactggttcaccc 3660 caaccttcca tatttatctg ttcaaaggag caagaacttt catataggaatagaaacatg 3720 ctggccgaag atttcatcca gaagtcaaca tcctgcaatt atgttgaaaagagtagtact 3780 ttcttcaaaa tataaaatgc caagcacttc aggcctatgt tttgcttatattgttttcag 3840 gtgctcaaaa tgcaaaacac aaaacaaatc ctgcatttag atacacctcaactaaatcca 3900 aagtccccat tcagtatatt ccatatttgc ctgattttac tattcggtgtgtttgcatag 3960 atgttgctac ttggtgggtt tttctccgta tgcacattgg tatacagtctctgagaactg 4020 gcttggtgac tttgcttcac tacaggttaa aagaccataa gcaaactggttatttaaaat 4080 gtaaaaagga atatgaaagt cttattaaaa cacttcattg aaaatatacagtctaaattt 4140 attatttaaa ttttactagc aaaagtctta ggtgaacaat caactagtatttgttgagct 4200 cctatttgcc cagagatggt catatttaaa cagaagtata cgtttttcagtttcaacatg 4260 aattttttta tttctgtcag ttatgacatc cacgagcatc actttttgtgtctgtttttt 4320 tttttttctt ggactaaatt caactgcatg gaagcggtgg tcagaaggttgttttatacg 4380 agaacaggca gaaagtgccc attgttcagg attctaatag ctacatctacttaatatctt 4440 catttctaaa ttgactgctt ttaccttttt ctcatgttta tataatggtatgcttgcata 4500 tatttcatga atacattgta catattatgt taatatttac acaatttaaaatatagatgt 4560 gttttatttt gaagtgagaa aatgaacatt aacaggcatg tttgtacagctagaatatat 4620 tagtaagata ctgtttttcg tcattccaga gctacaacta ataacacgaggttccaaagc 4680 tgaagacttt gtataaagta tttgggtttt gttcttgtat tgctttctttcaacagtttc 4740 aaaataaaat atcatacaaa tattgaggga aatgttttca tatttttcaaaataggtttt 4800 tattgttgaa tgtacatcta ccccagcccc tcaaaagaaa aactgtttacatagaaattc 4860 ctacacatac gtttgcgtat atgttatttt aaacatcttt gtggtgagaattttttcccc 4920 gatattctcc ttctgtcaaa gtcagaacaa attcagggaa tttattttctggcagttgtg 4980 ctccagtcct tttaaaattg tacatgaaca tgttttagaa acaatatggaggatgatgca 5040 tacatgtcgg tcaagttcag cgctcgacat tttatggaaa gatttttttaaccttaccac 5100 gaaatactta actactgttt aagtgaattg acttatttca ctttagtttttgaactgtga 5160 ttattggtat actgttatat cctcaacttg gatttatggt aaccccttttagttcatgga 5220 gaccaaaatt tggggtattt ataatagtca gcgcaggaat gcacatggaatatctacttg 5280 tccttttgaa cctcacgagt catccagaat gtatagacag gaaaagcatgtcttatttaa 5340 aactgtaatt tatgggctca ggatctgacc gcagtcccgg gagtaagcatttcaaagggg 5400 gaaggcagtg tggtccctac cctgtgtgaa tgtgaggatg tagacatccatcagtgcaac 5460 tcgagctcca tcctcctccg atttctaagg ctccagtttt ctggagggacagtcatcatg 5520 ttttgattta tctgggagaa aactgtggtg cacagcttgt gaggagggcaaggttgtgac 5580 gttcgagctt agttctggtg ttattctgtc tcctcttctt tgtcatcagccaaaacgtgg 5640 tttttaaaga gagtcatgca ggttagaaat aatgtcaaaa atatttaggaatttaataac 5700 ctttaagtca gaaactaaaa caaatactga aatattagct cttcctacacttcgtgttcc 5760 cctttagctg cctgaaaatc aagattgctc ctactcagat cttctgagtggctaaaactt 5820 atggatatga aaaatgagat tgaatgatga ctatgctttg ctatcattgttacctttcct 5880 caatactatt tggcaactac tgggactctt cagcacaaaa ggaatagatctatgattgac 5940 cctgatttta attgtgaaat tatatgattc atatatttta tgaatcagaataaccttcaa 6000 ataaaataaa tctaagtcgg ttaaaatgga tttcatgatt ttccctcagaaaatgagtaa 6060 cggagtccac ggcgtgcaat ggtaattata aattggtgat gcttgtttgcaaattgccca 6120 ctcgtgataa gtcaacagcc aatatttaaa actttgttcg ttactggctttaccctaact 6180 ttctctagtc tactgtcaat atcattttaa tgtaattgat tgtatatagtctcaagaatg 6240 gttggtgggc atgagttcct agagaactgt ccaagggttg ggaaaatccaaattctcttc 6300 ctggctccag cactgatttt gtacataaac attaggcagg ttgcttaacctttttatttc 6360 aaactctctc aactctaaag tgctaataat aatctcagtt accttatctttgtcacaggg 6420 tgttcttttt tatgaagaaa aatttgaaaa tgataaaagc taagatgccttctaacttca 6480 taagcaaacc tttaactaat tatgtatctg aaagtcaccc ccacataccaactcaacttt 6540 tttcctgtga acacataaat atatttttat agaaaaacaa atctacataaaataaatcta 6600 ctgtttagtg agcagtatga cttgtacatg ccattgaaaa ttattaatcagaagaaaatt 6660 aagcagggtc tttgctatac aaaagtgttt tccactaatt ttgcatgcgtatttataaga 6720 aaaatgtgaa tttggtggtt ttattctatc ggtataaagg catcgatattttagatgcac 6780 ccgtgtttgt aaaaatgtag agcacaatgg aattatgctg gaagtctcaaataatatttt 6840 tttcctattt tatactcatg gaagagataa gctaaagagg ggacaataatgagaaatgtt 6900 ggtgtgcttt tctaagcatt taaaacataa ttgccaattg aaaccctaaatatgtttaca 6960 taccattaag atatgattca tgtaacaatg ttaaattaat tataatgggattgggtttgt 7020 tatctgtggt agtatatatc ctagtgttcc tatagtgaaa taagtagggttcagccaaag 7080 ctttctttgt tttgtacctt aaattgttcg attacgtcat caaaagagatgaaaggtatg 7140 tagaacaggt tcacgtgatt acctttttct tttggcttgg attaatattcatagtagaac 7200 tttataaaac gtgtttgtat tgtaggtggt gtttgtatta tgcttatgactatgtatggt 7260 ttgaaaatat tttcattata catgaaattc aactttccaa ataaaagttctacttcatgt 7320aatccaaaa                                                         7329

TABLE LIIIc Nucleotide sequence alignment of 282P1G03 v.1 (SEQ ID NO:164) and 282P1G03 v.4 (SEQ ID NO: 165)

TABLE LIVc Peptide sequences of protein coded by 28P1G03 v.4 (SEQ ID NO:166) MEPLLLGRGL IVYLMFLLLK FSKAIEIPSS VQQVPTIIKQ SKVQVAFPFD EYFQIECEAK  60 GNPEPTFSWT KDGNPFYFTD HRIIPSNNSG TFRIPNEGHI SHFQGKYRCF ASNKLGIAMS 120 EEIEFIVPSV PKLPKEKIDP LEVEEGDPIV LPCNPPKGLP PLHIYWMNIE LEHIEQDERV 180 YMSQKGDLYF ANVEEKDSRN DYCCFAAFPR LRTIVQKMPM KLTVNSLKHA NDSSSSTEIG 240 SKANSIKQRK PKLLLPPTES GSESSITILK GEILLLECFA EGLPTPQVOW NKIGGDLPKG 300 RETKENYGKT LKIENVSYQD KGNYRCTASN FLGTATHDFH VIVEEPPRWT KKPQSAVYST 360 GSNGILLCEA EGEPQPTIKW RVNGSPVDNH PFAGDVVFPR EISFTNLQPN HTAVYQCEAS 420 NVHGTILANA NIDVVDVRPL IQTKDGENYA TVVGYSAFLH CEFFASPEAV VSWQKVEEVK 480 PLEGRRYHIY ENGTLQINRT TEEDAGSYSC WVENAIGKTA VTANLDIRNA TKLRVSPKNP 540 RIPKLHMLEL HCESKCDSHL KHSLKLSWSK DGEAFEINGT EDGRIIIDGA NLTISNVTLE 600 DQGIYCCSAH TALDSAADIT QVTVLDVPDP PENLHLSERQ NRSVRLTWEA GADHNSNISE 660 YIVEFEGNKE EPGRWEELTR VQGKKTTVIL PLAPFVRYQF RVIAVNEVGR SQPSQPSDHH 720 ETPPAAPDRN PQNIRVQASQ PKEMIIKWEP LKSMEQNGPG LEYRVTWKPQ GAPVEWEEET 780 VTNHTLRVMT PAVYAPYDVK VQAINQLGSG PDPQSVTLYS GEDLPEQPTF LKVIKVDKDT 840 ATLSWGLPKK LNGNLTGYLL QYQIINDTYE IGELNDINIT TPSKPSWHLS NLNATTKYKF 900 YLRACTSQGC GKPITEESST LGEGSKGIGK ISGVNLTQKT HPIEVFEPGA EHIVRLMTKN 960 WGDNDSIFQD VIETRGREYA GLYDDISTQG WFIGLMCAIA LLTLLLLTVC FVKRNRGGKY1020 SVKEKEDLHP DPEIQSVKDE TFGEYSDSDE KPLKGSLRSL NRDMQPTESA DSLVEYGEGD1080 HGLFSEDGSF IGAYAGSKEK GSVESNGSSTATFPLRA                          1117

TABLE LVc Amino acid sequence alignment of 282P1G03 v.1 (SEQ ID NO:167)and 282P1G03 v.4 (SEQ ID NO:168)

TABLE LIId Nucleotide sequence of transcript variant 282P1G03 v.5 (SEQID NO: 169) cggaccctgc gcgcccccgt cccggctccc ggccggctcg ggggagaaggcgcccgaggg   60 gaggcgccgg acagatcgcg tttcggaggc ggcgcaggtg ctgtaaactgcaaaccataa  120 tcctgtctta atactgcaaa caaatcatag tggaactaag gggaacttaatttactgttt  180 ccaggttaac taaggtctca gctgtaaacc aaaagtgaga ggagacattaagattttcat  240 tcttaccggg ttgtcttctt cctgaagagc aatggagccg cttttacttggaagaggact  300 aatcgtatat ctaatgttcc tcctgttaaa attctcaaaa gcaattgaaataccatcttc  360 agttcaacag gttccaacaa tcataaaaca gtcaaaagtc caagttgcctttcccttcga  420 tgagtatttt caaattgaat gtgaagctaa aggaaatcca gaaccaacattttcgtggac  480 taaggatggc aacccttttt atttcactga ccatcggata attccatcgaacaattcagg  540 aacattcagg atcccaaacg aggggcacat atctcacttt caagggaaataccgctgctt  600 tgcttcaaat aaactgggaa tcgctatgtc agaagaaata gaatttatagttccaagtgt  660 tccaaaactc ccaaaagaaa aaattgaccc tcttgaagtg gaggagggagatccaattgt  720 cctcccatgc aatcctccca aaggcctccc acctttacac atttattggatgaatattga  780 attagaacac atcgaacaag atgaaagagt atacatgagc caaaagggagatctatactt  840 cgcaaacgtg gaagaaaagg acagtcgcaa tgcatcatgt tgctttgctgcatttccaag  900 attaaggact attgtacaga aaatgccaat gaaactaaca gttaacagttcaaattccat  960 caagcaaaga aaacccaaac tgctgttgcc tcccactgag agtggcagtgagtcttcaat 1020 taccatcctc aaaggggaaa tcttgctgct tgagtgtttt gctgaaggcttgccaactcc 1080 acaggttgat tggaacaaaa ttggtggtga cttaccaaag gggagagaaacaaaagaaaa 1140 ttatggcaag actttgaaga tagagaatgt ctcctaccag gacaaaggaaattatcgctg 1200 cacagccagc aatttcttgg gaacagccac tcacgatttt cacgttatagtagaagagcc 1260 tcctcgctgg acaaagaagc ctcagagtgc tgtgtatagc accggaagcaatggcatctt 1320 gttatgtgag gctgaaggag aacctcaacc cacaatcaag tggagagtcaatggctcccc 1380 agttgacaat catccatttg atggtgatgt tgtcttcccc agggaaatcagttttaccaa 1440 ccttcaacca aatcatactg cagtgtacca gtgtgaagcc tcaaatgtccatggaactat 1500 ccttgccaat gccaatattg atgttgtgga tgtccgtcca ttgatacaaaccaaagatgg 1560 agaaaattac gctacagtgg ttgggtacag tgctttctta cattgcgagttctttgcttc 1620 acctgaggca gtcgtgtcct ggcagaaggt ggaagaagtg aaacccctggagggcaggcg 1680 gtatcatatc tatgaaaatg gcacattgca gatcaacaga accaccgaagaagatgctgg 1740 gtcttactcg tgttgggtag aaaatgctat aggaaaaact gcagtcacagccaatttgga 1800 tattagaaat gctacaaaac ttagagtttc tcctaagaat cctcgtatccccaaattgca 1860 tatgcttgaa ttacattgtg aaagcaaatg tgactcacat ttgaaacacagtttgaagtt 1920 gtcctggagt aaagatggag aagcctttga aattaatggc acagaagatggcaggataat 1980 tattgatgga gctaatttga ccatatctaa tgtaacttta gaggaccaaggtatttactg 2040 ctgttcagct catactgctc tagacagtgc tgccgatata actcaagtaactgttcttga 2100 tgttccggat ccaccagaaa accttcactt gtctgaaaga cagaacaggagtgttcggct 2160 gacctgggaa gctggagctg accacaacag caatattagc gagtatattgttgaatttga 2220 aggaaacaaa gaagagcctg gaaggtggga ggaactgacc agagtccaaggaaagaaaac 2280 cacagttatc ttacctttgg ctccatttgt gagataccag ttcagggtcatagccgtgaa 2340 cgaagtaggg agaagtcagc ctagccagcc gtcagaccat catgaaacaccaccagcagc 2400 tccagatagg aatccacaaa acataagggt tcaagcctct caacccaaggaaatgattat 2460 aaagtgggag cctttgaaat ccatggagca gaatggacca ggcctagagtacagagtgac 2520 ctggaagcca cagggagccc cagtggagtg ggaagaagaa acagtcacaaaccacacatt 2580 gcgggtgatg acgcctgctg tctatgcccc ttatgatgtc aaggtccaggctatcaatca 2640 actaggatct gggcctgacc ctcagtcagt gactctctat tctggagaagactatcctga 2700 tacagctcca gtgatccatg gggtggacgt tataaacagt acattagttaaagttacctg 2760 gtcaacagtt ccaaaggaca gagtacatgg acgtctgaaa ggctatcagataaattggtg 2820 gaaaacaaaa agtctgttgg atggaagaac acatcccaaa gaagtgaacattctaagatt 2880 ttcaggacaa agaaactctg gaatggttcc ttccttagat gcctttagtgaatttcattt 2940 aacagtctta gcctataact ctaaaggagc tggtcctgaa agtgagccttatatatttca 3000 aacaccagaa ggagtacctg aacagccaac ttttctaaag gtcatcaaagttgataaaga 3060 cactgccact ttatcttggg gactacctaa gaaattaaat ggaaacttaactggctatct 3120 tttgcaatat cagataataa atgacaccta cgagattgga gaattaaatgatattaacat 3180 tacaactcca tcaaagccca gctggcacct ctcaaacctg aatgcaactaccaagtacaa 3240 attctacttg agggcttgca cttcacaggg ctgtggaaaa ccgatcacggaggaaagctc 3300 caccttagga gaagggagta aaggtatcgg gaagatatca ggagtaaatcttactcaaaa 3360 gactcaccca atagaggtat ttgagccggg agctgaacat atagttcgcctaatgactaa 3420 gaattggggc gataacgata gcatttttca agatgtaatt gagacaagagggagagaata 3480 tgctggttta tatgatgaca tctccactca aggctggttt attggactgatgtgtgcgat 3540 tgctcttctc acactactat tattaactgt ttgctttgtg aagaggaatagaggtggaaa 3600 gtactcagtt aaagaaaagg aagatttgca tccagaccca gaaattcagtcagtaaaaga 3660 tgaaaccttt ggtgaataca gtgacagtga tgaaaagcct ctcaaaggaagccttcggtc 3720 ccttaatagg gatatgcagc ctactgaaag tgctgacagc ttagtcgaatacggagaggg 3780 agaccatggt ctcttcagtg aagatggatc atttattggt gcctacgctggatctaagga 3840 gaagggatct gttgaaagca atggaagttc tacagcaact tttccccttcgggcataaac 3900 acaacatatg taagcaacgc tactggttca ccccaacctt ccatatttatctgttcaaag 3960 gagcaagaac tttcatatag gaatagaaac atgctggccg aagatttcatccagaagtca 4020 acatcctgca attatgttga aaagagtagt actttcttca aaatataaaatgccaagcac 4080 ttcaggccta tgttttgctt atattgtttt caggtgctca aaatgcaaaacacaaaacaa 4140 atcctgcatt tagatacacc tcaactaaat ccaaagtccc cattcagtatattccatatt 4200 tgcctgattt tactattcgg tgtgtttgca tagatgttgc tacttggtgggtttttctcc 4260 gtatgcacat tggtatacag tctctgagaa ctggcttggt gactttgcttcactacaggt 4320 taaaagacca taagcaaact ggttatttaa aatgtaaaaa ggaatatgaaagtcttatta 4380 aaacacttca ttgaaaatat acagtctaaa tttattattt aaattttactagcaaaagtc 4440 ttaggtgaac aatcaactag tatttgttga gctcctattt gcccagagatggtcatattt 4500 aaacagaagt atacgttttt cagtttcaac atgaattttt ttatttctgtcagttatgac 4560 atccacgagc atcacttttt gtgtctgttt tttttttttt cttggactaaattcaactgc 4620 atggaagcgg tggtcagaag gttgttttat acgagaacag gcagaaagtgcccattgttc 4680 aggattctaa tagctacatc tacttaatat cttcatttct aaattgactgcttttacctt 4740 tttctcatgt ttatataatg gtatgcttgc atatatttca tgaatacattgtacatatta 4800 tgttaatatt tacacaattt aaaatataga tgtgttttat tttgaagtgagaaaatgaac 4860 attaacaggc atgtttgtac agctagaata tattagtaag atactgtttttcgtcattcc 4920 agagctacaa ctaataacac gaggttccaa agctgaagac tttgtataaagtatttgggt 4980 tttgttcttg tattgctttc tttcaacagt ttcaaaataa aatatcatacaaatattgag 5040 ggaaatgttt tcatattttt caaaataggt ttttattgtt gaatgtacatctaccccagc 5100 ccctcaaaag aaaaactgtt tacatagaaa ttcctacaca tacgtttgcgtatatgttat 5160 tttaaacatc tttgtggtga gaattttttc cccgatattc tccttctgtcaaagtcagaa 5220 caaattcagg gaatttattt tctggcagtt gtgctccagt ccttttaaaattgtacatga 5280 acatgtttta gaaacaatat ggaggatgat gcatacatgt cggtcaagttcagcgctcga 5340 cattttatgg aaagattttt ttaaccttac cacgaaatac ttaactactgtttaagtgaa 5400 ttgacttatt tcactttagt ttttgaactg tgattattgg tatactgttatatcctcaac 5460 ttggatttat ggtaacccct tttagttcat ggagaccaaa atttggggtatttataatag 5520 tcagcgcagg aatgcacatg gaatatctac ttgtcctttt gaacctcacgagtcatccag 5580 aatgtataga caggaaaagc atgtcttatt taaaactgta atttatgggctcaggatctg 5640 accgcagtcc cgggagtaag catttcaaag ggggaaggca gtgtggtccctaccctgtgt 5700 gaatgtgagg atgtagacat ccatcagtgc aactcgagct ccatcctcctccgatttcta 5760 aggctccagt tttctggagg gacagtcatc atgttttgat ttatctgggagaaaactgtg 5820 gtgcacagct tgtgaggagg gcaaggttgt gacgttcgag cttagttctggtgttattct 5880 gtctcctctt ctttgtcatc agccaaaacg tggtttttaa agagagtcatgcaggttaga 5940 aataatgtca aaaatattta ggaatttaat aacctttaag tcagaaactaaaacaaatac 6000 tgaaatatta gctcttccta cacttcgtgt tcccctttag ctgcctgaaaatcaagattg 6060 ctcctactca gatcttctga gtggctaaaa cttatggata tgaaaaatgagattgaatga 6120 tgactatgct ttgctatcat tgttaccttt cctcaatact atttggcaactactgggact 6180 cttcagcaca aaaggaatag atctatgatt gaccctgatt ttaattgtgaaattatatga 6240 ttcatatatt ttatgaatca gaataacctt caaataaaat aaatctaagtcggttaaaat 6300 ggatttcatg attttccctc agaaaatgag taacggagtc cacggcgtgcaatggtaatt 6360 ataaattggt gatgcttgtt tgcaaattgc ccactcgtga taagtcaacagccaatattt 6420 aaaactttgt tcgttactgg ctttacccta actttctcta gtctactgtcaatatcattt 6480 taatgtaatt gattgtatat agtctcaaga atggttggtg ggcatgagttcctagagaac 6540 tgtccaaggg ttgggaaaat ccaaattctc ttcctggctc cagcactgattttgtacata 6600 aacattaggc aggttgctta acctttttat ttcaaactct ctcaactctaaagtgctaat 6660 aataatctca gttaccttat ctttgtcaca gggtgttctt ttttatgaagaaaaatttga 6720 aaatgataaa agctaagatg ccttctaact tcataagcaa acctttaactaattatgtat 6780 ctgaaagtca cccccacata ccaactcaac ttttttcctg tgaacacataaatatatttt 6840 tatagaaaaa caaatctaca taaaataaat ctactgttta gtgagcagtatgacttgtac 6900 atgccattga aaattattaa tcagaagaaa attaagcagg gtctttgctatacaaaagtg 6960 ttttccacta attttgcatg cgtatttata agaaaaatgt gaatttggtggttttattct 7020 atcggtataa aggcatcgat attttagatg cacccgtgtt tgtaaaaatgtagagcacaa 7080 tggaattatg ctggaagtct caaataatat ttttttccta ttttatactcatggaagaga 7140 taagctaaag aggggacaat aatgagaaat gttggtgtgc ttttctaagcatttaaaaca 7200 taattgccaa ttgaaaccct aaatatgttt acataccatt aagatatgattcatgtaaca 7260 atgttaaatt aattataatg ggattgggtt tgttatctgt ggtagtatatatcctagtgt 7320 tcctatagtg aaataagtag ggttcagcca aagctttctt tgttttgtaccttaaattgt 7380 tcgattacgt catcaaaaga gatgaaaggt atgtagaaca ggttcacgtgattacctttt 7440 tcttttggct tggattaata ttcatagtag aactttataa aacgtgtttgtattgtaggt 7500 ggtgtttgta ttatgcttat gactatgtat ggtttgaaaa tattttcattatacatgaaa 7560 ttcaactttc caaataaaag ttctacttca tgtaatccaaaa                    7602

TABLE LIIId Nucleotide sequence alignment of 282P1G03 v.1 (SEQ ID NO:170) and 282P1G03 v.5 (SEQ ID NO: 171)

TABLE LIVd Peptide sequences of protein coded by 282P1G03 v.5 (SEQ IDNO: 172) MEPLLLGRGL IVYLMFLLLK FSKAIEIPSS VQQVPTIIKQ SKVQVAFPFDEYFQIECEAK   60 GNPEPTFSWT KDGNPFYFTD HRIIPSNNSG TFRIPNEGHI SHFQGKYRCFASNKLGIAMS  120 EEIEFIVPSV PKLPKEKIDP LEVEEGDPIV LPCNPPKGLP PLHIYWMNIELEHIEQDERV  180 YMSQKGDLYF ANVEEKDSRN DYCCFAAFPR LRTIVQKMPM KLTVNSSNSIKQRKPKLLLP  240 PTESGSESSI TILKGEILLL ECFAEGLPTP QVDWNKIGGD LPKGRETKENYGKTLKIENV  300 SYQDKGNYRC TASNFLGTAT HDFHVIVEEP PRWTKKPQSA VYSTGSNGILLCEAEGEPQP  360 TIKWRVNGSP VDNHPFAGDV VFPREISFTN LQPNHTAVYQ CEASNVHGTILANANIDVVD  420 VRPLIQTKDG ENYATVVGYS AFLHCEFFAS PEAVVSWQKV EEVKPLEGRRYHIYENGTLQ  480 INRTTEEDAG SYSCWVENAI GKTAVTANLD IRNATKLRVS PKNPRIPKLHMLELHCESKC  540 DSHLKHSLKL SWSKDGEAFE INGTEDGRII IDGANLTISN VTLEDQGIYCCSAHTALDSA  600 ADITQVTVLD VPDPPENLHL SERQNRSVRL TWEAGADHNS NISEYIVEFEGNKEEPGRWE  660 ELTRVQGKKT TVILPLAPFV RYQFRVIAVN EVGRSQPSQP SDHHETPPAAPDRNPQNIRV  720 QASQPKEMII KWEPLKSMEQ NGPGLEYRVT WKPQGAPVEW EEETVTNHTLRVMTPAVYAP  780 YDVKVQAINQ LGSGPDPQSV TLYSGEDYPD TAPVIHGVDV INSTLVKVTWSTVPKDRVHG  840 RLKGYQINWW KTKSLLDGRT HPKEVNILRF SGQRNSGMVP SLDAFSEFHLTVLAYNSKGA  900 GPESEPYIFQ TPEGVPEQPT FLKVIKVDKD TATLSWGLPK KLNGNLTGYLLQYQIINDTY  960 EIGELNDINI TTPSKPSWHL SNLNATTKYK FYLRACTSQG CGKPITEESSTLGEGSKGIG 1020 KISGVNLTQK THPIEVFEPG AEHIVRLMTK NWGDNDSIFQ DVIETRGREYAGLYDDISTQ 1080 GWFIGLMCAI ALLTLLLLTV CFVKRNRGGK YSVKEKEDLH PDPEIQSVKDETFGEYSDSD 1140 EKPLKGSLRS LNRDMQPTES ADSLVEYGEG DHGLFSEDGS FIGAYAGSKEKGSVESNGSS 1200TATFPLRA                                                          1208

TABLE LVd Amino acid sequence alignment of 282P1G03 v.1 (SEQ ID NO: 173)and 282P1G03 v.5 (SEQ ID NO: 174)

TABLE LIIe Nucleotide sequence of transcript variant 282P1G03 v.6 (SEQID NO: 175) cggaccctgc gcgcccccgt cccggctccc ggccggctcg ggggagaaggcgcccgaggg   60 gaggcgccgg acagatcgcg tttcggaggc ggcgcaggtg ctgtaaactgcaaaccataa  120 tcctgtctta atactgcaaa caaatcatag tggaactaag gggaacttaatttactgttt  180 ccaggttaac taaggtctca gctgtaaacc aaaagtgaga ggagacattaagattttcat  240 tcttaccggg ttgtcttctt cctgaagagc aatggagccg cttttacttggaagaggact  300 aatcgtatat ctaatgttcc tcctgttaaa attctcaaaa gcaattgaaataccatcttc  360 agttcaacag gttccaacaa tcataaaaca gtcaaaagtc caagttgcctttcccttcga  420 tgagtatttt caaattgaat gtgaagctaa aggaaatcca gaaccaacattttcgtggac  480 taaggatggc aacccttttt atttcactga ccatcggata attccatcgaacaattcagg  540 aacattcagg atcccaaacg aggggcacat atctcacttt caagggaaataccgctgctt  600 tgcttcaaat aaactgggaa tcgttatgtc agaagaaata gaatttatagttccaaaatt  660 agaacacatc gaacaagatg aaagagtata catgagccaa aagggagatctatacttcgc  720 aaacgtggaa gaaaaggaca gtcgcaatga ctactgttgc tttgctgcatttccaagatt  780 aaggactatt gtacagaaaa tgccaatgaa actaacagtt aacagtttaaagcatgctaa  840 tgactcaagt tcatccacag aaattggttc caaggcaaat tccatcaagcaaagaaaacc  900 caaactgctg ttgcctccca ctgagagtgg cagtgagtct tcaattaccatcctcaaagg  960 ggaaatcttg ctgcttgagt gttttgctga aggcttgcca actccacaggttgattggaa 1020 caaaattggt ggtgacttac caaaggggag agaaacaaaa gaaaattatggcaagacttt 1080 gaagatagag aatgtctcct accaggacaa aggaaattat cgctgcacagccagcaattt 1140 cttgggaaca gccactcacg attttcacgt tatagtagaa gagcctcctcgctggacaaa 1200 gaagcctcag agtgctgtgt atagcaccgg aagcaatggc atcttgttatgtgaggctga 1260 aggagaacct caacccacaa tcaagtggag agtcaatggc tccccagttgacaatcatcc 1320 atttgctggt gatgttgtct tccccaggga aatcagtttt accaaccttcaaccaaatca 1380 tactgctgtg taccagtgtg aagcctcaaa tgtccatgga actatccttgccaatgccaa 1440 tattgatgtt gtggatgtcc gtccattgat acaaaccaaa gatggagaaaattacgctac 1500 agtggttggg tacagtgctt tcttacattg cgagttcttt gcttcacctgaggcagtcgt 1560 gtcctggcag aaggtggaag aagtgaaacc cctggagggc aggcggtatcatatctatga 1620 aaatggcaca ttgcagatca acagaaccac cgaagaagat gctgggtcttactcatgttg 1680 ggtagaaaat gctataggaa aaactgcagt cacagccaat ttggatattagaaatgctac 1740 aaaacttaga gtttctccta agaatcctcg tatccccaaa ttgcatatgcttgaattaca 1800 ttgtgaaagc aaatgtgact cacatttgaa acacagtttg aagttgtcctggagtaaaga 1860 tggagaagcc tttgaaatta atggcacaga agatggcagg ataattattgatggagctaa 1920 tttgaccata tctaatgtaa ctttagagga ccaaggtatt tactgctgttcagctcatac 1980 tgctctagac agtgctgccg atataactca agtaactgtt cttgatgttccggatccacc 2040 agaaaacctt cacttgtctg aaagacagaa caggagtgtt cggctgacctgggaagctgg 2100 agctgaccac aacagcaata ttagcgagta tattgttgaa tttgaaggaaacaaagaaga 2160 gcctggaagg tgggaggaac tgaccagagt ccaaggaaag aaaaccacagttatcttacc 2220 tttggctcca tttgtgagat accagttcag ggtcatagcc gtgaacgaagtagggagaag 2280 tcagcctagc cagccgtcag accatcatga aacaccacca gcagctccagataggaatcc 2340 acaaaacata agggttcaag cctctcaacc caaggaaatg attataaagtgggagccttt 2400 gaaatccatg gagcagaatg gaccaggcct agagtacaga gtgacctggaagccacaggg 2460 agccccagtg gagtgggaag aagaaacagt cacaaaccac acattgcgggtgatgacgcc 2520 tgctgtctat gccccttatg atgtcaaggt ccaggctatc aatcaactaggatctgggcc 2580 tgaccctcag tcagtgactc tctattctgg agaagactat cctgatacagctccagtgat 2640 ccatggggtg gacgttataa acagtacatt agttaaagtt acctggtcaacagttccaaa 2700 ggacagagta catggacgtc tgaaaggcta tcagataaat tggtggaaaacaaaaagtct 2760 gttggatgga agaacacatc ccaaagaagt gaacattcta agattttcaggacaaagaaa 2820 ctctggaatg gttccttcct tagatgcctt tagtgaattt catttaacagtcttagccta 2880 taactctaaa ggagctggtc ctgaaagtga gccttatata tttcaaacaccagaaggagt 2940 acctgaacag ccaacttttc taaaggtcat caaagttgat aaagacactgccactttatc 3000 ttggggacta cctaagaaat taaatggaaa cttaactggc tatcttttgcaatatcagat 3060 aataaatgac acctacgaga ttggagaatt aaatgatatt aacattacaactccatcaaa 3120 gcccagctgg cacctctcaa acctgaatgc aactaccaag tacaaattctacttgagggc 3180 ttgcacttca cagggctgtg gaaaaccgat cacggaggaa agctccaccttaggagaagg 3240 gagtaaaggt atcgggaaga tatcaggagt aaatcttact caaaagactcacccaataga 3300 ggtatttgag ccgggagctg aacatatagt tcgcctaatg actaagaattggggcgataa 3360 cgatagcatt tttcaagatg taattgagac aagagggaga gaatatgctggtttatatga 3420 tgacatctcc actcaaggct ggtttattgg actgatgtgt gcgattgctcttctcacact 3480 actattatta actgtttgct ttgtgaagag gaatagaggt ggaaagtactcagttaaaga 3540 aaaggaagat ttgcatccag acccagaaat tcagtcagta aaagatgaaacctttggtga 3600 atacagtgac agtgatgaaa agcctctcaa aggaagcctt cggtcccttaatagggatat 3660 gcagcctact gaaagtgctg acagcttagt cgaatacgga gagggagaccatggtctctt 3720 cagtgaagat ggatcattta ttggtgccta cgctggatct aaggagaagggatctgttga 3780 aagcaatgga agttctacag caacttttcc ccttcgggca taaacacaacatatgtaagc 3840 aacgctactg gttcacccca accttccata tttatctgtt caaaggagcaagaactttca 3900 tataggaata gaaacatgct ggccgaagat ttcatccaga agtcaacatcctgcaattat 3960 gttgaaaaga gtagtacttt cttcaaaata taaaatgcca agcacttcaggcctatgttt 4020 tgcttatatt gttttcaggt gctcaaaatg caaaacacaa aacaaatcctgcatttagat 4080 acacctcaac taaatccaaa gtccccattc agtatattcc atatttgcctgattttacta 4140 ttcggtgtgt ttgcatagat gttgctactt ggtgggtttt tctccgtatgcacattggta 4200 tacagtctct gagaactggc ttggtgactt tgcttcacta caggttaaaagaccataagc 4260 aaactggtta tttaaaatgt aaaaaggaat atgaaagtct tattaaaacacttcattgaa 4320 aatatacagt ctaaatttat tatttaaatt ttactagcaa aagtcttaggtgaacaatca 4380 actagtattt gttgagctcc tatttgccca gagatggtca tatttaaacagaagtatacg 4440 tttttcagtt tcaacatgaa tttttttatt tctgtcagtt atgacatccacgagcatcac 4500 tttttgtgtc tgtttttttt tttttcttgg actaaattca actgcatggaagcggtggtc 4560 agaaggttgt tttatacgag aacaggcaga aagtgcccat tgttcaggattctaatagct 4620 acatctactt aatatcttca tttctaaatt gactgctttt acctttttctcatgtttata 4680 taatggtatg cttgcatata tttcatgaat acattgtaca tattatgttaatatttacac 4740 aatttaaaat atagatgtgt tttattttga agtgagaaaa tgaacattaacaggcatgtt 4800 tgtacagcta gaatatatta gtaagatact gtttttcgtc attccagagctacaactaat 4860 aacacgaggt tccaaagctg aagactttgt ataaagtatt tgggttttgttcttgtattg 4920 ctttctttca acagtttcaa aataaaatat catacaaata ttgagggaaatgttttcata 4980 tttttcaaaa taggttttta ttgttgaatg tacatctacc ccagcccctcaaaagaaaaa 5040 ctgtttacat agaaattcct acacatacgt ttgcgtatat gttattttaaacatctttgt 5100 ggtgagaatt ttttccccga tattctcctt ctgtcaaagt cagaacaaattcagggaatt 5160 tattttctgg cagttgtgct ccagtccttt taaaattgta catgaacatgttttagaaac 5220 aatatggagg atgatgcata catgtcggtc aagttcagcg ctcgacattttatggaaaga 5280 tttttttaac cttaccacga aatacttaac tactgtttaa gtgaattgacttatttcact 5340 ttagtttttg aactgtgatt attggtatac tgttatatcc tcaacttggatttatggtaa 5400 ccccttttag ttcatggaga ccaaaatttg gggtatttat aatagtcagcgcaggaatgc 5460 acatggaata tctacttgtc cttttgaacc tcacgagtca tccagaatgtatagacagga 5520 aaagcatgtc ttatttaaaa ctgtaattta tgggctcagg atctgaccgcagtcccggga 5580 gtaagcattt caaaggggga aggcagtgtg gtccctaccc tgtgtgaatgtgaggatgta 5640 gacatccatc agtgcaactc gagctccatc ctcctccgat ttctaaggctccagttttct 5700 ggagggacag tcatcatgtt ttgatttatc tgggagaaaa ctgtggtgcacagcttgtga 5760 ggagggcaag gttgtgacgt tcgagcttag ttctggtgtt attctgtctcctcttctttg 5820 tcatcagcca aaacgtggtt tttaaagaga gtcatgcagg ttagaaataatgtcaaaaat 5880 atttaggaat ttaataacct ttaagtcaga aactaaaaca aatactgaaatattagctct 5940 tcctacactt cgtgttcccc tttagctgcc tgaaaatcaa gattgctcctactcagatct 6000 tctgagtggc taaaacttat ggatatgaaa aatgagattg aatgatgactatgctttgct 6060 atcattgtta cctttcctca atactatttg gcaactactg ggactcttcagcacaaaagg 6120 aatagatcta tgattgaccc tgattttaat tgtgaaatta tatgattcatatattttatg 6180 aatcagaata accttcaaat aaaataaatc taagtcggtt aaaatggatttcatgatttt 6240 ccctcagaaa atgagtaacg gagtccacgg cgtgcaatgg taattataaattggtgatgc 6300 ttgtttgcaa attgcccact cgtgataagt caacagccaa tatttaaaactttgttcgtt 6360 actggcttta ccctaacttt ctctagtcta ctgtcaatat cattttaatgtaattgattg 6420 tatatagtct caagaatggt tggtgggcat gagttcctag agaactgtccaagggttggg 6480 aaaatccaaa ttctcttcct ggctccagca ctgattttgt acataaacattaggcaggtt 6540 gcttaacctt tttatttcaa actctctcaa ctctaaagtg ctaataataatctcagttac 6600 cttatctttg tcacagggtg ttctttttta tgaagaaaaa tttgaaaatgataaaagcta 6660 agatgccttc taacttcata agcaaacctt taactaatta tgtatctgaaagtcaccccc 6720 acataccaac tcaacttttt tcctgtgaac acataaatat atttttatagaaaaacaaat 6780 ctacataaaa taaatctact gtttagtgag cagtatgact tgtacatgccattgaaaatt 6840 attaatcaga agaaaattaa gcagggtctt tgctatacaa aagtgttttccactaatttt 6900 gcatgcgtat ttataagaaa aatgtgaatt tggtggtttt attctatcggtataaaggca 6960 tcgatatttt agatgcaccc gtgtttgtaa aaatgtagag cacaatggaattatgctgga 7020 agtctcaaat aatatttttt tcctatttta tactcatgga agagataagctaaagagggg 7080 acaataatga gaaatgttgg tgtgcttttc taagcattta aaacataattgccaattgaa 7140 accctaaata tgtttacata ccattaagat atgattcatg taacaatgttaaattaatta 7200 taatgggatt gggtttgtta tctgtggtag tatatatcct agtgttcctatagtgaaata 7260 agtagggttc agccaaagct ttctttgttt tgtaccttaa attgttcgattacgtcatca 7320 aaagagatga aaggtatgta gaacaggttc acgtgattac ctttttcttttggcttggat 7380 taatattcat agtagaactt tataaaacgt gtttgtattg taggtggtgtttgtattatg 7440 cttatgacta tgtatggttt gaaaatattt tcattataca tgaaattcaactttccaaat 7500 aaaagttcta cttcatgtaatccaaaa                                     7527

TABLE LIIIe Nucleotide sequence alignment of 282P1G03 v.1 (SEQ ID NO:176) and 282P1G03 v.6 (SEQ ID NO: 177)

TABLE LIVe Peptide sequences of protein coded by 282P1G03 v.6 (SEQ IDNO: 178) MEPLLLGRGL IVYLMFLLLK FSKAIEIPSS VQQVPTIIKQ SKVQVAFPFDEYFQIECEAK   60 GNPEPTFSWT KDGNPFYFTD HRIIPSNNSG TFRIPNEGHI SHFQGKYRCFASNKLGIAMS  120 EEIEFIVPKL EHIEQDERVY MSQKGDLYFA NVEEKDSRND YCCFAAFPRLRTIVQKMPMK  180 LTVNSLKHAN DSSSSTEIGS KANSIKQRKP KLLLPPTESG SESSITILKGEILLLECFAE  240 GLPTPQVDWN KIGGDLPKGR ETKENYGKTL KIENVSYQDK GNYRCTASNFLGTATHDFHV  300 IVEEPPRWTK KPQSAVYSTG SNGILLCEAE GEPQPTIKWR VNGSPVDNHPFAGDVVFPRE  360 ISFTNLQPNH TAVYQCEASN VHGTILANAN IDVVDVRPLI QTKDGENYATVVGYSAFLHC  420 EFFASPEAVV SWQKVEEVKP LEGRRYHIYE NGTLQINRTT EEDAGSYSCWVENAIGKTAV  480 TANLDIRNAT KLRVSPKNPR IPKLHMLELH CESKCDSHLK HSLKLSWSKDGEAFEINGTE  540 DGRIIIDGAN LTISNVTLED QGIYCCSAHT ALDSAADITQ VTVLDVPDPPENLHLSERQN  600 RSVRLTWEAG ADHNSNISEY IVEFEGNKEE PGRWEELTRV QGKKTTVILPLAPFVRYQFR  660 VIAVNEVGRS QPSQPSDHHE TPPAAPDRNP QNIRVQASQP KEMIIKWEPLKSMEQNGPGL  720 EYRVTWKPQG APVEWEEETV TNHTLRVMTP AVYAPYDVKV QAINQLGSGPDPQSVTLYSG  780 EDYPDTAPVI HGVDVINSTL VKVTWSTVPK DRVHGRLKGY QINWWKTKSLLDGRTHPKEV  840 NILRFSGQRN SGMVPSLDAF SEFHLTVLAY NSKGAGPESE PYIFQTPEGVPEQPTFLKVI  900 KVDKDTATLS WGLPKKLNGN LTGYLLQYQI INDTYEIGEL NDINITTPSKPSWHLSNLNA  960 TTKYKFYLRA CTSQGCGKPI TEESSTLGEG SKGIGKISGV NLTQKTHPIEVFEPGAEHIV 1020 RLMTKNWGDN DSIFQDVIET RGREYAGLYD DISTQGWFIG LMCAIALLTLLLLTVCFVKR 1080 NRGGKYSVKE KEDLHPDPEI QSVKDETFGE YSDSDEKPLK GSLRSLNRDMQPTESADSLV 1140 EYGEGDHGLF SEDGSFIGAY AGSKEKGSVE SNGSSTATFPLRA                   1183

TABLE LVe Amino acid sequence alignment of 282P1G03 v.1 (SEQ ID NO: 179)and 282P1G03 v.6 (SEQ ID NO: 180)

TABLE LIIf Nucleotide sequence of transcript variant 282P1G03 v.7 (SEQID NO: 181) cggaccctgc gcgcccccgt cccggctccc ggccggctcg ggggagaaggcgcccgaggg 60 gaggcgccgg acagatcgcg tttcggaggc ggcgcaggtg ctgtaaactgcaaaccataa 120 tcctgtctta atactgcaaa caaatcatag tggaactaag gggaacttaatttactgttt 180 ccaggttaac taaggtctca gctgtaaacc aaaagtgaga ggagacattaagattttcat 240 tcttaccggg ttgtcttctt cctgaagagc aatggagccg cttttacttggaagaggact 300 aatcgtatat ctaatgttcc tcctgttaaa attctcaaaa gcaattgaaataccatcttc 360 agttcaacag gttccaacaa tcataaaaca gtcaaaagtc caagttgcctttcccttcga 420 tgagtatttt caaattgaat gtgaagctaa aggaaatcca gaaccaacattttcgtggac 480 taaggatggc aacccttttt atttcactga ccatcggata attccatcgaacaattcagg 540 aacattcagg atcccaaacg aggggcacat atctcacttt caagggaaataccgctgctt 600 tgcttcaaat aaactgggaa tcgctatgtc agaagaaata gaatttatagttccaagtgt 660 tccaaaactc ccaaaagaaa aaattgaccc tcttgaagtg gaggagggagatccaattgt 720 cctcccatgc aatcctccca aaggcctccc acctttacac atttattggatgaatattga 780 attagaacac atcgaacaag atgaaagagt atacatgagc caaaagggagatctatactt 840 cgcaaacgtg gaagaaaagg acagtcgcaa tgactactgt tgctttgctgcatttccaag 900 attaaggact attgtacaga aaatgccaat gaaactaaca gttaacagtttaaagcatgc 960 taatgactca agttcatcca cagaaattgg ttccaaggca aattccatcaagcaaagaaa 1020 acccaaactg ctgttgcctc ccactgagag tggcagtgag tcttcaattaccatcctcaa 1080 aggggaaatc ttgctgcttg agtgttttgc tgaaggcttg ccaactccacaggttgattg 1140 gaacaaaatt ggtggtgact taccaaaggg gagagaaaca aaagaaaattatggcaagac 1200 tttgaagata gagaatgtct cctaccagga caaaggaaat tatcgctgcacagccagcaa 1260 tttcttggga acagccactc acgattttca cgttatagta gaagataacatctctcatga 1320 gctcttcact ttacatccag agcctcctcg ctggacaaag aagcctcagagtgctgtgta 1380 tagcaccgga agcaatggca tcttgttatg tgaggctgaa ggagaacctcaacccacaat 1440 caagtggaga gtcaatggct ccccagttga caatcatcca tttgctggtgatgttgtctt 1500 ccccagggaa atcagtttta ccaaccttca accaaatcat actgctgtgtaccagtgtga 1560 agcctcaaat gtccatggaa ctatccttgc caatgccaat attgatgttgtggatgtccg 1620 tccattgata caaaccaaag atggagaaaa ttacgctaca gtggttgggtacagtgcttt 1680 cttacattgc gagttctttg cttcacctga ggcagtcgtg tcctggcagaaggtggaaga 1740 agtgaaaccc ctggagggca ggcggtatca tatctatgaa aatggcacattgcagatcaa 1800 cagaaccacc gaagaagatg ctgggtctta ctcatgttgg gtagaaaatgctataggaaa 1860 aactgcagtc acagccaatt tggatattag aaatgctaca aaacttagagtttctcctaa 1920 gaatcctcgt atccccaaat tgcatatgct tgaattacat tgtgaaagcaaatgtgactc 1980 acatttgaaa cacagtttga agttgtcctg gagtaaagat ggagaagcctttgaaattaa 2040 tggcacagaa gatggcagga taattattga tggagctaat ttgaccatatctaatgtaac 2100 tttagaggac caaggtattt actgctgttc agctcatact gctctagacagtgctgccga 2160 tataactcaa gtaactgttc ttgatgttcc ggatccacca gaaaaccttcacttgtctga 2220 aagacagaac aggagtgttc ggctgacctg ggaagctgga gctgaccacaacagcaatat 2280 tagcgagtat attgttgaat ttgaaggaaa caaagaagag cctggaaggtgggaggaact 2340 gaccagagtc caaggaaaga aaaccacagt tatcttacct ttggctccatttgtgagata 2400 ccagttcagg gtcatagccg tgaacgaagt agggagaagt cagcctagccagccgtcaga 2460 ccatcatgaa acaccaccag cagctccaga taggaatcca caaaacataagggttcaagc 2520 ctctcaaccc aaggaaatga ttataaagtg ggagcctttg aaatccatggagcagaatgg 2580 accaggccta gagtacagag tgacctggaa gccacaggga gccccagtggagtgggaaga 2640 agaaacagtc acaaaccaca cattgcgggt gatgacgcct gctgtctatgccccttatga 2700 tgtcaaggtc caggctatca atcaactagg atctgggcct gaccctcagtcagtgactct 2760 ctattctgga gaagactatc ctgatacagc tccagtgatc catggggtggacgttataaa 2820 cagtacatta gttaaagtta cctggtcaac agttccaaag gacagagtacatggacgtct 2880 gaaaggctat cagataaatt ggtggaaaac aaaaagtctg ttggatggaagaacacatcc 2940 caaagaagtg aacattctaa gattttcagg acaaagaaac tctggaatggttccttcctt 3000 agatgccttt agtgaatttc atttaacagt cttagcctat aactctaaaggagctggtcc 3060 tgaaagtgag ccttatatat ttcaaacacc agaaggagta cctgaacagccaacttttct 3120 aaaggtcatc aaagttgata aagacactgc cactttatct tggggactacctaagaaatt 3180 aaatggaaac ttaactggct atcttttgca atatcagata ataaatgacacctacgagat 3240 tggagaatta aatgatatta acattacaac tccatcaaag cccagctggcacctctcaaa 3300 cctgaatgca actaccaagt acaaattcta cttgagggct tgcacttcacagggctgtgg 3360 aaaaccgatc acggaggaaa gctccacctt aggagaaggg agtaaaggtatcgggaagat 3420 atcaggagta aatcttactc aaaagactca cccaatagag gtatttgagccgggagctga 3480 acatatagtt cgcctaatga ctaagaattg gggcgataac gatagcatttttcaagatgt 3540 aattgagaca agagggagag aatatgctgg tttatatgat gacatctccactcaaggctg 3600 gtttattgga ctgatgtgtg cgattgctct tctcacacta ctattattaactgtttgctt 3660 tgtgaagagg aatagaggtg gaaagtactc agttaaagaa aaggaagatttgcatccaga 3720 cccagaaatt cagtcagtaa aagatgaaac ctttggtgaa tacagtgacagtgatgaaaa 3780 gcctctcaaa ggaagccttc ggtcccttaa tagggatatg cagcctactgaaagtgctga 3840 cagcttagtc gaatacggag agggagacca tggtctcttc agtgaagatggatcatttat 3900 tggtgcctac gctggatcta aggagaaggg atctgttgaa agcaatggaagttctacagc 3960 aacttttccc cttcgggcat aaacacaaca tatgtaagca acgctactggttcaccccaa 4020 ccttccatat ttatctgttc aaaggagcaa gaactttcat ataggaatagaaacatgctg 4080 gccgaagatt tcatccagaa gtcaacatcc tgcaattatg ttgaaaagagtagtactttc 4140 ttcaaaatat aaaatgccaa gcacttcagg cctatgtttt gcttatattgttttcaggtg 4200 ctcaaaatgc aaaacacaaa acaaatcctg catttagata cacctcaactaaatccaaag 4260 tccccattca gtatattcca tatttgcctg attttactat tcggtgtgtttgcatagatg 4320 ttgctacttg gtgggttttt ctccgtatgc acattggtat acagtctctgagaactggct 4380 tggtgacttt gcttcactac aggttaaaag accataagca aactggttatttaaaatgta 4440 aaaaggaata tgaaagtctt attaaaacac ttcattgaaa atatacagtctaaatttatt 4500 atttaaattt tactagcaaa agtcttaggt gaacaatcaa ctagtatttgttgagctcct 4560 atttgcccag agatggtcat atttaaacag aagtatacgt ttttcagtttcaacatgaat 4620 ttttttattt ctgtcagtta tgacatccac gagcatcact ttttgtgtctgttttttttt 4680 ttttcttgga ctaaattcaa ctgcatggaa gcggtggtca gaaggttgttttatacgaga 4740 acaggcagaa agtgcccatt gttcaggatt ctaatagcta catctacttaatatcttcat 4800 ttctaaattg actgctttta cctttttctc atgtttatat aatggtatgcttgcatatat 4860 ttcatgaata cattgtacat attatgttaa tatttacaca atttaaaatatagatgtgtt 4920 ttattttgaa gtgagaaaat gaacattaac aggcatgttt gtacagctagaatatattag 4980 taagatactg tttttcgtca ttccagagct acaactaata acacgaggttccaaagctga 5040 agactttgta taaagtattt gggttttgtt cttgtattgc tttctttcaacagtttcaaa 5100 ataaaatatc atacaaatat tgagggaaat gttttcatat ttttcaaaataggtttttat 5160 tgttgaatgt acatctaccc cagcccctca aaagaaaaac tgtttacatagaaattccta 5220 cacatacgtt tgcgtatatg ttattttaaa catctttgtg gtgagaattttttccccgat 5280 attctccttc tgtcaaagtc agaacaaatt cagggaattt attttctggcagttgtgctc 5340 cagtcctttt aaaattgtac atgaacatgt tttagaaaca atatggaggatgatgcatac 5400 atgtcggtca agttcagcgc tcgacatttt atggaaagat ttttttaaccttaccacgaa 5460 atacttaact actgtttaag tgaattgact tatttcactt tagtttttgaactgtgatta 5520 ttggtatact gttatatcct caacttggat ttatggtaac cccttttagttcatggagac 5580 caaaatttgg ggtatttata atagtcagcg caggaatgca catggaatatctacttgtcc 5640 ttttgaacct cacgagtcat ccagaatgta tagacaggaa aagcatgtcttatttaaaac 5700 tgtaatttat gggctcagga tctgaccgca gtcccgggag taagcatttcaaagggggaa 5760 ggcagtgtgg tccctaccct gtgtgaatgt gaggatgtag acatccatcagtgcaactcg 5820 agctccatcc tcctccgatt tctaaggctc cagttttctg gagggacagtcatcatgttt 5880 tgatttatct gggagaaaac tgtggtgcac agcttgtgag gagggcaaggttgtgacgtt 5940 cgagcttagt tctggtgtta ttctgtctcc tcttctttgt catcagccaaaacgtggttt 6000 ttaaagagag tcatgcaggt tagaaataat gtcaaaaata tttaggaatttaataacctt 6060 taagtcagaa actaaaacaa atactgaaat attagctctt cctacacttcgtgttcccct 6120 ttagctgcct gaaaatcaag attgctccta ctcagatctt ctgagtggctaaaacttatg 6180 gatatgaaaa atgagattga atgatgacta tgctttgcta tcattgttacctttcctcaa 6240 tactatttgg caactactgg gactcttcag cacaaaagga atagatctatgattgaccct 6300 gattttaatt gtgaaattat atgattcata tattttatga atcagaataaccttcaaata 6360 aaataaatct aagtcggtta aaatggattt catgattttc cctcagaaaatgagtaacgg 6420 agtccacggc gtgcaatggt aattataaat tggtgatgct tgtttgcaaattgcccactc 6480 gtgataagtc aacagccaat atttaaaact ttgttcgtta ctggctttaccctaactttc 6540 tctagtctac tgtcaatatc attttaatgt aattgattgt atatagtctcaagaatggtt 6600 ggtgggcatg agttcctaga gaactgtcca agggttggga aaatccaaattctcttcctg 6660 gctccagcac tgattttgta cataaacatt aggcaggttg cttaacctttttatttcaaa 6720 ctctctcaac tctaaagtgc taataataat ctcagttacc ttatctttgtcacagggtgt 6780 tcttttttat gaagaaaaat ttgaaaatga taaaagctaa gatgccttctaacttcataa 6840 gcaaaccttt aactaattat gtatctgaaa gtcaccccca cataccaactcaactttttt 6900 cctgtgaaca cataaatata tttttataga aaaacaaatc tacataaaataaatctactg 6960 tttagtgagc agtatgactt gtacatgcca ttgaaaatta ttaatcagaagaaaattaag 7020 cagggtcttt gctatacaaa agtgttttcc actaattttg catgcgtatttataagaaaa 7080 atgtgaattt ggtggtttta ttctatcggt ataaaggcat cgatattttagatgcacccg 7140 tgtttgtaaa aatgtagagc acaatggaat tatgctggaa gtctcaaataatattttttt 7200 cctattttat actcatggaa gagataagct aaagagggga caataatgagaaatgttggt 7260 gtgcttttct aagcatttaa aacataattg ccaattgaaa ccctaaatatgtttacatac 7320 cattaagata tgattcatgt aacaatgtta aattaattat aatgggattgggtttgttat 7380 ctgtggtagt atatatccta gtgttcctat agtgaaataa gtagggttcagccaaagctt 7440 tctttgtttt gtaccttaaa ttgttcgatt acgtcatcaa aagagatgaaaggtatgtag 7500 aacaggttca cgtgattacc tttttctttt ggcttggatt aatattcatagtagaacttt 7560 ataaaacgtg tttgtattgt aggtggtgtt tgtattatgc ttatgactatgtatggtttg 7620 aaaatatttt cattatacat gaaattcaac tttccaaata aaagttctacttcatgtaat 7680 ccaaaa 7686

TABLE LIIIf Nucleotide sequence alignment of 282P1G03 v.1 (SEQ ID NO:182) and 282P1G03 v.7 (SEQ ID NO: 183)

TABLE LIVf Peptide sequences of protein coded by 282P1G03 v.7 (SEQ IDNO: 184) MEPLLLGRGL IVYLMFLLLK FSKAIEIPSS VQQVPTIIKQ SKVQVAFPFDEYFQIECEAK 60 GNPEPTFSWT KDGNPFYFTD HRIIPSNNSG TFRIPNEGHI SHFQGKYRCFASNKLGIAMS 120 EEIEFIVPSV PKLPKEKIDP LEVEEGDPIV LPCNPPKGLP PLHIYWMNIELEHIEQDERV 180 YMSQKGDLYF ANVEEKDSRN DYCCFAAFPR LRTIVQKMPM KLTVNSLKHANDSSSSTEIG 240 SKANSIKQRK PKLLLPPTES GSESSITILK GEILLLECFA EGLPTPQVDWNKIGGDLPKG 300 RETKENYGKT LKIENVSYQD KGNYRCTASN FLGTATHDFH VIVEDNISHELFTLHPEPPR 360 WTKKPQSAVY STGSNGILLC EAEGEPQPTI KWRVNGSPVD NHPFAGDVVFPREISFTNLQ 420 PNHTAVYQCE ASNVHGTILA NANIDVVDVR PLIQTKDGEN YATVVGYSAFLHCEFFASPE 480 AVVSWQKVEE VKPLEGRRYH IYENGTLQIN RTTEEDAGSY SCWVENAIGKTAVTANLDIR 540 NATKLRVSPK NPRIPKLHML ELHCESKCDS HLKHSLKLSW SKDGEAFEINGTEDGRIIID 600 GANLTISNVT LEDQGIYCCS AHTALDSAAD ITQVTVLDVP DPPENLHLSERQNRSVRLTW 660 EAGADHNSNI SEYIVEFEGN KEEPGRWEEL TRVQGKKTTV ILPLAPFVRYQFRVIAVNEV 720 GRSQPSQPSD HHETPPAAPD RNPQNIRVQA SQPKEMIIKW EPLKSMEQNGPGLEYRVTWK 780 PQGAPVEWEE ETVTNHTLRV MTPAVYAPYD VKVQAINQLG SGPDPQSVTLYSGEDYPDTA 840 PVIHGVDVIN STLVKVTWST VPKDRVHGRL KGYQINWWKT KSLLDGRTHPKEVNILRFSG 900 QRNSGMVPSL DAFSEFHLTV LAYNSKGAGP ESEPYIFQTP EGVPEQPTFLKVIKVDKDTA 960 TLSWGLPKKL NGNLTGYLLQ YQIINDTYEI GELNDINITT PSKPSWHLSNLNATTKYKFY 1020 LRACTSQGCG KPITEESSTL GEGSKGIGKI SGVNLTQKTH PIEVFEPGAEHIVRLMTKNW 1080 GDNDSIFQDV IETRGREYAG LYDDISTQGW FIGLMCAIAL LTLLLLTVCFVKRNRGGKYS 1140 VKEKEDLHPD PEIQSVKDET FGEYSDSDEK PLKGSLRSLN RDMQPTESADSLVEYGEGDH 1200 GLFSEDGSFI GAYAGSKEKG SVESNGSSTA TFPLRA 1236

TABLE LVf Amino acid sequence alignment of 282P1G03 v.1 (SEQ ID NO: 185)and 282P1G03 v.7 (SEQ ID NO: 186)

TABLE LIIg Nucleotide sequence of transcript variant 282P1G03 v.8 (SEQID NO: 187) cggaccctgc gcgcccccgt cccggctccc ggccggctcg ggggagaaggcgcccgaggg 60 gaggcgccgg acagatcgcg tttcggaggc ggcgcaggtg ctgtaaactgcaaaccataa 120 tcctgtctta atactgcaaa caaatcatag tggaactaag gggaacttaatttactgttt 180 ccaggttaac taaggtctca gctgtaaacc aaaagtgaga ggagacattaagattttcat 240 tcttaccggg ttgtcttctt cctgaagagc aatggagccg cttttacttggaagaggact 300 aatcgtatat ctaatgttcc tcctgttaaa attctcaaaa gcaattgaaataccatcttc 360 agttcaacag gttccaacaa tcataaaaca gtcaaaagtc caagttgcctttcccttcga 420 tgagtatttt caaattgaat gtgaagctaa aggaaatcca gaaccaacattttcgtggac 480 taaggatggc aacccttttt atttcactga ccatcggata attccatcgaacaattcagg 540 aacattcagg atcccaaacg aggggcacat atctcacttt caagggaaataccgctgctt 600 tgcttcaaat aaactgggaa tcgctatgtc agaagaaata gaatttatagttccaaaatt 660 agaacacatc gaacaagatg aaagagtata catgagccaa aagggagatctatacttcgc 720 aaacgtggaa gaaaaggaca gtcgcaatga ctactgttgc tttgctgcatttccaagatt 780 aaggactatt gtacagaaaa tgccaatgaa actaacagtt aacagtttaaagcatgctaa 840 tgactcaagt tcatccacag aaattggttc caaggcaaat tccatcaagcaaagaaaacc 900 caaactgctg ttgcctccca ctgagagtgg cagtgagtct tcaattaccatcctcaaagg 960 ggaaatcttg ctgcttgagt gttttgctga aggcttgcca actccacaggttgattggaa 1020 caaaattggt ggtgacttac caaaggggag agaaacaaaa gaaaattatggcaagacttt 1080 gaagatagag aatgtctcct accaggacaa aggaaattat cgctgcacagccagcaattt 1140 cttgggaaca gccactcacg attttcacgt tatagtagaa gataacatctctcatgagct 1200 cttcacttta catccagagc ctcctcgctg gacaaagaag cctcagagtgctgtgtatag 1260 caccggaagc aatggcatct tgttatgtga ggctgaagga gaacctcaacccacaatcaa 1320 gtggagagtc aatggctccc cagttgacaa tcatccattt gctggtgatgttgtcttccc 1380 cagggaaatc agttttacca accttcaacc aaatcatact gctgtgtaccagtgtgaagc 1440 ctcaaatgtc catggaacta tccttgccaa tgccaatatt gatgttgtggatgtccgtcc 1500 attgatacaa accaaagatg gagaaaatta cgctacagtg gttgggtacagtgctttctt 1560 acattgcgag ttctttgctt cacctgaggc agtcgtgtcc tggcagaaggtggaagaagt 1620 gaaacccctg gagggcaggc ggtatcatat ctatgaaaat ggcacattgcagatcaacag 1680 aaccaccgaa gaagatgctg ggtcttactc atgttgggta gaaaatgctataggaaaaac 1740 tgcagtcaca gccaatttgg atattagaaa tgctacaaaa cttagagtttctcctaagaa 1800 tcctcgtatc cccaaattgc atatgcttga attacattgt gaaagcaaatgtgactcaca 1860 tttgaaacac agtttgaagt tgtcctggag taaagatgga gaagcctttgaaattaatgg 1920 cacagaagat ggcaggataa ttattgatgg agctaatttg accatatctaatgtaacttt 1980 agaggaccaa ggtatttact gctgttcagc tcatactgct ctagacagtgctgccgatat 2040 aactcaagta actgttcttg atgttccgga tccaccagaa aaccttcacttgtctgaaag 2100 acagaacagg agtgttcggc tgacctggga agctggagct gaccacaacagcaatattag 2160 cgagtatatt gttgaatttg aaggaaacaa agaagagcct ggaaggtgggaggaactgac 2220 cagagtccaa ggaaagaaaa ccacagttat cttacctttg gctccatttgtgagatacca 2280 gttcagggtc atagccgtga acgaagtagg gagaagtcag cctagccagccgtcagacca 2340 tcatgaaaca ccaccagcag ctccagatag gaatccacaa aacataagggttcaagcctc 2400 tcaacccaag gaaatgatta taaagtggga gcctttgaaa tccatggagcagaatggacc 2460 aggcctagag tacagagtga cctggaagcc acagggagcc ccagtggagtgggaagaaga 2520 aacagtcaca aaccacacat tgcgggtgat gacgcctgct gtctatgccccttatgatgt 2580 caaggtccag gctatcaatc aactaggatc tgggcctgac cctcagtcagtgactctcta 2640 ttctggagaa gactatcctg atacagctcc agtgatccat ggggtggacgttataaacag 2700 tacattagtt aaagttacct ggtcaacagt tccaaaggac agagtacatggacgtctgaa 2760 aggctatcag ataaattggt ggaaaacaaa aagtctgttg gatggaagaacacatcccaa 2820 agaagtgaac attctaagat tttcaggaca aagaaactct ggaatggttccttccttaga 2880 tgcctttagt gaatttcatt taacagtctt agcctataac tctaaaggagctggtcctga 2940 aagtgagcct tatatatttc aaacaccaga aggagtacct gaacagccaacttttctaaa 3000 ggtcatcaaa gttgataaag acactgccac tttatcttgg ggactacctaagaaattaaa 3060 tggaaactta actggctatc ttttgcaata tcagataata aatgacacctacgagattgg 3120 agaattaaat gatattaaca ttacaactcc atcaaagccc agctggcacctctcaaacct 3180 gaatgcaact accaagtaca aattctactt gagggcttgc acttcacagggctgtggaaa 3240 accgatcacg gaggaaagct ccaccttagg agaagggagt aaaggtatcgggaagatatc 3300 aggagtaaat cttactcaaa agactcaccc aatagaggta tttgagccgggagctgaaca 3360 tatagttcgc ctaatgacta agaattgggg cgataacgat agcatttttcaagatgtaat 3420 tgagacaaga gggagagaat atgctggttt atatgatgac atctccactcaaggctggtt 3480 tattggactg atgtgtgcga ttgctcttct cacactacta ttattaactgtttgctttgt 3540 gaagaggaat agaggtggaa agtactcagt taaagaaaag gaagatttgcatccagaccc 3600 agaaattcag tcagtaaaag atgaaacctt tggtgaatac agtgacagtgatgaaaagcc 3660 tctcaaagga agccttcggt cccttaatag ggatatgcag cctactgaaagtgctgacag 3720 cVtagtcgaa tacggagagg gagaccatgg tctcttcagt gaagatggatcatttattgg 3780 tgcctacgct ggatctaagg agaagggatc tgttgaaagc aatggaagttctacagcaac 3840 ttttcccctt cgggcataaa cacaacatat gtaagcaacg ctactggttcaccccaacct 3900 tccatattta tctgttcaaa ggagcaagaa ctttcatata ggaatagaaacatgctggcc 3960 gaagatttca tccagaagtc aacatcctgc aattatgttg aaaagagtagtactttcttc 4020 aaaatataaa atgccaagca cttcaggcct atgttttgct tatattgttttcaggtgctc 4080 aaaatgcaaa acacaaaaca aatcctgcat ttagatacac ctcaactaaatccaaagtcc 4140 ccattcagta tattccatat ttgcctgatt ttactattcg gtgtgtttgcatagatgttg 4200 ctacttggtg ggtttttctc cgtatgcaca ttggtataca gtctctgagaactggcttgg 4260 tgactttgct tcactacagg ttaaaagacc ataagcaaac tggttatttaaaatgtaaaa 4320 aggaatatga aagtcttatt aaaacacttc attgaaaata tacagtctaaatttattatt 4380 taaattttac tagcaaaagt cttaggtgaa caatcaacta gtatttgttgagctcctatt 4440 tgcccagaga tggtcatatt taaacagaag tatacgtttt tcagtttcaacatgaatttt 4500 tttatttctg tcagttatga catccacgag catcactttt tgtgtctgtttttttttttt 4560 tcttggacta aattcaactg catggaagcg gtggtcagaa ggttgttttatacgagaaca 4620 ggcagaaagt gcccattgtt caggattcta atagctacat ctacttaatatcttcatttc 4680 taaattgact gcttttacct ttttctcatg tttatataat ggtatgcttgcatatatttc 4740 atgaatacat tgtacatatt atgttaatat ttacacaatt taaaatatagatgtgtttta 4800 ttttgaagtg agaaaatgaa cattaacagg catgtttgta cagctagaatatattagtaa 4860 gatactgttt ttcgtcattc cagagctaca actaataaca cgaggttccaaagctgaaga 4920 ctttgtataa agtatttggg ttttgttctt gtattgcttt ctttcaacagtttcaaaata 4980 aaatatcata caaatattga gggaaatgtt ttcatatttt tcaaaataggtttttattgt 5040 tgaatgtaca tctaccccag cccctcaaaa gaaaaactgt ttacatagaaattcctacac 5100 atacgtttgc gtatatgtta ttttaaacat ctttgtggtg agaattttttccccgatatt 5160 ctccttctgt caaagtcaga acaaattcag ggaatttatt ttctggcagttgtgctccag 5220 tccttttaaa attgtacatg aacatgtttt agaaacaata tggaggatgatgcatacatg 5280 tcggtcaagt tcagcgctcg acattttatg gaaagatttt tttaaccttaccacgaaata 5340 cttaactact gtttaagtga attgacttat ttcactttag tttttgaactgtgattattg 5400 gtatactgtt atatcctcaa cttggattta tggtaacccc ttttagttcatggagaccaa 5460 aatttggggt atttataata gtcagcgcag gaatgcacat ggaatatctacttgtccttt 5520 tgaacctcac gagtcatcca gaatgtatag acaggaaaag catgtcttatttaaaactgt 5580 aatttatggg ctcaggatct gaccgcagtc ccgggagtaa gcatttcaaagggggaaggc 5640 agtgtggtcc ctaccctgtg tgaatgtgag gatgtagaca tccatcagtgcaactcgagc 5700 tccatcctcc tccgatttct aaggctccag ttttctggag ggacagtcatcatgttttga 5760 tttatctggg agaaaactgt ggtgcacagc ttgtgaggag ggcaaggttgtgacgttcga 5820 gcttagttct ggtgttattc tgtctcctct tctttgtcat cagccaaaacgtggttttta 5880 aagagagtca tgcaggttag aaataatgtc aaaaatattt aggaatttaataacctttaa 5940 gtcagaaact aaaacaaata ctgaaatatt agctcttcct acacttcgtgttccccttta 6000 gctgcctgaa aatcaagatt gctcctactc agatcttctg agtggctaaaacttatggat 6060 atgaaaaatg agattgaatg atgactatgc tttgctatca ttgttacctttcctcaatac 6120 tatttggcaa ctactgggac tcttcagcac aaaaggaata gatctatgattgaccctgat 6180 tttaattgtg aaattatatg attcatatat tttatgaatc agaataaccttcaaataaaa 6240 taaatctaag tcggttaaaa tggatttcat gattttccct cagaaaatgagtaacggagt 6300 ccacggcgtg caatggtaat tataaattgg tgatgcttgt ttgcaaattgcccactcgtg 6360 ataagtcaac agccaatatt taaaactttg ttcgttactg gctttaccctaactttctct 6420 agtctactgt caatatcatt ttaatgtaat tgattgtata tagtctcaagaatggttggt 6480 gggcatgagt tcctagagaa ctgtccaagg gttgggaaaa tccaaattctcttcctggct 6540 ccagcactga ttttgtacat aaacattagg caggttgctt aacctttttatttcaaactc 6600 tctcaactct aaagtgctaa taataatctc agttacctta tctttgtcacagggtgttct 6660 tttttatgaa gaaaaatttg aaaatgataa aagctaagat gccttctaacttcataagca 6720 aacctttaac taattatgta tctgaaagtc acccccacat accaactcaacttttttcct 6780 gtgaacacat aaatatattt ttatagaaaa acaaatctac ataaaataaatctactgttt 6840 agtgagcagt atgacttgta catgccattg aaaattatta atcagaagaaaattaagcag 6900 ggtctttgct atacaaaagt gttttccact aattttgcat gcgtatttataagaaaaatg 6960 tgaatttggt ggttttattc tatcggtata aaggcatcga tattttagatgcacccgtgt 7020 ttgtaaaaat gtagagcaca atggaattat gctggaagtc tcaaataatatttttttcct 7080 attttatact catggaagag ataagctaaa gaggggacaa taatgagaaatgttggtgtg 7140 cttttctaag catttaaaac ataattgcca attgaaaccc taaatatgtttacataccat 7200 taagatatga ttcatgtaac aatgttaaat taattataat gggattgggtttgttatctg 7260 tggtagtata tatcctagtg ttcctatagt gaaataagta gggttcagccaaagctttct 7320 ttgttttgta ccttaaattg ttcgattacg tcatcaaaag agatgaaaggtatgtagaac 7380 aggttcacgt gattaccttt ttcttttggc ttggattaat attcatagtagaactttata 7440 aaacgtgttt gtattgtagg tggtgtttgt attatgctta tgactatgtatggtttgaaa 7500 atattttcat tatacatgaa attcaacttt ccaaataaaa gttctacttcatgtaatcca 7560 aaa 7563

TABLE LIIIg Nucleotide sequence alignment of 282P1G03 v.1 (SEQ ID NO:188) and 282P1G03 v.8 (SEQ ID NO: 189)

TABLE LIVg Peptide sequences of protein coded by 282P1G03 v.8 (SEQ IDNO: 190) MEPLLLGRGL IVYLMFLLLK FSKAIEIPSS VQQVPTIIKQ SKVQVAFPFDEYFQIECEAK 60 GNPEPTFSWT KDGNPFYFTD HRIIPSNNSG TFRIPNEGHI SHFQGKYRCFASNKLGIAMS 120 EEIEFIVPKL EHIEQDERVY MSQKGDLYFA NVEEKDSRND YCCFAAFPRLRTIVQKMPMK 180 LTVNSLKHAN DSSSSTEIGS KANSIKQRKP KLLLPPTESG SESSITILKGEILLLECFAE 240 GLPTPQVDWN KIGGDLPKGR ETKENYGKTL KIENVSYQDK GNYRCTASNFLGTATHDFHV 300 IVEDNISHEL FTLHPEPPRW TKKPQSAVYS TGSNGILLCE AEGEPQPTIKWRVNGSPVDN 360 HPFAGDVVFP REISFTNLQP NHTAVYQCEA SNVHGTILAN ANIDVVDVRPLIQTKDGENY 420 ATVVGYSAFL HCEFFASPEA VVSWQKVEEV KPLEGRRYHI YENGTLQINRTTEEDAGSYS 480 CWVENAIGKT AVTANLDIRN ATKLRVSPKN PRIPKLHMLE LHCESKCDSHLKHSLKLSWS 540 KDGEAFEING TEDGRIIIDG ANLTISNVTL EDQGIYCCSA HTALDSAADITQVTVLDVPD 600 PPENLHLSER QNRSVRLTWE AGADHNSNIS EYIVEFEGNK EEPGRWEELTRVQGKKTTVI 660 LPLAPFVRYQ FRVIAVNEVG RSQPSQPSDH HETPPAAPDR NPQNIRVQASQPKEMIIKWE 720 PLKSMEQNGP GLEYRVTWKP QGAPVEWEEE TVTNHTLRVM TPAVYAPYDVKVQAINQLGS 780 GPDPQSVTLY SGEDYPDTAP VIHGVDVINS TLVKVTWSTV PKDRVHGRLKGYQINWWKTK 840 SLLDGRTHPK EVNILRFSGQ RNSGMVPSLD AFSEFHLTVL AYNSKGAGPESEPYIFQTPE 900 GVPEQPTFLK VIKVDKDTAT LSWGLPKKLN GNLTGYLLQY QIINDTYEIGELNDINITTP 960 SKPSWHLSNL NATTKYKFYL RACTSQGCGK PITEESSTLG EGSKGIGKISGVNLTQKTHP 1020 IEVFEPGAEH IVRLMTKNWG DNDSIFQDVI ETRGREYAGL YDDISTQGWFIGLMCAIALL 1080 TLLLLTVCFV KRNRGGKYSV KEKEDLHPDP EIQSVKDETF GEYSDSDEKPLKGSLRSLNR 1140 DMQPTESADS LVEYGEGDHG LFSEDGSFIG AYAGSKEKGS VESNGSSTATFPLRA 1195

TABLE LVg Amino acid sequence alignment of 282P1G03 v.1 (SEQ ID NO: 191)and 282P1G03 v.8 (SEQ ID NO: 192)

TABLE LIIh Nucleotide sequence of 282P1G03 v.28 (SEQ ID NO: 193)cggaccctgc gcgcccccgt cccggctccc ggccggctcg ggggagaagg cgcccgaggg 60gaggcgccgg acagatcgcg tttcggaggc ggcgcagttt ccaggttaac taaggtctca 120gctgtaaacc aaaagtgaga ggagacatta agattttcat tcttaccggg ttgtcttctt 180cctgaagagc aatggagccg cttttacttg gaagaggact aatcgtatat ctaatgttcc 240tcctgttaaa attctcaaaa gcaattgaaa taccatcttc agttcaacag gttccaacaa 300tcataaaaca gtcaaaagtc caagttgcct ttcccttcga tgagtatttt caaattgaat 360gtgaagctaa aggaaatcca gaaccaacat tttcgtggac taaggatggc aacccttttt 420atttcactga ccatcggata attccatcga acaattcagg aacattcagg atcccaaacg 480aggggcacat atctcacttt caagggaaat accgctgctt tgcttcaaat aaactgggaa 540tcgctatgtc agaagaaata gaatttatag ttccaagtgt tccaaaactc ccaaaagaaa 600aaattgaccc tcttgaagtg gaggagggag atccaattgt cctcccatgc aatcctccca 660aaggcctccc acctttacac atttattgga tgaatattga attagaacac atcgaacaag 720atgaaagagt atacatgagc caaaagggag atctatactt cgcaaacgtg gaagaaaagg 780acagtcgcaa tgactactgt tgctttgctg catttccaag attaaggact attgtacaga 840aaatgccaat gaaactaaca gttaacagtt taaagcatgc taatgactca agttcatcca 900cagaaattgg ttccaaggca aattccatca agcaaagaaa acccaaactg ctgttgcctc 960ccactgagag tggcagtgag tcttcaatta ccatcctcaa aggggaaatc ttgctgcttg 1020agtgttttgc tgaaggcttg ccaactccac aggttgattg gaacaaaatt ggtggtgact 1080taccaaaggg gagagaaaca aaagaaaatt atggcaagac tttgaagata gagaatgtct 1140cctaccagga caaaggaaat tatcgctgca cagccagcaa tttcttggga acagccactc 1200acgattttca cgttatagta gaagagcctc ctcgctggac aaagaagcct cagagtgctg 1260tgtatagcac cggaagcaat ggcatcttgt tatgtgaggc tgaaggagaa cctcaaccca 1320caatcaagtg gagagtcaat ggctccccag ttgacaatca tccatttgct ggtgatgttg 1380tcttccccag ggaaatcagt tttaccaacc ttcaaccaaa tcatactgct gtgtaccagt 1440gtgaagcctc aaatgtccat ggaactatcc ttgccaatgc caatattgat gttgtggatg 1500tccgtccatt gatacaaacc aaagatggag aaaattacgc tacagtggtt gggtacagtg 1560ctttcttaca ttgcgagttc tttgcttcac ctgaggcagt cgtgtcctgg cagaaggtgg 1620aagaagtgaa acccctggag ggcaggcggt atcatatcta tgaaaatggc acattgcaga 1680tcaacagaac caccgaagaa gatgctgggt cttactcatg ttgggtagaa aatgctatag 1740gaaaaactgc agtcacagcc aatttggata ttagaaatgc tacaaaactt agagtttctc 1800ctaagaatcc tcgtatcccc aaattgcata tgcttgaatt acattgtgaa agcaaatgtg 1860actcacattt gaaacacagt ttgaagttgt cctggagtaa agatggagaa gcctttgaaa 1920ttaatggcac agaagatggc aggataatta ttgatggagc taatttgacc atatctaatg 1980taactttaga ggaccaaggt atttactgct gttcagctca tactgctcta gacagtgctg 2040ccgatataac tcaagtaact gttcttgatg ttccggatcc accagaaaac cttcacttgt 2100ctgaaagaca gaacaggagt gttcggctga cctgggaagc tggagctgac cacaacagca 2160atattagcga gtatattgtt gaatttgaag gaaacaaaga agagcctgga aggtgggagg 2220aactgaccag agtccaagga aagaaaacca cagttatctt acctttggct ccatttgtga 2280gataccagtt cagggtcata gccgtgaacg aagtagggag aagtcagcct agccagccgt 2340cagaccatca tgaaacacca ccagcagctc cagataggaa tccacaaaac ataagggttc 2400aagcctctca acccaaggaa atgattataa agtgggagcc tttgaaatcc atggagcaga 2460atggaccagg cctagagtac agagtgacct ggaagccaca gggagcccca gtggagtggg 2520aagaagaaac agtcacaaac cacacattgc gggtgatgac gcctgctgtc tatgcccctt 2580atgatgtcaa ggtccaggct atcaatcaac taggatctgg gcctgaccct cagtcagtga 2640ctctctattc tggagaagac tatcctgata cagctccagt gatccatggg gtggacgtta 2700taaacagtac attagttaaa gttacctggt caacagttcc aaaggacaga gtacatggac 2760gtctgaaagg ctatcagata aattggtgga aaacaaaaag tctgttggat ggaagaacac 2820atcccaaaga agtgaacatt ctaagatttt caggacaaag aaactctgga atggttcctt 2880ccttagatgc ctttagtgaa tttcatttaa cagtcttagc ctataactct aaaggagctg 2940gtcctgaaag tgagccttat atatttcaaa caccagaagg agtacctgaa cagccaactt 3000ttctaaaggt catcaaagtt gataaagaca ctgccacttt atcttgggga ctacctaaga 3060aattaaatgg aaacttaact ggctatcttt tgcaatatca gataataaat gacacctacg 3120agattggaga attaaatgat attaacatta caactccatc aaagcccagc tggcacctct 3180caaacctgaa tgcaactacc aagtacaaat tctacttgag ggcttgcact tcacagggct 3240gtggaaaacc gatcacggag gaaagctcca ccttaggaga agggagtaaa ggtatcggga 3300agatatcagg agtaaatctt actcaaaaga ctcacccaat agaggtattt gagccgggag 3360ctgaacatat agttcgccta atgactaaga attggggcga taacgatagc atttttcaag 3420atgtaattga gacaagaggg agagaatatg ctggtttata tgatgacatc tccactcaag 3480gctggtttat tggactgatg tgtgcgattg ctcttctcac actactatta ttaactgttt 3540gctttgtgaa gaggaataga ggtggaaagt actcagttaa agaaaaggaa gatttgcatc 3600cagacccaga aattcagtca gtaaaagatg aaacctttgg tgaatacagt gacagtgatg 3660aaaagcctct caaaggaagc cttcggtccc ttaataggga tatgcagcct actgaaagtg 3720ctgacagctt agtcgaatac ggagagggag accatggtct cttcagtgaa gatggatcat 3780ttattggtgc ctacgctgga tctaaggaga agggatctgt tgaaagcaat ggaagttcta 3840cagcaacttt tccccttcgg gcataaacac aacatatgta agcaacgcta ctggttcacc 3900ccaaccttcc atatttatct gttcaaagga gcaagaactt tcatatagga atagaaacat 3960gctggccgaa gatttcatcc agaagtcaac atcctgcaat tatgttgaaa agagtagtac 4020tttcttcaaa atataaaatg ccaagcactt caggcctatg ttttgcttat attgttttca 4080ggtgctcaaa atgcaaaaca caaaacaaat cctgcattta gatacacctc aactaaatcc 4140aaagtcccca ttcagtatat tccatatttg cctgatttta ctattcggtg tgtttgcata 4200gatgttgcta cttggtgggt ttttctccgt atgcacattg gtatacagtc tctgagaact 4260ggcttggtga ctttgcttca ctacaggtta aaagaccata agcaaactgg ttatttaaaa 4320tgtaaaaagg aatatgaaag tcttattaaa acacttcatt gaaaatatac agtctaaatt 4380tattatttaa attttactag caaaagtctt aggtgaacaa tcaactagta tttgttgagc 4440tcctatttgc ccagagatgg tcatatttaa acagaagtat acgtttttca gtttcaacat 4500gaattttttt atttctgtca gttatgacat ccacgagcat cactttttgt gtctgttttt 4560ttttttttct tggactaaat tcaactgcat ggaagcggtg gtcagaaggt tgttttatac 4620gagaacaggc agaaagtgcc cattgttcag gattctaata gctacatcta cttaatatct 4680tcatttctaa attgactgct tttacctttt tctcatgttt atataatggt atgcttgcat 4740atatttcatg aatacattgt acatattatg ttaatattta cacaatttaa aatatagatg 4800tgttttattt tgaagtgaga aaatgaacat taacaggcat gtttgtacag ctagaatata 4860ttagtaagat actgtttttc gtcattccag agctacaact aataacacga ggttccaaag 4920ctgaagactt tgtataaagt atttgggttt tgttcttgta ttgctttctt tcaacagttt 4980caaaataaaa tatcatacaa atattgaggg aaatgttttc atatttttca aaataggttt 5040ttattgttga atgtacatct accccagccc ctcaaaagaa aaactgttta catagaaatt 5100cctacacata cgtttgcgta tatgttattt taaacatctt tgtggtgaga attttttccc 5160cgatattctc cttctgtcaa agtcagaaca aattcaggga atttattttc tggcagttgt 5220gctccagtcc ttttaaaatt gtacatgaac atgttttaga aacaatatgg aggatgatgc 5280atacatgtcg gtcaagttca gcgctcgaca ttttatggaa agattttttt aaccttacca 5340cgaaatactt aactactgtt taagtgaatt gacttatttc actttagttt ttgaactgtg 5400attattggta tactgttata tcctcaactt ggatttatgg taaccccttt tagttcatgg 5460agaccaaaat ttggggtatt tataatagtc agcgcaggaa tgcacatgga atatctactt 5520gtccttttga acctcacgag tcatccagaa tgtatagaca ggaaaagcat gtcttattta 5580aaactgtaat ttatgggctc aggatctgac cgcagtcccg ggagtaagca tttcaaaggg 5640ggaaggcagt gtggtcccta ccctgtgtga atgtgaggat gtagacatcc atcagtgcaa 5700ctcgagctcc atcctcctcc gatttctaag gctccagttt tctggaggga cagtcatcat 5760gttttgattt atctgggaga aaactgtggt gcacagcttg tgaggagggc aaggttgtga 5820cgttcgagct tagttctggt gttattctgt ctcctcttct ttgtcatcag ccaaaacgtg 5880gtttttaaag agagtcatgc aggttagaaa taatgtcaaa aatatttagg aatttaataa 5940cctttaagtc agaaactaaa acaaatactg aaatattagc tcttcctaca cttcgtgttc 6000ccctttagct gcctgaaaat caagattgct cctactcaga tcttctgagt ggctaaaact 6060tatggatatg aaaaatgaga ttgaatgatg actatgcttt gctatcattg ttacctttcc 6120tcaatactat ttggcaacta ctgggactct tcagcacaaa aggaatagat ctatgattga 6180ccctgatttt aattgtgaaa ttatatgatt catatatttt atgaatcaga ataaccttca 6240aataaaataa atctaagtcg gttaaaatgg atttcatgat tttccctcag aaaatgagta 6300acggagtcca cggcgtgcaa tggtaattat aaattggtga tgcttgtttg caaattgccc 6360actcgtgata agtcaacagc caatatttaa aactttgttc gttactggct ttaccctaac 6420tttctctagt ctactgtcaa tatcatttta atgtaattga ttgtatatag tctcaagaat 6480ggttggtggg catgagttcc tagagaactg tccaagggtt gggaaaatcc aaattctctt 6540cctggctcca gcactgattt tgtacataaa cattaggcag gttgcttaac ctttttattt 6600caaactctct caactctaaa gtgctaataa taatctcagt taccttatct ttgtcacagg 6660gtgttctttt ttatgaagaa aaatttgaaa atgataaaag ctaagatgcc ttctaacttc 6720ataagcaaac ctttaactaa ttatgtatct gaaagtcacc cccacatacc aactcaactt 6780ttttcctgtg aacacataaa tatattttta tagaaaaaca aatctacata aaataaatct 6840actgtttagt gagcagtatg acttgtacat gccattgaaa attattaatc agaagaaaat 6900taagcagggt ctttgctata caaaagtgtt ttccactaat tttgcatgcg tatttataag 6960aaaaatgtga atttggtggt tttattctat cggtataaag gcatcgatat tttagatgca 7020cccgtgtttg taaaaatgta gagcacaatg gaattatgct ggaagtctca aataatattt 7080ttttcctatt ttatactcat ggaagagata agctaaagag gggacaataa tgagaaatgt 7140tggtgtgctt ttctaagcat ttaaaacata attgccaatt gaaaccctaa atatgtttac 7200ataccattaa gatatgattc atgtaacaat gttaaattaa ttataatggg attgggtttg 7260ttatctgtgg tagtatatat cctagtgttc ctatagtgaa ataagtaggg ttcagccaaa 7320gctttctttg ttttgtacct taaattgttc gattacgtca tcaaaagaga tgaaaggtat 7380gtagaacagg ttcacgtgat tacctttttc ttttggcttg gattaatatt catagtagaa 7440ctttataaaa cgtgtttgta ttgtaggtgg tgtttgtatt atgcttatga ctatgtatgg 7500tttgaaaata ttttcattat acatgaaatt caactttcca aataaaagtt ctacttcatg 7560taatccaaaa 7570

TABLE LIIIh Nucleotide sequence alignment of 282P1G03 v.1 (SEQ ID NO:194) and 282P1G03 v.28 (SEQ ID NO: 195)

TABLE LIVh Peptide sequences of protein coded by 282P1G03 v.28 (SEQ IDNO: 196) MEPLLLGRGL IVYLMFLLLK FSKAIEIPSS VQQVPTIIKQ SKVQVAFPFDEYFQIECEAK 60 GNPEPTFSWT KDGNPFYFTD HRIIPSNNSG TFRIPNEGHI SHFQGKYRCFASNKLGIAMS 120 EEIEFIVPSV PKLPKEKIDP LEVEEGDPIV LPCNPPKGLP PLHIYWMNIELEHIEQDERV 180 YMSQKGDLYF ANVEEKDSRN DYCCFAAFPR LRTIVQKMPM KLTVNSLKHANDSSSSTEIG 240 SKANSIKQRK PKLLLPPTES GSESSITILK GEILLLECFA EGLPTPQVDWNKIGGDLPKG 300 RETKENYGKT LKIENVSYQD KGNYRCTASN FLGTATHDFH VIVEEPPRWTKKPQSAVYST 360 GSNGILLCEA EGEPQPTIKW RVNGSPVDNH PFAGDVVFPR EISFTNLQPNHTAVYQCEAS 420 NVHGTILANA NIDVVDVRPL IQTKDGENYA TVVGYSAFLH CEFFASPEAVVSWQKVEEVK 480 PLEGRRYHIY ENGTLQINRT TEEDAGSYSC WVENAIGKTA VTANLDIRNATKLRVSPKNP 540 RIPKLHMLEL HCESKCDSHL KHSLKLSWSK DGEAFEINGT EDGRIIIDGANLTISNVTLE 600 DQGIYCCSAH TALDSAADIT QVTVLDVPDP PENLHLSERQ NRSVRLTWEAGADHNSNISE 660 YIVEFEGNKE EPGRWEELTR VQGKKTTVIL PLAPFVRYQF RVIAVNEVGRSQPSQPSDHH 720 ETPPAAPDRN PQNIRVQASQ PKEMIIKWEP LKSMEQNGPG LEYRVTWKPQGAPVEWEEET 780 VTNHTLRVMT PAVYAPYDVK VQAINQLGSG PDPQSVTLYS GEDYPDTAPVIHGVDVINST 840 LVKVTWSTVP KDRVHGRLKG YQINWWKTKS LLDGRTHPKE VNILRFSGQRNSGMVPSLDA 900 FSEFHLTVLA YNSKGAGPES EPYIFQTPEG VPEQPTFLKV IKVDKDTATLSWGLPKKLNG 960 NLTGYLLQYQ IINDTYEIGE LNDINITTPS KPSWHLSNLN ATTKYKFYLRACTSQGCGKP 1020 ITEESSTLGE GSKGIGKISG VNLTQKTHPI EVFEPGAEHI VRLMTKNWGDNDSIFQDVIE 1080 TRGREYAGLY DDISTQGWFI GLMCAIALLT LLLLTVCFVK RNRGGKYSVKEKEDLHPDPE 1140 IQSVKDETFG EYSDSDEKPL KGSLRSLNRD MQPTESADSL VEYGEGDHGLFSEDGSFIGA 1200 YAGSKEKGSV ESNGSSTATF PLRA 1224

TABLE LVh Amino acid sequence alignment of 282P1G03 v.1 (SEQ ID NO: 197)and 282P1G03 v.28 (SEQ ID NO: 198)

1. An isolated protein comprising the amino acid sequence of SEQ IDNO:3.
 2. A composition comprising an excipient and the protein ofclaim
 1. 3. A method of generating a mammalian immune response directedto a protein, comprising: exposing cells of the mammal's immune systemto the protein of claim 1, whereby the mammalian immune response to theprotein is elicited, wherein the immune response is activation of a Bcell, whereby the induced B cell generates antibodies that specificallybind to the protein.